<SEC-DOCUMENT>0001193125-17-133418.txt : 20170424
<SEC-HEADER>0001193125-17-133418.hdr.sgml : 20170424
<ACCEPTANCE-DATETIME>20170424061803
ACCESSION NUMBER:		0001193125-17-133418
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		20
FILED AS OF DATE:		20170424
DATE AS OF CHANGE:		20170424

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UroGen Pharma Ltd.
		CENTRAL INDEX KEY:			0001668243
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-217201
		FILM NUMBER:		17777141

	BUSINESS ADDRESS:	
		STREET 1:		9 HA'TA'ASIYA ST
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4365007
		BUSINESS PHONE:		972 9 770 7601

	MAIL ADDRESS:	
		STREET 1:		9 HA'TA'ASIYA ST
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4365007
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>d142578df1a.htm
<DESCRIPTION>AMENDMENT NO. 1 TO FORM F-1
<TEXT>
<HTML><HEAD>
<TITLE>Amendment No. 1 to Form F-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>As filed with the Securities and Exchange Commission April 24, 2017 </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right"><B>Registration No. 333-217201 </B></P>  <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>Amendment No. 1
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>to </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>FORM F-1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>UNDER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>THE SECURITIES ACT OF&nbsp;1933 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>UroGen Pharma Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Exact name of Registrant as specified in its charter) </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Translation of Registrant&#146;s
name into English) </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>State of Israel <BR></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable<BR></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center">(State or other jurisdiction of<BR>incorporation or organization)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(Primary Standard Industrial<BR>Classification Code Number)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(I.R.S. Employer<BR>Identification Number)</TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>9 Ha&#146;Ta&#146;asiya Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Ra&#146;anana 4365007, Israel </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Tel: +972 (9)
770-7601 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Address, including zip code, and telephone number, including area code, of Registrant&#146;s principal executive offices) </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Urogen Pharma, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>689 Fifth Avenue, 14th
Floor </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>New York, New York 10022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Telephone: +1 (646) 768-9780 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Name, address,
including zip code, and telephone number, including area code, of agent for service) </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Copies to:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Divakar Gupta</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Daniel I. Goldberg</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Joshua A.
Kaufman<BR>Cooley&nbsp;LLP<BR>The Grace Building<BR>1114 Avenue of the Americas<BR>New York, NY 10036<BR>Telephone: (212)&nbsp;479-6000<BR>Facsimile: (212)&nbsp;479-6275</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Yaron Sobol</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Steven Berelowitz</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Hamburger Evron &amp;
Co.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>The Museum Tower</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>4 Berkowitz
Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Tel-Aviv 6423806, Israel</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">Telephone:&nbsp;+972&nbsp;(3)&nbsp;607-4040</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Facsimile: +972 (3) 607-4004</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Eric W. Blanchard</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Brian K. Rosenzweig</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Covington &amp; Burling
LLP<BR>The New York Times Building<BR>620 Eighth Avenue<BR>New York, NY 10018-1405<BR>Telephone: (212) 841-1000<BR>Facsimile: (212) 841-1010</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Chaim Friedland</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Ari Fried</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Gornitzky &amp; Co.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Zion House</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>45 Rothschild Blvd.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Tel Aviv 6578403, Israel</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">Telephone:&nbsp;+972&nbsp;(3)&nbsp;710-9191</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Facsimile:&nbsp;+972&nbsp;(3)&nbsp;560-6555</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Approximate date of commencement of proposed sale to the public: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">As soon as practicable after the effective date of this Registration Statement. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933,
check the following box.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is filed to register additional securities for an offering
pursuant to Rule&nbsp;462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT
STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is a <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment filed pursuant to
Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is a <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment
filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT
STYLE="font-family:Times New Roman">&#9744;</FONT> </P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&nbsp;405 of the
Securities Act of 1933. Emerging growth company&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9746;</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If an emerging growth company that prepares its
financial statements in accordance with U.S.&nbsp;GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#134; provided pursuant to
Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9746;</FONT> </P>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CALCULATION OF REGISTRATION
FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>TITLE OF EACH CLASS OF SECURITIES<BR>TO BE REGISTERED</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>PROPOSED MAXIMUM</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>AGGREGATE<BR>OFFERING&nbsp;PRICE&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>AMOUNT OF<BR>REGISTRATION<BR>FEE&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Ordinary Shares, par value NIS 0.01 per share</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$55,730,766</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$6,460*</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$5,795 of which was previously paid. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule&nbsp;457(o) under the Securities Act of 1933, as amended. Includes the ordinary shares that the underwriters
have the option to purchase. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">(2)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Calculated pursuant to Rule&nbsp;457(o) based on an estimate of the proposed maximum aggregate offering price. </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file&nbsp;a further amendment which specifically states that this Registration Statement shall
thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine.
</B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">&#134; The term &#147;new or revised financial accounting standard&#148; refers to any update issued by the Financial Accounting Standards Board to its
Accounting Standards Codification after April&nbsp;5, 2012. </P>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#cc062a"><B>The information contained in this preliminary prospectus is not complete and may be changed. We
may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these
securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><FONT COLOR="#cc062a">SUBJECT TO COMPLETION, DATED APRIL&nbsp;24, 2017 </FONT></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>3,461,538 Ordinary Shares </B></P>  <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g15c64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>UroGen Pharma Ltd. </B></P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We
are offering 3,461,538 ordinary shares. This is our initial public offering and no public market currently exists for our ordinary shares. We expect the initial public offering price to be between $12.00 and $14.00 per share. We have applied to have
our ordinary shares listed on the NASDAQ Global Market under the symbol &#147;URGN.&#148; </P>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; as defined in the
Jumpstart Our Business Startups Act of 2012 and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investing in our ordinary shares involves a high degree of risk. Please read &#147;<A HREF="#toc142578_2">Risk Factors</A>&#148; beginning on page 14 of this
prospectus. </B></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Public Offering Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Underwriting Discounts and
Commissions<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds to UroGen Pharma Ltd. Before Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We have agreed to reimburse the underwriters for certain expenses. See &#147;Underwriting.&#148; </TD></TR></TABLE>  <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain of our
existing investors and their affiliated entities and other entities have indicated an interest in purchasing up to an aggregate of approximately $20.0 million worth of our ordinary shares in this offering at the initial public offering price.
However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, less or no shares in this offering to any of these persons and any of these persons may determine to
purchase more, less or no shares in this offering. In addition, the underwriters will receive the same underwriting discounts and commissions on any shares purchased by these persons as they will on any other shares sold to the public in this
offering. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Delivery of the ordinary shares is expected to be made on or
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017. We have granted the underwriters an option for a period of 30 days to purchase up to an additional 519,230 ordinary shares. If the
underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and the total proceeds to us, before
expenses, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="84%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:16pt; font-family:ARIAL"><B>Jefferies </B></P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:16pt; font-family:ARIAL" ALIGN="right"><B>Cowen&nbsp;and&nbsp;Company </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:13pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="92%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:13pt; font-family:ARIAL"><B>Raymond James </B></P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:13pt; font-family:ARIAL" ALIGN="right"><B>Oppenheimer &amp; Co. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Prospectus dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2017 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_1a">Market, Industry and Other Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_1">Prospectus Summary </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_3">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_4">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_5">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_6">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_7">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_8">Selected Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_9">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_10">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_11">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_12">Principal Shareholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_13">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_14">Description of Share Capital</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_15">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_16">Taxation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_17">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_18">Expenses of this Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_19">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_20">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_21">Enforcement of Civil Liabilities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_22">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_23">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we nor the underwriters have authorized anyone to provide you with information that is different from that contained in this prospectus, any amendment or
supplement to this prospectus, or in any free writing prospectus we may authorize to be delivered or made available to you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may
give you. We and the underwriters are offering to sell ordinary shares and seeking offers to purchase ordinary shares only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the
date on the front of this prospectus, regardless of the time of delivery of this prospectus or any sale of ordinary shares. Our business, financial condition, results of operations and prospects may have changed since the date on the front cover of
this prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For investors outside of the United States: Neither we nor any of the underwriters have taken any action to permit this offering or possession or
distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the
distribution of this prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MitoGel, VesiGel, Vesimune, UroGen and RTGel are trademarks of ours that we use in this prospectus. This prospectus also includes
trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in this prospectus appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
or &#153; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to our trademark and tradenames. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_1a"></A>MARKET, INDUSTRY AND OTHER DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus contains estimates, projections and other information concerning our industry, our business, and the markets for our product candidates. Information
that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this
information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research
firms and other third parties, industry, medical and general publications, government data and similar sources. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, assumptions and estimates of our and
our industry&#146;s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#147;Risk Factors.&#148; These and other factors could cause our future performance to
differ materially from our assumptions and estimates. See &#147;Special Note Regarding Forward-Looking Statements.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">ii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>This summary highlights selected information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making
your investment decision. Before deciding to invest in our ordinary shares, you should read this entire prospectus carefully, including the sections of this prospectus entitled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations&#148; and our financial statements and the related notes included elsewhere in this prospectus. Unless the context otherwise requires, references in this prospectus to the
&#147;company,&#148; &#147;UroGen Pharma,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to UroGen Pharma Ltd. and its subsidiary, Urogen Pharma, Inc. The terms &#147;shekel,&#148; &#147;Israeli shekel&#148; and &#147;NIS&#148; refer
to New Israeli Shekels, the lawful currency of the State of Israel, and the terms &#147;dollar,&#148; &#147;U.S. dollar&#148; or &#147;$&#148; refer to United States dollars, the lawful currency of the United States. All references to
&#147;shares&#148; in this prospectus refer to ordinary shares of UroGen Pharma Ltd., par value NIS 0.01 per share. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. We have an
innovative and broad pipeline of product candidates that we believe can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Our lead product candidates, MitoGel and VesiGel, are
proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug which is currently used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. We are
developing our product candidates as chemoablation agents, which means they are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma,
or UTUC, and low-grade bladder cancer. We believe that MitoGel and VesiGel, which are both local drug therapies, have the potential to significantly improve patients&#146; quality of life by replacing costly, sub-optimal and burdensome tumor
resection surgeries as the first-line standard of care. MitoGel and VesiGel may also reduce the need for bladder, kidney and upper urothelial tract removals, which are typically performed on patients whose cancer progresses despite undergoing tumor
resection surgical procedures. Additionally, we believe that our product candidates, which are based on novel formulations of approved drugs, may qualify for streamlined regulatory pathways to market approval. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that urothelial cancer, which is comprised of bladder cancer and UTUC, affects a large and underserved patient population. Annual expenditures for Medicare
alone in the United States for the treatment of urothelial cancer were estimated to be at least $4 billion in 2010 and are projected to be at least $5&nbsp;billion in 2020. The majority of the historical expenditures was spent on tumor resection
surgeries such as transurethral resection of bladder tumor, or TURBT, and bladder, kidney and upper urothelial tract removals. In 2012, the estimated prevalence of urothelial cancer in the United States was 625,000 with an annual incidence of
approximately 80,000. The 2012 prevalence of each of low-grade non-muscle invasive bladder cancer, or NMIBC, and low-grade UTUC in the United States was approximately 325,000 and 14,500, respectively. No drugs have been approved by the U.S. Food and
Drug Administration, or the FDA, for the treatment of NMIBC in more than 15 years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MitoGel and VesiGel are formulated using our proprietary reverse thermally
triggered hydrogel, or RTGel, technology. We believe that RTGel-based drug formulations, which provide for the sustained release of an active drug, may improve the efficacy of treatment of various types of urothelial cancer without compromising the
safety of the patient or interfering with the natural flow of fluids in the urinary tract. Our formulations are designed to achieve this by increasing the dwell time as well as the tissue coverage throughout the organ of the active drug.
Consequently, we believe that RTGel-based drug formulations may enable us to overcome the anatomical and physiological challenges that have historically contributed to the lack of drug development for the treatment of urothelial cancer. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MitoGel and VesiGel are administered locally using the standard practice of intravesical instillation directly into the bladder or upper urothelial tract via a
catheter. Instillation is expected to take place in the physician&#146;s office </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
as a same-day treatment, in comparison with TURBT or similar tumor surgical procedures, which are operations conducted under general anesthesia in a hospital setting and often require at least an
overnight stay. Tumor surgical procedures often have limited success due to the inability to properly identify, reach and resect all tumors. We believe that an effective chemoablation agent can potentially provide better eradication of tumors
irrespective of the detectability and location of the tumors. In addition, by removing the need for surgery, patients may avoid potential complications associated with surgery and <FONT STYLE="white-space:nowrap">hospital-acquired</FONT> infections.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are currently evaluating the safety and efficacy of MitoGel, our novel sustained-release formulation of MMC, in UTUC patients pursuant to an ongoing
&#147;Compassionate Use&#148; program. &#147;Compassionate Use&#148; is the use outside of a clinical trial of an investigational, or not approved, medical product when patient enrollment in a clinical trial is not possible, typically due to patient
ineligibility or a lack of ongoing clinical trials. Of the 13&nbsp;patients with confirmed low-grade UTUC who have been evaluated endoscopically, or through the use of a nonsurgical viewing instrument to examine the urinary tract, in the program to
date, eight have achieved a complete response and five have achieved a partial response at the primary evaluation time. Of the eight patients who have achieved a complete response at the primary evaluation time, three have subsequently experienced
recurrences to date. Thus far in this Compassionate Use program, MitoGel has been observed to be well-tolerated. We have obtained Orphan Drug Designation for MitoGel for the treatment of UTUC. In November 2016, we filed an investigational new drug,
or IND, application with the FDA for MitoGel, which was accepted by the FDA in December 2016. We commenced a single pivotal, open-label, single-arm Phase 3 clinical trial for the treatment of low-grade UTUC in the first quarter of 2017. We intend to
pursue the FDA&#146;s 505(b)(2) regulatory pathway for MitoGel, which is a streamlined, lower-cost and more well-defined pathway to drug approval when compared to traditional drug development. We believe that MitoGel has the potential to become the
first FDA-approved drug for the treatment of low-grade UTUC serving as a first-line chemoablation agent, sparing patients from repeated tumor resection surgeries and potentially reducing the need for kidney and upper urothelial tract removals. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we are currently evaluating the safety and efficacy of VesiGel, our novel sustained-release high dose formulation of MMC, for the treatment of low-grade
NMIBC in a Phase 2 study being conducted in Europe and Israel. This study is expected to be completed in the second quarter of 2017. To date, 19 of 22, or approximately 86%, of the patients evaluated in our ongoing Phase 2a clinical trial who were
treated in the VesiGel high dose group (80mg MMC) achieved a complete response at the primary evaluation time. Moreover, approximately 79% of the patients who achieved a complete response at the primary evaluation time and who have been followed for
12 months thereafter, without receiving additional treatments, remained recurrence free. This compares to approximately 40% to 60% of patients who historically achieve a <FONT STYLE="white-space:nowrap">12-month</FONT> durable complete response with
TURBT as first-line treatment, followed by adjuvant treatments of MMC instillations into the bladder. We plan to file an IND for VesiGel in the second half of 2017, and, if accepted, to commence a Phase 2b clinical trial for VesiGel shortly
thereafter. We also intend to pursue a 505(b)(2) regulatory pathway for VesiGel. We believe that VesiGel has the potential to replace tumor resection surgery and become the new first-line standard of care for the treatment of low-grade NMIBC. </P>
 <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our clinical stage pipeline also includes Vesimune, our proprietary immunotherapy product candidate for the treatment of high-grade NMIBC, which may include
Carcinoma in Situ, or CIS. Vesimune is a novel, liquid formulation of Imiquimod, a generic toll-like receptor 7, or TLR7, agonist. Toll-like receptor agonists play a key role in initiating the innate immune response system. We believe that the
combination of Vesimune with additional immunotherapy drugs, such as immune checkpoint inhibitors or chemotherapy drugs like VesiGel, could represent a valid alternative to the current standard of care for the post TURBT adjuvant treatment of
high-grade NMIBC. BotuGel is our proprietary novel RTGel-based formulation of BOTOX, a branded drug, that we believe can potentially serve as an effective treatment option for patients suffering from overactive bladder. In October&nbsp;2016, we
announced the licensing of the worldwide rights to BotuGel to Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc, which plans to commence a Phase 2 clinical trial of BotuGel in the second half of
2017, pursuant to the exclusive license agreement we entered into with Allergan in October 2016, or the Allergan Agreement. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Product Candidate Pipeline </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following chart summarizes the current status of our product candidate pipeline. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g80t12.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview of Upper Tract Urothelial Carcinoma </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">UTUC refers to malignant changes of the transitional urothelial cells lining the upper urothelial tract, comprised of the renal pelvis and ureter. UTUC is nearly three
times more common in men than women and affects mostly the elderly. UTUC accounts for approximately 5% to 10% of all new cases of urothelial cancer, which corresponds to an estimated annual incidence in the United States of up to 7,500 cases. In
2012, the estimated prevalence of UTUC in the United States was approximately 45,000, of which approximately 14,500 had low-grade disease. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The key prognostic
factor at the time of diagnosis of UTUC is whether the tumor is in the muscle-invasive or non-muscle invasive stage. The number, size and location of tumors presented also represent important prognostic factors for UTUC. Approximately 40% of the
patients diagnosed annually with UTUC in the United States present with non-muscle invasive UTUC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Limitations of Current Treatment Options for Upper Tract
Urothelial Carcinoma </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are currently no drugs approved by the FDA for the treatment of UTUC, representing a significant unmet medical need. Moreover,
the anatomical complexity of the upper urothelial tract, particularly the renal pelvis, presents significant challenges to the proper identification and ability to reach and resect all tumors in tumor resection surgical procedures. Consequently,
patients with high-grade disease or patients with low-grade disease that present with a large number of tumors typically undergo nephroureterectomy, which is kidney and upper urothelial tract removal. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Tumor resection, which aims to be a kidney sparing surgical procedure, is conducted only in patients with low-grade disease that present with a limited number of
tumors. Such procedures are followed by adjuvant chemotherapy treatment, typically with MMC. However, the upper urothelial tract&#146;s anatomical constraints limit the effectiveness of surgical procedures and adjuvant chemotherapy treatments,
leading to high rates of recurrence and risk for progression in this patient population. In a study published in 2009 in the Journal of Endourology evaluating 57 patients with low-grade UTUC who underwent tumor resections, recurrence occurred in
89.5% of patients with a mean of 5.5 recurrences per patient over a four-year period. Moreover, </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
approximately 20% of the patients in this study progressed and ultimately underwent kidney and upper tract removal. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>MitoGel: Our Solution for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that MitoGel, our novel sustained-release RTGel-based formulation of MMC, has the potential to become the first FDA-approved drug for the treatment of
low-grade UTUC and to serve as a first-line chemoablation agent, sparing patients from repeated tumor resection surgical procedures and potentially reducing the need for kidney and upper urothelial tract removal. We believe that MitoGel can overcome
the significant anatomical and physiological constraints presented by the upper urothelial tract. MitoGel is administered directly into the upper urothelial tract using standard catheters and conforms to the complex anatomy of the upper urothelial
tract. Once instilled, MitoGel converts into gel form in less than 10 minutes at body temperature. Subsequently, upon contact with urine, MitoGel gradually dissolves and releases the active drug, MMC, over a period of several hours versus several
minutes for MMC in its current water-based formulation, without compromising the safety of the patient or interfering with the natural flow of fluids from the upper urothelial tract to the bladder. We believe that this substantial increase in dwell
time of MMC positions MitoGel as a potential first-line chemoablation treatment alternative to tumor resection surgery for the treatment of low-grade UTUC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview of Non-Muscle Invasive Bladder Cancer </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Bladder cancer accounts for
approximately 90% to 95% of all new cases of urothelial cancer in the United States, with a prevalence of approximately 580,000. Bladder cancer is nearly three to four times more common in men than women, and, with an average age at diagnosis of 73,
mostly affects the elderly. Bladder cancer is described as non-muscle invasive or muscle-invasive based on how far into the wall of the bladder the cancer has invaded. Muscle-invasive bladder cancer, or MIBC, has an average five-year survival of 15%
to 63%, depending on severity. MIBC has a worse prognosis than NMIBC, which has a five-year survival rate of approximately 90%. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">NMIBC accounts for approximately
80% of all new cases of bladder cancer diagnosed in the United States each year, which corresponds to an estimated annual incidence and prevalence of approximately 60,000 and 465,000 cases, respectively. NMIBC is divided into two grades, low and
high, with high-grade tumors more likely to recur and progress into muscle-invasive tumors. Overall, approximately 70% of patients with NMIBC present with low-grade disease at diagnosis. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Limitations of Current Treatment Options for Non-Muscle Invasive Bladder Cancer </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The standard of care for treating NMIBC patients is TURBT followed by adjuvant chemotherapy or immunotherapy treatment. TURBT is a surgical operation for tumor removal
conducted under general anesthesia in a hospital setting and often requires at least an overnight stay. Moreover, TURBT&#146;s success is tied to the physician&#146;s ability to overcome challenges in properly identifying, reaching and resecting all
tumors. Patients treated with the current standard of care have up to an approximately 60% rate of recurrence of NMIBC within one year, and the rate of progression of NMIBC to MIBC is between 20% and 30%. As a consequence, NMIBC patients have to
undergo periodic and expensive follow-ups that can include multiple repeated TURBT procedures and adjuvant chemotherapy and immunotherapy treatments. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No drugs have
been approved by the FDA as first-line treatment for NMIBC and only three drugs have been approved by the FDA for NMIBC, all used as adjuvant treatment, following TURBT. Efficacy of drug treatments has historically been limited due to challenges
presented by bladder physiology, specifically the fact that urine is produced and voided frequently, thus diluting the concentration of the drug almost immediately and causing the excretion of the drug from the bladder at first urine voiding. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>VesiGel: Our Solution for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that VesiGel, our novel sustained-release RTGel-based formulation of high dose MMC, has the potential to replace TURBT and become the new first-line standard
of care for the treatment of low-grade NMIBC. VesiGel, a chemoablation agent, is administered locally using standard catheters in a physician&#146;s </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
office as a same-day treatment, in comparison with TURBT surgical procedures, which are operations conducted under general anesthesia in a hospital setting and often require at least an overnight
stay. Once instilled, VesiGel converts into gel form in approximately 15 minutes at body temperature. Subsequently, upon contact with urine, VesiGel gradually dissolves and releases the active drug, MMC, over a period of several hours versus the
time until first voiding, often less than an hour, for MMC in its current water-based formulation, without compromising the safety of the patient or interfering with the natural flow of urine out of the bladder. We designed VesiGel to conform to the
bladder&#146;s anatomy and persist in the bladder despite urine flow and bladder movement. VesiGel has demonstrated significantly increased dwell time of MMC in the bladder and prolonged exposure of MMC to the tissue, enabling the chemoablation of
both visible and undetected tumors. We are not aware of any drugs currently in development for the treatment of NMIBC, other than VesiGel, that take into consideration the specific challenges of bladder physiology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>RTGel: Our Reverse Thermally Triggered Hydrogel Platform Technology </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have
developed RTGel, a novel proprietary polymeric biocompatible reverse thermal gelation hydrogel, which, unlike the general characteristics of most forms of matter, is liquid at lower temperatures and converts into gel form when heated. We believe
that these characteristics promote ease of delivery into and retention of drugs in body cavities, including the bladder and the upper urothelial tract, by conforming to the anatomy of the target organ while preventing rapid excretion of the drug.
RTGel&#146;s components are polymer-based and are all FDA approved as inactive ingredients. We formulate RTGel with an active drug: MMC in the case of MitoGel and VesiGel, and botulinum toxin in the case of BotuGel. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that RTGel, when formulated with an active drug, may allow for the improved efficacy of treatment of various types of urothelial cancer without compromising
the safety of the patient or interfering with the natural flow of fluids in the urinary tract. RTGel achieves this by: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increasing the exposure of active drugs in the bladder and upper urothelial tract by significantly extending the dwell time of such drugs while conforming to the anatomy of the bladder and the upper urothelial tract,
which allows for enhanced drug tissue coverage; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administering higher doses of an active drug than would otherwise be possible using standard water-based formulations; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining the active drug&#146;s molecular structure and mode of action. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These characteristics of RTGel enable
sustained release of MMC in the urinary tract for both MitoGel and VesiGel, and of botulinum toxin in the case of BotuGel. Further, RTGel may be particularly effective in the bladder and upper urothelial tract where tumor visibility and access are
challenging, and where there exists a significant amount of urine flow and voiding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Competitive Strengths </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Potential ability to develop non-surgical, first-line drug therapies for uro-oncology.</I></B><B>&nbsp;</B><B></B>Leveraging our innovative
formulation technology, we are developing two lead product candidates, MitoGel and VesiGel, as potential replacements to first-line therapy for low-grade UTUC and NMIBC, respectively. Both MitoGel and VesiGel are chemoablation agents designed to
overcome the challenges posed by the anatomy of the urinary tract by increasing the dwell time and enhancing the tissue coverage of MMC. Clinical data generated to date supports our belief that our lead product candidates may be able to replace the
current first-line tumor surgical procedures, providing a chemoablation treatment that has the potential to better eradicate tumors irrespective of their detectability and location within the urinary tract. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Expertise in developing proprietary formulations of drugs for clinical benefit.</I></B>&nbsp;We focus on developing proprietary RTGel formulations
of previously approved drugs whose efficacy for a particular indication is limited by current formulations or routes of administration. While we have not yet brought a drug to market, our expertise has enabled us to develop proprietary RTGel-based
formulations for several previously approved drugs to date, including clinical stage proprietary formulations of MMC and botulinum </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">
toxin. With over 10 Ph.D. and medical doctors on our staff, we have a strong research and development team to advance our product candidates. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Lower development risks and costs for our pipeline product candidates. </I></B><B></B>We expect the approval process for each of our current
uro-oncology product candidates to be conducted according to the FDA&#146;s 505(b)(2) regulatory pathway, a streamlined, lower-cost and more well-defined pathway to drug approval when compared to traditional drug development. Furthermore, two of our
product candidates, MitoGel and Vesimune, have received Orphan Drug Designation from the FDA for the treatment of UTUC and CIS, respectively, which we expect will provide seven years of marketing exclusivity following FDA approval, if received. </P>
 <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Leverageable proprietary formulation technology</I></B><B>.</B><B>&nbsp;</B><B></B>We believe that RTGel has multiple potential applications
beyond urology. Our formulation know-how may enable us to develop different drug formulations to facilitate the delivery, retention and sustained release of active drugs to a variety of targeted body cavities. In October 2016, we announced that we
licensed worldwide rights to a proprietary RTGel formulation with Botulinum Toxin and other clostridial, or intestinal bacteria, toxins to Allergan for the treatment of overactive bladder and related indications. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Strong intellectual property position. </I></B>We have a robust intellectual property portfolio that includes four issued patents in the United
States and several patent applications filed worldwide that are directed to methods, systems, new compounds and compositions for treating urinary tract cancer. Our intellectual property covers, among other things, our lead product candidates,
MitoGel and VesiGel, as well as RTGel. The four issued patents are expected to expire between 2024 and 2031. In addition, we have 12&nbsp;issued patents worldwide that relate to our other product candidates. These issued patents are expected to
expire between 2030 and 2031. We also have 45 pending patent applications filed worldwide covering our various product candidates. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Experienced and accomplished leadership team with proven track record</I></B><B>.</B>&nbsp;We have an experienced management team, with each
member possessing more than 15 years of biopharmaceutical and related industry experience. We believe that our leadership team is well-positioned to lead us through clinical development, regulatory approval and commercialization for our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Growth Strategy </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Establish
each of our lead product candidates, MitoGel and VesiGel, as the first-line therapy in its target indication.</I></B>&nbsp;We believe that our lead product candidates have the potential to replace costly, sub-optimal and burdensome tumor resection
procedures as first-line therapy and may also reduce the need for bladder, kidney and upper urothelial tract removals. We believe that data from an ongoing Compassionate Use program provide preliminary evidence of the potential safety and efficacy
of MitoGel for the treatment of low-grade UTUC. In November 2016, we filed an IND for MitoGel, which was accepted by the FDA in December 2016. We commenced a single pivotal Phase 3 clinical trial for MitoGel in the first quarter of 2017 pursuant to
the FDA&#146;s 505(b)(2) regulatory pathway. For VesiGel, which is currently in a Phase 2a clinical trial for the treatment of low-grade NMIBC, we expect to commence a Phase 2b clinical trial in the first half of 2018. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Expand our uro-oncology product pipeline.</I></B> A Phase 1 clinical trial of Vesimune was completed under an IND in 12 patients with CIS, an
aggressive form of high-grade NMIBC. In the study, 10 patients were evaluated for response of which 40% achieved a complete response rate with Vesimune as single-agent treatment. We believe that combining Vesimune with immune checkpoint inhibitors
or chemotherapy has the potential to serve as a treatment option for high-grade urothelial tumors. We are also pursuing preclinical oncology programs that take advantage of our RTGel technology. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Establish ourselves as a commercial supplier of our MMC.</I></B><I> </I>We believe that by working with our existing third party manufacturer of
the MMC needed for our product candidates MitoGel and VesiGel, we may be able to also become an approved commercial supplier of MMC in the United States. There are currently only two suppliers of MMC approved for sale in the United States. By
working with our existing third party manufacturer of MMC and/or engaging an additional third party manufacturer of MMC to provide us with a </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">
commercial scale supply of MMC, we may target the generic urothelial cancer market in order to sell our formulation of MMC, which could increase potential revenue streams. This may also
potentially enable us to reduce the manufacturing cost of our lead product candidates, MitoGel and VesiGel. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Utilize our proprietary
technology to expand our pipeline to other body cavities and indications.</I></B>&nbsp;We believe that RTGel may be suitable for multiple additional applications. Our know-how may enable us to develop different drug formulations to facilitate the
delivery, retention and sustained release of active drugs to a variety of targeted body cavities and for multiple indications. Beyond the urinary tract, we may target the gastrointestinal tract and female reproductive system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Associated with Our Business </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business is subject to a number of
risks of which you should be aware before making an investment decision. These risks are discussed more fully in the &#147;Risk Factors&#148; section of this prospectus immediately following this prospectus summary. These risks include the
following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have a limited operating history and have incurred significant losses and negative cash flows since our inception, and we anticipate that we will continue to incur significant losses and negative cash flows for the
foreseeable future, which makes it difficult to assess our future viability. </TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have limited clinical trial experience with our product candidates and to date have generated only limited clinical data for our product candidates.&nbsp;Results of earlier studies and trials may not be predictive of
future trial results, and our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have not applied for regulatory approvals to market any of our product candidates, and we may be delayed in obtaining or fail to obtain such regulatory approvals and to commercialize our product candidates.
</TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If the FDA does not conclude that MitoGel, VesiGel or our other product candidates satisfy the requirements under Section&nbsp;505(b)(2) of the Federal Food Drug and Cosmetic Act, or if the requirements for such product
candidates are not as we expect, the regulatory approval pathway for these product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either
case may not be successful. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Even if our product candidates receive regulatory approval, they may fail to achieve the broad degree of physician adoption and use and market acceptance necessary for commercial success.&nbsp;Further, if MitoGel or
VesiGel or any of our other product candidates produces undesirable side effects that we may not have detected in our previous preclinical studies and clinical trials, our ability to obtain and maintain marketing approval or physician and market
acceptance for these product candidates would be significantly harmed.</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We are and expect to continue to be dependent on third-party subcontractors and single-source suppliers for the supply of sufficient quantities at acceptable costs of certain raw materials, compounds and components
necessary to produce MitoGel, VesiGel and Vesimune for preclinical studies, clinical trials and, if approved, commercial supply.</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may receive only limited protection, or no protection, from our issued patents and patent applications.&nbsp;If our efforts to obtain, protect or enforce our patents and other intellectual property rights related to
our product candidates and technologies are not adequate, we may not be able to compete effectively. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The market opportunities for our product candidates may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our product candidates, if approved, will face significant competition from competing technologies and our failure to compete effectively may prevent us from achieving significant market penetration. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">It may be difficult for us to profitably sell our product candidates if coverage and reimbursement for these products is limited by government authorities and/or third-party payor policies. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Based upon the expected value of our assets, including any goodwill, and the expected nature and composition of our income and assets, we presently do not anticipate that we will be a passive foreign investment company,
or a PFIC, for the taxable year ending December 31, 2017. However, it is not certain that the nature and composition of our income and assets will be as we currently expect, or that we will receive milestone payments in 2017 pursuant to the Allergan
Agreement. If we do not receive milestone payments as anticipated or other non-passive income, we likely will be classified as a PFIC for 2017. Our status as a PFIC is a fact-intensive determination made on an annual basis and we cannot provide any
assurances regarding our PFIC status for the current or future taxable years.&nbsp;If we are classified as a PFIC for any taxable year, our U.S. shareholders may suffer adverse tax consequences as a result (such as having gains realized on the sale
of our ordinary shares treated as ordinary income, rather than capital gain, the loss of the preferential rate applicable to dividends received on our ordinary shares by individuals who are U.S. shareholders, and having interest charges apply to
distributions by us and gains from the sale of our shares). Additionally, if we are classified as a PFIC, each holder of our ordinary shares who is a U.S. person will generally be required to file an annual information return on IRS Form&nbsp;8621
(Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund). We do not currently intend to provide investors with the information that would enable them to make a qualified electing fund election, or QEF
election. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate Information </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were incorporated
under the laws of the State of Israel in April 2004 under the name TheraCoat Ltd. In September 2015, we changed our name to UroGen Pharma Ltd. Our principal executive offices are located at 9 Ha&#146;Ta&#146;asiya Street, Ra&#146;anana 4365007,
Israel, and our telephone number is +972 (9) 770-7601. Our website address is <I>http://www.urogen.com</I>. The information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus. We have
included our website address as an inactive textual reference only. Our agent for service of process in the United States is Urogen Pharma, Inc., located at 689 Fifth Avenue, 14th Floor, New York, New York 10022, and its telephone number is +1 (646)
768-9780. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Implications of Being an &#147;Emerging Growth Company&#148; and a Foreign Private Issuer </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a company with less than $1.07&nbsp;billion in revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart
Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a requirement to have only two years of audited financial statements and only two years of related Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations disclosure in our initial
registration statement; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may take advantage of these provisions for up to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging
growth company upon the earlier to occur of:&nbsp;(1)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more;&nbsp;(2)&nbsp;the date on which we have issued more than $1.0 billion in
nonconvertible debt during the previous three years; or&nbsp;(3)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, or the SEC. We may choose to take advantage of some but
not all of these reduced burdens, and therefore the information that we provide holders of our ordinary shares may be different than the information you might receive from other public companies in which you hold equity. In addition,
Section&nbsp;107 of the JOBS Act also provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards applicable to public companies. We have irrevocably elected to
opt out of such extended transition period. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon consummation of this offering, we will report under the Securities Exchange Act of 1934, as amended, or the
Exchange Act, as a non-U.S. company with foreign private issuer status. Even after we no longer qualify as an emerging growth company, as long as we continue to qualify as a foreign private issuer under the Exchange Act, we will be exempt from
certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations with respect to a security registered under the Exchange Act; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sections of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> containing unaudited financial statements and other specified
information, and current reports on Form&nbsp;8-K upon the occurrence of specified significant events. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Both foreign private issuers and emerging
growth companies are also exempt from certain more stringent executive compensation disclosure rules. Thus, even if we no longer qualify as an emerging growth company, but remain a foreign private issuer, we will continue to be exempt from the more
stringent compensation disclosures required of companies that are neither an emerging growth company nor a foreign private issuer. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE OFFERING </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Ordinary shares offered by us </P></TD>
<TD>3,461,538 ordinary shares </TD></TR></TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Ordinary shares to be outstanding immediately after this offering </P></TD>
<TD>10,960,708 ordinary shares </TD></TR></TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Option to purchase additional ordinary shares </P></TD>
<TD>We have granted the underwriters an option for a period of 30 days after the date of this prospectus to purchase up to 519,230 additional ordinary shares. </TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds to us from this offering will be approximately $39.3&nbsp;million, or approximately $45.6&nbsp;million if the underwriters exercise their option to purchase additional ordinary shares in full, after deducting
the underwriting discounts and commissions and estimated offering expenses payable by us, based on an assumed initial public offering price of $13.00&nbsp;per ordinary share, which is the midpoint of the price range set forth on the cover of this
prospectus. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We expect to use the net proceeds from this offering, together with our existing cash resources, to advance our clinical pipeline, including specifically to complete our single pivotal Phase&nbsp;3 clinical trial of
MitoGel; to file an IND for, and to initiate our planned Phase&nbsp;2b clinical trial of, VesiGel; to fund continued research and clinical development of our other product candidates, including Vesimune, and for working capital and other general
corporate purposes. </TD></TR></TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Use of Proceeds&#148; for more information about the intended use of proceeds from this offering. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Tax considerations </P></TD>
<TD>Based upon the expected value of our assets, including any goodwill, and the expected nature and composition of our income and assets, we presently do not anticipate that we will be classified as a passive foreign investment company, or a PFIC,
for the taxable year ending December&nbsp;31, 2017. However, it is not certain that the nature and composition of our income and assets will be as we currently expect, or that we will receive milestone payments in 2017 pursuant to the Allergan
Agreement. If we do not receive milestone payments as anticipated or other non-passive income, we likely will be classified as a PFIC for 2017. As a result, we cannot provide any assurances regarding our PFIC status for the current or future taxable
years. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Risk factors </P></TD>
<TD>See &#147;Risk Factors&#148; and other information included in this prospectus for a discussion of factors that you should consider carefully before deciding to invest in our ordinary shares. </TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Proposed NASDAQ Global Market symbol </P></TD>
<TD>We have applied to have our ordinary shares listed on the NASDAQ Global Market under the symbol &#147;URGN.&#148; </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Directed share program </P></TD>
<TD> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">At our request, the underwriters have reserved 346,154 ordinary shares, or 10% of the shares being offered by this prospectus
</P></TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:9.5pt; font-family:ARIAL">
(excluding the ordinary shares that may be issued upon the underwriters&#146; exercise of their option to purchase additional shares), for sale at the initial public offering price to certain
eligible directors, officers and employees and persons having business or other relationships with us and related persons through a directed share program. The number of our ordinary shares available for sale to the general public in the public
offering will be reduced by the number of shares these individuals purchase. Any reserved shares that are not so purchased will be offered by the underwriters to the general public on the same basis as the other shares offered hereby. Shares
purchased by our directors and officers will be subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> lock-up restriction in the lock-up agreements described in &#147;Underwriting&#151;No Sales of Similar Securities&#148;. Jefferies LLC and
Cowen and Company, LLC, in their sole discretion, may release any of the securities subject to these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time. We have agreed to indemnify the underwriters conducting the directed share
program against certain liabilities and expenses, including liabilities under the Securities Act, in connection with the directed share program. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise stated, the number of ordinary shares to be outstanding after this offering is based on 2,305,743&nbsp;ordinary shares outstanding as of December 31,
2016 and assumes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance by us of 3,461,538 ordinary shares in this offering; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of 5,193,427 ordinary shares upon the conversion of all Series A preferred shares into ordinary shares, which will occur automatically upon the closing of this offering; </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">but excludes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,399,499 ordinary shares reserved for issuance under our 2010 Israeli Share Option Plan upon the exercise of outstanding options at a weighted average exercise price of $4.75 per share; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">304,000 ordinary shares reserved for issuance upon the vesting of outstanding restricted share units; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">278,400 ordinary shares reserved for issuance upon the achievement of certain milestones under the Vesimune asset purchase agreement with Telormedix SA; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of 728,312 Series A-1 preferred shares upon the exercise of outstanding warrants to purchase Series A-1 preferred shares (assuming their exercise for cash) and the conversion thereof into ordinary shares,
which will occur automatically upon the closing of this offering; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1.4 million ordinary shares available for issuance pursuant to the terms of our 2017 Equity Incentive Plan. </TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless
otherwise indicated, all information in this prospectus: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assumes an initial public offering price of $13.00 per ordinary share, the midpoint of the range set forth on the cover of this prospectus; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assumes no exercise of the underwriters&#146; option to purchase up to 519,230 additional ordinary shares; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reflects a 3.2-for-1 share split effected on April&nbsp;19, 2017, by means of distribution of a share dividend of 2.2 ordinary shares for each ordinary share then outstanding; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">gives effect to the adoption of our amended and restated articles of association prior to the closing of this offering, which will replace our amended and restated articles of association as currently in effect.
</TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain of our existing investors and their affiliated entities and other entities have indicated an interest in purchasing up to an aggregate of
approximately $20.0 million worth of our ordinary shares in this offering at the initial public offering price. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell
more, less or no shares in this offering to any of these persons and any of these persons may determine to purchase more, less or no shares in this offering. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following tables present summary financial data for our business. We derived the summary statements of operations data for the years ended December&nbsp;31,
2016 and 2015 from our audited financial statements included elsewhere in this prospectus. We maintain our books and records in U.S. dollars, and prepare our financial statements in accordance with accounting principles generally accepted in the
United States, or U.S. GAAP, as issued by the Financial Accounting Standards Board, or FASB. You should read this data together with our financial statements and related notes appearing elsewhere in this prospectus and the information under the
captions &#147;Capitalization&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results are not necessarily indicative of our future results, and our interim period
results are not necessarily indicative of results to be expected for a full year or any other interim period. </I></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands, except share and<BR>per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Statements of operations data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Finance expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss per ordinary share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average number of ordinary shares outstanding used in computing loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO<BR>FORMA<SUP STYLE="font-size:85%; vertical-align:top">(1) </SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA&nbsp;AS<BR>ADJUSTED<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">63,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Data presented on a pro forma basis to reflect the automatic conversion of all outstanding preferred shares into an aggregate of 5,193,427 ordinary shares. As of December 31, 2016, we had outstanding warrants to
purchase 728,312 Series&nbsp;A-1 preferred shares at an exercise price of $7.81&nbsp;per share. The warrants will expire upon the closing of this offering, unless they are exercised beforehand. If the warrants are exercised for cash in full, we
would expect that our cash and cash equivalents would increase by $5.1&nbsp;million, our total shareholders&#146; equity in respect of Series A-1 preferred shares would increase by $2,000 and our additional paid-in capital would increase by
$8.7&nbsp;million. If the warrants are net share settled in full, the aggregate impact on our capitalization would be an increase of 290,766 shares. The Series A-1 preferred shares convert on a one-for-one basis with ordinary shares.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Data presented on a pro forma as adjusted basis to give further effect to the sale of 3,461,538 ordinary shares in this
offering at an assumed initial public offering price of $13.00 per ordinary share, which is the midpoint of the price range set forth on </P></TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the cover of this prospectus, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. At December 31, 2016, actual cash and cash equivalents
reflected $1,427,700 in offering expenses paid through that date, liabilities included $521,000 of accrued offering expenses, and assets included $250,000 of non-current assets related to offering expenses. Each $1.00 increase or decrease in the
assumed initial public offering price of $13.00 per ordinary share, which is the midpoint of the price range set forth on the cover of this prospectus, would increase or decrease, respectively, the amount of cash and cash equivalents, total assets
and total shareholders&#146; equity by $3.2 million, assuming the number of ordinary shares offered by us, as set forth on the cover of this prospectus, remains the same and after deducting the underwriting discounts and commissions and estimated
offering expenses payable by us. We may also increase or decrease the number of ordinary shares we are offering. An increase or decrease of 100,000 in the number of ordinary shares we are offering would increase or decrease, respectively, the amount
of securities, cash and cash equivalents, total assets and total shareholders&#146; equity by $1.2&nbsp;million, assuming the assumed initial public offering price per ordinary share, as set forth on the cover of this prospectus, remains the same.
The pro forma as adjusted information is illustrative only, and we will adjust this information based on the actual initial public offering price and other terms of this offering determined at pricing. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Working capital is defined as total current assets minus total current liabilities. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing in our ordinary shares involves a high degree of risk. You should carefully consider the risks and uncertainties described below, in addition to the other
information set forth in this prospectus, including the financial statements and the related notes included elsewhere in this prospectus, before purchasing our ordinary shares. If any of the following risks actually occurs, our business, financial
condition, cash flows and results of operations could be negatively impacted. In that case, the trading price of our ordinary shares would likely decline and you might lose all or part of your investment. Additional risks and uncertainties not
currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, cash flows and results of operations. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have a limited operating history and have incurred significant losses and negative cash flows since our inception, and we anticipate that we will continue to
incur significant losses and negative cash flows for the foreseeable future, which makes it difficult to assess our future viability. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical
stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We are not profitable and have incurred net losses in each period since we commenced operations in 2004, including net losses of
$1.9&nbsp;million and $12.7&nbsp;million for the years ended December&nbsp;31, 2016 and 2015, respectively. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Our ability to ultimately
achieve recurring revenues and profitability is dependent upon our ability to successfully complete the development of our product candidates, obtain necessary regulatory approvals for and successfully manufacture, market and commercialize our
products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that we will continue to expend substantial resources in the foreseeable future for the clinical development of our current product candidates
or any additional product candidates and indications that we may choose to pursue in the future. These expenditures will include costs associated with research and development, conducting preclinical studies and clinical trials, and payments for
third-party manufacturing and supply, as well as sales and marketing of any of our product candidates that are approved for sale by regulatory agencies. Because the outcome of any clinical trial is highly uncertain, we cannot reasonably estimate the
actual amounts necessary to successfully complete the development and commercialization of our clinical stage and preclinical drug candidates and any other drug candidates that we may develop in the future. Other unanticipated costs may also arise.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our future capital requirements depend on many factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of, and the costs involved in, clinical development and obtaining regulatory approvals for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in regulatory requirements during the development phase that can delay or force us to stop our activities related to any of our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of commercialization activities if our products are approved for sale, including marketing, sales and distribution costs; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of third-party manufacturing of our products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and characteristics of any other product candidates we develop or acquire; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish and maintain strategic collaborations, licensing or other commercialization arrangements, and the terms and timing of such arrangements; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent and rate of market acceptance of any approved products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the expenses needed to attract and retain skilled personnel; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs associated with being a public company; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including potential litigation costs and the outcome of such litigation; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing, receipt and amount of sales of, or royalties on, future approved products, if any; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any product liability or other lawsuits related to our products; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">scientific breakthroughs in the field of urothelial cancer treatment and diagnosis that could significantly diminish the need for our product candidates or make them obsolete; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in reimbursement policies that could have a negative impact on our future revenue stream. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we have
limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Drug
development is a highly speculative undertaking and involves a substantial degree of risk. To date, we have not obtained any regulatory approvals for any of our product candidates, commercialized any of our product candidates or generated any
material revenue. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will require substantial additional financing to achieve our goals, and a failure to obtain this capital when needed and on acceptable
terms, or at all, could force us to delay, limit, reduce or terminate our product development, commercialization efforts or other operations. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our
inception, almost all of our resources have been dedicated to the preclinical and clinical development of our lead product candidates, MitoGel and VesiGel. As of December&nbsp;31, 2016, we had cash and cash equivalents of $21.4&nbsp;million. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe we have sufficient cash and cash equivalents to fund our operating expenses and capital expenditure requirements for at least the next 12 months. We expect
that we will require additional capital to complete clinical trials, obtain regulatory approval for and commercialize our product candidates. However, our operating plan may change as a result of many factors currently unknown to us, and we may need
to seek additional funds sooner than planned, through public or private equity, convertible debt or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing
arrangements, or a combination of these approaches. In any event, we will require additional capital to pursue preclinical and clinical activities, and pursue regulatory approval for, and to commercialize, our pipeline product candidates. Even if we
believe that we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any additional fundraising efforts may divert the attention of our management from day-to-day activities, which may adversely affect our ability to develop and
commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may negatively impact the holdings or
the rights of our shareholders, and the issuance of additional securities, whether equity or debt, by us or the possibility of such issuance may cause the market price of our shares to decline. The incurrence of indebtedness could result in
increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights
and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than would be desirable and
we may be required to relinquish rights to some of our technologies, intellectual property or product candidates or otherwise agree to terms unfavorable to us, any of which may harm our business, financial condition, cash flows, operating results
and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If adequate funds are not available to us on a timely basis, we may be required or choose to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for our product candidates or any of our future product candidates; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay, limit, reduce or terminate our other research and development activities; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay, limit, reduce or terminate our establishment or expansion of manufacturing, sales and marketing or distribution capabilities or other activities that may be necessary to commercialize MitoGel, VesiGel or any of
our other product candidates. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which
could harm our business, financial condition, cash flows and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution to our shareholders, including purchasers of ordinary shares in this
offering, restrict our operations or require us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Until such time, if ever, as we can
generate substantial product revenues, we expect to finance our cash needs through equity, convertible debt or debt financings, as well as selectively continuing to enter into collaborations, strategic alliances and licensing arrangements. We do not
currently have any committed external source of funds other than funding under the existing exclusive license agreement we entered into with Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc, in
October 2016, or the Allergan Agreement. Under the Allergan Agreement, we may receive additional material milestone payments upon the successful completion of certain development, regulatory and commercial milestones and royalties with respect to
future sales of collaboration products by Allergan. Allergan may unilaterally terminate our existing collaboration for any reason upon advance notice. To the extent that we raise additional capital through the sale of equity or convertible debt
securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as an ordinary shareholder. Debt financing, if available, may involve agreements
that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring and distributing dividends, and may be secured by all or a portion of our assets. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we raise funds by selectively continuing to enter into additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to
relinquish additional valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity,
convertible debt or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise
prefer to develop and market ourselves. If we are unable to raise additional funds through other collaborations, strategic alliances or licensing arrangements, we may be required to terminate product development or future commercialization efforts
or to cease operations altogether. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Business and Strategy </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are dependent on the success of our lead product candidates, including obtaining regulatory approval to market our product candidates in the United States.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have invested almost all of our efforts and financial resources in the research and development of our lead product candidates, MitoGel and VesiGel. Our
future success depends on our ability to market and sell these product candidates. However, these drugs are in various stages of clinical development and each of these drugs has yet to receive marketing approval from the U.S. Food and Drug
Administration, or the FDA, or any other regulatory agency. Our product candidates&#146; marketability is subject to significant risks associated with successfully completing current and future clinical trials, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s timely acceptance of our IND filing for VesiGel, which we intend to submit in the second half of 2017, and our other product candidates for which we plan to file an IND. Without such IND acceptances, we
will be unable to commence clinical trials in the United States; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s acceptance of our parameters for regulatory approval relating to MitoGel, VesiGel and our other product candidates, including our proposed indications, primary and secondary endpoint assessments and
measurements, safety evaluations and regulatory pathways; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s acceptance of the number, design, size, conduct and implementation of our clinical trials, our trial protocols and the interpretation of data from preclinical studies or clinical trials;
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully complete the clinical trials of our product candidates, including timely patient enrollment and acceptable safety and efficacy data and our ability to demonstrate the safety and efficacy of
the product candidates undergoing such clinical trials; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to complete in a timely fashion the single pivotal Phase 3 clinical trial for MitoGel for the treatment of low-grade UTUC, and that the single pivotal Phase 3 clinical trial, even if successfully completed,
will be sufficient to support a New Drug Application, or NDA, submission; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA&#146;s acceptance of the sufficiency of the data we collected from our preclinical studies and are collecting from
our ongoing Phase 2a clinical trial with VesiGel in low-grade non-muscle invasive bladder </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
cancer, or NMIBC, and expect to collect from toxicological studies that we may conduct to support the submission of an IND without requiring additional preclinical studies or clinical trials, and
our ability to commence a Phase 2b clinical trial in the United States for VesiGel in low-grade NMIBC following an IND submission, if accepted; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s willingness to schedule an advisory committee meeting in a timely manner to evaluate and decide on the approval of our potential future NDAs for MitoGel and VesiGel; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the recommendation of the FDA&#146;s advisory committee to approve our applications to market MitoGel and VesiGel and our other product candidates in the United States, without limiting the approved labeling,
specifications, distribution or use of the products, or imposing other restrictions; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s satisfaction with the safety and efficacy of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of adverse events associated with our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timely and satisfactory performance by third-party contractors of their obligations in relation to our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our success in educating physicians and patients about the benefits, administration and use of our product candidates, if approved, particularly in light of the fact that there are currently no drugs approved by the FDA
for the treatment of UTUC and the FDA has not approved a drug for the treatment of NMIBC in more than 15 years; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability, perceived advantages, relative cost, safety and efficacy of alternative and competing treatments for the indications addressed by our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our marketing, sales and distribution strategy, and operations, as well as that of any current and future licensees; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to develop, validate and maintain a commercially viable manufacturing process that is compliant with current good manufacturing practices, or cGMP; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain, protect and enforce our intellectual property rights with respect to our product candidates; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully train users with respect to the safe instillation of MitoGel and VesiGel. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of these
clinical, regulatory and commercial risks are beyond our control. Accordingly, we cannot assure you that we will be able to advance any of our product candidates through clinical development, or to obtain regulatory approval of or commercialize any
of our product candidates. If we fail to achieve these objectives or overcome the challenges presented above, we could experience significant delays or an inability to successfully commercialize our product candidates. Accordingly, we may not be
able to generate sufficient revenues through the sale of our product candidates to enable us to continue our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be unable to obtain regulatory
approval for our product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The research, development, testing, manufacturing, labeling, packaging, approval, promotion, advertising, storage,
recordkeeping, marketing, distribution, post-approval monitoring and reporting, and export and import of drug products are subject to extensive regulation by the FDA, and by foreign regulatory authorities in other countries. These regulations differ
from country to country. To gain approval to market our product candidates, we must provide clinical data that adequately demonstrate the safety and efficacy of the product for the intended indication. We have not yet obtained regulatory approval to
market any of our product candidates in the United States or any other country. Our business depends upon obtaining these regulatory approvals. There are currently no drugs approved by the FDA for the treatment of UTUC and only three drugs have been
approved by the FDA for NMIBC, with the last approval having occurred over 15 years ago.&nbsp;The FDA can delay, limit or deny approval of our product candidates for many reasons, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to satisfactorily demonstrate that the product candidates are safe and effective for the target indication; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s disagreement with our trial protocol, the interpretation of data from preclinical studies or clinical trials, or adequate conduct and control of clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the population studied in the clinical trial may not be sufficiently broad or representative to assess safety in the patient population for which we seek approval; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to demonstrate that clinical or other benefits of our product candidates outweigh any safety or other perceived risks; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s determination that the 505(b)(2) regulatory pathway is not available for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s determination that additional preclinical studies or clinical trials are required; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s non-approval of the formulation, labeling or the specifications of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s failure to accept the manufacturing processes or facilities of third-party manufacturers with which we contract; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential for approval policies or regulations of the FDA to significantly change in a manner rendering our clinical data insufficient for approval; or </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">resistance to approval from the FDA&#146;s advisory committee for any reason including safety or efficacy concerns. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we eventually complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA may grant approval contingent on the
performance of costly and potentially time-consuming additional post-approval clinical trials or subject to restrictive Risk Evaluation and Mitigation Strategies. The FDA may also approve our product candidates for a more limited indication or a
narrower patient population than we originally requested, and the FDA may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. To the extent we seek regulatory approval in
foreign countries, we may face challenges similar to those described above with regulatory authorities in applicable jurisdictions. Any delay in obtaining, or inability to obtain, applicable regulatory approval for any of our product candidates
would delay or prevent commercialization of our product candidates and would thus negatively impact our business, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>To
date, we have only generated limited clinical data for our product candidates. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Positive results in preclinical testing and early clinical trials do not
ensure that later clinical trials will be successful. A number of pharmaceutical companies have suffered significant setbacks in clinical trials, including in Phase&nbsp;3 clinical trials, after promising results in preclinical testing and early
clinical trials. These setbacks have included negative safety and efficacy observations in later clinical trials, including previously unreported adverse effects. For example, to date, we have enrolled only 22 patients into the ongoing UTUC
Compassionate Use program of MitoGel. Thus far only 13 patients who were confirmed with low-grade UTUC disease have been evaluated for response, and eight achieved a complete response and the remaining five achieved a partial response at the primary
evaluation time. Of the eight patients who achieved a complete response at the primary evaluation time, three have subsequently experienced recurrences to date. The data generated by our Compassionate Use program may not be as reliable as data
generated from a clinical trial. For instance, consistent with the nature of Compassionate Use programs, our Compassionate Use program is investigator-initiated and driven, with no uniform protocol with respect to dosing or primary endpoint. The
data collected in our Compassionate Use program is based on individual physician reports and has not undergone independent monitoring or quality assurance. Further, we have only evaluated patients who have been diagnosed with tumors up to three
centimeters in diameter. Due to the intricate anatomy of the renal pelvis and the calyceal system, we also face the risk that MitoGel may not reach all tumors. To date in our preclinical testing, Compassionate Use program and clinical trials, we
have observed several adverse events and serious adverse events, consisting primarily of burning sensation, rash, urgency in urination and pain during urination. These adverse events are known MMC-related adverse events and are indicated as
potential side effects of MMC usage on the MMC label. However, we cannot assure you that adverse events related to MitoGel and VesiGel that are not directly attributable to MMC specifically will not occur. Our Compassionate Use program is ongoing
and prior results may not be replicated in additional Compassionate Use patients or in patients with tumors larger than three centimeters in diameter, or in our single pivotal Phase&nbsp;3 clinical trial, which is currently expected to evaluate
approximately 70 patients. In addition, this trial may not be successful. If our clinical trials do not ultimately indicate that our product candidates are safe or efficacious for their intended application, the FDA may not approve any NDA that we
may file to market such product candidates, and our business would not be able to generate revenue from the sale of any such product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have limited experience in conducting clinical trials and have never obtained approval for any product
candidates, and may be unable to do so&nbsp;successfully. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a company, we have limited experience in conducting clinical trials and have never progressed
a product candidate through to regulatory approval. In part because of this lack of experience, our clinical trials may require more time and incur greater costs than we anticipate. We cannot be certain that the planned clinical trials will begin or
conclude on time, if at all. Large-scale trials will require significant additional financial and management resources. In addition, due to the significant lack of drug development for non-muscle invasive urothelial cancers over the past 15 years,
neither we nor any third-party clinical investigators, clinical research organizations, or CROs, and/or consultants are likely to have extensive experience conducting clinical trials for the indications we are targeting. Third-party clinical
investigators do not operate under our control. Any performance failure on the part of such third parties could delay the clinical development of our product candidates or delay or prevent us from obtaining regulatory approval or commercializing our
current or future product candidates, depriving us of potential product revenue and resulting in additional losses. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have not applied for regulatory
approvals to market any of our other product candidates, and we may be delayed in obtaining or failing to obtain such regulatory approvals and to commercialize our product candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The process of developing, obtaining regulatory approval for and commercializing our product candidates is long, complex, costly and uncertain, and delays or failure
can occur at any stage. The research, testing, manufacturing, labeling, marketing, sale and distribution of drugs are subject to extensive and rigorous regulation by the FDA and foreign regulatory agencies, as applicable. These regulations are
agency-specific and differ by jurisdiction. We are not permitted to market any product candidate in the United States until we receive approval of an NDA from the FDA, or in any foreign countries until we receive the requisite approval from the
respective regulatory agencies in such countries. To gain approval of an NDA or other equivalent regulatory approval, we must provide the FDA or relevant foreign regulatory authority with preclinical and clinical data that demonstrates the safety
and efficacy of the product for the intended indication. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before we can submit an NDA to the FDA or comparable similar applications to foreign regulatory
authorities, we must conduct Phase 3 clinical trials, or a pivotal/registration trial equivalent, for each product candidate. We commenced a single pivotal, open-label, single-arm Phase 3 clinical trial of MitoGel for the treatment of low-grade UTUC
in the first quarter of 2017. This clinical trial is substantially broader than our previous and ongoing Phase 1 and Phase 2 clinical trials and the Compassionate Use program for MitoGel for the treatment of patients with UTUC and requires us to
enroll a considerably larger number of patients in multiple clinics and medical centers across multiple countries. Based on our discussions with the FDA, our current expectation is that our pivotal clinical trial for MitoGel will evaluate
approximately 70 patients. We are also planning to commence a Phase 2b clinical trial of VesiGel in the first half of 2018. Before commencing a clinical trial for VesiGel in the United States, we must first file an IND, which must be accepted by the
FDA. We cannot assure you that the FDA will not decide to materially alter these parameters, including potentially requiring a pivotal study with a control arm, during the trial or require us to conduct more than one pivotal trial before submitting
an NDA. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Phase 3 clinical trials often produce unsatisfactory results even though prior clinical trials were successful. Moreover, the results of clinical
trials may be unsatisfactory to the FDA or foreign regulatory authorities even if we believe those clinical trials to be successful. The FDA or applicable foreign regulatory agencies may suspend one or all of our clinical trials or require that we
conduct additional clinical, preclinical, manufacturing, validation or drug product quality studies and submit that data before considering or reconsidering any NDA or comparable foreign regulatory application that we may submit. Depending on the
extent of these additional studies, approval of any applications that we submit may be significantly delayed or may cause the termination of such programs, or may require us to expend more resources than we have available. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of these outcomes occur, we may not receive regulatory approval for the corresponding product candidates, and our business would not be able to generate revenue
from the sale of any such product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be able to advance our preclinical product candidates into clinical development and through regulatory
approval and commercialization. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain of our product candidates are currently in preclinical development and are therefore currently subject to the risks
associated with preclinical development, including the risks associated with: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">generating adequate and sufficient preclinical safety and efficacy data in a timely fashion to support the initiation of clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining regulatory approval to commence clinical trials in any jurisdiction, including the filing and acceptance of INDs; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">contracting with the necessary parties to conduct a clinical trial; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enrolling sufficient numbers of patients in clinical trials; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">timely manufacture of sufficient quantities of the product candidate for use in clinical trials. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are unsuccessful
in advancing our preclinical product candidates into clinical trials in a timely fashion, our business may be harmed. Even if we are successful in advancing our preclinical product candidates into clinical development, their success will be subject
to all of the clinical, regulatory and commercial risks described elsewhere in &#147;Risk Factors.&#148; Accordingly, we cannot assure you that we will be able to develop, obtain regulatory approval for, commercialize or generate significant revenue
from our product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical drug development involves a lengthy and expensive process with an uncertain outcome, results of earlier studies and
trials may not be predictive of future trial results, and our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. A failure of one or more of our clinical trials can occur at
any time during the clinical trial process. We do not know whether future clinical trials, if any, will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. Clinical trials can
be delayed, suspended or terminated for a variety of reasons, including failure to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">generate sufficient preclinical, toxicology, or other <I>in vivo</I> or <I>in vitro </I>data to support the initiation or continuation of clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain regulatory approval, or feedback on trial design, in order to commence a trial; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identify, recruit and train suitable clinical investigators; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reach agreement on acceptable terms with prospective CROs and clinical trial sites, and have such CROs and sites effect the proper and timely conduct of our clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain and maintain institutional review board, or IRB, approval at each clinical trial site; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identify, recruit and enroll suitable patients to participate in a trial; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">have a sufficient number of patients complete a trial or return for post-treatment follow-up; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ensure clinical investigators and clinical trial sites observe trial protocol or continue to participate in a trial; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">address any patient safety concerns that arise during the course of a trial; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">address any conflicts with new or existing laws or regulations; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add a sufficient number of clinical trial sites; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacture sufficient quantities at the required quality of product candidate for use in clinical trials; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">raise sufficient capital to fund a trial. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patient enrollment is a significant factor in the timing and success of
clinical trials and is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical
trials and clinicians&#146; and patients&#146; or caregivers&#146; perceptions as to the potential advantages of the drug candidate being studied in relation to other available therapies, including any new drugs or treatments that may be developed
or approved for the indications we are investigating. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in
which such trials are being conducted, by the trial&#146;s data safety monitoring board, by the FDA or by the applicable foreign regulatory authorities. Such authorities may suspend or terminate one or more of our clinical trials due to a number of
factors, including our failure to conduct the clinical trial in accordance with relevant regulatory requirements or clinical protocols, inspection of the clinical trial operations or trial site by the FDA or foreign regulatory authorities resulting
in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the
clinical trial. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we experience delays in carrying out or completing any clinical trial of our product candidates, the commercial prospects of our product
candidates may be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate
development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business and financial condition. In addition, many of the factors that cause, or lead
to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The
market opportunities for our product candidates may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Cancer therapies are sometimes characterized as first-line, second-line or third-line. When cancer is detected early enough, first-line therapy, often chemotherapy,
hormone therapy, surgery, radiotherapy or a combination of these, is sometimes adequate to cure the cancer or prolong life. Second- and third-line therapies are administered to patients when prior therapy is not or is no longer effective. For
urothelial cancers, the current first-line standard of care is surgery designed to remove one or more tumors.&nbsp;Chemotherapy is currently used in treating urothelial cancer only as an adjuvant, or supplemental therapy, after tumor
resection.&nbsp;We are designing our lead product candidates with the goal of replacing surgery as the first-line standard of care for certain urothelial cancers. We intend to seek approval of MitoGel for the first-line treatment of low-grade UTUC
and of VesiGel for the first-line treatment of low-grade NMIBC in both cases as a chemoablation agent to replace tumor resection surgeries. However, there is no guarantee that our product candidates, if approved, would be approved for first-line or
even later lines of therapy, and, that prior to any such approvals, we will not have to conduct additional clinical trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our projections of both the number of
people who have the cancers we are targeting, as well as the subset of people with these cancers who have previously failed prior treatments, and who have the potential to benefit from treatment with our product candidates, are based on our beliefs
and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new studies may change the estimated
incidence or prevalence of these cancers and the number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment
with our product candidates. Even if we receive regulatory approval for our product candidates and obtain significant market share, because the potential target populations are small, we may never achieve profitability without obtaining regulatory
approval for additional indications, including the use of the products as first- or second-line therapy. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>MitoGel or VesiGel or any of our other product
candidates may produce undesirable side effects that we may not have detected in our previous preclinical studies and clinical trials. This could prevent us from gaining marketing approval or market acceptance for these product candidates, or from
maintaining such approval and acceptance, and could substantially increase commercialization costs and even force us to cease operations. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As with most
pharmaceutical products, use of MitoGel or VesiGel or our other product candidates may be associated with side effects or adverse events that can vary in severity and frequency. Our proprietary reverse thermal gelation hydrogel, or RTGel, which is
used in the formulation of MitoGel and VesiGel, has not undergone extensive testing in humans. Side effects or adverse events associated with the use of MitoGel and VesiGel may be observed at any time, including in clinical trials or once a product
is commercialized, and any such side effects or adverse events may negatively affect our ability to obtain regulatory approval or market our product candidates. To date in our clinical trials, we have observed several adverse events and serious
adverse events, consisting primarily of burning sensation, rash, urgency in urination and pain during urination. These adverse events are known MMC-related adverse events and are indicated as potential side effects of MMC usage on the MMC label.
However, we cannot assure you that we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
will not observe additional drug-related serious adverse events in the future or that the FDA will not determine them as such. Side effects such as toxicity or other safety issues associated with
the use of our product candidates could require us to perform additional studies or halt development or sale of these product candidates or expose us to product liability lawsuits, which will harm our business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, the commenced single pivotal Phase 3 clinical trial for MitoGel and the planned Phase 2b clinical trial for VesiGel will involve a larger patient base than
that previously studied, and the commercial marketing of MitoGel and VesiGel, if approved, will further expand the clinical exposure of the drugs to a wider and more diverse group of patients than those participating in the clinical trials, which
may identify undesirable side effects caused by these products that were not previously observed or reported. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA and foreign regulatory agency regulations
require that we report certain information about adverse medical events if our products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date upon which we become aware of the
adverse event as well as the nature and severity of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event,
especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or a foreign regulatory agency
could take action including enforcing a hold on or cessation of clinical trials, withdrawal of approved drugs from the market, criminal prosecution, the imposition of civil monetary penalties or seizure of our products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, in the event we discover the existence of adverse medical events or side effects caused by one of our product candidates, a number of other potentially
significant negative consequences could result, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to file an NDA or similar application for our product candidates because of insufficient risk-reward, or the denial of such application by the FDA or foreign regulatory authorities; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authorities suspending or withdrawing their approval of the product; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authorities requiring the addition of labeling statements, such as warnings or contraindications or distribution and use restrictions; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authorities requiring us to issue specific communications to healthcare professionals, such as letters alerting them to new safety information about our product, changes in dosage or other
important information; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authorities issuing negative publicity regarding the affected product, including safety communications; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our being limited with respect to the safety-related claims that we can make in our marketing or promotional materials; </TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our being required to change the way the product is administered, conduct additional preclinical studies or clinical trials or restrict or cease the distribution or use of the product; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our being sued and held liable for harm caused to patients. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any of these events could prevent us from achieving
approval or market acceptance of the affected product candidate and could substantially increase commercialization costs or even force us to cease operations. We cannot assure you that we will resolve any issues related to any product-related
adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if our product candidates receive marketing approval, we may continue to face future developmental and regulatory difficulties. In addition, we are subject
to government regulations and we may experience delays in obtaining required regulatory approvals to market our proposed product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we
complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA or applicable foreign regulatory agency may grant approval contingent on the performance of additional costly post-approval clinical trials,
risk mitigation requirements and surveillance requirements to monitor the safety or efficacy of the product, which could negatively impact us by reducing revenues or increasing expenses, and cause the approved product candidate not to be
commercially viable. Absence of long-term safety data may further limit the approved uses of our products, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA or applicable foreign regulatory agency also may approve our product candidates for a more limited indication or a
narrower patient population than we originally requested, or may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. Furthermore, any such approved product will remain
subject to extensive regulatory requirements, including requirements relating to manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, distribution and recordkeeping. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we fail to comply with the regulatory requirements of the FDA or other applicable foreign regulatory authorities, or previously unknown problems with any approved
commercial products, manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposed sanctions or other setbacks, including the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or imposition of restrictions on operations, including costly new manufacturing requirements; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory agency refusal to approve pending applications or supplements to applications; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension of any ongoing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or withdrawal of marketing approval; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an injunction or imposition of civil or criminal penalties or monetary fines; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seizure or detention of products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">bans or restrictions on imports and exports; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issuance of warning letters or untitled letters; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or imposition of restrictions on operations, including costly new manufacturing requirements; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal of regulatory authorities to approve pending applications or supplements to applications. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, various
aspects of our operations are subject to federal, state or local laws, rules and regulations, any of which may change from time to time. Costs arising out of any regulatory developments could be time-consuming and expensive and could divert
management resources and attention and, consequently, could adversely affect our business, financial condition, cash flows and results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if
our product candidates receive regulatory approval, they may fail to achieve the broad degree of physician adoption and use and market acceptance necessary for commercial success. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we obtain FDA or foreign regulatory approvals for our product candidates, the commercial success of such products will depend significantly on their broad
adoption and use by physicians, for approved indications, including, in the case of MitoGel, for the first-line treatment of low-grade UTUC, and in the case of VesiGel, for the first-line treatment of low-grade NMIBC, and for other therapeutic
indications that we may seek to pursue with any of our product candidates. Physicians treating low-grade UTUC and low-grade NMIBC have never had to consider first-line treatments other than surgery. The degree and rate of physician and patient
adoption of our product candidates, if approved, will depend on a number of factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical indications for which the product is approved; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of adverse side effects; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patient satisfaction with the results and administration of our product and overall treatment experience, including relative convenience, ease of use and avoidance of, or reduction in, adverse side effects;
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which physicians recommend our products to patients; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">physicians&#146; and patients&#146; willingness to adopt new therapies in lieu of other products or treatments, including willingness to adopt our lead product candidates as locally-administered drug replacements to
current surgical standards of care; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of treatment, safety and efficacy in relation to alternative treatments, including the recurrence rate of our treatments; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which the costs of our product candidates are reimbursed by third-party payors, and patients&#146; willingness to pay for our products; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether treatment with our product candidates, including the treatment of low-grade UTUC with MitoGel and the treatment of
low-grade NMIBC with VesiGel, will be deemed to be an elective procedure by third-</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
party payors; if so, the cost of treatment would be borne by the patient and would be less likely to be broadly adopted; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">proper training and administration of our products by physicians or nurses; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the revenues and profitability that our products will offer physicians as compared to alternative therapies; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our sales and marketing efforts, especially the success of any targeted marketing efforts directed toward physicians and clinics and any direct-to-consumer marketing efforts we may initiate.
</TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If MitoGel, VesiGel or any of our other product candidates is approved for use, but fails to achieve the broad degree of physician adoption and
market acceptance necessary for commercial success, our operating results and financial condition would be adversely affected. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are not successful in
developing, receiving regulatory approval for and commercializing our preclinical and clinical product candidates other than MitoGel or VesiGel, our ability to expand our business and achieve our strategic objectives could be impaired. </I></B></P>
 <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we will devote a substantial portion of our resources on the continued clinical testing and potential approval of MitoGel for the treatment of low-grade
UTUC and VesiGel for the treatment of low-grade NMIBC, another key element of our strategy is to discover, develop and commercialize a portfolio of products based on our proprietary RTGel platforms to serve additional therapeutic markets. We are
seeking to do so through our internal research programs, but our resources are limited, and those that we have are geared towards clinical testing and seeking regulatory approval of MitoGel, VesiGel and our other existing product candidates. We may
also explore strategic collaborations for the development or acquisition of new products, but we may not be successful in entering into such relationships. While we have commenced a single pivotal Phase 3 clinical trial for MitoGel and plan to
commence a Phase 2b clinical trial for VesiGel, all of our other potential product candidates remain in the preclinical and/or early clinical stages of development. Research programs to identify product candidates require substantial technical,
financial and human resources, regardless of whether any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical
development for many reasons, including: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the research methodology used may not be successful in identifying potential product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competitors may develop alternatives that render our product candidates obsolete or less attractive; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may in a subsequent trial be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">intellectual property or other proprietary rights of third parties for product candidates we develop may potentially block our entry into certain markets, or make such entry economically impracticable.
</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we fail to develop and successfully commercialize other product candidates, our business and future prospects may be harmed and our business will
be more vulnerable to any problems that we encounter in developing and commercializing our product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our product candidates, if approved, will face
significant competition with competing technologies and our failure to compete effectively may prevent us from achieving significant market penetration. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biopharmaceutical industry is intensely competitive and subject to rapid and significant technological change. Our potential competitors include large and
experienced companies that enjoy significant competitive advantages over us, such as greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition and more experience and expertise in
obtaining marketing approvals from the FDA and foreign regulatory authorities. These companies may develop new drugs to treat the indications that we target, or seek to have existing drugs approved for use for the treatment of the indications that
we target. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are aware that other companies, such as Merck Sharp &amp; Dohme Corp., Viventia Bio Inc., Telesta Therapeutics Inc., Heat Biologics, Inc., Viralytics
Limited, AADi, LLC, Biocancell Ltd., Halozyme Therapeutics, Inc., Astellas </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Pharma Inc., Cold Genesys, Inc., Altor BioScience Corporation, FKD Therapies Oy, Nippon Kayaku Co., Ltd, Spectrum Pharmaceuticals, Inc., Taris Biomedical LLC and&nbsp;Handok Inc., are conducting
or have recently conducted clinical trials for product candidates for the treatment of low-grade and high-grade NMIBC, including CIS. In addition, we are aware of several pharmaceutical companies that are developing drug candidates for
muscle-invasive bladder cancer. On May 18, 2016, the FDA approved Tecentriq (Atezolizumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma, a form of muscle invasive bladder cancer. We do not know whether these
potential competitors are already developing, or plan to develop, low-grade UTUC or high-grade UTUC treatments or treatments for other indications that we are pursuing, and we may be unable to ascertain whether such activities are underway in the
future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment
in this industry. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis products that are more effective, easier to administer or less costly than our product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we face competition from existing standards of treatment, including transurethral resection of bladder tumor, or TURBT, surgery for bladder cancer. If we
are not able to demonstrate that our product candidates are at least as safe and effective as such courses of treatment, medical professionals may not adopt our product candidates in replacement of the existing standard of care, which is first-line
tumor surgical procedures. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have no experience in marketing or distributing products and no internal capability to do so, and are therefore subject to
certain risks in relation to the commercialization of our product candidates once approved. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have not yet established a commercial organization for the
marketing, sale and distribution of our product candidates. Therefore, even if we receive approval to market our product candidates in the United States or other markets, in order to successfully commercialize our product candidates, we will need to
either build marketing, sales, distribution, managerial and other non-technical capabilities or contract with third parties to obtain these capabilities. This involves many challenges, such as recruiting and retaining talented personnel, training
employees, setting the appropriate system of incentives, managing additional headcount and integrating new business units into an existing corporate infrastructure. The development of our own sales infrastructure or contracting with third parties
will involve substantial expense, much of which we will incur well in advance of any marketing or sales. Moreover, we do not have experience as a company in establishing a significant sales infrastructure, and we cannot be certain that we will
successfully develop this capability or contract successfully with third parties for the necessary services. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain personnel for medical
affairs, marketing and sales. If we fail to establish an effective sales and marketing infrastructure or contract with third parties to do so, we will be unable to successfully commercialize our product candidates, which in turn would have an
adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have entered into a licensing agreement and in the future may enter into
collaborations with other third parties for the development or commercialization of our product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2016, we entered into the Allergan Agreement. Under the Allergan Agreement, we granted Allergan an exclusive worldwide license to research, develop,
manufacture and commercialize pharmaceutical products that contain RTGel and clostridial toxins (including BOTOX), alone or in combination with certain other active ingredients, which we refer to collectively as the Licensed Products. Either party
may terminate the Allergan Agreement for uncured material breach by the other party and for the insolvency of the other party. We may terminate the Allergan Agreement if Allergan or its affiliates challenges any of our patents licensed to Allergan
and such patent challenge is not required under a court order or subpoena and is not a defense against a claim, action or proceeding asserted by us, our affiliates or licensees against Allergan, its affiliates or sublicensees. In addition, Allergan
may unilaterally terminate the Allergan Agreement for any reason upon advance notice. If Allergan has the right to terminate the Allergan Agreement due to our uncured material breach, Allergan may elect to continue the agreement and reduce all
future milestone and royalty payment obligations to us by a specified percentage. In the event of any termination of the Allergan Agreement, Allergan will assign or grant a right of reference to any regulatory documentation related to RTGel to us,
all rights and licenses to Allergan will terminate, and the license Allergan granted to us under their improvements to RTGel will continue. If any of these events occurs, we will not be able to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
obtain, or may be delayed in obtaining, marketing approvals for the Licensed Products and will not be able to, or may be delayed in our efforts to, successfully commercialize the Licensed
Products, and our business will be harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may utilize a variety of types of collaboration, distribution and other marketing arrangements with third parties to
develop our product candidates and commercialize our approved product candidates, if any. We are not currently party to any such arrangement. Our ability to generate revenues from these arrangements will depend on our collaborators&#146; abilities
and efforts to successfully perform the functions assigned to them in these arrangements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our existing collaboration with Allergan and any future collaborations
that we enter into, may pose a number of risks, including the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not perform their obligations as expected; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product candidates developed by collaborators may not perform sufficiently in clinical trials to be determined to be safe and effective, thereby delaying or terminating the drug approval process and reducing or
eliminating milestone payments to which we would otherwise be entitled if the product candidates had successfully met their endpoints and/or received FDA approval; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not pursue development and commercialization of our product candidates that receive marketing approval or may elect not to continue or renew development or commercialization programs based on clinical
trial results, changes in the collaborators&#146; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new
formulation of a product candidate for clinical testing; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are
more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the
commercialization of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or
products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or
commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would divert management attention and resources, be
time-consuming and expensive; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual
property or proprietary information or expose us to potential litigation; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product
candidates. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all.
If the Allergan Agreement, and any future collaborations that we enter into, do not result in the successful development and commercialization of products or if one of our collaborators terminates its
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our
development of our product candidates could be delayed and we may need additional resources to develop our product candidates. All of the risks relating to product development, regulatory approval and commercialization described in this prospectus
also apply to the activities of our collaborators. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, subject to its contractual obligations to us, if a collaborator of ours were to be involved in a
business combination, it might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new
collaborators and our perception in the business and financial communities could be harmed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If in the future we acquire or in-license technologies or product
candidates, we may incur various costs, may have integration difficulties and may experience other risks that could harm our business and results of operations. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the future, we may acquire or in-license additional product candidates and technologies. Any product candidate or technologies we in-license or acquire will likely
require additional development efforts prior to commercial sale, including extensive preclinical or clinical testing, or both, and approval by the FDA and applicable foreign regulatory authorities, if any. All product candidates are prone to risks
of failure inherent in pharmaceutical product development, including the possibility that the product candidate, or product developed based on in-licensed technology, will not be shown to be sufficiently safe and effective for approval by regulatory
authorities. If intellectual property related to product candidates or technologies we in-license is not adequate, we may not be able to commercialize the affected products even after expending resources on their development. In addition, we may not
be able to manufacture economically or successfully commercialize any product candidate that we develop based on acquired or in-licensed technology that is granted regulatory approval, and such products may not gain wide acceptance or be competitive
in the marketplace. Moreover, integrating any newly acquired or in-licensed product candidates could be expensive and time-consuming. If we cannot effectively manage these aspects of our business strategy, our business may be materially harmed. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We currently contract with third-party subcontractors and single-source suppliers for certain raw materials, compounds and components necessary to produce
MitoGel, VesiGel and Vesimune for preclinical studies and clinical trials, and expect to continue to do so to support commercial scale production of MitoGel, VesiGel and Vesimune, if approved. There are significant risks associated with contracting
with single-source suppliers. Furthermore, our existing third-party subcontractors and single-source suppliers may not be able to meet the increased need for certain raw materials, compounds and components that may result from our potential
commercialization efforts. This increases the risk that we will not have sufficient quantities of MitoGel, VesiGel or Vesimune or be able to obtain such quantities at an acceptable cost, which could delay, prevent or impair our development or
commercialization efforts. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently rely on third party subcontractors and suppliers for certain compounds and components necessary to produce MitoGel,
VesiGel and Vesimune for our preclinical studies and clinical trials. We currently depend on a single source for MMC for MitoGel and VesiGel. We also currently depend on single sources for the gel contained in MitoGel and VesiGel, and Imiquimod for
Vesimune. Because there are a limited number of suppliers for the raw materials that we use to manufacture our product candidates, we may need to engage alternate suppliers to prevent a possible disruption of the manufacture of the materials
necessary to produce our product candidates for our clinical trials, and if approved, ultimately for commercial sale. We do not have any control over the availability of raw materials. If we or our manufacturers are unable to purchase these raw
materials on acceptable terms, at sufficient quality levels, or in adequate quantities, if at all, the development and commercialization of our product candidates or any future product candidates, would be delayed or there would be a shortage in
supply, which would impair our ability to meet our development objectives for our product candidates or generate revenues from the sale of any approved products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to continue to rely on these or other subcontractors and suppliers to support our commercial requirements if MitoGel, VesiGel or any of our other product
candidates is approved for marketing by the FDA or foreign regulatory authorities. Even if we establish ourselves as an approved commercial supplier of MMC, we plan to continue to rely on third parties for such production of MMC, as well as for the
raw materials, compounds and components necessary to produce our product candidates and for preclinical studies and clinical trials. We would expect that if we become a commercial supplier of MMC, through a third party manufacturer of MMC, it would
provide us with enhanced </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
control of material supply for both clinical trials and the commercial market, enable the more rapid implementation of process changes, and allow for better long-term margins. However, we have no
experience as a company in the commercial supply of drugs and may never be successful as a commercial supplier of MMC. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we are successful in being
approved as a commercial supplier of MMC, cost-overruns, unexpected delays, equipment failures, labor shortages, natural disasters, power failures, production failures or product recalls, and numerous other factors could prevent us from realizing
the intended benefits of our sales strategy and have a material adverse effect on our business. Further, establishing ourselves as a commercial supplier of MMC will require additional investment, will be time-consuming and may be subject to delays,
including because of shortage of labor, compliance with regulatory requirements or receipt of necessary regulatory approvals. In addition, building out our MMC commercial supply capabilities may cost more than we currently anticipate, and delays or
problems may adversely impact our ability to provide supply for the development and commercialization of our product candidates as well as our financial condition. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our continuing reliance on third party subcontractors and suppliers entails a number of risks, including reliance on the third party for regulatory compliance and
quality assurance, the possible breach of the manufacturing or supply agreement by the third party, and the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. In addition, third
party subcontractors and suppliers may not be able to comply with cGMP or quality system regulation, also called QSR, or similar regulatory requirements outside the United States. If any of these risks transpire, we may be unable to timely retain
alternate subcontractors or suppliers on acceptable terms and with sufficient quality standards and production capacity, which may disrupt and delay our clinical trials or the manufacture and commercial sale of our product candidates, if approved.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our failure or the failure of our third-party subcontractors and suppliers to comply with applicable regulations could result in sanctions being imposed on us,
including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely
affect supplies of MitoGel, VesiGel or any of our other product candidates that we may develop. Any failure or refusal to supply or any interruption in supply of the components for MitoGel, VesiGel or any other product candidates or products that we
may develop could delay, prevent or impair our clinical development or commercialization efforts. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Failure to obtain marketing approval in international
jurisdictions would prevent our product candidates from being marketed abroad. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order to market and sell our products in the European Union and other
jurisdictions, we or our third-party collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time
required to obtain approval may differ substantially from that required to obtain FDA approval. Regulatory approval processes outside the United States generally include all of the risks associated with obtaining FDA approval. In addition, in many
countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the United States on a
timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory
authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive the necessary approvals to commercialize our product candidates in any particular market. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We intend to rely on third parties and consultants to assist us in conducting our single pivotal Phase 3 clinical trial for MitoGel, our Phase 2b clinical trial
for VesiGel and certain clinical trials for our other product candidates. If these third parties or consultants do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or
commercialize MitoGel, VesiGel or any of our other product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not have the ability to independently conduct many of our preclinical studies
or our clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, and other third parties, such as CROs to conduct clinical trials on our product candidates. Third parties play a significant role in the conduct
of our clinical trials and the subsequent collection and analysis of data. These third parties are not our employees, and except for remedies </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
available to us under our agreements, we have limited ability to control the amount or timing of resources that any such third party will devote to our clinical trials. Due to the limited drug
development for non-muscle invasive urothelial cancers over the past 15 years, neither we nor any third-party clinical investigators, CROs and/or consultants are likely to have extensive experience conducting clinical trials for the indications we
are targeting. If our CROs or any other third parties upon which we rely for administration and conduct of our clinical trials do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be
replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, or if they otherwise perform in a substandard manner, our
clinical trials may be extended, delayed, suspended or terminated, and we may not be able to complete development of, obtain regulatory approval for, or successfully commercialize our product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We and the third parties upon whom we rely are required to comply with Good Clinical Practice, or GCP, regulations, which are regulations and guidelines enforced by
regulatory authorities around the world for products in clinical development. Regulatory authorities enforce these GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and clinical trial sites. If we or
our third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and our submission of marketing applications may be delayed or the regulatory authorities may require us to
perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, a regulatory authority will determine that any of our clinical trials comply or complied with applicable GCP regulations. In
addition, our clinical trials must be conducted with material produced under current cGMP regulations, which are enforced by regulatory authorities. Our failure to comply with these regulations may require us to repeat clinical trials, which would
delay the regulatory approval process. Moreover, our business may be impacted if our CROs, clinical investigators or other third parties violate federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security
laws. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order for our clinical trials to be carried out effectively and efficiently, it is imperative that our CROs and other third parties communicate and
coordinate with one another. Moreover, our CROs and other third parties may also have relationships with other commercial entities, some of which may compete with us. Our CROs and other third parties may terminate their agreements with us upon as
few as 30 days&#146; notice under certain circumstances. If our CROs or other third parties conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate
their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for any other reason, we may need to conduct
additional clinical trials or enter into new arrangements with alternative CROs, clinical investigators or other third parties. We may be unable to enter into arrangements with alternative CROs on commercially reasonable terms, or at all. Switching
or adding CROs, clinical investigators or other third parties can involve substantial cost and require extensive management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays may
occur, which can impact our ability to meet our desired clinical development timelines. Although we carefully manage our relationship with our CROs, clinical investigators and other third parties, there can be no assurance that we will not encounter
such challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, prospects, financial condition or results of operations </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our ability to market our product candidates, if approved, will be limited to certain indications. If we want to expand the indications for which we may market
our products, we will need to obtain additional regulatory approvals, which may not be granted. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are currently developing MitoGel for the treatment of
low-grade UTUC, and VesiGel and Vesimune for the treatment of bladder cancer. The FDA and other applicable regulatory agencies will restrict our ability to market or advertise our products to the scope of the approved label for the applicable
product and for no other indications, which could limit physician and patient adoption. We may attempt to develop and, if approved, promote and commercialize new treatment indications for our products in the future, but we cannot predict when or if
we will receive the regulatory approvals required to do so. Failure to receive such approvals will prevent us from promoting or commercializing new treatment indications. In addition, we would be required to conduct additional clinical trials or
studies to support approvals for additional indications, which would be time consuming and expensive, and may produce results that do not support regulatory approvals. If we do not obtain additional regulatory approvals, our ability to expand our
business will be limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If our product candidates are approved for marketing, and we are found to have improperly promoted off-label
uses, or if physicians misuse our products, we may become subject to prohibitions on the sale or marketing of our products, significant sanctions, and product liability claims, and our image and reputation within the industry and marketplace could
be harmed. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about drug products. In
particular, a product may not be promoted for uses or indications that are not approved by the FDA or such other regulatory agencies as reflected in the product&#146;s approved labeling. For example, if we receive marketing approval for MitoGel for
treatment of low-grade UTUC, the first indication we are pursuing, we cannot promote the use of our product in a manner that is inconsistent with the approved label. However, physicians are able, in their independent medical judgment, to use MitoGel
on their patients in an off-label manner, such as for the treatment of other urology indications. If we are found to have promoted such off-label uses, we may receive warning letters and become subject to significant liability, which would harm our
business. The federal government has levied large administrative, civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. If we become the target of such an
investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would harm our business. In addition, management&#146;s attention could be diverted from our business operations, significant legal
expenses could be incurred, and our reputation could be damaged. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we are deemed by the
FDA to have engaged in the promotion of our products for off-label use, we could be subject to prohibitions on the sale or marketing of our products or significant fines and penalties, and the imposition of these sanctions could also affect our
reputation with physicians, patients and caregivers, and our position within the industry. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Physicians may also misuse our products or use improper techniques,
potentially leading to adverse results, side effects or injury, which may lead to product liability claims. If our products are misused or used with improper technique, we may become subject to costly litigation. Product liability claims could
divert management&#146;s attention from our core business, be expensive to defend, and result in sizable damage awards against us that may not be covered by insurance. We currently carry product liability insurance covering our clinical trials with
policy limits that we believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although we maintain such insurance, any claim that may be brought against us could result in a court
judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Furthermore, the use of our products for conditions other than those approved by the FDA may
not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to manage our growth
effectively, our business could be disrupted. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December 31, 2016, we had 29 full-time employees and four part-time employees, of which all except two
are based in Israel. We will need to continue to expand our development, quality, sales, managerial, operational, finance, marketing and other resources to manage our operations and clinical trials, continue our development activities and
commercialize our product candidates, if approved. Our management, personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our expansion strategy requires that we: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manage our clinical trials effectively; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identify, recruit, retain, incentivize and integrate additional employees; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manage our internal development efforts effectively while carrying out our contractual obligations to third parties; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue to improve our operational, financial and management controls, reporting systems and procedures. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Due to our
limited financial resources and our limited experience in managing a larger company, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our
operations may lead to significant costs and may divert our management and business development resources. Any inability to manage expansion could delay the execution of our development and strategic objectives, or disrupt our operations; and if we
are not successful in commercializing our product candidates, either on our own </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
or through collaborations with one or more third parties, our revenues will suffer and we would incur significant additional losses. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any of our other
products we develop. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even
greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability
claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer
protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require significant
financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for our product candidates or products we develop; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injury to our reputation and significant negative media attention; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical trial participants or cancellation of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs to defend the related litigation, which may be only partially recoverable even in the event of successful defenses; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a diversion of management&#146;s time and our resources; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to trial participants or patients; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of revenues; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exhaustion of any available insurance and our capital resources; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize any product we develop. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our inability to obtain and maintain sufficient product
liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of products we may develop. We currently carry general clinical trial product
liability insurance in an amount that we believe is adequate to cover the scope of our ongoing clinical programs. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an
amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim
for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient
capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing MitoGel, VesiGel or any
other product candidate, we intend to expand our insurance coverage to include the commercialization of MitoGel, VesiGel or any other approved product that we may have; however, we may be unable to obtain this liability insurance on commercially
reasonable terms. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop our product
candidates, conduct our clinical trials and commercialize any of the products we develop. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our success depends in part on our continued ability to attract,
retain and motivate highly qualified management, clinical and scientific personnel. We believe that our future success is highly dependent upon the contributions of members of our senior management, as well as our senior scientists and other members
of our management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of our product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we have not historically experienced unique difficulties in attracting and retaining qualified employees, we could experience such problems in the future. For
example, competition for qualified personnel in the pharmaceutical field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our
clinical development and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject
to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output. Moreover, although we have established a U.S. subsidiary, we
are domiciled in Israel and are predominantly based in Israel, which may make it difficult to hire necessary U.S.-based personnel. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our internal computer
systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a disruption of our drug development programs. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from
cyber-security threats, including computer viruses, harmful code and unauthorized access, natural disasters, fire, terrorism, war and telecommunication and electrical failures. If a disruption event were to occur and cause interruptions in our
operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and
significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary
information, we could incur liability and the further development of our product candidates could be delayed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Under applicable employment laws, we may not be
able to enforce covenants not to compete. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We generally enter into non-competition agreements as part of our employment agreements with our employees. These
agreements generally prohibit our employees, if they cease working for us, from competing directly with us or working for our competitors or clients for a limited period. We may be unable to enforce these agreements under the laws of the
jurisdictions in which our employees work and it may be difficult for us to restrict our competitors from benefitting from the expertise our former employees or consultants developed while working for us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, Israeli labor courts have required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive
activities of the former employee will harm one of a limited number of material interests of the employer which have been recognized by the courts as justification for the enforcement of non-compete undertakings, such as the protection of a
company&#146;s trade secrets or other intellectual property. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our employees, independent contractors, clinical investigators, CROs, consultants and vendors
may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are
exposed to the risk that our employees, independent contractors, clinical investigators, CROs, consultants and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or
negligent conduct, breach of contract or disclosure of unauthorized activities to us that violates: FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA; manufacturing standards;
federal, state and foreign healthcare fraud and abuse laws; or laws that require the reporting of financial information or data accurately. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Specifically, research,
sales, marketing, education and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a
wide range of pricing, discounting, education, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the
course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We intend to adopt a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by employees and other
third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a
failure to be in compliance with such laws. If any such actions are instituted against us, even if we are successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business. Violations of such
laws subject us to numerous penalties, including, but not limited to, the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, additional reporting requirements and oversight if
we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, possible exclusion from participation in Medicare, Medicaid and other federal healthcare
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our
business and our results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our business involves the use of hazardous materials and we and our third party manufacturers and suppliers must
comply with environmental laws and regulations, which can be expensive and restrict how we do business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our research and development activities and our
third party subcontractors&#146; and suppliers&#146; activities involve the controlled storage, use and disposal of hazardous materials owned by us, including Mitomycin C, or MMC, key components of our product candidates, and other hazardous
compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. Despite our efforts, we cannot eliminate the risk of contamination.
This could cause an interruption of our commercialization efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of
these materials and specified waste products. Although we believe that the safety procedures utilized by us and our subcontractors and suppliers for handling and disposing of these materials generally comply with the standards prescribed by these
laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our
resources and state or federal or other applicable authorities may curtail our use of certain materials and interrupt our business operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore,
environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Exchange rate fluctuations between the U.S. Dollar and the New Israeli Shekel may negatively affect our earnings. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The U.S. dollar is our functional and reporting currency. However, a significant portion of our operating expenses are incurred in New Israeli Shekels, or NIS, which is
the lawful currency of the State of Israel. As a result, we are exposed to the risks that the NIS may appreciate relative to the dollar, or, if the NIS instead devalues relative to the dollar, that the inflation rate in Israel may exceed such rate
of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations in Israel would increase and our dollar-denominated results of operations would be adversely
affected. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation (if any) of the NIS against the dollar. For example, although the dollar appreciated against the NIS in 2015 by 0.3%, the level of
devaluation of the dollar against the NIS in 2016 was 1.5%. If the dollar cost of our operations in Israel increases, our dollar-measured results of operations will be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If our efforts to obtain,
protect or enforce our patents and other intellectual property rights related to our product candidates and technologies are not adequate, we may not be able to compete effectively and we otherwise may be harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial success depends in part upon our ability to obtain and maintain patent protection and utilize trade secret protection for our intellectual property and
proprietary technologies, our products and their uses, as well as our ability to operate without infringing upon the proprietary rights of others. We rely upon a combination of patents, trade secret protection and confidentiality agreements,
assignment of invention agreements and other contractual arrangements to protect the intellectual property related to hydrogel-based pharmaceutical compositions for optimal delivery of a drug in internal cavities such as the bladder, the method for
treating urothelial cancer using hydrogel-based compositions, the method for treating overactive bladder topically without the need for injections, an in-dwelling ureter catheter system for optimal delivery of a drug into the renal cavity, and
pharmaceutical compositions comprising an imidazoquinolin (amine) and lactic acid for use in a method for the treatment of bladder diseases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We seek patent
protection for all of our product candidates, and we have established several patent families comprised of issued patents and pending patent applications covering our proprietary RTGel formulation technology and the formulations, methods of use and
manufacturing aspects of our product candidates. In the United States, we currently have three granted patents related to methods, systems and compositions for treating bladder cancer and upper urinary tract system conditions that relate to our lead
product candidates MitoGel and VesiGel and one patent related to our RTGel formulation, which are expected to remain in effect until between 2024 and 2031. We also have nine pending patent applications relating to the product candidates MitoGel and
VesiGel in Europe, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
United States and Israel, and five pending patent applications relating to the product candidate BotuGel in the United States and the European Union, as well as in each of Russia, China and
Israel. In addition, we have two&nbsp;granted patents related to Vesimune in the United States as well as two granted patents in the European Union, two granted patents in Japan and one granted patent in each of Australia, Mexico, China, Brazil,
Eurasia, and Hong Kong, each of which is expected to remain in effect until 2030. In addition to the issued patents mentioned above, our portfolio includes pending patent applications relating to Vesimune in the United States, Hong Kong, the
European Union, Canada, Korea, Brazil and Israel. Moreover, we hold five granted patents in the United States as well as patent applications filed worldwide that relate to novel formulations of phospholipid drug analogs (saturated lipid conjugate
compositions) for the treatment of urinary tract cancer. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Limitations on the scope of our intellectual property rights may limit our ability to prevent third
parties from designing around such rights and competing against us. For example, our patents do not claim a new compound. Rather, the active pharmaceutical ingredients of our products are existing compounds and our granted patents and pending patent
applications are directed to, among other things, novel formulations of these existing compounds with our RTGel. Accordingly, other parties may compete with us, for example, by independently developing or obtaining competing topical formulations
that design around our patent claims, but which may contain the same active ingredients, or by seeking to invalidate our patents. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable
competitors to quickly duplicate or surpass our technological achievements, eroding our competitive position in the market. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">However, the patent applications that
we own or license may fail to result in granted patents in the United States or foreign jurisdictions, or if granted may fail to prevent a potential infringer from marketing its product or be deemed invalid and unenforceable by a court. Competitors
in the field of reverse thermal gel therapies have created a substantial amount of scientific publications, patents and patent applications and other materials relating to their technologies. Our ability to obtain and maintain valid and enforceable
patents depends on various factors, including interpretation of our technology and the prior art and whether the differences between them allow our technology to be patentable. Patent applications and patents granted from them are complex, lengthy
and highly technical documents that are often prepared under very limited time constraints and may not be free from errors that make their interpretation uncertain. The existence of errors in a patent may have an adverse effect on the patent, its
scope and its enforceability. Our pending patent applications may not issue, and the scope of the claims of patent applications that do issue may be too narrow to adequately protect our competitive advantage. Also, our granted patents may be subject
to challenges or narrowly construed and may not provide adequate protection. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to claims that we infringe, misappropriate or otherwise
violate the intellectual property rights&nbsp;of third parties. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if our patents do successfully issue, third parties may challenge the validity,
enforceability or scope of such granted patents or any other granted patents we own or license, which may result in such patents being narrowed, invalidated or held unenforceable. For example, patents granted by the European Patent Office may be
opposed by any person within nine months from the publication of their grant. Also, patents granted by the United States Patent and Trademark Office, or USPTO, may be subject to reexamination and other challenges. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, even if they are not challenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing
around our claims. To meet such challenges, which are part of the risks and uncertainties of developing and marketing product candidates, we may need to evaluate third party intellectual property rights and, if appropriate, to seek licenses for such
third party intellectual property or to challenge such third party intellectual property, which may be costly and may or may not be successful, which could also have an adverse effect on the commercial potential for MitoGel, VesiGel and any of our
product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may receive only limited protection, or no protection, from our issued patents and patent applications. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we encounter delays in our clinical trials or regulatory approval of our product candidates, the period of time during which we could market any of our product
candidates under patent protection could be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either (i) file any
patent application related to hydrogel-based pharmaceutical compositions for optimal delivery of a drug in internal cavities such as the bladder, the method for treating urothelial cancer using hydrogel-based compositions, the method for treating
overactive bladder topically </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
without the need for injections, an in-dwelling ureter catheter system for optimal delivery of a drug into the renal cavity, and pharmaceutical compositions comprising an imidazoquinolin (amine)
and lactic acid for use in a method for the treatment of bladder diseases or any of our product candidates or (ii) conceive and invent any of the inventions claimed in our patents or patent applications. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent application process, also known as patent prosecution, is expensive and time consuming, and we or any future licensors and licensees may not be able to
prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or any future licensors or licensees will fail to identify patentable aspects of inventions made in
the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, these and any of our patents and applications may not be prosecuted and<B> </B>enforced in a manner consistent with the
best interests of our business. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, etc.,
although we are unaware of any such defects that we believe are of material import. If we or any future licensors or licensees fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or
eliminated. If any future licensors or licensees, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the
form or preparation of our patents or patent applications, such patents or applications may be invalid and unenforceable. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on
our business. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The strength of patents in the pharmaceutical field involves complex legal and scientific questions and can be uncertain. This uncertainty
includes changes to the patent laws through either legislative action to change statutory patent law or court action that may reinterpret existing law in ways affecting the scope or validity of issued patents. The patent applications that we own or
in-license may fail to result in issued patents in the United States or foreign countries with claims that cover our product candidates. Even if patents do successfully issue from the patent applications that we own or in-license, third parties may
challenge the validity, enforceability or scope of such patents, which may result in such patents being narrowed, invalidated or held unenforceable. For example, patents granted by the European Patent Office may be challenged, also known as opposed,
by any person within nine months from the publication of their grant. Any successful challenge to our patents could deprive us of exclusive rights necessary for the successful commercialization of our product candidates. Furthermore, even if they
are unchallenged, our patents may not adequately protect our product candidates, provide exclusivity for our product candidates, or prevent others from designing around our claims. If the breadth or strength of protection provided by the patents we
hold or pursue with respect to our product candidates is challenged, it could dissuade companies from collaborating with us to develop, or threaten our ability to commercialize our product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available;
however the life of a patent, and the protection it affords, is limited. Without patent protection for our product candidates, we may be open to competition from generic versions of our product candidates. Further, if we encounter delays in our
development efforts, including our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A considerable number of our patents and patent applications are entitled to effective filing dates prior to March&nbsp;16, 2013. For U.S. patent applications in which
patent claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third party, for example a competitor, or instituted by the USPTO to determine who was the first to invent any of the subject matter
covered by those patent claims. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license
on commercially reasonable terms. Our participation in an interference proceeding may fail and, even if successful, may result in substantial costs and distract our management. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our trade secrets may not have sufficient intellectual property protection. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the protection afforded by patents, we also rely on trade secret protection to protect proprietary know-how that may not be patentable or that we elect
not to patent, processes for which patents may be difficult to obtain or enforce, and any other elements of our product candidates, and our product development processes (such as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
manufacturing and formulation technologies) that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. If the
steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating any trade secrets. Misappropriation or unauthorized disclosure of our trade secrets could significantly
affect our competitive position and may have an adverse effect on our business. Furthermore, trade secret protection does not prevent competitors from independently developing substantially equivalent information and techniques and we cannot
guarantee that our competitors will not independently develop substantially equivalent information and techniques. The FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on
a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#146;s disclosure policies may change in the future, if at all. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In an effort to protect our trade secrets and other confidential information, we require our employees, consultants, advisors, and any other third parties that have
access to our proprietary know-how, information or technology, for example, third parties involved in the formulation and manufacture of our product candidates, and third parties involved in our clinical trials to execute confidentiality agreements
upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#146;s relationship with us is
kept confidential and not disclosed to third parties. However, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed despite having such confidentiality agreements. Adequate remedies may not
exist in the event of unauthorized use or disclosure of our trade secrets. In addition, in some situations, these confidentiality agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants, or
advisors have previous employment or consulting relationships. To the extent that our employees, consultants or contractors use any intellectual property owned by third parties in their work for us, disputes may arise as to the rights in any related
or resulting know-how and inventions. If we are unable to prevent unauthorized material disclosure of our trade secrets to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could harm our
business, operating results and financial condition. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability
to protect our products. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly on
obtaining and enforcing patents. Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal complexity, and therefore, is costly, time-consuming and inherently uncertain. In addition, the United States has
recently enacted and is currently implementing wide-ranging patent reform legislation. Further, recent U.S. Supreme Court rulings have either narrowed the scope of patent protection available in certain circumstances or weakened the rights of patent
owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For our U.S. patent applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law. In
September 2011, the Leahy-Smith America Invents Act, or the America Invents Act, or AIA, was signed into law. The AIA includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be
prosecuted and may also affect patent litigation. The USPTO is currently developing regulations and procedures to govern administration of the AIA, and many of the substantive changes to patent law associated with the AIA. It is not clear what
other, if any, impact the AIA will have on the operation of our business. Moreover, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of
our issued patents, all of which could harm our business and financial condition. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An important change introduced by the AIA is that, as of March 16, 2013, the
United States transitioned to a &#147;first-to-file&#148; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent
application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of
the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and
most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our
patents or patent applications. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit
and provide opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the
evidentiary standard in United States federal court necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would
be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the
third party as a defendant in a district court action. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations
governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by
governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The USPTO and various
foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent prosecution process. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Periodic maintenance fees and various other governmental fees on any issued patent and/or pending patent applications are due to be paid to the USPTO and foreign patent
agencies in several stages over the lifetime of a patent or patent application. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees. While an inadvertent lapse may
sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are many situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or
complete loss of patent rights in the relevant jurisdiction. If we fail to maintain the patents and patent applications directed to our product candidates, our competitors might be able to enter the market earlier than should otherwise have been the
case, which could harm our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive. The requirements for
patentability may differ in certain countries, particularly developing countries. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a
claimed drug. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in
all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we
have patent protection, but enforcement on infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of
certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the
infringement of our patents or marketing of competing products in violation of our proprietary rights generally. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Proceedings to enforce our patent rights in
foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the
damages or other remedies awarded, if any, may not be commercially meaningful. In addition, certain countries in Europe and certain developing countries, including India and China, have compulsory licensing laws under which a patent owner may be
compelled to grant licenses to third parties. In those countries, we may have limited remedies if our patents are infringed or if we are compelled to grant a license to our patents to a third party, which could materially diminish the value of those
patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that
we own or license. Finally, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to protect our trademarks from infringement, our business prospects may be harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We own trademarks that identify MitoGel, VesiGel and Vesimune and have registered these trademarks in the United States and Israel. Although we take steps to monitor
the possible infringement or misuse of our trademarks, it is possible that third parties may infringe, dilute or otherwise violate our trademark rights. Any unauthorized use of our trademarks could harm our reputation or commercial interests. In
addition, our enforcement against third-party infringers or violators may be unduly expensive and time-consuming, and the outcome may be an inadequate remedy. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and
time consuming. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Third parties may infringe or misappropriate our intellectual property, including our existing patents, patents that may issue to us in the
future, or the patents of our licensors to which we have a license. As a result, we may be required to file infringement claims to stop third-party infringement or unauthorized use. Further, we may not be able to prevent, alone or with our
licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Generic drug manufacturers may develop, seek approval for, and launch generic versions of our products. If we file an infringement action against such a generic drug
manufacturer, that company may challenge the scope, validity or enforceability of our or our licensors&#146; patents, requiring us and/or our licensors to engage in complex, lengthy and costly litigation or other proceedings. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, if we or one of our licensors initiated legal proceedings against a third party to enforce a patent covering our product candidates, the defendant could
counterclaim that the patent covering our product candidates is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous
grounds upon which a third party can assert invalidity or unenforceability of a patent. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, within and outside of the United States, there has been a
substantial amount of litigation and administrative proceedings, including interference and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in various foreign jurisdictions, regarding patent and other
intellectual property rights in the pharmaceutical industry. Recently, the AIA introduced new procedures including <I>inter partes</I> review and post grant review. The implementation of these procedures brings uncertainty to the possibility of
challenges to our patents in the future, including challenges by competitors who perceive our patents as blocking entry into the market for their products, and the outcome of such challenges. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Such litigation and administrative proceedings could result in revocation of our patents or amendment of our patents such that they do not cover our product candidates.
They may also put our pending patent applications at risk of not issuing, or issuing with limited and potentially inadequate scope to cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is
unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. Additionally, it is also possible that prior art of
which we are aware, but which we do not believe affects the validity or enforceability of a claim, may, nonetheless, ultimately be found by a court of law or an administration panel to affect the validity or enforceability of a claim. If a defendant
were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a negative impact on our
business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Enforcing our or our licensor&#146;s intellectual property rights through litigation is very expensive, particularly for a
company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant
management time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the
marketplace. The occurrence of any of the foregoing could harm our business, financial condition or results of operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, during the course of
litigation or administrative proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative,
the market price for our ordinary shares could be significantly harmed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may become subject to claims for remuneration or royalties for assigned service
invention rights by our employees, which could result in litigation and adversely affect our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A significant portion of our intellectual property
has been developed by our employees in the course of their employment for us. Under the Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee during the scope of his or her employment with a company are regarded as
&#147;service inventions.&#148; The Israeli Compensation and Royalties Committee, or the Committee, a body constituted under the Patent Law, has previously held, in certain cases, that employees may be entitled to remuneration for service inventions
that they develop during their service for a company despite their explicit waiver of such right. Therefore, although we enter into agreements with all of our employees pursuant to which they waive their right to special remuneration for service
inventions created in the scope of their employment or engagement and agree that any such inventions are owned exclusively by us, we may face claims by employees demanding remuneration beyond their regular salary and benefits. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Third party claims alleging intellectual property infringement may adversely affect our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties, for example, the intellectual property
rights of competitors. Our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents owned or controlled by third parties. Numerous U.S. and foreign issued patents and pending
patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our
activities related to our product candidates may give rise to claims of infringement of the patent rights of others. We cannot assure you that our product candidates will not infringe existing or future patents. We may not be aware of patents that
have already issued that a third party might assert are infringed by our product candidates. It is also possible that patents of which we are aware, but which we do not believe are relevant to our product candidates, could nevertheless be found to
be infringed by our product candidates. Nevertheless, we are not aware of any issued patents that we believe would prevent us from marketing our product candidates, if approved. There may also be patent applications that have been filed but not
published that, when issued as patents, could be asserted against us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Third parties making claims against us for infringement or misappropriation of their
intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Further, if a patent infringement suit were brought against
us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. Defense of these claims, regardless of their merit, would cause us to incur substantial
expenses and, and would be a substantial diversion of management time and employee resources from our business. In the event of a successful claim of infringement against us by a third party, we may have to (i) pay substantial damages, including
treble damages and attorneys&#146; fees if we are found to have willfully infringed the third party&#146;s patents; (ii) obtain one or more licenses from the third party; (iii) pay royalties to the third party; and/or (iv) redesign any infringing
products. Redesigning any infringing products may be impossible or require substantial time and monetary expenditure. Further, we cannot predict whether any required license would be available at all or whether it would be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
available on commercially reasonable terms. In the event that we could not obtain a license, we may be unable to further develop and commercialize our product candidates, which could harm our
business significantly. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access
to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to
enter into licenses on acceptable terms. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Defending ourselves or our licensors in litigation is very expensive, particularly for a company of our size, and <FONT
STYLE="white-space:nowrap">time-consuming.</FONT> Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other
proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the
foregoing could harm our business, financial condition or results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to claims that our employees, consultants or independent
contractors have wrongfully used or disclosed confidential information of third parties. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We employ individuals who were previously employed at other
biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information of these third parties or
our employees&#146; former employers. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. We may also be
subject to claims that former employees, consultants, independent contractors, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and
other claims challenging our right to and use of confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages, we may lose our rights therein. Such an outcome could have a negative impact
on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Government Regulation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If the FDA does not conclude
that MitoGel, VesiGel, or our other product candidates satisfy the requirements under Section 505(b)(2) of the Federal Food Drug and Cosmetic Act, or Section 505(b)(2), or if the requirements for such product candidates are not as we expect, the
approval pathway for these product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We commenced a single pivotal Phase 3 clinical trial for MitoGel and expect to commence a Phase&nbsp;2b clinical trial of VesiGel under the FDA&#146;s Section 505(b)(2)
regulatory pathway. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, added Section 505(b)(2) to the Federal Food, Drug and Cosmetic Act. Section 505(b)(2) permits the filing of an NDA where at
least some of the information required for approval comes from studies that were not conducted by or for the applicant, and for which the applicant has not received a right of reference, which could expedite the development program for MitoGel,
VesiGel and our other product candidates by potentially decreasing the amount of preclinical and clinical data that we would need to generate in order to obtain FDA approval. However, while we believe that our product candidates are reformulations
of existing drugs or biologics and, therefore, will not be treated as new chemical entities, or NCEs, the submission of an NDA under the Section 505(b)(2) or similar regulatory pathway does not preclude the FDA from determining that the product
candidate that is the subject of such submission is an NCE and therefore not eligible for review under such regulatory pathway. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the FDA does not allow us
to pursue the Section 505(b)(2) or similar regulatory pathway as anticipated, we may need to conduct additional preclinical experiments and clinical trials, provide additional data and information, and meet additional standards for regulatory
approval. If this were to occur, the time and financial resources required to obtain FDA approval for these product candidates, and complications and risks associated with these product candidates, would likely increase significantly. Moreover,
inability to pursue the Section 505(b)(2) or similar regulatory pathway could result in new competitive products reaching the market more quickly than our product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
candidates, which would likely harm our competitive position and prospects. Even if we are allowed to pursue the Section 505(b)(2) or similar regulatory pathway, our product candidates may not
receive the requisite approvals for commercialization. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, notwithstanding the approval of a number of products by the FDA under Section 505(b)(2) over
the last few years, certain competitors and others have objected to the FDA&#146;s interpretation of Section 505(b)(2). If the FDA&#146;s interpretation of Section 505(b)(2) is successfully challenged, the FDA may be required to change its 505(b)(2)
policies and practices, which could delay or even prevent the FDA from approving any NDA that we submit under Section 505(b)(2). In addition, the pharmaceutical industry is highly competitive, and Section 505(b)(2) NDAs are subject to special
requirements designed to protect the patent rights of sponsors of previously approved drugs that are referenced in a Section 505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval of our potential
future NDAs for up to 30 months depending on the outcome of any litigation. It is not uncommon for a manufacturer of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements
for, pending competing products. If successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it
considers and responds to the petition. In addition, even if we are able to utilize the Section 505(b)(2) regulatory pathway for our product candidates, there is no guarantee this would ultimately lead to faster product development or earlier
approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, even if these product candidates are approved under the Section 505(b)(2) pathway, as the case may be, the approval may be subject to
limitations on the indicated uses for which the products may be marketed or to other conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the products. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We expect current and future legislation affecting the healthcare industry, including healthcare reform, to impact our business generally and to increase
limitations on reimbursement, rebates and other payments, which could adversely affect third-party coverage of our products, our operations, and/or how much or under what circumstances healthcare providers will prescribe or administer our products,
if approved. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change
the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated
goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, in March 2010, President Obama signed into law the Patient Protection and Affordable Care Act and the Health Care and Education Affordability
Reconciliation Act of 2010, or collectively, the ACA, a law intended, among other things, to broaden access to health insurance, improve quality of care, and reduce or constrain the growth of healthcare spending. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Provisions of the ACA relevant to the pharmaceutical industry include the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government
healthcare programs, not including orphan drug sales; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively;
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts on negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage
gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage
to additional individuals and by adding new mandatory eligibility categories for certain </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
individuals with income at or below 133% of the Federal Poverty Level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability;</P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">new requirements to report annually certain financial arrangements with physicians and teaching hospitals; as defined in the ACA and its implementing regulations, including reporting any payment or &#147;transfer of
value&#148; provided to physicians and teaching hospitals and any ownership and investment interests held by physicians and their immediate family members during the preceding calendar year; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of healthcare fraud and abuse laws, including the federal civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance; and
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There have been judicial and Congressional challenges to certain aspects of the ACA. As a result, there have been delays in the implementation of, and action taken to
repeal or replace, certain aspects of the ACA. In January 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the
implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. Further, in January 2017, Congress
adopted a budget resolution for fiscal year 2017, or the Budget Resolution, that authorizes the implementation of legislation that would repeal portions of the ACA. Following the passage of the Budget Resolution, in March 2017, the U.S. House of
Representatives introduced legislation known as the American Health Care Act, which, if enacted, would amend or repeal significant portions of the ACA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee
on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of an amount greater than $1.2 trillion for the years 2013 through 2021, triggering the
legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which started in 2013 and, following passage of the Bipartisan
Budget Act of 2015, will stay in effect through 2025 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to
several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.&nbsp;Additionally, there have been several recent U.S. Congressional
inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program
reimbursement methodologies for drugs.&nbsp;Further, the U.S. House of Representatives recently formed an Affordable Drug Pricing Task Force to advance legislation intended to control pharmaceutical drug costs and investigate pharmaceutical drug
pricing, and the U.S. Senate has requested information from certain pharmaceutical companies in connection with an investigation into pharmaceutical drug pricing practices. If healthcare policies or reforms intended to curb healthcare costs are
adopted, or if we experience negative publicity with respect to the pricing of our products or the pricing of pharmaceutical drugs generally, the prices that we charge for any approved products may be limited, our commercial opportunity may be
limited and/or our revenues from sales of our products may be negatively impacted. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we obtain regulatory approval and commercialization of MitoGel, VesiGel or
any of our other product candidates, these laws may result in additional reductions in healthcare funding, which could have an adverse effect on our customers and accordingly, our financial operations. Legislative and regulatory proposals have been
made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or
interpretations will be changed, or what the impact of such changes on the marketing approvals of MitoGel, VesiGel or our other product candidates may be. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we cannot predict the full effect on our business of the implementation of existing legislation or the enactment
of additional legislation pursuant to healthcare and other legislative reform, we believe that legislation or regulations that would reduce reimbursement for, or restrict coverage of, our products could adversely affect how much or under what
circumstances healthcare providers will prescribe or administer our products. This could adversely affect our business by reducing our ability to generate revenues, raise capital, obtain additional licensees and market our products. In addition, we
believe the increasing emphasis on managed care in the United States has and will continue to put pressure on the price and usage of pharmaceutical products, which may adversely impact product sales. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be unable to obtain Orphan Drug Designation or exclusivity for future product candidates we may develop. If our competitors are able to obtain orphan drug
exclusivity for their products that are for the same indication as our product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Orphan Drug Act of 1983, the FDA may designate a product as an orphan drug if it is intended to treat an orphan disease or condition, defined as a patient
population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, Orphan Drug Designation entitles a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax
advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has Orphan Drug Designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other
application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to
assure sufficient product quantity. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although the FDA has granted MitoGel orphan drug designation for the treatment of UTUC and to Vesimune for treatment of CIS, we
may not receive orphan drug designation for any of our other product candidates. If our competitors are able to obtain orphan drug exclusivity for their products that are the same or similar to our product candidates before our drug candidates are
approved, we may not be able to have competing product candidates approved by the FDA for a significant period of time. Any delay in our ability to bring our product candidates to market would negatively impact our business, revenue, cash flows and
operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Orphan Drug Designation may not ensure that we will enjoy market exclusivity in a particular market, and if we fail to obtain or maintain orphan
drug exclusivity for our product candidates, we may be subject to earlier competition and our potential revenue will be reduced. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Orphan Drug Designation
entitles a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax advantages, user-fee waivers and market exclusivity for certain periods of time. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MitoGel and Vesimune have been granted Orphan Drug Designation for the treatment of UTUC and CIS, respectively, in the United States. Even if we obtain Orphan Drug
Designation for our other product candidates, we may not be the first to obtain regulatory approval for any particular orphan indication due to the uncertainties associated with developing biopharmaceutical products. Further, even if we obtain
Orphan Drug Designation for a product candidate, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. In addition, if a competitor
obtains approval and marketing exclusivity for a drug product with an active moiety that is the same as that in a product candidate we are pursuing for the same indication, approval of our product candidate would be blocked during the period of
marketing exclusivity unless we could demonstrate that our product candidate is clinically superior to the approved product. In addition, if a competitor obtains approval and marketing exclusivity for a drug product with an active moiety that is the
same as that in a product candidate we are pursuing for a different orphan indication, this may negatively impact the market opportunity for our product candidate. There have been legal challenges to aspects of the FDA&#146;s regulations and
policies concerning the exclusivity provisions of the Orphan Drug Act, and future challenges could lead to changes that affect the protections afforded our product candidates in ways that are difficult to predict. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we receive regulatory approval for our product candidates, we will be subject to ongoing regulatory
obligations and continued regulatory review, which may result in significant additional expenses, limit or withdraw regulatory approval and subject us to penalties if we fail to comply with applicable regulatory requirements. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If and when regulatory approval has been granted, our product candidates or any approved product will be subject to continual regulatory review by the FDA and/or
non-U.S. regulatory authorities. Additionally, any product candidates, if approved, will be subject to extensive and ongoing regulatory requirements, including labeling and other restrictions and market withdrawal and we may be subject to penalties
if we fail to comply with regulatory requirements or experience unanticipated problems with our products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any regulatory approvals that we receive for our product
candidates may also be subject to limitations on the approved indications for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including phase 4 clinical
trials, and surveillance to monitor the safety and efficacy of the product. In addition, if the applicable regulatory agency approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting,
storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as
well as continued compliance with cGMP and GCP for any clinical trials that we conduct post-approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Later discovery of previously unknown problems with our
product candidates, including adverse events of unanticipated severity or frequency, or problems with our third-party manufacturers&#146; processes, or failure to comply with regulatory requirements, may result in, among other things: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, warnings letters or holds on clinical trials </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizure or detention, or refusal to permit the import or export of products; and injunctions or the imposition of civil or criminal penalties. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ongoing regulatory requirements may also change from time to time, potentially harming or making costlier our commercialization efforts. We cannot predict the
likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or other countries. If we are slow or unable to adapt to changes in existing requirements or the
adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our
business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our relationships with healthcare professionals, independent contractors, clinical investigators, CROs, consultants and vendors in connection with
our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws. If we are unable to
comply, or have not fully complied, with such laws, we could face penalties. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may currently be or may become subject to various U.S. federal and state
health care laws, including those intended to prevent health care fraud and abuse. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal Anti-Kickback Statute prohibits, among other things, persons or
entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of
an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid Remuneration has been
broadly defined to include anything of value, including, but not limited to, cash, improper discounts, and free or reduced price items and services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Federal false claims laws, including the federal False Claims Act, or FCA, and civil monetary penalties law impose
penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent or making a false record or statement to
avoid, decrease or conceal an obligation to pay money to the federal government. The FCA has been used to, among other things, prosecute persons and entities submitting claims for payment that are inaccurate or fraudulent, that are for services not
provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many states have similar fraud and abuse statutes and regulations that may be broader in scope and may apply regardless of payor, in addition to items and services
reimbursed under Medicaid and other state programs. State and federal authorities have aggressively targeted medical technology companies for, among other things, alleged violations of these anti-fraud statutes, based on improper research or
consulting contracts with doctors, certain marketing arrangements that rely on volume-based pricing, off-label marketing schemes, and other improper promotional practices. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, among other things, imposes criminal liability for knowingly and willfully executing,
or attempting to execute, a scheme to defraud any healthcare benefit program or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for
healthcare benefits, items or services. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH Act,
and their implementing regulations, also impose certain obligations, including mandatory contractual terms, on certain types of individuals and entities with respect to safeguarding the privacy, security and transmission of individually identifiable
health information without proper written authorization. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our operations will also be subject to the federal transparency requirements under the ACA, which require
certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#146;s Health Insurance Program, with specific exceptions, to annually report to the Centers for
Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS, information related to payments and other transfers of value provided to physicians and teaching hospitals and certain ownership and
investment interests held by physicians and their immediate family members. We may also be subject to state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other
healthcare providers or marketing expenditures, and/or state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidelines promulgated by the
federal government. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of our business activities, including but not limited to our relationships with healthcare providers, violate any of the aforementioned
laws, we may be subject to administrative, civil and/or criminal penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs,
contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Also, the U.S. Foreign Corrupt
Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. We cannot assure you that our
internal control policies and procedures will protect us from reckless or negligent acts committed by our employees, future distributors, partners, collaborators or agents. Violations of these laws, or allegations of such violations, could result in
fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Legislative or regulatory healthcare reforms in the United States or abroad may make it more difficult and costly
for us to obtain regulatory clearance or approval of our product candidates or any future product candidates and to produce, market, and distribute our products after clearance or approval is obtained. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, legislation is drafted and introduced in Congress in the United States or by governments in foreign jurisdictions that could significantly change the
statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA or foreign regulatory agency regulations and guidance are often revised or
reinterpreted by the FDA or the applicable foreign regulatory agency in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or
lengthen review times of our product candidates or any future product candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our
business in the future. Such changes could, among other things, require: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes to manufacturing methods; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recall, replacement, or discontinuance of one or more of our products; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional recordkeeping. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each of these would likely entail substantial time and cost and could harm our business and
our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition, and results of operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could
negatively impact our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory
procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce
hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from
our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We maintain workers compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous
materials or other work-related injuries with policy limits that we believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although we maintain such insurance, this insurance may not
provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may
impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>It may be difficult for us to profitably sell our product candidates if coverage and reimbursement for these products is limited by government authorities and/or
third-party payor policies. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to any healthcare reform measures which may affect reimbursement, market acceptance and sales of MitoGel, VesiGel
and our other product candidates, if approved, will depend on the coverage and reimbursement policies of government authorities and third-party payors. Government authorities and third-party payors, such as private health insurers and health
maintenance organizations, decide which medications they will cover and establish reimbursement levels. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A primary trend in the U.S. healthcare industry and
elsewhere is cost containment. Third party payors decide which drugs they will pay for and establish reimbursement and co-payment levels. Government and other third-party payors are increasingly challenging the prices charged for health care
products, examining the cost effectiveness of drugs in addition to their safety and efficacy, and limiting or attempting to limit both coverage and the level of reimbursement for prescription drugs. We cannot be sure that coverage will be available
for MitoGel, VesiGel or our other product candidates, if approved, or, if coverage is available, the level of reimbursement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the
United States, the principal decisions about reimbursement for new medicines are typically made by CMS, an agency within the U.S. Department of HHS, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under
Medicare. Private payors often follow CMS. It is difficult to predict what CMS as well as other payors will decide with respect to reimbursement for fundamentally novel products such as ours, as there is no body of established practices and
precedents for these new products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Reimbursement may impact the demand for, and/or the price of, any product for which we obtain marketing approval. Assuming we
obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high.&nbsp;Patients who are prescribed medications for the treatment
of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs.&nbsp;Patients are unlikely to use our products unless coverage is provided
and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards
that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available.&nbsp;There may be significant delays in obtaining coverage and reimbursement for newly approved
drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all
cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Reimbursement by a third-party payor may depend upon
a number of factors including the third-party payor&#146;s determination that use of a product is: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a covered benefit under its health plan; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">safe, effective and medically necessary; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appropriate for the specific patient; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost-effective; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">neither experimental nor investigational. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Obtaining coverage and reimbursement approval for a product from a government
or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. Further, no uniform policy requirement for
coverage and reimbursement for drug products exists among third-party payors in the United States.&nbsp;Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination
process may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. We may
not be able to provide data sufficient to gain acceptance with respect to coverage and/or sufficient reimbursement levels. We cannot be sure that coverage or adequate reimbursement will be available for MitoGel, VesiGel or any of our other product
candidates, if approved. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, our future products. If reimbursement is not available, or is available only to limited levels, we may not be able to
commercialize MitoGel, VesiGel or our other product candidates, or achieve profitably at all, even if approved. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Legislative or regulatory healthcare reforms
in the United States may make it more difficult and costly for us to obtain regulatory clearance or approval of MitoGel, VesiGel or any of our other product candidates and to produce, market, and distribute our products after clearance or approval
is obtained. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the
regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our
business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of MitoGel, VesiGel or any of our other product candidates. We cannot determine what effect
changes in regulations, statutes, legal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes to manufacturing methods; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">change in protocol design; </TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional treatment arm (control); </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recall, replacement, or discontinuance of one or more of our products; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional recordkeeping. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each of these would likely entail substantial time and cost and could harm our business and
our financial results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to an Investment in Our Ordinary Shares </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>An active, liquid and orderly trading market for our ordinary shares may not develop, which may inhibit the ability of our shareholders to sell ordinary shares
following this offering. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering there has been no public market for our ordinary shares. An active, liquid or orderly trading market in our
ordinary shares may not develop upon completion of this offering, or if it does develop, it may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you
consider reasonable. The lack of an active market may also reduce the fair market value of your shares. An inactive market may also impair our ability to raise capital in the future by selling shares and may impair our ability to acquire other
companies by using our shares as consideration. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The market price of our ordinary shares may be subject to fluctuation and you could lose all or part of your
investment. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The initial public offering price for the shares will be determined by negotiations between us and representatives of the underwriters and may
not be indicative of prices that will prevail in the trading market. The price of our ordinary shares may decline following this offering. The stock market in general has been, and the market price of our ordinary shares in particular will likely
be, subject to fluctuation, whether due to, or irrespective of, our operating results and financial condition. The market price of our ordinary shares on the NASDAQ Global Market may fluctuate as a result of a number of factors, some of which are
beyond our control, including, but not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated variations in our and our competitors&#146; results of operations and financial condition; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">physician and market acceptance of our products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the mix of products that we sell; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our success or failure to obtain approval for and commercialize our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in earnings estimates or recommendations by securities analysts, if our ordinary shares are covered by analysts; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">development of technological innovations or new competitive products by others; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of technological innovations or new products by us; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">publication of the results of preclinical or clinical trials for MitoGel, VesiGel or our other product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure by us to achieve a publicly announced milestone; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays between our expenditures to develop and market new or enhanced product candidates and the generation of sales from those products; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments concerning intellectual property rights, including our involvement in litigation brought by or against us; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory developments and the decisions of regulatory authorities as to the approval or rejection of new or modified products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the amounts that we spend to develop, acquire or license new products, technologies or businesses; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in our expenditures to promote our products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our sale or proposed sale, or the sale by our significant shareholders, of our ordinary shares or other securities in the future; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in key personnel; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">success or failure of our research and development projects or those of our competitors; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the trading volume of our ordinary shares; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic and market conditions and other factors, including factors unrelated to our operating performance. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These factors and any corresponding price fluctuations may negatively impact the market price of our ordinary shares and result in substantial losses being incurred by
our investors. In the past, following periods of market volatility, public company shareholders have often instituted securities class action litigation. If we were involved in securities litigation, it could impose a substantial cost upon us and
divert the resources and attention of our management from our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If equity research analysts do not publish research or reports about our business or
if they issue unfavorable commentary or downgrade our ordinary shares, the price of our ordinary shares could decline. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trading market for our ordinary
shares will rely in part on the research and reports that equity research analysts publish about us and our business, if at all. We do not have control over these analysts and we do not have commitments from them to write research reports about us.
The price of our ordinary shares could decline if no research reports are published about us or our business, or if one or more equity research analysts downgrade our ordinary shares or if those analysts issue other unfavorable commentary or cease
publishing reports about us or our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Future sales of our ordinary shares could reduce the market price of our ordinary shares. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our existing shareholders, particularly our directors, their affiliates, or our executive officers, sell a substantial number of our ordinary shares in the public
market, the market price of our ordinary shares could decrease significantly. The perception in the public market that our shareholders might sell our ordinary shares could also depress the market price of our ordinary shares and could impair our
future ability to obtain capital, especially through an offering of equity securities. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Substantially all of our shares outstanding prior to this offering and
our shares issuable upon the exercise of warrants and vested options are subject to lock-up agreements with the underwriters that restrict the ability of their holders to transfer such shares for 180 days after the date of this prospectus.
Consequently, upon expiration of the lock-up agreements, 7,499,170 of our ordinary shares, plus 3,431,811 ordinary shares issuable upon the exercise of our outstanding options or warrants, will be eligible for sale in the public market, of which
approximately 7,814,470 ordinary shares will be subject to restrictions on volume and manner of sale pursuant to Rule 144 under the Securities Act of 1933, as amended. However, we intend to file one or more registration statements on Form S-8 with
the SEC covering all of the ordinary shares issuable under our 2010 Israeli Share Option Plan and such shares will be available for resale following the expiration of the restrictions on transfer. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After this offering, the holders of approximately 5,921,789 ordinary shares will be entitled to registration rights, subject to the terms of the lock-up agreements
described above. The market price of our ordinary shares may drop significantly when the restrictions on resale by our existing shareholders lapse and these shareholders are able to sell our ordinary shares into the market. In addition, our sale of
additional ordinary shares or similar securities in order to raise capital might have a similar negative impact on the share price of our ordinary shares. A decline in the price of our ordinary shares might impede our ability to raise capital
through the issuance of additional ordinary shares or other equity securities, and may cause you to lose part or all of your investment in our ordinary shares. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Investors in this offering will experience immediate substantial dilution in net tangible book value. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The initial public offering price of our ordinary shares in this offering is considerably greater than the net tangible book value per share of our outstanding ordinary
shares immediately after this offering. Accordingly, investors in this offering will incur immediate dilution of $7.77 per share, as of December 31, 2016, based on an assumed initial public offering price of $13.00 per share, the midpoint of the
estimated initial public offering price range shown on the cover of this prospectus. In addition, if outstanding options to purchase our ordinary shares are exercised in the future, you will experience additional dilution. Please see the section
entitled &#147;Dilution.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The significant share ownership position of our officers, directors and entities affiliated with certain of our
directors may limit your ability to influence corporate matters. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After giving effect to this offering, our officers, directors and entities affiliated with
certain of our directors will beneficially own or control, directly or indirectly, approximately 30% of our outstanding ordinary shares (or 28% if the underwriters exercise in full their option to purchase additional ordinary shares). In addition,
our directors, officers and employees and persons having business or other relationships with us and related persons may further increase their ownership in our company pursuant to the directed share program. At our request, the underwriters have
reserved 346,154 ordinary shares, or 10% of the shares being offered by this prospectus (excluding the ordinary shares that may be issued upon the underwriters&#146; exercise of their option to purchase additional shares), for sale at the initial
public offering price to certain eligible directors, officers, employees and others through a directed share program. Accordingly, these persons will be able to significantly influence, though not independently determine, the outcome of matters
required to be submitted to our shareholders for approval, including decisions relating to the election of our board of directors, and the outcome of any proposed merger or consolidation of our company. These interests may not be consistent with
those of our other shareholders. In addition, these persons&#146; significant interest in us may discourage third parties from seeking to acquire control of us, which may adversely affect the market price of our ordinary shares. In addition, certain
of our existing investors and their affiliated entities have indicated non-binding interest in purchasing up to an aggregate of approximately $13.0 million of our ordinary shares in this offering at the initial public offering price. Any purchases
in this offering by existing investors affiliated with our directors would further increase the influence these entities could exert. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have broad
discretion as to the use of the net proceeds from this offering and may not use them effectively. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently intend to use the net proceeds we receive
from this offering, together with our existing cash resources, to advance our clinical pipeline and specifically, to complete our single pivotal Phase 3 clinical trial of MitoGel for the treatment of low-grade UTUC, to file an IND for, and to
initiate our Phase 2b clinical trial of VesiGel for the treatment of low-grade NMIBC, and to fund continued research and clinical development of our other product candidates and for other general corporate purposes. However, our management will have
broad discretion in the application of the net proceeds. Our shareholders may not agree with the manner in which our management chooses to allocate the net proceeds from this offering. The failure by our management to apply these funds effectively
could harm our business, financial condition and results of operation. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have never paid cash dividends on our share capital, and we do not anticipate paying any cash dividends in the foreseeable future. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never declared or paid cash dividends on our share capital, nor do we anticipate paying any cash dividends on our share capital in the foreseeable future. We
currently intend to retain all available funds and any future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our ordinary shares will be investors&#146; sole source of gain for the
foreseeable future. In addition, Israeli law limits our ability to declare and pay dividends, and may subject our dividends to Israeli withholding taxes. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We
will incur significant increased costs as a result of operating as a public company in the United States, and our management will be required to devote substantial time to new compliance initiatives. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a public company whose ordinary shares are listed in the United States, we will be subject to an extensive regulatory regime, requiring us, among other things, to
maintain various internal controls and facilities and to prepare and file periodic and current reports and statements, including reports on the effectiveness of our internal control over financial reporting pursuant to Section 404 of the
Sarbanes-Oxley Act of 2002. Complying with these requirements will be costly and time consuming. We will need to retain additional employees to supplement our current finance staff, and we may not be able to do so in a timely manner, or at all. In
the event that we are unable to demonstrate compliance with our obligations as a public company in a timely manner, or are unable to produce timely or accurate financial statements, we may be subject to sanctions or investigations by regulatory
authorities, such as the SEC or the NASDAQ Global Market, and investors may lose confidence in our operating results and the price of our ordinary shares could decline. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our independent registered public accounting firm was not engaged to perform an audit of our internal control over financial reporting, and as long as we remain an
emerging growth company, as such term is defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, we will be exempt from the requirement to have an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
independent registered public accounting firm perform such audit. Accordingly, no such opinion was expressed or will be expressed any during any such period. Once we cease to qualify as an
emerging growth company our independent registered public accounting firm will be required to attest to our management&#146;s annual assessment of the effectiveness of our internal controls over financial reporting, which will entail additional
costs and expenses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, we are only in the early stages of determining formally whether our existing internal controls over financial reporting systems
are compliant with Section 404 and whether there are any material weaknesses or significant deficiencies in our existing internal controls. These controls and other procedures are designed to ensure that information required to be disclosed by us in
the reports that we file with the SEC is disclosed accurately and is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We presently do not anticipate to be classified as a passive foreign investment company for the current taxable year. If, however, we are or become classified as
a PFIC, our U.S. shareholders may suffer adverse tax consequences as a result. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Generally, for any taxable year, if at least 75% of our gross income is
passive income, or at least 50% of the value of our assets is attributable to assets that produce passive income or are held for the production of passive income, including cash, we would be characterized as a passive foreign investment company, or
PFIC, for U.S. federal income tax purposes. For purposes of these tests, passive income includes dividends, interest gains from commodities and securities transactions, the excess of gains over losses from the disposition of assets which produce
passive income (including amounts derived by reason of the temporary investment of funds raised in offerings of our shares) and rents and royalties other than rents and royalties which are received from unrelated parties in connection with the
active conduct of a trade or business. If we are characterized as a PFIC, our U.S. shareholders may suffer adverse tax consequences, including having gains realized on the sale of our ordinary shares treated as ordinary income, rather than capital
gain, the loss of the preferential rate applicable to dividends received on our ordinary shares by individuals who are U.S. holders, and having interest charges apply to distributions by us and gains from the sales of our shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our status as a PFIC will depend on the nature and composition of our income and the nature, composition and value of our assets (which, assuming we are not a
&#147;controlled foreign corporation,&#148; or a CFC, under Section 957(a) of the Internal Revenue Code of 1986, as amended, or the Code, for the year being tested, may be determined based on the fair market value of each asset, with the value of
goodwill and going concern value determined in large part by reference to the market value of our common shares, which may be volatile) from time to time. Our status may also depend, in part, on how quickly we utilize the cash proceeds from this
offering in our business. Based upon the expected value of our assets, including any goodwill, and the expected nature and composition of our income and assets, we presently do not anticipate that we will be classified as a PFIC for the taxable year
ending December&nbsp;31, 2017. However, it is not certain that the nature and composition of our income and assets will be as we currently expect, or that we will receive milestone payments in 2017 pursuant to the Allergan Agreement. If we do not
receive milestone payments as anticipated or other non-passive income, we likely will be classified as a PFIC for 2017. Our status as a PFIC is a fact-intensive determination made on an annual basis. We cannot provide any assurances regarding our
PFIC status for the current or future taxable years, and our U.S. tax counsel has not provided any opinion regarding our PFIC status. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>As a foreign private
issuer, we are permitted, and intend, to follow certain home country corporate governance practices instead of otherwise applicable NASDAQ requirements, and we will not be subject to certain U.S. securities laws including, but not limited to, U.S.
proxy rules and the filing of certain Exchange Act reports. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a foreign private issuer, we will be permitted, and intend, to follow certain home country
corporate governance practices instead of those otherwise required by the NASDAQ Stock Market for domestic U.S. issuers. Following our home country governance practices as opposed to the requirements that would otherwise apply to a U.S. company
listed on the NASDAQ Global Market may provide less protection to you than what is accorded to investors under the NASDAQ Rules applicable to domestic U.S. issuers. See the section titled &#147;Management&#151;Corporate Governance Practices.&#148;
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a foreign private issuer, we will be exempt from the rules and regulations under the Securities Exchange Act of 1934, or the Exchange Act, related to the
furnishing and content of proxy statements, including the requirement to disclose the compensation of our Chief Executive Officer, Chief Financial Officer, President of Israel Operations and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the other two most highly compensated executive officers on an individual basis. Nevertheless, pursuant to regulations promulgated under the Israeli Companies Law, 5759-1999, or the Israeli
Companies Law, we are required to disclose the annual compensation of our five most highly compensated office holders on an individual basis. Such disclosure will not be as extensive as that required of a U.S. domestic issuer. Our officers,
directors and principal shareholders will also be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file reports and
financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act and we will be exempt from filing quarterly reports with the SEC under the Exchange Act. Moreover, we
will not be required to comply with Regulation FD, which restricts the selective disclosure of material information, although we intend to voluntarily adopt a corporate disclosure policy substantially similar to Regulation FD. These exemptions and
leniencies will reduce the frequency and scope of information and protections to which you may otherwise have been eligible in relation to a U.S. domestic issuer. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We would lose our foreign private issuer status if a majority of our shares are owned by U.S. residents and a majority of our directors or executive officers are U.S.
citizens or residents or we fail to meet additional requirements necessary to avoid loss of foreign private issuer status. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly higher. If
we are not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive than the forms available to a foreign private issuer. We
may also be required to modify certain of our policies to comply with accepted governance practices associated with U.S. domestic issuers. Such conversion and modifications will involve additional costs. In addition, we would lose our ability to
rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are an emerging
growth company and the reduced disclosure requirements applicable to emerging growth companies may make our ordinary shares less attractive to investors. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an emerging growth company, as defined in the JOBS Act, and we may take advantage of certain exemptions from various requirements that are applicable to other
public companies that are not emerging growth companies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For as long as we remain an emerging growth company we are permitted and intend to rely on exemptions from
certain disclosure requirements that are applicable to other public companies that are not &#147;emerging growth companies.&#148; These exemptions include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">being permitted to provide only two years of audited financial statements, in addition to any required unaudited condensed consolidated interim financial statements, with correspondingly reduced &#147;Management&#146;s
discussion and analysis of financial condition and results of operations&#148; disclosure; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing
additional information about the audit and the financial statements; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure obligations regarding executive compensation; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will remain an emerging growth company until the earliest of: (i) the last day of our fiscal year during which we have total annual gross revenues of at least
$1.07&nbsp;billion; (ii) the last day of our fiscal year following the fifth anniversary of the closing of this offering; (iii) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt;
or (iv) the date on which we are deemed to be a &#147;large accelerated filer&#148; under the Exchange Act. We have opted out of the extended transition period made available to emerging growth companies to comply with newly adopted public company
accounting requirements. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When we are no longer deemed to be an emerging growth company, we will not be entitled to the exemptions provided in the JOBS Act
discussed above. We cannot predict if investors will find our ordinary shares less attractive as a result of our reliance on exemptions under the JOBS Act. If some investors find our ordinary shares less
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
attractive as a result, there may be a less active trading market for our ordinary shares and our share price may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to our Operations in Israel </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our headquarters, research
and development and other significant operations are located in Israel and, therefore, our results may be adversely affected by political, economic and military instability in Israel. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our headquarters and research and development facilities are located in Ra&#146;anana, Israel. In addition, the majority of our key employees, officers and directors
are residents of Israel. If these or any future facilities in Israel were to be damaged, destroyed or otherwise unable to operate, whether due to war, acts of hostility, earthquakes, fire, floods, hurricanes, storms, tornadoes, other natural
disasters, employee malfeasance, terrorist acts, power outages or otherwise, or if performance of our research and development is disrupted for any other reason, such an event could delay our clinical trials or, if our product candidates are
approved and we choose to manufacture all or any part of them internally, jeopardize our ability to manufacture our products as promptly as our prospective customers will likely expect, or possibly at all. If we experience delays in achieving our
development objectives, or if we are unable to manufacture an approved product within a timeframe that meets our prospective customers&#146; expectations, our business, prospects, financial results and reputation could be harmed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Political, economic and military conditions in Israel may directly affect our business. Since the establishment of the State of Israel in 1948, a number of armed
conflicts have taken place between Israel and its neighboring countries, Hamas (an Islamist militia and political group that controls the Gaza Strip) and Hezbollah (an Islamist militia and political group based in Lebanon). In addition, several
countries, principally in the Middle East, restrict doing business with Israel, and additional countries may impose restrictions on doing business with Israel and Israeli companies whether as a result of hostilities in the region or otherwise. Any
hostilities involving Israel, terrorist activities, political instability or violence in the region or the interruption or curtailment of trade or transport between Israel and its trading partners could adversely affect our operations and results of
operations and adversely affect the market price of our ordinary shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial insurance does not cover losses that may occur as a result of an event
associated with the security situation in the Middle East. Although the Israeli government is currently committed to covering the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, there can be no assurance
that this government coverage will be maintained, or if maintained, will be sufficient to compensate us fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business, financial condition and
results of operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, our operations could be disrupted by the obligations of our employees to perform military service. As of December 31, 2016, we had
31&nbsp;employees based in Israel. Of these employees, some may be military reservists, and may be called upon to perform military reserve duty of up to 36 days per year (and in some cases more) until they reach the age of 40 (and in some cases, up
to the age of 45 or older). Additionally, they may be called to active duty at any time under emergency circumstances. In response to increased tension and hostilities in the region, there have been, at times, call-ups of military reservists, and it
is possible that there will be additional call-ups in the future. Our operations could be disrupted by the absence of these employees due to military service. Such disruption could harm our business and operating results. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The Israeli government grants we have received for research and development activities restrict our ability to manufacture products and transfer technologies
outside of Israel and require us, in addition to the payment of royalties, to satisfy specified conditions. If we fail to satisfy these conditions, we may be required to refund grants previously received and incur financial penalties. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have received grants under the Israeli Law for the Encouragement of Industrial Research, Development and Technological Innovation, 5754-1984, or the R&amp;D Law,
from the Israel Innovation Authority of the Ministry of Economy and Industry in Israel, or the IIA, formerly known as the Office of the Chief Scientist, an independent and impartial public entity, for some of our development programs. As of
December&nbsp;31, 2016, we had received grants in the aggregate amount of $2.1&nbsp;million. We have applied, and may in the future apply, to receive additional grants from the IIA. However, we cannot predict whether we will be entitled to any
future grants, or the amounts of any such grants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A recipient of a grant from the IIA is obligated to pay royalties generally at a rate of 3% to 5% on revenues from sales
of products developed with IIA-funded technology, up to the amount of the grant related to any such products plus accrued interest. Under the R&amp;D Law, a company that received grants from the IIA may not transfer IIA-funded technology or
manufacture products developed with IIA-funded technology outside of the State of Israel without first obtaining the approval of the IIA. For example, under the Allergan Agreement, Allergan has the option to manufacture products developed with
IIA-funded technology outside of Israel and, although Allergan has not yet exercised this option, we have requested approval from the IIA for a possible transfer. We may not receive any such approval upon any request, which could prevent us, for
example, from out-licensing our product candidates or complying with our existing agreements. Even if we do receive such approvals, we may be required to pay increased royalties of up to 300% of the amount of the original grant and other amounts. If
we do not receive such approvals, we may be required to pay significant penalties. The IIA may also impose certain conditions on any arrangement under which it permits us to transfer IIA-funded technology outside of the State of Israel. Furthermore,
the consideration available to our shareholders in a transaction involving the transfer outside of the State of Israel of IIA-funded technology (such as a merger or similar transaction) may be reduced by any amounts that we are required to pay to
IIA. The restrictions under the R&amp;D Law will continue to apply even after we have repaid the full amount of royalties due to the IIA. If we fail to satisfy the conditions of the R&amp;D Law, we may be required to refund the amounts of the grants
previously received, together with interest and penalties, and may become subject to criminal charges. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Provisions of Israeli law and our amended and restated
articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, us, even when the terms of such a transaction are favorable to us and our shareholders. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Israeli corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions
involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types of transactions. For example, a tender offer for all of a company&#146;s issued and outstanding shares can only be completed if
shareholders not accepting the tender offer hold less than 5% of the issued share capital. Completion of the tender offer also requires approval of a majority of the offerees that do not have a personal interest in the tender offer, unless
shareholders not accepting the tender offer hold less than 2% of the company&#146;s outstanding shares. Furthermore, the shareholders, including those who indicated their acceptance of the tender offer, may, at any time within six months following
the completion of the tender offer, petition an Israeli court to alter the consideration for the acquisition, unless the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek such appraisal rights. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty
with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain
circumstances but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years from the date of the transaction during which sales and dispositions of shares of the participating
companies are subject to certain restrictions. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no disposition of the shares has occurred.
These provisions could delay, prevent or impede an acquisition of us or our merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>It may be difficult to enforce a judgment of a U.S. court against us, our officers and directors or the Israeli experts named in this prospectus in Israel or the
United States, to assert U.S. securities laws claims in Israel or to serve process on our officers and directors and these experts. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are incorporated in
Israel. The majority of our directors and most of our executive officers listed in this prospectus reside outside of the United States, and most of our assets and most of the assets of these persons are located outside of the United States.
Therefore, a judgment obtained against us, or any of these persons, including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not be enforced by an Israeli
court. It may also be difficult for you to effect service of process on these persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an
alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert
witnesses, which can be a time consuming and costly process. Certain matters of procedure will also be governed by Israeli law. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is little binding case law in
Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a judgment against us in Israel, you may not be able to collect any damages awarded by either a U.S. or foreign court. Please see the section
entitled &#147;Enforcement of Civil Liabilities&#148; for additional information on your ability to enforce a civil claim against us and our executive officers or directors named in this prospectus. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Your rights and responsibilities as a shareholder will be governed by Israeli law, which differs in some material respects from the rights and responsibilities of
shareholders of U.S. companies. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The rights and responsibilities of the holders of our ordinary shares are governed by our amended and restated articles of
association and by Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders in U.S. companies. In particular, a shareholder of an Israeli company has a duty to act in good
faith and in a customary manner in exercising its rights and performing its obligations towards the company and other shareholders, and to refrain from abusing its power in the company, including, among other things, in voting at a general meeting
of shareholders on matters such as amendments to a company&#146;s articles of association, increases in a company&#146;s authorized share capital, mergers and acquisitions and related party transactions requiring shareholder approval, as well as a
general duty to refrain from discriminating against other </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">shareholders. In addition, a shareholder who is aware that it possesses the power to determine the
outcome of a vote at a meeting of the shareholders or to appoint or prevent the appointment of a director or executive officer in the company has a duty of fairness toward the company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is limited case law available to assist us in understanding the nature of these duties or the implications of these provisions. These provisions may be
interpreted to impose additional obligations and liabilities on holders of our ordinary shares that are not typically imposed on shareholders of U.S. companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and
expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;assume,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;due,&#148; &#147;estimate,&#148;
&#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;positioned,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148;
&#147;will,&#148; &#147;would,&#148; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are
not limited to, statements about: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and conduct of our clinical trials of MitoGel, VesiGel and our other product candidates, including statements regarding the timing, progress and results of current and future preclinical studies and clinical
trials, and our research and development programs; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of MitoGel, VesiGel and our other product candidates; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans regarding utilization of regulatory pathways that would allow for accelerated marketing approval in the United States;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding timing for application for and receipt of regulatory approval for any of our product candidates;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ongoing and planned discovery and development of product candidates;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding future growth, including our ability to develop, and obtain regulatory approval for, new product candidates; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain adequate intellectual property rights and adequately protect and enforce such rights; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to maintain our collaboration with Allergan, enter into and successfully complete other collaborations, licensing arrangements or in-license or acquire rights to other products, product candidates or
technologies; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans to develop and commercialize our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding the market opportunity for our product candidates;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding expenses, future revenues, capital requirements and the need for additional financing; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our planned level of capital expenditures and our belief that our existing cash and cash equivalents will be sufficient to fund our operations for at least the next 12 months; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the impact of our research and development expenses as we continue developing product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the maintenance of our foreign private issuer status; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the impact of government laws and regulations; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the use of proceeds from this offering. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Forward-looking statements are based on our
management&#146;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management&#146;s beliefs and assumptions, and are not guarantees of future performance or development and
involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this prospectus may turn out to be inaccurate. Factors that may cause actual
results to differ materially from current expectations include, among other things, those listed under &#147;Risk Factors&#148; and </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">elsewhere in this prospectus.
Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The forward-looking statements included in this
prospectus speak only as of the date of this prospectus. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we assume no
obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with
the SEC after the date of this prospectus. See &#147;Where You Can Find More Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate that the net proceeds from the sale of 3,461,538 ordinary shares in this offering will be approximately $39.3 million, after deducting the underwriting
discounts and commissions and estimated offering expenses payable by us, based on an assumed initial public offering price of $13.00 per ordinary share, which is the midpoint of the price range set forth on the cover of this prospectus. If the
underwriters exercise their option to purchase 519,230 additional ordinary shares in full, we estimate that the net proceeds to us from this offering will be approximately $45.6&nbsp;million, after deducting the underwriting discounts and
commissions and estimated offering expenses payable by us. Each $1.00 increase (decrease) in the assumed initial public offering price of $13.00 per ordinary share would increase (decrease) the net proceeds to us from this offering, after deducting
the underwriting discounts and commissions and estimated offering expenses payable by us, by $3.2 million, assuming that the number of ordinary shares offered by us, as set forth on the cover of this prospectus, remains the same. We may also
increase or decrease the number of ordinary shares we are offering. An increase (decrease) of 100,000 in the number of ordinary shares we are offering would increase (decrease) the net proceeds to us from this offering, after deducting the
underwriting discounts and commissions and estimated offering expenses payable by us, by $1.2&nbsp;million, assuming the assumed initial public offering price stays the same. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to use the net proceeds from this offering, together with our existing cash resources, to advance our clinical pipeline, including specifically: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $17.0 million to complete our single pivotal Phase 3 clinical trial of MitoGel for the treatment of low-grade UTUC; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $14.0 million to file an IND for, and to initiate our Phase 2b clinical trial of, VesiGel for the treatment of low-grade NMIBC; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the remainder to fund continued research and clinical development of our other product candidates, including Vesimune, and for working capital and other general corporate purposes. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Due to the uncertainties inherent in the clinical development and regulatory approval process, it is difficult to estimate with certainty the exact amounts of the net
proceeds from this offering that may be used for any of the above purposes on a stand-alone basis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pending our application of the net proceeds from this offering,
we plan to invest such proceeds in depositary institutions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_5"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never declared or paid cash dividends to our shareholders and we do not intend to pay cash dividends in the foreseeable future. We intend to reinvest any
earnings in developing and expanding our business. Any future determination relating to our dividend policy will be at the discretion of our board of directors in compliance with applicable legal requirements and will depend on a number of factors,
including future earnings, our financial condition, operating results, contractual restrictions, capital requirements, business prospects, our strategic goals and plans to expand our business, applicable law and other factors that our board of
directors may deem relevant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">See &#147;Risk Factors&#151;Risks Related to an Investment in Our Ordinary Shares&#151;We have never paid cash dividends on our share
capital, and we do not anticipate paying any cash dividends in the foreseeable future&#148; and, for an explanation concerning the payment of dividends under Israeli law, see &#147;Description of Share Capital&#151;Dividend and Liquidation
Rights.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_6"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth our cash and cash equivalents and capitalization as of December&nbsp;31, 2016 on: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an actual basis; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a pro forma basis to reflect the automatic conversion of all outstanding preferred shares into an aggregate of 5,193,427 ordinary shares; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a pro forma as adjusted basis to give further effect to the sale of 3,461,538 ordinary shares in this offering at an assumed initial public offering price of $13.00 per ordinary share, which is the midpoint of the price
range set forth on the cover of this prospectus, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The pro forma and pro forma as adjusted data included in the table below are also unaudited. You should read this information together with our condensed consolidated
interim financial statements appearing elsewhere in this prospectus and the information set forth under the headings &#147;Selected Financial Data,&#148; &#147;Use of Proceeds&#148; and &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations.&#148; </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA<BR>AS&nbsp;ADJUSTED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ordinary shares, NIS 0.01 par value: 17,600,000 shares authorized at December&nbsp;31, 2016, actual;
32,000,000 shares authorized pro forma and 100,000,000&nbsp;shares authorized pro forma as adjusted; 2,305,743 issued and outstanding as of December&nbsp;31, 2016, actual; 7,499,170 shares issued and outstanding, pro forma; 10,960,708 issued and
outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A and <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares, NIS 0.01 par value: 14,400,000
shares authorized at December&nbsp;31, 2016, actual; zero shares authorized pro forma and pro forma as adjusted; 5,193,427 shares issued and outstanding at December&nbsp;31, 2016, actual; zero shares issued and outstanding, pro forma and pro forma
as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total shareholders&#146; equity<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total capitalization<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>Each $1.00 increase or decrease in the assumed initial public offering price of $13.00 per ordinary share, which is the midpoint of the price range set forth on the
cover of this prospectus, would increase or decrease, respectively, the amount of cash and cash equivalents, total equity and total capitalization by $3.2 million, assuming the number of ordinary shares offered by us, as set forth on the cover of
this prospectus, remains the same, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares we are offering. An increase or decrease
of 100,000 in the number of ordinary shares we are offering would increase or decrease, respectively, the amount of cash and cash equivalents, total equity and total capitalization by $1.2&nbsp;million, assuming the assumed initial public offering
price per ordinary share, as set forth on the cover of this prospectus, remains the same. At December 31, 2016, actual cash and cash equivalents reflected $1,427,700 in offering expenses paid through that date. The pro forma as adjusted information
is illustrative only, and we will adjust this information based on the actual initial public offering price and other terms of this offering determined at pricing. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As of December 31, 2016, we had outstanding warrants to purchase 728,312 Series&nbsp;A-1 preferred shares at an exercise price of $7.81 per share. The warrants will expire upon the closing of this offering, unless they
are exercised beforehand. If the warrants are exercised in cash in full, we would expect that our cash and cash equivalents would increase by $5.1&nbsp;million, our shareholders&#146; equity in respect of Series&nbsp;A-1 preferred shares would
increase by $2,000 and our additional paid-in capital would increase by $8.7&nbsp;million. If the warrants are net share settled in full, the aggregate impact on our capitalization would be an increase of 290,766 shares. The <FONT
STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> preferred shares are converted on a one-for-one basis with ordinary shares. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_7"></A>DILUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you invest in our ordinary shares in this offering, your interest will be immediately diluted to the extent of the difference between the initial public offering
price per ordinary share in this offering and the net tangible book value per ordinary share after this offering. Dilution results from the fact that the initial public offering price per ordinary share is substantially in excess of the net tangible
book value per ordinary share. As of December&nbsp;31, 2016, we had a historical net tangible book value per ordinary share of $7.07. Our net tangible book value per share represents total tangible assets less total liabilities, all divided by the
number of shares outstanding on December&nbsp;31, 2016. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After giving effect to the sale of ordinary shares in this offering at an assumed initial public offering
price of $13.00 per ordinary share, which is the midpoint of the price range set forth on the cover of this prospectus, and after deducting the underwriting discounts and commissions and estimated offering expenses, and after taking into account the
automatic conversion of all of our outstanding preferred shares into an aggregate of 5,193,427 ordinary shares in connection with this offering, our pro forma as adjusted net tangible book value at December&nbsp;31, 2016 would have been $5.23 per
share. This represents an immediate increase in pro forma as adjusted net tangible book value of $3.06 per share to new investors and immediate dilution of $7.77 per ordinary share to new investors. The following table illustrates this dilution per
ordinary share: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Assumed initial public offering price per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Historical net tangible book value per ordinary share as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Decrease in net tangible book value per ordinary share due to conversion of preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net tangible book value per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in pro forma net tangible book value per ordinary share attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma as adjusted net tangible book value per ordinary share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dilution per ordinary share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A $1.00 increase (decrease) in the assumed initial public offering price of $13.00 per ordinary share, which is the midpoint of the price range set forth on the cover
of this prospectus, would increase (decrease) our pro forma as adjusted net tangible book value as of December&nbsp;31, 2016 after this offering by approximately $0.29 per ordinary share, and would increase (decrease) dilution to investors in this
offering by $0.71 per ordinary share, assuming that the number of ordinary shares offered by us, as set forth on the cover of this prospectus, remains the same, after deducting the underwriting discounts and commissions and estimated offering
expenses payable by us. We may also increase or decrease the number of ordinary shares we are offering. An increase (decrease) of 100,000 in the number of ordinary shares we are offering would increase (decrease) our pro forma as adjusted net
tangible book value as of December&nbsp;31, 2016 after this offering by approximately $0.06 per ordinary share, and would decrease (increase) dilution to investors in this offering by approximately $0.06 per ordinary share, assuming the assumed
initial public offering price per ordinary share remains the same, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The pro forma and pro forma as adjusted information is illustrative only, and we will adjust this information based on the actual initial public offering price and
other terms of this offering determined at pricing. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the underwriters exercise in full their option to purchase 519,230 additional ordinary shares, the pro
forma as adjusted net tangible book value will increase to $5.54&nbsp;per ordinary share, representing an immediate increase in pro forma as adjusted net tangible book value to existing shareholders of $0.31&nbsp;per ordinary share and an immediate
dilution of $0.31&nbsp;per ordinary share to new investors participating in this offering. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may choose to raise additional capital due to market conditions
or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance of these
securities could result in further dilution to our equity holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table shows, as of December&nbsp;31, 2016, on a pro forma basis, the number of ordinary shares purchased
from us, the total consideration paid to us and the average price paid per share during the last five years by existing shareholders and by new investors purchasing ordinary shares in this offering at an assumed initial public offering price of
$13.00 per ordinary share, which is the midpoint of the price range set forth on the cover of this prospectus, before deducting the underwriting discounts and commissions and estimated offering expenses payable by us: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(In thousands, except share and per share amounts and percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B><br><B>SUBSCRIBED FOR/</B><br><B>PURCHASED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>CONSIDERATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AVERAGE</B><br><B>PRICE<BR>PER</B><br><B>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Existing shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,499,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,461,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,960,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A $1.00 increase (decrease) in the assumed initial public offering price of $13.00&nbsp;per ordinary share (the midpoint of the price range set forth on the cover page
of this prospectus) would increase (decrease) the total consideration paid by investors participating in this offering, total consideration paid by all shareholders and the average price per share paid by all shareholders by approximately
$3.5&nbsp;million, $3.5&nbsp;million and $0.32, respectively, assuming that the number of ordinary shares offered by us, as set forth on the cover page of this prospectus, remains the same and before deducting the underwriting discounts and
commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similarly, a 100,000 share increase (decrease) in the number of ordinary shares offered by us, as set
forth on the cover of this prospectus, would increase (decrease) the total consideration paid by investors participating in this offering, total consideration paid by all shareholders and the average price per share paid by all shareholders by
approximately $1.3&nbsp;million, $1.3&nbsp;million and $0.05, respectively, assuming the assumed initial public offering price of $13.00&nbsp;per ordinary share (the midpoint of the price range set forth on the cover of this prospectus) remains the
same, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of ordinary shares in the table
above shown as issued and outstanding on a pro forma as adjusted basis is based on ordinary shares outstanding as of December&nbsp;31, 2016 and assumes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance by us of 3,461,538 ordinary shares in this offering; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of 5,193,427 ordinary shares upon the conversion of all Series A preferred shares into ordinary shares, which will occur automatically upon the closing of this offering; </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">but excludes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of 728,312 Series A-1 preferred shares upon the exercise of outstanding warrants to purchase Series A-1 preferred shares (assuming their exercise for cash) and the conversion thereof into ordinary shares,
which will occur automatically upon the closing of this offering; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,399,499 ordinary shares reserved for issuance under our 2010 Israeli Share Option Plan upon the exercise of outstanding options at a weighted average exercise price of $4.75 per share; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">304,000 ordinary shares reserved for issuance upon the vesting of outstanding restricted share units; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">278,400 ordinary shares reserved for issuance upon the achievement of certain milestones under the Vesimune asset purchase agreement with Telormedix SA; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1.4 million ordinary shares available for issuance pursuant to the terms of our 2017 Equity Incentive Plan. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain of
our existing investors and their affiliated entities and other entities have indicated an interest in purchasing up to an aggregate of approximately $20.0&nbsp;million worth of our ordinary shares in this offering at the initial public offering
price. The foregoing discussion does not reflect the potential purchase of any shares in this offering by these persons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_8"></A>SELECTED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following tables present selected financial data for our business. We derived the selected statements of operations data for the years ended December&nbsp;31,
2016 and 2015 and the selected balance sheet data as of December&nbsp;31, 2016 and 2015 from our audited financial statements included elsewhere in this prospectus. We maintain our books and records in U.S. dollars, and prepare our financial
statements in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, as issued by the Financial Accounting Standards Board, or FASB. You should read this data together with our financial statements and related
notes appearing elsewhere in this prospectus and the information under the captions &#147;Capitalization&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results are not
necessarily indicative of our future results, and our interim period results are not necessarily indicative of results to be expected for a full year or any other interim period. </I></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands, except share and<BR>per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Statements of operations data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Finance expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss per ordinary share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average number of ordinary shares outstanding used in computing loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents<SUP STYLE="font-size:85%; vertical-align:top"></SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Working capital is defined as total current assets minus total current liabilities. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following discussion and
analysis should be read in conjunction with &#147;Selected Financial Data&#148; and our financial statements and related notes included elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain
forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the
timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under &#147;Risk Factors&#148; and elsewhere in this prospectus. You should
carefully read the &#147;Risk Factors&#148; section of this prospectus to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled
&#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. We have an
innovative and broad pipeline of product candidates that we believe can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on <FONT STYLE="white-space:nowrap">uro-oncology.</FONT> Our lead
product candidates, MitoGel and VesiGel, are proprietary formulations of the chemotherapy drug MMC, which is currently used for urothelial cancer treatment only in a water-based formulation as an adjuvant therapy. We are developing our product
candidates as chemoablation agents, which means they are designed to remove tumors by <FONT STYLE="white-space:nowrap">non-surgical</FONT> means, to treat several forms of <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive urothelial
cancer, including <FONT STYLE="white-space:nowrap">low-grade</FONT> UTUC and <FONT STYLE="white-space:nowrap">low-grade</FONT> bladder cancer. We believe that MitoGel and VesiGel, which are both local drug therapies, have the potential to
significantly improve patients&#146; quality of life by replacing costly, <FONT STYLE="white-space:nowrap">sub-optimal</FONT> and burdensome tumor resection and kidney removal surgeries as the first-line standard of care. MitoGel and VesiGel may
also reduce the need for bladder, kidney and upper urothelial tract removals, which are typically performed on patients whose cancer progresses despite undergoing tumor resection surgical procedures. Additionally, we believe that our product
candidates, which are based on novel formulations of previously approved drugs, may qualify for streamlined regulatory pathways to market approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our lead
product candidates, MitoGel and VesiGel, are formulated using our proprietary RTGel technology. We believe that RTGel-based drug formulations, which provide for the sustained release of an active drug, may improve the efficacy of treatment of
various types of urothelial cancer without compromising the safety of the patient or interfering with the natural flow of fluids from the urinary tract to the bladder. Our formulations are designed to achieve this by increasing the dwell time as
well as the tissue coverage throughout the organ of the active drug. Consequently, we believe that RTGel-based drug formulations may enable us to overcome the anatomical and physiological challenges that have historically contributed to the lack of
drug development for the treatment of urothelial cancer. No drugs have been approved by the FDA for the treatment of <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive bladder cancer, or NMIBC, in more than 15 years. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our clinical stage pipeline also includes Vesimune, our proprietary immunotherapy product candidate for the treatment of high-grade NMIBC. We acquired Vesimune from
Telormedix SA, a private Swiss-based biotechnology company, in the fourth quarter of 2015. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We entered into an exclusive license agreement with Allergan
Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc in October 2016, or the Allergan Agreement. Allergan paid us a nonrefundable upfront license fee of $17.5&nbsp;million, and we are eligible to receive
additional material milestone payments upon the successful completion of certain development, regulatory and commercial milestones. Under the Allergan Agreement, Allergan is solely responsible, at its expense, for developing, obtaining regulatory
approvals for and commercializing the Licensed Products worldwide. Allergan will pay us a tiered royalty in the low single digits based on worldwide annual net sales of Licensed Products, subject to certain reductions for the market entry of
competing products and/or loss of our patent coverage of Licensed Products. We are responsible for payments to any third party under our existing agreement and certain future agreement for certain RTGel-related third party intellectual properties.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have incurred net losses in each period since our formation in 2004. We incurred net losses of $1.9&nbsp;million and
$12.7&nbsp;million for the years ended December&nbsp;31, 2016 and 2015, respectively. As of December&nbsp;31, 2016 and 2015, our accumulated deficit was $27.2&nbsp;million and $25.3&nbsp;million, respectively. We expect to continue to incur losses
for the foreseeable future, and our losses may fluctuate significantly from year to year. We expect that our expenses will increase substantially in connection with our ongoing activities as we: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conduct the single pivotal Phase 3 clinical trial for MitoGel, and plan to initiate a Phase 2b clinical trial for VesiGel, each pursuant to the FDA&#146;s 505(b)(2) regulatory pathway; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiate an additional clinical trial for Vesimune in combination with another agent; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue the preclinical development of our other product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">file an NDA seeking regulatory approval for any product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any products for which we obtain regulatory approval; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain, expand and protect our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add equipment and physical infrastructure to support our research and development; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hire additional clinical development, quality control and manufacturing personnel; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Components of Results of Operations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenues </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not currently have any products approved for sale and to date, we have not recognized any revenues from sales of MitoGel, VesiGel or Vesimune. During the year
ended December&nbsp;31, 2016, we recognized revenues of $17.5&nbsp;million from a payment received under the Allergan Agreement. In the future, we may generate revenue from a combination of product sales, reimbursements, <FONT
STYLE="white-space:nowrap">up-front</FONT> payments, milestone payments, and royalties in connection with the Allergan Agreement and future collaborations. If we fail to achieve clinical success and/or to obtain regulatory approval of any of our
product candidates in a timely manner, our ability to generate future revenue will be impaired. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and development expenses, net </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The largest component of our total operating expenses has historically been, and we expect will continue to be, research and development. Research and development
expenses consist primarily of: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">salaries and related costs, including share-based compensation expense, for our personnel in research and development functions; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses incurred under agreements with third parties, including CROs, subcontractors, suppliers and consultants, preclinical studies and clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses incurred to acquire, develop and manufacture preclinical study and clinical trial materials; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">facility and equipment costs, including depreciation expense, maintenance and allocated direct and indirect overhead costs; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in process research and development costs related to intellectual property purchased from others. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expense all
research and development costs as incurred. In light of the fact that our employees and internal resources may be engaged in projects for multiple programs at any time, our focus is on total research and development expenditures, and we do not
allocate our internal research and development expenses by project. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2016, we have received grants of $2.1&nbsp;million in the aggregate
from the IIA for research and development funding. Pursuant to the terms of the grants, we are required to pay royalties to the Government of Israel on revenues from sales of products for which the research and development was funded, in whole or in
part, by the IIA. Pursuant to the terms of the grants, we are obligated to pay the IIA royalties of 3.0% to 4.5% on revenues from sales of products developed from a project financed in whole or in part by IIA grants, up to a limit of 100% of the
amount of the grant received, plus annual interest calculated at a rate based on <FONT STYLE="white-space:nowrap">12-month</FONT> LIBOR. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to paying any royalties due, we must abide by other restrictions associated with receiving such grants under
the R&amp;D Law, which will continue to apply to us following full repayment to the IIA. For example, under the Allergan Agreement, Allergan has the option to manufacture products developed with IIA-funded technology outside of Israel, which would
require approval from the IIA. Although Allergan has not yet exercised this option, we have requested approval from the IIA for a possible transfer. We may not receive such approval. Even if we do receive such approval, we may be required to pay
increased royalties of up to 300% of the amount of the original grant and other amounts. See &#147;Risk Factors&#151;The Israeli government grants we have received for research and development activities restrict our ability to manufacture products
and transfer technologies outside of Israel and require us, in addition to the payment of royalties, to satisfy specified conditions. If we fail to satisfy these conditions, we may be required to refund grants previously received and incur financial
penalties.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are currently focused on advancing our product candidates, and our future research and development expenses will depend on their clinical
success. Research and development expenses will continue to be significant and will increase over at least the next several years as we continue to develop our product candidates and conduct preclinical studies and clinical trials of our product
candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not believe that it is possible at this time to accurately project total expenses required for us to reach commercialization of our product
candidates. Due to the inherently unpredictable nature of preclinical and clinical development, we are unable to estimate with certainty the costs we will incur and the timelines that will be required in the continued development and approval of our
product candidates. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. See &#147;Risk Factors&#151;Risks Related to Our Business and Strategy.&#148; In addition,
we cannot forecast which product candidates may be subject to future collaborations, if and when such arrangements will be entered into, if at all, and to what degree such arrangements would affect our development plans and capital requirements.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under applicable accounting rules, we deduct the IIA grants from research and development expenses as the applicable costs are incurred. We also had a preclinical
collaboration for BotuGel with Allergan into which we initially entered into in February 2014. We deduct amounts received from the preclinical collaboration with Allergan from our research and development expenses as the applicable costs are
incurred. As a result, our research and development expenses are shown on our financial statements net of the IIA grants and amounts received from the preclinical collaboration. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>General and administrative expenses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative
expenses consist primarily of personnel costs, including share-based compensation, related to directors, executive, finance, and human resource functions, facility costs and external professional service costs, including legal, accounting and audit
services and other consulting fees. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We anticipate that our general and administrative expenses will increase in the future as we increase our administrative
headcount and infrastructure to support our continued research and development programs and the potential approval and commercialization of our product candidates. We also anticipate that we will incur increased expenses related to audit, legal,
regulatory and <FONT STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with NASDAQ and SEC requirements, director and officer insurance premiums, director compensation, and other costs associated with
being a public company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, if any of our product candidates receives regulatory approval and if we determine to invest in building a commercial
infrastructure to support the marketing of our products, we expect to incur greater expenses. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Finance expenses, net </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Finance expenses, net, consist primarily of finance expenses on warrants. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Income taxes </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have yet to generate taxable income in Israel, as we
have historically incurred operating losses resulting in carry forward tax losses totaling approximately $14.2&nbsp;million as of December&nbsp;31, 2016. We anticipate that we will continue to generate tax losses for the foreseeable future and that
we will be able to carry forward these tax losses indefinitely to future taxable years. Accordingly, we do not expect to pay taxes in Israel until we have taxable income after the full utilization of our carry forward tax losses. We have provided a
full valuation allowance with respect to the deferred tax assets related to these carry forward losses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comparison of the years ended December&nbsp;31, 2016 and 2015 </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
following table summarizes our results of operations for the years ended December&nbsp;31, 2016 and 2015: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cost of revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses, net <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Finance expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes share-based compensation expense as follows: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Revenues </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our total revenues increased by $17.5&nbsp;million from $0 in the
year ended December&nbsp;31, 2015 to $17.5&nbsp;million in the year ended December&nbsp;31, 2016, due to the nonrefundable upfront license fee received under the Allergan Agreement. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and development expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses
decreased by $228,000, or 2%, to $10.3&nbsp;million in the year ended December&nbsp;31, 2016 from $10.5&nbsp;million in the year ended December&nbsp;31, 2015. Approximately $4.1&nbsp;million of the decrease relates to
<FONT STYLE="white-space:nowrap">in-process</FONT> research and development costs in connection with intellectual property related to Vesimune that we purchased from Telormedix SA in 2015. This decrease is partly offset by an increase of
$3.9&nbsp;million primarily attributable to an increase in share-based compensation to consultants and employees of $997,000, an increase of $546,000 in payroll mainly due to increased headcount and a $1.2&nbsp;million increase relating to research
and development expense offsets in 2015 from IIA grants and from our prior preclinical collaboration with Allergan for BotuGel. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have assessed that, of our
$10.3&nbsp;million aggregate research and development expenditures in 2016 (after adjusting for an aggregate $49,000 of <FONT STYLE="white-space:nowrap">off-setting</FONT> third-party contributions) approximately 34% were allocated to the
development of MitoGel, approximately 8% were allocated to the development of VesiGel, and approximately 57% were allocated to other products and unallocated expenses. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have assessed that, of our $10.5&nbsp;million aggregate research and development expenditures in 2015 (after adjusting for an aggregate $1.2&nbsp;million of <FONT
STYLE="white-space:nowrap">off-setting</FONT> third-party contributions) approximately 30% were allocated to the development of MitoGel, approximately 5% were allocated to the development of VesiGel, approximately 35% were allocated to the
development of Vesimune, and approximately 30% were allocated to other products and unallocated expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and administrative expenses </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses increased by $4.5&nbsp;million, or 237%, to $6.4&nbsp;million in the year ended December&nbsp;31, 2016 from $1.9&nbsp;million in the
year ended December&nbsp;31, 2015. The increase in general and administrative expenses resulted primarily from an increase in share-based compensation expenses to employees and directors of $521,000, an increase of $773,000 in payroll and an
increase in professional services expenses of $2.8&nbsp;million of which $1.7 million relates to this offering. The increase was primarily related to our strengthening of our senior management team and payments to professional services consultants
hired by us in preparation for this offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Finance expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Finance
expenses, net, increased by $2.4&nbsp;million, or 800%, to $2.7&nbsp;million in the year ended December&nbsp;31, 2016 from $279,000 in the year ended December&nbsp;31, 2015. The change in finance expense was primarily due to the increased fair value
of the warrants converted to Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidity </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our inception, we have incurred losses and negative
cash flows from our operations. For the year ended December&nbsp;31, 2016, we incurred a net loss of $1.9&nbsp;million while net cash of $4.2&nbsp;million was provided from our operating activities. As of December&nbsp;31, 2016, we had working
capital of $18.9&nbsp;million, and an accumulated deficit of $27.2&nbsp;million. Our principal source of liquidity as of December&nbsp;31, 2016 consisted of cash and cash equivalents of $21.4&nbsp;million. As of April&nbsp;3, 2017, our cash and cash
equivalents totaled approximately $18.0&nbsp;million. We believe that our existing cash and cash equivalents will enable us to fund our operations for at least the next 12&nbsp;months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Capital resources </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Overview </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Through December&nbsp;31, 2016, we have financed our operations primarily through private placements of equity securities and convertible notes and through the upfront
payment received under the Allergan Agreement. Total invested capital as of December&nbsp;31, 2016 was $36.3&nbsp;million, which included ordinary shares and Series A preferred shares and warrants to purchase Series
<FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares, as well as convertible notes. The convertible notes were issued during the first half of 2014 and converted in their entirety into Series A preferred shares and warrants to purchase
Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares on October 20, 2014. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Such preferred shares will be converted into ordinary shares of the same
number upon the closing of this offering, in accordance with our articles of association. The warrants to purchase preferred shares expire upon the closing of this offering. We expect that all of the warrants will be exercised for cash or on a
cashless basis prior to the closing of this offering. The preferred shares issuable upon exercise of the warrants will automatically convert into ordinary shares upon the closing of this offering. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash flows </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our statement of cash
flows for the years ended December&nbsp;31, 2016 and 2015: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Net cash provided by (used in) operating activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The use of cash in 2015
and the cash provided in 2016 resulted primarily from our net losses adjusted for <FONT STYLE="white-space:nowrap">non-cash</FONT> charges and measurements and changes in components of working capital. Adjustments to net loss for <FONT
STYLE="white-space:nowrap">non-cash</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
items mainly include depreciation and amortization, fair value adjustment of the preferred <FONT STYLE="white-space:nowrap">A-1</FONT> warrants, share-based compensation and in process R&amp;D.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by operating activities was $4.2&nbsp;million in the year ended December&nbsp;31, 2016, compared to $7.2&nbsp;million used in operating
activities in the year ended December&nbsp;31, 2015. The $11.4&nbsp;million increase was attributable primarily to the decrease of $10.8&nbsp;million in the loss for the year which mainly related to the $17.5&nbsp;million revenue from Allergan,
partly offset by an increase of $4.5&nbsp;million in general and administrative expenses as a result of strengthening our senior management team and payments to professional services consultants hired by us in preparation for this offering. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Net cash used in investing activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The use of cash in investing
activities relates primarily to the purchase of property and equipment and changes in restricted deposits. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities was $793,000
in the year ended December&nbsp;31, 2016, compared to $301,000 in the year ended December&nbsp;31, 2015. The use of cash in investing activities mainly related to leasehold improvements in the Israel and the U.S. offices. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Net cash provided by (used in) financing activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in
financing activities was $9,000 in the year ended December&nbsp;31, 2016, compared to $21.6&nbsp;million provided by financing activities in the year ended December&nbsp;31, 2015, the difference of which mainly related to funds raised pursuant to
the 2015 and 2014 Share Purchase Agreements. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2015, we entered into a share purchase agreement, to which we refer as the 2015 Share Purchase
Agreement. In September 2014, we entered into a share purchase agreement, to which we refer as the 2014 Share Purchase Agreement. During 2015, we raised $18.1&nbsp;million from the 2015 Share Purchase Agreement and $3.6&nbsp;million from the 2014
Share Purchase Agreement. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Funding Requirements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe
that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could use
our capital resources sooner than we currently expect. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our present and future funding requirements will depend on many factors, including, among other things: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the progress, timing and completion of clinical trials for MitoGel and VesiGel; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preclinical studies and clinical trials for Vesimune or any of our other product candidates; </TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs related to obtaining regulatory approval for MitoGel, VesiGel and Vesimune and any of our other product candidates, and any delays we may encounter as a result of regulatory requirements or adverse clinical
trial results with respect to any of these product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selling, marketing and patent-related activities undertaken in connection with the commercialization of MitoGel and VesiGel and any of our other product candidates, and costs involved in the development of an effective
sales and marketing organization; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs involved in filing and prosecuting patent applications and obtaining, maintaining and enforcing patents or defending against claims or infringements raised by third parties, and license royalties or other
amounts we may be required to pay to obtain rights to third party intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential new product candidates we identify and attempt to develop; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">revenues we may derive either directly or in the form of royalty payments from future sales of MitoGel, VesiGel, Vesimune, BotuGel and any other product candidates. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For more information as to the risks associated with our future funding needs, see &#147;Risk Factors&#151;We will require substantial additional financing to achieve
our goals, and a failure to obtain this capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, commercialization efforts or other operations.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Contractual obligations and commitments </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our known contractual obligations as of December&nbsp;31, 2016 are summarized in the following table. The obligations detailed below do not include grants received from
the IIA pursuant to which we will owe royalties or reimbursement upon commercialization of our product candidates. As of December 31, 2016, the maximum royalty amount payable by us under these funding arrangements is $2.1&nbsp;million, excluding
interest. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAYMENTS DUE BY PERIOD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LESS&nbsp;THAN&nbsp;1&nbsp;YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>1&nbsp;TO&nbsp;3&nbsp;YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>3&nbsp;TO&nbsp;7&nbsp;YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease obligations <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Operating lease obligations consist of payments pursuant to a lease agreement for our Israeli offices and laboratory facility and our NY offices. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In November 2014, we entered into a new lease agreement for our Israeli offices effective from February 1, 2015 for a period of three years, with an option to extend the lease agreement by an additional three years. In
April 2016, we signed an addendum to the November 2014 lease agreement in order to increase the office space rented and extend the rental period. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">UroGen Pharma, Inc. entered into a new lease agreement for its New York office for a period of seven years, which period commenced on May&nbsp;1, 2016. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Off-balance</FONT> Sheet Arrangements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As
of the date of this prospectus and during the periods presented, we do not and did not, respectively, have any <FONT STYLE="white-space:nowrap">off-</FONT> balance sheet arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Quantitative and Qualitative Disclosure about Market Risk </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Market risk is
the risk of loss related to changes in market prices, including interest rates and foreign exchange rates, of financial instruments that may adversely impact our financial position, results of operations or cash flows. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Foreign currency exchange risk </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The U.S. dollar is our functional and
reporting currency. However, a significant portion of our operating expenses are incurred in NIS. As a result, we are exposed to the risk that the NIS may appreciate relative to the dollar, or, if the NIS instead devalues relative to the dollar,
that the inflation rate in Israel may exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations in Israel would increase and our
dollar-denominated results of operations would be adversely affected. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation, if any, of the NIS against the dollar. For example, although the dollar
appreciated against the NIS in 2015 by 0.3%, the level of devaluation of the dollar against the NIS in 2016 was 1.5%. If the dollar cost of our operations in Israel increases, our dollar-measured results of operations will be adversely affected. Our
operations also could be adversely affected if we are unable to effectively hedge against currency fluctuations in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not currently engage in
currency hedging activities in order to reduce this currency exposure, but we may begin to do so in the future. Instruments that may be used to hedge future risks may include foreign currency forward and swap contracts. These instruments may be used
to selectively manage risks, but there can be no assurance that we will be fully protected against material foreign currency fluctuations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidity risk
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We monitor forecasts of our liquidity reserve (comprising cash and cash equivalents and deposits). We generally carry this out based on our expected cash
flows in accordance with practice and limits set by our management. We are in the research and development stage and we are therefore exposed to liquidity risk. However, we believe that our existing cash and cash equivalents will enable us to fund
our operating expenses and capital expenditure requirements for at least the next 12 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Critical Accounting Policies and Estimates </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our management&#146;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in
accordance with U.S. GAAP, as issued by the FASB. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and
liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. Actual results may differ from these estimates under different assumptions or conditions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While our significant accounting policies are more fully described in the notes to our financial statements appearing elsewhere in this prospectus, we believe that the
accounting policies discussed below are critical to our financial results and to the understanding of our past and future performance, as these policies relate to the more significant areas involving management&#146;s estimates and assumptions. We
consider an accounting estimate to be critical if: (i)&nbsp;it requires us to make assumptions because information was not available at the time or it included matters that were highly uncertain at the time we were making our estimate and
(ii)&nbsp;changes in the estimate could have a material impact on our financial condition or results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Share-Based Compensation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We account for our share-based compensation for employees and directors in accordance with the provisions of ASC 718, Compensation&#151;Stock Compensation, U.S. GAAP
&#147;Stock-based Payment,&#148; which requires us to measure the cost of share-based compensation based on the fair value of the award on the grant date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We <FONT
STYLE="white-space:nowrap">re-measure</FONT> equity awards granted to <FONT STYLE="white-space:nowrap">non-employees</FONT> at each reporting period at fair value until they have vested. The fair value of equity awards is charged to the statement of
operations over the service period using the straight- line method. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Option Valuations </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We selected the Black-Scholes option pricing model as the most appropriate method for determining the estimated fair value of our share-based awards. The resulting cost
of a share incentive award is recognized as an expense over the requisite service period of the award, which is usually the vesting period. We recognize compensation expense over the vesting period using the straight-line method, and classify these
amounts in the financial statements based on the department to which the related employee reports. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The determination of the grant date fair value of options using
an option pricing model is affected by estimates and assumptions regarding a number of complex and subjective variables. These variables include the expected volatility of our share price over the expected term of the options, share option exercise
and cancellation behaviors, risk-free interest rates and expected dividends, which are estimated as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Fair value of our ordinary shares</I>. Because our shares are not publicly traded, we must estimate the fair value of ordinary shares, as discussed below in &#147;&#151;Valuation of our ordinary shares.&#148;
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Volatility</I>. The expected share price volatility was based on the historical volatility of the ordinary shares of comparable companies that are publicly traded. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected term</I>. The expected term of options granted represents the period of time that options granted are expected to be outstanding. Since adequate historical experience is not available to provide a reasonable
estimate, the expected term for grants to employees for at the money options (except senior management) is determined based on the midpoint between the available exercise dates (the end of the vesting periods) and the last available exercise date
(the contracted expiry date). The expected term for grants to <FONT STYLE="white-space:nowrap">non-employees,</FONT> senior management, directors, and out of the money options granted to employees, is determined based on the contractual life of the
options. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Risk-free rate</I>. The risk-free interest rate is based on the yield from U.S. Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> bonds with a term equivalent to the expected term of the options.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected dividend yield</I>. We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future. Consequently, we used an expected dividend yield of zero.
</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of the assumptions used in the Black-Scholes option pricing model change significantly, share-based compensation for future awards may differ
materially compared with the awards granted previously. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table presents the weighted-average assumptions used to estimate the fair value of options granted on the
dates indicated below. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility (%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">72.72&nbsp;-&nbsp;80.00</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">69.78&nbsp;-&nbsp;76.68</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">5.8&nbsp;-&nbsp;8.5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">1&nbsp;-&nbsp;7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free rate (%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">1.4&nbsp;-&nbsp;2.27</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.38&nbsp;-&nbsp;2.08</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected dividend yield (%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table presents the grant dates, number of underlying shares and related exercise prices of options granted to employees and
<FONT STYLE="white-space:nowrap">non-employees</FONT> since January&nbsp;1, 2015, as well as the estimated fair value of the underlying ordinary shares on the grant date. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:60.15pt; font-size:8pt; font-family:ARIAL"><B>DATE OF GRANT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>SHARES<BR>SUBJECT TO<BR>AWARDS<BR>GRANTED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CLASS&nbsp;OF<BR>SHARES<BR>SUBJECT&nbsp;TO<BR>THE<BR>AWARDS<BR>GRANTED</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TYPE OF<BR>EQUITY<BR>INSTRUMENT<BR>AWARDED</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EXERCISE<BR>PRICE&nbsp;PER<BR>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ESTIMATED<BR>FAIR&nbsp;VALUE<BR>PER&nbsp;ORDINARY<BR>SHARE AT<BR>GRANT DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">August - September 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291,405<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ordinary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Options&nbsp;and&nbsp;RSUs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">$0-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">October - December 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,011,192<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ordinary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">$1.78-5.94</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">January 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ordinary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">April - June 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ordinary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">$0-5.94</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">3.19&nbsp;-&nbsp;3.28</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">November 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ordinary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$5.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes 28,800 ordinary shares issuable upon the vesting of restricted share units, which were granted contingent upon the consummation of the completed purchase of intellectual property from Telormedix SA, and
excludes 28,800 ordinary shares issuable upon the vesting of restricted share units, the grant of which is contingent upon the closing of this offering. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Excludes 9,600 ordinary shares issuable upon the vesting of options, the grant of which is contingent upon the closing of this offering. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on the assumed initial public offering price of $13.00 per share, the midpoint of the range set forth on the cover page of this prospectus, the intrinsic value of
the awards outstanding as of December&nbsp;31, 2016 was $23.3&nbsp;million, of which $12.7 million related to vested options and $10.6 million related to unvested options. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Valuation of our ordinary shares </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Due to the absence of an active market for
our ordinary shares, the fair value of our ordinary shares for purposes of determining the exercise price for award grants was determined in good faith by our management during the fourth quarter of 2015 in relation to grants up to
September&nbsp;30, 2015 and during the first, second, third and fourth quarters of 2016. In connection with preparing our financial statements, our management considered the fair value of our ordinary shares based on a number of objective and
subjective factors, consistent with the methodologies outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held- Company Equity Securities Issued as Compensation, referred to as the AICPA Practice
Aid. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2010-2013 Awards </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ordinary share price was estimated based on
the price at which the most recent financing (from external investors) took place, based on our assumption that no significant changes have occurred between the financing closing date and the grant date. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2014 Awards </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ordinary share price was derived from the price used in the
financing round on October 20, 2014, based on our assumption that no significant changes have occurred between grant date and the financing round closing date. The derivation of ordinary share price was performed under the option pricing method, or
OPM, valuation framework, as described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2015 and 2016 Awards </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
ordinary share price was estimated based on valuations performed as of September&nbsp;30, 2015, November&nbsp;15, 2015, December&nbsp;31, 2015, March&nbsp;31, 2016, June&nbsp;30, 2016, September&nbsp;30, 2016 and December&nbsp;31, 2016, as described
below, and based on our assumption that no significant changes have occurred between grant date and the valuation date. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Fair value of our ordinary shares for
2014 Awards&#151;Methodology </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The valuation of the ordinary shares as of October 20, 2014 was performed under the OPM framework and using the Backsolve method,
which infers the equity value consistent with the financing round on October&nbsp;20, 2014. The OPM method is regarded as a common framework for allocating the equity value between the different share classes and other securities. Under this
approach, the financial instruments issued by the company (preferred shares, warrants, employee options and ordinary shares) are deemed as contingent claims whose future payoffs depends on our (future) equity value. The OPM was implemented by using
the Monte Carlo simulation technique, which generates different scenarios of the equity value and the resulting payoff to the holders of our financial instruments. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underlying asset, or the equity value, was estimated by implementing the Backsolve method. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the above allocation process, we applied a discount of lack of marketability, or DLOM, to the price of an ordinary share. Specifically, we applied the average
strike put option in order to estimate the DLOM. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Fair value of our ordinary shares for 2015 and 2016 Awards&#151;Methodology </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The probability of an IPO event in the near future was estimated to be 20% as of December&nbsp;31, 2016, September&nbsp;30, 2016, June&nbsp;30, 2016 and March&nbsp;31,
2016, and 15% as of December&nbsp;31, 2015. The valuation was conducted through the use of the Hybrid model. The Hybrid approach combines two probability-weighted scenarios: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Scenario I&#151;IPO Event. The probability of this scenario was estimated at 20% and 15% as of the valuation dates described above. </TD></TR></TABLE>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:7%; font-size:9.5pt; font-family:ARIAL">The valuation of our financial instruments was based on the estimated range of equity value upon an IPO and the resulting payoff per each financial
instrument. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Scenario II&#151;Liquidation Event. The probability of this scenario was estimated at 80% and 85% as of the valuation dates described above. </TD></TR></TABLE>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:7%; font-size:9.5pt; font-family:ARIAL">The valuation of the ordinary share price under this scenario was performed under the OPM framework using the Monte Carlo simulation technique, in
similar fashion to the approach used for the 2014 valuation, as described above. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:7%; font-size:9.5pt; font-family:ARIAL">As of September&nbsp;30, 2015, the financing round in October 2015
was highly expected to be closed. As such the equity value used in the OPM method was derived from this financing round (the Backsolve method). The closing date of this round was November&nbsp;15, 2015. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of September&nbsp;30, 2016, the equity value used in the OPM method was derived from the financing round in October 2015 and the incremental value derived from the
Allergan Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2016, the equity value used in the OPM method was derived from a DCF calculation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We applied a DLOM to the ordinary share price, using the average strike put option. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of an ordinary share was calculated as the weighted average of the ordinary share prices, derived from the calculations made under the two scenarios
described above. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Future option awards </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the completion of our
initial public offering and the listing of our shares on the NASDAQ Global Market, the determination of the fair market value of our ordinary shares for purposes of setting the exercise price of future option awards or other share-based compensation
to employees and other grantees will be based on the market price of our shares and will no longer require good faith estimates by our board of directors based on various comparisons or benchmarks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Accounting treatment of the warrants to purchase preferred shares </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our warrants to purchase preferred shares are exercisable into <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> preferred shares of the company, nominal value
NIS&nbsp;0.01 per share, for an exercise price of $7.81 per share commencing on the date of the issuance and expiring at the earlier of a qualified IPO, certain M&amp;A events, or four years from the date of issuance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event that the warrants are exercised in connection with a qualified IPO or certain M&amp;A events, the holder may elect to convert the warrants on a net share
basis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The warrants are classified as liabilities in accordance with ASC 480, as they are freestanding instruments, exercisable into Series <FONT
STYLE="white-space:nowrap">A-1</FONT> preferred shares, which are redeemable upon certain events that represent &#147;Deemed Liquidation&#148; events. Accordingly, the warrants are measured at fair value at the end of every reporting period, and
changes in their fair value are recognized in earnings. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Accounting treatment of the Series A Preferred Shares </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Series A preferred shares are classified within permanent equity because they are not subject to liability classification under the scope of ASC 480, and because
they meet all of the requirements for equity classification under ASC <FONT STYLE="white-space:nowrap">480-10S99.</FONT> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Accounting treatment of intellectual
property assets purchased from Telormedix SA </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2015, we entered into an asset purchase agreement with Telormedix SA pursuant to which we
purchased all of the intellectual property assets of Telormedix in consideration of 691,200 shares of our Series A preferred shares at a price per share of $5.94. Upon the occurrence of any one of three specified regulatory milestones, we are
required to issue an additional 92,800 Series A preferred shares, or 92,800 ordinary shares in the event any milestone is achieved following the completion of this offering. If all three milestones are achieved, we would be required to issue in
total an aggregate of 278,400 Series A preferred shares, or 278,400 ordinary shares in the event the milestones are achieved after the completion of this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The acquired intellectual property costs totaling $4.1&nbsp;million were expensed as incurred to research and development costs in accordance with ASC&nbsp;730, as the
intellectual property is purchased from others for a particular research and development project and has no alternative future uses and therefore no separate economic value. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenue recognition </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Virtually all the Company&#146;s revenues are
derived from the license agreement with Allergan, to license worldwide rights to some of its products. Revenue is recognized only when all of the following conditions have been met: (i)&nbsp;there is persuasive evidence of an arrangement;
(ii)&nbsp;delivery has occurred: (iii)&nbsp;the fee is fixed or determinable: and (iv) collectability of the fee is reasonably assured. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The license agreement
contains two deliverables: (a)&nbsp;the license component and (b)&nbsp;Allergan&#146;s right to require supply services of RTGel vials from the Company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In an
arrangement with multiple deliverables, the delivered item or items shall be considered a separate unit of accounting if all of the following criteria are met: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(a)&nbsp;The delivered item or items have value to the customer on a standalone basis. The item or items have value on a standalone if they are sold separately by any
vendor or the customer could resell the delivered item(s) on a standalone basis. In the context of a customer&#146;s ability to resell the delivered item(s), this criterion does not require the existence of an observable market for the
deliverable(s), and </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(b)&nbsp;If the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the
undelivered item or items is considered probable and substantially in the control of the vendor. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When deliverables are separable, arrangement consideration is
allocated to the separate units of accounting based on the relative selling price of each deliverable (where the amount allocable to the delivered element is limited to the amount not contingent on the delivery of future products or services) and
the appropriate revenue recognition principles are applied to each unit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The license component has standalone value (and therefore is accounted for separately from
the supply services) since Allergan can use the license for its intended purposes without the Company&#146;s supply services. The four </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
conditions of ASC&nbsp;605 were met as of December&nbsp;31, 2016: (1)&nbsp;persuasive evidence of an arrangement exists since the Company and Allergan engaged with a binding agreement;
(2)&nbsp;delivery has occurred or services have been rendered since all documents and data Allergan has requested relating to the Company&#146;s know-how were provided before December&nbsp;31, 2016 and Allergan can use the license for its intended
purposes without the supply services (except for immaterial support services); (3)&nbsp;the fee is fixed or determinable, as indicated in the license agreement; and (4)&nbsp;collectability is reasonably assured. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Therefore, as of December&nbsp;31, 2016, the consideration received in an amount of $17.5 million represents arrangement consideration for both the license of the
intellectual property as well as Allergan&#146;s right to future supply services (which would be provided in consideration for future payments to the Company according to the pricing stipulated in the supply agreement). The Company determined that
the pricing of the supply services represents their standalone selling price. Accordingly, the Company allocated the entire upfront fee of $17.5 million to the license component. In addition, revenue from the supply services would be recorded in an
amount equal the consideration stipulated in the agreement for these services, when these services are provided. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As described in Note&nbsp;1, the Company is also
entitled to milestone payments and royalties based on Allergan&#146;s revenue from its product, which are not considered fixed or determinable until their occurrence. Therefore, these amounts would only be recognized when the conditions for payment
are met, and they become due and payable. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Deferred taxes </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Income
taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities
and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. We have provided a full
valuation allowance with respect to its deferred tax assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">See note 2q of the accompanying financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Internal Control Over
Financial Reporting </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Failure to achieve and maintain effective internal controls in accordance with Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the
Sarbanes-Oxley Act, could have a material adverse effect on our business, results of operation or financial condition. In addition, current and potential shareholders could lose confidence in our financial reporting, which could have a material
adverse effect on the price of our ordinary shares. Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act and the related rules adopted by the SEC and the Public Company Accounting Oversight Board, starting with the second annual report that we
file with the SEC after the consummation of this offering, our management will be required to report on the effectiveness of our internal control over financial reporting. In addition, once we no longer qualify as an &#147;emerging growth
company&#148; under the JOBS Act and lose the ability to rely on the exemptions related thereto discussed above, our independent registered public accounting firm will also need to attest to the effectiveness of our internal control over financial
reporting under Section&nbsp;404. We have not yet commenced the process of determining whether our existing internal controls over financial reporting systems are compliant with Section&nbsp;404 and whether there are any material weaknesses or
significant deficiencies in our existing internal controls. This process will require the investment of substantial time and resources, including by our Chief Financial Officer and other members of our senior management. In addition, we cannot
predict the outcome of this determination and whether we will need to implement remedial actions in order to implement effective control over financial reporting. The determination and any remedial actions required could result in us incurring
additional costs that we did not anticipate. Irrespective of compliance with Section&nbsp;404, any failure of our internal controls could have a material adverse effect on our stated results of operations and harm our reputation. As a result, we may
experience higher than anticipated operating expenses, as well as higher independent auditor fees during and after the implementation of these changes. If we are unable to implement any of the required changes to our internal control over financial
reporting effectively or efficiently or are required to do so earlier than anticipated, it could adversely affect our operations, financial reporting and/or results of operations and could result in an adverse opinion on internal controls from our
independent auditors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>JOBS Act </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As an &#147;emerging
growth company,&#148; as defined in the JOBS Act, we may take advantage of certain temporary exemptions from various reporting requirements, including, but not limited to, not being required to comply with the auditor attestation requirements of
Section&nbsp;404 of the Sarbanes Oxley Act (and the rules and regulations of the SEC thereunder). When these exemptions cease to apply, we expect to incur additional expenses and devote increased management effort toward ensuring compliance with
them. We cannot predict or estimate the amount of additional costs we may incur as a result of becoming a public company or the timing of such costs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The JOBS Act
additionally permits emerging growth companies such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have irrevocably elected not to avail ourselves of
this provision and, as a result, we will comply with new or revised accounting standards as other public companies that are not emerging growth companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical stage biopharmaceutical company focused on
developing novel therapies designed to change the standard of care for urological pathologies. We have an innovative and broad pipeline of product candidates that we believe can overcome the deficiencies of current treatment options for a variety of
urological conditions with a focus on uro-oncology. Our lead product candidates, MitoGel and VesiGel, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is currently used off-label for urothelial cancer
treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. We are developing our product candidates as chemoablation agents, which means they are designed to remove tumors by non-surgical means, to treat
several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, or UTUC, and low-grade bladder cancer. We believe that MitoGel and VesiGel, which are both local drug therapies, have the potential to
significantly improve patients&#146; quality of life by replacing costly, sub-optimal and burdensome tumor resection and kidney removal surgeries as the first-line standard of care. MitoGel and VesiGel may also reduce the need for bladder, kidney
and upper urothelial tract removals, which are typically performed on patients whose cancer progresses despite undergoing tumor resection surgical procedures. Additionally, we believe that our product candidates, which are based on formulations of
previously approved drugs, may qualify for streamlined regulatory pathways to market approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our lead product candidates, MitoGel and VesiGel, are formulated
using our proprietary reverse thermally triggered hydrogel, or RTGel, technology. We believe that RTGel-based drug formulations, which provide for the sustained release of an active drug, may improve the efficacy of treatment of various types of
urothelial cancer without compromising the safety of the patient or interfering with the natural flow of fluids from the urinary tract to the bladder. Our formulations are designed to achieve this by increasing the dwell time as well as the tissue
coverage throughout the organ of the active drug. Consequently, we believe that RTGel-based drug formulations may enable us to overcome the anatomical and physiological challenges that have historically contributed to the lack of drug development
for the treatment of urothelial cancer. No drugs have been approved by the U.S. Food and Drug Administration, or the FDA, for the treatment of non-muscle invasive bladder cancer, or NMIBC, in more than 15&nbsp;years. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are currently evaluating the safety and efficacy of MitoGel, our novel sustained-release formulation of MMC, in UTUC patients pursuant to an ongoing
&#147;Compassionate Use&#148; program. &#147;Compassionate Use&#148; is the use outside of a clinical trial of an investigational, or not approved, medical product when patient enrollment in a clinical trial is not possible, typically due to patient
ineligibility or a lack of ongoing clinical trials. Of the 13 patients with confirmed low-grade UTUC who have been evaluated endoscopically, or through the use of a nonsurgical viewing instrument to examine the urinary tract, in the program, eight
have achieved a complete response and five have achieved a partial response at the primary evaluation time. Thus far, MitoGel has been observed to be well-tolerated. We have obtained Orphan Drug Designation for MitoGel for the treatment of UTUC. We
filed an investigational new drug, or IND, application for MitoGel with the FDA in November 2016, which was accepted by the FDA in December 2016. We commenced a single pivotal, open-label, single-arm Phase 3 clinical trial for the treatment of
low-grade UTUC in the first quarter of 2017. The clinical trial is being conducted in the United States and Europe with anticipated enrollment of approximately 70 patients. We intend to pursue the FDA&#146;s 505(b)(2) regulatory pathway for MitoGel,
which is a streamlined, lower-cost and more well-defined pathway to drug approval when compared to traditional drug development. We believe that MitoGel has the potential to become the first FDA-approved drug for the treatment of low-grade UTUC and
to serve as a first-line chemoablation agent, sparing patients from repeated tumor resection surgeries and potentially reducing the need for kidney and upper urothelial tract removal. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we are currently evaluating the safety and efficacy of VesiGel, our novel sustained-release high dose formulation of MMC, for the treatment of low-grade
NMIBC in a Phase 2a study being conducted in Europe and Israel. This study is expected to be completed in the second quarter of 2017. To date, 19&nbsp;of 22, or 86%, of the patients with confirmed low-grade NMIBC evaluated in our ongoing
Phase&nbsp;2a clinical trial who were treated in the VesiGel high dose group (80mg MMC) achieved a complete response at the primary evaluation time. Approximately 79% of the patients who achieved a complete response at the primary evaluation time
and who have been followed for 12 months thereafter, without receiving any additional treatments, remained recurrence free and were able to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
sustain a durable complete response during those 12&nbsp;months. This compares to approximately 40% to 60% of patients who historically have been able to sustain a 12-month durable complete
response following transurethral resection of bladder tumor, or TURBT, as first-line treatment followed by adjuvant treatments of MMC instillations into the bladder. We plan to file an IND for VesiGel in the second half of 2017, and, if accepted, to
commence a Phase 2b U.S. based clinical trial for VesiGel shortly thereafter. We also intend to pursue a 505(b)(2) regulatory pathway for VesiGel. We believe that VesiGel has the potential to replace tumor resection surgery and become the new
first-line standard of care for the treatment of low-grade NMIBC to replace tumor resection surgery as first-line treatment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that urothelial cancer,
which is comprised of bladder cancer and UTUC, affects a large and underserved patient population. Annual expenditures for Medicare alone in the United States for the treatment of urothelial cancer were estimated to be at least $4 billion in 2010
and are projected to be at least $5 billion in 2020. The majority of the historical expenditures was spent on tumor resection surgeries such as TURBT and bladder, kidney and upper urothelial tract removal. In 2012, the estimated prevalence of
urothelial cancer in the United States was 625,000 with an annual incidence of approximately 80,000. The 2012 prevalence of each of low-grade NMIBC and low-grade UTUC in the United States was approximately 325,000 and 14,500, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our clinical stage pipeline also includes Vesimune, our proprietary immunotherapy product candidate for the treatment of high-grade NMIBC, which may include Carcinoma
in Situ, or CIS. Vesimune is a novel, liquid formulation of Imiquimod, a generic toll-like receptor 7, or TLR7, agonist. Toll-like receptor agonists play a key role in initiating the innate immune response system. We believe that the combination of
Vesimune with additional immunotherapy drugs, such as immune checkpoint inhibitors or chemotherapy drugs like VesiGel, could represent a valid alternative to the current standard of care for the post TURBT adjuvant treatment of high-grade NMIBC.
BotuGel is our proprietary novel RTGel-based formulation of BOTOX, a branded drug, that we believe can potentially serve as an effective treatment option for patients suffering from overactive bladder. In October 2016, we announced the licensing of
the worldwide rights to BotuGel to Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc, which plans to commence a Phase&nbsp;2 clinical trial of BotuGel in the second half of 2017, pursuant to the
exclusive license agreement we entered into with Allergan in October 2016, or the Allergan Agreement. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Product Candidate Pipeline </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following chart summarizes the current status of our product candidate pipeline. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g80t12.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Uro-Oncological Indications Targeted by Our Product Candidates </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our product candidates are administered locally using the standard practice of intravesical instillation directly into the bladder or upper urothelial tract via a
catheter. The instillation into the bladder is expected to take place in a physician&#146;s office as a same-day treatment, in comparison with TURBT or similar tumor surgical procedures, which are operations conducted under general anesthesia in a
hospital setting and often require at least an overnight stay. Tumor surgical procedures often have limited success due to the inability to properly identify, reach and resect all tumors. We believe that an effective chemoablation agent can
potentially provide better eradication of tumors irrespective of the detectability and location of the tumors. In addition, by removing the need for surgery, patients may avoid potential complications associated with surgery and hospital-acquired
infections. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Bladder Cancer </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The bladder is a hollow organ in the pelvis
with flexible muscular walls. Its main function is to store urine before it leaves the body. Urine is produced by the kidneys and is then carried to the bladder through the upper urothelial tract tubes, called ureters. The bladder wall has four main
layers. The innermost lining is comprised of cells called urothelial or transitional cells, and this inner layer is called the urothelium or transitional epithelium. Beneath the urothelium, there is a layer called the lamina propria. Next is a thick
layer of muscle called the muscularis propria followed by a layer of perivesical fat. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g06l57.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">NMIBC tumor types are circled </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Bladder cancer accounts for approximately 90% to 95% of all new cases of urothelial cancer in the United States, with a prevalence of approximately 580,000. Bladder
cancer is nearly three to four times more common in men than women, and, with an average age at diagnosis of 73, mostly affects the elderly. Bladder cancers are described as non-muscle invasive or muscle-invasive based on how far into the wall of
the bladder they have invaded. The magnitude and rate of the spreading of the cancer is called &#147;staging,&#148; which ranges from Ta to T1 for NMIBC, and T2 to T4 for muscle-invasive bladder cancers, as defined by the American Joint Committee on
Cancer TNM System. In addition, Carcinoma in Situ, or CIS, a form of NMIBC, has a staging designation of Tis. Muscle-invasive bladder cancer, or MIBC, has an average five-year survival rate of 15% to 63%, depending on severity. MIBC represents a
worse prognosis than NMIBC, which has a five-year survival rate of approximately 90%. NMIBC accounts for approximately 80% of all new cases of bladder cancer diagnosed in the United States each year, which corresponds to an estimated annual
incidence and prevalence of approximately 60,000 and 465,000 cases, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Non-muscle invasive bladder cancers are divided into two grades, low and high, with high-grade tumors more likely to recur
and progress into muscle-invasive tumors. CIS tumors are all high-grade. Overall, approximately 70% of patients with NMIBC present with low-grade disease at diagnosis. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The chart below indicates the prevalence of stage and grade of bladder cancer in the United States. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g58g66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Upper Tract Urothelial Carcinoma </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">UTUC
refers to malignant changes of the transitional urothelial cells lining the upper urothelial tract of the renal pelvis and ureter. UTUC typically exhibits high local recurrence and development of metastases. Similar to NMIBC, the prognosis of
patients with UTUC correlates with the stage and grade of disease at the time of initial diagnosis. The key prognostic factor at the time of diagnosis of UTUC is whether the tumor is in the muscle-invasive or non-muscle invasive stage. The number,
size and location of tumors presented also represent important prognostic factors for UTUC. Approximately 40% of the patients diagnosed annually with UTUC in the United States present with non-muscle invasive UTUC. Non-muscle invasive UTUC is also
divided into two grades, low and high. In two studies conducted in 1997 and 2003 of 30 and 20 patients with non-muscle invasive UTUC, 87% and 75% of patients were diagnosed with low-grade non-muscle UTUC, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The chart below indicates the prevalence of stage and grade of UTUC in the United States. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g21p99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">UTUC accounts for approximately 5% to 10% of all new cases of urothelial cancer, which corresponds to an estimated annual incidence
in the United States of up to 7,500 cases. In 2012, the estimated prevalence of UTUC in the United States was approximately 45,000, of which approximately 14,500 had low-grade disease. UTUC is nearly three times more common in men than women and
affects mostly the elderly. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are currently no drugs approved by the FDA for the treatment of UTUC, representing a significant unmet medical need. Moreover,
the anatomical complexity of the upper urothelial tract, particularly the renal pelvis, presents significant challenges to the proper identification and ability to reach and resect all tumors in tumor resection surgical procedures. Consequently,
patients with high-grade disease or patients with low-grade disease that present with a large number of tumors typically undergo nephroureterectomy, which is kidney and upper urothelial tract removal. In addition, the stage and grade of UTUC are
often misdiagnosed, which we believe is due to the structural complexity of the upper urothelial tract. Due to these factors, the current standard of care for the treatment of UTUC is nephroureterectomy. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Tumor resection, which aims to be a kidney sparing surgical procedure, is conducted only in patients with low-grade disease that present with a limited number of
tumors. Such procedures are followed by adjuvant chemotherapy treatment, typically with MMC. However, the upper urothelial tract&#146;s anatomical constraints limit the effectiveness of surgical procedures and adjuvant chemotherapy treatments,
leading to high rates of recurrence and risk for progression in this patient population. In a study published in 2009 in the Journal of Endourology evaluating 57&nbsp;patients with low-grade UTUC who underwent tumor resections, 89.5% of patients
with a mean of 5.5&nbsp;recurrences per patient over a four-year period. Moreover, approximately 20% of the patients in this study progressed and ultimately underwent kidney and upper tract removal. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that because tumor resection procedures followed by adjuvant chemotherapy therapy are sub-optimal, nephroureterectomy is often used even in patients that may
be otherwise candidates for organ sparing treatments. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Non-Muscle Invasive Bladder Cancer </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patients treated with the current standard of care have up to an approximately 60% rate of recurrence of NMIBC within one year, and the rate of progression of NMIBC to
MIBC is between 20% and 30%. As a consequence, NMIBC patients often undergo multiple repeat TURBT procedures and adjuvant chemotherapy and immunotherapy treatments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The standard of care for treating NMIBC patients is TURBT followed by adjuvant chemotherapy or immunotherapy treatment.
TURBT is a surgical operation for tumor removal conducted under general anesthesia in a hospital setting and often requires at least an overnight stay. Moreover, TURBT&#146;s success is tied to the physician&#146;s ability to overcome challenges in
properly identifying, reaching and resecting all tumors. No drugs have been approved by the FDA as first-line treatment for NMIBC and only three drugs have been approved by the FDA for NMIBC, all used as adjuvant treatment, following TURBT. Efficacy
of drug treatments has historically been limited due to challenges presented by bladder physiology, specifically the fact that urine is produced and voided frequently, thus diluting the concentration of the drug almost immediately and causing the
excretion of the drug from the bladder at first urine voiding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Competitive Strengths </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe our lead product candidates for uro-oncology, which are being developed by leveraging our expertise in drug development and our proprietary formulation
technology, have the ability to replace the costly, sub-optimal and burdensome tumor resection procedures that represent the current first-line standard of care. Furthermore, we believe our proprietary formulation technology has broad applications
and may allow us to develop additional product candidates for indications within and beyond the urinary tract. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Potential ability to develop
non-surgical, first-line drug therapies for uro-oncology.</I></B><B>&nbsp;</B><B></B>Leveraging our innovative formulation technology, we are developing two lead product candidates, MitoGel and VesiGel, as potential replacements to first-line
treatment for low-grade UTUC and NMIBC, respectively. Both MitoGel and VesiGel are chemoablation agents designed to overcome the challenges posed by the anatomy of the urinary tract by increasing the dwell time and enhancing the tissue coverage of
MMC. Clinical data generated to date supports our belief that our lead product candidates may be able to replace the current first-line tumor surgical procedures, providing a chemoablation treatment that has the potential to better eradicate tumors
irrespective of their detectability and location within the urinary tract. To date, of the 13 low-grade UTUC patients treated with MitoGel in an ongoing Compassionate Use program and evaluated endoscopically for efficacy, eight have achieved a
complete response and the remaining five have achieved a partial response at the primary evaluation time. In the case of VesiGel, to date, 19 of 22, or approximately 86%, of the patients treated with the high dose of VesiGel in the ongoing Phase 2a
trial, which is evaluating the efficacy and safety of VesiGel&#146;s chemoablation properties, achieved a complete response at the primary evaluation time. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Expertise in developing proprietary formulations of drugs for clinical benefit.</I></B>&nbsp;We focus on developing proprietary RTGel formulations
of previously approved drugs whose efficacy for a particular indication is limited by current formulations or routes of administration. While we have not yet brought a drug to market, our expertise has enabled us to develop proprietary RTGel-based
formulations for several previously approved drugs to date, including clinical stage proprietary formulations of MMC and botulinum toxin. Our formulations are designed to significantly increase the dwell time and exposure of the drugs to the target
sites and limit the need for urine retention, potentially providing enhanced clinical activity, reduced patient burden and increased patient compliance over existing formulations and modes of administration. With over 10 Ph.Ds. and medical doctors
on our staff, we have a strong research and development team to advance our product candidates. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Lower development risks and costs for our
pipeline product candidates. </I></B><B></B>We expect the approval process for each of our current uro-oncology product candidates to be conducted according to the FDA&#146;s 505(b)(2) regulatory pathway, a streamlined, lower-cost and more
well-defined pathway to drug approval when compared to traditional drug development. Furthermore, two of our product candidates, MitoGel and Vesimune, have received Orphan Drug Designation from the FDA for the treatment of UTUC and CIS,
respectively, which we expect will provide seven years of marketing exclusivity following FDA approval, if received. We submitted an IND for MitoGel in November 2016, which was accepted by the FDA in December 2016. We commenced a single pivotal,
open-label, single-arm Phase&nbsp;3 clinical trial for the treatment of low-grade UTUC in the first quarter of 2017. The clinical trial is being conducted in the United States and Europe with anticipated enrollment of approximately 70 patients.
Additionally, we expect that our product candidates will be safe and well-tolerated because they are novel formulations of previously approved drugs. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Leverageable proprietary formulation technology</I></B><B>.</B><B>&nbsp;</B><B></B>We believe that RTGel has multiple potential applications
beyond urology. Our formulation know-how may enable us to develop different drug formulations to facilitate the delivery, retention and sustained release of active drugs to a variety of targeted body cavities. We believe that our proprietary
formulation technology can improve the efficacy of locally administered drugs in body cavities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">
such as the stomach, uterus and rectum that present anatomical and physiological challenges related to frequent wash out, rapid excretion and bodily secretions. In October 2016, we announced that
we licensed worldwide rights to a proprietary RTGel formulation with BOTOX to Allergan for the treatment of overactive bladder and related indications pursuant to the Allergan Agreement. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Strong intellectual property position. </I></B>We have a robust intellectual property portfolio that includes four issued patents in the United
States and several patent applications filed worldwide that are directed to methods, systems, new compounds and compositions for treating urinary tract cancer. Our intellectual property covers, among other things, our lead product candidates,
MitoGel, Vesimune and VesiGel, as well as RTGel. The four issued patents are expected to expire between 2024 and 2031. In addition, we have 12 issued patents worldwide related to our other product candidates. These issued patents are expected to
expire between 2030 and 2031. We also have 45 pending patent applications filed worldwide covering all of our product candidates. Additionally, the FDA has granted Orphan Drug Designation to MitoGel for the treatment of UTUC and Vesimune for the
treatment of CIS bladder cancer, which potentially entitles us to marketing exclusivity for MitoGel and Vesimune for seven years following approval, if granted, by the FDA. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Experienced and accomplished leadership team with proven track record</I></B><B>.</B>&nbsp;We have an experienced management team, with each
member possessing more than 15 years of biopharmaceutical and related industry experience. Our Chief Executive Officer, Ron Bentsur, successfully navigated Auryxia (ferric citrate) through the 505(b)(2) streamlined regulatory pathway to FDA
approval. In addition, our Chairman, Arie Belldegrun, M.D., is a seasoned biotech executive and is currently the Chairman, Chief Executive Officer and President of Kite Pharma, as well as a director of Teva Pharmaceutical Industries. We believe that
our leadership team is well-positioned to lead us through clinical development, regulatory approval and commercialization for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Growth
Strategy </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to become the leading biopharmaceutical company focused on the development of novel therapies for local treatment of urological pathologies.
The key elements of our strategy are as follows: </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Establish each of our lead product candidates, MitoGel and VesiGel, as the first-line
treatment in its target indication.</I></B>&nbsp;We believe that data from treatments in an ongoing Compassionate Use program currently being conducted in the United States, Europe and Israel provide evidence of the potential safety and efficacy of
MitoGel for the treatment of low-grade UTUC. We submitted an IND for MitoGel with the FDA in November 2016, which was accepted by the FDA in December 2016, and we commenced a single pivotal Phase 3 clinical trial in the first quarter of 2017
pursuant to the FDA&#146;s 505(b)(2) regulatory pathway. We are currently conducting a Phase 2a randomized, open-label, single-arm, active-controlled clinical trial of VesiGel for the treatment of low-grade NMIBC outside the United States. We expect
to file an IND for VesiGel in the second half of 2017, and, if accepted, to commence a Phase&nbsp;2b U.S. based clinical trial shortly thereafter. We also expect to pursue a 505(b)(2) regulatory pathway for VesiGel. We believe that these local drug
treatments have the potential to replace the costly, sub-optimal and burdensome tumor resection and kidney removal surgeries to become the first-line standard of care. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Expand our uro-oncology product pipeline.</I></B> A Phase 1 clinical trial of Vesimune was completed under an IND in 12 patients with CIS, an
aggressive form of high-grade urinary bladder cancer. In the study, 10 patients were evaluated for response, of which 40% achieved a complete response rate with Vesimune as a single-agent treatment. We believe that combining Vesimune with immune
checkpoint inhibitors or chemotherapy has the potential to serve as a treatment option for high-grade urothelial tumors. We are also pursuing preclinical oncology programs that take advantage of our RTGel technology. Our preclinical programs are
being developed for high-grade bladder cancer and high-grade UTUC. We may also evaluate in-licensing or acquiring additional product candidates for the treatment of urological cancers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Establish ourselves as a commercial supplier of our MMC.</I></B><I> </I>We believe that by working
with our existing third party manufacturer of the MMC needed for our product candidates MitoGel and VesiGel, we may be able to also become an approved commercial supplier of MMC in the United States. There are currently only two suppliers of MMC
approved for sale in the United States. By working with our existing third party manufacturer of MMC and/or engaging an additional third party manufacturer of MMC to provide us with a commercial scale supply of MMC, we may target the generic
urothelial cancer market in order to sell our formulation of MMC, which could increase potential revenue streams. This may also potentially enable us to reduce the manufacturing cost of our lead product candidates, MitoGel and VesiGel. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Utilize our proprietary technology to expand our pipeline to other body cavities and indications.</I></B>&nbsp;We believe that RTGel may be
suitable for multiple additional applications. Our know-how may enable us to develop different drug formulations to facilitate the delivery, retention and sustained release of active drugs to a variety of targeted body cavities. Beyond the urinary
tract, we may target the gastrointestinal tract and the female reproductive system. In the future, we may also choose to develop our RTGel technology in combination with other drugs to treat cancer and other indications endemic to such body
cavities. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Evaluate and selectively pursue potential collaborations to develop improved formulations and product life-cycle management
strategies.</I></B>&nbsp;We entered into the Allergan Agreement to research, develop, manufacture and commercialize pharmaceutical products that contain RTGel and clostridial toxins (including BOTOX), alone or in combination with certain other
active ingredients. This collaboration provides us with funding for our research and development efforts, and may accelerate the development and commercialization of our approved products, if any. In addition, we may in-license or acquire additional
product candidates for urological indications. Such collaborations would allow us to obtain financial support and to capitalize on the expertise and resources of our potential partners, which could allow for new and improved versions of approved or
clinical stage drugs, and could accelerate the development and commercialization of additional product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>RTGel: Our Reverse Thermally Triggered
Hydrogel Platform Technology </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have developed RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel, which, unlike the general
characteristics of most forms of matter, is liquid at lower temperatures and converts into gel form when heated. We believe that these characteristics promote ease of delivery into and retention of drugs in body cavities, including the bladder and
the upper urothelial tract, by conforming to the anatomy of the target organ while preventing rapid excretion of the drug. The following images show the progression of four stages of RTGel at different temperatures. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g142578g10y51.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">LT: Liquid at low temperature </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">BT: Converts into gel form at body temperature </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RTGel&#146;s
components are polymer-based and are inactive ingredients that have been approved by the FDA for use in other products such as Oraqix, a periodontal gel, Namenda, an oral solution for Alzheimer&#146;s disease, and Xeloda, an oral chemotherapy. We
formulate RTGel with an active drug: MMC in the case of MitoGel and VesiGel, and botulinum toxin in the case of BotuGel. The resulting formulations are instilled intravesically in liquid form directly into the bladder or upper urothelial tract using
standard instillation methodologies via catheters and thereafter convert into gel form at body temperature. Subsequently, upon contact with urine, RTGel gradually dissolves and releases the active drug over a period of several hours, and is less
affected by urine creation and voiding cycles as compared to water formulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that RTGel, when formulated with an active drug, may allow for the improved efficacy of treatment of various
types of urothelial cancer without compromising the safety of the patient or interfering with the natural flow of fluids from the urinary tract to the bladder. RTGel achieves this by: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increasing the exposure of active drugs in the bladder and upper urothelial tract by significantly extending the dwell time of the active drug while conforming to the anatomy of the bladder and the upper urothelial
tract, which allows for enhanced drug tissue coverage. For example, the average dwell time of the standard MMC water formulation, currently used as adjuvant treatment, in the upper urothelial tract is approximately five minutes, compared to
approximately six hours when MMC is formulated with RTGel; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administering higher doses of an active drug than would otherwise be possible using standard water-based formulations. For instance, it is only possible to dissolve 0.5 mg of MMC in 1 ml of water while it is possible to
formulate up to 8 mg of MMC with 1 ml of RTGel; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining the active drug&#146;s molecular structure and mode of action. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These characteristics of RTGel enable
sustained release of MMC in the urinary tract for both MitoGel and VesiGel, and of botulinum toxin in the case of BotuGel. Further, RTGel may be particularly effective in the bladder and upper urothelial tract where tumor visibility and access are
challenging, and where there exists a significant amount of urine flow and voiding. We believe that these characteristics of RTGel may prove useful for the local delivery of active drugs to other bodily cavities in addition to the bladder and upper
urothelial tract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>MMC&#151;Our Target Active Drug for the Treatment of UTUC and NMIBC </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MMC is a generic drug currently utilized off-label as the standard adjuvant chemotherapy for the treatment of low-grade UTUC and NMIBC after tumor resection, such as
TURBT. MMC is typically administered using a water-based formulation, which has a relatively short dwell time in the bladder limited to first voiding. MMC often causes temporary irritation of the bladder, including the need to urinate frequently and
urgently. This often results in first voiding occurring shortly after instillation. In the upper urothelial tract, the dwell time is limited to approximately five minutes as urine flows continuously and no active retention by the patient is
feasible. Numerous <I>in vitro</I> models, <I>in vivo</I> studies and computer simulations have shown that increased dwell time of MMC in the bladder results in more efficacious treatment of bladder cancer. In one such study, it was shown that MMC
activity increased with exposure time. Specifically, the MIC90, or mean inhibitory concentration that causes 90% inhibition in cell growth, was 11-fold lower when exposure time was increased from 30 minutes to eight hours. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MMC&#146;s main effect is on the cancer cell&#146;s DNA, and has been demonstrated to be most effective when the cancer cell is in its S-phase, or synthesis phase,
during which the DNA is replicated. Each cancer cell goes through various phases during the cell cycle. However, the cell cycle is not synchronized in all cancer cells, which means that at any given point in time only a portion of the cancer cells
are at their S-phase, or susceptible to the instilled MMC in the bladder. Thus, because our RTGel-based MMC sustained-release formulations, MitoGel and VesiGel, provide for a significantly longer dwell time of MMC in the upper urothelial tract and
in the bladder as compared to standard MMC water formulations, there is a greater chance that tumor cells will go through their S-phase while the instilled MMC is still present using MitoGel or VesiGel, potentially resulting in a higher percentage
of tumor cells being affected by the instilled MMC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>MitoGel: Our Product Candidate for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are developing MitoGel, our novel sustained-release formulation of MMC, for the treatment of low-grade UTUC. We have observed preliminary evidence of the efficacy of
MitoGel in an ongoing investigator-initiated Compassionate Use program for the treatment of severe, non-resectable UTUC. Additionally, the FDA granted MitoGel Orphan Drug Designation for the treatment of UTUC. We plan to develop MitoGel through the
FDA&#146;s 505(b)(2) regulatory pathway. We submitted an IND for MitoGel in November 2016, which was accepted by the FDA in December 2016. We commenced a single pivotal Phase 3 clinical trial for MitoGel in the first quarter of 2017. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Limitations of Current Therapies for Upper Tract Urothelial Carcinoma </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are currently no drugs approved by the FDA for the treatment of UTUC, representing a significant unmet medical need. The current standard-of-care for the
treatment of UTUC is nephroureterectomy, which is complete kidney and upper urothelial tract removal. Recent advances in resection instrument technology have allowed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
physicians in some cases to treat patients with low-grade UTUC using tumor resection, a kidney-sparing treatment, rather than nephroureterectomy followed by adjuvant chemotherapy, typically MMC,
treatment. However, the specific anatomy and physiology of the upper urothelial tract make the performance of organ sparing endoscopic tumor resection and instillation of adjuvant chemotherapy challenging, leading to high recurrence and progression
rates. Patients often undergo multiple resection procedures, which increases the probability of potential complications of resection by means of a ureteroscope, a device for examining the inside of the urinary tract, including perforation and
ureteral stricture, or a narrowing of the ureter. A recent study published in 2009 in the Journal of Endourology, evaluating 57 patients with low-grade UTUC who underwent tumor resections showed that recurrence occurred in 89.5% of patients, with a
mean of 5.5 recurrences per patient, over a four-year period. Moreover, approximately 20% of the patients in this study progressed and ultimately underwent kidney and upper tract removal. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MMC is currently administered using a water-based formulation, which limits the dwell time in the bladder until first voiding. In the upper urothelial tract, the dwell
time of MMC is approximately five minutes as urine flows continuously and no active retention by the patient is feasible. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Solution: MitoGel </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MitoGel is our novel sustained-release RTGel-based formulation of MMC that we are developing for the treatment of low-grade UTUC. RTGel is liquid at lower temperatures
and converts into gel form at body temperature. This temperature-dependent viscosity characteristic allows the simple and convenient instillation of the cooled MitoGel in its liquid form to the upper urothelial tract via standard catheters. Once
instilled, MitoGel converts into gel form in less than 10 minutes at body temperature. Subsequently, upon contact with urine, MitoGel gradually dissolves and releases the active drug, MMC, over a period of several hours versus several minutes for
MMC in its current water-based formulation. We believe that this substantial increase in dwell time of MMC positions MitoGel as a potential first-line chemoablation treatment for low-grade UTUC, sparing patients from repeated tumor resection
surgeries and potentially reducing the need for kidney and upper urothelial tract removal. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Orphan Drug Designation granted to MitoGel for the treatment of UTUC
potentially entitles us to marketing exclusivity for MitoGel for seven years following approval by the FDA, if granted, as well as priority review of our New Drug Application, or NDA. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Initial Clinical Results for MitoGel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MitoGel is being evaluated in
an ongoing investigator-initiated Compassionate Use program for the treatment of severe, non-resectable UTUC, which commenced in September 2014 and is ongoing. The Compassionate Use program, which is being conducted in the United States, Europe and
Israel, includes patients diagnosed with unilateral and bilateral UTUC, low- and high-grade UTUC, as well as patients with a solitary kidney. Patients in the Compassionate Use program receive six instillations of MitoGel administered directly to the
upper urothelial tract. Consistent with the nature of Compassionate Use programs, which are investigator-initiated programs, a statistical plan or primary endpoint is not being used as in a regular clinical trial. Approximately four weeks following
the completion of the treatment course, the patients are evaluated for response. Patients are visually evaluated endoscopically, with additional confirmation through urine cytology, or examination of cells collected from a urine specimen. At the
evaluation time, which is approximately four weeks following the completion of the treatment course, patients are deemed to have achieved a complete response if, in the judgment of the physician, no tumors initially diagnosed by the physician are
detected and a partial response if, in the judgment of the physician, the size or number of tumors has decreased or if, following an initial complete response, there is tumor recurrence within three months after the evaluation time. Safety and
feasibility of treatment with MitoGel are also being evaluated. To date, we have treated 22&nbsp;patients, with more than 130 instillations of MitoGel performed. Of the 22&nbsp;patients treated, 18 were assessed as having low-grade UTUC. Of the
18&nbsp;patients assessed as having low-grade disease, 14 completed six instillations of MitoGel. Of these 14&nbsp;patients, 13 have been evaluated endoscopically for response and one could not be evaluated. Of the 13 patients who have been
evaluated endoscopically for response, eight have achieved a complete response and five have achieved a partial response at the primary evaluation time. Of the eight patients who have achieved a complete response at the primary evaluation time,
three have subsequently experienced recurrences to date. Due to the severity of low-grade UTUC and the extensive related tumor burden of the patients entering this Compassionate Use program, we believe that there may be a high likelihood of
recurrence in such patients. In order to mitigate recurrence in patients participating in our single pivotal Phase&nbsp;3 clinical trial, as part of the protocol for the trial, patients who achieve a complete response at the primary disease
evaluation visit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
will be followed for durability of response and will receive monthly MitoGel maintenance instillations for up to 12 months.</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Thus far in the study, MitoGel has been observed to be well-tolerated. The main observed adverse events, or AEs, related to MitoGel have been fatigue, allergic
reaction, nausea, fever, and dysuria, which is pain or difficulty while urinating. All of the AEs that have been observed to date are known side effects associated with the use of MMC and appear on the MMC label as potential side effects. Various
serious adverse events, or SAEs, were also reported most of which were determined to be unrelated to treatment with MitoGel. These SAEs include acute pyelonephritis, a kidney infection caused by bacteria; hydronephrosis, which is the swelling of the
upper urinary tract due to a build-up of urine caused by some degree of obstruction; severe arrhythmia, which is a severe abnormal heart rhythm; cardiac asthma, which is a medical diagnosis of wheezing, coughing or shortness of breath due to
congestive heart failure; aggravation of renal function; hyperkalemia, which is a condition of elevated levels of potassium in the blood; pancytopenia, which is a deficiency of red cells, white cells and platelets in the blood; scarring and
narrowing of the calyceal infundibulum, which was most probably present at baseline; asymptomatic extravasation from the upper tract, which is leakage of fluids from the upper tract to the surrounding tissue; and death. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This Compassionate Use program was allowed by the FDA to accumulate safety and efficacy data. We commenced a single pivotal, open-label, single-arm Phase&nbsp;3
clinical trial of MitoGel for the treatment of low-grade UTUC in the first quarter of 2017. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following images show pre-treatment and post-MitoGel treatment
results from one low-grade UTUC patient in the Compassionate Use program. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g142578g04e65.jpg" ALT="LOGO">



<IMG SRC="g142578g21v14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">(Courtesy of Dr. J. Gregory Wirth, Geneva Hospital, Switzerland) </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The top left image is a pre-treatment ureteroscopic view of a tumor located in the ureter. The bottom left image is a pre-treatment x-ray revealing an obstruction
within the ureter in which no contrast (black) can be visualized in the distal ureter (denoted by arrow). The top right image is a post-treatment ureteroscopic view of the same location following MitoGel chemoablation treatment. The bottom right
image is a post-treatment x-ray of the ureter which reveals no obstruction within the ureter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>IND-Enabling Studies for MitoGel </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of our IND-enabling work for MitoGel, we have completed a large-scale Good Laboratory Practices, or GLP, toxicity study in an upper urothelial tract swine model
in which more than 250 instillations of MitoGel were performed. This study evaluated the safety of the procedure and MitoGel administration, also utilizing higher dosage levels than those used in the clinical settings. In this GLP toxicology study,
the instillation of MitoGel was found to be safe. We are also currently conducting chemistry, manufacturing and controls, or CMC, studies as part of our IND-enabling efforts. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Next Steps in the Clinical Development of MitoGel </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on
discussions with the FDA, we intend to develop MitoGel through the FDA&#146;s 505(b)(2) regulatory pathway. We submitted an IND for MitoGel in November 2016, which was accepted by the FDA in December 2016. We commenced a single pivotal, open-label,
single-arm Phase 3 clinical trial of MitoGel for the treatment of low-grade UTUC in the first quarter of 2017. </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g74a36.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This Phase&nbsp;3 clinical trial is being conducted in the United States and Europe with anticipated enrollment of approximately
70 patients. We expect this clinical trial, if successfully completed, to support an NDA for low-grade UTUC for MitoGel. The patients will initially receive six weekly instillations of MitoGel. The primary efficacy endpoint is expected to be the
complete response rate, defined as the percentage of patients with a complete response at the primary disease evaluation visit, which occurs approximately four weeks following the sixth weekly instillation. In addition, patients who achieve a
complete response at the primary disease evaluation visit will be followed for durability of response. Such patients will also receive monthly MitoGel maintenance instillations for up to 12&nbsp;months. If this clinical trial is successfully
completed, we currently anticipate submitting an NDA for MitoGel in 2018. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>VesiGel: Our Product Candidate for the Treatment of Low-Grade Non-Muscle Invasive
Bladder Cancer </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">VesiGel is our novel sustained-release formulation of high dose MMC that we are developing for the treatment of low-grade NMIBC as a first-line
non-surgical chemoablation alternative to TURBT. We are currently conducting a Phase 2a randomized, open-label, single-arm active-controlled clinical trial in Europe and Israel to evaluate the safety and efficacy of VesiGel (40mg and 80mg MMC) in
low-grade NMIBC. We commenced the trial in September 2013 and the last patient was enrolled in March 2016. To date, 19 of 22, or approximately 86%, of the patients with confirmed <FONT STYLE="white-space:nowrap">low-grade</FONT> NMIBC treated in
this trial have been observed to achieve complete responses in the 80mg MMC dose group of VesiGel at the primary evaluation time, and therefore did not need surgical intervention. Approximately 79% of the patients who achieved a complete response at
the primary evaluation time with VesiGel treatment and who have been followed for 12&nbsp;months thereafter remained recurrence free and were able to sustain a durable complete response during those 12 months after treatment without receiving any
additional treatment. This compares to approximately 40% to 60% of patients who historically have been able to sustain a 12-month durable complete response following TURBT as first-line treatment followed by additional adjuvant treatments of MMC
instillations into the bladder. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to complete the one year follow-up of the Phase 2a clinical trial in the first half of 2017. We met with the FDA in
mid-2016 to discuss potential next steps in the clinical development plan for VesiGel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Limitations of Current Therapies for Non-Muscle Invasive Bladder Cancer </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Tumor grade and stage are the most important variables for determining the likelihood of progression from NMIBC to MIBC. The three stages of NMIBC are: Ta (70%), T1
(20%) and CIS or Tis (10%). Approximately 70% of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">NMIBC patients have a tumor that is classified as low-grade upon diagnosis. Ta and CIS are limited to the
urothelial layer, and T1 is limited to the layer below, which is the lamina propria. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Recurrence, which occurs in approximately 80% of patients, is the primary
threat for NMIBC patients. Multiplicity, or number of tumors, tumor size and prior recurrence rate are the most important variables in determining the likelihood and potential severity of recurrence. In T1 and CIS NMIBC patients, progression, which
occurs in approximately 45% of patients, is the main threat. Treatment ranges from one or more TURBT procedures followed by adjuvant chemotherapy or immunotherapy instillation(s) in NMIBC patients with a low risk of recurrence to cystectomy for the
treatment of NMIBC patients with a high risk of recurrence. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TURBT is conducted in a hospital setting under general anesthesia and can often have side effects and
complications. The most common complications, risks and limitations of TURBT include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">bleeding at the time of surgery that requires clot irrigation and mild burning; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">infection of the bladder; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injured urethra and bladder perforation with potential intra-abdominal leakage; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">re-seeding and cell migration; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">repeat TURBT procedures, which are necessary for approximately 10% of patients within three months; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">complete removal of tumor tissue often not being feasible; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential recurrence of up to 25% of the tumors at the original treatment site; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">some tumors not being detectable. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Post-operative adjuvant treatments for NMIBC, which are given to prevent re-seeding
of the cancerous cells, consist primarily of chemotherapy in the case of low-grade tumors and immunotherapy in the case of high-grade tumors, and are administered intravesically via catheter. Adjuvant intravesical chemotherapy is used primarily in
low-grade tumors following TURBT in order to try to delay tumor recurrence, but is not used as a chemoablation agent. The rationale is to expose tumors to high local drug concentrations while minimizing the systemic exposure, thereby enhancing the
treatment effect and reducing the drug toxicity. However, these traditional adjuvant treatments to treating bladder cancer have been limited because, after instillation, the drug concentration is reduced and the drug is washed out due to urine
voiding. As a result, the cancerous tissue is not exposed to the chemotherapy drug for the optimal length of time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No drugs have been approved by the FDA as
first-line treatment for NMIBC and only three drugs have been </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">approved for NMIBC, all used as adjuvant treatment: Thiotepa, which was approved in 1959; bacille
Calmette-Guerin, or BCG, which was approved in 1989; and Valstar, which was approved in 1998. MMC is the drug used most often for intravesical chemotherapy. It is used off-label as an adjuvant treatment in the post-operative setting for low-grade
tumors with high risk of recurrence. Other drugs that can be used include docetaxe and gemcitabine. BCG, an immunotherapy-based drug, is used as an adjuvant treatment for patients with high-grade NMIBC. Upon recurrence, which occurs in approximately
35% of patients, the patients undergo another round of BCG therapy with a response rate of 30% to 50%. Radical cystectomy, or surgical removal of the bladder, is also a common treatment option for patients who fail multiple intravesical BCG
therapies. However, treatment with BCG is associated with severe side effects, as evidenced by a Black Box warning on the label, which is a warning placed on a prescription drug&#146;s label by the FDA and is designed to call attention to serious or
life-threatening risks. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are not aware of any drugs currently in development for the treatment of NMIBC that take into consideration bladder physiology,
specifically the fact that urine is produced and voided frequently, thus diluting the concentration of the active drug almost immediately. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Solution:
VesiGel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">VesiGel, an RTGel-based formulation of high dose MMC, is our product candidate for the treatment of low-grade NMIBC. VesiGel is administered
locally using standard catheters and is designed to conform to the bladder&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
anatomy and persist in the bladder despite urine flow and bladder movement. Once instilled, VesiGel converts into gel form within approximately 15 minutes at body temperature. Subsequently, upon
contact with urine, VesiGel gradually dissolves and releases the active drug, MMC, over a period of several hours versus the time until first voiding, often less than an hour, for MMC in its current water-based formulation, without compromising the
safety of the patient or interfering with the natural flow of urine out of the bladder. We believe that the resulting significantly increased dwell time of MMC in the bladder prolongs exposure of MMC to the tissue and therefore has the potential to
chemoablate visible and unseen tumors. As a result of these properties, our goal is to develop VesiGel as a first-line chemoablation non-surgical alternative to TURBT for the treatment of low-grade NMIBC. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Ongoing Phase 2a Clinical Trial </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are currently conducting a Phase
2a randomized, open-label, single-arm, active-controlled clinical trial in Europe and Israel to evaluate the safety and efficacy of VesiGel 0.06% (40 mg MMC in 64 ml gel) and VesiGel 0.12% (80 mg MMC in 64 ml gel) in low-grade NMIBC compared to the
intravesical instillation of 40 mg of MMC in water (MMC 0.1%). We commenced the trial in September 2013 and the last patient was enrolled in March 2016. In this trial, patients underwent six weekly instillations according to their assigned treatment
arm. The primary endpoint of the trial used for observational purposes only is the complete response rate at the primary disease endpoint, which is evaluated approximately four weeks after the sixth weekly installation. Safety, feasibility of local
treatment with VesiGel and durability of response are also being evaluated. To date, we have enrolled 81 patients, 65 of whom have been evaluated for response. Of the 65 patients evaluable to date, 20, 22 and 23 patients are in the VesiGel 0.06%,
VesiGel 0.12% and MMC 0.10% groups, respectively. The results to date indicate complete response rates at the primary evaluation time of 45%, 86% and 70% for VesiGel 0.06%, VesiGel 0.12% and MMC 0.10%, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In treating low-grade NMIBC, resection of small tumors is primarily conducted in the outpatient setting, typically without anesthesia using fulguration, a procedure
that destroys the diseased area in the lining of the bladder by burning using electric current. The effectiveness of tumor resection in these cases is high and the one year recurrence rate is estimated to be only 10%. However, larger, multiple
tumors are surgically removed using TURBT, a procedure conducted in the operating room in a hospital setting under general anesthesia, which often requires at least an overnight stay. TURBT is associated with increased risks and costs and higher
recurrence rates that can reach up to 60%. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When evaluating the effect of chemoablation on large tumors that would typically be treated with TURBT, we observed a
more profound difference in the complete response rate between the VesiGel 0.12% arm compared to the MMC 0.10% control arm. In tumors less than or equal to 1 cm<SUP STYLE="font-size:85%; vertical-align:top">2 </SUP>in size, the complete response
rate at the primary evaluation time was 78% (18 patients) and 88% (16 patients) in the MMC 0.10% control group and the VesiGel 0.12% group, respectively. However, in tumors greater than 1 cm<SUP STYLE="font-size:85%; vertical-align:top">2 </SUP>in
size, the complete response rate at the primary evaluation time was 40% (five patients) and 83% (six patients) in the control group and VesiGel 0.12% group, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The graph below illustrates the complete response rates by tumor size for the VesiGel 0.12% and MMC 0.10% control
treatment arms. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g61v53.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also observed a&nbsp;difference in the complete response rate between the VesiGel 0.12% arm compared to the MMC 0.10% control arm
when evaluating the effect of chemoablation on the number of tumors.&nbsp;In cases of three or fewer tumors, the complete response rate at the primary evaluation time was 80% (15 patients) and 81% (16 patients) in the MMC 0.10% control group and the
VesiGel 0.12% group, respectively. However, in cases of more than three tumors, the complete response rate at the primary evaluation time was 50% (eight patients) and 100% (six patients) in the MMC 0.10% control group and the VesiGel 0.12% group,
respectively.</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The graph below illustrates the complete response rates by tumor volume for the VesiGel 0.12% and MMC 0.10% control treatment arms. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g51j14.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, the incidence of AEs reported for both VesiGel groups in the study has been low and appears similar to that of the
active control group, with the majority of the AEs having occurred in the VesiGel 0.12% group. The main observed AEs related to VesiGel have been dysuria, allergy, lower urinary tract symptoms, and hematuria, or the presence of blood in the urine.
The AEs that have occurred were associated with the use of MMC, MMC intravesical instillation or the cystoscopy procedure itself. The MMC-related AEs were primarily burning sensation, rash, urgency, and dysuria, which is painful or difficult
urination. These AEs appear on the MMC label as potential side effects. SAEs were also reported, including allergy, weakness, hematuria, difficult or labored breathing, lower urinary tract </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
symptoms other than dysuria, and death. None were determined to be related to VesiGel, except for two allergy cases that were resolved. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following images show cytoscopic views of complete responses in a low-grade NMIBC patient treated with VesiGel. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g49x55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The image to the left is a pre-treatment cystoscopic view of a tumor located in the bladder. The image to the right is a
post-treatment cystoscopic view of the same location following VesiGel chemoablation treatment. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I></I><B><I>Dose Escalation Study for VesiGel</I></B><I> </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In parallel to the ongoing Phase&nbsp;2a clinical trial, in the first half of 2015, we initiated a dose escalation study for patients with NMIBC in Europe and Israel to
evaluate the safety and efficacy of VesiGel at dose levels higher than 80&nbsp;mg MMC. To date, we have enrolled 14&nbsp;patients. All patients to date have been treated with the 120&nbsp;mg MMC in 60&nbsp;ml gel dose, or 0.2% concentration. Of the
12 low-grade NMIBC patients evaluated to date, 10 have achieved a complete response (83%). However, at the 120&nbsp;mg MMC dose level, we also observed a higher rate of MMC-related AEs than in patients treated with the 80&nbsp;mg MMC dose. Five of
12&nbsp;patients did not complete six weekly instillations due to their non-compliance, although three of these five patients achieved a complete response. As a result, we have determined to focus our development efforts going forward on the
80&nbsp;mg MMC dose level. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Phase 1 Clinical Trial for VesiGel </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In early 2014, we completed a Phase 1 clinical trial in India evaluating two earlier formulations of VesiGel. Patients underwent six weekly instillations according to
their assigned treatment of RTGel (40 ml) formulated with either 40 mg MMC or 80 mg MMC. Following completion of the six instillations, patients were evaluated for safety and efficacy. We enrolled 19 patients, 15 of whom were evaluated for response
to treatment. Of the 15 evaluable patients, seven achieved a complete response, with two out of five from the 40 mg MMC arm and five out of 10 from the 80 mg MMC arm. Patients were followed for one year after treatment. The results of this study led
to the initiation of the ongoing Phase 2a clinical trial, in which we are using a higher volume of RTGel, 64 ml compared to 40 ml, in an attempt to further enhance the efficacy of the 40 mg and 80 mg MMC VesiGel dose groups, by increasing the dwell
time of the drug. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I></I><B><I>Durability of Response</I></B><I> </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Per
protocol, the patients in our Phase 2a and Phase 1 clinical trials were followed for 12 months after the primary disease evaluation time point. To date, 41 patients treated with different VesiGel formulations completed the <FONT
STYLE="white-space:nowrap">12-month</FONT> follow-up period, 28 of whom achieved a complete response at the primary disease evaluation time point and did not receive any additional treatments. Of these 28 patients, 28 (100%), 25 (89%), 24 (86%) and
22 (79%) had durable complete responses at three, six, nine and 12 months, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The graph below demonstrates the durability data for the patients treated with VesiGel who achieved a complete response at
the primary disease evaluation time point and were followed for 12 months. </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g29c20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that these results support our belief that VesiGel, acting as a chemoablation agent, can replace TURBT, with the
possibility of improving durability of response. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Next Steps in the Clinical Development of VesiGel </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to complete the ongoing Phase 2a clinical trial in the first half of 2017. We met with the FDA in mid-2016 to discuss next steps in the clinical development
program for VesiGel. We plan to file an IND for VesiGel in the second half of 2017 and, if accepted, to commence a U.S. based Phase 2b clinical trial for VesiGel shortly thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Vesimune: Our Product Candidate for the Treatment of High-Grade NMIBC </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
are developing Vesimune, our immune-modulation product candidate, for the treatment of high-grade NMIBC. A Phase 1 dose escalation study was conducted in 23 NMIBC patients and Vesimune appeared to be well-tolerated in the study. This was followed by
a Phase 1 pilot study under an IND in 12 patients with CIS bladder cancer in the United States. 40% of the 10 evaluable patients achieved a complete response, and Vesimune was observed to be well-tolerated in the trial. We intend to further
investigate the use of Vesimune for the treatment of high-grade NMIBC, as a single agent or possibly combining it with VesiGel, MitoGel or with immune checkpoint inhibitors. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Limitations of Current Therapies for High-Grade NMIBC </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">High-grade
NMIBC is a highly aggressive form of bladder cancer. TURBT is the initial treatment of choice for high-grade NMIBC; however, the high rates of recurrence and significant risk of progression to muscle-invasive tumors are particularly dangerous.
Bladder removal can be the first treatment of choice for young, otherwise healthy patients with high-grade disease or for patients who cannot tolerate BCG. BCG, an immunotherapy-based drug, is the current standard of care as an adjuvant therapy
post-resection in high-grade tumors. However, treatment with BCG is associated with severe side effects, as evidenced by a Black Box warning on the label.</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our
Solution: Vesimune </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that Vesimune, our immune-modulation product candidate, could represent a valid alternative to the current standard of care
for the BCG adjuvant, post TURBT treatment of high-grade NMIBC. Vesimune&#146;s active ingredient is Imiquimod, an imidazoquinoline, synthetic immune modulator, which specifically targets TLR7, which is expressed in bladder cancer cells. Toll-like
receptors are pattern recognition receptors whose importance in stimulating innate and adaptive immunity has been established by recent studies and approval by the FDA of various cancer immunotherapies. Toll-like receptors are able to sense
microbial components as well as host-derived endogenous molecules released by injured tissues and play a critical role in defending against invading pathogens. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Imiquimod, in its topical formulation, is FDA approved for several indications, including superficial basal cell carcinoma. Vesimune is a liquid formulation of
Imiquimod for intravesical administration that has been optimized for delivery in the urinary tract. Vesimune does not use our RTGel technology. We believe that Vesimune may elicit an adaptive immune response in the presence of released bladder
cancer antigens, which may translate into a long lasting acquired immune response. We also believe the combination of Vesimune with immune checkpoint inhibitors could further increase the adaptive immune response and potentially represent a viable
alternative to BCG for the adjuvant treatment of high-grade NMIBC or UTUC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have obtained Orphan Drug Designation for Vesimune for the treatment of CIS in the bladder. We have an active IND for
Vesimune, which has been effective since 2013. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We acquired Vesimune from Telormedix SA, a private Swiss-based biotechnology company, in the fourth quarter of 2015.
Telormedix conducted all of the previous studies related to Vesimune, including the Phase&nbsp;1 and Phase&nbsp;1b studies. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Vesimune Clinical Results and
Post-Study Follow-Up </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Vesimune was evaluated in a Phase 1 dose escalation study that enrolled 23 patients diagnosed with NMIBC. Vesimune was well-tolerated
at the doses used. Subsequently, a Phase 1b study of Vesimune was conducted under an IND in patients with CIS bladder cancer in the United States. The Phase 1b study was commenced in April 2013 and completed in February 2014. Patients were dosed
with Vesimune 0.4% weekly for six weeks. The study was designed to evaluate the safety and preliminary efficacy of Vesimune in CIS patients. The primary efficacy endpoint for observational purposes only was the rate of complete response at five to
seven weeks after the sixth weekly instillation. Twelve patients were enrolled into the pilot study, of which 10 patients were evaluable for response. Four of the 10 patients, or 40%, achieved a complete response. Vesimune was observed to be well
tolerated in this trial. The most common AEs related to Vesimune were urination urgency, dysuria, fatigue, urinary tract infections and hematuria. One SAE, a urinary tract infection, was observed and was resolved. For observational purposes,
patients were followed for an additional six month period beyond the completion of the study, referred to as the Post-Study Follow Up. Of the four patients who had achieved a complete response with Vesimune in the study, two patients remained
disease free at the end of the Post-Study Follow Up while receiving no additional therapy. The two other patients who had achieved a complete response with Vesimune in the study also remained disease free at the end of the Post-Study Follow Up while
receiving BCG therapy during this period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The chart below represents the complete response rates for patients receiving only Vesimune: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g87e13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Next Steps in the Clinical Development of Vesimune </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to further investigate the use of Vesimune for the treatment of high-grade NMIBC, as a single agent or possibly combined with MitoGel, VesiGel or other
immunotherapy agents. Such a combination study would evaluate whether this multimodality approach, harnessing the power of the immune system together with the chemoablation properties of VesiGel or MitoGel, can provide a safe and effective approach
for the treatment of high-grade urothelial tumors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preclinical Programs </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Using our proprietary RTGel formulation technology, we are pursuing additional preclinical programs to expand and enhance our uro-oncology product portfolio. In
particular, we are pursuing preclinical programs for high-grade bladder cancer and high-grade UTUC using checkpoint inhibitors such as an anti PD-L1 or an anti CTLA-4. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">94 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>License Agreement with Allergan </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2016, we entered into the Allergan Agreement with Allergan and granted Allergan an exclusive worldwide license to research, develop, manufacture and
commercialize pharmaceutical products that contain RTGel and clostridial toxins (including BOTOX), alone or in combination with certain other active ingredients, to which we refer as the Licensed Products, which are approved for the treatment of
adults with overactive bladder who cannot use or do not adequately respond to anticholinergics. Additionally, we granted Allergan a non-exclusive, worldwide license to use certain of our trademarks as required for Allergan to practice its exclusive
license with respect to the Licensed Products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Allergan Agreement, Allergan is solely responsible, at its expense, for developing the Licensed Products
and obtaining all regulatory approvals for Licensed Products worldwide. Allergan is also solely responsible, at its expense, for commercializing the Licensed Products worldwide after receiving the regulatory approval to do so. Allergan is required
to use commercially reasonable efforts to develop and commercialize the Licensed Products for overactive bladder in certain major market countries. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will supply
Allergan with certain quantities of RTGel for development of Licensed Products through Phase 2 clinical trials using BOTOX together with RTGel in patients with overactive bladder, at Allergan&#146;s request and expense. Allergan has the right to
reduce the next milestone payment to us if there is a material supply failure from us. Prior to completion of the first Phase 2 clinical trial, Allergan has the right to request that we transfer to Allergan our manufacturing process for RTGel and
Allergan will assume the responsibility to manufacture RTGel and Licensed Product for its own development and commercialization activities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Allergan paid us a
nonrefundable upfront license fee of $17.5 million, and we are eligible to receive additional material milestone payments of up to an aggregate of $207.5 million upon the successful completion of certain development, regulatory and commercial
milestones, including $7.5 million upon submission of an IND to the FDA for a Licensed Product; $20.0 million upon initiation of a Phase 3 clinical trial for a Licensed Product for overactive bladder; $15.0 million upon initiation of a Phase 3
clinical trial for a Licensed Product for a specified second indication; $50.0 million and $25.0 million upon the first commercial sale of a Licensed Product for overactive bladder in the United States and the European Union, respectively; $25.0
million and $15.0 million upon the first commercial sale of a Licensed Product for a specified second indication in the United States and the European Union, respectively; and $50.0 million upon net sales of all Licensed Products of $500.0 million.
Allergan will pay us a tiered royalty in the low single digits based on worldwide annual net sales of Licensed Products, subject to certain reductions for the market entry of competing products and/or loss of our patent coverage of Licensed
Products. We are responsible for payments to any third party under our existing agreement and certain future agreement for certain RTGel-related third party intellectual properties. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Allergan Agreement, Allergan granted us a non-exclusive, sublicensable, fully paid-up, perpetual, worldwide license under any improvements Allergan makes to
the composition, formulation, or manufacture of RTGel for the research, development, manufacture and commercialization of any product containing RTGel and any active ingredient (other than a clostridial toxin) for all indications other than
indications covered by the agreement and an exclusive, sublicensable, royalty-bearing (in low single digits), perpetual worldwide license under such improvements for use in the prevention or treatment of oncology indications. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to continue to research, develop and commercialize other products combining RTGel with other active ingredients, except that there are certain restrictions with
respect to the overactive bladder and neurogenic detrusor overactivity indications. Neurogenic detrusor overactivity is when a known neurologic abnormality impairs the signaling systems between the bladder and the central nervous system, and the
brain is unable to inhibit the detrusor muscles controlling urination. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Either party may terminate the Allergan Agreement for uncured material breach by the other
party and for the insolvency of the other party. We may terminate the Allergan Agreement if Allergan or its affiliates challenges any of our patents licensed to Allergan and such patent challenge is not required under a court order or subpoena and
is not a defense against a claim, action or proceeding asserted by us, our affiliates or licensees against Allergan, its affiliates or sublicensees. In addition, Allergan may unilaterally terminate the Allergan Agreement for any reason upon advance
notice. If Allergan has the right to terminate the Allergan Agreement due to our uncured material </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">95 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
breach, Allergan may elect to continue the agreement and reduce all future milestone and royalty payment obligations to us by a specified percentage. In the event of any termination of the
Allergan Agreement, Allergan will assign or grant a right of reference to any regulatory documentation related to RTGel to us, all rights and licenses to Allergan will terminate, and the license Allergan granted to us under their improvements to
RTGel will continue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Intellectual Property </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our patent estate includes
patents and applications with claims directed to our MitoGel, VesiGel, RTGel, BotuGel and Vesimune product candidates, as well as broader claims for potential future product candidates. On a worldwide basis, our patent estate includes approximately
60 issued patents and pending patent applications for our product candidates as well as for a manufacturing process, a method of treatment, intravesical devices and systems and a combination products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, we currently have four issued patents and several patent applications worldwide related to methods, systems and compositions for treating bladder
cancer and upper urinary tract system conditions related to our lead product candidates, MitoGel and VesiGel, as well as RTGel, both on its own and formulated with other drugs. The four issued patents are expected to remain in effect until between
2024 and 2031. We also have nine pending patent applications relating to MitoGel and VesiGel in Europe, the United States and Israel, and five pending patent applications relating to BotuGel in the United States and the European Union, as well as in
each of Russia, China, and Israel. In addition, we have two&nbsp;granted patents related to Vesimune in the United States as well as granted patents in the European Union, Hong Kong, Japan, Australia, Brazil, Eurasia, Mexico and China, each of which
are expected to remain in effect until 2030. In addition to the issued patents mentioned above, our portfolio includes pending patent applications relating to Vesimune in the United States, the European Union, Canada, Korea, Hong Kong and Israel.
Moreover, we hold five granted patents in the United States as well as patent applications filed worldwide that relate to novel formulations of phospholipid drug analogs (saturated lipid conjugate compositions) for the treatment of urinary tract
cancer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our patents and patent applications mainly relate to hydrogel-based pharmaceutical compositions for optimal delivery of any drug to the internal cavity
such as a bladder and/or urinary tract; the method for treating urothelial cancer using hydrogel based composition; the method for treating overactive bladder topically without a need for injections; special catheters and in-dwelling ureter-catheter
systems for optimal delivery of a drug into the renal cavity; pharmaceutical compositions comprising an imidazoquinolin-amine (specifically imiquimod) and lactic acid for treating bladder cancer diseases, and novel phospholipid drug analogs for
treating cancer or infections. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to patents, we have filed for trademark registration with the United States Patent and Trademark Office, or the USPTO,
for &#147;MitoGel&#148;, &#147;VesiGel&#148;, &#147;RTGel&#148; and &#147;BotuGel&#148;. Furthermore, we rely upon trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position.</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Preparing and filing patent applications is a joint endeavor of our research and development team and our in-house and external patent attorneys. Our patent attorneys
conduct patent prior-art searches and then analyze the data in order to provide our research and development team with recommendations on a routine basis. This results in: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">protecting our product candidates that are under development; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">encouraging pharmaceutical companies to negotiate development agreements with us; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preventing competitors from attempting to design-around our inventions. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We submit applications directly to the USPTO as
provisional patent applications. Then usually we continue filing under the Patent Cooperation Treaty, or PCT, which is an international patent law treaty that provides a unified procedure for filing a single initial patent application to seek patent
protection for an invention simultaneously in any one of the designated member states. Although a PCT application does not issue as a patent, it allows the applicant to seek protection in any of the member states through national-phase applications.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Competition </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The standard of care for treating NMIBC patients is the
TURBT procedure for tumor resection, followed by post-operative adjuvant chemotherapy or immunotherapy instillations, administered to prevent re-seeding of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">96 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
cancerous cells. The adjuvant agents used are predominately generic treatments and regimens. Only four drugs have been approved for bladder cancer: Thiotepa, which was approved by the FDA in
1959; BCG, which was approved by the FDA in 1989; Valstar, which was approved by the FDA in 1998; and Tecentriq, which was approved by the FDA in 2016. Despite the approval of these drugs, there remain high unmet needs in the bladder cancer market.
BCG has been used to treat patients with CIS and high-grade T1 since 1990. Thiotepa and Valstar are rarely used, MMC is used off-label as the standard adjuvant treatment in the post-TURBT setting for low-grade NMIBC patients and Tecentriq is used to
treat locally advanced or metastic urothelial carcinoma only. Off-label means that while the FDA has not approved MMC as adjuvant treatment in the post-TURBT setting for low-grade NMIBC patients, physicians are permitted to utilize it as standard of
care for this indication as part of medical practice. However, off-label usage as a standard of care does not change the FDA&#146;s approval criteria and does not suggest that FDA approval is more likely than for other investigational drugs. In the
UTUC space, there are no approved drugs used to treat the disease. Tumor resection surgeries are conducted in some cases of low-grade UTUC; however, partial or complete kidney and upper urothelial tract removal is the standard of care for frequently
recurring UTUC. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are several products in the development pipeline, most of which are second- or third line-treatments mainly targeted for high-grade
NMIBC patients who have failed BCG treatment. All are targeted to reduce recurrence, but none are developed to reduce the need for TURBT and other tumor resection therapies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are aware that other companies, such as Merck Sharp&nbsp;&amp; Dohme Corp., Viventia Bio Inc., Telesta Therapeutics Inc., Heat Biologics, Inc., Viralytics Limited,
AADi, LLC, Biocancell Ltd., Halozyme Therapeutics, Inc., Astellas Pharma Inc., Cold Genesys, Inc., Altor BioScience Corporation, FKD Therapies Oy, Nippon Kayaku Co., Ltd,&nbsp;Spectrum Pharmaceuticals, Inc., Taris Biomedical LLC and&nbsp;Handok
Inc., are conducting or have recently conducted clinical trials for product candidates for the treatment of low-grade and high-grade NMIBC, including CIS. In addition, we are aware of several pharmaceutical companies that are developing drug
candidates for muscle-invasive bladder cancer. The U.S. Food and Drug Administration approved Tecentriq (atezolizumab) for the treatment of locally advanced or metastic urothelial carcinoma, a form muscle invasive bladder cancer, on May&nbsp;18,
2016. We do not know whether these potential competitors are already developing, or plan to develop, low-grade UTUC or high-grade UTUC treatments or other indications that we are pursuing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we face competition from existing standards of treatment, including TURBT, which is surgery for bladder cancer. If we are not able to demonstrate that our
product candidates are at least as safe and effective as such courses of treatment, medical professionals may not adopt our product candidates to replace the existing standard of care, which is a first-line tumor surgical procedure for both bladder
cancer and UTUC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biopharmaceutical industry is intensely competitive and subject to rapid and significant technological change. Our potential competitors
include large and experienced companies that enjoy significant competitive advantages over us, such as greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition, and more experience and
expertise in obtaining marketing approvals from the FDA and foreign regulatory authorities. These companies may develop new drugs to treat the indications that we target, or seek to have existing drugs approved for use for the treatment of the
indications that we target. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These potential competitors may therefore introduce competing products without our prior knowledge and without our ability to take
preemptive measures in anticipation of their commercial launch. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in this industry. Our
competitors may succeed in developing, acquiring or licensing on an exclusive basis products that are more effective, easier to administer or less costly than our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Government Regulation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA and comparable regulatory agencies in state
and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate research and
development activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, packaging, recordkeeping, tracking, approval, import, export, distribution, advertising and promotion of our products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">97 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The process required by the FDA before product candidates may be marketed in the United States generally involves the
following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">nonclinical laboratory and animal tests that must be conducted in accordance with good laboratory practices, or GLPs; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission of an IND, which must become effective before clinical trials may begin; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval by an independent institutional review board, or IRB, for each clinical site or centrally before each trial may be initiated; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed product candidate for its intended use, performed in accordance with good clinical practices, or GCPs;
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of an NDA; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of an FDA advisory committee review, if applicable; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pre-approval inspection of manufacturing facilities and selected clinical investigators for their compliance with cGMP and GCPs; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">FDA approval of an NDA to permit commercial marketing for particular indications for use. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the commencement of
marketing of controlled substances, the DEA must also determine the controlled substance schedule, taking into account the recommendation of the FDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The testing
and approval process requires substantial time, effort and financial resources. Preclinical studies include laboratory evaluation of drug substance chemistry, pharmacology, toxicity and drug product formulation, as well as animal studies to assess
potential safety and efficacy. Prior to commencing the first clinical trial with a product candidate, we must submit the results of the preclinical tests and preclinical literature, together with manufacturing information, analytical data and any
available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical studies may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA,
within the 30-day time period, raises safety concerns or questions about the conduct of the clinical trial by imposing a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can
begin. Submission of an IND may not result in FDA authorization to commence a clinical trial. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development, as well as amendments to
previously submitted clinical trials. Further, an independent IRB for each study site proposing to conduct the clinical trial must review and approve the plan for any clinical trial, its informed consent form and other communications to study
subjects before the clinical trial commences at that site. The IRB must continue to oversee the clinical trial while it is being conducted, including any changes to the study plans. Regulatory authorities, an IRB or the sponsor may suspend or
discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk, the clinical trial is not being conducted in accordance with the FDA&#146;s or the IRB&#146;s
requirements, if the drug has been associated with unexpected serious harm to subjects, or based on evolving business objectives or competitive climate. Some studies also include a data safety monitoring board, which receives special access to
unblinded data during the clinical trial and may advise us to halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, for purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 1&#151;Studies are initially conducted to test the product candidate for safety, dosage tolerance, structure-activity relationships, mechanism of action, absorption, metabolism, distribution and excretion in
healthy volunteers or subjects with the target disease or condition. If possible, Phase 1 trials may also be used to gain an initial indication of product effectiveness. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2&#151;Controlled studies are conducted with groups of subjects with a specified disease or condition to provide enough data to evaluate the preliminary efficacy, optimal dosages and dosing schedule and expanded
evidence of safety. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 3&#151;These clinical trials are undertaken in larger subject populations to provide statistically significant
evidence of clinical efficacy and to further test for safety in an expanded subject population at multiple </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">98 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
clinical trial sites. Evidence is considered to be statistically significant when the probability of the result occurring by random chance, rather than from the efficacy of the treatment, is
sufficiently low. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. These trials may be done globally to support global registrations so long as the
global sites are also representative of the U.S. population and the conduct of the study at global sites comports with FDA regulations and guidance, such as compliance with GCPs. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may require, or companies may pursue, additional clinical trials after a product is approved. These so-called Phase 4 studies may be made a condition to be
satisfied after approval. The results of Phase 4 studies can confirm the effectiveness of a product candidate and can provide important safety information. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trials must be conducted under the supervision of qualified investigators in accordance with GCP requirements, which includes the requirements that all
research subjects provide their informed consent in writing for their participation in any clinical trial, and the review and approval of the study by an IRB. Investigators must also provide information to the clinical trial sponsors to allow the
sponsors to make specified financial disclosures to the FDA. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the trial procedures, the parameters to be used in monitoring safety and the
efficacy criteria to be evaluated and a statistical analysis plan. Information about some clinical trials, including a description of the trial and trial results, must be submitted within specific timeframes to the National Institutes of Health, or
NIH, for public dissemination on their ClinicalTrials.gov website. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The manufacture of investigational drugs for the conduct of human clinical trials is subject to
cGMP requirements. Investigational drugs and active pharmaceutical ingredients imported into the United States are also subject to regulation by the FDA relating to their labeling and distribution. Further, the export of investigational drug
products outside of the United States is subject to regulatory requirements of the receiving country as well as U.S. export requirements under the Federal Food, Drug and Cosmetic Act, or the FDCA. Progress reports detailing the results of the
clinical trials must be submitted at least annually to the FDA and the IRB and more frequently if SAEs occur. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrent with clinical trials, companies usually
complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in
accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of
the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>505(b)(2) Regulatory Approval Process </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section 505(b)(2) of the FDCA,
or 505(b)(2), provides an alternate regulatory pathway to FDA approval for new or improved formulations or new uses of previously approved drug products. Specifically, 505(b)(2) permits the filing of an NDA where at least some of the information
required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. The applicant may rely upon the
FDA&#146;s prior findings of safety and efficacy for an approved product that acts as the reference listed drug for purposes of a 505(b)(2) NDA. The FDA may also require 505(b)(2) applicants to perform additional studies or measurements to support
any changes from the reference listed drug. The FDA may then approve the new product candidate for all or some of the labeled indications for which the referenced product has been approved, as well as for any new indication sought by the 505(b)(2)
applicant. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Orange Book Listing </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section 505 of the FFDCA
describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A
505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy, but where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for
which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">99 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
applicant to rely, in part, on the FDA&#146;s prior findings of safety and efficacy for an existing product, or published literature, in support of its application. Section 505(j) establishes an
abbreviated approval process for a generic version of approved drug products through the submission of an abbreviated new drug application, or ANDA. An ANDA provides for marketing of a generic drug product that has the same active ingredients,
dosage form, strength, route of administration, labeling, performance characteristics and intended use, among other things, to a previously approved product. ANDAs are termed &#147;abbreviated&#148; because they are generally not required to include
preclinical and clinical data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator drug through in vitro, in vivo or
other testing. The generic version must deliver the same amount of active ingredients into a subject&#146;s bloodstream in the same amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions written for the
reference listed drug. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA patents whose claims
cover the applicant&#146;s product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book. These
products may be cited by potential competitors in support of approval of an ANDA or 505(b)(2) NDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any applicant who files an ANDA seeking approval of a generic
equivalent version of a drug listed in the Orange Book or a 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA that (1) no patent information on the drug product that is the subject of the application has been
submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires; or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted.
This last certification is known as a Paragraph IV certification. Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through a
Paragraph IV certification. If the applicant does not challenge the listed patents or does not indicate that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all of the listed
patents claiming the referenced product have expired. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the competitor has provided a Paragraph IV certification to the FDA, the competitor must also send notice
of the Paragraph IV certification to the holder of the NDA for the reference listed drug and the patent owner once the application has been accepted for filing by the FDA. The NDA holder or patent owner may then initiate a patent infringement
lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification prevents the FDA from approving the application until the earlier of 30
months from the date of the lawsuit, expiration of the patent, settlement of the lawsuit, a decision in the infringement case that is favorable to the applicant or such shorter or longer period as may be ordered by a court. This prohibition is
generally referred to as the 30-month stay. In instances where an ANDA or 505(b)(2) NDA applicant files a Paragraph IV certification, the NDA holder or patent owner regularly take action to trigger the 30-month stay, recognizing that the related
patent litigation may take many months or years to resolve. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#146;s
decision to initiate patent litigation. The applicant may also elect to submit a statement certifying that its proposed label does not contain, or carves out, any language regarding the patented method-of-use rather than certify to a listed
method-of-use patent. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Exclusivity </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA provides periods of
regulatory exclusivity, which provides the holder of an approved NDA limited protection from new competition in the marketplace for the innovation represented by its approved drug for a period of three or five years following the FDA&#146;s approval
of the NDA. Five years of exclusivity are available to NCEs. An NCE is a drug that contains no active moiety that has been approved by the FDA in any other NDA. An active moiety </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">is the molecule or ion, excluding those appended portions of the molecule that cause the drug to be an ester, salt, including a salt with hydrogen or coordination
bonds, or other noncovalent, or not involving the sharing of electron pairs between atoms, derivatives, such as a complex (<I>i.e.</I>, formed by the chemical interaction of two compounds), chelate (<I>i.e.</I>, a chemical compound), or clathrate
(<I>i.e.</I>, a polymer framework that traps molecules), of the molecule, responsible for the therapeutic activity of the drug substance. During the exclusivity period, the FDA may not accept for review or approve an ANDA or a 505(b)(2) NDA
submitted by another company that contains the previously </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">100 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
approved active moiety. An ANDA or 505(b)(2) application, however, may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a product is not eligible for the NCE exclusivity, it may be eligible for three years of exclusivity. Three-year exclusivity is available to the holder of an NDA,
including a 505(b)(2) NDA, for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials, other than bioavailability or bioequivalence trials,
was essential to the approval of the application and was conducted or sponsored by the applicant. This three-year exclusivity period protects against FDA approval of ANDAs and 505(b)(2) NDAs for the condition of the new drug&#146;s approval. As a
general matter, three-year exclusivity does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year and three-year exclusivity will not delay the submission or approval of
a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and efficacy. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The Orphan Drug Act </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Orphan Drug Act, the FDA may grant
Orphan Drug Designation to drugs intended to treat a rare disease or condition &#150; generally a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan Drug Designation must be requested before submitting an
NDA. After the FDA grants Orphan Drug Designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the regulatory
review and approval process.&nbsp;The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA Orphan Drug Designation is entitled to a seven-year exclusive marketing period in the United
States for that product, for that indication.&nbsp;During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical
superiority to the product with orphan drug exclusivity.&nbsp;Orphan drug exclusivity does not prevent FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition.&nbsp;Among the other
benefits of Orphan Drug Designation are tax credits for certain research and a waiver of the NDA application user fee. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>NDA Submission and Review by the FDA
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Assuming successful completion of the required clinical and preclinical testing, among other items, the results of product development, including
chemistry, manufacture and controls, nonclinical studies and clinical trials are submitted to the FDA, along with proposed labeling, as part of an NDA. The submission of an NDA requires payment of a substantial user fee to the FDA. These user fees
must be filed at the time of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in some circumstances. One basis for a waiver of the application user fee is
if the applicant employs fewer than 500 employees, including employees of affiliates, the applicant does not have an approved marketing application for a product that has been introduced or delivered for introduction into interstate commerce, and
the applicant, including its affiliates, is submitting its first marketing application. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, under the Pediatric Research Equity Act, or PREA, an NDA or
supplement to an NDA for a new active ingredient, indication, dosage form, dosage regimen or route of administration must contain data that are adequate to assess the safety and efficacy of the drug for the claimed indications in all relevant
pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of
some or all pediatric data until after approval of the product for use in adults or full or partial waivers from the pediatric data requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA must
refer applications for drugs that contain active ingredients, including any ester or salt of the active ingredients, that have not previously been approved by the FDA to an advisory committee or provide in an action letter a summary of the reasons
for not referring it to an advisory committee. The FDA may also refer drugs which present difficult questions of safety, purity or potency to an advisory committee. An advisory committee is typically a panel that includes clinicians and other
experts who review, evaluate and make a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully
when making decisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">101 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA reviews applications to determine, among other things, whether a product is safe and effective for its intended
use and whether the manufacturing controls are adequate to assure and preserve the product&#146;s identity, strength, quality and purity. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The
FDA will not approve an application unless it determines that the manufacturing processes and facilities, including contract manufacturers and subcontracts, are in compliance with cGMP requirements and adequate to assure consistent production of the
product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCPs. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once the FDA receives an application, it has 60 days to review the NDA to determine if it is substantially complete to permit a substantive review, before it accepts
the application for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. The FDA&#146;s NDA review times may differ based on whether the application is a standard review or priority review application.
The FDA may give a priority review designation to drugs that are intended to treat serious conditions and provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions. Under the
goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA has set the review goal of 10 months from the 60-day filing date to complete its initial review of a standard NDA for an NME and make a decision on
the application. For non-NME standard applications, the FDA has set the review goal of 10 months from the submission date to complete its initial review and to make a decision on the application. For priority review applications, the FDA has set the
review goal of reviewing NME NDAs within six months of the 60-day filing date and non-NME applications within six months of the submission date. Such deadlines are referred to as the PDUFA date. The PDUFA date is only a goal and the FDA does not
always meet its PDUFA dates. The review process and the PDUFA date may also be extended if the FDA requests or the NDA sponsor otherwise provides additional information or clarification regarding the submission. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once the FDA&#146;s review of the application is complete, the FDA will issue either a Complete Response Letter, or CRL, or approval letter. A CRL indicates that the
review cycle of the application is complete and the application is not ready for approval. A CRL generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical
or preclinical testing, or other information or analyses in order for the FDA to reconsider the application. The FDA has the goal of reviewing 90% of application resubmissions in either two or six months of the resubmission date, depending on the
kind of resubmission. Even with the submission of additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#146;s
satisfaction, the FDA may issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may delay or refuse approval of an NDA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require
post-marketing testing and surveillance to monitor safety or efficacy of a product, or impose other conditions, including distribution restrictions or other risk management mechanisms. For example, the FDA may require a risk evaluation and
mitigation strategy, or REMS, as a condition of approval or following approval to mitigate any identified or suspected serious risks and ensure safe use of the drug. The FDA may prevent or limit further marketing of a product, or impose additional
post-marketing requirements, based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling
claims, are subject to further testing requirements, FDA notification and FDA review and approval. Further, should new safety information arise, additional testing, product labeling or FDA notification may be required. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which such product may be marketed or may include
contraindications, warnings or precautions in the product labeling, which has resulted in a Black Box warning. The FDA also may not approve the inclusion of labeling claims necessary for successful marketing. Once approved, the FDA may withdraw the
product approval if compliance with pre- and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, the FDA may require Phase 4 post-marketing studies to monitor the effect
of approved products, and may limit further marketing of the product based on the results of these post-marketing studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">102 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Post-approval Requirements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including manufacturing, periodic reporting,
product sampling and distribution, advertising, promotion, drug shortage reporting, compliance with any post-approval requirements imposed as a conditional of approval such as Phase 4 clinical trials, REMS and surveillance, recordkeeping and
reporting requirements, including adverse experiences. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After approval, most changes to the approved product, such as adding new indications or other labeling
claims are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any approved products and the establishments at which such products are manufactured, as well as new application fees for supplemental
applications with clinical data. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and to list their drug products, and are subject to periodic announced and unannounced
inspections by the FDA and these state agencies for compliance with cGMPs and other requirements, which impose procedural and documentation requirements upon us and our third-party manufacturers. We cannot be certain that we or our present or future
suppliers will be able to comply with the cGMP regulations and other FDA regulatory requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Changes to the manufacturing process are strictly regulated and
often require prior FDA approval before being implemented, or FDA notification. FDA regulations also require investigation and correction of any deviations from cGMPs and specifications, and impose reporting and documentation requirements upon the
sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to
comply with regulatory requirements, may result in withdrawal of marketing approval, mandatory revisions to the approved labeling to add new safety information or other limitations, imposition of post-market studies or clinical trials to assess new
safety risks, or imposition of distribution or other restrictions under a REMS program, among other consequences. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA closely regulates the marketing and
promotion of drugs. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA. Physicians, in their independent professional medical judgement, may prescribe legally available products for
uses that are not described in the product&#146;s labeling and that differ from those tested by us and approved by the FDA. We, however, are prohibited from marketing or promoting drugs for uses outside of the approved labeling. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the distribution of prescription pharmaceutical products, including samples, is subject to the Prescription Drug Marketing Act, or PDMA, which regulates
the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical
product samples and impose requirements to ensure accountability in distribution. The Drug Supply Chain Security Act also imposes obligations on manufacturers of pharmaceutical products related to product and tracking and tracing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Failure to comply with any of the FDA&#146;s requirements could result in significant adverse enforcement actions. These include a variety of administrative or judicial
sanctions, such as refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, cyber letters, modification
of promotional materials or labeling, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution, debarment, injunctions, fines, consent decrees, corporate
integrity agreements, refusals of government contracts and new orders under existing contracts, exclusion from participation in federal and state healthcare programs, restitution, disgorgement or civil or criminal penalties, including fines and
imprisonment. Any of these sanctions could result in adverse publicity, among other adverse consequences. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Healthcare Regulations </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business activities, including but not limited to, research, sales, promotion, distribution, medical education and other activities following product approval will
be subject to regulation by numerous regulatory and law enforcement authorities in the United States in addition to the FDA, including potentially the Department of Justice, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">103 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Department of Health and Human Services and its various divisions, including the CMS and the Health Resources and Services Administration, the Department of Veterans Affairs, the Department of
Defense and state and local governments. Our business activities must comply with numerous healthcare laws and regulations, including those described below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or
reward, or in return for, the referral of an individual for, or purchasing, leasing, ordering, or arranging for the purchase, lease or order of, any good, facility, item or service reimbursable under Medicare, Medicaid or other federal healthcare
programs. The term remuneration has been interpreted broadly to include anything of value. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are
drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the
requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case
basis based on a cumulative review of all of its facts and circumstances. Additionally, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, amended
the intent requirement of the federal Anti-Kickback Statute, and other healthcare criminal fraud statutes, so that a person or entity no longer needs to have actual knowledge of the federal Anti-Kickback Statute, or the specific intent to violate
it, to have violated the statute. The ACA also provided that a violation of the federal Anti-Kickback Statute is grounds for the government or a whistleblower to assert that a claim for payment of items or services resulting from such violation
constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal civil and criminal false claims laws, including the federal
False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government, including the Medicare and Medicaid programs, or
knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, and our business activities, are subject to the civil monetary penalties statute which imposes penalties against any person or entity who, among other things, is
determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a condition of receiving Medicaid coverage for prescription drugs, the Medicaid Drug Rebate Program requires manufacturers to calculate and report to CMS their
Average Manufacturer Price, or AMP, which is used to determine rebate payments shared between the states and the federal government and, for some multiple source drugs, Medicaid payment rates for the drug, and for drugs paid under Medicare Part B,
to also calculate and report their average sales price, which is used to determine the Medicare Part B payment rate for the drug. In January 2016, CMS issued a final rule regarding the Medicaid Drug Rebate Program, effective April 1, 2016, that,
among other things, revises the manner in which the AMP is to be calculated by manufacturers participating in the program and implements certain amendments to the Medicaid rebate statute created under the ACA. Drugs that are approved under a
biologics license application, or BLA, or an NDA, including a 505(b)(2) NDA, are subject to an additional requirement to calculate and report the manufacturer&#146;s best price for the drug and inflation penalties which can substantially increase
rebate payments. For BLA and NDA drugs, the Veterans Health Care Act requires manufacturers to calculate and report to the Department of Veterans Affairs a different price called the Non-Federal AMP, offer the drugs for sale on the Federal Supply
Schedule, and charge the government no more than a statutory price referred to as the Federal Ceiling Price, which includes an inflation penalty. A separate law requires manufacturers to pay rebates on these drugs when paid by the Department of
Defense under its TRICARE Retail Pharmacy Program. Knowingly submitting false pricing information to the government creates potential federal False Claims Act liability. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit knowingly and willfully
executing, or attempting to execute, a scheme to defraud any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">104 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any
healthcare benefit program, regardless of whether the payor is public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and
knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to
healthcare matters. Additionally, the ACA amended the intent requirement of some of these criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have
committed a violation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, the federal Open Payments program pursuant to the Physician Payments Sunshine Act, created under Section 6002 of the ACA and
its implementing regulations, require some manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with specified exceptions) to
report annually information related to specified payments or other transfers of value provided to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals
and to report annually specified ownership and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately and completely the required information for all payments, transfers of value and
ownership or investment interests may result in civil monetary penalties of up to an aggregate of $150,000 per year and up to an aggregate of $1.0 million per year for &#147;knowing failures.&#148; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended
by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, impose requirements relating to the privacy, security and transmission of individually identifiable health information. Among
other things, HITECH makes HIPAA&#146;s security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service
on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file
civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health
information in some circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many states have also adopted laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any third-party
payor, including commercial insurers. We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by
the federal government, and/or state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Enforcement actions can be brought by federal or state governments or as &#147;qui tam&#148; actions brought by individual whistleblowers in the name of the government.
Depending on the circumstances, failure to comply with these laws can result in penalties, including criminal, civil and/or administrative criminal penalties, damages, fines, disgorgement, debarment from government contracts, individual
imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, exclusion of products from reimbursement under
government programs, refusal to allow us to enter into supply contracts, including government contracts, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations, any of which could adversely
affect our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Coverage and Reimbursement </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to
commercialize any products successfully also will depend in part on the extent to which coverage and adequate reimbursement for our products, once approved, and related treatments will be available from government health administration authorities,
private health insurers and other organizations. Government authorities and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">105 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
other&nbsp;third-party&nbsp;payors, such as private health insurers and health maintenance organizations, determine which medications they will cover and establish reimbursement levels. Assuming
we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment
of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided and
reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards
that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Government
authorities and other third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are
requiring that drug companies provide them with predetermined discounts from list prices as a condition of coverage, are using restrictive formularies and preferred drug lists to leverage greater discounts in competitive classes, and are challenging
the prices charged for medical products. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the United States.&nbsp;Therefore, coverage and reimbursement for drug products can
differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor
separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot be sure that
coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product
candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing
approval. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Healthcare Reform Measures </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The United States and some
foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals designed to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in
the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical
industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, in March 2010, the ACA was
passed, which is changing health care financing by both governmental and private insurers and significantly affecting the U.S. pharmaceutical industry. The ACA, among other things, subjected manufacturers to new annual fees and taxes for specified
branded prescription drugs, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, expanded health care fraud and abuse laws, revised the methodology by which rebates owed by manufacturers to the
state and federal government for covered outpatient drugs under the Medicaid Drug Rebate Program are calculated, imposed an additional rebate similar to an inflation penalty on new formulations of drugs, extended the Medicaid Drug Rebate Program to
utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, expanded the 340B program which caps the price at which manufacturers can sell covered outpatient pharmaceuticals to specified hospitals, clinics and
community health centers, and provided incentives to programs that increase the federal government&#146;s comparative effectiveness research. Most recently, in January 2017, Congress voted to adopt a budget resolution for fiscal year 2017, or the
Budget Resolution, that authorizes the implementation of legislation that would repeal portions of the ACA. The Budget Resolution is not a law; however, it is widely viewed as the first step toward the passage of repeal legislation. Further, on
January 20, 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would
impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. Congress also could consider subsequent legislation to replace elements of the ACA that are
repealed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">106 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011,
the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years
2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which
went into effect in April 2013, following passage of the Bipartisan Budget Act of 2015, and will remain in effect through 2025 unless additional U.S. Congressional action is taken. In addition, in January 2013, President Obama signed into law the
American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from
three to five years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices.
Specifically, there have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce
the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. Additional health reform measures may continue and affect our business in unknown ways. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The Foreign Corrupt Practices Act </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Foreign Corrupt Practices Act,
or FCPA, prohibits any U.S. individual or business from paying, offering or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or
decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the
companies to maintain books and records that accurately and fairly reflect all transactions of the companies, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international
operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Foreign Regulation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to regulations in
the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products to the extent we choose to develop or sell any products outside of the United States. The
approval process varies from country to country and the time may be longer or shorter than that required to obtain FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly
from country to country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Manufacturing, Supply and Production </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do
not own or operate manufacturing facilities for the production of our product candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely on third-party contract manufacturers for all of
our required raw materials, active ingredients and finished products for our preclinical research and clinical trials, including the single pivotal Phase 3 clinical trial for MitoGel. We do not have long-term agreements with any of these third
parties. We also do not have any current contractual relationships for the manufacture of commercial supplies of our product candidates if they are approved. If product candidates are approved by any regulatory agency, we intend to enter into
agreements with a third-party contract manufacturer and one or more back-up manufacturers for the commercial production of those products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Development and
commercial quantities of any products that we develop will need to be manufactured in facilities, and by processes, that comply with the requirements of the FDA and the regulatory agencies of other jurisdictions in which we are seeking approval. We
currently employ internal resources to manage our manufacturing contractors. The relevant manufacturers of our drug products for our current preclinical and clinical trials have advised us that they are compliant with both cGLP and cGMP. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our product candidates, if approved, may not be producible in sufficient commercial quantities, in compliance with regulatory requirements or at an acceptable cost. We
and our contract manufacturers are, and will be, subject to extensive governmental regulation in connection with the manufacture of any pharmaceutical products or medical devices. We and our contract manufacturers must ensure that all of the
processes, methods and equipment are compliant with cGMP and cGLP for drugs on an ongoing basis, as mandated by the FDA and foreign regulatory authorities, and conduct extensive audits of vendors, contract laboratories and suppliers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">107 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Marketing, Sales and Distribution </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Given our stage of development, we do not have any internal sales, marketing or distribution infrastructure or capabilities, and our marketing department currently
consists only of a marketing director, whose main responsibility is to produce marketing and communication materials, exhibitions, website content and to identify unmet needs in the urology market, assess their commercial potential and advise on the
prioritization of the development of our future product candidates accordingly. We have recently formed a U.S. subsidiary, Urogen Pharma, Inc., to support our U.S. development and potential commercialization efforts. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event that we receive regulatory approvals for our products in markets outside of the United States, we intend, where appropriate, to pursue commercialization
relationships, including strategic alliances and licensing, with pharmaceutical companies and other strategic partners, which are equipped to market or sell our products through their well-developed sales, marketing and distribution organizations in
such countries. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we may out-license some or all of our worldwide patent rights to more than one party to achieve </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">the fullest development, marketing and distribution of any products we develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employees </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December 31, 2016, we had 29 full-time employees and four
part-time employees, 31 based in Israel and two based in the United States. Of these employees, 22 are primarily engaged in research and development activities and nine are primarily engaged in general and administrative matters. A total of 11
employees have an M.D. or Ph.D. degree. None of our employees is represented by a labor union. We have never experienced any employment-related work stoppages and believe our relationships with our employees are good. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Israeli labor laws govern the length of the workday and workweek, minimum wages for employees, procedures for hiring and dismissing employees, determination of
severance pay, annual leave, sick days, advance notice of termination, payments to the National Insurance Institute, and other conditions of employment and include equal opportunity and anti-discrimination laws. While none of our employees is party
to any collective bargaining agreements, certain provisions of the collective bargaining agreements between the Histadrut (General Federation of Labor in Israel) and the Coordination Bureau of Economic Organizations (including the
Industrialists&#146; Associations) are applicable to our employees in Israel by order of the Israeli Ministry of Economy and Industry. These provisions primarily concern pension fund benefits for all employees, insurance for work-related accidents,
recuperation pay and travel expenses. We generally provide our employees with benefits and working conditions beyond the required minimums. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Facilities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our principal executive offices are located at 9 HaTa&#146;asiya St., Ra&#146;anana 4365007, Israel, where we lease an approximately 11,205 square foot facility. This
Israeli facility houses our administrative headquarters and our research and development laboratories. We also maintain an office at 689 Fifth Avenue, New York, New York, where we lease approximately 1,588 square foot of space, which serves as the
headquarters for our U.S. subsidiary. We believe that our existing facilities are adequate to meet our current needs, and that suitable additional or alternative spaces will be available in the future on commercially reasonable terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Environmental, Health and Safety Matters </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are subject to extensive
environmental, health and safety laws and regulations in a number of jurisdictions, primarily Israel, governing, among other things: the use, storage, registration, handling, emission and disposal of chemicals, waste materials and sewage; chemicals,
air, water and ground contamination; air emissions and the cleanup of contaminated sites, including any contamination that results from spills due to our failure to properly dispose of chemicals, waste materials and sewage. Our operations use
chemicals and produce waste materials and sewage and require permits from various governmental authorities including, local municipal authorities, the Ministry of Environmental Protection and the Ministry of Health. The Ministry of Environmental
Protection and the Ministry of Health, local authorities and the municipal water and sewage company conduct periodic inspections in order to review and ensure our compliance with the various regulations. These laws, regulations and permits could
potentially require the expenditure by us of significant amounts for compliance or remediation. If we fail to comply with such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">108 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
laws, regulations or permits, we may be subject to fines and other civil, administrative or criminal sanctions, including the revocation of permits and licenses necessary to continue our business
activities. In addition, we may be required to pay damages or civil judgments in respect of third-party claims, including those relating to personal injury (including exposure to hazardous substances we use, store, handle, transport, manufacture or
dispose of), property damage or contribution claims. Some environmental, health and safety laws allow for strict, joint and several liability for remediation costs, regardless of comparative fault. We may be identified as a responsible party under
such laws. Such developments could have a material adverse effect on our business, financial condition and results of operations.&nbsp;In addition, laws and regulations relating to environmental, health and safety matters are often subject to
change. In the event of any changes or new laws or regulations, we could be subject to new compliance measures or to penalties for activities which were previously permitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal and Corporate Structure </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our legal and commercial name is UroGen
Pharma Ltd. We were formed as a company in the State of Israel in April 2004. Urogen Pharma, Inc., our wholly owned subsidiary, was incorporated under the laws of the State of Delaware in October 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal Proceedings </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, we may become party to litigation or
other legal proceedings that we consider to be a part of the ordinary course of our business. We are not currently involved in any legal proceedings that could reasonably be expected to have a material adverse effect on our business, financial
condition or results of operations. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Scientific Advisory Board </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
maintain a Scientific Advisory Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">109 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers, Key Personnel and Directors </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table
sets forth information relating to our executive officers, key personnel and directors as of April&nbsp;24, 2017. Unless otherwise stated, the address for our executive officers, key personnel and directors is c/o UroGen Pharma Ltd., 9
Ha&#146;Ta&#146;asiya Street, Ra&#146;anana 4365007, Israel. </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:22.25pt; font-size:8pt; font-family:ARIAL"><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>POSITION</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Executive Officers</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ron Bentsur</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chief Executive Officer and Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gil Hakim</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">President, Israeli Operation</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gary Titus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chief Financial Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Key Personnel</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Mark Schoenberg, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Medical Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Non-Employee Directors</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Arie Belldegrun, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chairman of the Board of Directors</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Kathryn E. Falberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stuart Holden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chaim Hurvitz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ran Nussbaum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pini Orbach, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Director</P></TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Executive Officers </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Ron Bentsur </I>has served as our Chief
Executive Officer since August 2015, and as a member of our board of directors since October 2015. Mr. Bentsur has served as a member of the board of directors of Stemline Therapeutics, Inc. since 2009 and as a director of Advanced Inhalation
Technologies, Ltd. since August 2015. Mr. Bentsur has more than 15 years of experience in the biotech industry. Until 2015, Mr. Bentsur served for more than five years as the Chief Executive Officer of Keryx Biopharmaceuticals, Inc., and during his
tenure, Keryx received FDA approval pursuant to the FDA&#146;s 505(b)(2) regulatory pathway for Auryxia (ferric citrate) and launched it commercially in the United States. Prior to that Mr. Bentsur served as Chief Executive Officer of XTL
Biopharmaceuticals Ltd., a position he held from January 2006 until April 2009. From October 2000 Mr. Bentsur was with Keryx and served as its Chief Financial Officer from June 2003 until his departure in January 2006. From July 1998 to October
2000, Mr.&nbsp;Bentsur served as Director of Technology Investment Banking at Leumi Underwriters, where he was responsible for all technology/biotechnology private placement and advisory transactions. From June 1994 to July 1998, Mr.&nbsp;Bentsur
worked as an investment banker in New York City, spending most of this period at ING Barings Furman Selz. Mr. Bentsur holds a B.A. in Economics and Business Administration with distinction from the Hebrew University of Jerusalem, Israel and an
M.B.A. (Magna Cum Laude), from New York University&#146;s Stern School of Business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Gil Hakim</I> has served as our President, Israeli Operation since August
2015 and, prior to that, served as our Chief Executive Officer since August 2010. Mr. Hakim has more than 20 years of experience in the biotech industry. Prior to joining us, Mr. Hakim served as Director of New Product Development at Medispec Ltd.
from 2004 to 2010, and was in charge of product development in fields such as cardiology, urology and dermatology. Prior to Medispec, from 2002 to 2004, Mr. Hakim was Director of Marketing and Clinical Research at MTRE Advanced Technologies Ltd., a
wholly owned subsidiary of Mennen Medical Ltd. that develops thermoregulation devices. Prior to that, from 2000 to 2002, he was Business Development Manager at Omrix Biopharmaceuticals, Inc. (acquired by Johnson &amp; Johnson in 2008), which
develops biological glue and blood derivative products. Before that, from 1998 to 2000, he served as European Product Manager at Biosense-Webster (Johnson &amp; Johnson) in Belgium, following Johnson &amp; Johnson&#146;s acquisition of Biosense
Israel, where he was also part of the Research and Development team. Mr.&nbsp;Hakim holds a B.Sc. in Life Sciences from Ben-Gurion University, Israel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">110 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Gary Titus</I> has served as our Chief Financial Officer since July 2015. Mr. Titus has been a member of the board
of directors of ImmunoCellular Therapeutics, Ltd. since January 2013. Mr. Titus has more than 20 years of business experience in the healthcare and biopharmaceutical industries, primarily in senior management roles. Prior to his appointment as our
Chief Financial Officer, from 2014 to 2015, Mr. Titus held the position of Chief Financial Officer of BioCardia, Inc. Prior to that, from 2008 to 2013, Mr. Titus was Senior Vice President and Chief Financial Officer at SciClone Pharmaceuticals, Inc.
From 2006 to 2008, Mr. Titus was Senior Vice President of Finance and Chief Financial Officer at Kosan Biosciences, Inc. From 2003 to 2006, he was Chief Financial Officer and Vice President at Nuvelo, Inc. Earlier in his career, Mr.&nbsp;Titus held
a variety of positions at other companies, including Metabolex, Inc., Intrabiotics Pharmaceuticals, Inc. and Johnson &amp; Johnson. Mr. Titus holds a B.Sc. in Accounting from the University of South Florida and a B.Sc. in Finance from the University
of Florida. Mr. Titus also completed the Global BioExecutive Program at the University of California Berkeley&#146;s Haas School of Business. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Key
Personnel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Mark Schoenberg, M.D.</I> has served as our Medical Director since February 2016. Dr. Schoenberg has over 20 years of experience in clinical
practice and research focused on the care of patients with all forms of bladder cancer. Since April 2014, Dr. Schoenberg has been University Professor and Chairman of the Urology Department at The Montefiore Medical Center for The Albert Einstein
College of Medicine of Yeshiva University. Prior to joining Montefiore, from 2005 to 2014, Dr.&nbsp;Schoenberg served as Director of Urologic Oncology and Bernard L. Schwartz Distinguished Professor of Urology at Johns Hopkins Hospital. Dr.
Schoenberg is also the past chair of the Medical Advisory Board of the Bladder Cancer Advocacy Network, the author of The Guide to Living with Bladder Cancer, co-editor of The Textbook of Bladder Cancer, a contributor to Campbell&#146;s Urology and
a seminars editor of the journal Urologic Oncology. Dr.&nbsp;Schoenberg received his M.D. (Alpha Omega Alpha) from the University of Texas Health Sciences Center and completed his residency in General Surgery and Urology at the Hospital of The
University of Pennsylvania, where he served as chief resident and urology instructor, before completing basic research and clinical urologic oncology fellowships at Johns Hopkins under the auspices of The American Cancer Society. Dr. Schoenberg is a
fellow of the American College of Surgeons, as well as a member of the American Association of Cancer Research, the Society of Urologic Oncology and the American Urological Association. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Directors </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Arie Belldegrun, M.D.</I> has served as our
Chairman since December 2012. Dr. Belldegrun is Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to
joining UCLA, he was a research fellow at the National Cancer Institute/National Institute of Health in surgical oncology and immunotherapy under Dr.&nbsp;Steven A. Rosenberg. Dr. Belldegrun has more than 20 years of experience in the life science
and biotech industry. In 1996 he founded Agensys, Inc., a biotechnology company, and served as its founding Chairman of the board of directors and as a board member until 2007, when it was acquired by Astellas Pharma Inc. Dr.&nbsp;Belldegrun was
also a founder and the Vice-Chairman of the board of directors and Chairman of the scientific advisory board of Cougar Biotechnology, Inc., a biotechnology company, from 2003 to 2009, when it was acquired by Johnson &amp; Johnson. He currently
serves as Chairman and Chief Executive Officer of Kite Pharma, Inc. (NASDAQ: KITE), Chairman of Arno Therapeutics, Inc., and Two River Group and as a board member of Teva Pharmaceutical Industries Ltd. Dr.&nbsp;Belldegrun completed his M.D. at the
Hebrew University Hadassah Medical School in Jerusalem, Israel, his post graduate studies in Immunology at the Weizmann Institute of Science, Israel, and his residency in Urologic Surgery at Harvard Medical School. Dr. Belldegrun has authored
several books in oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy, and cancer vaccines. Dr.&nbsp;Belldegrun is certified by the American Board of Urology and is a Fellow of the
American College of Surgeons and the American Association of Genitourinary Surgeons. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Kathryn E. Falberg</I> has served as our director since April 2017. She
previously served as Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals plc, a multi-national specialty biopharmaceutical company, from March 2012 to March 2014 after serving as Senior Vice President and Chief Financial
Officer since December 2009. Her responsibilities at Jazz Pharmaceuticals included strategy, corporate development, corporate communications and information technology. From 2001 through 2009, Ms. Falberg served as a corporate director and audit
committee chair for several companies. From 1995 to 2001, Ms. Falberg was with Amgen Inc., a biotechnology company, where she served as Senior Vice President, Finance and Strategy and Chief Financial Officer and prior to that as Vice President Chief
Accounting Officer, and Vice President, Treasurer. Ms. Falberg also serves </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">111 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
as a member of the board of directors for the public biopharmaceutical companies Aimmune Therapeutics, Inc., aTyr Pharma, Inc., Axovant Sciences Ltd., BioMarin Pharmaceutical Inc. and The Trade
Desk, Inc., a publicly held technology company. Ms. Falberg also served on the board of directors of Medivation, Inc. from 2013 to 2016 and Halozyme Therapeutics, Inc. from 2007 to 2016. Ms. Falberg received an M.B.A. in Finance and B.A., in
Economics from the University of California, Los Angeles and is a certified public accountant (inactive). </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stuart Holden, M.D.</I> has served as our
director since December 2015. Dr. Holden has been the Chairman of ProQuest Investments&#146; Scientific Advisory Board since it was founded in 1998. Since May 2014, Dr. Holden has served as a member of the UCLA faculty as a Health Sciences Clinical
Professor of Urology, Spielberg Family Chair in Urologic Oncology, in the Department of Urology at the UCLA David Geffen School of Medicine and Associate Director of the UCLA Institute of Urologic Oncology. Dr. Holden has worked in the field of
prostate cancer for more than 36 years. Dr. Holden also serves as Medical Director of the Prostate Cancer Foundation since the foundation&#146;s inception in 1993. Dr. Holden was the director of the Louis Warschaw Prostate Cancer Center at
Cedars-Sinai Medical Center and the first holder of the Warschaw, Robertson, Law Families Chair in Prostate Cancer. Dr.&nbsp;Holden has served as a member of the board of directors of Telormedix SA since 2008, and served as a member of the board of
directors of Acurian, Inc. from 1999 through 2014. In addition, he was a founding partner at Tower Urology in Los Angeles. Dr. Holden received a B.A. degree from the University of Wisconsin-Madison and completed his medical degree and received his
surgical training at Weill Cornell Medical College and the New York Hospital&#151;Cornell University Medical College. He completed his urology residency at Emory University School of Medicine and fellowships in urology and developmental genetics at
Memorial Sloan-Kettering Cancer Center. He also was awarded a clinical fellowship from the American Cancer Society. Dr.&nbsp;Holden was appointed to serve on our board by ProQuest Investments IV, L.P., one of our shareholders, pursuant to rights
granted to such shareholder under our articles of association as in effect prior to this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Chaim Hurvitz</I> has served as our director since May 2013.
Mr. Hurvitz has 31 years of experience in the life sciences industry. Mr. Hurvitz currently serves as Chief Executive Officer of CH Health, a private venture capital firm, a position he has held since May 2011. Prior to that, Mr. Hurvitz was a
member of the senior management of Teva Pharmaceutical Industries Ltd., serving as the President of Teva International Group from 2002 until 2010, as President and Chief Executive Officer of Teva Pharmaceuticals Europe from 1992 to 1999 and as Vice
President Israeli Pharmaceutical Sales from 1999 until 2002. Mr. Hurvitz served as a director of Teva Pharmaceutical Industries Ltd. from 2010 to 2014. Mr.&nbsp;Hurvitz served as a director of Aposense Ltd. from 2010 to 2014. Mr. Hurvitz currently
serves as Chairman of Galmed Pharmaceuticals Ltd. Mr. Hurvitz has been Chairman of the pharmaceuticals branch of the Manufacturer&#146;s Association of Israel since 2001 and is a member of its board. Mr.&nbsp;Hurvitz received a B.A. in Political
Science and Economics from Tel Aviv University, Israel. Mr. Hurvitz was appointed to serve on our board by Shirat HaChaim Ltd., one of our shareholders, pursuant to rights granted to such shareholder under our articles of association as in effect
prior to this offering. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Ran Nussbaum</I> has served as our director since May 2013. Mr. Nussbaum is a managing partner and the co-founder of The Pontifax
Group, a group of Israeli-based life sciences venture funds focusing on investments in development stage bio-pharmaceutical and med-tech technologies and a shareholder of our company. He also serves as a board member on many of Pontifax&#146;s
portfolio companies, including Kite Pharma, Inc., BioBlast Pharma Ltd., Eloxx Pharmaceuticals Ltd., Nutrina&nbsp;Ltd., OCON Medical Ltd and Quiet Therapeutics Ltd. Mr. Nussbaum was appointed to serve on our board by Pontifax (Israel) III Limited
Partnership and Pontifax Cayman&nbsp;III Limited, two of our shareholders, pursuant to rights granted to such shareholders under our articles of association as in effect prior to this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Pini Orbach, Ph.D.</I> has served as our director since October 2014. Dr. Orbach has served as a director of Quiet Therapeutics Ltd. since January 2013. Dr. Orbach
has 10 years of experience in executive positions. Since February 2010, Dr. Orbach has been the head of Pharma and Life Science at Arkin Holdings. Dr. Orbach was the Chief Executive Officer of NanoDoc Technology, Inc. from 2010 to 2015, Chairman of
the board of directors of cCAM Biotherapeutics Ltd. from 2014 to 2015, and served as a Director of Quiet Therapeutics Ltd. since January 2013, FusiMab Ltd. from 2011 to 2014, HealOr Ltd. from 2010 to 2013, Metallo-Therapy Ltd. from 2011 to 2015,
Insuline Medical Ltd. from December 2013 to January 2015, and CollPlant Holdings Ltd. from May 2013 to August 2014. Prior to joining Arkin Holdings, Dr. Orbach served as Chief Executive Officer of several healthcare companies in Israel. Dr. Orbach
received his Ph.D. from the Department of Physiology and Functional Genomics at the University of Florida, and was a postdoctoral fellow at the Cardiovascular Research Center at Harvard Medical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">112 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
School. Dr.&nbsp;Orbach was appointed to serve on our board by Arkin Communications Ltd., one of our shareholders, pursuant to rights granted to such shareholder under our articles of association
as in effect prior to this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Arrangements Concerning Election of Directors; Family Relationships </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors consists of seven directors. Currently serving directors will continue to serve pursuant to their appointment until the first annual general
meeting of shareholders held after this offering.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>We are not a party to, and are not aware of, any voting agreements among our shareholders. In addition, there are no family relationships among
our executive officers and directors. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate Governance Practices </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Companies incorporated under the laws of the State of Israel, whose shares are publicly traded, including companies with shares listed on the NASDAQ Global Market, are
considered public companies under Israeli law and are required to comply with various corporate governance requirements under Israeli law relating to such matters as the composition and responsibilities of the audit committee and the compensation
committee (subject to certain exceptions that we intend to utilize), and a requirement to have an internal auditor. This is the case even if our shares are not listed on the Tel Aviv Stock Exchange, or TASE, which our shares are not expected to be.
These requirements are in addition to the corporate governance requirements imposed by the NASDAQ Rules and other applicable provisions of U.S. securities laws to which we will become subject (as a foreign private issuer) upon the closing of this
offering and the listing of our ordinary shares on the NASDAQ Global Market. Under the NASDAQ Rules, a foreign private issuer may generally follow its home country rules of corporate governance in lieu of the comparable requirements of the NASDAQ
Rules, except for certain matters including the composition and responsibilities of the audit committee and the independence of its members within the meaning of the rules and regulations of the SEC. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to rely on this &#147;home country practice exemption&#148; with respect to the following NASDAQ requirements: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Quorum</I>. As permitted under the Israeli Companies Law and pursuant to our amended and restated articles of association to be effective upon the closing of this offering, the quorum required for an ordinary meeting
of shareholders will consist of at least two shareholders present in person, by proxy or by other voting instrument in accordance with the Israeli Companies Law, who hold at least 33<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>/<SUB
STYLE="font-size:85%; vertical-align:bottom">3</SUB>% of the voting power of our shares (and in an adjourned meeting, with some exceptions, at least two shareholders), instead of 33<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>/<SUB
STYLE="font-size:85%; vertical-align:bottom">3</SUB>% of the issued share capital required under the NASDAQ Rules. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Nomination of Directors</I>. With the exception of directors elected by our board of directors due to a vacancy, our directors are elected at an annual general meeting of our shareholders and hold office until the
next annual general meeting following his or her election. See &#147;Board Practices&#151;Board of Directors.&#148; The nominations for directors, which are presented to our shareholders by our board of directors, are generally made by the board of
directors itself or a duly authorized committee thereof, in accordance with the provisions of our amended and restated articles of association and the Israeli Companies Law. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Proxy Statements.</I> We will not be required to and, in reliance on home country practice, we do not intend to, comply with certain NASDAQ Rules regarding the provision of proxy statements for general meetings of
shareholders. Israeli corporate law does not have a regulatory regime for the solicitation of proxies. We intend to provide notice convening an annual general meeting, including an agenda and other relevant documents. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Shareholder Approval.</I> We will not be required to and, in reliance on home country practice, we do not intend to, comply with certain NASDAQ Rules regarding shareholder approval for certain issuances of securities
under NASDAQ Rule 5635. In accordance with the provisions of our amended and restated articles of association and the Israeli Companies Law, our board of directors is authorized to issue securities, including shares, warrants and convertible notes.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Executive Sessions</I>. We will not be required to and, in reliance on home country practice, we do not intend to, comply with certain NASDAQ Rules regarding regularly scheduled meetings at which only independent
directors are present. In accordance with the provisions of our amended and restated articles and the Israeli Companies Law, such regularly scheduled meetings at which only independent directors are present are not required. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other than as stated above, we currently intend to take all actions necessary for us to maintain compliance as a foreign private issuer under the applicable corporate
governance requirements of the Sarbanes-Oxley Act, the rules adopted by the SEC and the NASDAQ Global Market&#146;s listing standards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">113 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Practices </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Board of
Directors </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, our board of directors is responsible for setting our general policies and supervising the performance of
management. Our board of directors may exercise all powers and may take all actions that are not specifically granted to our shareholders or to management. Our executive officers are responsible for our day-to-day management and have individual
responsibilities established by our board of directors. Our Chief Executive Officer is appointed by, and serves at the discretion of, our board of directors, subject to the terms of the employment agreement that we have entered into with him. All
other executive officers are also appointed by our board of directors, and are subject to the terms of any applicable employment agreements that we may enter into with them. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under our amended and restated articles of association, to be effective upon the closing of this offering, our board of directors must consist of at least five
directors and not more than nine directors. Our board of directors will consist of seven directors upon the closing of this offering. Other than vacancies to be filled through selection by the remaining members of our board, the Israeli Companies
Law and our amended and restated articles of association provide that directors are elected annually at the general meeting of our shareholders by a vote of the holders of a majority of the voting power represented present and voting in person, by
proxy or by other voting instrument at that meeting. We have only one class of directors. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, our board of directors is required
to employ independent judgment and discretion when voting, and is prohibited from entering into any voting arrangements with respect to actions taken at meetings of the board. Further, the Israeli Companies Law provides that in the event a director
learns about an alleged breach of law or improper conduct of business relating to a company matter, said director must promptly take action to summon a meeting of the board of directors to address any such breach. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with the exemptions available to foreign private issuers under NASDAQ rules, we do not intend to follow the requirements of the NASDAQ rules with regard
to the process of nominating directors. Instead, we intend to follow Israeli law and practice, in accordance with which our board of directors (or a committee thereof) is authorized to recommend to our shareholders director nominees for election.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, our amended and restated articles of association allow our board of directors to appoint directors to fill vacancies on our board of directors,
including filling empty board seats up to the maximum number of directors permitted under our articles of association, for a term of office equal to the remaining period of the term of office of each director whose office has been vacated. Vacancies
on our board of directors may be filled by a vote of a simple majority of the directors then in office. A director so appointed will hold office until the next annual general meeting of our shareholders in which the other directors then in office
are proposed to be replaced or reappointed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Directors may be removed from office by a resolution at a general meeting of shareholders adopted by a majority of the
voting power of our company or under other circumstances set forth in our amended and restated articles of association. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, we would
be required to include on our board of directors at least two members, each of whom qualifies as an external director, and as to whom special qualifications, voting requirements and other provisions would be applicable. We would also be required to
include one such external director on each of our board committees. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under regulations promulgated under the Israeli Companies Law, Israeli companies whose shares
are traded on stock exchanges such as the NASDAQ Stock Market that do not have a controlling shareholder (as defined therein) and which comply with the requirements of the jurisdiction where the company&#146;s shares are traded with respect to the
appointment of independent directors and the composition of an audit committee and compensation committee, may elect not to follow the Israeli Companies Law requirements with respect to the composition of its audit committee and compensation
committee and the appointment of external directors. As we do not have a controlling shareholder, we intend to comply with the requirements of the NASDAQ Stock Market with respect to the composition of our board and such committees, and therefore we
will be exempt from the Israeli Companies Law requirements with respect thereto, including the appointment of external directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">114 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Leadership Structure of the Board </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with the Israeli Companies Law and our amended and restated articles of association, our board of directors is required to appoint one of its members to
serve as chairman of the board of directors. Our board of directors has appointed Arie Belldegrun, M.D. to serve as chairman of the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board
Committees </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law and our amended and restated articles of association, our board of directors is permitted to form committees, and to
delegate to any such committee powers allotted to the board of directors, subject to certain exceptions. In general, the board of directors may overturn a resolution adopted by a committee it has formed; provided, however, that the board&#146;s
decision shall not affect the ability of third parties, who were not aware of such decision, to rely on the committee&#146;s resolution prior to the time it is overturned. Only members of the board of directors can be members of a board committee,
unless the committee is solely advisory. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the listing of our ordinary shares on the NASDAQ Global Market, our audit committee will consist of Kathryn&nbsp;E. Falberg, Pini Orbach and Stuart Holden.
Kathryn&nbsp;E. Falberg will serve as chairperson of the audit committee. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Israeli Companies Law Requirements </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, we will be required to appoint an audit committee following the closing of this offering. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>NASDAQ Listing Requirements </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the NASDAQ Rules, we are required to
maintain an audit committee consisting of at least three independent directors, each of whom is financially literate and one of whom has accounting or related financial management expertise. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the NASDAQ Stock Market. Our
board of directors has determined that Kathryn&nbsp;E. Falberg is an audit committee financial expert as such term is defined by the SEC rules and has the requisite financial experience as defined by the NASDAQ Rules. Each of the members of our
audit committee is &#147;independent&#148; as such term is defined in Rule 10A-3(b)(1) under the Exchange Act and satisfies the independent director requirements under the NASDAQ Rules. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Audit Committee Role </I></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our audit committee charter, to be effective upon
the closing of this offering, sets forth the responsibilities of the audit committee consistent with the rules and regulations of the SEC and the NASDAQ Rules, as well as the requirements for such committee under the Israeli Companies Law, including
the following: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the board of directors in
accordance with Israeli law; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending the engagement or termination of the person filling the office of our internal auditor; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our board of directors. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our audit committee provides assistance to our board of directors in fulfilling its legal and fiduciary obligations in matters involving our accounting, auditing,
financial reporting, internal control and legal compliance functions by pre-approving the services performed by our independent accountants and reviewing their reports regarding our accounting practices and systems of internal control over financial
reporting. Our audit committee also oversees the audit efforts of our independent accountants and takes those actions that it deems necessary to satisfy itself that the auditors are independent of management. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, our audit committee is responsible for: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">determining whether there are deficiencies in the business management practices of our company, including in consultation with our internal auditor or the independent auditor, and making recommendations to the board of
directors to improve such practices; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">115 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest and whether such transaction is extraordinary or material under the Israeli
Companies Law) (see &#147;Approval of Related Party Transactions under Israeli Law&#151;Fiduciary Duties of Directors and Executive Officers&#148;); </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">establishing the approval process for certain transactions with a controlling shareholder or in which a controlling shareholder has a personal interest; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">where the board of directors approves the working plan of the internal auditor, examining such working plan before its submission to the board of directors and proposing amendments thereto; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">examining our internal audit controls and internal auditor&#146;s performance, including whether the internal auditor has sufficient resources and tools to fulfill his responsibilities; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top">examining the scope of our auditor&#146;s work and compensation and submitting a recommendation with respect thereto to our board of directors or shareholders, depending on which of them is considering the appointment
of our auditor; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top">establishing procedures for the handling of employees&#146; complaints as to the management of our business and the protection to be provided to such employees. </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Compensation, Nominating and Corporate Governance Committee and Compensation Policy </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the listing of our ordinary shares on the NASDAQ Global Market, we intend to establish a compensation, nominating and corporate governance committee. The members
of this committee will be Arie Belldegrun, Ran Nussbaum and Chaim Hurvitz. Arie Belldegrun will serve as chairperson of the committee. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Israeli Companies
Law Requirements </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, the board of directors of a public company must appoint a compensation committee. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The duties of the compensation, nominating and corporate governance committee include the recommendation to the company&#146;s board of directors of a policy regarding
the terms of engagement of office holders, to which we refer as a compensation policy. That policy must be adopted by the company&#146;s board of directors, after considering the recommendations of the compensation, nominating and corporate
governance committee, and will need to be approved by the company&#146;s shareholders, which approval requires what we refer to as a Special Majority Approval for Compensation. A Special Majority Approval for Compensation requires shareholder
approval by a majority vote of the shares present and voting at a meeting of shareholders called for such purpose, provided that either: (i) such majority includes at least a majority of the shares held by all shareholders who are not controlling
shareholders and do not have a personal interest in such compensation arrangement, excluding abstentions; or (ii) the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in the compensation
arrangement and who vote against the arrangement does not exceed 2% of the company&#146;s aggregate voting rights. We intend to adopt a compensation policy in conjunction with our listing on the NASDAQ Stock Market, which policy would be in effect
until the fifth anniversary of this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if the company&#146;s shareholders do not approve the compensation policy, the board of directors may resolve to
approve the compensation policy if and to the extent the board determines, in its judgment following internal discussions, that approval of the compensation policy is in the best interests of the company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The compensation policy must serve as the basis for decisions concerning the financial terms of employment or engagement of office holders, including exculpation,
insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy must relate to certain factors, including advancement of the company&#146;s long-term objectives, business
plan and policies, and creation of appropriate incentives for office holders. It must also consider, among other things, the company&#146;s risk management, size and the nature of its operations. The compensation policy must furthermore consider the
following additional factors: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the education, skills, expertise and accomplishments of the relevant office holder; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the office holder&#146;s roles and responsibilities and prior compensation agreements with him or her; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relationship between the terms offered and the average compensation of the company&#146;s personnel; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">116 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the impact of disparities in salary upon work relationships in the company; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility of reducing variable compensation at the discretion of the board of directors; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility of setting a limit on the exercise value of non-cash variable equity-based compensation; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as to severance compensation, the period of service of the office holder, the terms of his or her compensation during such service period, the company&#146;s performance during that period of service, the person&#146;s
contribution towards the company&#146;s achievement of its goals and the maximization of its profits, and the circumstances under which the person is leaving the company. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The compensation policy must also include the following principles: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the link between variable compensation and long-term performance and measurable criteria; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relationship between variable and fixed compensation, and the ceiling for the value of variable compensation; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conditions under which an office holder would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was restated in the
company&#146;s financial statements; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the minimum holding or vesting period for variable, equity-based compensation; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maximum limits for severance compensation. </TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Compensation, Nominating and Corporate Governance Committee Roles
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The compensation, nominating and corporate governance committee is responsible for (i) recommending the compensation policy to our board of directors for its
approval (and subsequent approval by our shareholders) and (ii) duties related to the compensation policy and to the compensation of our office holders, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending whether a compensation policy should continue in effect, if the then-current policy has a term of greater than five years from a company&#146;s initial public offering, or otherwise three years (approval of
either a new compensation policy or the continuation of an existing compensation policy must in any case occur five years from a company&#146;s initial public offering, or otherwise every three years); </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending to the board of directors periodic updates to the compensation policy; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assessing implementation of the compensation policy; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">determining whether to approve the terms of compensation of certain office holders which, according to the Israeli Companies Law, require the committee&#146;s approval; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">determining whether the compensation terms of a candidate for the position of the chief executive officer of the company needs to be brought to approval of the shareholders. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our compensation, nominating and corporate governance charter, to be effective upon the closing of this offering, sets forth the responsibilities of the compensation,
nominating and corporate committee, which include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the responsibilities set forth in the compensation policy; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving the granting of options and other incentive awards to the extent such authority is delegated by our board of directors; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing, evaluating and making recommendations regarding the compensation and benefits for our non-employee directors. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, our compensation, nominating and corporate governance committee is responsible for: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing our corporate governance functions on behalf of the board; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">making recommendations to the board regarding corporate governance issues; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identifying and evaluating candidates to serve as our directors consistent with the criteria approved by the board; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and evaluating the performance of the board </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">serving as a focal point for communication between director candidates, non-committee directors and our management; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">117 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selecting or recommending to the board for selection candidates to the board; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">making other recommendations to the board regarding affairs relating to our directors. </TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Disclosure of Compensation
of Executive Officers </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For so long as we qualify as a foreign private issuer, we are not required to comply with the proxy rules applicable to U.S. domestic
companies, including the requirement applicable to emerging growth companies to disclose the compensation of our Chief Executive Officer, Chief Financial Officer, President, Israeli Operation and other two most highly compensated executive officers
on an individual, rather than on an aggregate, basis. Nevertheless, under regulations promulgated under the Israeli Companies Law, we are required to disclose the annual compensation of our five most highly compensated office holders (as defined
under the Israeli Companies Law) on an individual basis, rather than on an aggregate basis, as was previously permitted for Israeli public companies listed overseas. This disclosure will not be as extensive as that required of a U.S. domestic
issuer. We intend to commence providing such disclosure, at the latest, in the notice (which is generally part of the proxy statement) for our 2017 annual general meeting of shareholders, which will be filed under cover of a Report of Foreign
Private Issuer on Form 6-K and we may elect to provide such information at an earlier date. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Internal Auditor </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, the board of directors of an Israeli public company must appoint an internal auditor recommended by the audit committee. An internal
auditor may not be: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a person (or a relative of a person) who holds more than 5% of the company&#146;s outstanding shares or voting rights; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a person (or a relative of a person) who has the power to appoint a director or the general manager of the company; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an office holder (including a director) of the company (or a relative thereof); or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a member of the company&#146;s independent accounting firm, or anyone on its behalf. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The role of the internal auditor
is to examine, among other things, our compliance with applicable law and orderly business procedures, and to report to the chief executive officer, the chairman of the board and the chairman of the audit committee. The internal auditor is entitled
to receive notice of audit committee meetings and to participate in them. In addition, the internal auditor may request that the chairman of the audit committee convene a meeting within a reasonable time to discuss an issue raised by the internal
auditor. The internal auditor is responsible for preparing a proposal for an annual or periodical audit plan and submit such plan to the board of directors or the audit committee for their approval. We intend to appoint an internal auditor following
the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Approval of Related Party Transactions under Israeli Law </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fiduciary Duties of Directors and Executive Officers </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli
Companies Law codifies the fiduciary duties that office holders owe to a company. Each person listed in the table under &#147;Executive Officers and Directors&#148; is an office holder under the Israeli Companies Law. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An office holder&#146;s fiduciary duties consist of a duty of care and a duty of loyalty. The duty of care requires an office holder to act with the level of care with
which a reasonable office holder in the same position would have acted under the same circumstances. The duty of loyalty includes an obligation that an office holder act in good faith and in the best interests of the company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The duty of care includes a duty to use reasonable means to obtain: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">information on the advisability of a given action brought for his or her approval or performed by virtue of his or her position; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all other important information pertaining to any such action. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The duty of loyalty includes a duty to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refrain from any conflict of interest between the performance of his or her duties to the company and his or her other duties or personal affairs; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">118 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refrain from any activity that is competitive with the company; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refrain from exploiting any business opportunity of the company to receive a personal gain for himself or herself or others; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disclose to the company any information or documents relating to the company&#146;s affairs which the office holder received as a result of his or her position as an office holder. </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli Companies Law requires that an office holder promptly disclose to the board of directors any personal interest that he or she may be aware of and all
related material information or documents concerning any existing or proposed transaction with the company. An interested office holder&#146;s disclosure must be made promptly and in any event no later than the first meeting of the board of
directors at which the transaction is considered. A personal interest includes an interest of any person in an action or transaction of a company, including a personal interest of such person&#146;s relative or of a corporate body in which such
person or a relative of such person is a 5% or greater shareholder, director or general manager or in which he or she has the right to appoint at least one director or the general manager, but excluding a personal interest stemming from one&#146;s
ownership of shares in the company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A personal interest also includes the personal interest of a person for whom the office holder holds a voting proxy or the
personal interest of the office holder with respect to his or her vote on behalf of a person for whom he or she holds a proxy even if such person has no personal interest in the matter. An office holder is not, however, required to disclose a
personal interest if it derives solely from the personal interest of his or her relative in a transaction that is not considered an extraordinary transaction. Under the Israeli Companies Law, an &#147;extraordinary transaction&#148; is defined as
any of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a transaction other than in the ordinary course of business; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a transaction that is not on market terms; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a transaction that may have a material impact on a company&#146;s profitability, assets or liabilities. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If it is
determined that an office holder has a personal interest in a transaction, which is not an extraordinary transaction, approval by the board of directors is required for the transaction, unless the company&#146;s articles of association provide for a
different method of approval. Further, so long as an office holder has disclosed his or her personal interest in a transaction, the board of directors may approve an action by the office holder that would otherwise be deemed a breach of his or her
duty of loyalty. However, a company may not approve a transaction or action that is not in the company&#146;s interest or that is not performed by the office holder in good faith. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An extraordinary transaction in which an office holder has a personal interest requires approval first by the company&#146;s audit committee and subsequently by the
board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The compensation of, or an undertaking to indemnify or insure, an office holder who is not a director generally requires approval first by the
company&#146;s compensation committee, then by the company&#146;s board of directors. If such compensation arrangement or an undertaking to indemnify or insure is inconsistent with the company&#146;s stated compensation policy, or if the office
holder is the chief executive officer (apart from a number of specific exceptions), then such arrangement is further subject to a Special Majority Approval for Compensation. If the shareholders of a company do not approve the compensation terms of
office holders at a meeting of the shareholders, other than directors, the compensation committee and board of directors may override the shareholders&#146; decision, subject to certain conditions. Arrangements regarding the compensation,
indemnification or insurance of a director require the approval of the compensation committee, board of directors and shareholders by simple majority, in that order, and under certain circumstances, a Special Majority Approval for Compensation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Generally, a person who has a personal interest in a matter which is considered at a meeting of the board of directors or the audit committee may not be present at such
a meeting or vote on that matter unless the chairman of the audit committee or board of directors (as applicable) determines that he or she should be present in order to present the transaction that is subject to approval. If a majority of the
members of the audit committee or the board of directors (as applicable) has a personal interest in the approval of a transaction, then all directors may participate in discussions of the audit committee or the board of directors (as applicable) on
such transaction and the voting on approval thereof, but shareholder approval is also required for such transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">119 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to Israeli law, the disclosure requirements regarding personal interests that apply to directors and executive officers also apply to a controlling shareholder
of a public company. In the context of a transaction involving a shareholder of the company, a controlling shareholder also includes a shareholder who holds 25% or more of the voting rights in the company if no other shareholder holds more than 50%
of the voting rights in the company. For this purpose, the holdings of all shareholders who have a personal interest in the same transaction will be aggregated. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The approval of the audit committee, the board of directors and the shareholders of the company, in that order, is required for (i) extraordinary transactions with a
controlling shareholder or in which a controlling shareholder has a personal interest, (ii) the engagement with a controlling shareholder or his or her relative, directly or indirectly, for the provision of services to the company, (iii) the terms
of engagement and compensation of a controlling shareholder or his or her relative who is not an office holder or (iv) the employment of a controlling shareholder or his or her relative by the company, other than as an office holder. In addition,
the shareholder approval requires one of the following, which we refer to as a Special Majority: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at least a majority of the shares held by all shareholders who do not have a personal interest in the transaction and who are present and voting at the meeting approves the transaction, excluding abstentions; or
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the shares voted against the transaction by shareholders who have no personal interest in the transaction and who are present and voting at the meeting do not exceed 2% of the aggregate voting rights in the company.
</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that any such transaction with a controlling shareholder is for a period extending beyond three years and under certain conditions,
five years from a company&#146;s initial public offering, approval is required at the end of such period unless, with respect to certain transactions, the audit committee determines that the duration of the transaction is reasonable given the
circumstances related thereto. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Arrangements regarding the compensation, indemnification or insurance of a controlling shareholder in his or her capacity as an
office holder require the approval of the compensation committee, board of directors and shareholders by a Special Majority. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to regulations promulgated
under the Israeli Companies Law, certain transactions with a controlling shareholder or his or her relative, or with directors or other office holders, that would otherwise require approval of a company&#146;s shareholders may be exempt from
shareholder approval under certain conditions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Shareholder Duties </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Israeli Companies Law, a shareholder has a duty to act in good faith and in a customary manner toward the company and other shareholders and to refrain
from abusing his or her power in the company, including, among other things, in voting at a general meeting and at shareholder class meetings with respect to the following matters: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an amendment to the company&#146;s articles of association; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase of the company&#146;s authorized share capital; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a merger; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the approval of related party transactions and acts of office holders that require shareholder approval. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A shareholder
also has a general duty to refrain from discriminating against other shareholders. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, certain shareholders have a duty of fairness toward the company.
These shareholders include a controlling shareholder, a shareholder who knows that he or she has the power to determine the outcome of a shareholder vote and a shareholder who has the power to appoint or to prevent the appointment of an office
holder of the company or other power towards the company. The Israeli Companies Law does not define the substance of the duty of fairness, except to state that the remedies generally available upon a breach of contract will also apply in the event
of a breach of the duty to act with fairness. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">120 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Exculpation, Insurance and Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an
office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association.
Our amended and restated articles of association which will be effective upon the closing of this offering include such a provision. A company may not exculpate in advance a director from liability arising out of a breach of the duty of care with
respect to a distribution. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a company may indemnify an office holder in respect of the following liabilities and expenses incurred
for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#146;s award approved by a court. However, if an undertaking to indemnify an office
holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#146;s activities when the undertaking to
indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reasonable litigation expenses, including attorneys&#146; fees, incurred by the office holder (1) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such
investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding, and (ii) no financial liability was imposed upon him or her as a substitute for the criminal
proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2) in connection with a monetary sanction; and
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reasonable litigation expenses, including attorneys&#146; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in
connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder,
if and to the extent provided in the company&#146;s articles of association: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a financial liability imposed on the office holder in favor of a third party. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a
company may not indemnify, exculpate or insure an office holder against any of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe
that the act would not harm the company; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an act or omission committed with intent to derive illegal personal benefit; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a fine, civil fine, monetary sanction or forfeit levied against the office holder. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">121 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, exculpation, indemnification and insurance of office holders in a public company must be
approved by the compensation committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders. See &#147;Approval of Related Party Transactions under Israeli Law&#151;Fiduciary
Duties of Directors and Executive Officers.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated articles of association to be effective upon the closing of this offering will permit us
to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by the Israeli Companies Law. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have obtained directors
and officers liability insurance for the benefit of our office holders and intend to increase such coverage in an amount standard for a company of our size prior to the closing of this offering. We intend to maintain such increased coverage and pay
all premiums thereunder to the fullest extent permitted by the Israeli Companies Law. In addition, prior to the closing of this offering, we intend to enter into agreements with each of our directors and executive officers exculpating them from
liability to us for damages caused to us as a result of a breach of duty of care and undertaking to indemnify them, in each case, to the fullest extent permitted by our amended and restated articles of association to be effective upon the closing of
this offering and Israeli law, including with respect to liabilities resulting from this offering to the extent that these liabilities are not covered by insurance. In the opinion of the SEC, however, indemnification of directors and office holders
for liabilities arising under the Securities Act is against public policy and therefore unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to adopt a Code of Business Conduct and Ethics applicable to all of our directors and employees, including our Chief Executive Officer, Chief Financial
Officer, controller or principal accounting officer, or other persons performing similar functions, which is a &#147;code of ethics&#148; as defined in Item 16B of Form 20-F promulgated by the SEC. Upon the effectiveness of the registration
statement of which this prospectus forms a part, the full text of the Code of Business Conduct and Ethics will be posted on our website at www.urogen.com. Information contained on, or that can be accessed through, our website does not constitute a
part of this prospectus and is not incorporated by reference herein. If we make any amendment to the Code of Business Conduct and Ethics or grant any waivers, including any implicit waiver, from a provision of the code of ethics, we will disclose
the nature of such amendment or waiver on our website to the extent required by the rules and regulations of the SEC. Under Item 16B of Form 20-F, if a waiver or amendment of the Code of Business Conduct and Ethics applies to our principal executive
officer, principal financial officer, principal accounting officer or controller and relates to standards promoting any of the values described in Item 16B(b) of Form 20-F, we are required to disclose such waiver or amendment on our website in
accordance with the requirements of Instruction 4 to such Item 16B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compensation of Executive Officers and Directors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The aggregate compensation paid and equity-based compensation and other payments expensed by us to our directors and executive officers with respect to the year ended
December 31, 2016 was $1.8 million. This amount does not include business travel, relocation, professional and business association dues and expenses reimbursed to office holders, and other benefits commonly reimbursed or paid by companies in our
industry. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December 31, 2016, options to purchase 865,228 ordinary shares granted to our directors and executive officers were outstanding under our 2010
Israeli Share Option Plan at a weighted average exercise price of $4.73&nbsp;per share and 275,200&nbsp;restricted share units were granted to our directors and executive officers under our 2010 Israeli Share Option Plan. Such number excludes
options to purchase up to 9,600&nbsp;ordinary shares and 28,800&nbsp;restricted share units, which are contingent upon the closing of this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to
adopt a director compensation policy following a review by compensation experts and approval by our shareholders in accordance with Israeli law. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not
have any written agreements with any director providing for benefits upon the termination of such director&#146;s relationship with our company, other than our employment agreement with our Chief Executive Officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">122 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Agreements with Executive Officers; Consulting and Directorship Services Provided by Directors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the closing of this offering, we will have entered into written employment agreements with all of our executive officers. These agreements contain standard
provisions for a company in our industry regarding non-solicitation, confidentiality of information, non-competition and assignment of inventions. Our executive officers will not receive benefits upon the termination of their respective employment
with us, other than payment of salary and benefits (and limited accrual of vacation days) during the required notice period for termination of their employment, which varies for each individual. In addition, we have entered into an agreement for
management services with the chairman of our board of directors. See &#147;Certain Relationships and Related Party Transactions&#151;Agreements and Arrangements with, and Compensation of, Directors and Executive Officers&#148; for additional
information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Incentive Plans </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2017 Equity Incentive Plan
</I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors adopted our 2017 Equity Incentive Plan, or our 2017 Plan, in March 2017 and our shareholders approved our 2017 Plan in April
2017. Our 2017 Plan, which will become effective upon the consummation of this offering, provides for the grant of incentive stock options to our employees and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock
awards, restricted stock unit awards, performance stock awards, performance cash awards, and other forms of stock awards to our employees, directors and consultants. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Authorized Shares.</I> The maximum number of ordinary shares that may be issued under our 2017 Plan as of the date of this prospectus is 1.4&nbsp;million. In
addition, the number of ordinary shares reserved for issuance under our 2017 Plan will automatically increase on January&nbsp;1st of each calendar year, from January&nbsp;1, 2018 through January&nbsp;1, 2026, so that the number of such shares
reserved for issuance will equal 12&nbsp;percent of the total number of ordinary shares outstanding on the last day of the calendar month prior to the date of each automatic increase, or a lesser number of shares determined by our board of
directors. The maximum number of ordinary shares that may be issued upon the exercise of incentive stock options under our 2017 Plan is 5,600,000. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Ordinary
Shares subject to stock awards granted under our 2017 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, do not reduce the number of shares available for issuance under our 2017 Plan.
Additionally, shares issued pursuant to stock awards under our 2017 Plan that we repurchase or that are forfeited, as well as shares used to pay the exercise price of a stock award or to satisfy the tax withholding obligations related to a stock
award, become available for future grant under our 2017 Plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan Administration.</I> Our board of directors, or a duly authorized committee of our board of
directors, will administer our 2017 Plan. Our board of directors may also delegate to one or more of our officers the authority to (1)&nbsp;designate employees (other than officers) to receive specified stock awards and (2)&nbsp;determine the number
of shares subject to such stock awards. Under the 2017 Plan, our board of directors has the authority to determine the terms of awards, including recipients, the exercise, purchase or strike price of stock awards, if any, the number of shares
subject to each stock award, the fair market value of an Ordinary Share, the vesting schedule applicable to the awards, together with any vesting acceleration, the form of consideration, if any, payable upon exercise or settlement of the award and
the terms of the award agreements. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Section&nbsp;162(m) Limits.</I> At such time as necessary for compliance with Section&nbsp;162(m) of the Code, no
participant may be granted stock awards covering more than 230,000 of our ordinary shares under the 2017 Plan during any calendar year pursuant to stock options, stock appreciation rights and other stock awards whose value is determined by reference
to an increase over an exercise price or strike price of at least 100% of the fair market value of our ordinary shares on the date of grant. Additionally, no participant may be granted in a calendar year a performance stock award covering more than
230,000 of our ordinary shares or a performance cash award having a maximum value in excess of $3.0 million under our 2017 Plan. The limitations are designed to allow us to grant compensation that will not be subject to the $1,000,000 annual
limitation on the income tax deductibility of compensation paid to a covered executive officer imposed by Section&nbsp;162(m) of the Code. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock
Options.</I> Incentive stock options and nonstatutory stock options are granted pursuant to stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price for stock
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">123 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
options, within the terms and conditions of the 2017 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our Ordinary Shares on
the date of grant. Options granted under the 2017 Plan vest at the rate specified in the stock option agreement as determined by the plan administrator. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restricted Stock Unit Awards.</I> Restricted stock unit awards are granted pursuant to restricted stock unit award agreements adopted by the plan administrator.
Restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to our board of directors, or a duly authorized committee of our board of directors, and permissible under applicable law. A
restricted stock unit award may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator or in any other form of consideration set forth in the restricted stock unit award agreement.
Additionally, dividend equivalents may be credited in respect of shares covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, restricted stock units that have not vested will be forfeited upon the
participant&#146;s cessation of continuous service for any reason. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restricted Stock Awards.</I> Restricted stock awards are granted pursuant to restricted stock
award agreements adopted by the plan administrator. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past services to us or any other form of legal consideration that may be acceptable to our board
of directors, or a duly authorized committee of our board of directors, and permissible under applicable law. The plan administrator determines the terms and conditions of restricted stock awards, including vesting and forfeiture terms. If a
participant&#146;s service relationship with us ceases for any reason, we may receive through a forfeiture condition or a repurchase right any or all of the Ordinary Shares held by the participant that have not vested as of the date the participant
terminates service with us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock Appreciation Rights.</I> Stock appreciation rights are granted pursuant to stock appreciation grant agreements adopted by the
plan administrator. The plan administrator determines the purchase price or strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of our Ordinary Shares on the date of grant. A stock
appreciation right granted under the 2017 Plan vests at the rate specified in the stock appreciation right agreement as determined by the plan administrator. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Performance Awards.</I> The 2017 Plan permits the grant of performance-based stock and cash awards that may qualify as performance-based compensation that is not
subject to the $1,000,000 limitation on the income tax deductibility imposed by Section&nbsp;162(m) of the Code. Our compensation committee may structure awards so that the stock or cash will be issued or paid only following the achievement of
certain pre-established performance goals during a designated performance period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Other Stock Awards.</I> The plan administrator may grant other awards based in
whole or in part by reference to our Ordinary Shares. The plan administrator will set the number of shares under the stock award and all other terms and conditions of such awards. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Changes to Capital Structure.</I> In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split or
recapitalization, appropriate adjustments will be made to (1)&nbsp;the class and maximum number of shares reserved for issuance under the 2017 Plan, (2)&nbsp;the class and maximum number of shares by which the share reserve may increase
automatically each year, (3)&nbsp;the class and maximum number of shares that may be issued upon the exercise of incentive stock options, (4)&nbsp;the class and maximum number of shares subject to stock awards that can be granted in a calendar year
(as established under the 2017 Plan pursuant to Section&nbsp;162(m) of the Code) and (5)&nbsp;the class and number of shares and exercise price, strike price or purchase price, if applicable, of all outstanding stock awards. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Transactions.</I> Our 2017 Plan provides that in the event of certain specified significant transactions, including: (1)&nbsp;a sale of all or substantially all of
our assets, (2)&nbsp;the sale or disposition of more than 50% of our outstanding securities, (3)&nbsp;the consummation of a merger or consolidation where we do not survive the transaction and (4)&nbsp;the consummation of a merger or consolidation
where we do survive the transaction but our Ordinary Shares outstanding prior to such transaction are converted or exchanged into other property by virtue of the transaction, unless otherwise provided in an award agreement or other written agreement
between us and the award holder, the administrator may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">124 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
take one or more of the following actions with respect to such stock awards:&nbsp;(1)&nbsp;arrange for the assumption, continuation or substitution of a stock award by a successor corporation,
(2)&nbsp;arrange for the assignment of any reacquisition or repurchase rights held by us to a successor corporation, (3)&nbsp;accelerate the vesting, in whole or in part, of the stock award and provide for its termination prior to the transaction,
(4)&nbsp;arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by us, (5)&nbsp;cancel or arrange for the cancellation of the stock award prior to the transaction in exchange for a cash payment, if any, determined
by the board or (6)&nbsp;make a payment, in the form determined by the board, equal to the excess, if any, of the value of the property the participant would have received upon exercise of the awards prior to the transaction over any exercise price
payable by the participant in connection with the exercise. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of a change in control, awards granted under the 2017 Plan will not receive automatic
acceleration of vesting and exercisability, although this treatment may be provided for in an award agreement. Under the 2017 Plan, a change in control is defined to include (1)&nbsp;the acquisition by any person or company of more than 50% of the
combined voting power of our then outstanding stock, (2)&nbsp;a merger, consolidation or similar transaction in which our stockholders immediately prior to the transaction do not own, directly or indirectly, more than 50% of the combined voting
power of the surviving entity (or the parent of the surviving entity), (3)&nbsp;a sale, lease, exclusive license or other disposition of all or substantially all of our assets other than to an entity more than 50% of the combined voting power of
which is owned by our stockholders, (4)&nbsp;our stockholders approve and the board approves a plan of complete dissolution or liquidation or a complete dissolution or liquidation of the Company otherwise occurs except for a liquidation into a
parent corporation and (5) a circumstance in which the members of the Incumbent Board (as defined in the 2017 Plan) no longer constitute a majority of the members of the board. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Transferability.</I> A participant may not transfer stock awards under our 2017 Plan other than by will, the laws of descent and distribution or as otherwise
provided under our 2017 Plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan Amendment or Termination.</I> Our board of directors has the authority to amend, suspend or terminate our 2017 Plan, provided
that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. Certain material amendments also require the approval of our stockholders. No incentive stock options may be granted
after the tenth anniversary of the date our board of directors adopted our 2017 Plan. No stock awards may be granted under our 2017 Plan while it is suspended or after it is terminated. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Acceleration Upon Death</I>. Our 2017 Plan provides that if a participant dies while in a service relationship with us, all vested options and stock appreciation
rights held by the participant as of the date of death shall be exercisable by the participant&#146;s estate, by a person who acquired the right to exercise the option or stock appreciation right by bequest or inheritance, or by a person designated
to exercise the option or stock appreciation right upon the participant&#146;s death, but only within the period ending on the earlier of (i)&nbsp;the date 18 months following the date of death (or such longer or shorter period specified in the
participant&#146;s award agreement), and (ii)&nbsp;the expiration of the term of such option or stock appreciation right as set forth in the award agreement. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2017 Israeli Equity Incentive Sub Plan </I></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our 2017 Israeli Equity
Incentive Sub Plan will govern equity awards granted to our Israeli employees, directors and service providers. The 2017 Israeli Equity Incentive Sub Plan was adopted under our 2017 Equity Incentive Plan. The 2017 Israeli Equity Incentive Sub
Plan&nbsp;provides for the grant by us of awards pursuant to Sections 102 and 3(i) of the Israeli Income Tax Ordinance New Version, 5721 - 1961, or the Ordinance, and the rules and regulations promulgated thereunder. The 2017 Israeli Equity
Incentive Sub Plan is effective with respect to awards granted from 30 days after the date we submitted it to the Israeli Tax Authority, or the ITA. The 2017 Israeli Equity Incentive Sub Plan&nbsp;provides for awards to be granted to those of our or
our affiliates&#146; employees, directors and officers who are not Controlling Shareholders, as defined in the Ordinance, and who are considered Israeli residents, to the extent that such awards either are (i)&nbsp;intended to qualify for special
tax treatment under the &#147;capital gains track&#148; provisions of Section&nbsp;102(b)(2) of the Ordinance or (ii)&nbsp;not intended to qualify for such special tax treatment. For more information regarding the &#147;capital gains stock,&#148;
see &#147;&#151;2010 Israeli Share Option Plan.&#148; The 2017 Israeli Equity Incentive Sub Plan also provides for the grant of awards under Section&nbsp;3(i) of the Ordinance to our Israeli non-employee service providers and Controlling
Shareholders, who are not eligible for such special tax treatment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">125 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2010 Israeli Share Option Plan </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In September 2010, we adopted our 2010 Israeli Share Option Plan, or the 2010 Plan. The 2010 Plan provides for the grant of share options and restricted share units to
our company&#146;s employees, non-employee directors and consultants. The reserved pool of shares under the 2010 Plan is 2,703,499&nbsp;shares. On March&nbsp;29, 2017, our board resolved that as of the consummation of this offering, shares that are
forfeited, cancelled, terminated or expire unexercised under the 2010 Plan shall not be available for issuance under new awards. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2010 Plan provides for
the grant by us of awards pursuant to Sections 102 and 3(i) of the Ordinance and the rules and regulations promulgated thereunder. Section 102 of the Ordinance allows employees, directors and officers who are not controlling shareholders and who are
Israeli residents, to receive favorable tax treatment for compensation in the form of shares or options. Section 102 of the Ordinance includes two alternatives for tax treatment involving the issuance of options or shares to a trustee for the
benefit of the grantees and also includes an additional alternative for the issuance of options or shares directly to the grantee. Section 102(b)(2) of the Ordinance, which provides the most favorable tax treatment for grantees, permits the issuance
to a trustee under the &#147;capital gains track.&#148; In order to comply with the terms of the capital gains track, all options granted under a specific plan and subject to the provisions of Section 102 of the Ordinance, as well as the shares
issued upon exercise of such options and other shares received following any realization of rights with respect to such options, such as share dividends and share splits, must be registered in the name of a trustee selected by the board of directors
and held in trust for the benefit of the relevant employee, director or officer. The trustee may not release these options or shares to the relevant grantee before the second anniversary of the registration of the options in the name of the trustee.
However, under this track, we are not allowed to deduct an expense with respect to the issuance of the options or shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2010 Plan provides for awards to be
granted to our employees or those of our affiliates, directors and officers who are not controlling shareholders, as defined in the Ordinance, and who are considered Israeli residents, to the extent that such awards either are (i) intended to
qualify for special tax treatment under the &#147;capital gains track&#148; provisions of Section 102(b)(2) of the Ordinance or (ii) not intended to qualify for such special tax treatment. The 2010 Plan also provides for the grant of awards under
Section 3(i) of the Ordinance to our Israeli non-employee service providers and controlling shareholders, who are not eligible for such special tax treatment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
2010 Plan is administered by our board of directors. Although awards under the 2010 Plan may be granted until 10 years after the effective date of the 2010 Plan, as of the consummation of this offering, we will not grant additional awards under the
2010 Plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The terms of options granted under the 2010 Plan, including the exercise price, vesting provisions and the duration are determined by our board of
directors and set forth in an award agreement. Except as provided in the applicable award agreement, or in the discretion of the compensation committee, an option may be exercised only to the extent that it is then exercisable and, generally, shall
expire for employees 90 days following termination of the service of the grantee, and in the case of retiring directors, not later than nine months following our listing on the NASDAQ Global Market. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Restricted share units are awards covering a number of hypothetical units with respect to shares that are granted subject to such vesting and transfer restrictions and
conditions of payment as our board of directors may determine in an award agreement. Restricted share units are payable in cash, ordinary shares of equivalent value or a combination thereof. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of any dividend (excluding any ordinary dividend) or other distribution, recapitalization, share split, reverse share split, reorganization, merger,
consolidation, split-up, split-off, combination, repurchase or exchange of shares or similar event (including a change in control) that affects the ordinary shares, the board of directors will make any such adjustments in such manner as it may deem
equitable, including any or all of the following: (i)&nbsp;adjusting the number of shares available for grant under the 2010 Plan, and (ii) providing for a substitution or assumption of awards. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All unvested options shall vest in their entirety upon (i)&nbsp;the sale of all or substantially all of the shares of the Company, (ii)&nbsp;a merger, consolidation or
reorganization in which the Company is not the surviving entity, or (iii)&nbsp;the sale, transfer or disposition of all or substantially all of the assets of the Company. Further, in such event the optionholders may elect to exchange the options for
ordinary shares on a cashless exercise basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">126 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_12"></A>PRINCIPAL SHAREHOLDERS</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth information with respect to the beneficial ownership of our ordinary shares as of March&nbsp;31, 2017 by: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person or entity known by us to own beneficially 5% or more of our outstanding ordinary shares; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our directors and executive officers individually; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our executive officers and directors as a group. </TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The beneficial ownership of our ordinary shares is
determined in accordance with the rules of the SEC and generally includes any shares over which a person exercises sole or shared voting or investment power, or the right to receive the economic benefit of ownership. For purposes of the table below,
we deem ordinary shares issuable pursuant to options that are currently exercisable or exercisable within 60 days of March&nbsp;31, 2017 to be outstanding and to be beneficially owned by the person holding the options for the purposes of computing
the percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
percentage of shares beneficially owned has been computed on the basis of 8,229,402&nbsp;ordinary shares outstanding as of March&nbsp;31, 2017, which reflects the assumed exercise for cash of all of our warrants to purchase preferred shares and the
subsequent conversion of all of our preferred shares into ordinary shares.&nbsp;For purposes of calculating the number of ordinary shares into which each preferred share will convert immediately prior to the consummation of this offering, we have
assumed an initial public offering price of $13.00 per ordinary share, the midpoint of the range set forth on the cover page of this prospectus. This calculation, before giving effect to this offering, does not give effect to any shares that may be
acquired pursuant to the directed share program. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of March&nbsp;31, 2017 and based on their reported registered office, 43 of our shareholders were U.S. persons,
holding in aggregate approximately 25.0% of our outstanding ordinary shares immediately prior to this offering. We have also set forth below information known to us regarding any significant change in the percentage ownership of our ordinary shares
by any major shareholders during the past three years. Except where otherwise indicated, we believe, based on information furnished to us by such owners, that the beneficial owners of the ordinary shares listed below have sole investment and voting
power with respect to such shares. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the closing of this offering, all of our shareholders, including the shareholders listed below, will have the
same voting rights attached to their ordinary shares, and neither our principal shareholders nor our directors and executive officers will have different or special voting rights with respect to their ordinary shares. See &#147;Description of Share
Capital&#151;Voting Rights.&#148; A description of any material relationship that our principal shareholders have had with us or any of our predecessors or affiliates within the past three years is included under &#147;Certain Relationships and
Related Party Transactions.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">127 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain of our existing shareholders and their affiliated entities have indicated an interest in purchasing our
ordinary shares in this offering at the initial public offering price. The following table does not reflect any such potential purchases by these existing shareholders or their affiliated entities. If any shares are purchased by these persons, the
number of ordinary shares beneficially owned after this offering and the percentage of ordinary shares beneficially owned after this offering would increase from that set forth in the table below. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise noted below, the address of each shareholder, director and executive officer is c/o UroGen Pharma Ltd., 9 Ha&#146;Ta&#146;asiya St., Ra&#146;anana
4365007, Israel. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER AND<BR>PERCENTAGE</B><br><B>OF&nbsp;ORDINARY&nbsp;SHARES</B><br><B>BENEFICIALLY&nbsp;OWNED</B><br><B>PRIOR TO OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE&nbsp;OF&nbsp;ORDINARY</B><br><B>SHARES BENEFICIALLY</B><br><B>OWNED AFTER THE</B><br><B>OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ASSUMING</B><br><B>NO</B><br><B>EXERCISE</B><br><B>OF&nbsp;OPTION<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(15)</SUP>+</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ASSUMING</B><br><B>FULL</B><br><B>EXERCISE</B><br><B>OF<BR>OPTION<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(15)</SUP>+</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:112.40pt; font-size:8pt; font-family:ARIAL"><B>NAME OF BENEFICIAL OWNER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>5% or Greater Shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Arkin Communication Ltd.<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,726,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pontifax (Israel) III Limited Partnership<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">936,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pontifax Cayman III Limited Partnership<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">437,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">ProQuest Investments IV, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Telormedix SA<SUP STYLE="font-size:85%; vertical-align:top"> (5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tatham Investments Ltd.<SUP STYLE="font-size:85%; vertical-align:top"> (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="16"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Directors and Executive Officers</B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>&nbsp;</B></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Arie Belldegrun, M.D.<SUP STYLE="font-size:85%; vertical-align:top"> (7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ron Bentsur<SUP STYLE="font-size:85%; vertical-align:top"> (8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Kathryn E. Falberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chaim Hurvitz<SUP STYLE="font-size:85%; vertical-align:top"> (9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pini Orbach, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top"> (10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stuart Holden, M.D.<SUP STYLE="font-size:85%; vertical-align:top"> (11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">707,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gil Hakim<SUP STYLE="font-size:85%; vertical-align:top"> (12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gary Titus<SUP STYLE="font-size:85%; vertical-align:top"> (13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ran Nussbaum<SUP STYLE="font-size:85%; vertical-align:top"> (14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,374,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">All directors and executive officers as a group (nine&nbsp;persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,245,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Indicates beneficial ownership of less than 1% of the total ordinary shares outstanding. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">+</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Does not include ordinary shares which may be purchased in this offering. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 1,347,369 ordinary shares issuable upon conversion of preferred shares and (ii) 378,950 ordinary shares issuable upon exercise of outstanding warrants to purchase preferred shares and conversion thereof
into ordinary shares. Mr. Moshe Arkin is the sole beneficial owner of Arkin Communication Ltd. The percentage ownership of Arkin Communication Ltd. increased from 15.8% as of December&nbsp;31, 2014, in connection with its initial investment, to
21.0% as of December&nbsp;31, 2015, in connection with its additional investment. The address of Arkin Communication Ltd. is 6&nbsp;HaChoshlim St., Bldg. C, Herzliya 46724, Israel. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 272,691 ordinary shares; (ii) 562,604 ordinary shares issuable upon conversion of preferred shares; (iii) 86,112 ordinary shares issuable upon exercise of outstanding warrants to purchase preferred
shares and conversion thereof into ordinary shares and (iv) 15,330&nbsp;ordinary shares issuable upon exercise of outstanding options. Does not include 21,815 ordinary shares issuable upon exercise of outstanding options which have not vested.
Pontifax Management Fund III L.P. is the general partner of Pontifax (Israel) III Limited Partnership, and Pontifax Management III G.P. (2011) Ltd. is the general partner of Pontifax Management Fund III L.P. Tomer Kariv and Ran Nussbaum are
directors of Pontifax Management GP and, as such, hold voting and/or dispositive power over the shares held by Pontifax (Israel) III Limited Partnership. The address of Pontifax (Israel) III Limited Partnership is 14&nbsp;Shenkar St., Herzliya
4672514, Israel. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Consists of (i) 127,308 ordinary shares; (ii) 262,654 ordinary shares issuable upon conversion of preferred shares; (iii)
40,204 ordinary shares issuable upon exercise of outstanding warrants to purchase preferred shares and conversion thereof into ordinary </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">128 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
shares and (iv) 7,152 ordinary shares issuable upon exercise of outstanding options. Does not include 10,184 ordinary shares issuable upon exercise of outstanding options which have not vested.
Pontifax Management Fund III L.P. is the general partner of Pontifax Cayman III Limited Partnership, and Pontifax Management III G.P. (2011) Ltd. is the general partner of Pontifax Management Fund III L.P. Tomer Kariv and Ran Nussbaum are directors
of Pontifax Management GP and, as such, hold voting and/or dispositive power over the shares held by Pontifax Cayman III Limited Partnership. The address of Pontifax Cayman III Limited Partnership is 14 Shenkar St., Herzliya 4672514, Israel.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 842,105 ordinary shares issuable upon conversion of preferred shares. ProQuest Associates IV LLC is the managing member and sole general partner of ProQuest Investments VI, L.P. Jay Moorin and Alain
Schreiber are the managing members of ProQuest Associates IV LLC and, as such, hold voting and/or dispositive power over the shares held by ProQuest Investments IV, L.P. The percentage ownership of ProQuest Associates IV LLC increased from 0% to
10.2% during 2015 in connection with its initial investments. The address of ProQuest Investments IV, L.P. is 2430 Vanderbilt Beach Road, 108-190, Naples, FL 34109, USA. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 691,200 ordinary shares issuable upon conversion of preferred shares. Does not include up to 278,400 ordinary shares that may be issued in the future upon the achievement of certain milestones under the
Vesimune asset purchase agreement with Telormedix SA. 62.6% of the beneficial ownership of these securities is held by ProQuest Investments IV, L.P., and 37.4% of the beneficial ownership of these securities is held by Aravis SA. Alain Schreiber,
Stuart Holden, Johanna Holldack and Jean-Philippe Tripet, through these entities, share voting and dispositive power over the shares held by Telormedix. The percentage ownership of Telormedix SA increased from 0% to 8.4% during 2015 in connection
with its initial investments. The address of Telormedix SA is Via della Posta&nbsp;10, <FONT STYLE="white-space:nowrap">H-6934</FONT> Bioggio, Switzerland. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 113,600 ordinary shares; (ii) 260,389 ordinary shares issuable upon conversion of preferred shares and (iii)&nbsp;42,089 ordinary shares issuable upon exercise of outstanding warrants to purchase
preferred shares and conversion thereof into ordinary shares. Tatham Investments Ltd. is beneficially owned by Shimon Elkabetz. The address of Tatham Investments Ltd. is <FONT STYLE="white-space:nowrap">2-4&nbsp;Arch,</FONT> Makarios&nbsp;III Ave,
Capital Center, 703&nbsp;Nicosia, Cyprus. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 84,211 ordinary shares issuable upon conversion of preferred shares held by Bellco Capital, LLC through several entities controlled by it, a company beneficially owned by Arie Belldegrun, M.D. and his
spouse Rebecka Belldegrun, M.D. and (ii)&nbsp;174,482 ordinary shares issuable upon exercise of outstanding options. Does not include 120,000 ordinary shares issuable upon exercise of outstanding options which have not vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 33,683 ordinary shares issuable upon conversion of preferred shares and 136,600 ordinary shares issuable upon exercise of outstanding restricted share units. Does not include 138,600 ordinary shares issuable
upon outstanding restricted share units which have not vested, and 28,800 ordinary shares issuable upon the vesting of restricted share units, the grant of which is contingent upon the closing of this offering. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;100,000 ordinary shares, 252,632 ordinary shares issuable upon conversion of preferred shares and 42,105 ordinary shares issuable upon exercise of outstanding warrants to purchase preferred shares
and conversion thereof into ordinary shares beneficially held by Shirat HaChaim Ltd., a company beneficially owned by Chaim Hurvitz, and (ii)&nbsp;25,723 ordinary shares issuable upon exercise of outstanding options. Does not include 32,000 ordinary
shares issuable upon exercise of outstanding options which have not vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 19,241 ordinary shares issuable upon exercise of outstanding options. Does not include 32,000 ordinary shares issuable upon exercise of outstanding options which have not vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of beneficial ownership of securities held by Telormedix SA described in note 5 above and of 16,000 ordinary shares issuable upon exercise of outstanding options. Does not include 32,000 ordinary shares
issuable upon exercise of outstanding options which have not vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 18,822 ordinary shares; (ii) 4,211 ordinary shares issuable upon conversion of preferred shares and (iii)&nbsp;204,234 ordinary shares issuable upon exercise of outstanding options. Does not include
52,667 ordinary shares issuable upon exercise of outstanding options which have not vested, of which 48,000 were granted in January 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 16,841 ordinary shares issuable upon conversion of preferred shares and 51,800 ordinary shares issuable upon exercise of outstanding options. Does not include 50,600 ordinary shares issuable upon exercise of
outstanding options which have not vested, of which 48,000 were granted in January 2016. Does not include 9,600 ordinary shares issuable upon exercise of options, the grant of which is contingent upon the closing of this offering. </TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of beneficial ownership of securities held by Pontifax (Israel) III Limited Partnership and Pontifax Cayman III Limited Partnership described in notes&nbsp;2 and 3 above. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Underwriters&#146; option to purchase additional ordinary shares, as set out on the cover page of this prospectus. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">129 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_13"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Agreements with Shareholders </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Registration rights agreement
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into an investors&#146; rights agreement dated September 18, 2014, as amended on October 1, 2015 and on April 12, 2016, or the Registration
Rights Agreement, with certain of our shareholders. The Registration Rights Agreement provides that certain holders of our ordinary shares have the right to demand that we file a registration statement or request that their ordinary shares be
covered by a registration statement that we are otherwise filing. Any registration rights with respect to this offering have been waived. The registration rights are described in more detail under &#147;Description of Share Capital&#151;Registration
Rights.&#148; All rights under the Registration Rights Agreement, other than the registration rights, will terminate upon the closing of this offering. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Telormedix SA agreement </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into an asset purchase
agreement, or the agreement, dated as of October&nbsp;1, 2015, with Telormedix SA. Also on October 1, 2015, we entered into the 2015 Share Purchase Agreement, as further described below, pursuant to which ProQuest, which beneficially owns 62.6% of
Telormedix, became a 10% beneficial owner of the company. Pursuant to the 2015 Share Purchase Agreement, ProQuest appointed Stuart Holden, M.D., who is a member of the board of directors of Telormedix, to our board of directors. Pursuant to the
agreement, we purchased all of the intellectual property assets of Telormedix in consideration for an aggregate amount of 691,200 Series A preferred shares with a liquidation preference of $5.94 per share. This includes 172,800 of our Series A
preferred shares, which are being held in escrow and will be automatically released to Telormedix on the earlier of (i)&nbsp;12 months from the date of initial closing and (ii)&nbsp;the consummation of this offering, unless we have raised a valid
claim prior to the expiration of this period. Upon the occurrence of three specified regulatory milestones, we will issue an additional 92,800 Series&nbsp;A preferred shares, or 92,800 ordinary shares in the event the milestone is achieved following
the completion of this offering, to Telormedix upon the occurrence of each milestone, for an aggregate potential maximum amount of 278,400 Series&nbsp;A preferred shares, or 278,400 ordinary shares in the event the milestone is achieved following
the completion of this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Agreements and Arrangements with, and Compensation of, Directors and Executive Officers </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Employment agreements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into written employment
agreements with each of our executive officers. These agreements contain customary provisions and representations, including confidentiality, non-competition, non-solicitation and inventions assignment undertakings by the executive officers.
However, the enforceability of the non-competition provisions may be limited under applicable law. The agreements are terminable by us at will, subject to prior notice, which varies for each individual. Our executive officers will not receive
benefits upon termination of their respective employment with us, other than payment of salary and benefits (and limited accrual of vacation days) during the required notice period for termination of their employment. However, Ron Bentsur, our Chief
Executive Officer, and Gary Titus, our Chief Financial Officer, will be entitled to accelerated vesting of their restricted stock units and stock options, respectively, in the event of termination without cause. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Consulting and option agreements </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We entered into an agreement
with our chairman of the board of directors, Arie Belldegrun, M.D., for management services pertaining to the development of our business. These services included serving as chairman of the board of directors, assisting us in our financing
activities and overseeing our clinical development activities. In consideration of these services, as of December&nbsp;31, 2016, we had issued Dr.&nbsp;Belldegrun options under our 2010 Israeli Share Option Plan to purchase 128,000 ordinary shares
at $4.02 per share and 166,482 ordinary shares at $5.00 per share. The agreement had no fixed term and was terminable at will (i)&nbsp;by Dr.&nbsp;Belldegrun upon 30 days&#146; prior written notice and (ii)&nbsp;by us at any time pursuant to the
directions of our board of directors or shareholders. The agreement contained customary provisions and representations, including confidentiality and inventions assignment undertakings by Dr. Belldegrun. On March&nbsp;29, 2017, our board resolved to
terminate the agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have also entered into an option agreement with our other non-executive directors, Pini Orbach, Chaim Hurvitz and Stuart Holden and
option agreements with Pontifax (Israel) III Limited Partnership and Pontifax Cayman III </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">130 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Limited Partnership, which are represented by our non-executive director Ran Nussbaum, according to which each was granted options under our 2010 Israeli Share Option Plan in the number and on
the terms set out in the section above titled &#147;Principal Shareholders.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Financing agreements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Between 2012 and 2015, Arkin Communications Ltd. or Arkin, which appointed Pini Orbach, Ph.D., to our board of directors, Pontifax (Israel) III Limited Partnership, or
Pontifax IL, and Pontifax Cayman III Limited Partnership, or Pontifax CM, which appointed Ran Nussbaum to our board of directors, Shirat HaChaim Ltd., or Shirat HaChaim, a company controlled by our director Chaim Hurvitz, Bellco Capital LLC, or
Bellco, through several entities controlled by it (the beneficial owners of Bellco Capital are Rebecka Belldegrun, M.D. and our chairman Arie Belldegrun, M.D.) and ProQuest Investments IV, L.P., or ProQuest, which appointed Stuart Holden, M.D. to
our board of directors, invested in the company an aggregate amount of approximately $22.4 million in consideration of the securities described below: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From January
2012 through July 2013, we entered into share purchase agreements with Pontifax IL, Pontifax CM, Shirat HaChaim and other investors, pursuant to which the company issued to the investors 1,375,233 ordinary shares at $5.00 per share, of which
272,691, 127,308 and 100,000 ordinary shares were issued to Pontifax IL, Pontifax CM and Shirat HaChaim, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September 18, 2014, we entered into the
2014 Share Purchase Agreement with Arkin, Pontifax IL, Pontifax CM, Shirat HaChaim and other investors, pursuant to which the company issued to the investors 1,456,573 Series A preferred shares at $5.94 per share and 728,312 warrants exercisable
into shares of Series A-1 preferred shares at $7.81 per share, of which 757,894, 172,224, 80,402 and 84,210 shares and 378,950, 86,112, 40,204 and 42,105 warrants were issued to Arkin, Pontifax IL, Pontifax CM and Shirat HaChaim, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October 1, 2015, we entered into the 2015 Share Purchase Agreement with ProQuest, Arkin, Pontifax&nbsp;IL, Pontifax CM, Shirat HaChaim, Bellco and other investors,
pursuant to which the company issued to the investors 3,045,654 Series A preferred shares at $5.94 per share, of which 842,105, 589,475, 390,380, 182,252, 168,422 and 84,211 shares were issued to ProQuest, Arkin, Pontifax IL, Pontifax CM, Shirat
HaChaim and Bellco, respectively. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Lease agreement </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our U.S.
subsidiary, UroGen Pharma, Inc., entered into a lease agreement, dated as of November 2015 and commencing as of May 2016, for office space in New York, which serves as the headquarters for our U.S. subsidiary. Our U.S. subsidiary shares the office
space equitably with Kite Pharma, Inc., a Delaware corporation, who is a co-signatory to such lease agreement. Arie Belldegrun, M.D., our chairman, serves as the Chairman and Chief Executive Officer of Kite Pharma. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Directed Share Program </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At our request, the underwriters have
reserved 346,154 ordinary shares, or 10% of the shares being offered by this prospectus (excluding the ordinary shares that may be issued upon the underwriters&#146; exercise of their option to purchase additional shares), for sale at the initial
public offering price to certain eligible directors, officers and employees and persons having business or other relationships with us and related persons through a directed share program. The number of our ordinary shares available for sale to the
general public in the public offering will be reduced by the number of shares these individuals purchase. Any reserved shares that are not so purchased will be offered by the underwriters to the general public on the same basis as the other shares
offered hereby. Shares purchased by our directors and officers will be subject to the 180-day lock-up restriction in the lock-up agreements described in &#147;Underwriting&#151;No Sales of Similar Securities&#148;. Jefferies LLC and Cowen and
Company, LLC, in their sole discretion, may release the securities subject to these lock-up agreements at any time. We have agreed to indemnify the underwriters conducting the directed share program against certain liabilities and expenses,
including liabilities under the Securities Act, in connection with the directed share program. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Indemnification agreements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated articles of association permit us to exculpate, indemnify and insure each of our directors and office holders to the fullest extent permitted
by the Israeli Companies Law. Immediately prior to the closing of this offering, we intend to enter into indemnification agreements with each of our directors and executive officers, undertaking to indemnify them to the fullest extent permitted by
Israeli law, including with respect to liabilities resulting from a public offering of our shares, to the extent that these liabilities are not covered by insurance. We </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">131 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
have also obtained Directors and Officers insurance for each of our executive officers and directors. For further information, see &#147;Management&#151;Exculpation, Insurance and Indemnification
of Directors and Officers.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Relationships </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Family members of
Chaim Hurvitz beneficially own more than 10% of Pontifax IL and Pontifax CM. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">132 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_14"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following descriptions of our share capital and provisions of our amended and restated articles of association which will be effective upon the closing of this
offering are summaries and do not purport to be complete. A form of our amended and restated articles of incorporation will be filed with the SEC as an exhibit to our registration statement, of which this prospectus forms a part. The description of
the ordinary shares reflects changes to our capital structure that will occur immediately prior to the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the closing of this offering, our authorized share capital will consist of 100,000,000 ordinary shares, par value NIS 0.01 per share, of which 10,960,708 shares
will be issued and outstanding (assuming that the outstanding warrants are not exercised and that the underwriters do not exercise their option to purchase additional ordinary shares). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our outstanding ordinary shares are validly issued, fully paid and non-assessable. Our ordinary shares are not redeemable and do not have any preemptive rights.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All ordinary shares will have identical voting and other rights in all respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Number and Purpose of the Company </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our registration number with
the Israeli Registrar of Companies is 513537621. Our purpose as set forth in our amended and restated articles of association is to engage in any lawful activity. Following the completion of this offering and the resulting registration of our shares
for trading, our registration number is expected to change to reflect our becoming a public company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Conversion of Preferred Shares </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the closing of this offering, all of our preferred shares outstanding will automatically convert into ordinary shares, and will have no further preferences,
privileges or priority rights of any kind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer of Shares </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
fully paid ordinary shares are issued in registered form and may be freely transferred under our amended and restated articles of association, unless the transfer is restricted or prohibited by another instrument, applicable law or the rules of a
stock exchange on which the shares are listed for trade. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our amended and restated articles of association or the laws of the State of Israel,
except for ownership by nationals of some countries that are, or have been, in a state of war with Israel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Election of Directors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ordinary shares do not have cumulative voting rights for the election of directors. As a result, the holders of a majority of the voting power represented at a
meeting of shareholders have the power to elect all of our directors. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under our amended and restated articles of association to be effective upon the closing
of this offering, our board of directors must consist of at least five and not more than nine directors. Our board of directors will consist of seven directors upon the closing of this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to our amended and restated articles of association, each of our directors, will be appointed by a simple majority vote of holders of our ordinary shares,
participating and voting at an annual general meeting of our shareholders. Each director will serve until the next annual general meeting following his or her election and his or her successor is duly elected and qualified or until his or her
earlier death, resignation or removal by a vote of the majority of the aggregate voting power of our company at a general meeting of our shareholders or until his or her office expires by operation of law. In addition, our amended and restated
articles of association allow our board of directors to appoint directors to fill vacancies on the board of directors, including filling empty board seats up to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">133 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
maximum number of directors permitted under our articles of association, to serve until the next annual general meeting of shareholders. Our amended and restated articles of association do not
have a retirement age requirement for our directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Dividend and Liquidation Rights </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Israeli Companies Law, dividend
distributions are determined by the board of directors and do not require the approval of the shareholders of a company unless the company&#146;s articles of association provide otherwise. Our amended and restated articles of association do not
require shareholder approval of a dividend distribution and provide that dividend distributions may be determined by our board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the
Israeli Companies Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, according to our then last reviewed or audited financial statements, provided that the end of the period
to which the financial statements relate is not more than six months prior to the date of the distribution. If we do not meet such criteria, then we may distribute dividends only with court approval. In each case, we are only permitted to distribute
a dividend if our board of directors and the court, if applicable, determines that there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing and foreseeable obligations as they become due. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to
their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the
future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Exchange Controls </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are currently no Israeli currency
control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the shares or interest or other payments to non-residents of Israel, except for shareholders who are subjects of countries that are, or have been, in
a state of war with Israel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Shareholder Meetings </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Israeli law, we
are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months after the date of the previous annual general meeting. All meetings other than the annual general meeting of
shareholders are referred to in our amended and restated articles of association as extraordinary meetings. Our board of directors may call extraordinary meetings whenever it sees fit, at such time and place, within or outside of Israel, as it may
determine. In addition, the Israeli Companies Law provides that our board of directors is required to convene an extraordinary meeting upon the written request of (i) any two or more of our directors or one-quarter or more of the members of our
board of directors, or (ii) one or more shareholders holding, in the aggregate, either (a) 5% or more of our outstanding issued shares and 1% of our outstanding voting power, or (b) 5% or more of our outstanding voting power. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the provisions of the Israeli Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are
the shareholders of record on a date to be decided by the board of directors, which may be between four and 40 days prior to the date of the meeting. Furthermore, the Israeli Companies Law requires that resolutions regarding the following matters
must be passed at a general meeting of our shareholders: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">amendments to our articles of association; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appointment or termination of our auditors; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appointment of external directors (if applicable); </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval of certain related party transactions; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increases or reductions of our authorized share capital; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a merger; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">134 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the exercise of our board of director&#146;s powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management.
</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli Companies Law requires that a notice of any annual general meeting or extraordinary meeting be provided to shareholders at least 21 days
prior to the meeting and if the agenda of the meeting includes the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, or an approval of a merger, notice must be provided at least
35 days prior to the meeting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law shareholders are not permitted to take action by way of written consent in lieu of a meeting. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Israeli Companies Law, whenever we cannot convene or conduct a general meeting in the manner prescribed under the law or our articles of association, the court
may, upon our, shareholders&#146; or directors&#146; request, order that we convene and conduct a general meeting in the manner the court deems appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Voting Rights </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Quorum Requirements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to our amended and restated articles of association, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a
vote before the shareholders at a general meeting. As a foreign private issuer, the quorum required for our general meetings of shareholders consists of at least two shareholders present in person, by proxy or by other voting instrument in
accordance with the Israeli Companies Law who hold or represent between them at least 33<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>/<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>% of the total outstanding voting rights. A
meeting adjourned for lack of a quorum is generally adjourned to the same day in the following week at the same time and place or to a later time or date if so specified in the notice of the meeting. At the reconvened meeting, any two or more
shareholders present in person or by proxy shall constitute a lawful quorum. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Vote Requirements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated articles of association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by the
Israeli Companies Law or by our amended and restated articles of association. Under the Israeli Companies Law, each of (i) the approval of an extraordinary transaction with a controlling shareholder, and (ii) the terms of employment or other
engagement of the controlling shareholder of the company or such controlling shareholder&#146;s relative (even if such terms are not extraordinary) requires the approval described above under &#147;Management&#151;Approval of Related Party
Transactions under Israeli Law&#151;Fiduciary Duties of Directors and Executive Officers&#151;Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions.&#148; Additionally, (i) the approval and extension of a
compensation policy and certain deviations therefrom require the approvals described above under &#147;Management&#151;Compensation, Nominating and Governance Committee and Compensation Policy&#151;Israeli Companies Law Requirements,&#148; and (ii)
the terms of employment or other engagement of the chief executive officer of the company require the approvals described above under &#147;Management&#151;Approval of Related Party Transactions under Israeli Law&#151;Fiduciary Duties of Directors
and Executive Officers&#151;Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions.&#148; Under our amended and restated articles of association, (i) the removal of a director from office requires the adoption of a
resolution at a general meeting of shareholders by a majority of the aggregate voting rights of our company, and (ii) the alteration of the rights, privileges, preferences or obligations of any class of our shares requires a simple majority of the
class so affected (or such other percentage of the relevant class that may be set forth in the governing documents relevant to such class), in addition to the ordinary majority vote of all classes of shares voting together as a single class at a
shareholder meeting. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further exceptions to the simple majority vote requirement are a resolution for the voluntary winding up, or an approval of a scheme of
arrangement or reorganization, of the company pursuant to Section 350 of the Israeli Companies Law, that governs the settlement of debts and reorganization of a company, which requires the approval of holders of 75% of the voting rights represented
at the meeting and voting on the resolution. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Access to Corporate Records </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, shareholders are provided access to: minutes of our general meetings; our shareholders register and principal shareholders register,
articles of association and annual audited financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">135 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
statements; and any document that we are required by law to file publicly with the Israeli Companies Registrar or the Israel Securities Authority. In addition, shareholders may request to be
provided with any document related to an action or transaction requiring shareholder approval under the related party transaction provisions of the Israeli Companies Law. We may deny this request if we believe it has not been made in good faith or
if such denial is necessary to protect our interest or protect a trade secret or patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Modification of Class Rights </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law and our amended and restated articles of association, the rights attached to any class of shares, such as voting, liquidation and
dividend rights, may be amended by adoption of a resolution by the holders of a majority of the shares of that class present at a separate class meeting, or otherwise in accordance with the rights attached to such class of shares, as set forth in
our amended and restated articles of association. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into the Registration Rights Agreement with certain of our shareholders as part of the 2014 Share Purchase Agreement. Upon the closing of this offering,
holders of a total of 5,921,789 of our ordinary shares will have the right to require us to register these shares under the Securities Act under specified circumstances and will have incidental registration rights as described below. After
registration pursuant to these rights, these shares will become freely tradable without restriction under the Securities Act. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Demand Registration Rights
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If at any time after 180 days after the effective date of this registration statement, we receive a request from holders of at least 30% of the registrable
securities then outstanding that we file a Form F-1 registration statement with respect to registrable securities then outstanding having an anticipated aggregate offering price of at least $5.0 million, then we shall (a) within 10 days after the
date such request is given, give demand notice to all holders other than the initiating holders; and (b) as soon as practicable, and in any event within 60 days after the date such request is given by the initiating holders, file a Form F-1
registration statement under the Securities Act covering all registrable securities that the initiating holders requested to be registered and any additional registrable securities requested to be included in such registration by any other holders,
as specified by notice given by each such holder to us within 20 days of the date the demand notice is given. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will not be obligated to file a registration
statement at such time if in the good faith judgment of our board of directors, such registration would be materially detrimental to us and our shareholders, because such action would (a) materially interfere with a significant acquisition,
corporate reorganization, or other similar transaction involving us; (b) require premature disclosure of material information that we have a bona fide business purpose for preserving as confidential; or (c) render us unable to comply with
requirements under the Securities Act or Exchange Act. In such event we may defer the requested filing for a period of not more than 60 days. We may not invoke this right more than once in any 12-month period and, during such 60 day period, we shall
not register any securities for our own account or that of any other shareholder other than in an &#147;Excluded Registration&#148;: (i) a registration relating to the sale of securities to our or a subsidiary&#146;s employees pursuant to a stock
option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration
statement covering the sale of the registrable securities; or (iv) a registration in which the only ordinary shares being registered are ordinary shares issuable upon conversion of debt securities that are also being registered. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition we shall not be obligated to effect, or to take any action to effect, any demand registration (a) during the period that is 60 days before our good faith
estimate of the date of filing of, and ending on a date that is 180 days after the effective date of, our initiated registration, provided that we are actively employing in good faith commercially reasonable efforts to cause such registration
statement to become effective; (b) after we have effected two demand registrations; or (c) if the initiating holders propose to dispose of shares of registrable securities that may be immediately registered on Form F-3. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Form F-3 Registration Rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If at any time when we are eligible to
use a Form F-3 registration statement, we receive a request from holders of the registrable securities then outstanding that we file a Form F-3 registration statement with respect to outstanding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">136 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
registrable securities of such holders having an anticipated aggregate offering price of at least $3.0 million, then we shall (a) within 10 days after the date such request is given, give a
demand notice to all holders other than the initiating holders; and (b) as soon as practicable, and in any event within 45 days after the date such request is given by the initiating holders, file a Form F-3 registration statement under the
Securities Act covering all registrable securities requested to be included in such registration by any other holders, as specified by notice given by each such holder to us within 20 days of the date the demand notice is given. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We shall not be obligated to effect, or to take any action to effect, any Form F-3 registration (a) during the period that is 30 days before our good faith estimate of
the date of filing of, and ending on a date that is 90 days after the effective date of, our initiated registration, provided, that we are actively employing in good faith commercially reasonable efforts to cause such registration statement to
become effective; or (b) if we have effected two Form F-3 demand registrations within the 12-month period immediately preceding the date of such request. A Form F-3 registration shall not be counted as &#147;effected&#148; until such time as the
applicable registration statement has been declared effective by the SEC, unless the initiating holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand
registration statement, in which case such withdrawn registration statement shall be counted as &#147;effected.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Piggyback Registration Rights
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, if we propose to register (including, for this purpose, a registration effected by us for shareholders other than the holders) any of our
securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), we shall, at such time, promptly give each holder notice of such registration. Upon the request
of each holder given within 20 days after such notice is given by us, we shall, subject to underwriter requirements, cause to be registered all of the registrable securities that each such holder has requested to be included in such registration. We
shall have the right to terminate or withdraw any registration initiated by us before the effectiveness of such registration, whether or not any holder has elected to include registrable securities in such registration. The expenses of such
withdrawn registration shall be borne by us. Any piggyback registration rights with respect to this offering have been waived. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Provisions </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will pay all registration expenses (other than underwriting discounts and selling commissions) and the reasonable fees and expenses of a single counsel for the
selling shareholders, related to any demand or piggyback registration. The demand, Form F-3 and piggyback registration rights described above will expire with respect to each holder of registrable securities upon such time as Rule 144 or another
similar exemption under the Securities Act is available for the sale of all of such holder&#146;s shares without limitation during a three-month period without registration. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Termination of Registration Rights </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No holder shall be entitled
to exercise any registration rights after, and all such rights shall terminate upon the earlier to occur of (a) (i) any dissolution or liquidation of us; (ii) the proper commencement, by or against us, of any bankruptcy or insolvency proceeding
under any bankruptcy or insolvency or similar law, whether voluntary or involuntary and (iii) the appointment of a receiver or liquidator to all or substantially all of our assets, and (b) the fifth anniversary of the completion of this offering.
</P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the registration rights shall terminate as to any shares of registrable securities when such shares have been (i) registered under the Securities
Act pursuant to an effective registration statement filed thereunder and disposed of in accordance with the registration statement covering them, or (ii) publicly sold pursuant to Rule 144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Acquisitions under Israeli Law </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Full Tender Offer </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A person wishing to acquire shares of an Israeli public company and who would as a result hold over 90% of the target company&#146;s issued and outstanding share
capital is required by the Israeli Companies Law to make a tender offer to all of the company&#146;s shareholders for the purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli
company and who would as a result hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer to all of the shareholders who hold shares of the relevant class for the purchase of all of
the issued and outstanding shares of that class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">137 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
capital of the company or of the applicable class, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of the shares that the acquirer
offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will also be accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company
or of the applicable class of shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether
such shareholder accepted the tender offer or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender offer was for less than fair value and that the fair value should be
paid as determined by the court. However, under certain conditions, the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli court as described above. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If (i) the shareholders who did not respond to or accept the tender offer hold at least 5% of the issued and outstanding share capital of the company or of the
applicable class or the shareholders who accept the offer constitute less than a majority of the offerees that do not have a personal interest in the acceptance of the tender offer, or (ii) the shareholders who did not accept the tender offer hold
2% or more of the issued and outstanding share capital of the company (or of the applicable class), the acquirer may not acquire shares from shareholders who accepted the tender offer that will increase its holdings to more than 90% of the
company&#146;s issued and outstanding share capital or of the applicable class. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Special Tender Offer </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli Companies Law provides that, subject to certain exceptions, an acquisition of shares of an Israeli public company must be made by means of a special tender
offer if as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement does not apply if there is already another holder of at least 25% of the voting rights in the company.
Similarly, the Israeli Companies Law provides that, subject to certain exceptions, an acquisition of shares in a public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of
more than 45% of the voting rights in the company, if there is no other shareholder of the company who holds more than 45% of the voting rights in the company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A
special tender offer must be extended to all shareholders of a company. A special tender offer may be consummated only if (i) the offeror acquired shares representing at least 5% of the voting power in the company and (ii) the number of shares
tendered by shareholders who accept the offer exceeds the number of shares held by shareholders who object to the offer (excluding the offeror, controlling shareholders, holders of 25% or more of the voting rights in the company or any person having
a personal interest in the acceptance of the tender offer or any of their relatives or any entity controlled by them). If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the
purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer,
unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer. Shares purchased in contradiction to the tender offer rules under the Israeli Companies Law, will have no rights and will
become dormant shares. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Merger </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli Companies Law permits
merger transactions if approved by each party&#146;s board of directors and, unless certain requirements described under the Israeli Companies Law are met, by a majority vote of each party&#146;s shareholders. In the case of the target company,
approval of the merger further requires a majority vote of each class of its shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For purposes of the shareholder vote, unless a court rules otherwise, the
merger will not be deemed approved if a majority of the votes of shares represented at the meeting of shareholders that are held by parties other than the other party to the merger, or by any person (or group of persons acting in concert) who holds
(or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25% or more of the directors of the other party, vote against the merger. If, however, the merger involves a merger with a company&#146;s own controlling
shareholder or if the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">138 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same Special Majority approval that governs all extraordinary transactions with
controlling shareholders (as described under &#147;Management&#151;Approval of Related Party Transactions under Israeli Law&#151;Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions&#148;). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the transaction would have been approved by the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes of
certain shareholders as provided above, a court may still approve the merger upon the petition of holders of at least 25% of the voting rights of a company. For such petition to be granted, the court must find that the merger is fair and reasonable,
taking into account the respective values assigned to each of the parties to the merger and the consideration offered to the shareholders of the target company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern
that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may further give instructions to secure the rights of creditors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, a merger may not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger is filed with the Israeli
Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the shareholders of each party. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Anti-Takeover
Measures under Israeli Law </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli Companies Law allows us to create and issue shares having rights different from those attached to our ordinary
shares, including shares providing certain preferred rights with respect to voting, distributions or other matters and shares having preemptive rights. As of the closing of this offering, no preferred shares will be authorized under our amended and
restated articles of association. In the future, if we do authorize, create and issue a specific class of preferred shares, such class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or
prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization and designation of a class of preferred shares will require an amendment to our amended and
restated articles of association, which requires the prior approval of the holders of a majority of the voting power attaching to our issued and outstanding shares and voting at a general meeting. The convening of the meeting, the shareholders
entitled to participate and the majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Israeli Companies Law as described above in &#147;-Voting Rights.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Borrowing Powers </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Israeli Companies Law and our amended and
restated articles of association, our board of directors may exercise all powers and take all actions that are not required under law or under our amended and restated articles of association to be exercised or taken by our shareholders, including
the power to borrow money for company purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Changes in Capital </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
amended and restated articles of association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Israeli Companies Law and must be approved by a resolution duly passed by our shareholders at a
general meeting by voting on such change in the capital. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the
approval of both our board of directors and an Israeli court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The transfer agent and registrar for our ordinary shares is Computershare Trust Company, N.A. Its address is 250 Royall Street, Canton, MA 02021. Its telephone number
is <FONT STYLE="white-space:nowrap">+1&nbsp;(201)&nbsp;680-4503.</FONT> </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have applied to have our ordinary shares listed on the NASDAQ Global Market under the symbol &#147;URGN.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">139 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_15"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, no public market existed for our ordinary shares. Sales of substantial amounts of our ordinary shares following this offering, or the
perception that these sales could occur, could adversely affect prevailing market prices of our ordinary shares and could impair our future ability to obtain capital, especially through an offering of equity securities. Assuming that the
underwriters do not exercise their option to purchase additional ordinary shares with respect to this offering and assuming no exercise of options outstanding following this offering, we will have an aggregate of 10,960,708&nbsp;ordinary shares
outstanding upon the closing of this offering. Of these shares, the 3,461,538&nbsp;ordinary shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act, unless purchased by
&#147;affiliates&#148; (as that term is defined under Rule 144 of the Securities Act, or Rule 144), who may sell only the volume of shares described below and whose sales would be subject to additional restrictions described below, or purchased by
certain existing investors and their affiliated entities who are subject to lock-up agreements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The remaining 7,499,170&nbsp;ordinary shares will be held by our
existing shareholders and will be deemed to be &#147;restricted securities&#148; under Rule 144. Subject to certain contractual restrictions, including the lock-up agreements described below, restricted securities may only be sold in the public
market pursuant to an effective registration statement under the Securities Act or pursuant to an exemption from registration under Rule 144, Rule 701 or Rule 904 under the Securities Act. These rules are summarized below. Sales of these shares in
the public market after the restrictions under the lock-up agreements lapse, or the perception that those sales may occur, could cause the prevailing market price of our ordinary shares to decrease or to be lower than it might be in the absence of
those sales or perceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Eligibility of Restricted Shares for Sale in the Public Market </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Approximately 7,449,170 of our ordinary shares will be eligible for resale pursuant to Rule 144 after 90 days following the pricing of this offering as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">with respect to non-affiliates of our company who will hold an aggregate of 4,203,330 ordinary shares upon the consummation of this offering, following the expiration of a non-affiliate&#146;s six-month holding period
and subject to our compliance with the current public information requirements under Rule 144; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">with respect to affiliates of our company who will hold an aggregate of 3,245,840 ordinary shares upon the consummation of this offering, following the expiration of an affiliate&#146;s six-month holding period and
subject to our compliance with the current public information requirements under Rule 144, and subject to the volume, manner of sale and other limitations under Rule 144 applicable to securities held by affiliates. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In each case, the shares will also be subject to the contractual restrictions arising under the lock-up agreements described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Lock-Up Agreements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, all of our directors and executive officers and
holders of substantially all of our outstanding shares and our shares issuable upon the exercise of vested options have signed lock-up agreements. Pursuant to such lock-up agreements, such persons have agreed, subject to certain exceptions, not to
sell or otherwise dispose of ordinary shares or any securities convertible into or exchangeable for ordinary shares for a period of 180 days after the date of this prospectus without the prior written consent of Jefferies LLC and Cowen and Company,
LLC. Jefferies LLC and Cowen and Company, LLC may, in their sole discretion, at any time without prior notice, release all or any portion of the ordinary shares from the restrictions in any such agreement. Additionally, each person buying shares
through the directed share program will be subject to a 180-day lock-up period with respect to these shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 144 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Shares Held for Six Months </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, under Rule 144 as currently
in effect, and subject to the terms of any lock-up agreement, commencing 90 days after the closing of this offering, a person (or persons whose shares are aggregated), including an affiliate, who has beneficially owned our ordinary shares for six
months or more, including the holding period of any prior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">140 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
owner other than one of our affiliates (i.e., commencing when the shares were acquired from our company or from an affiliate of our company as restricted securities), is entitled to sell our
shares, subject to the availability of current public information about us. In the case of an affiliate shareholder, the right to sell is also subject to the fulfillment of certain additional conditions, including manner of sale provisions and
notice requirements, and to a volume limitation that limits the number of shares to be sold thereby, within any three-month period, to the greater of: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1% of the number of ordinary shares then outstanding; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the average weekly trading volume of our ordinary shares on the NASDAQ Global Market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The six month holding period of Rule 144 does not apply to sales of unrestricted securities. Accordingly, persons who hold unrestricted securities may sell them under
the requirements of Rule 144 described above without regard to the six-month holding period, even if they were considered our affiliates at the time of the sale or at any time during the ninety days preceding such date. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Shares Held by Non-Affiliates for One Year </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Rule 144 as
currently in effect, a person (or persons whose shares are aggregated) who is not considered to have been one of our affiliates at any time during the 90 days preceding a sale and who has beneficially owned the shares proposed to be sold for at
least one year, including the holding period of any prior owner other than one of our affiliates, is entitled to sell his, her or its shares under Rule 144 without complying with the provisions relating to the availability of current public
information or with any other conditions under Rule 144. Therefore, unless subject to a lock-up agreement or otherwise restricted, such shares may be sold immediately upon the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 701 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, under Rule 701, any of our employees, directors,
officers, consultants or advisors who received or purchased ordinary shares from us under our 2010 Israeli Share Option Plan or other written agreement before the closing of this offering is entitled to resell these shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The SEC has indicated that Rule 701 will apply to typical share options granted by an issuer before it becomes subject to the reporting requirements of the Exchange
Act, along with the shares acquired upon exercise of these options, including exercises after the closing of this offering. Securities issued in reliance on Rule 701 are restricted securities and, subject to the contractual restrictions described
above (see &#147;Lock-Up Agreements&#148;), may be sold beginning 90 days after the closing of this offering in reliance on Rule 144 by: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons other than affiliates, without restriction; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">affiliates, subject to the manner-of-sale, current public information and filing requirements of Rule 144, in each case, without compliance with the six-month holding period requirement of Rule 144. </TD></TR></TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Options and RSUs </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2016, restricted share units
and options to purchase a total of 2,665,099 ordinary shares were issued and outstanding. Such number excludes 28,800 ordinary shares issuable upon the vesting of restricted share units, the grant of which is contingent upon the closing of this
offering, and 9,600&nbsp;ordinary shares issuable upon exercise of options, the grant of which is contingent upon the closing of this offering. Substantially all of our ordinary shares issuable under these options or restricted share units are
subject to contractual lock-up agreements with us or the underwriters. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Form S-8 Registration Statement </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the completion of this offering, we intend to file a registration statement on Form S-8 under the Securities Act to register up to 1,500,000&nbsp;ordinary
shares, in the aggregate, issued or reserved for issuance under the 2010 Israeli Share Option Plan. The registration statement on Form S-8 will become effective automatically upon filing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Ordinary shares issued upon exercise of a share option and registered pursuant to the Form S-8 registration statement will, subject to vesting provisions and Rule 144
volume limitations applicable to our affiliates, be available for sale in the open market immediately unless they are subject to the 180 day lock-up period or, if subject to the lock-up, immediately after the 180 day lock-up period expires. See
&#147;Management&#151;Equity Incentive Plans&#151;2010 Israeli Share Option Plan.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">141 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the closing of this offering, holders of a total of 5,921,789 ordinary shares will have the right to require us to register these shares under the Securities
Act under specified circumstances and will have incidental registration rights. After registration pursuant to these rights, these shares will become freely tradable without restriction under the Securities Act. For more information on these
registration rights, see &#147;Description of Share Capital&#151;Registration Rights.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">142 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_16"></A>TAXATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following description is not intended to constitute a complete analysis of all tax consequences relating to&nbsp;the acquisition, ownership and disposition of
our ordinary shares. You should consult your own tax advisor&nbsp;concerning the tax consequences in your particular situation, as well as any tax consequences that may arise under&nbsp;the laws of any state, local, foreign or other taxing
jurisdiction. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Israeli Tax Considerations and Government Programs </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a brief summary of the material Israeli tax laws applicable to us. This section also contains a discussion of material Israeli tax consequences
concerning the ownership and disposition of our ordinary shares purchased by investors in this offering. This summary does not discuss certain tax benefits, including under the Law for Encouragement of Capital Investments, 5719-1959, to which we may
become eligible in the future if we establish a manufacturing facility for our products in Israel. This summary also does not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his or her personal
investment circumstances or to some types of investors subject to special treatment under Israeli law. Examples of such investors include residents of Israel or traders in securities who are subject to special tax regimes not covered in this
discussion. Because parts of this discussion are based on new tax legislation that has not yet been subject to judicial or administrative interpretation, the appropriate tax authorities or the courts may not accept the views expressed in this
discussion. The discussion below is subject to change, including due to amendments under Israeli law or changes to the applicable judicial or administrative interpretations of Israeli law, which change could affect the tax consequences described
below. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>General Corporate Tax Structure in Israel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Israeli
companies are generally subject to corporate tax, currently at the rate of 24% of a company&#146;s taxable income (to be reduced to 23% in 2018 and thereafter). In addition, capital gains realized by Israeli companies are subject to tax at the
regular corporate tax rate. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Taxation of our Shareholders </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Capital gains taxes applicable to non-Israeli resident shareholders.</I> Capital gain is generally subject to tax at the corporate tax rate of 24% in 2017 (to be
reduced to 23% in 2018 and thereafter) if generated by a company, or at the rate of 25% if generated by an individual, or 30% in the case of sale of shares by a substantial shareholder at the time of sale or at any time during the preceding 12-month
period. A person is considered to be a substantial shareholder if it holds, directly or indirectly, alone or together with another affiliated party, 10% or more of a company&#146;s means of control, which include, among other things, voting rights,
the right to receive profits of the company, the right to receive proceeds upon liquidation and the right to appoint a director. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Notwithstanding the foregoing, a
non-Israeli resident who derives capital gains from the sale of our shares that were purchased after the shares were listed for trading on the NASDAQ is exempt from Israeli tax on such capital gains so long as they were not attributable to a
permanent establishment that the non-resident maintains in Israel. In the case of a shareholder that is a corporation, in order for it to qualify as a non-Israeli resident for these purposes, it must be incorporated in, as well as managed and
controlled from, a jurisdiction other than the State of Israel, and persons who are Israeli residents may not either: (i) have a controlling interest (directly or indirectly, alone or together with another, or together with another Israeli resident)
exceeding 25% in one or more of the means of control in such corporation or (ii) be the beneficiaries of, or entitled to, 25% or more of the revenues or profits of such corporation, whether directly or indirectly. Such exemption is not applicable to
a person whose gains from selling or otherwise disposing of the shares are deemed to be business income. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, a sale of shares by a non-Israeli resident
may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shareholders may be required to demonstrate that they are exempt
from tax on their capital gains in order to avoid withholding at source at the time of sale. In transactions involving a sale of all of the shares of an Israeli resident company, such as a merger or other transaction, the Israel Tax Authority may,
among other things, require from shareholders who are not liable for Israeli tax the execution of a declaration in the form specified by that authority or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">143 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
a specific exemption from the Israeli Tax Authority to confirm their status as non-Israeli residents may be required to be presented, and, in the absence of such declaration or exemption, may
require the purchaser of the shares to withhold taxes. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, with respect to mergers involving an exchange of shares, Israeli tax law allows for tax
deferral in certain circumstances, but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years from the date of the transaction during which sales and dispositions of shares
of the participating companies are subject to certain restrictions. Moreover, with respect to certain share swap transactions in which the sellers receive shares in the acquiring entity that are publicly traded on a stock exchange, the tax deferral
is limited in time, and when such time expires, the tax becomes payable even if no disposition of such shares has occurred. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Taxation of non-Israeli shareholders
on receipt of dividends.</I> Non-Israeli residents are generally subject to Israeli withholding tax on the receipt of dividends paid on our ordinary shares at the rate of 25%, unless relief is provided in a treaty between Israel and the
shareholder&#146;s country of residence (subject to the receipt of a valid certificate from the Israel Tax Authority, allowing for such reduced withholding tax rate). With respect to a person who is considered a substantial shareholder at the time
of receiving the dividend or at any time during the preceding 12 months, subject to the terms of an applicable tax treaty, the applicable withholding tax rate is 30%. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Convention between the Government of the United States of America and the Government of the State of Israel with respect to Taxes on Income, or the
U.S.-Israel Tax Treaty, the maximum rate of tax withheld at source in Israel on dividends paid to a holder of our ordinary shares who is a U.S. resident (for the purposes of the U.S.-Israel Tax Treaty) is 25%. However, with regard to dividends paid
to a U.S. resident corporation which held 10% or more of our outstanding voting rights throughout the taxable year in which the dividend was distributed and which maintained its shareholdings at or above such threshold during the entire previous
taxable year, the maximum rate of withholding tax is generally 12.5%, provided that no more than 25% of our gross income for such preceding year consists of certain types of dividends and interest. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">U.S. residents who are subject to Israeli withholding tax on a dividend may be entitled to a credit or deduction for U.S. federal income tax purposes in the amount of
the taxes withheld, subject to detailed limitations under U.S. laws applicable to foreign tax credits. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Excess Tax.</I><B><I> </I></B>Individuals who are subject
to tax in Israel, whether an Israeli resident or a non-Israeli resident, are also subject to an additional tax on annual income exceeding NIS 640,000 in 2017 and thereafter (linked to the Israeli consumer price index) at a rate of 3%, including, but
not limited to, dividends, interest and capital gain, subject to the provisions of an applicable tax treaty. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Material U.S. Federal Income Tax Consequences to
U.S. Holders </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following discussion describes the material U.S. federal income tax consequences to U.S. Holders (as defined below) under present law of an
investment in our ordinary shares. The effects of any applicable state or local laws, or other U.S. federal tax laws such as estate and gift tax laws are not discussed. This summary applies only to investors who hold the ordinary shares as capital
assets (generally, property held for investment) and who have the U.S. dollar as their functional currency. This discussion is based on the Code, U.S. Treasury regulations promulgated thereunder, judicial decisions, published rulings and
administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, and the U.S.-Israel Tax Treaty, all as in effect as of the date of this offering. All of the foregoing authorities are subject to change, which change could apply
retroactively and could affect the tax consequences described below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following discussion does not address all U.S. federal income tax consequences relevant to
a holder&#146;s particular circumstances or to holders subject to particular rules, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">U.S. expatriates and certain former citizens or long-term residents of the United States; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons subject to the alternative minimum tax; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons holding our ordinary shares as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment for U.S. federal income tax purposes;
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">144 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">banks, insurance companies, and other financial institutions; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">real estate investment trusts and regulated investment companies; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">brokers, dealers, and traders in securities, commodities or currencies; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnerships, S corporations, and other entities or arrangements treated as partnerships for U.S. federal income tax purposes; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax-exempt organizations and governmental organizations; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who acquired our ordinary shares pursuant to the exercise of any employee share option or otherwise as compensation; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that own or are deemed to own 10% or more of our voting stock; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that hold their shares through a permanent establishment or fixed base outside the United States; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons deemed to sell our ordinary shares under the constructive sale provisions of the Code. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>U.S. HOLDERS ARE
URGED TO CONSULT THEIR TAX ADVISORS REGARDING THE APPLICATION OF THE U.S. FEDERAL TAX RULES TO THEIR PARTICULAR CIRCUMSTANCES AS WELL AS THE U.S. STATE AND LOCAL AND NON-U.S. TAX CONSEQUENCES TO THEM OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF THE
ORDINARY SHARES. </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For purposes of this discussion, a &#147;U.S. Holder&#148; is a beneficial owner of our ordinary shares that, for U.S. federal income tax
purposes, is or is treated as any of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an individual who is a citizen or resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation, or entity treated as a corporation for U.S. federal income tax purposes, created or organized under the laws of the United States, any state thereof, or the District of Columbia; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust that (1) is subject to the supervision of a U.S. court and the control of one or more &#147;United States persons&#148; (within the meaning of Section 7701(a)(30) of the Code), or (2) has a valid election in
effect to be treated as a United States person for U.S. federal income tax purposes. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you are a partner in a partnership (or other entity taxable
as a partnership for U.S. federal income tax purposes) that holds our ordinary shares, your tax treatment generally will depend on your status and the activities of the partnership. Partnerships holding our ordinary shares and the partners in such
partnerships should consult their tax advisors regarding the U.S. federal income tax consequences applicable to them. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As indicated below, this entire discussion is
subject to the discussion of the U.S. federal income tax rules applicable to a &#147;passive foreign investment company,&#148; or a PFIC. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Passive Foreign
Investment Company Considerations </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are classified as a PFIC in any taxable year, a U.S. Holder would be subject to special rules generally intended to
reduce or eliminate any benefits from the deferral of U.S. federal income tax that a U.S. Holder could derive from investing in a non-U.S. company that does not distribute all of its earnings on a current basis. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A non-U.S. corporation is classified as a PFIC for U.S. federal income tax purposes in any taxable year in which, after applying certain look-through rules with respect
to the income and assets of subsidiaries, either (i) at least 75% of its gross income is &#147;passive income&#148; or (ii) at least 50% of the average quarterly value of its total gross assets (which, assuming we are not a CFC for the year being
tested, would be measured by fair market value of the assets, and for which purpose the total value of our assets may be determined in part by the market value of our ordinary shares, which is subject to change) is attributable to assets that
produce &#147;passive income&#148; or are held for the production of passive income. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Passive income for this purpose generally includes dividends, interest,
royalties, rents, gains from commodities and securities transactions, the excess of gains over losses from the disposition of assets which produce passive income, and generally includes amounts derived by reason of the temporary investment of funds
raised in offerings of our ordinary shares. If a non-U.S. corporation owns directly or indirectly at least 25% by value of the stock of another </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">145 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
corporation, the non-U.S. corporation is treated for purposes of the PFIC tests as owning its proportionate share of the assets of the other corporation and as receiving directly its
proportionate share of the other corporation&#146;s income. If we are classified as a PFIC in any year with respect to which a U.S. Holder owns our ordinary shares, we will continue to be treated as a PFIC with respect to such U.S. Holder in all
succeeding years during which the U.S. Holder owns our ordinary shares, regardless of whether we continue to meet the tests described above unless the holder makes a so-called &#147;purging election&#148; with respect to our ordinary shares. <B>U.S.
Holders should consult with their tax advisors regarding the availability and consequences of any PFIC purging elections.</B> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We must determine our PFIC status
annually based on tests which are factual in nature, and our status will depend on our income, assets and activities each year. In addition, our status as a PFIC may depend on how quickly we use the cash proceeds from this offering in our business.
Based upon the expected value of our assets, including any goodwill, and the expected nature and composition of our income and assets, we presently do not anticipate that we will be classified as a PFIC for the taxable year ending December 31, 2017.
However, it is not certain that the nature and composition of our income and assets will be as we currently expect, or that we will receive milestone payments in 2017 pursuant to the Allergan Agreement in the amount currently anticipated. If we do
not receive milestone payments as anticipated or other non-passive income, we likely will be classified as a PFIC for 2017. We cannot provide any assurances regarding our PFIC status for the current or future taxable years, and our U.S. tax counsel
has not provided any opinion regarding our PFIC status. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are a PFIC, and you are a U.S. Holder, then unless you make one of the elections described below, a
special tax regime will apply to both (a) any &#147;excess distribution&#148; by us to you (generally, your ratable portion of distributions in any year which are greater than 125% of the average annual distribution received by you in the shorter of
the three preceding years or your holding period for our ordinary shares) and (b) any gain realized on the sale or other disposition of the ordinary shares. Under this regime, any excess distribution and realized gain will be treated as ordinary
income and will be subject to tax as if (a) the excess distribution or gain had been realized ratably over your holding period, (b) the amount deemed realized in each year had been subject to tax in each year of that holding period at the highest
marginal rate for such year (other than income allocated to the current period or any taxable period before we became a PFIC, which would be subject to tax at the U.S. Holder&#146;s regular ordinary income rate for the current year and would not be
subject to the interest charge discussed below), and (c) the interest charge generally applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those years. In addition, dividend distributions made to you will
not qualify for the lower rates of taxation applicable to long-term capital gains discussed under &#147;Taxation of Dividends and Other Distributions on our Ordinary Shares.&#148; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain elections exist that may alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment (such as mark-to-market
treatment) of our ordinary shares. If a U.S. Holder makes the mark-to-market election, then in lieu of being subject to the tax and interest change rules disclosed above, the U.S. Holder generally will recognize as ordinary income any excess of the
fair market value of the ordinary shares at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ordinary shares over their fair market value at the
end of the taxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). If a U.S. Holder makes the election, the U.S. Holder&#146;s tax basis in the ordinary shares will be
adjusted to reflect these income or loss amounts. Any gain recognized on the sale or other disposition of ordinary shares in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to
the extent of the net amount of income previously included as a result of the mark-to-market election). The mark-to-market election is available only if we are a PFIC and our ordinary shares are &#147;regularly traded&#148; on a &#147;qualified
exchange.&#148; Our ordinary shares will be treated as &#147;regularly traded&#148; in any calendar year in which more than a <I>de minimis</I> quantity of the ordinary shares are traded on a qualified exchange on at least 15 days during each
calendar quarter (subject to the rule that trades that have as one of their principle purposes the meeting of the trading requirement are disregarded). The NASDAQ Global Market is a qualified exchange for this purpose and, consequently, if the
ordinary shares are regularly traded, the mark-to-market election will be available to a U.S. Holder. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We do not currently intend to provide the information
necessary for U.S. Holders to make QEF elections. U.S. Holders should consult their tax advisors to determine whether any of these elections would be available and if so, what the consequences of the alternative treatments would be in their
particular circumstances. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">146 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are determined to be a PFIC, the general tax treatment for U.S. Holders described in this section would apply to
indirect distributions and gains deemed to be realized by U.S. Holders in respect of any of our subsidiaries that also may be determined to be PFICs. A mark-to-market election cannot be made with respect to the stock of any of our subsidiaries. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each U.S. Holder that is an investor of a PFIC is generally required to file an annual information return on IRS Form 8621 (Information Return by a Shareholder of a
Passive Foreign Investment Company or Qualified Electing Fund) containing such information as the U.S. Treasury Department may require. The failure to file IRS Form 8621 could result in the imposition of penalties and the extension of the statute of
limitations with respect to U.S. federal income tax. U.S. Holders should consult their tax advisors regarding whether we are a PFIC and the potential application of the PFIC rules. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Taxation of Dividends and Other Distributions on our Ordinary Shares </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussion under &#147;&#150; Passive Foreign Investment Company Considerations,&#148; above, the gross amount of any distribution to you with respect to
our ordinary shares will be included in your gross income as dividend income when actually or constructively received to the extent that the distribution is paid out of our current or accumulated earnings and profits (as determined under U.S.
federal income tax principles). To the extent the amount of the distribution exceeds our current and accumulated earnings and profits, it will be treated first as a return of your tax basis in our ordinary shares, and to the extent the amount of the
distribution exceeds your tax basis, the excess will be taxed as capital gain. We do not intend to calculate our earnings and profits under U.S. federal income tax principles. Therefore, a U.S. Holder should expect that the entire amount of any
distribution will generally be reported as dividend income. Any dividends will not be eligible for the dividends-received deduction allowed to corporations in respect of dividends received from other U.S. corporations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are not a PFIC for a given year in which a dividend is paid and the taxable year preceding the dividend, non-corporate U.S. Holders may qualify for the
preferential rates of taxation with respect to dividends on ordinary shares applicable to long-term capital gains (i.e., gains from the sale of capital assets held for more than one year) applicable to qualified dividend income (as discussed below).
We believe that we qualify as a resident of Israel for purposes of, and are eligible for the benefits of, the U.S.-Israel Tax Treaty, although there can be no assurance in this regard. Further, the IRS has determined that the U.S.-Israel Tax Treaty
is satisfactory for purposes of the qualified dividend rules and that it includes an exchange-of-information program. Therefore, subject to the discussion under &#147;&#151;Passive Foreign Investment Company Considerations&#148; above, if the
U.S.-Israel Tax Treaty is applicable, such dividends will generally be &#147;qualified dividend income&#148; in the hands of individual U.S. Holders, provided that certain conditions are met, including holding period and the absence of certain risk
reduction transaction requirements. The dividends will not be eligible for the dividends received deduction generally allowed to corporate U.S. Holders. As discussed in &#147;Taxation&#151;Israeli Tax Considerations,&#148; payments of dividends by
us may be subject to Israeli withholding tax. For U.S. federal income tax purposes, U.S. Holders will be treated as having received the amount of Israeli taxes withheld by us, and as then having paid over the withheld taxes to the Israeli taxing
authorities. As a result of this rule, the amount of dividend income included in gross income for U.S. federal income tax purposes by a U.S. Holder with respect to a payment of dividends may be greater than the amount of cash actually received (or
receivable) by the U.S. Holder from us with respect to the payment. Dividends will generally constitute foreign source income for foreign tax credit limitation purposes. Any tax withheld with respect to distributions on our ordinary shares at the
rate applicable to a U.S. Holder may, subject to a number of complex limitations, be claimed as a foreign tax credit against such U.S. Holder&#146;s U.S. federal income tax liability or may be claimed as a deduction for U.S. federal income tax
purposes. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income. For this purpose, dividends distributed by us with respect to our ordinary shares generally will constitute
&#147;passive category income&#148; or &#147;general category income.&#148; The rules with respect to the foreign tax credit are complex and involve the application of rules that depend upon a U.S. Holder&#146;s particular circumstances. You are
urged to consult your tax advisor regarding the availability of the foreign tax credit under your particular circumstances. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Taxation of Disposition of
the Ordinary Shares </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussion above under &#147;&#150; Passive Foreign Investment Company Considerations,&#148; you will recognize gain or
loss on any sale, exchange or other taxable disposition of an ordinary share equal to the difference between the amount realized on the disposition of the ordinary share and your adjusted tax basis in the ordinary share. The
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">147 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
tax basis in an ordinary share generally will be the cost of such ordinary share.&nbsp;Any such gain or loss will be capital gain or loss, and will be long-term capital gain or loss if you have
held the ordinary share for more than one year at the time of sale, exchange or other taxable disposition. Otherwise, such gain or loss will be short-term capital gain or loss. Long-term capital gains recognized by certain non-corporate U.S.
Holders, including individuals, generally will be taxable at a reduced rate. The deductibility of capital losses is subject to limitations. Any such gain or loss you recognize generally will be treated as U.S. source income or loss for foreign tax
credit limitation purposes. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Additional Medicare Tax </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain
U.S. Holders that are individuals, estates or trusts are subject to a 3.8% tax on all or a portion of their &#147;net investment income,&#148; which may include all or a portion of their dividend income and net gains from the disposition of ordinary
shares. Each U.S. Holder that is an individual, estate or trust is urged to consult its tax advisors regarding the applicability of the Medicare tax to its income and gains in respect of its investment in our ordinary shares. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Certain Reporting Requirements With Respect to Payments of Offer Price </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">U.S. Holders paying more than $100,000 for our shares will generally be required to file IRS Form 926 reporting such payment for our ordinary shares to us. Substantial
penalties may be imposed upon a U.S. Holder that fails to comply. Each U.S. Holder should consult its own tax advisor as to the possible obligation to file IRS Form 926. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Information Reporting and Backup Withholding </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">U.S. backup withholding
tax and information reporting requirements may apply to certain payments to certain holders of our ordinary shares. Information reporting will generally apply to payments of dividends on, and to proceeds from the sale or redemption of, our ordinary
shares made within the United States, or by a U.S. payer or U.S. middleman, to a holder of our shares, other than an exempt recipient (including a payee that is not a U.S. person that provides an appropriate certification and certain other persons).
Certain U.S. Holders are exempt from backup withholding, including corporations and certain tax-exempt organizations. A U.S. Holder will be subject to backup withholding if such holder is not otherwise exempt and such holder: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fails to furnish the holder&#146;s taxpayer identification number, which for an individual is ordinarily his or her social security number; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">furnishes an incorrect taxpayer identification number; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">is notified by the IRS that the holder previously failed to properly report payments of interest or dividends; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fails to certify under penalties of perjury that the holder has furnished a correct taxpayer identification number and that the IRS has not notified the holder that the holder is subject to backup withholding.
</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against
the U.S. Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. U.S. Holders should consult their tax advisors regarding their qualification for an exemption from backup withholding and the
procedures for obtaining such an exemption. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Additional Reporting Requirements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain U.S. Holders who are individuals (and under proposed regulations, certain entities) are required to report information relating to an interest in our ordinary
shares, subject to certain exceptions (including an exception for ordinary shares held in accounts maintained by financial institutions) by filing IRS Form 8938 (Statement of Specified Foreign Financial Assets) with their federal income tax return.
U.S. Holders should consult their tax advisors regarding the possible implications of these tax return disclosure obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">148 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_17"></A>UNDERWRITING</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the terms and conditions set forth in the underwriting agreement, dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017, Jefferies LLC, 520 Madison Avenue, New York, New York 10022, and Cowen and Company, LLC, 599 Lexington Avenue, 27th&nbsp;Floor, New York, New
York 10022, are serving as the representatives of the underwriters named below and the joint book-running managers for this offering. Pursuant to such agreement, we have agreed to sell to the underwriters, and each of the underwriters has agreed,
severally and not jointly, to purchase from us, the respective number of ordinary shares shown opposite its name below: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>ORDINARY&nbsp;SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Raymond James &amp; Associates, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Oppenheimer &amp; Co. Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,461,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters
of officers&#146; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the ordinary shares if any of them are purchased. If an
underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be terminated. We have agreed to indemnify the underwriters and certain of
their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the ordinary shares as permitted by
applicable laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can be given as
to the liquidity of the trading market for the ordinary shares, that you will be able to sell any of the ordinary shares held by you at a particular time or that the prices that you receive when you sell will be favorable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters are offering the ordinary shares subject to their acceptance of the ordinary shares from us and subject to prior sale. The underwriters reserve the
right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that they do not intend to confirm sales to any account over which they exercise discretionary
authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commission and Expenses </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised
us that they propose to offer the ordinary shares to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers, which may include the underwriters, at that price less a concession not in
excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share. The underwriters may allow and certain dealers may re-allow, a discount from the concession not in excess of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share to certain brokers and dealers. After the offering, the initial public offering price, concession and reallowance may be reduced by the representatives. No such reduction will
change the amount of proceeds to be received by us as set forth on the cover page of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">149 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table shows the public offering price, the underwriting discounts and commissions that we are to pay the
underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional ordinary shares. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER ORDINARY SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>ORDINARY<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>ORDINARY<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>ORDINARY<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>ORDINARY<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Underwriting discounts and commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately
$2,500,000. We also have agreed to reimburse the underwriters for up to $40,000 for certain expenses incurred in connection with this offering, including for their FINRA counsel fee. In accordance with FINRA Rule 5110, these reimbursed expenses are
deemed underwriting compensation for this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Determination of Offering Price </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, there has not been a public market for our ordinary shares. Consequently, the initial public offering price for our ordinary shares will be
determined by negotiations between us and the representatives. Among the factors to be considered in these negotiations will be prevailing market conditions, our financial information, market valuations of other companies that we and the
underwriters believe to be comparable to us, estimates of our business potential, the present state of our development and other factors deemed relevant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We offer
no assurances that the initial public offering price will correspond to the price at which the ordinary shares will trade in the public market subsequent to the offering or that an active trading market for the ordinary shares will develop and
continue after the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have applied to have our
ordinary shares listed on the NASDAQ Global Market under the symbol &#147;URGN.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stamp Taxes </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you purchase ordinary shares offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws and practices of the country of
purchase, in addition to the offering price listed on the cover page of this prospectus. However, no stamp taxes will be payable to the State of Israel in connection with the sale of shares offered hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Option to Purchase Additional Ordinary Shares </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have granted to the
underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase, from time to time, in whole or in part, up to an aggregate of 519,230 ordinary shares from us at the public offering price set forth on the cover page of
this prospectus, less underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase a number of additional ordinary shares proportionate to that
underwriter&#146;s initial purchase commitment as indicated in the table above. This option may be exercised only if the underwriters sell more ordinary shares than the total number set forth on the cover page of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">150 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>No Sales of Similar Securities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, our officers, directors and holders of substantially all of our outstanding share capital have agreed, subject to specified exceptions, not to directly or
indirectly: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open &#147;put equivalent position&#148; within the meaning of Rule 16a-1(h) under the Exchange Act,
or</TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>otherwise dispose of any share capital, options or warrants to acquire shares, or securities exchangeable or exercisable for or convertible into shares currently or hereafter owned either of record or
beneficially, or&nbsp; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>publicly announce an intention to do any of the foregoing for a period of 180 days after the date of this prospectus without the prior written consent of Jefferies LLC and Cowen and Company, LLC.
</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This restriction terminates after the close of trading of the ordinary shares on and including the
180<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day after the date of this prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Jefferies LLC and Cowen and Company, LLC may, in their sole
discretion and at any time or from time to time before the termination of the 180-day period, release all or any portion of the securities subject to lock-up agreements. There are no existing agreements between the underwriters and any of our
shareholders who will execute a lock-up agreement, providing consent to the sale of shares prior to the expiration of the lock-up period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stabilization </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, pursuant to Regulation M under the Exchange Act, certain persons participating in the offering may engage in short sale
transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the ordinary shares at
a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either &#147;covered&#148; short sales or &#147;naked&#148; short sales. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional ordinary shares in this offering. The
underwriters may close out any covered short position by either exercising their option to purchase additional ordinary shares or purchasing our ordinary shares in the open market. In determining the source of ordinary shares to close out the
covered short position, the underwriters will consider, among other things, the price of ordinary shares available for purchase in the open market as compared to the price at which they may purchase ordinary shares through the option to purchase
additional ordinary shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Naked&#148; short sales are sales in excess of the option to purchase additional ordinary shares. The underwriters must close out
any naked short position by purchasing ordinary shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our ordinary shares in the open
market after pricing that could adversely affect investors who purchase in this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A stabilizing bid is a bid for the purchase of ordinary shares on behalf
of the underwriters for the purpose of fixing or maintaining the price of the ordinary shares. A syndicate covering transaction is the bid for or the purchase of ordinary shares on behalf of the underwriters to reduce a short position incurred by
the underwriters in connection with the offering. Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our ordinary shares or
preventing or retarding a decline in the market price of our ordinary shares. As a result, the price of our ordinary shares may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement permitting the
underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the ordinary shares originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore
have not been effectively placed by such syndicate member. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we, nor any of the underwriters make any representation or prediction as to the direction or
magnitude of any effect that the transactions described above may have on the price of our ordinary shares. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at any time.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">151 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters may also engage in passive market making transactions in our ordinary shares on the NASDAQ Global Market
in accordance with Rule 103 of Regulation M during a period before the commencement of offers or sales of our ordinary shares in this offering and extending through the completion of distribution. A passive market maker must display its bid at a
price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified purchase limits are exceeded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Electronic Distribution </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A prospectus in electronic format may be made
available by e-mail or on the web sites or through online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective investors may view offering terms online and may be allowed to place orders online. The
underwriters may agree with us to allocate a specific number of ordinary shares for sale to online brokerage account holders. Any such allocation for online distributions will be made by the underwriters on the same basis as other allocations. Other
than the prospectus in electronic format, the information on the underwriters&#146; web sites and any information contained in any other web site maintained by any of the underwriters is not part of this prospectus, has not been approved and/or
endorsed by us or the underwriters and should not be relied upon by investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Directed Share Program </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At our request, the underwriters have reserved 346,154&nbsp;ordinary shares, or 10% of the shares being offered by this prospectus (excluding the ordinary shares that
may be issued upon the underwriters&#146; exercise of their option to purchase additional shares), for sale at the initial public offering price to certain eligible directors, officers and employees and persons having business or other relationships
with us and related persons through a directed share program. The number of our ordinary shares available for sale to the general public in the public offering will be reduced by the number of shares these individuals purchase. Any reserved shares
that are not so purchased will be offered by the underwriters to the general public on the same basis as the other shares offered hereby. We have agreed to indemnify the underwriters conducting the directed share program against certain liabilities
and expenses, including liabilities under the Securities Act, in connection with the directed share program. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Activities and Relationships </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial
and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriters and certain of their affiliates have, from time to time, performed, and may
in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the ordinary course of their various business activities, the underwriters and certain of their affiliates may make or hold a broad array of investments and actively
trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities
and/or instruments issued by us and our affiliates. If the underwriters or their respective affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies.
The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our
affiliates, including potentially the ordinary shares offered hereby. Any such short positions could adversely affect future trading prices of the ordinary shares offered hereby. The underwriters and certain of their respective affiliates may also
communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire,
long and/or short positions in such securities and instruments. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain of our existing investors and their affiliated entities and other entities have
indicated an interest in purchasing up to an aggregate of approximately $20.0 million worth of our ordinary shares in this offering at the initial public offering price. However, because indications of interest are not binding agreements or
commitments to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">152 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
purchase, the underwriters may determine to sell more, less or no shares in this offering to any of these persons and any of these persons may determine to purchase more, less or no shares in
this offering. Shares purchased by certain existing investors may be subject to the lock-up agreements described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Disclaimers About Non-U.S. Jurisdictions
</B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Australia </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus is not a disclosure document
for the purposes of Australia&#146;s Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not been lodged with the Australian Securities &amp; Investments Commission and is only directed to the categories of exempt persons set out
below. Accordingly, if you receive this prospectus in Australia: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You confirm and warrant that you are either: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>a &#147;sophisticated investor&#148; under section 708(8)(a) or (b) of the Corporations Act;&nbsp; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>a &#147;sophisticated investor&#148; under section 708(8)(c) or (d) of the Corporations Act and that you have provided an accountant&#146;s certificate to the company which complies with the requirements of
section 708(8)(c)(i) or (ii) of the Corporations Act and related regulations before the offer has been made; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a person associated with the Company under Section 708(12) of the Corporations Act; or </TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>a &#147;professional investor&#148; within the meaning of section 708(11)(a) or (b) of the Corporations Act. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the Corporations
Act any offer made to you under this prospectus is void and incapable of acceptance. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You warrant and agree that you will not offer any of the shares issued to
you pursuant to this prospectus for resale in Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708 of the Corporations Act. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>European Economic Area </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In relation to each member state of the
European Economic Area which has implemented the Prospectus Directive, each referred to herein as a Relevant Member State, no offer of any securities which are the subject of the offering contemplated by this prospectus has been or will be made to
the public in that Relevant Member State, except that with effect from and including the Relevant Implementation Date, an offer of such securities may be made to the public in that Relevant Member State: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>to any legal entity which is a &#147;qualified investor&#148; as defined in the Prospectus Directive;&nbsp; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>to fewer than 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the
representatives of the underwriters for any such offer; or&nbsp; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>in any other circumstances falling within Article 3(2) of the Prospectus Directive, </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">provided that no such offer
of securities shall require the company or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the purposes of this provision, the expression &#147;offer to the public&#148; in relation to any securities in any Relevant Member State means the communication in
any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe the securities, as the same may be varied in that Relevant Member State by
any measure implementing the Prospectus Directive in that Relevant Member State, and the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, the &#147;2010 PD Amending
Directive&#148;), and includes any relevant implementing measure in the Relevant Member State, and the expression &#147;2010 PD Amending Directive&#148; means Directive 2010/73/EU. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">153 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Hong Kong </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No
securities have been offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy or sell shares or debentures, whether as principal or agent; or to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or in other circumstances which do not result in the document being a &#147;prospectus&#148; as
defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32) or the Securities and Futures Ordinance (Cap.&nbsp;571) of Hong Kong. No document,
invitation or advertisement relating to the securities has been issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of
which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or
only to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong
Kong, and the securities may not be offered for subscription to members of the public in Hong Kong. Each person acquiring the securities will be required, and is deemed by the acquisition of the securities, to confirm that he is aware of the
restriction on offers of the securities described in this prospectus and the relevant offering documents and that he is not acquiring, and has not been offered any securities in circumstances that contravene any such restrictions. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Japan </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offering has not been and will not be registered under
the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948 of Japan, as amended), or FIEL, and the underwriters will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan
(which term as used herein means, unless otherwise provided herein, any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan
or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws, regulations and ministerial guidelines of Japan. </P>
 <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Singapore </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been and will not be
lodged or registered with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or the invitation for subscription or purchase of the securities may not be issued,
circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under
Section 274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii) to a relevant person as defined under Section 275(1), or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions, specified in
Section 275 of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of any other applicable provision of the SFA. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Where the
securities are subscribed or purchased under Section 275 of the SFA by a relevant person which is: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>a corporation (which is not an accredited investor as defined under Section 4A of the SFA) the sole business of which is to hold investments and the entire share capital of which is owned by one or more
individuals, each of whom is an accredited investor; or</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an individual who is an accredited investor, </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be
transferred for six months after that corporation or that trust has acquired the securities pursuant to an offer made under Section 275 of the SFA except: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B></B>to an institutional investor under Section 274 of the SFA or to a relevant person defined in Section 275(2) of the
SFA, or to any person pursuant to an offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">154 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>where no consideration is given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section 276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Switzerland </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The securities may not be publicly offered in
Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses
under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in
Switzerland. Neither this prospectus nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither this prospectus nor any other offering or marketing material relating to the offering, the company or the securities have been or will be filed with or approved
by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, or FINMA, and the offer of securities has not
been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of
securities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>United Kingdom </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus is only being
distributed to, and is only directed at, persons in the United Kingdom that are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive that are also (i) investment professionals falling within Article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, referred to herein as the Order, and/or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order and other persons to whom it may lawfully
be communicated. Each such person is referred to herein as a Relevant Person. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus and its contents are confidential and should not be distributed,
published or reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom. Any person in the United Kingdom that is not a Relevant Person should not act or rely on this document or any of its contents. Any
investment or investment activity to which this prospectus relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Israel </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This document does not constitute a prospectus under the
Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority. In the State of Israel, this document is being distributed only to, and is directed only at, and any offer of the
ordinary shares is directed only at, (i) a limited number of persons in accordance with the Securities Law and (ii) investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in
trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50 million and &#147;qualified
individuals&#148;, each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case purchasing for their own account or, where permitted under the Addendum, for the accounts of
their clients who are investors listed in the Addendum). Qualified investors will be required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to&nbsp;it. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Canada </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(A) Resale Restrictions </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The distribution of ordinary shares in Canada is being made only in the provinces of Ontario, Quebec, Alberta and British Columbia on a private placement basis exempt
from the requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where trades of these securities are made.&nbsp;Any resale of the ordinary shares in Canada must be made under applicable
securities laws which may vary depending on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">155 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable Canadian securities regulatory
authority.&nbsp;Purchasers are advised to seek legal advice prior to any resale of the securities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(B) Representations of Canadian Purchasers </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">By purchasing ordinary shares in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer from whom the purchase
confirmation is received that: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser is entitled under applicable provincial securities laws to purchase the ordinary shares without the benefit of a prospectus qualified under those securities laws as it is an &#147;accredited investor&#148;
as defined under National Instrument 45-106&#151;<I>Prospectus Exemptions</I>, </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser is a &#147;permitted client&#148; as defined in National Instrument 31-103&#151;<I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>, </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where required by law, the purchaser is purchasing as principal and not as agent, and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser has reviewed the text above under Resale Restrictions. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top">Conflicts of Interest </TD></TR></TABLE>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian purchasers are hereby notified that each of the underwriters are relying on the
exemption set out in section 3A.3 or 3A.4, if applicable, of National Instrument 33-105&#151;<I>Underwriting Conflicts </I>from having to provide certain conflict of interest disclosure in this document. </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top">Statutory Rights of Action </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Securities legislation in certain provinces or territories of Canada may provide a purchaser
with remedies for rescission or damages if the prospectus (including any amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory
for particulars of these rights or consult with a legal advisor. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top">Enforcement of Legal Rights </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our directors and officers as well as the experts named herein may be located
outside of Canada and, as a result, it may not be possible for Canadian purchasers to effect service of process within Canada upon us or those persons.&nbsp;All or a substantial portion of our assets and the assets of those persons may be located
outside of Canada and, as a result, it may not be possible to satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada. </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(F)</TD>
<TD ALIGN="left" VALIGN="top">Taxation and Eligibility for Investment </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian purchasers of ordinary shares should consult their own legal and tax
advisors with respect to the tax consequences of an investment in the ordinary shares in their particular circumstances and about the eligibility of the ordinary shares for investment by the purchaser under relevant Canadian legislation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">156 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_18"></A>EXPENSES OF THIS OFFERING</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the costs and expenses, other than the underwriting discounts and commissions, payable by us in connection with the sale of our ordinary
shares being registered. All amounts are estimates except for the SEC registration fee, the FINRA filing fee and the NASDAQ Global Market listing fee. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:18.65pt; font-size:8pt; font-family:ARIAL"><B>ITEM</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT&nbsp;TO<BR>BE PAID</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">The NASDAQ Global Market listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,940,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">157 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_19"></A>LEGAL MATTERS</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The validity of the issuance of our ordinary shares offered in this prospectus and certain other matters of Israeli law will be passed upon for us by Hamburger Evron
&amp; Co., Tel Aviv, Israel. As of the date of this prospectus, Hamburger Evron &amp; Co. beneficially owns an aggregate of 83,928 of our ordinary shares issuable upon the exercise of options. Certain matters of U.S. law will be passed upon for us
by Cooley&nbsp;LLP, New York, New York. Legal counsel to the underwriters are Gornitzky &amp; Co., Tel Aviv, Israel, with respect to Israeli law, and Covington &amp; Burling LLP, New York, New York, with respect to U.S. law. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_20"></A>EXPERTS</B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The financial
statements as of December 31, 2016 and 2015 and for each of the two years in the period ended December 31, 2016 included in this prospectus<B><SUP STYLE="font-size:85%; vertical-align:top"> </SUP></B>have been so included in reliance on the report
of Kesselman &amp; Kesselman, Certified Public Accountants (Israel), an independent registered public accounting firm and a member firm of PricewaterhouseCoopers International Limited, given on the authority of said firm as experts in auditing and
accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">158 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_21"></A>ENFORCEMENT OF CIVIL LIABILITIES</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in this
registration statement, most of whom reside outside of the United States, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets and substantially all of our directors and officers are located
outside of the United States, any judgment obtained in the United States against us or any of our directors and officers may not be collectible within the United States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have been informed by our legal counsel in Israel, Hamburger Evron &amp; Co., that it may be difficult to assert U.S. securities law claims in original actions
instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear
a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain
matters of procedure will also be governed by Israeli law. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have irrevocably appointed Urogen Pharma, Inc. as our agent to receive service of process in any
action against us in any U.S. federal or state court arising out of this offering or any purchase or sale of securities in connection with this offering. Subject to specified time limitations and legal procedures, Israeli courts may enforce a U.S.
judgment in a civil matter which, subject to certain exceptions, is non-appealable, including a judgment based upon the civil liability provisions of the Securities Act and the Exchange Act and including a monetary or compensatory judgment in a
non-civil matter, provided that among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment was obtained after due process before a court of competent jurisdiction, according to the laws of the state in which the judgment was given and the rules of private international law currently prevailing in
Israel; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevailing law of the foreign state in which the judgment was rendered allows for the enforcement of judgments of Israeli courts; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adequate service of process has been effected and the defendant has had a reasonable opportunity to be heard and to present his or her evidence; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment is not contrary to public policy of Israel, and the enforcement of the civil liabilities set forth in the judgment is not likely to impair the security or sovereignty of Israel; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment was not obtained by fraud and does not conflict with any other valid judgments in the same matter between the same parties; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an action between the same parties in the same matter is not pending in any Israeli court at the time the lawsuit is instituted in the foreign court; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment is enforceable according to the laws of Israel and according to the law of the foreign state in which the relief was granted. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and
transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in
force on the date of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price
index plus interest at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">159 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_22"></A>WHERE YOU CAN FIND MORE INFORMATION</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have filed with the SEC a registration statement on Form F-1 under the Securities Act relating to this offering of our ordinary shares. This prospectus does not
contain all of the information contained in the registration statement. The rules and regulations of the SEC allow us to omit certain information from this prospectus that is included in the registration statement. Statements made in this prospectus
concerning the contents of any contract, agreement or other document are summaries of all material information about the documents summarized, but are not complete descriptions of all terms of these documents. If we filed any of these documents as
an exhibit to the registration statement, you may read the document itself for a complete description of its terms. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You may read and copy the registration
statement, including the related exhibits and schedules, and any document we file with the SEC without charge at the SEC&#146;s public reference room at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may also obtain copies of the
documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. The SEC also
maintains a website that contains reports and other information regarding issuers that file electronically with the SEC. Our filings with the SEC are also available to the public through the SEC&#146;s website at <I>http://www.sec.gov</I>. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon completion of this offering, we will be subject to the information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and
under those requirements will file reports with the SEC. These other reports or other information may be inspected without charge at the locations described above. As a foreign private issuer, we will be exempt from the rules under the Exchange Act
related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition,
we will not be required under the Exchange Act to file reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We maintain a corporate website at <I>http://www.urogen.com</I>. Information contained on, or that can be accessed through, our website does not constitute a part of
this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">160 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_23"></A>CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="index"></A>TABLE OF CONTENTS </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><A HREF="#fin142578_1">Audited Financial Statements</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin142578_2">Report of independent registered public accounting firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin142578_3">Consolidated Balance sheets as of December&nbsp;31, 2016 and 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin142578_4">Consolidated Statements of operations for the years ended December&nbsp;
31, 2016 and 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin142578_5">Consolidated Statements of changes in shareholders&#146; equity for the years ended December&nbsp;31,
 2016 and 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin142578_6">Consolidated Statements of cash flows for the years ended December&nbsp;
31, 2016 and 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin142578_7">Notes to the consolidated financial statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

    <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g56i55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin142578_2"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">To the shareholders of </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations, changes in shareholders&#146; equity and cash flows
present fairly, in all material respects, the financial position of Urogen Pharma Ltd. (the Company) at December 31, 2016 and 2015, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2016
in conformity with accounting principles generally accepted in United States of America. These financial statements are the responsibility of the Company&#146;s management and Board of Directors. Our responsibility is to express an opinion on these
financial statements based on our audits. We conducted our audits of these statements in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting
principles used and significant estimates made by management and Board of Directors, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="font-size:50pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:145pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Tel-Aviv,&nbsp;Israel&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">/s/ Kesselman &amp; Kesselman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">March 8, 2017, except for the</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">effects of the share split
discussed</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">in note 1d to the consolidated</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">financial statements, as to which</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">the date is April 24, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certified Public Accountants (lsr.)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">A&nbsp;member&nbsp;firm&nbsp;of&nbsp;PricewaterhouseCoopers&nbsp;International Limited</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="68%"></TD></TR>

<TR STYLE="font-size:1px; font-family:ARIAL; font-size:9.5pt">
<TD COLSPAN="5" VALIGN="top" STYLE="BORDER-LEFT:1px dotted #000000; BORDER-TOP:1px dotted #000000; padding-left:8pt; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kesselman &amp; Kesselman, Trade Tower, 25 Hamered Street, Tel-Aviv 6812508,
Israel,</I></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;P.O Box 50005 Tel-Aviv 6150001 Telephone: +972-3-7954555, Fax: +972-3-7954556,
www.pwc.com/il</I></B></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin142578_3"></A>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in
thousands, except share and per share data) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><B>Assets</B></TD>
<TD VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CURRENT ASSETS:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL CURRENT ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">NON-CURRENT</FONT> ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><B>Liabilities and Shareholders&#146; equity</B></TD>
<TD VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CURRENT LIABILITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable, accrued expenses and advances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Employee related accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds&nbsp;from exercise of warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL CURRENT LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">NON-CURRENT</FONT> LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>COMMITMENTS AND CONTINGENCIES (Note 6)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>SHAREHOLDERS&#146; EQUITY:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ordinary shares, NIS 0.01 par value: 17,600,000 shares authorized at December&nbsp;31, 2016 and 2015;
2,305,743 and 2,300,959 issued and outstanding as of December&nbsp;31, 2016 and 2015, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A and <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares, NIS 0.01 par
value:<BR>14,400,000 shares authorized at December&nbsp;31, 2016 and 2015; 5,193,427 shares issued and outstanding at December&nbsp;31, 2016 and 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL SHAREHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin142578_4"></A>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S.
dollars in thousands, except share and per share data) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>REVENUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>COST OF REVENUES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>GROSS PROFIT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>OPERATING EXPENSES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>RESEARCH AND DEVELOPMENT EXPENSES, NET</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>GENERAL AND ADMINISTRATIVE EXPENSES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>OPERATING INCOME (LOSS)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>FINANCE EXPENSES, NET</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>NET LOSS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>LOSS PER ORDINARY SHARE BASIC AND DILUTED</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER ORDINARY
SHARE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin142578_5"></A>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share data) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ORDINARY</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PREFERRED</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ADDITIONAL</B><br><B><FONT STYLE="white-space:nowrap">PAID-IN&nbsp;CAPITAL</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED</B><br><B>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>BALANCE AS OF JANUARY 1, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">862,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>CHANGES DURING 2015:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Issuance of preferred shares, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,635,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Purchase of IP R&amp;D in consideration for Preferred A Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>BALANCE AS OF DECEMBER&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,193,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>CHANGES DURING 2016:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Exercise of options into ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>BALANCE AS OF DECEMBER&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,193,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(*) Represents amount less than one thousand </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin142578_6"></A>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S.
dollars in thousands) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CASH FLOWS FROM OPERATING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,689</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adjustments required to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">In process R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Share based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exchange rates differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value adjustment of warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in operating asset and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Decrease (increase) in prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in accounts payable, accrued expenses and advances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in employee related accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CASH FLOWS FROM INVESTING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in restricted deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CASH FLOWS FROM FINANCING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercise of options into ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds&nbsp;from exercise of warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of preferred shares from 2014 Share Purchase Agreement net of issuance cost</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>INCREASE IN CASH AND CASH EQUIVALENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>BALANCE OF CASH AND CASH EQUIVALENTS AT END OF THE YEAR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>SUPPLEMENTAL DISCLOSURES OF <FONT STYLE="white-space:nowrap">NON-CASH</FONT> INVESTING AND FINANCING
ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchase of IP R&amp;D in consideration for Preferred A Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Non cash issuance cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin142578_7"></A>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 1&#151;NATURE OF OPERATIONS </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">UroGen Pharma Ltd. (formerly TheraCoat Ltd.) is an Israeli company incorporated in April 2004 (&#147;UPL&#148;). </TD></TR></TABLE>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">UroGen Pharma Inc., a subsidiary of UPL, was incorporated in Delaware in October 2015 and began operating in February 2016 (&#147;UPI&#148;). </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">UPL and UPI (together the &#147;Company&#148;) is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change
the standard of care for urological pathologies. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">In August 2015 the Company entered into an agreement with Allergan Pharmaceuticals International Limited (&#147;Allergan&#148;), a wholly owned subsidiary of Allergan plc, pursuant to which the Company undertook to
supply its gel product and supporting services to Allergan for consideration of $750, to allow Allergan to conduct certain scientific investigations aimed at testing utility of the Company&#146;s gel product for the delivery of a certain proprietary
product of Allergan. Further, the Company granted Allergan a time limited option to negotiate an exclusive, worldwide right to research, develop, make and have made, use, sell, offer to sell and import the Company&#146;s product in combination with
Allergan&#146;s product. </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">Pursuant to the terms of the agreement from 2015, on October&nbsp;7, 2016, the Company entered into an
exclusive license agreement with Allergan to license worldwide rights to some of its products indicated for use with neurotoxins. As stipulated in the agreement, Allergan paid a <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront fee of
$17.5&nbsp;million in accordance with the terms of the license agreement. Allergan shall pay the Company additional milestone payments of up to $207.5&nbsp;million and tiered royalty payments as a percentage of net sales of the licensed product all
as stated in the agreement. </P>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">As of the date of approval of the consolidated financial statements, the Company has the ability to fund its planned operations for at least the next 12 months. However, in order to complete the clinical trials aimed at
developing a product until obtaining its marketing approval, the Company will need to raise additional funds. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">As described in Note 12, in April 2017, the Company&#146;s board of directors and shareholders approved an aggregate 3.2-for-1 share split of the Company&#146;s ordinary, Preferred A and Preferred A-1 shares. All of the
share and per share amounts reflected in these financial statements and the notes thereto have been adjusted, on a retroactive basis, to reflect this share split. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 2&#151;SIGNIFICANT ACCOUNTING POLICIES: </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Basis of presentation
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America
(&#147;U.S. GAAP&#148;). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. Use of estimates in the preparation of financial statements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. As applicable
to these consolidated financial statements, the most significant estimates and assumptions relate to the fair value of share-based compensation, the fair value of the warrants for preferred shares and timing of revenue recognition. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>c. Functional currency </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The U.S. dollar (&#147;Dollar&#148;) is
the currency of the primary economic environment in which the operations of the Company and subsidiary are conducted. Therefore, the functional currency of the Company is the Dollar. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accordingly, transactions in currencies other than the Dollar are measured and recorded in the functional currency using the exchange rate in effect at the date of the
transaction. At the balance sheet date, monetary assets and liabilities that are denominated in currencies other than the Dollar are measured using the official exchange rate at the balance sheet date. The effects of foreign currency <FONT
STYLE="white-space:nowrap">re-measurements</FONT> are recorded in the consolidated statements of operations as &#147;financial income (expenses).&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>d. Cash and cash equivalents </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or
less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>e. Property and
equipment </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">Property and equipment are stated at cost, net of accumulated depreciation. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s property and equipment are depreciated using the straight-line method on the basis of their estimated useful lives. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Annual rates of depreciation are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Computers and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">15-30</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">6-15</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Manufacturing equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Leasehold improvements are amortized using the straight-line method over the shorter of the expected lease term and the estimated useful life of the improvements. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>f. Impairment of long-lived assets </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company tests long-lived
assets, comprised solely of property and equipment, for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future undiscounted cash flows of the assets is less than the carrying amount of such
assets, an impairment loss would be recognized. The assets would be written down to their estimated fair values, calculated based on the present value of expected future discounted cash flows or some other fair value measure. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2016 and 2015, the Company did not recognize an impairment loss for its long-lived assets. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>g. Contingencies </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain conditions may exist as of the date of the
financial statements, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company&#146;s management assesses such contingent liabilities and such assessment inherently
involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company&#146;s management evaluates the perceived
merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Management applies
the guidance in ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">450-20-25</FONT></FONT> when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable that a loss has been
incurred and the amount of the liability can be estimated, then the estimated liability is recorded as accrued expenses in the Company&#146;s financial statements. If the assessment indicates that a potential loss contingency is not probable but is
reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable are disclosed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accruing a provision for loss, the Company recognizes an accrual for the amount within a range of loss that represents the best estimate within the range. When no
amount within the range is a better estimate than any other amount, the Company accrues for the minimum amount within the range. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>h. Financial instruments </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When the Company issues preferred shares, it considers the provisions of ASC 480 in order to determine whether the preferred share should be classified as a liability.
If the instrument is not within the scope of ASC 480, the Company further analyzes the instrument&#146;s characteristics in order to determine whether it should be classified within temporary equity (mezzanine) or within permanent equity in
accordance with the provisions of ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">480-10-S99.</FONT></FONT> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When the Company issues other
freestanding instruments, the Company first analyzes the provisions of ASC&nbsp;480 in order to determine whether the instrument should be classified as a liability, with subsequent changes in fair value recognized in earnings in each period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the instrument is not within the scope of ASC 480, the Company further analyzes the provisions of <FONT STYLE="white-space:nowrap">ASC&nbsp;815-40</FONT> in order to
determine whether the instrument should be classified within equity or rather classified as an asset or liability, with subsequent changes in fair value recognized in earnings in each period. See note&nbsp;7 and note&nbsp;8. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>i. Share-based compensation </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company accounts for
employees&#146; and directors&#146; share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period. As
of December&nbsp;31, 2016 the Company has early adopted the policy to account for forfeitures as they occur according to the FASB&#146;s Accounting Standards Update <FONT STYLE="white-space:nowrap">(ASU)&nbsp;2016-09,</FONT> Improvements to Employee
Share-Based Payment Accounting. The adjustment for the beginning of the period was not material ($30) and therefore it was not reflected in the consolidated statements of changes in shareholders&#146; equity. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the straight-line method
and to value the awards based on the single-option award approach. Performance based awards are expensed over the requisite service period when the achievement of performance criteria is probable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Equity awards granted to <FONT STYLE="white-space:nowrap">non-employees</FONT> are <FONT STYLE="white-space:nowrap">re-measured</FONT> at each reporting period at fair
value until the commitment date had been reached which is usually the date the service is completed. The fair value of equity awards is charged to the statement of operations over the service period using the straight-line method. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>j. Revenue recognition </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Virtually all the Company&#146;s revenues are
derived from the license agreement with Allergan, to license worldwide rights to some of its products. Revenue is recognized only when all of the following conditions have been met: (i)&nbsp;there is persuasive evidence of an arrangement;
(ii)&nbsp;delivery has occurred: (iii)&nbsp;the fee is fixed or determinable: and (iv) collectability of the fee is reasonably assured. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The license agreement
contains two deliverables: (a)&nbsp;the license component and (b)&nbsp;Allergan&#146;s right to require supply services of RTGel vials from the Company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In an
arrangement with multiple deliverables, the delivered item or items shall be considered a separate unit of accounting if all of the following criteria are met: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(a)&nbsp;The delivered item or items have value to the customer on a standalone basis. The item or items have value on a standalone if they are sold separately by any
vendor or the customer could resell the delivered item(s) on a standalone basis. In the context of a customer&#146;s ability to resell the delivered item(s), this criterion does not require the existence of an observable market for the
deliverable(s), and </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(b)&nbsp;If the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the
undelivered item or items is considered probable and substantially in the control of the vendor. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When deliverables are separable, arrangement consideration is
allocated to the separate units of accounting based on the relative selling price of each deliverable (where the amount allocable to the delivered element is limited to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
amount not contingent on the delivery of future products or services) and the appropriate revenue recognition principles are applied to each unit. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The license component has standalone value (and therefore is accounted for separately from the supply services) since Allergan can use the license for its intended
purposes without the Company&#146;s supply services. The four conditions of ASC&nbsp;605 were met as of December&nbsp;31, 2016: (1)&nbsp;persuasive evidence of an arrangement exists since the Company and Allergan engaged with a binding agreement;
(2)&nbsp;delivery has occurred or services have been rendered since all documents and data Allergan has requested relating to the Company&#146;s know-how were provided before December&nbsp;31, 2016 and Allergan can use the license for its intended
purposes without the supply services (except for immaterial support services); (3)&nbsp;the fee is fixed or determinable, as indicated in the license agreement; and (4)&nbsp;collectability is reasonably assured. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Therefore, as of December&nbsp;31, 2016, the consideration received in an amount of $17.5 million represents arrangement consideration for both the license of the
intellectual property as well as Allergan&#146;s right to future supply services (which would be provided in consideration for future payments to the Company according to the pricing stipulated in the supply agreement). The Company determined that
the pricing of the supply services represents their standalone selling price. Accordingly, the Company allocated the entire upfront fee of $17.5 million to the license component. In addition, revenue from the supply services would be recorded in an
amount equal the consideration stipulated in the agreement for these services, when these services are provided. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As described in Note&nbsp;1, the Company is also
entitled to milestone payments and royalties based on Allergan&#146;s revenue from its product, which are not considered fixed or determinable until their occurrence. Therefore, these amounts would only be recognized when the conditions for payment
are met, and they become due and payable. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>k. Research and development costs </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development costs are expensed as incurred and consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other
employee benefits, subcontractors and materials used for research and development activities and professional services. Grants received from the Israel Innovation Authority, f/k/a the Office of the Chief Scientist of Israel&#146;s Ministry of
Industry, Trade and Labor (the &#147;IIA&#148;) are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the
grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred. In the year ended December&nbsp;31, 2015 the company deducted research and development expenses in the amount of $537. In
the year ended December&nbsp;31, 2016, the company had an increase of $175 to its research and development expenses as a result of its decision not to pursue one of its research programs that had been approved as a result of other financing
opportunities. The costs of services performed by others in connection with the research and development activities of an entity, including research and development conducted by others in behalf of the entity, shall be included in research and
development costs. The amount received from Allergan from the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> collaboration agreement signed in August 2015 was deducted from research and development expenses in the statements of operations as
the applicable costs were incurred. For the years ended December&nbsp;31, 2016 and 2015 an amount of $126 and $624, respectively, was deducted from research and development expenses. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The costs of intangibles that are purchased from others for a particular research and development project and that have no alternative future uses (in other research
and development projects or otherwise) and therefore no separate economic values are research and development costs at the time the costs are incurred. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
intellectual property costs totaling $4,103, as described in note&nbsp;8a(5), were expensed as incurred to research and development costs in accordance with ASC&nbsp;730, as the intellectual property was purchased from others for a particular
research and development project and has no alternative future use and therefore no separate economic value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>l. Income taxes: </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>1) Deferred taxes </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Income taxes are computed using the asset and liability
method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax
rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2) Uncertain income tax positions </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company follows a <FONT
STYLE="white-space:nowrap">two-step</FONT> approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence indicates that it is more likely than
not that the position will be sustained based on technical merits. If this threshold is met, the second step is to measure the tax benefit as the largest amount that is more likely than not of being realized upon ultimate settlement. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>m. Loss per share </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic loss per share (&#147;LPS&#148;) is computed
by dividing net loss for the year, after reducing cumulative dividends on preferred shares by the weighted average number of ordinary shares of the Company outstanding for each period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The calculation of diluted net loss per share excludes potential share issuances of ordinary shares upon the exercise of share options, warrants for preferred shares
and convertible preferred share as each of their effect is anti-dilutive. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>n. Fair value measurement </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market
participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into
three broad levels, which are described as follows: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for
assets or liabilities. The fair value hierarchy gives the highest priority to Level&nbsp;1 inputs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;2: Observable prices that are based on inputs not
quoted on active markets, but corroborated by market data. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level&nbsp;3: Unobservable inputs are used when little or no market data is available. The fair value
hierarchy gives the lowest priority to Level&nbsp;3 inputs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In determining fair value, the Company utilizes valuation techniques that maximize the use of
observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>o. Concentration of credit risks </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Financial instruments that
potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents. The Company deposits cash and cash equivalents with highly rated financial institutions, and, as a matter of policy, limits the amounts
of credit exposure to any single financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>p. Segment reporting </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Operating segments are reported in a manner
consistent with the internal reporting provided to the chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments. The Company operates in one operating segment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>q. IPO Costs </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company accounts for IPO costs in accordance with SEC Staff Accounting Bulletin Topic 5A. During the year ended December 31, 2016, the Company recorded $1.7 million in general and administrative expenses related to IPO costs. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>r. Newly issued and recently adopted accounting pronouncements </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">In August 2014, FASB issued ASU <FONT STYLE="white-space:nowrap">2014-15&#151;Presentation</FONT> of Financial Statements&#151;Going Concern (ASC Subtopic <FONT STYLE="white-space:nowrap">205-40):</FONT>
&#147;Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern&#148;. The update requires management to assess a company&#146;s ability to continue as a going concern and to provide related footnote disclosures in
certain circumstances. All entities are required to apply the new requirements in annual periods ending after December&nbsp;15, 2016, and interim periods thereafter. Early application is permitted. The Company adopted the provisions of these
pronouncement. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">In May 2014, the FASB issued Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">No.&nbsp;2014-09,</FONT> &#147;Revenue from Contracts with Customers&#148; (Topic 606), (&#147;ASU <FONT
STYLE="white-space:nowrap">2014-09&#148;).</FONT> ASU <FONT STYLE="white-space:nowrap">2014-09</FONT> requires entities to recognize revenue that represents the transfer of promised goods or services to customers in an amount equivalent to the
consideration to which the entity expects to be entitled to in exchange for those goods or services. The following steps should be applied to determine this amount: (1)&nbsp;identify the contract(s) with a customer; (2)&nbsp;identify the performance
obligations in the contract; (3)&nbsp;determine the transaction price; (4)&nbsp;allocate the transaction price to the performance obligations in the contract; and (5)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation.
ASU <FONT STYLE="white-space:nowrap">2014-09</FONT> supersedes the revenue recognition requirements in ASU 605, &#147;Revenue Recognition,&#148; and most industry-specific guidance in the Accounting Standards Codification. In August 2015, the FASB
issued ASU <FONT STYLE="white-space:nowrap">2015-14</FONT> on this same topic, which defers for one year the effective date of ASU <FONT STYLE="white-space:nowrap">2014-09,</FONT> therefore, the guidance is effective for the Company for annual
reporting periods, including interim periods therein, beginning January&nbsp;1, 2018. The new revenue standards may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of
adoption. The Company is currently evaluating the impact of adopting the guidance on its Consolidated Financial Statements. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> Leases (Topic 842) (&#147;ASU <FONT STYLE="white-space:nowrap">2016-02&#148;).</FONT> ASU
<FONT STYLE="white-space:nowrap">2016-02</FONT> supersedes existing guidance in Leases (Topic 840). The revised standard requires lessees to recognize the assets and liabilities arising from leases with lease terms greater than twelve months on the
balance sheet, including those currently classified as operating leases, and to disclose key information about leasing arrangements. Lessees will be required to recognize a lease liability and a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset on their balance sheets, while lessor accounting will remain largely unchanged. The guidance is effective for annual periods beginning after December&nbsp;15, 2018, with early adoption
permitted. The Company is currently evaluating the impact the adoption of ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> will have on its consolidated financial statements and related disclosures. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top">In March 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-09,</FONT> &#147;Improvements to Employee Share-Based Payment Accounting.&#148; ASU <FONT STYLE="white-space:nowrap">2016-09</FONT> is
aimed to simplifying the accounting for share-based payment transactions. Included in the update are modifications to the accounting for income taxes upon vesting or settlement of awards, employer tax withholding on share-based compensation and
financial statements presentation of excess tax benefits. The guidance also provides an accounting policy election to account for forfeitures as they occur. As permitted by ASU <FONT STYLE="white-space:nowrap">2016-09,</FONT> the Company
early-adopted this standard in the fourth quarter of 2016, using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of the beginning of the period in which the guidance is adopted. The impact of this
adoption is immaterial. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">In August 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-15,</FONT> &#147;Statement of Cash Flows:
Classification of Certain Cash Receipts and Cash Payments,&#148; which addresses the presentation of restricted cash and restricted cash equivalents (or amounts generally described as such) within the statement of cash flows under ASC 230, Statement
of Cash Flows, with the intent to reduce diversity in practice. Among others, this ASU addresses cash flow treatment such as debt prepayment or debt extinguishment costs and proceeds from the settlement of insurance claims. Entities are required to
disclose how the statement of cash flows reconciles to the balance </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
sheet if restricted cash is shown separately from cash and cash equivalents on the balance sheet. Entities must also disclose information about the nature of the restrictions. The amendments are
effective for public business entities for fiscal years beginning after December&nbsp;15, 2017, and interim periods within those fiscal years. Early adoption is permitted. A retrospective basis adoption is required. The Company is currently
evaluating the impact of the standard on its consolidated financial statements. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">6)</TD>
<TD ALIGN="left" VALIGN="top">In November 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-18,</FONT> &#147;Statement of Cash Flows (Topic 230): Restricted Cash&#148; (&#147;ASU
<FONT STYLE="white-space:nowrap">2016-18&#148;).</FONT> ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> amends the classification and presentation of changes in restricted cash or restricted cash equivalents in the statement of cash flows. The
ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> is effective for public business entities for fiscal years beginning after December&nbsp;15, 2017, and interim periods within those fiscal years. For all other entities, the amendments are
effective for fiscal years beginning after December&nbsp;15, 2018, and interim periods within fiscal years beginning after December&nbsp;15, 2019. Early adoption is permitted, including adoption in an interim period. The Company is currently
evaluating the impact the adoption of ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> will have on its consolidated financial statements. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE
3&#151;PROPERTY AND EQUIPMENT </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cost:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Computers and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Manufacturing equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less&#151;Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depreciation expense was $213 and $113 for the years ended December&nbsp;31, 2016 and 2015, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 4&#151;EMPLOYEE RIGHTS UPON RETIREMENT </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is required by law
to make severance payments upon dismissal of an employee or upon termination of employment in certain other circumstances. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company operates a number of
post-employment defined contribution plans. A defined contribution plan is a program that benefits an employee after termination of employment, under which the Company regularly makes fixed payments to a separate and independent entity so that the
Company has no legal or constructive obligation to pay additional contributions if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods. The fund assets are not
included in the Company&#146;s financial position. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company operates pension and severance compensation plans subject to Section&nbsp;14 of the Israeli
Severance Pay Law. The plans are funded through payments to insurance companies or pension funds administered by trustees. In accordance with its terms, the plans meet the definition of a defined contribution plan, as defined above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 5&#151;PROCEEDS FROM EXERCISE OF WARRANTS FOR PREFERRED SHARES </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Warrants for preferred shares are exercisable for Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares at an exercise price of $7.81 per share. As of
December&nbsp;31, 2016, the number of warrants for preferred shares that are exercisable for Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares is 728,312. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During 2016 the Company notified these warrant holders that it is ready to accept an exercise notice that is conditioned on the price per share that will be determined
in the anticipated IPO. As of December&nbsp;31, 2016 the Company received a total amount of $570 as consideration for the conditional cash exercise of the warrants. The cash received for the warrant exercises was recorded among current liabilities
as Proceeds from exercise of warrants for preferred shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 6&#151;COMMITMENT AND CONTINGENCIES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Lease agreement </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2016, the Company signed an addendum
to its November 2014 lease agreement in order to increase the office space rented and to extend the rent period. The Company has a lease agreement effective until 2019. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The rent expenses for the years ending December&nbsp;31, 2016 and 2015 are approximately $218 and $121, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">UPI entered into a lease agreement for its office for a period of 7 years commencing on May&nbsp;1, 2016. As part of the agreement UPI provided the lessor with a letter
of credit which expires on December 2017 and shall be automatically annually renewed for approximately $75. The rent expenses for the year ended December&nbsp;31, 2016 are approximately $102. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The future minimum lease payments required in each of the next seven years under the lease agreements are $400 per year for the year 2017, $405 in 2018, $351 in 2019,
$192 per year for the years 2020 until 2022 and $80 in 2023. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. Grants from the Israel Innovation Authority (&#147;IIA&#148;), formerly known as the Office
of the Chief Scientist of the State of Israel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has received grants from the IIA for research and development funding. Up until 2007, the IIA
participation in the funding of the Company&#146;s operations was as part of the Director General Directive 8.2 of Israel by grants provided to Granot Ventures. Since 2008, the funding was provided directly to Company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is committed to pay royalties to the Government of Israel on proceeds from sales of products in the research and development of which the IIA participates
by way of grants. At the time the grants were received, successful development of the related projects was not assured. In the case of failure of a project that was partly financed as above, the Company is not obligated to pay any such royalties.
Under the terms of the funding from the IIA, royalties of <FONT STYLE="white-space:nowrap">3%-4.5%</FONT> are payable on sales of products developed from a project so funded, up to 100% of the amount of the grant received by the Company (dollar
linked); with the addition of annual interest at a rate based on <FONT STYLE="white-space:nowrap">12-month</FONT> LIBOR. The Company is subject to several conditions, including restrictions on its intellectual property. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2016, the maximum royalty amount payable by the Company under these funding arrangements is $2,105 (excluding interest). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>c. Financing success fees </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company entered into agreements with
third parties and shareholders in connection with fundraising efforts. In consideration of the services rendered, the Company undertook to pay those third parties and shareholders certain success fees from funds actually received by the Company
and/or options to purchase equity of the Company, at a rate agreed between the parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Total success fees to third parties for the year ended December&nbsp;31, 2016 consisted of 5,726 options to third
parties to purchase ordinary shares with a fair value of $9. For the year ended December&nbsp;31, 2015, total success fees to third parties were $108, and were payable in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 7&#151;FINANCIAL INSTRUMENTS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Warrants for preferred shares
</I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">In 2014, as part of a share purchase agreement (the&#147;2014 SPA&#148;), the Company issued warrants (the <FONT STYLE="white-space:nowrap">&#147;A-1</FONT> warrants&#148;) for preferred shares, see note 8a2.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">The <FONT STYLE="white-space:nowrap">A-1</FONT> warrants are exercisable into Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares of the Company, nominal value NIS 0.01 per share, for an exercise price
of $7.81 per share commencing on the date of the issuance and until the earlier of an IPO, M&amp;A event or four years. </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">The warrants
are exercisable for Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares, in consideration for cash representing the exercise price. In the event that the warrant is exercised in connection with an IPO or M&amp;A event, the holder may
elect to convert the warrant on a net share basis. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">A-1</FONT> warrants are classified as liabilities in
accordance with ASC 480, as they are freestanding instruments, exercisable into Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares, which are redeemable upon certain events that represent &#147;Deemed Liquidation&#148; events (see
also Note 8c3). Accordingly, the <FONT STYLE="white-space:nowrap">A-1</FONT> warrants are measured at fair value in every reporting period, and changes in their fair value are recognized in earnings within financial income (expense). </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2015 the fair value of the warrants for preferred shares was measured in accordance with the Hybrid Method. The Hybrid Method
combines the probabilities of an IPO scenario which was estimated at 15% and a liquidation event scenario which was estimated at 85%. The fair value was determined mainly based on the SPA price per share of $5.94 of Series A preferred shares and
assumptions related to achieving the required milestone for additional investment that was determined in the 2014 SPA, and expected volatility at a rate of 75.4%. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">The fair value of the preferred share warrants as of December&nbsp;31, 2016 was measured in accordance with the Hybrid Method. The Hybrid Method
combines the probabilities of an IPO scenario which was estimated at 20% and a liquidation event scenario which was estimated at 80%. As of December&nbsp;31, 2016 the fair value of the warrants for preferred shares was determined mainly based on
estimation of the company&#146;s equity value derived from DCF calculation and on assumption relating to the future revenue forecast, clinical success probabilities, relevant discount rates between <FONT STYLE="white-space:nowrap">10.5%-19%</FONT>
(10.5% for the cash flow expected to be derived from the license agreement with Allergan and 19% for the cash flows expected to be derived from the company&#146;s internal development) and expected volatility at a rate of 73.93%. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. The Company financial instruments measured in fair value and classified as Level&nbsp;3. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The table below sets forth a summary of the changes in the fair value of the warrants for preferred shares classified as Level&nbsp;3: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in fair value of warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>c.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>As of December&nbsp;31, 2016 and 2015 the fair value of all financial assets and liabilities, approximate their carrying amounts. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 8&#151;SHARE CAPITAL: </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Share capital </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2016 and 2015 the share capital of the Company was as follows: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AUTHORIZED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ISSUED&nbsp;AND&nbsp;OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ordinary shares of NIS 0.01 par value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A and <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares of NIS 0.01 par value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,193,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,193,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">In September 2014 (closing in October 2014), the Company signed the 2014 SPA with shareholders and new investors for an aggregate amount of up to $8,000 in exchange for Series A preferred shares at a price per share of
$5.94 and warrants to purchase Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares at a per share of $7.81. According to the 2014 SPA, each investor that invested more than $500 was required to transfer 50% of its investment at the
initial closing in October 2014 (the &#147;Initial Closing&#148;) and an additional 50% once the Company meets certain milestones the (&#147;Milestone Closing&#148;) or upon an investors&#146; waiver of attainment of the milestone.
</TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">During 2014, the Company received $4,304 and an additional amount of $130 in January 2015, net of issuance costs of $67, in exchange
for 758,118 Series A preferred shares and 379,088 <FONT STYLE="white-space:nowrap">A-1</FONT> warrants. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">In July 2015, at the Milestone Closing the
Company issued for total consideration of $3,500, 589,472 Series A preferred shares and 294,739 <FONT STYLE="white-space:nowrap">A-1</FONT> warrants at $7.81 price per Series A preferred share. </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">In October 2015, the Company reclassified 8,000,000 ordinary shares from the authorized but unissued share capital of the Company, into 8,000,000 Series A preferred shares NIS 0.01 each, so that the authorized share
capital of the Company, after giving effect to the additional Series A preferred shares, shall be follows: </TD></TR></TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:69.50pt; font-size:8pt; font-family:ARIAL"><B>CLASS&nbsp;OF SHARES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAR<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ordinary shares NIS 0.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A preferred shares NIS 0.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares NIS 0.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE></DIV>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top">In October 2015 (closing in November 2015), the Company signed a share purchase agreement (the &#147;2015 SPA&#148;) with shareholders and new investors for an aggregate amount of up to $18,084 in exchange for 3,045,652
Series A preferred shares of the Company at a price per share of $5.94. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top">In October 2015 the Company entered into an asset purchase agreement with Telormedix SA (&#147;TMX&#148;) pursuant to which the Company purchased all of the intellectual property assets of TMX (in process R&amp;D) in
consideration for 691,200 Series A preferred shares of the Company at a price per share of $5.94 (this includes 172,800 Series A preferred shares, which are being held in escrow and will be automatically released to TMX on the earlier of (i) 12
months from the date of initial closing, as set forth in the asset purchase agreement, and (ii)&nbsp;consummation of an IPO). The Company will issue an additional 92,800 Series A preferred shares upon occurrence of each of three milestones, for a
maximum potential of 278,400 Series A preferred shares. The intellectual property costs totaling $4,103 were expensed as incurred to research and development costs as there is no alternative future use and therefore no separate economic value.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. Terms of the Company&#146;s ordinary shares </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each ordinary share is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available, when and if
declared by the Board of Directors. Since its inception, the Company has not declared any dividends. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>c. Terms of the Company&#146;s convertible preferred
shares: </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Preferred shares of the Company include Series A and <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares. The exercise price of Series
A preferred shares is $5.94 and the exercise price of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares is $7.81. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">The holder of each preferred share shall: (i)&nbsp;be entitled to the number of votes which is equal to the number of ordinary shares into which such preferred share is then convertible, (ii)&nbsp;have voting rights and
powers equal to the voting rights and powers of any holder of ordinary shares and shall vote as a single class with the holders of ordinary shares, and (iii)&nbsp;be entitled to notice of any meeting of the shareholders. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">From and after the date of the issuance of any preferred shares, dividends at the rate per annum of 8% of the Original Purchase Price (as defined) per share shall accrue on such preferred shares (subject to appropriate
adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the preferred shares). </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">In the event of: (i)&nbsp;any dissolution or liquidation of the Company, (ii)&nbsp;the proper commencement by or against the Company of any bankruptcy or insolvency proceeding under any bankruptcy or insolvency or
similar law, whether voluntary or involuntary, (iii)&nbsp;the appointment of a receiver or liquidator to all or substantially all of the Company&#146;s assets, (iv)&nbsp;a Deemed Liquidation (as defined below) event (each of the foregoing, a
&#147;Liquidation Event&#148;), or (v)&nbsp;distribution of Dividends, then any Dividends, assets or proceeds of the Company available for distribution to the shareholders (&#147;Distributable Proceeds&#148;), shall be distributed among the
shareholders pursuant to the following order of preference: </TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">First, the holders of the preferred shares shall be entitled to receive out of the Distributable Proceeds, prior to and in preference to any distribution to any of the holders of the ordinary shares an amount per
preferred share equal to the higher of: (i)&nbsp;the Original Purchase Price plus any Accruing Dividends (as defined), accrued but unpaid thereon, whether or not declared, together with any other dividends declared but unpaid thereon less any amount
of Distributable Proceeds previously paid with regard to such shares (collectively, the &#147;Preferential A Amount&#148;) and (ii)&nbsp;such amount per share as would have been payable had all preferred shares been converted into ordinary shares
immediately prior to such Liquidation Event. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">If the assets (or securities) available for distribution shall be insufficient to permit the payment to holders of the preferred shares of the full Preferential A Amount, then the entire assets (or securities) available
for distribution shall be distributed <FONT STYLE="white-space:nowrap">pro-rata</FONT> among the holders of the preferred shares in proportion to the Preferential A Amount each such holder is otherwise entitled to receive. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Second, after payment in full of the Series A Liquidation Amount, the remaining assets of the Company available for distribution to the Company&#146;s shareholders shall be distributed among the holders of ordinary
shares, pro rata based on the number of shares held by each such holder. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Any of the following events shall be deemed a Liquidation Event (each a &#147;Deemed Liquidation&#148;): a transaction or
a series of related transactions which entails (i)&nbsp;any sale of all, or substantially all, of the Company&#146;s assets or technology, including by way of granting an exclusive license that is equivalent to the sale of all, or substantially all
of the Company&#146;s intellectual property; (ii)&nbsp;the consolidation, merger, or reorganization of the Company into any other entity, in which the Company is not the surviving entity; except, in each case, any transaction in which the
shareholders of the Company prior to the transaction hold more than fifty percent (50%) of the outstanding share capital of the Company or the surviving company, as applicable, immediately following such transaction; provided, however, that shares
of the surviving entity held by shareholders of the Company acquired by means other than the exchange or conversion of the shares of this Company shall not be used in determining if the shareholders of the Company own more than
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
fifty percent (50%) of the outstanding share capital of the surviving entity (or its parent), but shall be used for determining the total outstanding share capital of the surviving entity; and
(iii)&nbsp;any sale of all, or substantially all, of the Company&#146;s issued and outstanding share capital. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top">The holders of preferred shares shall have the following conversion rights: </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Optional conversion&nbsp;- each preferred share shall be convertible, at the option of the holder thereof, at any time after the date of issuance of such share into such number of fully paid shares of ordinary shares as
is determined by dividing the Original Purchase Price by the conversion price applicable to such share, in effect on the date that the certificate is surrendered for conversion. The initial conversion price of the preferred shares shall be the
Original Purchase Price; provided, however, that the conversion price for the preferred shares shall be subject to certain adjustments. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Automatic conversion&nbsp;- Each preferred share shall automatically be converted into ordinary shares at the Conversion Price at the time in effect for such preferred share, on the consummation of any one of the
following events: </TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top">Upon the closing of an IPO, where the Company&#146;s <FONT STYLE="white-space:nowrap">pre-money</FONT> valuation is $75,000 or more with net proceeds to the Company of $25,000 or more (a &#147;Qualified Public
Offering&#148;); or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii)</TD>
<TD ALIGN="left" VALIGN="top">In the event that holders of a majority of sixty percent (60%) of the then outstanding preferred shares, voting as a single class, consent to such. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top">The preferred shares also confer on their holders certain anti-dilution rights that adjust the conversion ratio in the event that the Company issues new shares at a price lower than the original issue price to the
respective preferred shareholders. </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">The Series A preferred shares are classified within permanent equity as they are not subject to
liability classification under the scope of ASC 480, and meet all the requirements of equity classification under ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">480-10-S99.</FONT></FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>d. Share-based compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2010, the Company&#146;s
board of directors approved a share option plan (the &#147;Plan&#148;) for grants to Company employees, consultants, directors, and other service providers. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Section&nbsp;102 of the Israeli Income Tax Ordinance
(&#147;Section&nbsp;102&#148;). The option grants are subject to the track chosen by the Company, either the &#147;regular income&#148; track or the &#147;capital gains&#148; track, as set out in Section&nbsp;102. The Company registered the Plan
under the capital gains track, which offers more favorable tax rates to the employees. As a result, and pursuant to the terms of Section&nbsp;102, the Company is not allowed to claim as an expense for tax purposes the amounts credited to the
employees in respect of options granted to them under the Plan, including amounts recorded as salary benefits in the Company&#146;s accounts, with the exception of the work-income benefit component, if any, determined on grant date. For <FONT
STYLE="white-space:nowrap">non-employees</FONT> and for <FONT STYLE="white-space:nowrap">non-Israeli</FONT> employees, the Plan is subject to Section 3(i) of the Israeli Income Tax Ordinance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The expected volatility is based on the historical volatility of comparable companies. The risk-free interest rate assumption is based on observed interest rates
appropriate for the expected term of the options granted in dollar terms. The expected term is the length of time until the expected dates of exercising the options, and is estimated for employees (except senior management) using the simplified
method due to insufficient specific historical information of employees&#146; exercise behavior, and for <FONT STYLE="white-space:nowrap">non-employees,</FONT> directors and senior management using the contractual term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the years ended December&nbsp;31, 2016 and 2015, the Company granted options to certain employees and <FONT
STYLE="white-space:nowrap">non-employees</FONT> as follows: </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>1) Options granted to employees and directors: </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Set forth below are grants made by the Company to employees as of December&nbsp;31, 2016. The majority of the options vest over a period of four years and expire on the
seventh anniversary of the date of grant. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">During 2015, the Company granted 1,098,777 options to employees and directors with exercise prices ranging from $0 to $5.94 per share. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">During 2016, the Company granted 404,813 options to employees and directors with exercise prices ranging from $5 to $5.94 per share. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of options granted to employees and directors during 2016 and 2015 was $906 and $2,334, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The total unrecognized compensation cost of employee options at December&nbsp;31, 2016 is $1,776, which is expected to be recognized over a weighted average period of
2.44 years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of options granted to employees and directors on the date of grant was computed using the Black-Scholes model. The underlying data used
for computing the fair value of the options are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Value of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">$2.98-5.54</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">$2.98-3.01</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">74.8%-80%</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">69.78%-76.68%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">1.4%-2.13%</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0.38%&#150;2.08%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">7 years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">1-7</FONT> years</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2) Options granted to consultants and other service providers: </I></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During
2016 and 2015, the Company granted 132,032 and 203,820 options, respectively, to consultants and service providers with an exercise price ranging from $0 to $5.94 per share. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value as of December&nbsp;31, 2016 and 2015 of options granted to consultants and other service providers during 2016 and 2015 was $671 and $57, respectively.
</P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of options granted to consultants and other service providers as of December&nbsp;31, 2016 and 2015 was computed using the Black-Scholes model.
The underlying data used for computing the fair value of the options are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Value of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">$1.58-7.96</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$2.98</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">72.72%-80%</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">73.31%-76.3%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">1.56%-2.27%</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1.88%&#150;2.07%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">5.8-8.5&nbsp;years</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">6.8-7</FONT> years</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">The following table summarizes the number of options outstanding under the Plan for the years ended December&nbsp;31, 2016 and 2015, and related information: </TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EMPLOYEES AND</B><br><B>DIRECTORS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CONSULTANTS AND</B><br><B>SERVICE PROVIDERS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>OPTIONS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED<BR>AVERAGE&nbsp;PRICE<BR>PER SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>OPTIONS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED<BR>AVERAGE&nbsp;PRICE<BR>PER SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Outstanding at January&nbsp;1, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">595,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Canceled/Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,088</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Outstanding at December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,686,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Canceled/Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,784</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Outstanding at December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,030,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">634,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top">The following tables summarize the outstanding and exercisable options as of December&nbsp;31, 2016: </TD></TR></TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="16" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="8" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTIONS OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTIONS EXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>EXERCISE</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PRICE&nbsp;PER&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:72.30pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>SHARE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF&nbsp;OPTIONS<BR>OUTSTANDING&nbsp;AT&nbsp;END<BR>OF YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED&nbsp;AVERAGE<BR>REMAINING<BR>CONTRACTUAL LIFE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF&nbsp;OPTIONS</B><br><B>EXERCISABLE&nbsp;AT&nbsp;END</B><br><B>OF YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED&nbsp;AVERAGE<BR>REMAINING&nbsp;CONTRACTUAL<BR>LIFE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">$0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">$1.56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">$1.78</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">$2.45</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">$4.02</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">$5.00</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,357,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">765,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">$5.94</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center">$6.73</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,665,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,430,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The aggregate intrinsic value of the total vested and exercisable options as of December&nbsp;31, 2016 is $5,683. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top">The following table illustrates the effect of share-based compensation on the statements of operations: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">6)</TD>
<TD ALIGN="left" VALIGN="top">In February, March, April, June and November 2016, the Company increased the number of ordinary shares reserved for issuance under the Company&#146;s share option/incentive plans and arrangements by 320,000, 208,000,
137,600, 131,200 and 90,220 ordinary shares, respectively, to a total amount of 2,703,499 ordinary shares. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 9&#151;TAXES ON INCOME
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is taxed under Israeli tax laws: </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Tax rates
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The income of the Company is taxed at the regular rate. The corporate tax rate for 2016 was 25% and for 2015 was 26.5%. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2016, the Economic Efficiency Law (Legislative Amendments for Implementing the Economic Policy for the 2017 and 2018 Budget Year), 2016 was published,
introducing a gradual reduction in corporate tax rate from 25% to 23%. However, the law also included a temporary provision setting the corporate tax rate in 2017 at 24%. As a result, the corporate tax rate will be 24% in 2017 and 23% in 2018 and
thereafter. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The change in tax rate as mentioned above has not affected the Company since the Company has not recognized taxes to date. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. Tax assessments </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All the tax assessments filed by 2013 are
considered final. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>c. Losses for tax purposes carried forward to future years </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2016, the Company had approximately $14,260 of net carry forward tax losses available to reduce future taxable income without limitation of use.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>d. Deferred income taxes: </I></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">In respect of:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net operating loss carry forward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and Development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">In-Process R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less&#151;valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The change in valuation allowance for the years ended December&nbsp;31, 2016 and 2015 were as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,948</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at the end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The main reconciling item between the statutory tax rate of the Company and the effective rate is the share based
compensation and provision for full valuation allowance in respect of tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>e.</B></TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2016 and 2015, the Company had not accrued a provision for uncertain tax positions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE
10&#151;LOSS PER ORDINARY SHARE: </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the calculation of basic and diluted loss per share for the periods indicated: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Basic and diluted:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss attributable to equity holders of the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dividend accumulated for preferred shares during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss attributable to equity holders of the Company, after deducting dividend accumulated for preferred
shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average number of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,305,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss per ordinary share (LPS)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the years ended December&nbsp;31, 2016 and 2015, all ordinary shares underlying outstanding options, <FONT STYLE="white-space:nowrap">A-1</FONT> warrants and
convertible preferred shares have been excluded from the calculation of the diluted loss per share since their effect was anti-dilutive. Diluted LPS does not include 2,665,099 and 2,199,838 ordinary shares underlying outstanding options for the
years ended December&nbsp;31, 2016 and 2015, respectively, 728,312 shares issuable upon exercise of the <FONT STYLE="white-space:nowrap">A-1</FONT> warrants for series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares for the years ended
December&nbsp;31, 2016 and 2015, and 5,193,427 shares issuable upon conversion of preferred shares for the years ended December&nbsp;31, 2016 and 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 11&#151;RELATED PARTIES-TRANSACTIONS AND BALANCES: </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Related parties
include the Chairman of the Board of Directors, the board members and the Chief Executive Officer of the Company. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Transactions with related parties
</I></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Payroll and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Management fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. Balances with related parties: </I></B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>c. Related parties: </I></B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">UPI entered into a lease agreement, dated as
of November 2015 and commencing as of May 2016, for office space in New York, which serves as the headquarters for UPI (see note 6). UPI shares the office space equitably with Kite Pharma, Inc., a Delaware corporation, who is a cosignatory to such
lease agreement. Arie Belldegrun, M.D., UPL&#146;s chairman, serves as the Chairman and Chief Executive Officer of Kite Pharma, Inc. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE
12&#151;SUBSEQUENT EVENTS: </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On April 19, 2017, the Company&#146;s board of directors and shareholders approved an aggregate 3.2-for-1 share split of the
Company&#146;s ordinary, Preferred A and Preferred A-1 shares. The share split was effected on April 19, 2017 by the issuance of 2.2&nbsp;ordinary shares for each outstanding ordinary, Preferred A and Preferred A-1 share held immediately prior to
the share split. The Company has evaluated subsequent events through March 8, 2017, the date the financial statements were available to be issued. In connection with the reissuance of the financial statements, the Company has evaluated subsequent
events through April 24, 2017, the date the financial statements were available to be reissued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>3,461,538 Ordinary Shares </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g15c64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>UroGen Pharma Ltd. </B></P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>PRELIMINARY PROSPECTUS
</B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:96pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Jefferies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Cowen and Company </B></P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Raymond James </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Oppenheimer &amp; Co.
</B></P>  <P STYLE="margin-top:96pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Through and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017 (25 days after the
date of this prospectus), all dealers that buy, sell or trade our ordinary shares, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&#146;s obligation to deliver a prospectus when
acting as an underwriter and with respect to an unsold allotment or subscription. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item 6.
Indemnification of Directors, Officers and Employees. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a company may not exculpate an office holder from liability for a breach
of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care, but only if a provision authorizing
such exculpation is included in its articles of association. Our amended and restated articles of association to be effective upon the closing of this offering include such a provision. A company may not exculpate in advance a director from
liability arising out of a breach of the duty of care with respect to a distribution. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a company may indemnify an office holder
with respect to the following liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association include a
provision authorizing such indemnification: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#146;s award approved by a court. However, if an undertaking to indemnify an office
holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#146;s activities when the undertaking to
indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reasonable litigation expenses, including attorneys&#146; fees, incurred by the office holder (1) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such
investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability was imposed upon him or her as a substitute for the criminal
proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2) in connection with a monetary sanction; and
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reasonable litigation expenses, including attorneys&#146; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in
connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder,
if and to the extent provided in the company&#146;s articles of association: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a financial liability imposed on the office holder in favor of a third party. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a
company may not indemnify, exculpate or insure an office holder against any of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe
that the act would not harm the company; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an act or omission committed with intent to derive illegal personal benefit; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a fine, civil fine, monetary sanction or forfeit levied against the office holder. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law,
exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the
shareholders. See &#147;Management&#151;Approval of Related Party Transactions under Israeli Law&#151;Fiduciary Duties of Directors and Executive Officers.&#148; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated articles of association to be effective upon the closing of this offering will permit us to exculpate, indemnify and insure our office holders
to the fullest extent permitted or to be permitted by the Israeli Companies Law. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have obtained directors and officers liability insurance for the benefit of our
office holders and intend to continue to maintain such coverage and pay all premiums thereunder to the fullest extent permitted by the Israeli Companies Law. In addition, prior to the closing of this offering, we intend to enter into agreements with
each of our directors and executive officers exculpating them from liability to us for damages caused to us as a result of a breach of duty of care and undertaking to indemnify them, in each case, to the fullest extent permitted by our amended and
restated articles of association to be effective upon the closing of this offering and Israeli law, including with respect to liabilities resulting from this offering to the extent that these liabilities are not covered by insurance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Insofar as the indemnification for liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, may be permitted to directors, officers or
persons controlling the registrant, we have been informed that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;7. Recent Sales of Unregistered Securities. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following list
sets forth information as to all securities we have sold since January&nbsp;1, 2014, which were not registered under the Securities Act. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In February 2014, we issued a series of unsecured subordinated convertible promissory notes to new investors and several of our existing shareholders These notes were amended in July 2014 and are referred to as the 2014
notes, as amended. Pursuant to the 2014 notes, we initially received an aggregate principal amount of $647,112, bearing interest at 6% per annum. The principal and all accrued interest on the 2014 notes was to be, on the consummation of the
investment of a specified amount, automatically converted into either: (i) Series A preferred shares at a five percent (5%) discount on the price per share; or (ii) into ordinary shares at a fifteen percent (15%) discount on the price per share, on
the date of conversion, as determined by our board of directors, all at the election of the 2014 note holders. On October 20, 2014, in lieu of such automatic conversion, we offered the holders of the 2014 notes the right to convert the 2014 notes
into Series A preferred shares at a price per share of $5.94 and to receive warrants for no additional consideration, all as if they were subscribing to purchase securities pursuant to the 2014 Share Purchase Agreement. All of the 2014 note holders
elected to convert the principal amounts of their notes on these terms immediately prior to the initial closing of the 2014 Share Purchase Agreement and waived their right to interest due or payable on the principal amount. All 2014 notes were
cancelled. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On October 20, 2014, June 28, 2015 and July 7 and 28, 2015, (i) we issued to certain investors and existing shareholders, 1,347,590 preferred shares for approximately $8.0 million, which will be converted into ordinary
shares prior to this offering. We further granted such investors and existing shareholders 673,827 warrants to purchase preferred shares (to be converted into warrants to purchase ordinary shares prior to this offering) at an exercise price of $7.81
per share; and (ii) we issued to the 2014 notes holders 108,983 preferred shares and 54,485 warrants to purchase preferred shares (to be converted into ordinary shares and warrants prior to this offering) at an exercise price of $7.81 in exchange
for their conversion of all principal and accrued interest due on the notes in an aggregate amount of $647,112. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">On November 12, 2015, we issued to Telormedix SA, or TMX, 691,200 preferred shares in consideration of any and all owned
knowledge or data of TMX, whether registered or unregistered, including, but not limited to, intellectual property, goodwill, clinical studies, and licenses. These shares will be converted into ordinary
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
shares prior to this offering. We also undertook to issue to TMX 278,400 additional preferred shares upon the achievement of certain milestones, which may be met in the future.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On December 10, 2015, we issued to certain investors and existing shareholders 3,045,652 preferred shares, which will be converted into ordinary shares prior to this offering for $18.1 million. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The sales of the above securities were deemed to be exempt from registration under the Securities Act because they were made outside of the U.S. to certain non-U.S.
individuals or entities pursuant to Regulation S or, in reliance upon the exemption from registration provided under Section 4(a)(2) of the Securities Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, we granted share options and restricted share units to employees, directors, consultants and service providers under our 2010 Israeli Share Option Plan
covering an aggregate of 2,665,099 ordinary shares, with exercise prices ranging from $0.00 to $6.72&nbsp;per share. Such number excludes 28,800 restricted share units and 9,600&nbsp;options, the grant of which is contingent upon the closing of this
offering. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We claimed exemption from registration under the Securities Act for these option grants described above under Section 4(a)(2), Regulation S, or
under Rule 701 of the Securities Act as transactions pursuant to written compensatory plans or pursuant to a written contract relating to compensation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No
underwriters were employed in connection with the securities issuances set forth in this Item. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;8. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>(a) Exhibits.</B> See the Exhibit Index attached to this registration statement, which is incorporated by reference herein. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>(b) Financial Statement Schedules.</B> Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is
shown in the financial statements or notes thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;9. Undertakings. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations
and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Insofar as indemnification for liabilities arising under
the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against
public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer,
or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be
governed by the final adjudication of such issue. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The undersigned Registrant hereby undertakes that: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">for purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this Registration Statement in reliance upon Rule&nbsp;430A and contained in a
form of prospectus filed by the Registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this Registration Statement as of the time it was declared effective; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form F-1 and has duly caused this Amendment No.&nbsp;1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Ra&#146;anana, Israel on this 24th day of April, 2017. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="3"><B>UROGEN PHARMA LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">/s/ Ron Bentsur</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Ron Bentsur</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>Chief Executive Officer</I></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the
capacities and on the dates indicated. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:49.50pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:23.50pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:22.00pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>DATE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">/s/ Ron Bentsur</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Ron
Bentsur</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Chief Executive Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>(Principal Executive Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">April&nbsp;24,2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">/s/ Gary Titus</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Gary
Titus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>(Principal Financial Officer and Principal Accounting Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">April&nbsp;24,2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Arie Belldegrun, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chairman</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">April&nbsp;24,2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Kathryn E. Falberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">April&nbsp;24,2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Stuart Holden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">April&nbsp;24,2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Chaim Hurvitz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">April&nbsp;24,2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Ran Nussbaum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">April&nbsp;24,2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Pini Orbach, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">April&nbsp;24,2017</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top">*By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:ARIAL">/s/ Ron Bentsur</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ron Bentsur</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Attorney-in-Fact</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" COLSPAN="3"><B>Urogen Pharma, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:ARIAL">/s/ Ron Bentsur</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">A<SMALL>UTHORIZED</SMALL> U.S. R<SMALL>EPRESENTATIVE</SMALL></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">April&nbsp;24, 2017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top">Name:&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ron Bentsur</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and CEO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

    <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ron Bentsur and Gary Titus, and each of them acting
individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Registration Statement, including <FONT
STYLE="white-space:nowrap">post-effective</FONT> amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule&nbsp;462(b) increasing the number of securities for which registration is sought, and to file the
same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and
perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and
agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">/s/ Kathryn E. Falberg</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Kathryn E. Falberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">April&nbsp;24,2017</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>EXHIBIT</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:33.85pt; font-size:8pt; font-family:ARIAL"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:83.90pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>EXHIBIT DESCRIPTION</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;1.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;3.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Articles of Association of the Registrant, adopted October 28, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;3.2*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Articles of Association of the Registrant to be effective upon closing of this offering</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;5.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Hamburger Evron &amp; Co., Israeli counsel to the Registrant, as to the validity of the ordinary shares</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Officer Indemnity and Exculpation Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.2*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2010 Israeli Share Option Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.3*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Investors&#146; Rights Agreement, dated September&nbsp;18, 2014, as amended on October 1, 2015 and April&nbsp;12, 2016, among the Registrant and the Registrant&#146;s shareholders</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.4*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Asset Purchase Agreement, dated October&nbsp;1, 2015, between the Registrant and Telormedix SA</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.5&#134;*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License Agreement, dated as of October&nbsp;7, 2016, by and between the Registrant and Allergan Pharmaceuticals International Limited</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.6*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of 2017 Equity Incentive Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.7*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of 2017 Israeli Equity Incentive Sub Plan to the 2017 Equity Incentive Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">21.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subsidiary of the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">23.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Kesselman &amp; Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">23.2</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Hamburger Evron &amp; Co. (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">24.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included in signature pages of Registration Statement)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">24.2</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney of Kathryn E. Falberg (included on page II-5 of Amendment No. 1 to the Registration Statement)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">99.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Dr.&nbsp;J. Gregory Wirth</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Previously filed. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="right">&#134;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment and this exhibit has been filed separately with the SEC. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d142578dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yaron Sobol, Adv. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hamburger Evron &amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Museum Tower </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4 Berkowitz St. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel Aviv 6423806 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Israel </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">April 24, 2017 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">UroGen Pharma Ltd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9 Ha&#146;Ta&#146;ssiya Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ra&#146;anana 4365007 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Israel</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Re: <B><U>Registration Statement on
Form&nbsp;F-1</U></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted
as Israeli counsel for UroGen Pharma Ltd., an Israeli company (the &#147;<B>Company</B>&#148;), in connection with the underwritten initial public offering by the Company, contemplating (i)&nbsp;the issuance and sale by the Company of 3,461,538
ordinary shares, nominal value NIS 0.01&nbsp;per share (&#147;<B>Ordinary Shares</B>&#148;) of the Company (the &#147;<B>Offering Shares</B>&#148;); and (ii)&nbsp;the potential issuance and sale by the Company of an additional 519,230 Ordinary
Shares (the &#147;<B>Additional Shares</B>&#148; and collectively with the Offering Shares, the &#147;<B>Shares</B>&#148;) that are subject to an option to purchase additional shares granted by the Company to the underwriters of the offering (the
&#147;<B>Offering</B>&#148;). This opinion letter is rendered pursuant to Item&nbsp;8(a) of Form F-1 promulgated by the U.S. Securities and Exchange Commission (the &#147;<B>SEC</B>&#148;) and Items 601(b)(5) and (b)(23) of the SEC&#146;s
Regulation&nbsp;S-K promulgated under the United States Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection
herewith, we have examined the originals, or photocopies or copies, certified or otherwise identified to our satisfaction, of: (i)&nbsp;the registration statement on Form F-1 (File No.&nbsp;333-217201) filed by the Company with the SEC (as amended
through the date hereof, the &#147;<B>Registration Statement</B>&#148;) to which this opinion is attached as an exhibit; (ii)&nbsp;a copy of the articles of association of the Company, as currently in effect; (iii)&nbsp;the amended articles of
association of the Company, to be in effect as of the closing of the sale of the Offering Shares (the &#147;<B>Amended Articles</B>&#148;); (iv)&nbsp;resolutions of the board of directors (the &#147;<B>Board</B>&#148;) and the shareholders of the
Company, which relate to the Registration Statement and the actions to be taken in connection with the Offering; and (v)&nbsp;such other corporate records, agreements, documents and other instruments, and such certificates or comparable documents of
public officials and of officers and representatives of the Company as we have deemed relevant and necessary as a basis for the opinions hereafter set forth. We have also made inquiries of such officers and representatives as we have deemed relevant
and necessary as a basis for the opinions hereafter set forth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In such examination, we have assumed the genuineness of all signatures, the legal capacity
of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, confirmed as photostatic copies and the authenticity of the originals of such
latter documents.&nbsp;As to all questions of fact material to these opinions that have not been independently established, we have relied upon certificates or comparable documents of officers and representatives of the Company. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, we are of the opinion that upon effectiveness of the Amended Articles
and payment to the Company of the consideration per Share in such amount and form as shall be determined by the Board or an authorized committee thereof, the Shares, when issued and sold in the Offering as described in the Registration Statement,
will be duly authorized, validly issued, fully paid and non-assessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of our firm are admitted to the Bar in the State of Israel, and we do not
express any opinion as to the laws of any other jurisdiction. This opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to our firm appearing under the caption &#147;Legal
Matters&#148; and &#147;Enforceability of Civil Liabilities&#148; in the prospectus forming part of the Registration Statement. In giving this consent, we do not thereby admit that we are within the category of persons whose consent is required
under Section&nbsp;7 of the Securities Act, the rules and regulations of the SEC promulgated thereunder or Item&nbsp;509 of the SEC&#146;s Regulation S-K under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion letter is rendered as of the date hereof and we disclaim any obligation to advise you of facts, circumstances, events or developments that may be
brought to our attention after the effective date of the Registration Statement that may alter, affect or modify the opinions expressed herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very
truly yours, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hamburger Evron&nbsp;&amp; Co. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Yaron Sobol</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Yaron Sobol, Adv.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d142578dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 23.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g142578g97l59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We hereby consent to the use in this Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> of Urogen Pharma Ltd. of our report dated March&nbsp;8,
2017 , except for the effects of the share split discussed in note 1d to the consolidated financial statements, as to which the date is April&nbsp;24 2017, relating to the financial statements, which appears in such Registration Statement. We also
consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Tel-Aviv,</FONT> Israel </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">/s/ Kesselman&nbsp;&amp; Kesselman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">April&nbsp;24, 2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Certified Public Accountants (lsr.)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">A member firm of PricewaterhouseCoopers International Limited</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578footer.jpg" ALT="LOGO">
 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g142578footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578footer.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M)4U7G9-]XJ$TB#P]I)MUN2D4Q\23"1[4:U;6HN'@_P"$?(BE_L%[J_\ )$C
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M=2#H4L5*NJU+!8;'4(4L77=_PTG\9+74-1T2]^ W@V?7],^*G@SX6S:7X?\
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M-RG4IQIQJRA"N^2FZG).FHUN14G5BI<C@YQ:/E\_M4:OHWA;Q;JGCSP]\'?
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MJQF(IYA7Q.'Y<)/"XJM0I1JUH8;#_987QM'XQ\46OCV_^*FC^,;;X9?#F_\
M'7@OXD>,]1\:6>L>+==U;QG)=?%'P1&-5U#0O!'A'5IM+U*PM/#VBIX<G@_L
MF6+4_#.DK8Z:]_ZSA1AA<:\-#DP4<91P^'PU65.OC,LJX?!QJXS#8K,(5*ZS
M*IBH8S S]K0Q.,R^F\+*M@\7[7'8S!X+DK.M+$9;4K2YIUZ>:5%B*-&>%P>/
MH_6<###^RP4N6I@:F!A"4IX7&4XXZ%+,Z,:];%RC+%5/0OBGXE\;Z-\5](E\
M,>(_'5WX=\'?"'QW\1_%_P ,/!^B>"-4D\:WVBZGHUIX,T2!M5\$:GXA^VZT
MT_BJ'R=%U6UE=M M$@B$LDGVGR:-9TYYY6:^M_4:64TJ6'FJBI4Z^;U<UH4\
M54GA:4\5&AAHY?5KUN2GBI+DC4A0JQISPF*[Y4:=:&387VGU.OC\?6_?KDUP
M6"HX>6,A)XBI'#0G]8Q>6TJ+G*A%TL5C'4Q%+V=+$8;SZP_:B^+6O:%X#U'P
M9\!_"7CS5/'MO\2IM+TOPK\>;$6Q3X?K;B.]75/$GPYT<VFGW=_=6VD7MOK-
MKHVM:-JTPLKW1<0W,]KV4H*>-PV$E+DI5\%#'SQ,73KX>EAO[8H8&5=5</4J
MTL30Q668K#YOD]7!5,3_ &C"I+#U88&%&OBZ7+"7[N52K?#JEF-++JE.I"K"
MO3JU\IK9A34Z$Z<:M&KA\1AL3A,PH8B-"5"E1^MX26/=;#X:M)J7[8-WHVH1
MZY?_  R5OA->>'?BCXDT?Q-IGC-]3^(^L:?\+;_2?#5U=6/PL@\(BWDL_$/C
M76M,TG0V'BLSW*:C:75[:Z>9_LT?+0K*MAJ=:SC+&83*,5@E",ZT*G]OYAA,
M'DE#%2I0E4P]?'X?%?V@J>'HXYPHT:U'W\53J48:*G4Y<.Y.GAU2QF(P&93Q
M$_94L#7P& S/&YI.G-1F\7A\KEE=;"8JMR8?GK*53!PQ6$>&Q&+G\.^._'GQ
M9\=?!&7Q)X2\3_":[T_Q+\1_%9TC2_&GQ$L].\9_#[P[X.TW1$N?$OA/Q'X4
M\":LEI)XZ\:Z.B6'B[PE!+#<>$WGL?.L-4CN;SMP]&-''3K2DJTJ61XF5>GS
M1JX?#8W%YG@L/E\'RU*E"I6Q660S/&8:I*G#$X;V-:E6I8;%X:488XBMSX.=
M*E2E&CBLSP%*A6J1EA\7&G0HX_&XEN"]Z+ISP>'P.,IT<1C,MK4LSI3AB<3.
M-%T_M2L#0* "@ H * "@ H * "@ H * "@ H * "@ H * *4FGVLNH6FINDA
MO+&UOK*V<3W"Q);ZC+837:O;)*(9G9]-M"LDD;O&$<1L@FD$F$L-1EB:.+<7
M[?#TZM*#YYJ*A6E2E43@I*G)MT*?+*47*"4E!Q4YJ6\<15AAZN%BTJ->=*I-
M<D'+GHQJQIM3<7.*2K5+QC)1FW%S4G"#C=K<P/(OCCHGPYU3X>:I?_%8^*U\
M$>$)[3QKJK>#]7^)>F:E;GPS+_:%M?S6WPHOK?7-:L[&X2._:R$=W LEC#>2
M0;[&.6#&=>E@:V#S*;<:F KT949<DZL(5IUJ<*4YT%&=*:C4<+U*U*5.C#VD
MYRA2]K(Z*%&MBHXG+Z$5/^T:%;#5(>Y&=2E4@_:T:4W:I&=:"E14:$XUJZF\
M-#G]LZ4_(_">A_LU_'*X^)FEZ!;>/!J&H:SX*\;>-_#NM3_'_P"$>KZ/KPF.
MK>#O'OA?PSXIF\-7G@O4;^ZT*6?_ (27PG:::^IRZ;.+N[N9$E%=$,)/#X6A
M[.+I4<NS#'QIN%2U;"8ZO2J5\PP[<9_6,/&M2SFK5K827)AZL<=5E[*7/-G(
ML53J58WY:KQV7T[<])3HX[ Q=/#4:S<X.ACYX9X'#TZ6+E[?$X.6'PKA5HM4
M&<[IND?LDM\0)=!6X\;:[K]]<WOPYO-:\3>(/VA?%WPT\0>)WT/5/"]WH&I_
M$+Q5J5_X!\4?%"+1-0U;PV)+K5[SQ' !/HD<D<ML;.'"G1H9E@\91ITX2P>>
MT:\O9N,:"QE.%"AA\57RV,E3E4G+#91"KBL5E:]K6HX'%XZO5G"GC:YM4J5,
MLKX&K4JSI5\NJ4%&7/*J\-)XZKCL%1S&SJ>RI1S#&JM@,-FG+1A7Q67+"4HR
MK9;&65X_MOV1_A@@^'?C&/XQZ1/X#EM?B=-XKT8_M<:WK/A:WU70[OP=#XDU
M/X]^$#>ZAIGAW_A';"ZT>1+SQ8FG6]KI/V6:.*/3U2#HI5:F9X^"IU)O&PK+
M*W4E*6&5:MG&)P^*C0KUY^QI8N6.QGU>:JUYUE/$484U453"\E+-T%@<';V'
MM,+5H2KTJ4:?UR5*AE*DY?4\/&->IA7@85:D_8X2G2J4J>.K5%#DS.I+$_2N
M@_!+X;:!K"^(]-TW7+G5#XBA\8Q76L^._'GB>!?$Z>#+KP /$,-GXC\37]K'
MJDWA"]N+&>Y2$/<^8MQ.9+I$G53<O9U\,XJG3JPS*C*$8JGR4LUQU+,L?1I<
MBB\/2J8ZBJ].E0=.&%<\1#"1H4\5B85<:<*-2*JTJDJD*\,OYIJM.<<3'+<.
ML/@)UWSM8IPHQHN56M[66(J87 XG$2K5\#@JM#)NOV</@[>6<6GS^&-0%A#\
M-4^$/V*#QIXZM+2?P##-+<VVE7UM:^)8X]0U&UNIY[BVURZ6;5K:>:2:WOHY
M79S#7[[%8A-TZN+GEU2<J;=+DJY165?+:M"--QCA:N"J+]Q4PRHSA3E.CS>Q
MJ3IRZZE2562=6,*O[[-*\HSITY0J3SF/+FD*T)1<*V'QJM[;"58SPMXP<:,7
M3@XO\)?L[?"GP3J3:OH>E>)YM2;Q(WC%KOQ'\2_B=XTD/BR3PIJ'@>;Q(1XR
M\8ZHO]N3>%=4O+":]V^=,K122N\UO#)$Y)3PD\"XQ6%GAL;A'",8P:P^8XFA
MC,;3C.*4X*OBL/#$2E"49QJSQ,X2B\9B_;XN"=:6(;DZDY8652\YN-7ZE%QP
MD:]-R]G6IT%[-TZ5:,Z:GA\)/D<\%A)4;+? 'X7-\.?#GPH_LGQ#'X,\'7FG
MZAX2CA^(7Q%M_$WAB\TFXFGTJ?0/'\'BM/%.D&R2XFM+<6NLQ+!92'3X@MCB
MW%8B<\5BL-C:TV\7A%)4ZT6Z=2U3"U,%5]I*GR.LZV&JU*==UN=U^=SK.=3W
MS3G=\PO:2S2K[;$QFE.-2K]:I8WVBC-.-*7UNA2Q*=)0M7BZB]^<W*WX0^"'
MPY\ :9XKT;P=I_B+P]I7C.%H];L+#X@?$)+:.XFM;BVO=8\/Q2>*7'@_Q)?M
M=W%Y?ZYH']F:EJ%_)_:5[=7&H 7(BJE5P4,NE&,,%1G5E2I4HJC&C&K5=>6'
MH.BH2H8*-24O8X"BX8+#PE.E0P].E.4'-+]SBH8V/O8J/L^:=7]][>=.%&FJ
MV+C6YXXW$2A0I*KB<7&MB*]I.M4J2J5'.EH?[/WPK\-CP:NCZ-KMNO@/0-4\
M*:"D_C[XA7Z7'A?5Y99KOPYXJ34?%,X\>Z%'-/*]K8>)QJ]O8LVZRCMR 05X
MPQ*QT:U.$X9E@L/EV)I\D%3JX3"4J]##0=)15-5*%+$XB%/$1C'$Q5>LU6O4
MFV1<J?LW"I4C4I8RMCZ=7VD_K%/%8FM2Q&)J0Q'-[>"Q%:A1J8BE&HJ->5*F
MZM.?)&WR_P")_#_['G@/5;'X9ZQ9_'W4KSPM)-I6DZ3H,W[;'Q-TS2[0>&+"
M[U;P1I&L^%)M=T[_ (1MO"5QI4FJ^#[6\;36M$LO[3TXI!#Y:ACE+$/,I5'*
MOA*>+JU,3B(.7ML/2QV ^N5L34Q$7',,'A\RPF#A4JXAXG"X?'QG34J>(K8B
M-2YT)4DJ=-+#1Q=?#RI4\)..']ABU1S"6%6$I825/^S<9+"XG'5*,,+'"XFI
M@W&K%2P]+#SAZ=XT\#? +0/A?\3_ (T/X!\6^,O"OC/P#KWB7Q/X=T_Q!XI@
MGU'PKXKM=/UWQ1=>$O!/CKQEHFD^ =;U&WLK'4[S^R8_#FISW.F0NQ?488$+
MQ&&K9:Z62^PJ>UCFN$I4X4JT76P^/>;SKX=T<5[93HTZ6;8N>)4,-75)5I*I
M"G+V=/E>7../K87$8:=*G&5!>SC6I^RPE2E0R]8&DL3A9TUAIIY=26 57&4'
M".#J5J5:K3PE?$N7;1_L\?"2XTR&ZUBS^(%Y WA#Q/X;O5\:_&KXO>)KD>$_
M&UK9-XI\.Z_>:]\1M274M-=+"U/DW-S=P6DEJ9;)HF)D;>O6CE];$UW7H1AA
M7@Y5*_+%4)_V-CZ^98+%3]M3@I/#XBM7FL17IQK3PE6I@L0Y8*4L,<>!B\93
MRZKA:>)HUI>UJX2$)U:>*P\\QP>'PE6E0=&I[2A*5/#X9PHX>:A1QU"CCL.H
M8^G#$K1T[P+\&/BUHNE>/]"2;6](\3^*?#/Q;T7Q-X>\4^,="-_K^@>';3PO
MX>US3[O1]9L)[?3D\.V,-FVF1^587,<EP;FTF>[G::(TZF%K9;B/9RHU\$ZF
M-PWM(M2OFE!SJSKTZB_?+%87$>SJ4<7"HOJ\HX:5.-.G&E'7GI5\/B<)!TY8
M94%E,U1Y%"-'+<QK8B%*C4I647ALQ56K1Q.'FIJ48RHUW3C2MR,?[-'P"/BS
M6[5?"_CL:G?^&/%<.I6\GCCXZ+X&?PM\4-4OW\6>&=.CF\4#PA#8W^JVUS>S
M^&=."&RDEM[];&U^TV\\LX!_4Z3AA?=IX!Y/12K+VDK93)8G*(T_K/-/$4<O
M]BZ=-P]K1P]*I5P55QI8NK0K:8GFJU:&(G)TJ\ZN85Z53#2>'J4L1B(TXX[$
MJ6$=.6%Q.*E7IUOK#]E7Q.)IO%T:E3$X.=:AH_$OX:?#+0;3Q+XSUB:71],\
M2^./A[XQ^($$]OXL\>2^)-7\"G2[+P18^ O!;:GJ%IX>\:W>K:/X.TY)_#/A
MVZU348-/CL;6#^TWT[4-**%:6%K993IJ=:6$Q>*Q."I0O+$+'XOVE2I4C7?-
M7CA80GC,3B:"J4<)"DZ];%5*67+,:6)<Z<<1A<70E&$*4<JGESUA1PU++E4]
MI4IU*2]G2J."G6>"E)JK0QU6E6H>TJVH5NLB^'_A?XA^(O _Q?\ $OA?XA>%
MO&OA."^A\.:/JWQ \1:2NAP7$]Y;SOJG@[P)\0+SPAJ,VI6CH\QNX;Z>6V:T
MM[X(]FMM:.E36"Q%3$TW%XG$89T*K;5=4Z>(A0G7PBY_:44H5:%%U'A7+#RQ
MF%HXO#UJLZ6'Q)G.HL7AX8:2E]5P^+^LT9<CH3J5*:=.EB;VI8I1E1E4C3HX
MJ-.K3H8C$T*V'I+$XJC/H]5^%O@36]%^('A_4]"%UI7Q1NIKWQU"=3UB*XUN
M[GT/2/#?VA=0@U!+O29H=%T'1[>W;39[,VW]GQ2V_E3 R'-P3H8/#J4H4\OK
MK$X9PG.G4HXA9A/-(UH582C552&/FZ\).;=.U.E!QHTJ=.&BF_:U:LE&JZ]#
MZK.-6,:M*6%]A+#2PWL*JG16&J4JE9UJ"IJE6JXC%8BK">(Q6(JU?+XOV3?@
ME ET(M,^("W-YXA7Q7<:H?CA\<FUY_$+>'Y?"MYJ8\1/\1CJ<<NH^'9?L&I(
MEVL>J106PU%+HVL!B)0A.C3PTJ<'AZ5+&4%2Y8^SEA\PQ%'&8S#U8)<M;#XC
M%X>GBZE"LITOK7/B%!5JU:<XLU5J5^:2KU'AY>U4I*K3J82C4P^%KT:B?/A\
M3A\/5J8:EB:$J=>&&F\/&HJ/N&SX:_9L^$O@W5/#>L>%K#QKH5]X5TC0_#^G
M?V?\7?B]#9W^A^&;K4[KP[I/BK2_^$Z-EXXL-,_M>_M[2'Q';ZJEO9R1V,06
MRMX;>+I^LU_;XG$2J>TJXN4JE;VB52%2M/"4L#/$RIU%*F\74PV'H1J8OD^L
MU*E&EB)U98B$:JRE0HNE2HJG&G"A.4J7LE[*=*+Q"Q7U>G4I<E2&"5?FG# 1
MDL%#VM>,*$88BO&IV$/PH\&6_P 2[GXNQQ>)CXYN]%7P[+=R^/O'T^@+HB+#
MMTZW\#3^)G\,6< F@6Y_<:/&WVIY;O/VJ>6:3GPZ6$6,C15OK_LU7<_WLIJA
M4JU:"4ZO/*"H2KXA4%3<?8T\1B:5+DI8BM"IM7_VCZC[7_F7>V]ARKV?+[>W
MM^?V?)[;VO+2]I[;VG-]7PM[_5,-[+Y]^(GA;]E7X+VWB=/''A_Q2;7XG^'/
M&^DZO8Z;IOQS^*D>E^#_ !+JMO<>/+/P[I7A6'Q%_P *?\*:IKWB+3'NQH$'
MANRN;Z33.7N;&S^S94I0A2P^3T/:QC0GE,*3IJLJL:F'JK#Y#AGCH?OG.C6I
M2I9-@YXAN,HXB. HJ^(OT^UK4ZU/..:G3J8">*Q<6_8QIQJ.E[;,<=+".U*K
M.5*'M<TQTZ$W)593Q]9O%R=;J?@]\/?@#K#:IXN\ >'?'6^SOKW0-:T[XD#X
MY:4S^(7T"PL=2U[5_ 'QIEMOMOC:]\,7]M97/C&YTB75KZRO[BUFU2>&XN8W
MWQ%!3R^O2G3IUL#G-'$1=.#HR4J/MZN'QE"ER2O@XXG'8>O6Q]"F\/'&YDJN
M8XR-;&U)XF?#0E"E7A&A[3#U\LEA[2BJM*2Y(1K8-3J)1^LPPM&I16#4Y588
M.A3PE##*C2PN&ITF_ /P'\*;WPQH>O>%/"/Q,\/6/@CQGXFTOPQX>^)GQ,\7
M^.&\*:UX%/BOX3WTOAJPU'XG^+M'TG14L9O$5A9PZ=<);FVFCF2!&2!H]UB,
M1.A@L=.JY5<VR_V[E4M4Q7U?,Y8+&.&)KR4Y5*M58+!8A25>M[.,ZD858/%8
MVG4JM1IT\7F6#453AAL31C.&'?L<#5E0@\51='"T73HPH0GC>:6&EAZ#IXS#
M8?V^'CB,LP;P\WQ/\&>"O!GPF_:%\1>/] UCQMX?\:+K?BWXCZ#\-Q%X#UK6
MO#&GZ18:*NE65S:^,M$N;[4(O!FB6<6I75QXCCN-7>.^BA2*TNK/1+7S,33H
MO 9;ED\-4Q5-XVA:G3E93S#'XVC>I&DITXPH3QDJ3^JP]IS:U:ZQ>+JXG$XC
MTL&Z]3-XXS"UH83%QPM+#TJU5I2A3P="M*#GB'#EC5C4K5UAL5)45@J/U6#K
M4H8)8H9I7P1\1^"O"OA+0/V>_B#?_"GPK::3=VM_X4^)6G^,OCH+>QO]+T*R
MT*W\.3^,_BI'>>!;OPY9Z9/#9Z?8W]WH8?49S<Z1=F.-AZ&:4ZN,Q&/P698M
M8[!UX5\-6JT.2.+E*=62JXK#8^K2J.<ZM-RC!X_"8V$/W=2-&%JE.KY&"G0>
M!I8K!X7ZOB:[H8FDJ_M/8QA[/$U)8?$X*E5I)JK7Q-.MB9X;$87$RGAU36*Y
M9-KM;/X ?#FS\/\ PA\.&/Q9+8_ Y=);P$UOX]\:: 8KW1["#3;?4O$%EX4U
MW2M/\573VD,T3Q:M97=MY6I:A;QV\=MJ%S#-I5Q4ZF9U,U4(4\3*G.A&*3J4
M:-"I2E0=*E2KRJQ5J$O9*K+FQ#C&#G6E.,9K9J<\)C,)7JRKK,*SQ.+JR5.G
M6Q&)EB)XR=:52A"C[)SQDWBO9894*$*\:4Z5&G]7PZI13_L[?"NZL/&&G7%A
MXPFA\<^,-+\?Z]<R?%7XKMJT/C'1)K:;2=>\-:X?&W]H^"+RU%C801CPY=:5
M&MMI]K:;/LUM%%'QP@J6'RW#4W*%/*)XB>%DIS56G+%T:U#%<U?F]O6CB*>(
MQ*K0KU*D*D\5BJLXNKB:\ZFDI<]?&8BI&,YX^G1I5HRA&5%PPU98C#\F'DGA
MZ,J%>,*E&=&E3G2E1P[A*/U>A[.+0OV;?@[X:T;4/#^F>'-8;2M2T3Q]X;GM
M]5\>_$/7Y;?1/BC>:=J/CVPTN]U[Q7>76B1ZOJ&DV-U*^G36KQSQR30-%)<3
M-+LY_N88;D@J%.GEU%4_9TU#V.4SQ$\OH2BHVE1PWUFK35&5Z<\.J.&JQJ8?
M#8:E2*$YX7%PQU&I..)IXN>/4G.4XO&U%!2Q4Z4W*E4Q%HRY:M2$IP]OBW!Q
M>-Q?M[>O_L]_"CQ+<>*;K5-"UD3^,+CP;?:S)I?CKQ_H'E:I\/C8_P#"'ZYX
M?70?%%FOA#Q%IR:;8Q+J^@C3;Z6*V2&>XEBRARC'DE.<93C.>.JYBYJI-36,
MQ&$G@,35A/FYZ:Q.#J2P^*I4W&CB:?*J].I[.'+%.,*5/#T(TX.AA< LLA3G
M"-2F\%"O+$TZ-6%12A7=#$REB,-6KJI7PM9NKAZE*?O'5>&_AAX,\+?V@VGV
M.JZA<ZMX>TOPIJVH^+?%7BOQWJ^J>'M%NO$-[INEZGK'C?6]6OK^WAN/%6OL
M3/<2/(-19)6=(HEB>)C#%X3%8&O3A+!XR4I5Z481IQJ2G@\+E\W+V:B_?PN#
MH0E9KFJ*KB'?$8C$5:I1YL/5P]:E5JQJX3G="3K59.C*IB)8JI.ES3?LYSJR
MBI5(VFZ.'P>&YOJ^!P=*AYK!^RM\&K70](\.PV?Q%72O#UW!=^&XS\=/CH]W
MX92WT:]\.C3/#.JR?$AK[PYX>ET/4+FQN-%TVYM=-N8?)2XM91;0^4Z_^U.4
ML4_K,ZE/$T:TJO[R>)HXR>$J8FCC)SO+&4:M7 X6JZ6*=:G&K3=6$8U*E64W
M%*E*HZ,8X;FJ4JL(T(JA3PU:A]95*O@:=%0IY?7A'&8FFJV!CAZOL:KHN;I1
MA"-V\_9G^$=YHOP]T$6/CK3K/X4V&K:3X!NM!^,GQE\-:]X?TO6TLX=0TU/%
M'A_Q]9:SJ%@;6PLK:*WO[^ZCMK:VCMK988%\NKK5*E?&ULQJU)2QN(P\<+6J
M\S4JU&-2G5Y:JBU&K*=:C2K5JM12JUZ].%:O.I5BII4HPH8:6#I4Z<,++$K&
M1IJG#EI8B,,12C*@G'_9XQI8O$4XTJ'LZ,:=64(TU&R1I_[,7P3TE-3@TSPG
MJ%A::Y\.H/A3KNGVWC?Q]%I>O>"+>?5;I+#7=+7Q0+36M6:YU[7I9->O89]7
ME?7=2>6_=K^X,U4ZTZ+?LE"G36+P.-A2C3IJA1Q&6PP-+!/#8=1]AA:-"CEN
M!PZPV'ITL-/#8:GAJE&=!.FQI\]&JJE2&(PZQJIUX5:D,1!YA7Q6)Q=18F$H
MU_;5<5C*^*C6=1UJ.*=/$T)TZ^'P]2EUWC+X/>!?'>N>'_$VN6WB2Q\0^%[*
M^TO2-:\&^/\ X@?#K4TTG4;O3;Z]T;4+SX?>)]%DUS19+S1].F_L_4FN[57M
M]R1*9)-^="3PV*GC*3_?5?J_M5/]Y2K?5)UZF']OAZG/0K>REB<1R^UI3]VO
M6@[PJ3BYG3ISP<< Z<8X:GSJDH15.IAU4I*C46%KTU&OA>>G&G&?U:I2YW1H
M2E>6'H.GQ%W^RW\&;RQUO29=)\:PZ-KOB"'Q5/H5C\8?C'IN@:/XDMO%T?CR
MWUOP=H.G>/H-/\!:E%XMB744G\-6VDLLC.BD12/&ZP_^R0R^%!N/]DNE]4E*
M3G4H0H8/$9=3HPJU'*I]66!Q-;"RPLI/#3HNG"=*2HT?9ZU9>VGC)U%%_P!H
MTIT<5%0C"EB8U*N'KU)UZ,%&E5KU*V%I5*F*J0EB9S=:4JK>)Q'M>X\.?#+3
M=%B^(OVJY+WGQ,UJ]U'7KWPV-0\&7J6AT6R\*Z.EMJ^C:M_;2^(K;PSI6F1W
M'B,ZM_:,]_'->6TEA +*PTPFE/!T<&^:,(5*N(J>RE*A%XK$U57Q-2C3HNG'
M"T:E5)QPU&T.7FE7EB,16Q6(Q!%JEC*>,IKFG0P^"PM-U[8F<J6"C-TUB9UU
M-8J2J5:RBZT)6POU?"S]HL/[2I@VW[/7PIM/AK;?"2+1_$1\$6&L6GB#2[6?
MXB_$BZ\0Z+K5AK,/B"PU/0?'5UXMD\3Z#=VVL0+<POIVL6WE,\RIM2>59%)*
M7]F\J]C_ &/3C1P;H_N'1HPP];!QI)T?9N5*.#KU<'&G-R@L&XX5)8>G3IQF
MG:D\<[*HLSG5J8J-9*O"M4K3C5J5)4Z_M(*<J\(XOGC%26-7UV+6+;K/H/"'
MPD\%^!M<N_$>@CQ;)K=_X>TSPMJ&H>(_B1\1_&DNHZ1HU[?W^E#44\9>*]4C
MO]3M;C4]0$6J7"27ZQ7<EN+G[.WE5ISR5+%4%:%+%UJ>(J1C&,/W]/!T, JM
M-Q2="=3"X;#PQ#HNG]:J4*6(Q/M<1"-59>QI^UH5O>E5PU&IAX2E.<G[&IBZ
MV-]E/FD_:QI8C$5Y895>?ZI"M5H87V-"<J;\P\>_!GX&^%?A1XJM?&<?Q*_X
M5UI?B:7XN^)6LOB7\?\ Q%K\6O:=<Q:O+KD=WX<\77WBFXL;34;:'6/[+L9)
M+&&\LQJ@M%N;?[3'S_6:>6K*,3=TO["G&.#DJ<JKIU,3B'>I7BHU'B92K8FH
MZV(QBK.%.K7E6J1H2K,[Z4<1C,5F"I1C4Q.=494,1"U.*K4E1]FZ%*F^6G3<
M\/3C@XTL-&G.OAU3R^$:E)PH/E?AOX9_9H\>M\3_  CX5\+?$^.'XBZ'X@U'
MQKHWQ \.?M*>"=-NM"^(NJWMSXHF\%Q_%>QTJS\,VVO:Q<3W-\G@LZ>;F:UM
MIYU9K"V>WZ%AZE/ QP*O1H9/7P%H*I[/%8>IAZE>MET>=2CC52PM7#8F6&AS
M.AAJGMXPC3EB*BJ\E''>SQN"S"C5<L5B:$W0KJ+J4\13PU# X:I5G.TL/B:\
M:$\#&=>LZF)J0G&HYSYJDW[-X4^!/PT\%>*[GQKH&F>(5\1WMMIT-Y=:Q\0/
MB%XGLKJ[TKPWIOA"S\07&B>)_%.H:9-XQ_X1?2K33)?$K69UBXMGNH[B^E%_
M=_:+C7J0AB:<.6$,75K5IQC""498BO\ 6L1&BE%?5J-?$*%>MA\/[*A4JTJ,
MYTW*A1<(=*GRX./+RK 4HT*-FXM482Q$J=&;BTZU*B\565"G6=2&'A*-.BJ<
M*=*,%G^!'PINO&U]\0+OPK]K\0ZE>_VK?6]YKGB.Z\)W.O'08_"Q\4R?#^XU
MA_"W_"8'PS&NDGQ -&&J&R+VIN_(=D;DA0I0I8FAR*5'$TL50E"I>I&G1QUO
MKU+#*HY+!T\:^>6,AA/8QQ4J^*G7526+Q3K=$ZM2=6C6=24:U!8>*G3;I3FL
M'4=;!JO*GR2Q*PE;DJX58AU5AJE'#SH\DL-AW2QM$_9L^$?AO2-9T31]*\66
MEKK>@VOA22\;XJ?%:ZU_1O"=E<)=6_A3P=XHO/&TNL^ O"RS11$Z/X:O])LG
M$,:/ R1HJUB*<<7AZN%Q3EB*>(G3GB95)SG7QCI*HJ<<?B92>(Q]."K8CEI8
MRK7IIXO&/DOC,4ZT4']5Q<,;AHPH5J$:L:$:<(0HX55VI57@\-&*PV"G4E"C
M*53"TJ-1O#8-\U\'A?8X%_\ LC_ S4$^&RSZ/X\@F^#^D7VA?#.^TWXV_'#1
M]6\'Z7J:/!?V^E:QI/Q%MKX/-8NM@T\UQ+-]@M[:P$@LK6""+I>(K/,,3FCJ
MR>.QE*C0Q%1O^/2H252$*U/^'54JB56NYPD\367ML2ZM7WS.G3IT<#'+*<%'
M 1K_ %F-&R<%76L)J]VO8Z_5H)\F%YZGU>-+VM3FOP_!WQIK/C/1=7^)'Q+T
M[QMX+\$>+/$?C#X?^$[;P#'X>UJPOM:TW7?#NDV'C/Q:?%6HQ>,],T+POXFU
MC3K58-%T.>Z:6&ZU:XU":)O-PHQCR5*F,IT\5C*F#Q67SFJ<*>&JX?&5:<\5
M.K@^6I!XBI2H4L,O93I8*%&IB[8#VE7#5,'I*52FXTL#5G@\$_J,YT^>=7$.
MK@%A:M'DQDY>UA2EF&&CF=6ZGBWB84*4,;#!0Q&%Q>GH_P"S;\&=$TCQ'H-O
MX3N]0TKQ1X:/@O4+7Q-XN\;>,/L'@W+,GA'PM/XL\1ZC-X(\+PRF.6'2O#LF
MEVD,MI:2PPI+9V[PDU*I0]C.K5E)U<-7GB'6JO'5:^#DZF#Q%;,>?Z_7Q&#J
MRJ5\)7K8F=7#8BOB<10G"MBL14JS3C"CB%B:5*G!QA6I0HJG#ZI3I8FWUJC2
MP/+]2I4<7&,*>+HTZ$:>*HT</0Q$:E'#T(4X'_9X\"VND1:#H]O,ME?^,_"7
MB[Q?JGC/4?$OQ2\:>(_^$'N8]5\,6,7C?XB^)-6U73GL-9L-*-M<3S:BMA9_
MVE!I<%A>:A'J5AM2JNEB,%6M&*P%6MBJ*I1A0D\=4I1PZQ=:I3BIUJGU>*P]
M:4W[;$X>CA,%7KRRW#RP-:/8TEA\RH<LI?VCA%@9\\Y3IQPG-[U"-.;:A1A&
M>(K86C1=*EALQK/,8PGB'5]MH^)/V??A=XNU_P 5^)O$6G^*]1U7QIH6G^&]
M>!^)WQ0M=+.DZ/?6VJ:/'HV@67C&'2_"][I^K6J7]I?Z+9Z?=VMY/=74$\=Q
M>7$D_-3I0I4Y4J=X\V+PV.4^:7MH8K!U_K.%K4J[;K494*O\-4JD(*DW0Y?8
M-TWT5*LZOL?:<LHT*&+PT8<D%3=#'8=X7&4ZE-15.LL30<85O:QFYNG0G)NI
M0HRI]/X8^%G@;P?<:#>:'I5VM]X:T?Q)H>DZEJGB#Q)XBU1++QAK>F^(_%4M
M_J?B+5[ZZUG5M6US2-.O+O5-1FNKZ>2V&^Y*LX;H]K->V4>6$:]/!4IQA"$(
M^SR^.(AA8QC"*C#D6*KNHX*+Q%2:JXEU:E.G*&#@GR*4ISY*M2NN>I4G>K.G
M"@JE3GD_:2H8>FL-@W4YOJ.%E5PN#]AAZ]:G4\PE_9)^ T]]JU]/X6\13G6M
M+\9Z'?:=/\4/BM-X?71?B!=MJ7BO1]/\,R^-VTC1]*NM68:G#::?8VL-CJ$4
M5_8):WD,<Z84(1PV'CA:+E"E"GEM.#YYNK3CDU2%7*?9UY2=>G++902P52G4
MC4P\)5:5*4:5:K">U2;JXBGBJD8.I3K8JOR^S@J4ZN.3CCW5H1BJ%:./3?\
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MTT7P+\9>'M'\%Z9XD^!.E_%7X9F?XN>);;]G;P[>_#B#P%\./%GC7Q/IFK>
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M?P]XZ^SVFE1>/M=\.Z!XF\-Z-XF\6) VDZS>V4%QIRJRVTAMELIO/<*6%Q.
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M8FO2ABY9/"4G4PU&O&D>$O@G\5_A3KBZ=#\']4\>:%HWBWX&ZGXF\3>%-?\
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@^:.TO9UJ5.K"Z?+4IPG&TH1:O4 % !0 4 % !0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g142578g04e65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g04e65.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[23^4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M    3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT
M<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D
M;W5B0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!O
MX            $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L
M=                %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A
M=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N
M=$8C4FQT                5&]P(%5N=$8C4FQT                4V-L
M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    '@X0DE-!!D       0    >.$))30/S       )           !
M #A"24T$"@       0  .$))32<0       *  $          3A"24T#]0
M    2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M 0!:    !@       0 U     0 M    !@       3A"24T#^       <
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #00    8
M!+    1J    !@!G #  - !E #8 -0    $
M 0             $:@  !+                       0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P  !+      4F=H=&QO;F<   1J    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    #CA"24T$#      :IP    $   "7    H
M <@  1T    :BP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ H "7 P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
M  ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !
M! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S
M-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($
M! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*2
M0U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M+TOTC.1_\<'ZO_\ SG8'^=5_[P(C/KST6S5GU*PCY[JA^7 2]R.]#[$B,CH
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M/'YQ_P"^A'<V" /F5-M@?I6TN\^ IUUR27Z*,NCAC$:1%!$QFL!L^:(ZIYX
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M_2-=^BL^DU6&]=Z4\MK(LWO<VMK=K@[<X[&-VEGYSD>"7;\0L]['T)_Q9_\
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M?))2VD1&G@DG222__]D .$))300A      !5     0$    / $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      2Y-30 J    "  '
M 1(  P    $  0   1H !0    $   !B 1L !0    $   !J 2@  P    $
M @   3$  @   !X   !R 3(  @   !0   "0AVD !     $   "D    T  M
MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R
M,#$V.C S.C$P(#(R.C(Q.C0P   #H $  P    '__P  H ( !     $   1J
MH , !     $   2P          8! P #     0 &   !&@ %     0   1X!
M&P %     0   28!*  #     0 "   " 0 $     0   2X" @ $     0
M            2     $   !(     3A"24T#_0      "           _^$!
M,$U- "H    (  <!$@ #     0     !&@ %     0   &(!&P %     0
M &H!*  #     0 "   !,0 "    '@   '(!,@ "    %    )"':0 $
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M 1$  A$! Q$!_\0 'P    8" P$             !08'" D*  0" PL!_\0
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M5([].;-(4N43DFC*KPJ ?*H))*2TF VQ@=HK7*D+F)GRT]XJ1/E+DS>Z)83
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MV&VILW9F*ERD_P"*+'Y7$RL1)FX:=*!!FS)4_.)9,M!?(HI424 #QI>"7MS
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M>[6F62".[04M$&S^T6%F[*&T,9,[HRU)EXG)(G9$3)BU"6F6,JBM.7*,R5+
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M_P#BC/SZ^.S_  $_#C_SF]\/]VZ/R_X?_P"H=I_[39_^^#O.TW^6V-_<8O\
MXHS\^OCL_P !/PX_\YO?#_=NC\O^'_\ J':?^TV?_O@[SM-_EMC?W&+_ .*,
M_/KX[/\  3\./_.;WP_W;H_+_A__ *AVG_M-G_[X.\[3?Y;8W]QB_P#BC/SZ
M^.S_  $_#C_SF]\/]VZ/R_X?_P"H=I_[39_^^#O.TW^6V-_<8O\ XHS\^OCL
M_P !/PX_\YO?#_=NC\O^'_\ J':?^TV?_O@[SM-_EMC?W&+_ .*,_/KX[/\
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M5+$QAG$LJ 449GRE0!9GK!_ZKQ)&=$$5(1],,\")SCPT^+C *C<;7V; )89
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MNS^'M[]#->G7!^O.#(>'O](UW^F+^ F/[?AM\7 //'Y)[.$G&/;'=G!]_O\
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M?#&>]"5+-;,5>%(L[6(>IK44M_;C29S(UAH65O;='(<*,@$'S"1QG!;!+?<
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M(F> T/\ 4?@WTA!-6>'_ +EZ59S5Z?EKJ>,$FIMKK5QE#M;=L1FG7&?8Q_Z
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MU.TTJK'(PVALY])*\%EPVT# & N0<DX*JV%O>(I(<$$DAFL;>UR_$;HR)>1
M*)CD4H-"Y+%R&^%[ B#-;]/B<Q^89>6"[Q&H7:2H*8+ ^[%FC.&#<J%& &H0
MLI(*P E84S&J6!8 !]0[[CO@F9,A8$CRX!^C:U(.4>G*8H0C ^@*-@<G!^9]
ME)VMD #[*@+OSO:0!GXDFNG[=",U>(GA8!3X7&@9JTY"U:? A<FE5\UXHCO.
M</$2@) X(W$^D[21M)WARP7T@]-\*G%VIUZW;Y18E3"I1S((#7NP8[M[OJ;Q
MJ'3,L'F>F-I44O(#]@!> <KO+,QX'I )^9R.I$@90/Z3Y%VT\BXKOT8L4E$Q
M2,K7U%*L;-2@^9W1K-;_ #AY;Q^7G:$W*5+!5?V)/W95\>Y]L?-__P!L&Q!)
M?U#;_IYQE3\.1XR4L[6JXH]A\>4%W4.AH;Q05-NN="MQH)HCYL51$SQ_+:D;
M8W1LA)/F1LLJ,#ZL<=++G3I0"I1%%)K1Q6V_BW#E'/;8V)L_:F'5*QF'ES):
MD%*@7S/E/B0;9GJ"3I6(_N[G9.Y:*>2YVU:BOT\[Y\TEOK%L\UAMBK  -\(+
M(J3KP<E74<,W3X/']^GNYA25 BVI:U6\5Z5]:1\P]L>P^*V"O\SATS)NSYBB
M4K()5*<_I6 ]!O+GR+PW2>,QE_DX(VD8W+QDGU,,Y!4< 9QDJ/EKH< D7\+<
MB[UZXVCS=:2DJ.HIN//F;1K3YC!(QN*GU@<;<  Y S[D8.W.[V+* >IE9DAM
M;Z%[='YVB(E68EJ4YV%=!>N_=I&DTA(X4%5&PE<$.7"Y!5CR<_?CW! Y'3.\
M(RN!1_=JU;JY=X:6+/:MW!H-'][1:G^A_H?[I5WRD\M4!\#7<=/8[EV]^_#4
M%4DDYR 3\OL\ ^X5JE3,#Z=:>403?TT-,PH.19^-Q6M*Z1Z//1$$50?IB(_^
M1E=D/P\=';(__P"@_$R/^G\>B'HOY?,1YN=-'N4/GE7!"XQG&3C=D >WXXZ!
M0@[C7K3]CI$MH$HB=R+L' + Y!SG /WX//[#QC[^E3=_0#7AZ\[#6&AB7&YO
M>-^*,E5.2-X"@?/*^Y^6.",9'R^9]WI(2ESKPXZF',!8-!ZT=HN_:WND-JL=
M')42%@)Y]C"G@3V9Y9,%0J@@D9W'V ST)*IJQ*0'468"]2$UYD[H<E"E D)+
M"Y-O7W^](D2[:=D++HNGAJ%IXKC?&16DK9XUE\HL5W+3J4VHH.0" 7P?M;NO
M0-C]FI24B;C I<RBDR_T@%6IK_+I2I#V:*4^>4A64L0;^?!WIPT>%XATVTD<
M9= #[@*.#GWSA1^W.1]P..NU1@DI\026"0D"M D 4/ENT]:@Q"F?-XC9-+@Z
M?&W*#!1Z6SRHYSC!4^XR%'L.1]_X#)]^KV&V?WX)" X-U.= 0 XUTIJ8AF8D
MC]3@LYY!ZZ;[ 6\H,<6E)'C(:,XP,[MS YQP 4]^ "5*\ <YYZ?-PBD)*5(8
MCB->O?R@3.)RK2JHN*^8<GV8\]('J+1D8BCQ%AL$L"I SQ]G(.W ^[C'R^Z.
M1A<P"<GS^FCTYPY6(+>(D5IS\F@L:@T%- /KT$.\IZF #'&"3G[)' !R?8YQ
MC//6)V@V*<1*.5+&45*%'S.]6?PA^--3:.EV'M7N%)E?RJH:LY( LQ?75QO,
M'O0]E%Q@C%. 98Q^E4G# YP0.,GG YP/;/OUY;-PTR2M0F4.:@W\MS ?'4-'
MI,E0FI24N H7^+<F(+6TA75TU56T?6)XF$##:I=,<'.2#CGVQC]I^1ZC50AM
M7\RU'WU.L:F%!*VWI(MJ>K:QK5EI22/S53&?< $D\XSC9]G &0#CC.?ETCTJ
M:@.-]M]JT.M[6C<E2\P"33<0Y-OFW'?K .+<)7V+Z6/!7&,8"X.0/<DYP01Q
MTYGL::&IX&]?1KF)%R@A0 -J]5,=GY&,2[@@W8^8'.>>&P<G &<_]75>8@+&
M56BGWV<<]=*Q< "T &@#<;#R'E !<:,;BKQ)CYAER3E?;V)93@>X^>><8ZHS
MY<I"<JBQ-O45/)G9FW7HT8=1$SPI6#0 @,QN[GTW$;P(95WS\+]@[@I57K3\
M,5EU.L<K"6!/+I*YU!]%9&B'+, 0)5 8$CD@%6JRYAEJ(*LR2V6PREF=ZN--
M#J[QQFW>R$K&2C.PH3*QF:B7 3, &[Z.8BIU3I'4&C+S56._T$]NKZ1V22.9
M'"R)DJ)X)" LL+@;E9#CW4X8$"XA;ZN*U/77I'E&)PL_"3ER)Z"B8@L01[C>
M./ C0P3JF+RPK)N*'/J!]QQSCI5#*Q'K?E7KSBO 5)&LT@8CV(&,_JCVXX'V
ML'_HZ91W(W/=NKVWVM!'76>E-@]LC^;!_G_[_P P#U%P.O3A?TW-! 7TR"#H
M S 8!*\B4AN3R2 5/L,<Y1FVC QEL=-RU *G -KL]>?D6XV:)Q6STWZM>-A2
M&D &XIMR=W)#J0Q./8CV.?YR/<](6<IT;<QO8?.]7K#Q4T>@J2'L'.]QI[-
MC14DU7+#%%#(\LK^D1[=SD$*!DA2Q.[  P0,X!]NH5N@%1\(:Y-_E3Z.U(GP
M\F9.6B6A*E*6KPY14FP#D5<F'O=H>U"6NEAO%TA#UTL:S01.BL*9< AQN0@,
M>2!D^Q)7!4]<QC<8N:L24N4$M4T:HK4OT^Z/H'L/V3DX.7+QV+2%SC^D$C-)
M6&((<5<4(=B]7H8=+1V]XP%C#,N00H7*X9]N[@#@#'#<#('68F02M0! "2H&
MK U(I?<U:&A:/7I67*@*8Y4) L3N=GYNS#6#=048=2O ,8 .0JG.>257.']/
M!]F&/8CJ52<B1J$W(U?XWMIOARYF514%D.0S*K4 :'KX[6\QQ!&X;.Y6VC!C
M(]0#98XY.XJ<MD9X8CH(HZM06S6#:E]-?I>+,J:@J)42?"7L27#,7/D0>4!5
MRE3RRJY667S P#,#NQZ2/FY (SD\>^!N)Z:I)2G-G27<!(+I ;04JW"-60E2
MB$I)0K0/E41Y$WW;Z@4> VV6]YB\I4F11(5#+ZBN\KNSG.[("KG@Y7'M@Y$P
MS$J5W=3_ $U*7&I'/@28[W9V9,F45Y@6+%55"X-:L3Z4@QV^RS2I)#M\UPLA
M;.PE#M*J$8A@H"_+(4@AFRC;.HTS5NXE*87\14*M8&@U^&^'8F>0QSD ^%TJ
M<\B'=J-NOP;Y:Z!@Q$XCD&_ ](VKM=2,%U4(S+YFU7W [B_!;>U^4Z@3^E#)
MRI4]&%6&@=Q2_#7*Q<HI1G27"FF'>"05$!MQWWN2YA08;6KQ)!"J$/M;D@,.
M5'!"OZ0X79CWR""HZL $.30/4 ,=>%-!O;E&3+QJ4K(7F*2X OI>[7I]:09K
M31A 8ZM51C_@V&W]+A-I&[];U*QV.2P.XD;T<=-H7<WI1QYN]G%J'6C!G3$J
MF$S$50 2Q_4&!)\(MN<4#,*1O5]N1H$E5=DB*1'[[PRLSECZ_2/LH6Y!3(<-
ME1TB4I0Y #/XG !=BQ)KNK"X<^-BIG>A/ZG/N6YGXP&T-":F$B<>=*[LJ;4?
M: 51DC+F-2VS?D%-B;V*QYQD*2X#!*15RD 6:H84X5&E83'H1+F([@+ENEBQ
M+%89S2FAJ:D&L!=5I\M,S!,.H8*,[E]F"E@#@@#:3@%AB,$\8 %:!0(W"_.U
M+MJSQ5F+\(!%Z*\-11R:U>G.K[HV(K2SPM')'RF%D] )=%!?> > &! ^?"$<
M#'5F5+4N60["ANVI]?C&7B4)SN 0EZ48N P?XW]-4]U-IJGJ$G@JJ.*IHIF>
M&6)PA66%L;DV8.Y#G&2!P WI7W):52IF<%@""6)#BHJS6+:^IC.Q6S\-C</,
MD3@E2)@5F2L!3$AE*"59AFRBXJ79VM&5WR[-/H2X&[VF&2?359((@1F0VNJ=
ME<4\KAA^B<$F&0G(7$6"VT-U. Q@Q1RK8$4%G;C5^+ORCY5[:=DU[#QDR;AD
MJF8*:ZTJ8_PQWC!VH'MPH"=(;?40,<*0"@?D$C;@+D')XS[KAC^& 1SJE!+$
M* &9C7< ?J(\_6"[;C8D,;V._3[0%L@0CW!99 QV_;VLH7AA[A?L'[_Y\!":
M&]RP'%]:CZO?2NK,@U#<""U#QLP:VK1:I^B#,A^)3WR"EO\ ZQWN,=I(.,=^
M?#3G.">03Z?;()(S[]!4DT!);0]-[/=XBG-E!!=R/1CIN!H(]'#I(KQ5&^F%
MJ&^&=V/#?9/CH[9;N<<?V!/$SSGY8.#_ #='1AZ+GD?E'FZQ%0J^4&X/I)^R
M23S@Y/L<YX^[CI'U8];N>D.RDER6TIN@32-I<;?<G@L,#:#R"5^?'&??\,].
M =@.N/#00X!J"%1[9=N+[W'U!2:>M$$DBLZM45)4[*6G#H)'9MN <'V)'.!\
M\BO/Q"9*0%&M<H9ZGH1?V?@9F.GIE)S!-U*9Z:LVOH]N(FI[4>'RP:,T_3VF
MWTRM5F-?KE<45YZBH*G<3* 6 'L.<<8SCV=L[''"3>^()F+4%6!2$@N+DD68
MM?C1^]&Q<-+PTN7D+*2?'<N[>*UPYWZ-I"NTG:^2EY,15$Q]K:-OWEB3PV/L
MC'\W..O4=C]HY,U21-R)4HAUDBIH26)-Z[O4O'(;7[. )6J0@E1\1 >Y(-P+
M5;A [;]$0ABNP, =IY!'N#SGD9]\#_X]>GX69@\0E(ES4GPI.4@%R:L"ZAY?
MM'"3\)B9!*9DE:2[.V^VNZM@>0@R4>A#(0R(H/OZ4&."PP<8/R]P&.,$GG U
M0$2TC('H#0:AZ:5I<TL+&*+*+YG %"]J#<[G7]H.5+H6)5!,>YFY/IR% &#R
M?8'CY#V^_GH*1,8K0;?TCW8Z^?E"(FI2^50 HX/G8,6ZOIO'1<4(4[ %!  9
M>!QR1R/^?_3U"G#ID$J2DN:'Q"U[>6@](D[W-1\WN:>5N)/-HTKAI*%X)$:-
M2"AX9?V^QW8'&?\ 1U%,E=ZE>9)R@YF#$DU;0!M*D$-YQ8E+5*5F20%4+\ ;
M;PX9M\(;3P5VD=42K3DI2^B5Q]I6!8$J%]O5[GV/.[V''CW:;!F1.5EEN%J)
M\09(H.#AO,N&M6/:.SV*.,V=+3=<LL U2X-:&NM&>'$T^M[#J.RI2^6$G@&Q
MS(H4C )X].X<>XW%?NZY.9*ERTA25YUEG<NW #<.(U:K1U,C"S0I*FHX<#CT
M_J(+>U WEQ!2H^R>,8]QSQP<_A^SJ'-4W'F7\M/+@T=%(D^).9VJ1R^HWVW"
M.OZC$C&50%(R1@$GY9S[@C_)S^/3:]=;NC%F;*%SZ"X-+[M6M6U(^2Q *QE1
MMF,!B#C)/I]\#GG&?\@^2%0'\P^+<^6L'=E"4@!W4DC+I>ATI8MI!7KJ6.HD
M;8NX8&YE&[''R(R.!D<X]OF.LG&%:E@#](:N\7N+>FM&-8MY"E#JN6I4M5.A
M85;S@ J+6D;>B(;F.2Q]*X;Y<XSQR<CV]P?;J67)2)9*B,Q!#=#IJ7BO.(4X
M.8%BQ#9A05 .O,:TWPUKQ =C;)W-M$Z/$M+?::.0VVYQ*ID23:WEPR28+/ Y
M5058E02#QZ=L*3W"RDN4+.93?J ;*&L+@D^E8X_M!L"7MB5_!ED8F6ETS7 *
MC6BRQ=SN<V'$0TZLTK=-(7NOT_>:>2EKK?*T4BN,+(N 5GB8@!XI5]2$ 9Y4
MX8'JZE0L+:&G&Y?A2/&L3AIV$G+D3T%$R66((]QO!T]ZP2 A0^IM@;TAL#'O
MC!)''_?Y]1A^(!H\5XTZFC60,R,I?=RV6.<G!]ACG\/\IXZ4I H]7U!&M[>;
MZ<8(#_J;_P#O(_\ *?\ JZ;!!O484['VG80P4*-JXX"B5&9<YVD< Y)]C@0@
MD?\ R]ZM?3IXL5%4J8LQ#..1<:VH3&W"""JXV'<"22"!^KC!^P1P=HR /45/
M#]*5I+N+#W^8B1!-$BCF^N[<2X_<:PY_L7H%;C61W^YC=3TI/DB0?;D 7:/V
M<G)S]D>Y+ #!VGCB )2%'P@O?+HP<AN;:W-C'K/8+L\)TV7M#%)4M$M0"$L'
M(8U(/#F=[P^B@-/#$J(JQX5< *QQA47:=H) ''LI](XYXZP#-9M7(H1KZ>5(
M]NE"4A@Q2E[(#:_S-PW#@\#U/5T\*;YY@@;*C<54 $C)R3EMWJ'(^S@8R#B:
M4E2VH0#\7=O(D\/A%M6(2A+A= P URBM33ZN'C;DU;8J"+:TX9U"@^6I)P#[
M<E0!A<>KU9^R <]6!)*595JH*M<VS7'K2*2]J2@_@*F-*W<U-]#2M:;[@+:T
M^O3M3VVVRS^HLDLN%4<9/IW,VX9R?1C(P0.!U'.5AP^?,6 L4L?)WTLS4ATK
M&SY\PB7+6A+ .X//4\*[XZV%YJZV$2+3HK[B%C];G*N<9VA>0"O"\$@@\=4I
M\R4I"D(0L+"? 6%*O9\I#;ZWK2.KV&C$JQ*<\PE/ZJM^D,;MSIONT*78K>E.
M_ED-M8A"VS!)8JH9L$,P.W)8\97V)ZJ2D34J)FE*@;Y>#W< U?3B^D>K$$R4
MI0+L^C\GKK[ZPH/U"*E@WN $>*5-Y8 KD, =JJV6 4-Z7]1Y8'<07YT2Y20A
M#$!U .7.]]7?K7/[M<V:$L<MS9G%-6@C"(TN^1T?:7+(R[&;R\NXCV\84LPW
M!LC?&'(*#'44I:YBDK4G*!0%Q5[%AO9ZZWW0[:"0B0$H++0"%F]$AD[PU"S5
M%'@T65H:T 13*C*4VJ3N\J3YJ#[D$Y).1AF7 (8-U?F(6^90.CJI6C.P/VCC
M/S$N:I(0 %@E*V>I"B=:!@UANJ#2#Q 90]/"S%5P0[YQE50,#GA,AE&,<[5<
MG (CZC=^%?M?[<FM&MAU 2YA!&8I4D:G]-*%]YJ?,P,K''("AY5VVQ'&&##
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M9XV!4^7(,'Y $G]GSQ@G(!&/;G=H(1B,Z6"DN "[#+0ZL;%VN6II&M@<1,D
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MMB?T!V?,+#3*>F;?HT>C'TL4XJF_3 BH^&EV0+ $#QR]M",@'D=A/$P1C/\
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M$4V85H+)T.6C?+BUZQT7/NHU8R&9I"NT*^YB1QCD?,DY^9'O[9/4R<5**:D
M\2D,3NW6W^<9REC5G'&U]*M737=9DWU+W ,@=+?*V&# J005R/;/MQ]^>"3G
MGIXF@W#O8@N?@7N/:(\^8L3\-19B^N[]T5KM55NV>,5#,LI._DMDDL3D@\??
MS^W'SZFEXA<KQ)4JP9B1\*.&WUC&GY5KJD%M-*4KO?GY07*;4MRHI1)354T)
M3U!HI67D9/J&XC\"0!SUHX?;>,D*="UJHS*)9F'$;F!!T,4IN$D3B53$()8V
M )J*4O<7TM"E6OO3J&&)8JFIDGAVX;S'8DC"$G)^USG/)S@DX]CO8?M/0">
M%!W(8FMFJRJ%HR)FR)()4G,*NQ30>;4WU/" VY:]I+O/YDLCPR'/#,V!\\@
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MI"A84E%,N4%+4J2QW#5Q3F#'73V]8*Y28\ ;5(8OC &<!1C9R23Z?F67)Z1
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M<):H4[Y@Q:K,3NYP89G\DR& <)LB<L",9PQB..'7TMDA@/4Q!!P6M(E)4!X
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M=76D2.7U/-\LP1%8@$0.O*X YSP">.2 ,Y./<8&'.)5+3F#J =5 DT46<AJ
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M;Z?!WOUIH3\%XFL ^@U9J%K"_O!-DTY4T\L=?1J6\IS(T1!)5"-Q  W>H*P
M YY^XG+<XF2P$/F.AWFNITM;ANC/ER%X7$IG2A_##@DFM=&!+M6K49H7CM_J
M2JI)8I%#-+'N\V,Y!7:"  "#N_$9SZ<;?FE12E25I HH%E<P:LWE0::O'4(6
MG$8=(425.EW>HW#=?3=!XU;>Q?:9%6 ><FUV>0 D-]MA@!,Y)&W.0!A1@9/5
MJ;.4N7E(W%P[U()=_2%$ALM62#0$<6WMKO\ I!7H8*V*#RF0R2/RC/@K'E.
M> 6.6.[+'UDGD<]5Y1R&8MOY4I3Q)=W^/M&FE* ,X2WA9N+%B[M^[7,=<%%,
MDSO(K"'+.P<OO<@\[<[@F,$#D%LG)4GBXDFB]69J6OP/G:*JS+<E7ZR[ .PX
M>U6UK'&_1Q34XI8>5D\J; &T+NY(.U@#Z=ONZ@'.1@8ZMRIF;*2+UH3\^7EZ
MQSVT9>>5.SIW-??S_?R:$Q-&\!E,VX!68#"A>< ,5(Y..6^9Y ]^I\R&\92
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MH&<9P>,8SQG.*>*1WDHB]M!ON2S^^ZMXVMEXU0:65!1=SFJ7 N+.*#=II4M
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M P<''!QR#[\<DC[.?EGI0FCGC3U'QTAJI14" PJP=[[CIUZ[9M@J&01+N+9
MP!C/W#YDG&/GC.>?;H S*2#K1]_%V/N.=B8)<LRR<P25:7/EOOSAQW:'LQ5W
MVH2MJ*1S2[LEF4 ,V5]MPP<8^6 /GSPMA.&7=O-[>S&AX@Z1J89"2<RTI)#'
M<SO?2K>_(Q(5HOMU)97IT2#;&P52IC &T,<@LJAFX^S@CC QP>K$J3E4"ICI
M3>XK8![Z1M)F(,M24 9C1.[,_P "+>YAY&CK13)3Q*T8CPN-P(R.>1@KC[7R
M&XX /RZUI2$I!(H0S'S;T(KRUC'Q,Y3$ T!(MK8OQ!=B1IO@'[C4$=+2R;%C
MD:5>"H#$#"X]ON^\#Y\#GIF+&66IB3X7KQ!)TU^=8BD3%9TJ?=1[L6]]8;;I
M.SQ5>K(HI548E!Y) 8^8=N/GZ@<D?,CVQCJMLZ4F9-.:Z2HOS3NW:C[19QTQ
M290*2Q().7@30=5AY513M8X:1('Q&Z1B5 656]*@\<#V!R>6(]_?'3MH( 2+
M^%3#_P"0?<-W*L&S5A9E&ZKN=26KIN)(U](5*TW2GLNE[E>)*@0P4]#/4.20
M,I##*[EN,A=HYQSQ^ S-LJ0I9<BA! WAR/@W-C:)=JXY,E*W4<H%21H$DEN8
M'SB@[\0ON\W=_P 3O<74D54:FAI+K/:*%R^]6AH)'5W7G /FM)&<<XC&<>PF
MVDIIYE@ B5_#WU30V:MGMK2L>!;9QOY_'S9^F8I3_P"();E2XT9H8OYO_$7K
M.?@/?ZQDQO02JKN&R,%E/J0,P.U<9R/2#Z?=>,9Y;J*66J?T*#D#X:"M''.M
M(O!0J].9;I@&]##@^QNK38-504KSM'3W K&>0H$J.A4X4XRV,G&?9> ,]9>.
MD2YLMRE2@"3X202[AJ4HP?A'I/X?;<_PK:J92E@(G)RI"K%3CR<[VW: Q+=I
M>XI545*RE2C1Y\UV&ULJ<*RMR<!B-^,<*/M!B.=5+990HY99-+@V+N]K[S<T
MJ\?5.%GRYTJ2OP.I+D))4/$ SO5V?3CN$&N6A@JH667:N\G#%L<JN. H]B#G
M+8'[<CJ+N JB5I>[J)MN< AXNA68.DAW--6X@^5>B3/R36)6O3Q[V1B2KL@(
M*[C@K@$L<CA??;@\<84Y9:DH4$S"63X5*9VU-"+%Z'E"B7+55@YOO<AV]:>=
MH$I=-75(B(AN=MK97T;C@AMH!)R,$D'CW(QCB-3$K")>4I+!E'>!YO6[?!X%
MX>JE)UT:C"F_TH:@4-R64>_6:1Z>>*5U=G4,RGC<,-DX9<Y56R&^9&3SU.N6
ML(2H!BE"B2*$N[,-=U2&.L4!*FYRR#E202X=/$TX5W\(&X+MJ";ZO^CE:F9A
M]H+AR,94X(R"<L2 2% QR3B) 4 Z5IWFIS4#M0-;F+N0(UY6&$U(6$42EB!H
M7<$ @;[U&G+C4_E:X$TIB^K1^8>58A@N0&YVC.[+851O(/MPV7RU!2RI02VB
M6 =]6?7>[F\3R\'5RATT!U)&E*BU7L[;H/>F-"1F%6EEQZ5DWE@GFAD(WMGU
M# ]O5M( (SGEHFDLD@ YJ&FCAO?7=$$_!9U$%*D@VIRX<O+?1EKLNF:6C'F/
M%'-(@&Q%3>S#(WDM(0-I<<$XSCTDC/5N7-2"D,Y#.6#%J.*V<O4>D558/^5(
M *3<BX%'H'OK\X-L]#1U<?DS4D!0J 2N/,3&U0OI_650OJ+!<\9R0&?*"4*6
M5*)(6:$EAFMP# \1S:(%818?PDL;AR+![U?2U_;I6QPLFVG58#$JC[:DX920
M,>HYRVX@;N3M^T#UI2P DE))!=GN["U>&\\(S,1*5DF-8)/ZCPJW#E#O?"!%
M]4U364<DR/YZQR DY)*S(&(!&0<-P,<@$Y. >O;/P[Q [K%R /\ [0(%/U R
MQOLP?2YCYJ_&3#%*L)/(R^)0!!;PI220:7\08<> ,3?Z0TN*FEIWP)%\E3L'
MM(& W!AQDAA]^T$_CGKKL3B"%$%T^)C8,U!I;WCYV6MCQ9W)X@<^A&IK7MY!
M44M3F'<DB.%W*51AY9.T$ YR6P21\\[< =/PN,8@'@]7-PWEN^L/1-*64E8!
M=+$%J@U- &):[G5]\0-^*7M?-H/5U76TM"%H;L7F+XW(DA)+@D JOJ&[C&<D
M#( W>?=M]D(3-3CI<K^'.-#+<J3,J2Z2  '+D!1(#7CZ?_"_M$,=@!@I\[^+
M)R!(4:K# )R>(DN. &G"&:">>&H:2J9/)7$8C.X%SY8QR@.1Z2?GA=I/)/7E
M2TJ3,*B5'*7RMZ#3A?W:/9$ *4E@YHY_I:M0:U .NI%([$NAEF5BV BL"HY!
M&6(P1AN!]XP!\P>G.DI<A04> KQO9^$/Q*DH0[$-:E#YO5AR<F$G[LZZI-,:
M=NMTJI=D5-22S,^0&;8APJ[\ ,3@8QR1Z<ENKDE&:854R 4S&CL-V_AO=Q'
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M42A(H*$L0WGJ_ 'GO+EYM,14O+3Y3=ECMWE2=S$@<\C>WH4AN2?PZ=-Q!8
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M@CKK]H+R35^[%Q<^O*P/D!\F3R6+&M'J&>@.O6^%DNFCO.H94DAC92"6W(W
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MK1@/)W=M+F +4W:^.L@58Z=<L"GI1>-Q.XDJO'VA@'YJ">< N6I*V(!#  N
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M-[D%2%)<@NY#BC4 (+ZAKGW#J[3[2PLOD90D;3@;5+,3D\ 9(4J3SP3P#EC
M):R"R-X<I5N#&C7]JD5BVG:2P/$M0:@4A5<O$N=:BT<K;H]*=O,<&.0 ,!@A
M4/IY)&<YQPN.!@@C& ^5*"?&0D5I4 6XM\?C5N)VK,6$!R2 4DNZB S$^(!R
M'\Q!JHZ6EAWJT>95#*9 -N2/N&[:&!!)RW)_5SSU'+2%K#DAS3WWC2EN%8S9
MN)4546]'5F)J+,+N7W<:$1W5D$,H>(CAGWACC!PS MM/V3D<;6^SC[R!/_$,
MPH"62%45E4S [W;=IZ6BJJ=+4QS*!  !! X<^=!IP$%UZ;R9Q(XP@964;#M.
MS@@DY*YV@YVL?Y\9O %)!4S:M>W$G7@;%M(H3UT++H0/YA[>G5H$/KTTB*D8
M/*\<.-V2S KR<D(HSO)VG&3DXZO2$KJ:,SZ@L6X\.?",[$3$!(S'Q:5'7!G]
M(->@Y9+?J>U5+DKY5= P.0V=DB,PXSAL>VY@<^XR.NS[-SNXQ<B<"P1.<:$.
ME%Z_I;=K>D<#VOEC%;(Q:$U="BQ9G;@7=BU[Z1:4\+EW6Y6"U2.V5>DIV0KM
M]1,<;;C[<[.,8(9L8Y!/7J^V$APM)<+ 55RV8>U]307I'PWMM 3-G(50H468
M"MAP>J2'&O&H?Q;4\Z-  1P-QX'W#(]\\^^/GGKSW$.%J!XY0H'GY"W[1#A0
M%(0$TL"Q#.P^[U#& 37]/#0V"LK*K*QQQ2-YK8*!"OMG!SSM_'Y\' ZO;&F+
M7/[L$'])RB[T?JC@5!:#'X9A*67<J\*JM1R :6<%_D(J*_%_\1W;K2.F[A87
MN='5ZIKIF2V6Z"6%JPS(^%D9$)*PH5RTA*J,'@D%3Z1M;\GA=@F3C6[V>$G#
MRB?$2Q.>K$,X.GZ:T%>B[*XK&8/&+G2E+"0@E9 4P=DA(4:.;M4M6C@Q3TU;
MJFOU)>*F[W&9Y9YG=MNYBL,*D[$A5L +&C$#TG()+@LQSY$ G#D!"*B6HK22
M6+OERFEPSDDU<Z".LQ6-G8N<)LY:B2]%%P/)OH+N]636IE\P,';:78CRHP&;
MYX() 8D 9+,0,_/('5!94K,HDAU40"+<=Y=P[B(@<Q%="7?=:OW@%G<1C.0%
M9T&-Q8E/O(! 5N1D>V"0=V.H5  9DV)'GSK70$>6Z$!#:%_3Y1:8^B(%3\27
MOAAE.?!!W'. /;/?GPV8(]1]+?:P/;YXR,PS2" ;G@.'/Z::PQ=AS^1CT8>H
M8BBJ!],1_>R^Q_\ +I[9?[ O$UT0]%_+YB/-L3E<#D\C'XYSS]X_;QTS>W"N
MM" :G0-6XXZ1+&_3R.'VR8W#! X^?SQ[<9 _[GI0^M]/J_'R+>9@A2=":VN^
MB+W17JT5;4U733H=J$JLL2D%HY-O!5^0?;WXP1D1S986!2H>HN+6B[@,=.P&
M(3/DJ((-0Y90U! -8G)\._B+L_<FU4<+UBTUZ@6*.JI&=5E,F,$J'D9FC+,"
M'V@D\%=PZK%+NAF4SN:YM*/K7@S-2/=.S/:?#XW#H"RD3 EEI*R%9B0P:A:M
MR>=7>1?3.JDAAI][$A=OJ;E7V%3N8C[_ 'QG)_#WZ870*@E09S1R-31GZ,=2
MIIRB0S*(+TIYU/,_:%PLVM?,:!G]<852,?94 @X_XW&??! SCY=5SB')2$D"
MV;=O]XD7@1E+3 JSL.5_A]H5&DU'3SQ*T.-\GL,\8Y&01P<;A\L_+JQ+Q*R,
M@#&H32X:_P"VL53@TA?B6&RYAH_O]>&L*[I:FI:RBBWMNE)(QNY"DC?D')]S
M[$G '5["3% LI1JS@E].+Z[KQD8L*3,+>$.=U*\'/6^#<NEJ=HY&0Y48.,CT
MLPSZ0!S_ )/^@]:@2@52U14U+^3.-S\.8B@9A47+DEA9N)_;A=H^I:DMY!DP
MW (QC;M.[.>!@\_(X!'L>G$ !\PY;AQI3U.KFT.#Y7-RQ X$&GPO Y14R3Q[
MHA'M3 / P3QZ> ><#Y_<3\AU&%)42 7(O$B0"U.FOQ'V%H,EK5Z1V(P1@%4Y
MVC QG^;)QP.H9R+KS, FV\AZ>?,<X5:BP',:6W:;^?'6#S;M11TRD*T:,1@L
MISMR &5LD<YY&/?.!GK.$XI*@5M6W+7JS0[N9BBS%S8-<7W^QL(TKQJX1QRJ
M)=[G R,9((W;<*W Y!^7M[^H 1&;XTJ6 :N7#\[N"=*><*F2MCF\(-R0S:$[
M[4WUX/"1WGN*E(C45'EJR4[' W$YY)V\X7W+$88^V.KLK%!LLM)36X&IN6XE
M_P#MW 6BGBL(I0S]\4H%"FA!%6U)L*V]X+<5DJ+R8JJXE@C,A ESSD 8((^R
M#GD\#)SQSUI8;"90%+753D@ZYGKP%1P :.=Q.)$O-+DUJQXU=SF N/7?2.&I
M:BU6*VR"&5($CIV+D8P OVCR,<@,1[DC( XR-(8,3!E*,R69A0-Y,332N[2*
M<O:'<@J6D+)?*%96?V!XO3YP1>.OQG6;0=)7:6TS715^HJ@2Q1K3R%V@)$B,
M\SQS!HT1R"P*@DG:IR6PW$+E8)("$@3&;1TU((J+VJ7T#D4C'VIMI02R5,LI
M_30A(<L+-8!@":4BN;JS5-UU5=JZ]7FKDJ[C<)C/--([,><$*NXMM1 0JJ,
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MQG/.2)DRLIRJ5F44O0.$U:N[31M=8JSNU6-46IFL3FOS(J:4%31KW@C7?O\
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M_//4#Y:U\N6E^JEH<*=:[X#7]*C8S9;.[#%<X/ RWL",^QX)P>F*H'!+F]*
M#0;K\/.$U/EUTVL6I_H@0Q\2?OA['_@.=Q\X'MGOUX:B 3@#)!]AQQD\GIJ@
M0 Y<OU4_;6&KMY_*/1SZ9$450/IB/[V7V/\ Y=/;+_8%XFNB'HOY?,1YLW1$
ML9T01]P< _(Y _F]_P#GZ3[=?6"-F.I(X?E<8!  (Q^ QG/1;W)-NN<$;J/N
M 93P?V9_G]_N_P"^>E@^]NG](VHIRF0#[@9^XGY\$$9_T_=QT00(T]PE@:-X
MY'AD4[EFB;8XY.,,H!_R$??TA -P\*%*2722"-06^$+;H_OYW.T:8_R+JVO,
M$9&V"KF>JA ]("A9#G'H&,'VX!&2>FE#,4*4@BQ269[ZE^J7?1D;6QN' "9I
M4E-@OQ-R)M<PZ'3/Q ^Z-G1(;C34UP"@J7AEF@DP<DD9D*#WQ@>X]R2.9$F:
M%!2E9LM@S7&6M2U]SF[WC8D]JL7+ S2Y9:PW<;$6<:Z0LMN^)17+$BW"QUR-
MMP3'(DJH<8W -,,Y(&,D>_RXZC2@9LZAK<5<U/K6]#36-)';)8+J0H%OY0"!
MHS4I9F$&:F^)30)&=UINCMG/*Q8!P/D*G.,_=\^0&YZNHFRGS&0@Y=]U4HYK
M4;FTUAZ^U[@MF=AHE].-3IQCIJOBB7*FB:.U:>K6(4[3(T$2D\^["=W'OQCV
M^0R2W5@8T2W5*E2T$@<]6W;ZU,9\[M1,FU:8"-R@$GF&UU](1C5WQ(^\M^26
M&U?5;3&ZE=SR2S2@8XQMDBR0#D<X#9X( ZE&V,2$LE,H-O'PJ.-.49<W;F*6
M722GS^G6Z&EZS[_=TM=&;\NZQN\\,H(--#524]/M8Y9=L6UB#P"&8CC[_>BO
M%3EWF+457!+^@'7"L9LS%3IKYEJKN.^XY?#SA&Y:J:1G9RSMNSN+;B3DY)/N
M<Y^>3S[]0G,2!1W>FK4>]#Q/**T:[.Q!!#*?V8P?VG_+SQTN4F^M7?4#JWT@
MC7R KECN)#>P!;./N]_E[?/'X9"Y6!:^AU%.K-N@,:>X.1NPK*#DG;SZO<\>
M^.#S\N>F  L+&K^7GJ+\H3,#K'5YFTC@<E<8]@ ,,??'OMXX/S'2!G9Z D_0
M[]/VA>NO.D<)I@(2 YW-P1G)SCY9]@3_ )#_ #]*5$WMIIUZQ&"5&MA44;AU
MRYP$2NLA"GDIG)^_V!.0!\Q\^F5I7AYTTY._R%0\!GXEXU][#@$8'MZ5_P"K
MI86/7G_N$/PBL@_VC':/(.0?K>M\YSGW_.W/O\O;HB'.O^I7K&'X$'PBB03X
M&.T9((8$U6M\A@<@@_G;P0?;'M\NB#.K^H^OG\8^_P!PA^$7S_P&.TG)R?[[
MUO[YSG_UM]\\_M)^\](P%@(,Z_ZE>L<O[A)\(W^(UVE]L?\ G>M_8'('_K;]
M_1E&X>D+WB_ZE>L?1\";X1P((\#7:7(]C];UOD?L/YV<?S= 2!80=XO^HQR_
MN%'PD.#_ &CG:;()8$U>MR<GYY.K,]##<(.\F?UJ]?..0^!7\)(>W@=[2C(V
MG%5K89'O@XU9ST,-PA>]F?UJKQCF/@7_  EA[>!_M./_ ,;UM_VLZ6#O9O\
M6KUCZ/@8?"6&<>"#M/RVX_WWK;[1QS_ZV<>P]OV^Y/2$ U(K!WLS^M7K'(?
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M _VF/S_\ZUK^WY:K^_Y>W3<ZW?,7M>!SO,=/]PI^$A_$<[2_\JUM^S_Y[/\
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MV=TK0J"3=+KVL\1D5F 'N?RTG<J2U$<'D5A!P<$X/1"Y4?U>XA!C],F\? +
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M*J#X9G8.CAD,2K^7Z+7NE90TV @>FU1W[L]5&<D!_,A7RSGS-F#@A&1O/7E
ME)\=#X]T+^7+\.#PMQ/Z?2^IJY3Z@K+C/B8&=P92#[$$'VZ(&1O/7E"?ZC^D
M/_&^THLSWGX<WA]"P,ZR&T6KN5J8YCSNV)ICOE>'D'I.&165AM*DATW$#(WG
MKRALVI_I<OQ*=$U!I-9^#CPVZ1J@<?5]3Z*[^6"8G. 4CNO<^D9U)X#(&4_(
MGHA0A)L3[?2"O^['?'I_%H\(G]%=Y?ZV^B%R#>?;Z1G[L=\>G\6CPB?T5WE_
MK;Z(,@X^WTC/W8[X]/XM'A$_HKO+_6WT09!Q]OI&?NQWQZ?Q:/")_17>7^MO
MH@R#C[?2,_=COCT_BT>$3^BN\O\ 6WT09!Q]OI&?NQWQZ?Q:/")_17>7^MOH
M@R#C[?2,_=COCT_BT>$3^BN\O];?1!D''V^D9^['?'I_%H\(G]%=Y?ZV^B#(
M./M](!9?IE_CZCEDC'AE\()"2.@)M'>G)"L0,X[N8^7RXZ(;D&\__B8J*=$2
MQG1!&=$$9T01G1!'?2TM36U-/1T5//5U=7/%34M+2PR5%34U,\BQ04]/!$KR
MS3S2LL<44:M))(RHBEB!T01+MVI^"EXR]7]O],]W.ZFG*/L)VZU9=J:W6"/7
MKY[D7V"6">JGKK?VVI95NUIIZ6&FD65=;U6D*MGDIY*.CK8)/,!$96!8/\/>
M_E3C%@?P(?!/\%MJTAK+47<C0%R[TZXLLUF_)==W(N]34Z?I5J8Y_K?U?15E
M:SZ;JX9Y8-OU;4M%J5H4)1*HG)<Z^OM#2LG@V[]WB3:I[::%[9"W:*[?Z.TQ
MH2R4%"(UL.C=.V?3%HAA'EHCBUV>CHZ&-<*_*P9(]LLV>B&UZ_>.Y:QZ,+!&
M?,+!EC!*C#[_ %,%5<G:PVL,A268_)@2".R\34'U6D@GD\F/ $TS1S.2\F'9
MC$JM(1DB-,JJX498$E>B" G\N:*MY5-E1+*-B":KHZABS(, (C((@/2#P"Q.
M#@GU=$$)[K6]Z6NU73SQM#')124ZAI*:9%<3QM'+&P:,*S;I8D]0(7& "..B
M ]=?*&W]S?"#X6N_U+<3W&[9:(O5RF$,=/?OR52T-_A9H4626CO5)'!=:;F5
MLFGJHB0I#C &"%!(L3UPM$9?=+Z/GHC6%HKK[V#[POHJ_2R5%10Z/UP_Y<TX
M8/TC4U'%=4\N_P!!N4()*NKJ+VR,2%I6 &"'!9U;KSZX1!%XG_ %XJ?")4S2
M]XNV%TIM)BJ%+1]Q]-;M2]O:YWD\J!?SCH(MEHGJI R4M!J.FLESJ2CF"BD1
M2_1#PH'Z0S3HAT9T01G1!&=$$9T01;*^AR_OF7?;^0KW*_V_^&7HAB[>?R,>
MD]T1%%8GZ6O^]34/\J+L_P#ZO=Q^B'(_4//X&/,EZ(FC.B",Z((SH@C.B"%0
M[0]E.[7?S65%V_[,]O=4]R-85P5X[-I>V2USTM,9!$;A=JP^7;;%:(I&5*F\
MWNLM]II"RFJK800>B$) #F+&'A@^CCZGNU#0ZJ\7_>*#1-),D$S]L>S/U'46
MK(A+RU+>]>WJBJ-*6FN@*LD]/I^QZTHI1ZJ>]#W!#"LZ!O>)G^U7PT/!%V$6
MA7MMX;M)7.\VY1(NMNYE W<G5LE6B%3<*6X:S_*U+9*V0#,ATM;;%3)SY%-"
M"1T#IH823<PK-8MPH^X]KM\,/U:!K9)!#"D7E0PK$DZA$@11'%'&J* B* 5'
ML#G!"0MMBL,%=6R/5S(4I#&[;\A X.1G>-OIW'.T8P0/QZ((*'<JBLSP2341
MA22@@V0O!B-I9G$CF.#:1E(U4>9N 0^8P4$XZ/WZ;HP0T.^5C7"E>JML,RS!
MVBE2< ^8T9S(5"1AN" L;.YW(R-N"Y'1!UU3RY<8;[5Z.I-37:.EU;;:6MII
M7D4T]910U%/4PR%D*R"0*?9AZ.%8@[U8A@"&A]::M[&Q\ZO?A"$=R/A>^%ON
ML:J;\S(=&W2I\S_PKHZ,:<J4GY#5,M-1[*"KG0X&;A1UZ-@;PP7HZZ\KQ(%$
M:OSB,7OI\$KNIIBFJKUV+US9^X5)&LLT.D=4RP:=U5+&AVK#07<)'IZXU+MA
M1^4%TW3)GFI8XW$*)E@1S/6O5'$0W]PNVO<#M/J6KT=W+T=J'0^IJ+U3V;4E
MLJ;;5-"6*QU=)YZ+%7V^<JQI;E02U-!5J-]-4S)ZNB) 0;&"1T0L9T01G1!&
M=$$9T004:EO[YJ.#_AY?UC_[QNB(RJIH;_U&!;HB2,Z((SH@C.B"'M^"GP ^
M(7QV:Z32O9_3;P:;H*V&FU;W)O<%3#H[2R.L<SPRU44;2W>^-321RTNG[6LU
M:XGIIZY[;;96N,1#2H)Y[HOD_#Z^#9X8/ S:;?J6DT]%W'[W?5R;CW9UE14M
M7?*"::-14TVDJ1U>AT?;SB2+R[0@N%53,*>\WF[>6L@3JOU%.N(B(J)^D%CX
MD]77V&]]L[/9KG-1T;5-SO$U*6 IQ4100TIEB108Q(R3R X.'!P5)R2L(:P/
M>#3N8T&D^Y4#UT595"73S1ML57BA2.L\R!E8JK,&W-GAMK'TL%X.M*0@?5_,
M-Y<>=MT*Q<ZJ"]W>XU+/EIPC2NLN]Y.25.WDQA55%49 C4>QP3T0L %1:Q1S
MTDJA958 3O*07 ).Y4]T7Y!B/5CA3T0;^NO>L'^$6VHIHEBCA9HF)9,(S+R?
M+W$Y)WD#:2/?U$DD=$$!=39(*S!>*,^^%\O<&!(RHR"O &!D$,1R0<=$$$.\
M]JXKP6>!(*99'#LWEX' 7E1&X"XDRZDKE7VX]QT01ITG9^*G=#+<S*J*,1Q(
MZ JJKN$K%_F 5++@NN,Y/N00J5KT=;XHE@D0[AL4L'E!X*^RAB,X#'VR1P3C
MW((.]5VQTIJ"QU]NO-J@N-%<:66FN%%71155%74\Z&&>FJZ.JAFI:JGJ(':.
M:&:*:&57821NK#I/+Y=5@BN7X^?@&=O=:4UW[B^$6MM_;?7/ER7"I[77(+1=
MM]2L@>26+3\L$+?F+<IP0M-!3Q/I%GCAIEMU@BDJ;FARZOU]X>%D7K\8J4]Q
MNVVO.T>L[[V\[F:4O.BM:Z:JA1WK3M^I&I*^CE>-9H) #NAJJ*LIY(JNW7&C
MEJ+?<J&:"NM]54T<\,[K$MZB"3T01G1!&=$$6ROH<O[YEWV_D*]RO]O_ (9>
MB&+MY_(QZ3W1$45B?I:_[U-0_P J+L__ *O=Q^B'(_4//X&/,EZ(FC.B",Z(
M(SVY^0Y/X <D_P W1!$Y_P /GX*O=/Q+TML[J]^ORYVE[+2B"NMMI2%*/N)K
MJC?;)'+14]P@FBTI8ZJ/<T5SNU)-=:^%=]OM$5%5T=[Z(C4O0>OTBX-X7_#3
MV2\/&E*'0G:7M[8M!Z6IIDJF%HI,UUQN$06(W+45YJGJ+Q?[G)'Z'N5YK:ZM
M9 (14&!%3HB-WZXP_>GTK;YZ/ZQ2TD2R!6=]N[#1Y."CX.]8W'!)&4?VYW!&
MX?=]-3N]N4$$#4XH;>D3/#%DO+$ZDJ"@5?8D+NR=W"C(*C@_,FOST^,$,Z[A
M5]LG[K:4HK?)$:FMMCQNR(.6D$Z)DKR'R< D#)!W!ACI8(6FTVV&UVT1^5'-
M55%/.SX&"Q:&4;3C?P67@E?ULG&2.DYVIKUO]@P>"$)6V37&.KDK]K/!-.SP
M2G$<DVYV(VE?T<4(0(D=1MDC).$(&>E@A%M161Z"MJ0HB=&F9I$R& =5 .WR
M51D?:O!Q)C&UE]NB"&]ZFJ76_**&E\Z6"%E!B,TBJ\DD9<$M"BA>/+1LXW[@
M"0I/1"5I\_L/I&W9FU,]5(&HY(XV_7#L44./46!7<V\\-N4'<!D_($'ET_1C
MAJ.KO5NMM:L51407#)6CE\S,?F2>B,M'&BMZ=X<9R"P#!,<]$!+#KYTAOG<?
MLGIGOA9_S"[QV2V:_P!/5AEEH)[W2?WY9KC,FR6NT_>*0TUWL%S%,I1:JUW"
MEDGC1HI#-3O+$2!R]#2W-CZ:6];-$$/C0^$YW1\/MNN7<OM+)<.ZG:2CAFN%
MUIX(A4Z[T100QM-55MYM]#30Q7VP4<:F6HOUIIH9[?3[YKO:*2BI9KK(1*E;
MT-]^\\M(B*Z(DC.B",Z((SH@@HU*M]8J.?\ VTOS/_O&Z(C*5.:^Y@6Z(DC.
MB",Z((EN^%Y\+7N#X\]=T=^U!27?3'8*Q7$+J#4\2?5*[6$]',@K--Z1GGC9
M"(^8KQ?5CG@MIW45*L]S\T4)#%*:@O\ "/1R\.?A=[,^&SM9I307:+2MHTMI
MRR6U*:DHK53&".-=ADE9Y"'FGJJBI:2JK:VLEGK:ZNEFJZZ>HJ)YIG;7GPW-
M\WUI3@'B*%AN5$5=46'U(.&=C)YG.Y&*2*%48.-PVHWMN&".A_6YW:7T9K5M
MH3!%>KXN.I5H^XF@K7'(R36?3C5DT<;F)#+7W&H9=NTY(9(%)VD#.<KP3T[H
M003O A:*Z[Z"UM>O/,?UZ^TU/&9-[@-!1>8 [%6+1_IT7:< +DAAP00?MPZ+
MPZZOJA87:9J:6FN"*T;RQ,AAF*MM+X<"08(R5;'!PI]0)(.OM2$>U1W0U73R
MPTOU>$PL1^G12LB@RDKO20L%0C!'.=PPP!8$$$+9I/5Z5E!$[&4SF(+)Y48=
M<X&28ERQ.X LP3C&<@@%B"%.ME[V(9*ABR*0^63;M)VL&&Y(W #>[@ >WOQT
M06Y</I S4:HM2I ?-_OBJ7(A1HRJ*HY/V@QY&,<C/&-V ""-1=26QF#;67W5
MI%VE06 'S)!).<C;G@8^X$$&*CO]F/EE*B.1U7?L\Q%YQCUR?:5B2, 9.?3C
MVZ((,$6JJ58RD;1N OV1.1@ A5YV%?L D#@>_P"'2-]M>._E!!'U?K"BI?JK
M.C1DR\D2 AHQA&3#,H955\DY!7@ ] #01%_XYO!IV)\;NBQ:-6TBZ=[B6:DE
M@T'W4MM'3-J#34[F6I6@K,S0_E_2E54EC<=.UU0D9,LU9:Y[5=O)N*+"@D5'
MII%)'Q!>'_N3X9^Y]][5=T+2MOOMH?SZ&XT;O4V'5%CFEFCM^I=,W)HH5N5E
MN/D2B*;RXJFDJH:NUW.EH;M05]!3$3 A5H1/HA8SH@BV5]#E_?,N^W\A7N5_
MM_\ #+T0Q=O/Y&/2>Z(BBL3]+7_>IJ'^5%V?_P!7NX_1#D?J'G\#'F2]$31G
M1!'=3T]15U$%)2035555314]-34\3SU%143NL4,$$,2M)---(RQQ11JSR.RH
MBEB 2"+A'P@O@?06:*Q>([Q=:;635<<=-?="]K;W#&]OTCADJ:"\ZFH9U,5Q
MUA'Y8J*.VSEZ'3;%7EAJ-0QPR64B%2R:!V^/3>_-K+5WLENM]*;?:(A2TT48
M^KQ1YC!V*'P%0CDXP 3ECZP!GI.NAYUYB&QKVYJ6SR('='2JBPTNT !RRE2I
MPN_(,@8-M/I&-V .B]OCI[7%OI6"%1L6K330RV02&::1<V^1?43&5PT3@N7;
M"D2#"L'P6SZ" /TQ^C00F^LJ*KJ$=&5A.LI.W);S=^=FT-D+CW&6VY7:QR5)
M"6O:"&B:KM0M7<_0\U6ICGEDHB^7PRH]PDC*X!9D9#L91P "W!!QTL$.V2VA
M_2\;!<8()"D?:(/J*G!!SR1G.<^W2?'<]+Z4T]CN<P0B'<=*;3L$\L--)+/.
MLC.\4DD3OO3 WE(RLH 'I3S"5(.65?25@B/&]ZQUG)<*V"2G$-*9I/*GEW2&
M<<A! 1RC*OI\R0>9$5(&%PQ(0OY>=_@S'YZ0!6Z6J-345M1^D$P_P"@L04=M
ML:Y3TD*2% .&&#E@P'1UU;G]X*ZBOE3AI]*>94J&[+#3)L79$V3)F-]ZS;A@
M%<#A X /!]RY!]B%@I:ICEJ((I%Y,DL95MA!_1^?*HR2WI.Q<95N<$L$Z(0O
MU[^T L%HK9X89EROU6NH9M@ 27;]<A)W9W;G6&1UX.#N(+'@@ZZZ]X/WX^_I
MRA<Q;[S!3JLD4[K,@],K^3N#HI&X9##A5<< EDRR^YZ(6*__ ,1/X8%NU/'?
M>^'AIT\M#K ?6+KK;M-8Z(I1:FVF:HN5]T=04L7E4>JF+>?7:=I M)J(K+/:
MX(-0L]-J AZ5-0VWQ7!='B=XY$:.2-F22-U*.CH2K(ZL RLK JRL 0000".B
M)8X]$$9T004:DCZQ4?\ TZ7]9O\ WC?AT1&2'/\ N5](%NB)(SH@B5_X3?PS
M-8?$3[VM27*.XV'L#VXJ*"X]VM9P"2F>M$SB6@T!IJM,;1'4VH(T>2JJ%)73
M]BCJKI,?KTUCH;H0U2FYGI^OD8]$?MIV6T#V/TEI31?;G2%MTMIG1M#06:UV
M.T4D5+0T-JHXE@BIX8X5&$5 K[V:6627=-*SN[.2(:Z_&'8V2XK]1:VEF @!
MDB4J<^5(,X?U*3&""!\\$<*1DMI<-OL+O=_C1Q6""W?[Y'1Q3E-[2Q1L(PC[
MMGI^\%7V9&1S]R\KT"K&]MU/(/4^PU#016"^)G67#4/?QXZX _4K#98/+Y/I
MEBEG!;TKC*3(3P"N1PWOTZ#?UZ=/[0\3PAZ1&GNQ&G9'C6![U57&\;@I\UE\
M\4L(!53O_1TJ$!L@AO8C;@@@V:TII15S.S(\$Y/E,2@/.-RB,^A-Q W %5)V
M[U++P00BE\M5/7FII&@]2Q (RG](6])*YV,=R'U @X93Z$##=T0G6[SZOR@9
MT[9[FBPK&'DA&W?N!+H 0N/T><^XP0 X!(/SZ(6%QBGKJ&C5XWFB2-0LB%V(
M=MOV2/,*DXQA1EMWVSG)Z(()&HM07>FB4T]MHWJG&%$R><55BQ)E3<=Y*>WE
M^V=Q8@]$'776@C[I2]*3"NH:"WQ1O((Y9X8FB$3-A22I(0H0P9E(!5068LJ]
M$$+"L^F%8""."420_P#L';RN0<'S%D/) +%5!R,GVW*I! 76W"V4\#^7#)')
MM.7AF9U4+ZLE&0G(!W#+<Y&%]R""$-U5-57.ZQ)#6UY@IH7&^=T(Q(Z@A$XV
M>8P4*609X(XSN((U:71HJH@U?<*ME# "&([(%4*SA?4K$^K! +>H-D^ZN""&
ML^,#P$]O?%YVDN.B;G%%:==VF*JN/;/7DD+/6:6U,Z1JBU;1!YZO2U\6)*+4
MELSY55 E+7TB+>;3:*FE(4$@OZC?UI%(7NIVOUOV6[AZM[6=Q[%5:;UMHF\5
M%DOUIJP"T-3"$EAJ::9?T59;;C1S4URM5QIV>EN5LJZ2OI9)*:IB=B)@7#PG
M_1"Q;*^AR_OF7?;^0KW*_P!O_AEZ(8NWG\C'I/=$116)^EK_ +U-0_RHNS_^
MKW<?HAR/U#S^!CS)>B)HSH@BYS\ KX-J4ULTOXX?$[I8_E&[4D-\[#:#O=*P
M:R6BHP]%W(O-OJ85*WZ\P%*C1T$IV6BQU*W\A[O<K<^GSK3JL1*4]!8>\6U+
M_;J(A*6@@6BACC2*.*'";-@15785''V#EANX.6]1'2#6NOIP\H9"$ZIHWH)(
M3&V\R.\;,I.5(&,,-K':V-OZQQRO0?D>GT^,$)S=;=']7@D%2%=0OFQ.S&3R
MY"%<HW(*AA^E0+@ ACR3T#K=U\F@@D3:J>P(9XRLE50U#R44F#*[0J2QC4C.
M]8P3A,.3]DC.T=+!"DVZ_P M_AM]YJ8P8:P;W$10LK^ESA#@M'@Y(R"NT'!)
M(Z0\;;J?,?/S@AL_B!J(:3N+I>X0S++"*2@E4(Q1HI8ZN575U.UXG&,LKJ&Y
MR05(Z7Y_O!$AEEM%'<;/#<8O5!5T-/40OG+;:B)9!@L&'V7]S@$ <=#Z:P0P
M?O\ AJ&[SK3HM710S>6TF7"I*F,QM$)/+;>%;;N4@D$?HW89.4'7RADE\GH9
M$FB"M#43AL@%MB$@%V\MF95)<[@<'[1YP>B" VW6]$AD<R@QQJNPY3](6*ED
M+$?<"I(QN.20V<]$$&R.BM*1P_7[A I=,K3)41D@NV2)"F]O<C**,+C#,6QM
M((Z;L;.U-3M!_P#8\\DS>5'-(K1!7B!<'<'_ ,(Q# Y! ^RK')! _IR73;5=
M$*J*JJXEEAGG@@IL^9%"S-%')^D0_I'V8&%RH(R1D]$)NZ;K[PNU_O\ 8[E0
M1_6;#=;?&8SY%=%0,K0A,(&<Q[T*NB[W$JCC."" P(6&Y:CKHJ2LDCI2C0S$
MJ2P*R&8!!QYHB:)I%*G:Q)# J"_.XO\ ."*]OQ3? 4M71W_Q3]H;%]6K:42W
M/O-I*VPDQ5E*B;ZKN3:J:)-L=52HIFUQ%& E73[M5.GUN'4-;<"'H4U#K%?'
MHB6,Z((*-2#]9J/;_#R_J_\ T1O^+T1&07-K_P!/_P#S MT1)"J=D.S>N?$)
MW<[?=E.VMN6Z:V[D:EM^F;%!*TD='3R5;EZR[72>**9Z2RV*VQ5E[OE<L,OU
M&T6^MK#&X@*DA"6!,>F?X+/#)H7P1=D] =B.V%/$UETU0"74.H)J:FIKGKS5
MUPBAFU+K.^F ,\MRO%PC ABEFF_)5GI[78:*06RST442?!M/J_HT0$N7AWET
MOU84E,8V9 ".A<+P"?<MO(8 @G&$!]V"\FC=4WM\*.(([*;5=Q<6]T+L8W,$
MS $O)3RHH8;0!DQ.-ZEHQD!O?GI8(,WUA6$\'D-+552*X-2&$4"L,;I'9BOW
MX5< *,>D>KI&M>G7/GI!%<KQ^VRKJ?$E>HJK;---!9D7R595=/J4$<2KPSEM
M@7<3D%B=K;1CI83?Y?3KIY'-#Z;GTQVUT-9ZB)A^3=/VY6B*MO1I:82R#8 %
MXED.4?D<YP-N2%@J:CB6>7;*%:E4;VRJC;GW$3%F4Y!8,,GV( 0 %R"$\2DI
M&J)*J&,+'AJ=' 96(*O^EV,2$..5( _6R,''1!'&GJ9:*KBEA9Q&-OFH3A7R
M"<GU'@?)CM; X!'(((46.]TM3$CO,@PF[RW=55@,%0A)R1G#*H4C!!.3CH@@
MJ5[45PF"D21.(PY#LF$!8HI=3E'C(QMD"@@8#9PW1!' V:FCBF:9FE$J8B"Q
MEV:4!2<DK]C!P&_5'H!);<""#U;+5 8HXVVX7[L!P65>?UOL^ILKSP&XR,D$
M==YM<'E(TSR^2@PZ!MNXG&T;$(,N<HBKZMQ*Y'N"00GU=11PS%UA,4):([F=
MR6"LD@7&TD9"'<!@ M[Y (((.%)21I(5_P ,DDD;11S\A&*;V\ODOZL*^25V
MJ0< #!((-$-N )*J%7.TRIR 5'F%_=F*@YR3A<A0 !P""(1_C:^ $=\.S%3X
MI^W=FA_LN]DK+-5:XI+?#_?.O.T-&'JKE-+!!3.]1?>W8>HU%132S0!M)MJ6
M@9ZZII=/4D1#D%BVA]NK>\4T^B)HME?0Y?WS+OM_(5[E?[?_  R]$,7;S^1C
MTGNB(HK$_2U_WJ:A_E1=G_\ 5[N/T0Y'ZAY_ QYDO1$T3U? -^&"GC]\3$W<
M#NC9?K7AE\/-99]0:]@KJ;S+9W'US4R-5Z,[4@2CRJNW5II)M0ZYC5*F--,6
M^*PUJ4<VLK36H=6?X0Q9HT>DA2:<CH*!*>CB@I:*(+#!3PQB)(%C7;&L4*J%
M2)0H0*FU57"8 ]F@&A?6M]_D-&LS1%".ZEDD-[EC=/*:,;0JMM5R4#;^6PPS
MA@0"!NP<8.%HSVOP(W^=(0\>N'&$"UJDKSS(&V^3&63;P?;[60QYWAN2$Y!Y
MP 0&OD>J_,>]BL-^C ^I%GJCY[+*8T9R6=HY)8RHVG'F$*I4^S9'J]6 L$!T
M>GI_*BK*Z%(4CD61<9))C7*X!]Q)M!R6R3C!(4[2",LE=<+;7-1I,TL ??3;
M0J1PPS%I&ADCRT8,;*_EC#$QOY9 VCH@AO\ XOA/;ZS25[@,E'4-;3%YD?V2
M(:J1L.A!22,>:"$DRGMCGH'1W\80]??A^_&';]FN^M)4=H-.K?()*:O2UU%&
M*ZG;?35)H&FIXO2TF^GF$00.C-(I W(_.P$+#<NZ&IZ*O@DA+HCS2FH+/A3#
MM#."YR"9)Y&4( <XW%^.>B#KK2D,MU!'*\XEA=5:H=8D# L=Y+*K84_+:""3
MP01@G:O1!!JTOIVA/%5_?CX9LSNSKEF4D+&QP@&,*,$\*>?F@ZZ800;JFST9
MP$I:==H ]$*J,#)X"X &"%!S^J,GW/2P0-VG35%61G?"CKN!(=1ZLNO R,CW
MVD8R6R 1[=$$*7:;?2VU=J001 *,!50889W-]G"[ODWS&![]$$'"IGH)+>I,
MT85D()3<V#ZAG*Y!R0.,^Y^7'1!U\^N7.&GZUGM]-<X8&<D.X&,$$Y(Y&<A5
M])Y;&"%(;)&2"->DK[)4(*.=89J:J!IYJ%XOK8G23:LD3PKO1DD5RA#YW*X0
MHP8@G0ZT@BHE\3KP9?VI_>\731]OF@[*]VORCJ7MV0C&#3E=!+"VJ- /+L"8
MTW5UM-463U2>9IBYVB!ZFLN%!=94(E0IPQN/AI$:O1#X*=2H^L3_ /TZ7Y+_
M ([?AT0W*.@GZ0*=$.BUK\ 'PD+IC1^HO&MJ^VS17?5ERN?;;L]]<@C$<>E[
M34PKK?5]N>1';S+QJ*C.CJ.LA:&>GCTUJFD_24]S<,1$LZ;J^>D6VZ*\/40T
M$\;QM)-'%A@,L-N<A6W<-E#CWX^1R.D?]F.^G)V/5V0>&E2JH3(')J$0*7,?
MZ+@X ;;['82"<9X!XY'2P1M698X**2;S4W1AI<9=63:QSM60*65<G RI(Y P
M>#KKKC! G<-3PM8J4()1.J@-4*/46##UR$@$>;_A%RH"#CT=(X%>9'Q+=>T$
M05^/JBJ[7WLTYK"J5FHKE;;4ZS.C[&EMLK)4QLS@*[+^@. V K#)'L%''H?M
M"===/PB1O2NI[3KC0NG]0V5XZB*YVRE<2POO\F18%AJ8G' 22&='1BNX8 P.
M1T0L)C?K%6FYS4TDL:T<@C!"J6<(XW,N=X51@\D@ML(W $@=$'77K!5OEKBH
MXML(3RHFVE4&T.HC3;Y9/H!RNX@D;CDDG!R00F<GG()P28V!/IP&VIG/Z0'[
M/)#8P",XW8 3H@@2T^'DJ%FK)7EB@;?@L B@#'I3]4<@GTCD,",%#T01OR5H
MDU#+,6\P+11XA8# C%1)Z,X W1Q^^" =P*@YX(->'[?>#K;V>K(EFC#0K$'0
M,6+^9O'&0&4>E5W XS_@]JX(Z((-?U^BCC4I)$-SARF 579MW$;?M9VA2I&U
M>"<8."" RY54=P<&)B,*K(0>'9G(P@;;&YRH7&TD'<I.\-M.C!UUT("[@B7*
M*&FV'T;FDDCW*=A!7;(0H!;:Q)7@JV& ]#+T01K6]YV\BU31/];A2(( !^GB
M!$,31 B3+ ;E:4@1(K DEB=Q!#@=,::+K%+4 ?HRK!FPS(#&'PK9QD*> O(!
M8K]O(0GKTW\Z00IT6GJ>2CEADIOK,,\30U GB1Z>HAE!CDC9)%V-'(I=)E>,
MHP;:V1@A-]V?S=_8'SH7I!'G,_%:\&S>"?QC:^[<V6WSTG;#5RP]RNT,SK_>
MXT3JB>J9K% X'_YG:@I;WI-$G/UN6AM%!<9UV7&!Y'#KKK?$R"XXBAZZUB:C
MZ'+^^9=]OY"O<K_;_P"&7HA%V\_D8])[HB**Q/TM?]ZFH?Y479__ %>[C]$.
M1^H>?P,>9W8+#>M57ZR:7TU:ZZ^:CU)=[;8-/V2V4\E7<KS>[S6P6ZTVJW4D
M0:6JK[C7U-/1T=-$K23U$T<2 LX'1$T>M9\-?P-:<\ /@S[1^':S);9=66JU
MIJGN[J.DA@1]4=W-6I3U^L[O45<.16T=KJ_JFD-/5$YDFATIIS3](\C"E#,1
M7)<O9]_6X0]RJ@K)(YT0F/RX_,>9-A!D3&&PO&W( (!R 3C(X"</7T]?3UI!
M"#ZD$=;<HY9'#M#"ZF14"_@4;(/"@D')]/*#'V0@=CO<]5HX]#[P0U_N#4M2
MU,LN&!#,K,"VWRU&UFRIP2VWY8=ED 7W)*]<.3?;F8(;19ZIY)F>5]VRNEIJ
M*(Y;TM-+(V&XVAE/&1N(XW8(#+!"GW"::LE:*-66.E012@^I9)I(58)N<%=T
M>\(2@])DR68KN!! 3)9FAC+)%Y>Y &)"EPP"^O&U"OI(RV,'+8.,9((:SXI*
M][KI6S)4 M66:KJ*5LJVZ6DGBAE@J KL&&?)D#+QL92"<]$(:BE?/RN-WVC1
M['73ZUVU>CGF5HJ2OK*8*79UQ-#!(RDDOR'+?9QM)VY R.B"WVI!%UY;V>K,
M=/7U48=U:%5D656"JN503>CU'!PH#,V06& %(6$-N4.IZ65Y9!35P@.^-9HU
MB8C. Z%'1N."2S-P2 ,YZ(2U=PKUZQKVK6>HJ&ZQQUMNDA253$ICD7RWC?#J
MT94KAE. 4;G@$');:0CE]XK8?6_!CY6@]2:UK_-15H0Q90</,-P7=[X+ ^PQ
MNX'.!NP!T0Z#/0ZMO$:32O2F!&!\D1.9,%?=\@IC<<\D 8 8MPW1!UUU]8"I
M->WQZYXITEIZ;>H\T56P@_;.4,<G'/F*!,A;@'/S((,]#J.KN"B&AN1J8@Q1
MIL3[8W.X%$S(AW>V3[X&W8<CH@@GZCT[57>[4=5/43^3N,4S(Q";2P4JN\R;
M&< 9:-R<[=R$#((/;KJX\H6/16AJ")(X%IJ>%U*LQVL)69U"C<>&EW-@,3@C
M*E"I&.B"$L\>7A%LOBT\*VO^TR4<4NNJ"@?6?:>NS#&U!W'TU;ZR>P4K54X*
M4])J&*IKM)7>:1PE-;;]5U63)302*0 L7W<[=#CI1H\_2LHZNWU=305]-/1U
MU%434E91U43P5-+54\C0U%-40R!9(9X)4>*6)U5XY%9& 8$=$6()E0?[XGX/
M^&E^[_';\>B$?@?;ZPH7;[0NH^Y^O=$]M='T;7'5G<'5NG-$Z9H5#'ZW?]57
MBCL=HIVV@E4EN%=3I(^,1H6=B%4D$*2P)W5CTMM)=GM%]@NPO:OL_I.">GTI
MVRTC8M&6B8Q!GJQ8;<*:JN]88U]5TO-<M3>;M4;$%3<ZZJJ'P[G<E_AQIUZ%
M]8K_ #O!]HM2206VSA#(XAJ(S"Q*LH0@#U#G;ZFRN"$'N27)!6"'%6FZM+10
MQSB$#R0 R?)GP"\C'T@8! 7ED*X#=)];TW] \=T$<ZMI)X12VUHUD/%0X+MY
ME,05>-02&QPN]PQ!0D D<]+!&Q1TDE?1%1&NQ9G7.2ZE(BL8= K+N&4]L\!<
M@XP>DZZO?JL$1\_$K[;SW/M5I_5])%*7TS=Q!4,I#!*.Y0E<G9R$6IBC 5O8
MR ,3GTK!#<_AY]S*BX_G#VOKIWF)II+S9C(Y)ADB,<=?%"#G:&@"S,5QCRB3
MC+=(=^[JU;^9W5@B2J\:98+YA6)SMWKA<-&C* P.P9')+EN!GW!)(Z6"$EN=
MI*N5DYW%^';+$99<%?2JCC.WVW?,<KT00C-^M$M.]5YB/&3,(U?&W*D!MP!S
ME@0"2%R,9 )Z((#K7!- V63$9VE9')7.&# QHN0JD;B P7(X(##/1!'*YN?R
MM;3 HC^M3+3R[DSN7>DB[F *D+N.#G"Y"YVC+$$+_!:*-*6<P(I*4RR[F9BL
MA 4N"=QP-A8[ %SP JJ#T00F5\M$4>?7(D8\R0+"<E!G<-OJ;C#9! ?!8LQ5
M=W1!!=IZ"KG@62ED*H@==P8J%<* =RY!W9P,8');U*<@$$*CIZW3+1P), SL
M"9, *'((PP,BJ64\  @;2067EP"$Y=>73PH%GTY'+417-H 94;RD/E\QH65A
M@L20I)(QZ3DKASMP"%A;+#%%+34OZ%&D1"&CVJQPIVA>?2),YPH]PV=V4R&Z
M\/KQ?TLP(@@YA5V8+>X#29^T8QC@ #'!VCV#;O<MQAT$5Y?I&7ABC[L>$&R=
M_;-;8ZG6'ANU?37"NK(8\UDW;'N%56S2^JZ()&HDF%OU.=$7]FF++06NVWRI
M38LTY8AZ"Q;?\JPR/Z'+^^9=]OY"O<K_ &_^&7HAR[>?R,>D]T1%%8GZ6O\
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MC+9(4$A1G[(ST0@>OL^ND.3>PP5+3.SLBKF5@A QC:0#)L& Q8<EL@88D $
MA8(5\H*VBCE2BB:I<*9&B4%&8[0&R=NT KA5++NY)*<J>B"$MFB#Q$RNPF?+
MO&2Q*EE''/I557( !/MM'I;DA.M-.O: .2W-@&+TA7&"C' ;CV &5R2/D#Z?
MM<@ A8W+;0LBS,S;I&1\.5]VY&<  X(4@[<!3QZ4 P01PH+1NU#;8@VY*N;'
M*,&64QXR0@!8#]*X&7=F R&;=T0E_<0M]RM%9;;>&HYUA2-,S18785)#*T1D
M_6"%]R_+'(/.2%@L"Y5*SH'EADB98C.S+EG&\!P200ADP!ZCP,%6"G(((66U
M&S2)3S3>1^@V5$3;%*HT(98^<;PT9) X QC# ME2"%3L^JJF6-:2WQ-.C^E6
M(Q%EF*NRD$^C9ZP000I/IQA>B"*_7TB[M%4:M\.?:#O@U)$+IVJ[DSZ5JYX0
MS,FE>YMJ;ZR9W52/+AU1I/34%-YK (UREVA3/@D.065S^.GSX_*E[4A_K$^"
M,>=+_P#5M^'1#R%Z$-UPBV_]&9T1'0VKQ4]V&IA-55ES[;]NZ"5@^8:6WTNH
MM2WJ-&3W%1+=-/M(@P2U-"V0%&3KG?\ ?RALRXY=:<-_E%DW5J-75-0FR)X9
MY&,J;<@1D.,L^["@$>Y53N&<D\=$,@Z=EKK/5UE3HVJF1134E0]*792\C*Q$
M9VMET "A7Y.%CS[\]$$*WI._+:*V6S312"HFJY@J;@/K-2[J?)A3WV;6613[
M;?22PSTE:^@Z;?K9JMO(7:TZ?_(L1OC2$5U5,LM9%$%1:=EY6"-FW-M# &3;
MPS$X](4E"0[,Y^^CCA7<> )!"\Q7&&XT$=1"5=612=Y)PVSE2H.-RL2O(?T_
MCQT/6HI]+D#72OI!"#:MI8I:NM#HK0UD,D$JX] C*>6ZC&1M9&]8 QZ2"RXP
M5!H_[!GUZ^<$5<-8Z)J]"^)6HLD",#;=<4Z4SHA"O3M<DEIYU8 ,%DC99![
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MK2,!YKN&RI;'2?3G;]S]X;J3O)ZL/A$D-76!GCF\P^DE2IR!AE)SR!DJRJY
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MJ4"@DC 9CR01O)8YC7C:"""Y+9G$:H%1IU0IY84&60YVF1X_1L5=VX,3N(X
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M*_E220*1Y1VH_$29L+M+/[/R_P BB9)V+/VT^*PV.G*7A<'@L;C\6H+PTQ"
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MFAF?M*@=VV=U84$7N"H'PL2IOT,2K* 8TT_BS^)J^ZR?AI.5WP)E%,K:A"P
MD@@B6WCSH[IR.]*DB5G) @\UOCY[9VG7UI[6UVK^U]#W&OHH:FS:)J-94*:C
MN"7*FFK+7#36MZCZP\MVHZ&LK+73!%J+I2TU54T$4\-/+(EE78;8B<0G!JV\
MI.*F!.21_P"F$U6=)4ADYG=:05(%UI!*016,V7^.7;B;LZ=M>7V#EKV9AS,$
M[')_Q(X:5W*TRYQ5-[O*$R)BT(G+<IDK4E,Q25$"'!^&GQ(Z)\5>G+W>NWVJ
MM):PL6F;I26>6YZ1O$=[ML==56^*Y+1U-9 SQ?6HZ:JIW>!6+PF5HYE2:.6-
M>-[0;*V;LM>%_P .VA_B$N>B:I<Q.0A"D%'A>62#X5@J!L;AX]B[ =J>T7::
M3M0]H^SQ[/8G SL.B1AU=^%SY4Y,[--4G$ + "Y)2@@95CQ D%)+C3I^MA#H
M,.'D^6Z-2J;R3SR,XW>PSP<XP3SH+"Q'"E*.V^V_VCT.-'ZJ8)C)41;%C8*6
M 9UQDLS9(YQP-V""6)'LV!P;$/I:CMS(].<$:TE3Y571219']\;, ^G(#OYA
M((X4;3@@ $DMP,%3Z^7UI?JD$!5_K3)Z%.3G.]N5RO#;N5SCV"J,MP/8,4 !
MUQW00G%ZL-'?*.2FJT9 6,JU"Y$L4@7TRQ,4(5@WIXX=2JOP>EZZZ^4$$:E:
MNHYI+978%11,L4LD:X$Z84P5Z?9)6>,*^ QV2"2/.8STG5-W$?2OO!!G@KCY
M1'FC>C!F"AB/96W;64Y&65B$ YQ[.GJ6"(X/ +6PU?TE#Q)Q1,S24'PL::EJ
M25VIYTW??L!<E\H[FW)]5KZ;)XQ+YB8].20[^3_Y?*+:'1#8K$?2V2%^%+1,
M?9?%#V@)_8-/=R">B')_4//X&'IZ4KK%K?04.D:RGDJ+=?=*4E=95G]314-Q
MI8Q/3IYC,Y^IU$I/JW,(9:<<X+](S>KTX[^MVZ&P2?#OK2X6Y=2]I-4RM^<>
M@;A]0H)ZEG,MRTY4?I;14Y(W.\-(R4[L ^]88Y?=B26J?OU>"'#7*O2,JJN&
MWIM7<21(R[L$^KT*<,G)" JI90=H &]=]#J?K!OA$*^[DUTE&X;E<C=G:A9\
M$J2[#TY(+;BNT+C@XZ0G@_U9]VZ"")40AZG:09%,C9)#*-WR]R0=S-N/MSCA
M=V[I:^IW\.M[7J((*.H:";RFD\A_3Z8PH+ !=S9!!R-F& !P"%7G &%@AL=X
M'U:_2TM:\B4=9LDB<9#15*JH1"FU0I!56W!B,97"ECM((.]CJ##<X;=<3YBS
MA$4,P$4;&(RQ2K(VW#"0!P_**6W,VX*200L4.H9*"F,5?,D9IP"CRG:!$%+&
M1,2 '>?2H;;L4L%8JK #7XP1SIH4N<BU4ZR%YA^C+!F$,+8,:E000\@VRLH4
MA1Y8VJV5"6Z;JL$,[U189M#]YZ*JH*6H?Z_=J"IHX(@NZ87%D5T#' 51*\L;
M.6;RE&YMH!PL$2!Z:TO!''NN,DC5<AW,$;R8XG899"R[9)&!)5CZ1M ]Q@L<
M.NC!!9\0%XI^SW8GO'W<M]M2Z5/;#M?KSN!26:6I%/3W>IT;I:Z:AAH):QJ>
MK:DBN+VY::2I6GJOJZS&04TQ0Q-9P0E?F91GRN^DI*IDR3G5+[U$M"EJE]XC
MQ(SA+9DN4NX%&C,VRK%#9F+&!Q/Y/&3$(DX?%F3+Q'Y6;/FHDHG_ )>;_#G=
MT9F?NELF9ERJ(!<1V:,\=%JU)I_M5J>[VVCT)#JINY%'W?HM4W&AM]3V6O\
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M5@BQ@^ES&,,P')*GC@?,AD*)H?22WO3MMEF6(Q34T,HQ(0':1=^78K&2S$D
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M!:+?=@^?:[9644NNM2#;B6GEI=-VVQ7&((:74\:.DG70C8.S]F,KM#M>3)F
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M2VNFCWB6"3J?5#2M/'#.R1.C1.BMPVX9<[0!C:!C<N#@9"\Y*CJGUZXP1U:
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MN_6W%"'#&#=5ZHI:NE4_6   "P+HK+ZAR0&;V5?=@<Y)]\$+FIZT'TY\+WA
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MW$BVBV5$PIM.Z=IY !OH=+Z<IK3IRW%MSB@M5,'=V!8K$Z0P:&R5*GZS4?\
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M$/WMINZ9_8D-OTI24>C>Z^I].U(,5)=XY*F@R!B4$BMB1 =H?;'))%Z<DL
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M8Z(;#^[!J:#4>C:FJL4,D]R2@GJ/JJ?X1I%5W\G*A61YR J'"^HIAN00=/\
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MY^T.&?2_RUZW00,WC2]U\MZ.V2&I9J-=\;L4V**<(#O(D4@;BP4GD8VX 4]
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M./581GNQ4RQ5-3Y\;/32Q^9N# KM4 $KP1G*X&6/S.#S@@ACU_UWIZ:O^I7
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.._#HB,LY\0O\ T_:/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g142578g06l57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g06l57.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[4XF4&AO=&]S:&]P(#,N,  X0DE-! 0
M     '$< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'
M' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'' (   *NHAP"4  )1VEL($AA:VEM
M' (% !=0;W=E<E!O:6YT(%!R97-E;G1A=&EO;@ X0DE-!"4      !!SHP'5
M=/<-:6"/-0F>)ZZJ.$))300]     ""H @   "!N:5<     7 !< #$ ,  N
M #$ .  W "X ,0 S #$ +@ R #4 7 !) $X 0P!( %  3P!0 %( 3@ P #<
M.0!% %@       $$  ;< )P?0_^ !P$ "0#J"F\(9  !  \ 6 ("  $ 6 (#
M    3 !E '0 = !E '(
M                                                 0         #
M     P   !T!  #_____                     $1)3E4B '@)M OH$Y/F
M168                                     3@                 !
M  H    "  (  @ "  (  @ "  (  @ "  (            -
M
M       !                                    #P
M
M
M
M
M
M
M
M
M         0              > D  %--5$H     $ !H"4@ 4  @ %4 ;@!I
M '8 90!R ', 80!L "  4 !R &D ;@!T &D ;@!G "  4 !# $P (  V "
M* !V #4 +@ X "X ,  I    26YP=71":6X 1D]235-/55)#10!215-$3$P
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M %1R=64 2%!#;VQO<DUO9&4 0T],3U)?34]$10!#;VQO<DUO9&4 ,C1B<'
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M90!44E5% %!A<&5R4VEZ941E9F%U;'1&;W),;V-A;&4 175R;W!E86X
M
M
M
M
M
M
M
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M4OWA<N(E?3W^/'<S7+LSS96LGLZ9(0R=B(B(B(B(B/Z!=][*=$T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                               !  $
M                   X0DE-!#H      2$    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585    !\ 7 !< #$ ,  N #$ .  W "X ,0 S #$ +@ R #4 7 !) $X
M0P!( %  3P!0 %( 3@ P #< .0!% %@       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q 8&            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=$!=0            %1O
M<"!5;G1&(U)L=$!P@  &         %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M  ,Q    #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG   ".P    MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X  #_0  ! :JJK/X   #A"24T#
M\@      "@  ________   X0DE-! T       0   !X.$))3009       $
M    'CA"24T#\P      "0           0 X0DE-! H       $  #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              ($   "70         !
M                  $              ET   ($
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   ($     %)G:'1L;VYG   "
M70    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "!     !29VAT;&]N9P   ET    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     \X0DE-! P     (G$
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MV@ , P$  A$#$0 _ .ZZ-T7HUG1\&RS QGO?C4N<YU-9))8V2X[%<_8/0_\
MRNQ?^V:__()^A?\ (G3_ /PK3_Y[8KR2FA^P>A_^5V+_ -L5_P#D$OV%T+_R
MNQ?^V*__ ""OI)*<[]C?5Z2/L.'+8W#T:I$\3[4CT7H D' Q 0)(--8T\?HK
ME<K_ !>9UO4.J9M65CL.?8;*]U;R=<C$SFUWQ8WV5_8=OZ/Z?JHW4/J3UOJ6
M7EY^5U"C[1G8K\*VIE+O2;4ZMFWT7/L=<W9G5_:O3_EV)W#'][\%/2#HWU>)
M:!@X9+Q+1Z-6H\6^WW)ATCZN'C"PS)VC]%5S^[]%<O1_B\RV9F)D')QF-J?Z
MMC:Z2/0(R?VEZ71YL_4ZM/L_N]3V79/^D]-5&?XK+G=.JP[K\8'']9S'5UN_
M2/M9CUU_:-SMWI_JSVV>C^E_2_H;*[$>&/[WX*>U_8?0=P;^S\3<9('HUR8Y
M_,3?L;ZOQ/V##B"9]&K@<_FK'S_JGGV]=OZQBY&.VRZD-J=D5.MMQ[&4VXM+
M<+(]1GHXSGW_ &F[]'O]99K?\76?7@# KZDWT\>O(JQ'&HCVY1Q3D49%+;/3
M?CV>AE_]<R?M'\[4@ /WE/5.Z/\ 5YH)=@X;0TPXFJH08F#[4AT7ZON):W Q
M"1R!362)_LKE,O\ Q<YEV%=BB_$>793,AMSZ7>K<UIRWN/4KVV;LC)<[._G/
M^!5_I/U(LZ=UJ_JWK5&S)&0"UC"UM8N]'T?1:TM<[T_2>RQEMOT/2]#T;/5]
M15&OF_!3MGI'U<$$X6& 9 /I5<@[7?F_FN3GHOU? +C@8@#?I$TUP/ZWM7-=
M/_Q=-HQL3'RG8EU>)G-RQ6,<%HJ%1Q[L??<ZVZS[58W'OL]>RS^9_P )Z;$(
M?XONK#'N8_/QLFS(O^VV,R,??2<E[<FC)L-#GN99[<MEM#[6V?IL2CU:DJC^
M]^"GJST3H F<#$&W5WZ&O2-=?;_*2'0^@%Q:.GXA<V-P%-<B>)]BYB[_ !>9
M-E#J_M[?5;3973:VK8)LQ>G],=ZE+#Z?V>VGI^3793^YDU^G^EI6ET3ZIY/2
M^O9'4G9%-E-@O:W;0UN19]HM^UN=FYA+K;78\>A5M_1^DRK]'3_A%0K=3K?L
M'H?_ )78O_;-?_D$OV#T/_RNQ?\ MFO_ ,@KQX3IJFA^P>A_^5V+_P!LU_\
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MU0ZIG.ROV5DW-?C&MQI]638W;_@J7_1?7M_,O=^C_P &I#EB(GW!<:UTXO\
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MTL]3?3D_]K?YKT<=7&HRROK%UEC7V4X%A-+7M=5Z5K@ZX6,;6QKQ6W<WTO\
M"5_HOTW_  /IH/5NK]7=C9%%^+LQLJC):7[+/8T-RVU2XUMKW;::K;GOL_PM
M?I5?X9:72\CKW[4?BYU/ZFUEA&1MV[GBP"G9%MOLMI=;^C=_->FS_C+K?7_^
M0NH_^%;_ /SV])3_ /_3Z'[+@9.!7AWY[<9N;@88O;907-::F.LK)S'[<:KU
M*FV_H;/T_P"C]:JQ6;/J[T:PV;>I5LOO]2NRUIK#WN8YV5DM>[=OL>SV>O\
M\36]ZN=,Z#T_*Z9BY-S2Z^_#QJ_4AI+&UL!BG>QVS?O=ZBC9]3<*RYQ==9Z#
MV.997#)(FMV/6+/3_F\;T=[?^U-S_P"EY.17^C24KI'2.FU=5&;@YC'M95:R
MO%K:QH;5;:ZT;?3VN^S,>W;C^WTO]$K'5\[/;792W L+'/#&VBVENX#W;F-=
M9O\ =M1L/H&'A]3LZE4^PVV-L;Z;BTL:+GMR+=C0QK_YRMGYZ77 315Y//\
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M>E=1R:* V_[+<?4+G.,BFVK=[W.]VRRS=^_ZGJ?SBWE0Z_\ \A=1_P#"M_\
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MJ'7_ /D+J/\ X5O_ //;U?5#K_\ R%U'_P *W_\ GMZ*U__6]'Z%_P B=/\
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M_?\ RD3I'3.J8>9?;EY1R*'UULJ8ZRQY#F#:YVVSV5^W;_I;;W_IK;58Z_\
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MYB23V-^G?VWT7_N?C?\ ;U?_ )-+]M]%_P"Y^-_V]7_Y-?,222GZ=_;?1?\
MN?C?]O5_^35+K?6.DV=%ZA77FX[WOQKFM:VUA))K?#6@.7S>DDI__]D .$))
M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M     0 X0DE-!"(      49-30 J    "  ( 1(  P    $  0   1H !0
M  $   !N 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(
M @   !0   "< 3L  @    H   "PAVD !     $   "\    Z  3_3   "<0
M !/],   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C S
M.C S(#$T.C(Q.C,T $=I;"!(86MI;0     #H $  P    '__P  H ( !
M  $   )=H , !     $   ($          8! P #     0 &   !&@ %
M 0   38!&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $
M     0              2     $   !(     3A"24T#_0      "
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M     0   @0         !@$#  ,    !  8   $:  4    !   !-@$;  4
M   !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
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M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %Z ;L# 1$  A$! Q$!_\0 'P
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M=<FZGZ?H(0?</?"]_%2M+^DE^_O3J"6YFX %M_9^6L(#X'OA> 9^U1M/./\
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MG4Q.D5TA!C_9I"#2$&/]FD(,:0CK6MML#F]5!(PG/4_0.GIU.NN9-1*2%++
MJ"18GQ*T#!]8D G2.0Y#VP?S?^&N84"6W8'YQ$5&/3'3^[1Q>^FL(.@Z] /V
M_P"W0J #O_,(IE('-TP?7XYT>S_Q]X17*<]2 ?GZ=]05&WPA]'/OZ/\ K"#(
M YL]/4Z%0 )) ;7D'TO"*!2<$Y&.Y]/S_P#CKDXYP@YT]3D'EP3\1ZC^/37'
M.GQ7^#XNEG^NW/:#&W72 J2.Y[]?[_[M,P^@(ZOI".61WU+@A]H10X[G^!H"
M#I[]N(093CH1CYOG^C0D#7Y;PCB5H&22/B>F?V:$@!S8 .7V U^4/?SBH4E7
M8@_1].#^O.F89LKW9VZ7_:$',DDC/49&/7T)QZGT[: N_0M"*Y!^?'^_^[1]
M>FOWA'#G;P59&!DG^/7T_5\VN(F)*"L%TAW:^FMAR@WU_6*A:%8.1U[9^?4I
M4E0"DD$*T//R@Q'I%0I*NH(/<9^COU^K4@@AQ?4?(M" %)[$$=?H^?4N#H7A
M%20,9_-KB21U?R?R8:M;]X0>Z/@/J].W_AJ0[W;HWU_2$'3TQ_NT<.SWA%,I
M/7(]>OSCY]0%).XU;U=OO" %))Q\Q/3I_OU(4"2!MK]/WA!E&3VR._3MU^CX
MZ@+25%.XV_:$&4]1E.1W!Q^S4A0)(!<C6$"BE/4C.?@,YU!4VQ\Q^L( H'MT
M ^./XZ:XI7F!YC<V&OH?]<X0*(2,GYA_L[_QGY]2I64.IFT<']_H(0<P^/\
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M)C<RDUJDR@5,S8DD !Q&4J2M/N+;<0ZTXE*T+2+3J43*:?\ E5!:9RE%P6S
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M0EC#2W'"A+)0^M8;(.J51X1BDZ74K,A(ETB5KFL%NDR_B)47 RL<R2 =&5<
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MT9IA,UMNH1(\QA$EMWRI#7.DIYE9\M'C>)44NHDRU$2IZ1G[PIF@D"Q#ETJ
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M2UKY&T$N//NK4IR1*D+=DON**W75DY%MSJB?63E5%4I<R>229BR"5."+>(D
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M>CC^??SA%/N<7$/W^Z6\4&?3_)Z#]/7[]@]>O88]-0P?-ZV+#T]/2)))#/\
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MEJJX\;Q">*:MS%(<>4%HIT>%Y9("5<SKODC)/N@G\V,XL+$_Q)4:IOY9,O\
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MB@_^E'H/YN[WH,]QGZM>IC;3[_J_SCS9LYO\0Z!/V_6.S[G)Q#GJ/$NXG_\
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M<N6EGG+:EN8PGF3DCMU[5ZFQJOI<DQ%3E1_[PW/7;47'SYR9,NIESIBD.99
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M"#2$<2,D>O?T'U?[.^H(?YO\HA^?5O+G^\,2XAWB_?\ 3XSJ6G$PZ,F5!YT
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MN!U(V-VB[*_@=$A2LB@E:$YB+FXS*+OHX!2.FUKSS0)+<R+'ELKYV)3*'V%
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M+D!>8@.-0 P:PT=]6LN0[AVRJM.H=PXF4JNA]]FJ--GD9D..*=D0Y><#!4Z
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MC3;&;/Q']O\ Q'Q+Q'B/8_V58BO#*##%*H^.>,**8N36_GD*6*CA[ ZN4O\
M[9,A 2G$J^6._5/*J.F7+3+G+G6-^'+\/N%4V$T/:5VA48JZFMRU7"_#U2A$
MRF32%*%2<7Q*1,01-G3E%2Z.GF%4J7)"*B8E<R9+3+F<XD=N*O/VYATJS*29
M2XDV(EZGP0TA:VVG&AYA2GD3RL(3E*"<(2,  #I@#A'"*#A<)E2Y:BL**ITZ
M8KO)\^:MRN:N:H9YA4HE14HDE1)+DF/H;V:\28=AV-F?7*EB0E&64W]N7* &
M7(A(9*;-:VC ,(:U97!Y3;U8?1O50($BU'VG$JI4K#E1?>6E24J96A!>C.LE
M04P[&<2ZE8Z+(!"LC4O%V,X#7RL6X?Q"?AE1)4"E5/,*1- 4'ESY;E,Z4K14
MN8DH(U#LU?[:L7X([0N'YW#&)X'AW$5--'A574DJ<:11_P#.HZE0[VEG@"RZ
M>8F9H"6B)KC4X +QX7)_^-S:>16JKM2W44RH\]3Z7+EL22N050FZHY$;94]3
MAEMN-5 VA22 U.2%K#CFYG97VRX;VB4RN&>*J6DIL=J)"Y!D+E@X;CD@RB)J
M9<N:5B74*1F5,I5$I6'5(-BA/Q_[7>P?&NRZJ1QUP#68@O!<.J45BURIRAB_
M#-0F<%29Z9TD(7-H):BA**M^^D%DU.8'OE2:>')QT,;WT.F[073&H='W6MRF
M);9G*/L<:\*1#:6DU&GQ2M2/EF*TVE=8A,EI#H5[=%9#7GMQ]?\ MP[(*C@>
M<K'^'T+G<*U<XYY1/>3<&J)JDM(FJ(!-&M2BFEFDJ4D 2IJLX0I>Q_87V[CM
M.HQ@?$]0!QIA\A!*O@EXY32P0:R2,Q_[N6$YJV4&#J[Z2D(4I$MZ>]W$WL9L
M#3G:GNSN53X4EEE;PM^FS&WI<WRP266:<RIQ]Q1QRE*L=2/76MD[%Y-"@3IR
M@L@@! \3[Z$@ D@&[?OME@W#>-8U,ER\/H#+"BW?S4*2PT<.DJ4+N[1KW<5W
MBYWSN:S5K,X?:,YMW9LD28ANEY#GV35.*LH3YT%:7\T\.CG',4A?*<$$ZL_'
M^(YV,RQ2I/=RO\DH9,Q0>X*P2;\AMIUV,X0['!2RI=9CJ_S:B K(I65"0>4L
M#*PV)<[VA??#%WPXK>+G<NV=HKBN])V@VQA1+AO6H-,N,5NNQ8CZ!!I<^HA:
MC*]J6%-O!U(YDD^\!C.#.+\%E2I (GU"YDR;F[E2T]W*DI?.26"U$Y@);DV!
M?G%I=M7#7"W!^!3\;I$RT8C4I_*R*8K[U:YLU"DI(2?@"=5E+. +%K237;O_
M $'<CQ)[<VGHE5A3K7V*VUK,Z5'BNE8:O9Y,<NQ,\Y0\Y3Z<VLJ"4Y2HJ'-S
M C5AUF'J_ITFH"5I2:I<FG!3E"D29*US5:%_[F5(N1X5M?3$^!\(5^%]EM9B
M59+_ "M5CLY*I84@!9E3YF662X=(*2%-=@87GB4W:A6/LI<'$?M-6+2FTYBF
MU-BH4^X)*(L>?."UM*1"=0Z@IJ:)4=8,-:LO)]WL<&C4&&+JJ]"Y"52\S9N8
M45!R "Y9RH)=SU$4#@/!J_$.*,,X6QR3.E]UDFRZE 6@"0"E25+64D!&6SV
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M&E5%/(H\B4RI#&6D>(( !#@ON%$EW*R23N8J.,2>'I^'R,+JY,M=-+4@24!
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MH;>K:_I!K="_\Q%=Q779$K^[M#MU3[+T&V:8^Z6RX1Y52DI2E3:EY'*X6#D
M_P"NH#OT^>WXDN,)F*\54_#J5*5(HQWJP"2@+E@EB +$N27]>4;0]CN$FEP>
M?7]V1-J"H(4$^++8"SFS;L.9T8M<29CGRTY%2Y28D1Q[RYZTI2"VH96AC'*2
M0>G?)4/0]-:P+34$U=73J3GJ4III:$EUDD@ I0/$7;0#77KFWOI(E($]E*8
MI9RX-U&W2S6VZQKO<6<>?N=QN1+/CH=JDA=3V^LV/%*O,<=4ZW"DSF/>Z\SL
MVI3W%)5V6ZL'IK]%7X0<&7V>?A$P*HGI[BMFX3Q+Q)4K*2A:JNKG57Y9:P7(
M4),BDE V\,M-A'R;[>#(XU_%90X',.;#D8QP;P\M*F4F50H-)/KQH 4I-563
M"GJI,;"_"[PUUNAWM"N*]XS3/D0Y$B'1W&TK<+R$X4\^KG/(6PK" E)&.N>O
M30GMEXAJ$88B1*69:YJ<J&)!'C^(@-[]#'UF[7^U2AJ<!G8?P_-=)*)7>H#
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M46]V/1[-O](@ZC0;V&[I'\;6.D*[8.S6T>UO"%X,57L*T*+8=1W)XA=N+@W
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MZQ4!.[TLL.& RDDV(^HZ#T+N8RFT=T*G:<?Y-JZ9,R P5>S265K1*C(6GE6
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M>PU<J6CQE*D+2?#N@ZD;MJ3L-(V.[',3PB9AT[A\RI4NIE%4Q1F96F)47;Q
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MTF*SR+ 5'OW_ +B+V<.UWL-N7S;TOJ8QNXO%AWIC[0V4S0^&:*UQ:.\6MO\
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MH,@W/1VJ-5IKTVU9Q8$B9';Q)2A85I_OKY>_K$;N]@^Q%O7Z^0TO#))W#GQ
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M'WIZ02CE.>;WN0E7*!CWB?UZ]@IAX="4VW\QY:W'D.L6/B&%4<F8/ @"ZK)
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MX'\?#2.#V;J_\1UN("P?H(^GO]&/V]=00_J&]^_T;L2H%AI[YQC\IL 'O@Y
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M0YM2I].J"KA7&D(IZ7'VZK%*/*E-A)()0/P'$_@D8"<]M6UA"I4J1/%0L+"
MHIG)4YSZ@A0L4EQ=B=";QJ[5)3,G2TTXF2^\8*ES 00YO\AKMJ=H3"Z*M<%/
MM6HUBT!$15JX^I)C55X"2\E66XGLW^DXHH5E* >H)SVP*%B%3B$NDJOZ?4I
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M1)+*@XRP\ZH*2%"2Q'J?T^D/OE&O-U:M^D1D6W<NQVY7#[P%\%NQVS]PT7Q
M]F^)3:VK;DT!JR*E;UY;75';.Z43^(;<"[-Q7X\>*]1;KH;%2955DUFH?94F
MILQPP2_EM_/N_IZ0'UL]GZZ.W/EZ[VC_ !K\)5'V1\4GA[O[:>J5WB0XA>+7
M?^WMHH,;;F;<-;W;NR;>'R18$NS+DBQWF(KFW%Q.,3ZJ7ZC2GJ.AE4M")!<*
M3&OO2[^^<0"+-T\].GITUY1(YPD[73;7XL^+"C[ET6+7=R=N/#QX-+/JUV5*
M#\KSQ==$VVO&FW2]2*]/8=EK>EUJG*E2'F7_ &A]WRI#_P!\4"I$@W%]57V:
M[GY#3D1\HG;"W9@;:[,<+5E2FK/X=:G?W"&]!>X@KBV J^]NYN[<1J^+OB)V
M2VNI+M/J-!H]9I$B4RJJP:Q34.59BXFR'D-QP @]W-K];N^FC^5W^1.P;X(2
MO*\-+AUI3CTM=0H$"[Z)5X]2IJJ)58%3A7O</GPJK0EMM*H50:0MM<BD%M @
M%T1TCD0G2 U//]'._7EM$L2C@$C^.NN*R0+<_P!XF,=NY81:]?<)'WNBU%SJ
M.ONQ'E$]/_1Q\.O75!XHS'AW&#+.68G#JA2%6=*^Z5E(Z@W^D5#";XIAPV-9
M3@^LY'OV(@1A+BIH5>KKC,V+*G29[R'VW2VPZY'EN-L-*2.I0L#"NG*4C/0@
MZ^-V("KIL3Q>9439BJFIQ94Q,X_%DSA.4[,[&U_,1OO(EJG?TZEIPD(13(40
M+,,CZFSN79M7UM"<<3UJU]5J[<UCV=Z31F*:"IN.5EN'.EMEY;[B0<<JN9:4
MJ[I4KOC7UA[)"*7@'AY2SF3-IT*FDW=;DWN6T8:Z&]GB]>R;%,,D8QC=-.7+
ME5V<R^\4SE&9(8'9VO\ 6$>@4>O4C9^O3Y:94>GUBO4Y,)HE: ORFE>8KER,
M>8I)][W>8]^^L@U4R7,"UI1E2I26+6L[V?6[ZL+'G%X5L_",0XWD4RS)4J12
MS.]7FU+(RW%@S,0+EC:SB*"0\_M]Q_TN?*YFE3;NH\[)&2&KKH#!:)!'7F34
M$DYZY.>^MSZ!2<<_#35(2'[CA;$Y#7?/A=1/!-KN].3](^+W%TA'#OXYYZ98
M"959Q_0SD ?#W6-4TA8_^DIJ?0<]XE*VZIRZ+M+A65JN>NGF)R>8563C.?B!
MC_=U^5U8ZIZR;^(OM:XTZ>?./T!X(1+PJ5*=FE(R[@,D!AK9O0/SC+[< +K/
M,/P48'0#'0'T^/YNGS=_(4I8Y0+:Z^N^O^H[)[@,=+?0\_I:'#VEU?2/3RP>
M_P QP?XZ?3KU4SY3<D?8^QM?1V$4:M 6G(&!W/,6]VOOL\.5M(H(0AQ93]]1
MR8[D!22KMCK\!V.O45$D$$6.Q+;#Z^EVBT,4DIEGPJ Z#?6QY^3\H=9:KS("
M4I=2DMALK23[Y!(Z'OD]_AR_ :J%*I+^+T)'6X?D3M9]XM.L1*.83)P0X+>(
M<[VT^GR$.]LQUD^Q8=)5Y2$I3@ $%)ST_;Z?7@5B4N6XL&-@.6AYV];_ %,6
M?6HDA4TB:%I)Z^]M.G6'56MW: &%<R>4 >G+T_\ I=<=?]N:H%)*0!H-6!+#
MWH-0\656J*R0E#->P8:Z->QZ=>89Q%"1A#>.N>7FS@= .F.G8>F.OKV[=LL@
MZW.W-P21HP=N?.+7G!0F*WNIQ[UZ#7]%1@?@I^8 =A\1D?1^T=]>\?3;Y6Y_
MZL(H]5H?-4:PT$G83Q9@PA8IM-D;W>R@\O*V:/N0PDLH   \M7V0,IR!W2?4
M'7T 4?\ J_\ #>%J'?SY7"I60[J%1@,XA1_]P31*/D>4?-@OP5^*M:4$2*>N
MXG8.,J54W$M$%I2FP%YU:$!0MF3S>-J@_'YSUQ\,8^;\VOG_ !]$#:W2X]2?
MERBGS9_;T[_[<_P=(Y ^)1UL=.GO6*_.">F/3\WQQ_MTCKBA^C'S']O\?/VZ
M:1R02_3?3ES](L4]..88 ]1CXE6"0"3GH,GI].H\]W'OTO'MD%E:^=GTN/KU
MC!:P$]0>V.WQ^)/;/?YO3MKS3AX@>8^OMHK4E\IW\72W/Z-ZPB=S= O_ %>1
MQ21W]3CT]2/ATZZ\[AU:L-[A]RVC?.[\HN7#B$H;X3EZ:D&_U?7HV\*7M*6%
M6BAM)^_HJ"O.2D#)YG4E">8@]CU],]3]-%JTK_,(4E3>*]]7/I]/KH+*XBFD
MSILNH09B6.0$>$,;$:#?Y>L05<&<YB+XIOBKR7W EB!'MN5*+2%+>:8BOE^8
MM*6PIQ3B66EK2AM)4X<@9)!U5\82/Z72I2<JE"<7!ZH)TZVWO\HQYPNI$K'*
MTSY6= [DH)_Q!0LI^NALVKPU?Q#-R]D-T;GX=M^MD=S*CN;>KG$-0[/J6WE:
MF2IE(I)I\JFP*E)&W$U"),64RE;[IJ*D>5SL!_&$'/GPN1DH*D3E$!=.HERU
MB'2QW27&GQ!FWCOQ6?,J\5E&5+"@FI3+EL[@9LI(9BX'B+OEUN&AGG$<-MI?
M&#XE'V9U9R-7XNUT:98$$RGHU(J%TPZ8TI*9B64H85/IP*G*6R\M"R\E(:"U
MY!]U/,2G"\)0J9_XE9,0H$ YAW@=)Z9=[:ZL8IRAW6(XVON5";+HY!E+<M+5
MD6RA>ZLP!MZ;-G4RISZIPR<*\NXI-0F74_MGSUQ^K!XU/I,DH@>>I[[\O#"6
MDM*6/\UR#'($YQYCZI,G$<2ITH2*<)F]SE<)2X5\!%F!YV9@!RWD["TUAX;H
M*NH7,343:5/>+6Y)5D22HON"+N][:VC8XX&[3C3.'[;N77;;AO15Q$OPTVVY
MY$Z2Z7G ARIK:^_.*"<+SD *R",8U\X.,Z&KF\88I-7,F3I0FK_+RE%(4IB'
M!:_Q.P-V:X+QC/M7K",;J9)KA+G+*<\R8C-*0&!'=NP<@>(Z:.'B2BV6&HU,
MJKB:;5V(S-/6AV#/4X65HR.9+94>8N)3U2?3Z.@\V'2IDF3.[Z2<@!"DJ);*
M2";N "X<!WL>IC7[&U([R3EGR:A84X5*'BL"2^Q>X4QW&\>F];;I#UH-7"W%
M=%0@>PS**Z'"I3<[F2B&EQLJ"?+\Q:4NCN4#OG58K<!DS<#1B5$.[FKF(4E*
M5DI&11!=)W&[%@=N?CP[%ZA.(?E9B4KIEYDKE%( RE+$AK@V-B3:VAC-FJA-
MH%O4BIW<XF0^LQA/DQV@VQ$<>23YG(G(\EOHA:R<\RNG0ZN:6*VFH\(J\37W
MDH*"5E0\*"1X"XN2-=201;0O1U)D5%75R:7+(#E02Y(44GX;N;W;4<[PGFY^
MX<6D7+0;<8$A<.H,^U.U=,8R8#BW0I$> I:.8)6K(63VZC/KJV^.<<I$U]#2
MTZ$U-.Z%*6!G2%*<N=+)&IN'=P\7'PQ@2IU/.KJB9W2Y2E)ERLV51 U4''F0
MP!('4/WW-4G'J/2K3H$&*9]6=0RXEU;(<9;4?\IF);[E+*3SI7@#)">F.M.Q
M.MD8A02<'PVG13S)RAWZT!IDQ2FS%R+ V9GWV:.=+(5(JZG$ZR:N>FG),L*=
MF&CFV8I( 86>\6NJV[9>W%E/VQ40VXW/ILQUVIRE#SI%4=0LI4\Z,*\WS DM
MC'7!'0=-5&DP[#^%OR5.A"9LU2Y<Q1EG,1.L<[WT;['6.^EJ,9XAQ!532=XB
M5+_M&6D> 2O\@UW)&XW9KWAY7#=7Y->VOM@RU*$B'3X["U$8+C;;00T2#UZI
M"<9^&>^1KZA=D&+'%.$J0J?,B4@ D,;I'EUY7>VL8CXYPU5!C*F3D$PE2DZ^
M+X5?,W-_0,\.#'8?0-96$6?%=(0:0@TA!I"#2$&D(-(0:0@TA!I$&X(Z1\P;
MCP_EM\7?Y2N]W]H]QZ1)_;[>GOGK&]?X*"4J\*'@1"DA0/#U9@((R""P]D$'
MH0>Q!Z$9'8G7$@Y@VF_H_P"\(E#CQHT1EN/%CL1F&D\K3,=IMEEI/?E;;;2E
M"$Y]$I URA%!$BID.2TQF$RWFT,NR4LMID.M-E1;:=>2D.K:;4M2D-J44I*E
M%(!)RA%J@4:+'DR:D[3*2W5Y*W0[48<-EN6]&YDJ9:?E%H2G#A*0M"G%(RD8
M[#2(NS&XY7/GSTV^76&U\,O"K;O#A%W0CQ:LN\']R=]=S-\4SZS38*95MU+<
MFJ(J4RC4MU*%N(C0E(#2)*%H?D DN=N4(=/V]V\O*'4)A0TO/24Q8R9$A"&I
M#Z6&P\^VWS>6V\Z$\[J&^=?(A:E)1S*Y0.8Y1,>4T2C*$%*J13%"F.%VF@P(
MI%/=/=R""UB(X<#*V/+5\^D/UCUQH<2&'$Q(L>*EYYR0ZF,RVPEU]U14Z^XE
MI*0MYU1*G'5 K6KJI1.D([E=4G'77!?P^O[PC%KQ2';2N1KKSN4.IM<J>AR[
M#>2!GH >OX0[?LH/$[R^'<84=\/J0E^?=J87ZMZVVBH80?\ YKA^C)K*=2GY
M":@O:YL[-NT0-0F3-M*93ZHZF#["]+:C!MSH\&Y#Q]Y74+<5V0!UYB3C&=?&
MW'ZJ=.Q+$4+21.I\24@)(*2I/>YLSDWVON"VMXW[HIA1_3UTPSJJ)*$.=B)8
M20!9K.3I<#TSJJ[Y63;<2S+/NZ&X^:A2$.!MV,AV+':92IB,]+\Q1 YUI"00
M!E1., YU]6.Q]7YKL]X=405#\JC,0V5)3X;I-S?06O>*93<$8Y7U>+XE@ZBA
M<FH/>K1,*5IS7F %)&P(MF/,6>$*VANYFL[E7E;5U*;D6;*<>G,4^?Y9CTU]
MIQCV=40+REAEU"BKE420KJ/4ZR.J6P5+)! N0;91>^MK6?4NQB^^-, GT&!8
M-BF%+4<3$F6B<N6"9LPD*<+(\2V8ES<,^@ ,,?B-4MNS>-*@7'3^6/"KEO;=
MW- ?:5RM%FFS9=MAUM:>4)PBW <I) R%9R2-;I=A2OZ]V,8U@RF7W-3Q-A"4
M,'**ND162_#N%*Q!0%KD$;1\?OQ%5,SA[\2W#/$TU)E+F'@S&JA:R0\S#\05
M132238B1A\O,-@0^L0RW'2YU,O.Z*9-245")<E::DM$*!]H$Y]2TJ&.;GZX.
M>OJ>VOEC6>"=.2L-DF+2K,&*5(44J27T909K7^4?H6P69)J*"FGRIB5R524+
M2M-TJ3W:2E6E\R=TZAC&4T+SBM'WIS 0"%!M10I)3S^ZK&>B<<V>HQ\XU3^_
ME!3&8AR2&<9G"F+MRN UFZ1ZZB?(2V::ASH,P<^7GY /UAQ-F-NRYD6'';4]
M+DEMB.TE)*W'5XY&VPC*BLCJ4CH/77K$Q*)(4XU+M_I[ZW_XOUB@8I.1(D]\
MI3)#GJVUAKMMI:)8]J-C-J[)BV]/WVOZV;<JM8CIGTRV:W785&?<8P0AU29/
M*XXA"AR'!.7< =-=M/WE2G^R IU 97U<@#<?<>=HUZXRXXETDR89-05*EZOF
M*4WOE#L6M=KW]9$=MIW#74I\6V;*K>UER5GV=2F:/2*M2JQ674,))?<5'9<4
M\[Y:05.%(.$@J/QU4%29]-,3+FI*9C.P8VO<Z[.>?RC%$WC"9B8*TU"@%'*[
MJ!!TT/TMS9H<2UM39-904*IL:FR$I):D0$H;0V?^C@8!*NA Z8Z#7KIYRC8%
M\H8CJ[\ST^C13SC=1(F!"IZC?_D2#H>9T=]-!&+S;/J5E2FH[JP_"<PJ/,QS
M$-E?NA:L#KUQVSUSJM2)A*7_ ,; DZOM[%MO*O4V+R:I(DK4 2 06+DCKH+W
MY-K"H4)U2D#E4D H2$]?]56"?7O^K/3.JC+! )V#'Y_6/#6HRK=OB/[,]OOK
MO=H52FN9:;4!CE&%#'I_?GIVU[D+24B]V#V.NGZ?**)4HL07W/E;VW2-:?Q8
MZ1-LKC&LZ_8JDQ%5FUK+K\.6R.5U%0MFJO1#(43T+K(APR@Y.$H0#C&M^OPX
M5,K%NS'%\&FCO138EBE),E*+I-/B-)+4);:A*RJ>XW))&L?-S\4M-/P7M6X:
MQ^0H2E3\-PJJD30/$FIPG$9G]Q1#9BC^P4ZD!(!Y1L\6_5HU?H5%KD)?G1*Q
M2J?4XSN1]\8GQ6I3*^G3WD. ^H[_ #:T1JJ>925512S4Y9E-/FR)B;^%<I:D
M*%[V*3K>/H%3U":B1(J)2LTJHDRY\M0N%2YJ0M"AK8A0/6+N?HP?X_;_ !\W
MGCMN3U/ZP=/G/;'\?LZ:1/B3T?R.D=3BN5)_@_P?CJ"??G8?,^D=H=KZ[^_)
MHL4QWH>N"4C&>I/7L>_SGYA].N 4 .3<_D ^]]-+!H]4A!)! ?FVK:;]?TA/
MZR\,*!_Z02?AT(Z?J(R.OP&NB8Q8B[!CH".A]DB*W*20G?:WGO\ 5NMN4(E<
M4@I0XE1_!&$GKU42K'0]\#&>WJ<C7F6"UM-QZZ_;Y[7>KTBEI8,;VTY_=VO]
M(P&W=R7+'J$@25N.T6;AN:TGF*V%Y(2\PH$<A0<*]?H.J56+&5)3\0:V_/\
M3KHVL>G$<&D5LI2BG^\0^7?E8]-M.1Z9+2*;M**[7]P+*H%J4F\+N3%<NVYZ
M9%CQ;BN)UCF,<5B4E9]I<CJ!4E*T\JG2%*R#JE5E;4*5+ED%DI9NGF?)ASL^
MD6F.')M(M4R73$DM< .UV38.=3KKI8O"'5'8W8JC7F[NA3MH=OZ9N N<]4UW
MJU0XJ*S[>^DB544248:;EO!:O-<#15D\R"D]=>"IQ.J0A,E#A*AD6S^$$N[:
M/Z]>453#\"E=Z*B92^,',73?33<\OE<,\- WT'#I157-7+DL"Q;GN&Y#'DUU
MV53(DJJ5^1 *EPG*J_W6Y'5R$+!'-C!R1G5-FU54"A"%%I:@I)2[ DWRL0QN
M7;?6+ZP'@23B(FSYM,QG+!4Z4#,G,,OA4DOT2;\]8B9W9N^;>->D5J4/+C^2
M85/@M(2W'IU.9Y$Q8T5I.$M-,,H;:0E  2A*0!J:F4JJ1*40ZR")JR[L0&#;
MZ#_>NQO#^$2,*H9%'*'=H2 "$[ L"&8.;6Y%WM#T.#KQ0I?#'385@730&*K:
MK$ATLU8M*=JD)ATJ4M#(+Z4<@*SRCD.2GH,'&M?N*NRZIJ\1GXIAA0JJ+D2E
MA(4Y+$H64E+D#2P!.N\6)V@]D%%Q8?S"*B:F8$DCNU90]K+3D(4S Z\A$@-0
M\9_;G<*_K"VVVGM^M3JK?==@4F94)\8HBQT/MJ0ZTIM$C*% ]0>4@C/3IJSJ
MGLAQ^JHZJ=//Y<L@+09J2N<I1$L=VE"2DAR%/9@YOK&)\,[!I>&F95XK/,R0
MC/E5HE.4N_B2%9LH;1GV)(AW%+XC+RI-KW+;E<H2JNW#>6Y2Y*@\E4=QQQ<A
M#*U%?WQN,X0$X("4^X.W2V:?LVXHH:"JP[^]-1*6524DDY25.""V[D$$,3I<
M/'7/[(L)K,6D5E+B")$I0&<#+=(1:V4^() ((<FVL>C[=.YI;5-LNJ6G1Y$V
M=278\UUQ]7EF0M 2R0TMXD82H%:>4DK/0CH=5L<%<75>$(PVHIU*E90"2QRN
M&27-PH/90N"QN\=A_#U0B9-QB7B4Y5)+G!1";,,Q*D@=V,R5%+.;M:^V+L[W
M;DVE8]5I[M+I]8B(>"XM1E(6_,B*>D#[PHE9 3&Y@EKEZA(& <8U;>.=GN)<
M*\-U-=44AGRKJ,]8"E2UM\+E(RE+%^>CM>*DKLUP"HQ.C7+KER%2T"6987DE
MS4[$H"0E3NSGR.D62L;^5LQ:-6:=!<I]?IZ'XTJ:AIQZ;+C.I*5,L942EL+5
MSDGL$Y..H.$*+%UU*U(I0?S$J6<Q2[Z7+OL&(.UP!<&*S)[+<(.)3Y<^=+FT
M<XA:9:LH2 /%=ANP+: ](<)P[;8WCQ VS(N:Z:A5:HB!7Y,:''DR%B,$LAIU
M"E)*5 D%[E!&>4<P'3(UM?V$]E4[CC"YV-5N>:M$Y<N2F8I[)$LJ/B%F62 '
M=B'W,8NX^XAP+L^KSA5"BG2I4DJ4M*!F?,4Y2 $DGPBY/*QM$O6UUC&QJ S3
MB?O@0CF0,%"%<H!".W0?[>PU]!>#.&QPSA2:-*0@@ 9;&R4AM /T;J-=1>*L
M>./5ZJAO"%$@LSWY>9/T;6,_J]6I]!I-2KE8DMP:71Z?,JE3F.DAJ) @1W)4
MN2X0"?+98:6XK )Y4G&3J\0[!]8M>(T[<\9/PY;JJM*I-(XCJ I=:F-0:?4I
ME%N6GT!QU]9;9><K\RDM4AB&ZX AN:]+1%4I2 '??3F;\O8U@XYQ)A%J4*:P
MS*BOH?CR&FGV'FCSMO,/M(?8>:6G*5M/-.(<:<22E:5 @Z-]8AQ\K'S]6CT%
M]L<I).%'"3RGKU/4=.PP23Z#KI$%0#;OHT8!MSNO8F[%+K%9L2MIK5/H%U7%
M955?$67$]EN2U:B[2JY3RW,98<68<UE;?G(2IAU/*ZTXMM05I$OS]_S^L*"7
MFP0.8=<]NHZ#)[?J/J<@=M(. 6>\=2I<=*N4N#FY"X!@_@#NKJ.PR,GTYD_$
M:1&;TYOLX)&\8#N/NQ8FTEHR[YW K0M^V8,RDP)=1=B2Y(9EUNIQZ/36BS#9
M??/M%0E,,A26RE <#CBDMY7I$O[8_P"_I&>HF1W DH<R%I0M*N57*I"P"E0.
M,<ISC)QA7NGKI!QIK=O*.PR&@2GFZI&58!(2.7F',<8&1VR?@.Y&D02&L?75
MO>VT)M0-Y-N+FW*O/:"BW-$F[C;>TBW:[>%L)0\B=1:5=;3SU!F2>="6_+J#
M;#I;Y%J*2DI6$GIHX=M]8Y"X?;3[_M'S5>/#^6UQ=_E*[W?VCW'I _M]HWL?
M!._FHN!#\GNS/ZA[2$2D:0@TA!I"#2$&D(-(0:0BA. 3WP"?JUP58/\ ^H'Z
M#3WSWA&.UZ*J;1JNUS%*I--EM( [H*HZP%'N>A(Q]6J5C$@5F$UTM9.4T\ZW
M_M0HLW7_ ''JP]8E5U+,8,)\HE__ /H#[OR#1!?4!2H[]3HDC[\Y2O;VEMEE
MP)34427?*=*PG"EX6E?*,].G?.ODCQC+IJCB7'9<J2F4*6HF!0 9U!3@G<_-
MK/M?>[ IJIV'88I)_N$29@62[2P@:#[[F^[O@%Y;/W#NE0[0J= ##LRW'C2Z
MHB0D,+#7GK=$D%>"Z&D%/WLE25 =#S8&OH!V"8NJHX+PRC2IS3R<JDZM=\P>
M[.XZ<K1=.!<<4_"4S%Z.I3WIQ F9*622EVRD;APXNSJ?>,;X@]OJ?9MIT^I6
MZD^V5!34.YJM$>'/YK#9#:'>3*DI40$E1]WW4@ZSLI(F@S,KN&6L7\0 NVQY
M\VVO%7X!XEF8OC-128RD"A2B8NBES$$!$M1!24N[@.2XN ;OK$47BAT:;*HO
M#)?ZH10B99->M>14@1AY^DU.+4J?'(Z+YT,U"8_GJ@AW*2"3G;+\*V(2E8?Q
M;A)F?W95;0UR9+'*)4V3-IYDP'X25+E2TJW+#81\JOQ_8.FEX[X=Q>C0!13*
M?$:%,T%((FRJB54RY02+Y9:)BU [%3:PSS9#8^X=Q>-6S9U1LZ=<%F79(I]X
M56:Q"<ETP(J-!1)?6\XE*VT?^4@^"AP9/08Z@Z^:?;XBGX8XCXWPJEF&5.HL
M=KI4J23_ '!*_/S%I"F 9)E93L""VYCZR\$=HU%/[&N!,=EXA).(8APC@=5.
M2E7A_-+PVG$](!/^,[.SDD,,RGO&P/Q!\)O#A:G#=>*%,6/MU5ZZ^JO3[LJ3
M,=J3;T:.T Y(IT,!,A;LAMGRFHC'NE:UJP<#&L> X]B%17RY<Q94)LVP)6Z4
M:)8.?B-VZ;",64?:#Q9B'%LI/>K.'RR$*OX)I*G*E**@,R4[MKM$!G!7!MRZ
MM]XT5AYNL4F@_+4ZFRGD$?*#4'SV(DTM+2E39?"0^E'NJ2/=.3UUG@+7^63+
M8DA#J#W=DG3U](V.XBQ,U>#2U2YB2M4E#E+%)5X00Y=P-V//I$J'%3MIME?.
MP>[UQWI85L71<5L[4W>NVJ]5J>F34Z MF"_)9-+D<Z3'Y'\.I44K*5@D8U7.
M$Y__ '<I*KA,P"]F8AA[YCD8U3XSH%3*#$%J^()44Z$W-_MKH!SA)_"PV[LR
MT^!;;;?&T]EZ+<V\E-MJX7859ID.-#NVX7EK$94 UN2L,LQ5-.*<J#SA0XF"
MF06W O %\XXTW%2A"'("O5]WT^;@-;6,7<,R,F#*G+4!D+OM:X<7)O[L&RW8
M3Q2[UKW%WMYPO;GVWM=4D[CU"MVU3+@VE<KCR;<NJC?YRBUFH5(KI]7:BE0C
M37Z2ZZA$AMXE\@ISV2<(RT2J@I 4P*@ _P 1(2?$>AT!87CQS,;2O$^Y?-=3
M$$D#(!F\G%_2X?2;^Z4L3[6J2G@VMR%'??S@GRUL@@)0#U2 !TSUSUU3*=2N
M\,K4!3B^Y/RZ.+;Q>=#4?]S+;5@X#Z!AZZV\M=H2>V*ESI:]_LTCZ<]R.I]X
M'L3VZ=^O6XQ:43^AZ?;UB\ZB2M2):QH6/U\P#Y#UY0L=*G] 5@!!Q@]<? J[
MCH<]NW;O@Y2C=.E];>[-^L4FHD.#S#<N1?TL>O6YB#/QLK>4I[8>\DH!0ZQ>
M%MNNCDSS,+I-3CH41[Q'+(D%.04_A!)Z*UNG^$VO+\988I7_ /JJ]"3R/YJG
MF'DX:4"-?2-"?QGX5EI>",72GX:G%\.F+8#XY=+4RAH]^[G'7G$PG![=XN_A
M>V+KY/,Y,V[M]ETDGJ[ B_)KHSCT<AJ&#U'J-:W=I5"<,X]XNH@FTG':_*''
MPS9RIR3ZIF#Y_/9SLUKDXMV?\&X@+BHX=PPN"?\ RZ9$I76RD$7WAS'F([E0
M^?U_WZLIQ^OI%\<K:?3RCJ5(2D9&?@#VQT^C\VH!!=H$/L^\6]Z63TQ]7\?Q
MW&N"BW72S<MW=QNW[WCL3+)_;?\ CWO&-3Y@2%85D\OP['J/SG'\>NN,Q@G6
M]CH!H?+HP&F]XJM-)+BVNI.I#=??FQA-ZQ/4DK(4,<H!'?)'JGOVZ#Y\_3KS
MNZ?_ *O(:<]^I/J8KLB0]FL#OM;GOU'T,(?<=4Z.#'3G.>N,E61UR1Z9Z8^&
M?376?0V=M]W_ (]8J<JGRJ2P)(8G34/;3:W\.T-RNN4A07A9PI2^9&.GNY]/
M]+/7']VJ7-2E2G ^S_KS;]=8N.C2)A92-^1WT#G:P'GK>&X5^M3Z>M;\"2_!
M]UTGV5Y;!*ADI+@20%$9Z$ =?FUY9],@95\DM;5G<V+MORTTVBZZ6AIERB%2
M<ZC<DAP'T9M=W;:W.$%NR^+H\DA=T5M05TY%5!]2 %''*$<V/=[ $GH,=AC5
M(FRY:U,,IZVU;GS\K[[Q7:+#:-!&:G%SXO"D/S^=CKZ0U6ZJD\Z\^Y(==?=7
MS%3CSBG"H*/<E6<]?S],=^FNM4J6AMV^;Z^R_P!HNZCE4R4M)EY.HLQNY=M-
M#ML-!#?;C>SSD%/-A6<XP23\$D8R/I]<]^OCG**+CX2Y_?YC78F_.+EI$E$N
MYS:$?S\H1&X5AU/=(6E*R5*2%$=!VP >_09)_5KQK0F9XB_-GYW;U'[Q<$A8
ME95* *0[AN=O7S,.=\-VR$WGQH;.1BR'6J+637Y+8[*CPRE"UJ'IU7G/4#.0
M.N=5;!*:35U<N3/<H*T6.A90+'7YFW32+)[5ZU-!P?4S:=I<Q4J800&^-"@2
M="2]P;:/L8W,39]OR[=N B R74/5(((0@G[US*;!R.Y/N]^GJ-7RG \)ES%2
MYE,A0=6910#<NJ]C\]/I&F4K'<5E8C0 SUY5*E!1)+,2 ]CO\CY/$3E6M>N/
MW)<5U-4:3$5;SSTQ<F4T0A!8!992T%*"''%)Y2TD C_2Z]!JNTV X'-E%J66
MDA)5F4!;2UP Y+:1M]08WA?].P_"35(F+KQ+DF6@J<J7=14SD :$V8$7&L7/
M;7<*3'DO4*M>;-I-P?>74S<R%19167$/)))4GG<&"!V('4#.L?=L/#V$2N :
M\"2G*N6^4I'@(>]N>YU;Z>;BGA60JG35T1[J?1$J24,,Z"/AT!+$V!\QT>]-
MHELQ*92W7*?&;?Y6L.!I)6II30\]70'HHC YL=3UZZ^8E'A&%X8)U6G(@S#.
M%P-5#=@]Q;33SC!J*S%)M;4/5*4E!4+JL+V#/Y&UK6TB1_@KIC%-VME^4RB.
MW-N6K2VD-I"4I8?+ ;2"  4GDY@?@KZ-?2;\-V%2:'@&DGRV_P"YFS5V#.%"
M6;['0:,T:C]K]1.G\3J7.FF:>[2D$E]%+%A\W^9AY6MA8Q1"4;\8_P 2.[^>
MW^+*^L],]/L9J>>GK]'KI"-:CA9JG'5O7X9.U7#9:' %8CUB;E</[.W-#WZN
M7>NPDTZ)1:Y'D147]4K+:I#EP-O4U)-2BTUEYV<W4HL586I2>?2()'DW/ESU
M>]QIZ:@)WO+>'%S7]W-Q.&+;>Z>-M^-P([:[/;4;;U/A1EV-$H%>W"3MW2:K
M]GW$$F[:FS5KNBU*I4P1D6E$,*DKH:I8-3$SS5*GW[_T1SA^OO?SO]!<PZVR
M*IQ7\7G$CP06%O=O1O#PRU.H<&%3WFWIV[V)NBCT&'=.X]E[JT.E,M528J/<
M\>#3ZHEE3]:I])?=+D6H3*&9GLW41_K^/E!K$#]WMYCZ_K%IVGXFMZ=M:YM;
MQ#[B;J7=5-C6N-/B[X<=YX];J;M1HU#H%9OZ6WM%744E"4*2[;53I3]';J/^
M6"#3'F(C4$I<4YJ??T]??+2%M- ]MM#8=-FN_P GAK^XO%%Q9[I3]K[6@W!Q
M0&T.-2^=\>(>B0^&6M6W3]Z:/L)MM7(5G;6678;UX2DTW;ZV[DI4/[*KLFPO
MEBM2JA,8>;C,1WY32XTUT&Q^N_[:<H#R;=QRV'+3KY<XS%V\/%"NSA._Q:5%
M'$;3:#M=Q40;8N&LT2X[ M7CPW+X99-I+NB"B%45UFK6X+_MFNRFH%P3XD9N
MJW!:D),]%,;1S\SW[;Y^=H6\O,:[NQ ^G)W>\9);?$IN%2O#OXBI%B<2_$!<
MM;VYXB]DJ!1:?Q V_*MKB=V<I-[7I9,JKV'N1<CL>+"O)BI,527)H%>IU.C,
MNV[.:CE(*0$O=H6)]-QK<'Z>7J]H739^S>*[C3F;J<8=,XX;SV*N3;7B3N';
M/:_9^GR("N&RG6!M-<,:UZS2=UK5G<LZ\+AW!9,V:]6S6:0JF3Y<=$.(L,HR
M]_S^L1T;5]!8L=WW._Z6AHG'!Q$[W[<75O!OCM=Q1<6&[&ZFQ^[$%WY)VEM2
MEV[P+;7V.U<E&HRK W)IU<:2[N15 Q.>I]T5&D7'-J\*KR_,:BM-,H#4BY#^
MI/OY?6T"+$#D[,1S-O,_M8Q+QPW.F1XKG':\H@./[%\+[[G)E*0IVE5EQ24I
M62H(!) ',1RGXZX?Y_\ T_K'*X0?_=;J[ZL-[/RYO&CWQX?RVN+O\I7>[^T>
MX]<HD_H/M&]CX)W\U%P(?D]V9_4/:1$2D:0@TA!I"#2$&D(-(0:0@T9]81YG
M4I4AQ*@"E04D].P(Y?3X\V"/K[Z\\Q 7*GH/PS I!'0@@@#R,2DLM"@6*5!0
M/4&(0]QU,VGN7=5%>C/.R3=<RH%"6T^6B#-4'6U$_P"JVDCRP3@_#7RH[6Z6
M7@W:%BN'RI91^<5,67&8J0;N_-]MNL;P\$3A7\.X?D4\PT(!(US L[BUWN^Y
M^?OHU;GS&KSHE-+D*0:"N53'4' >6X@DO)0D@I<3S!..BAT)[9UL5^&?B&3.
MIY^$E834HE3TH!=[* WWZ@===>592245.'3JM(4G\]*3.S ?^&Y%Q?0M8VUY
MQ'7:=]W'1KS3!JDARM4U53;AUBFU)WVJ,M#LGRY,AX.Y"'6$CF&$]N@3@Y&Z
M,B53T] F;F49Z_B0J\LN_P#CO8>;.08V0Q?AO#:GAN5/PU*45:9#R:FG.686
M&F8 $W< /?>\89XH\>W-Q.%FD799R6S"VMW:IL&3':1Y;<"FW%2)]+D+: 2!
MY)JB:*R@).,OYR< :S-^&G$S0]H-?ATTY48U@U;+DI ++J**;3UDI.K#+32Z
MU0-W9NL?+;\;?"6)2>S_  O$Z].>KPS':&IG3EL"FEKI%30+ +76:F;1Y@+$
M$G5,/R\(>MVQ=?!K9%0BTBD)K]L52Y+(KM13%974'95-J(J$),J06B]R_(]7
MIRFD%1 2?=)][&D7XV\"FX%^(#B.8L+-+Q#AF#X[3)929>6HI?R<X @E*VJL
M/J"I3 N6*; FTNQWB2OQ/LPX8D&MG&1A]//PX2A,5EDJHZN<@((!WEJES #<
M)F)>S/=^(2P>%^LU[<.%=UISMTK[I,%NY9>V,BYDL5*JPXHYP]1:6^\EM4%L
M(4KV= /FGG2 <C6H>%458FM2JDES"0LFXRK9G+*&4V2[7S%N4;/\/_\ 4L^E
MHUTI2F7-5+ JE2U*2$J(2'45-F)L3\(LYY:X.X?&-PY_;%69<.PFS,_:>GV[
M[70;QITIM#")@YG&%I,2. 8[D985SA8RLI/3FUL#A%)6FEEIG)0$E )RJSJ4
M5!R7ZVYM;6-I^%,&QR?A7Y3$:K\TJ4%*3," @@* 4$,%$')>Y8FPY1*Q4&&M
M_-F[[M2QJG3GW]QK#K=OTV6\XH1J;/K%/4TVJH)!\QMAI;@#J@.B0?7.JOA:
MUT5?+9A+$Q)+L2[BW4,+$,;7O:,:\8856)E5E.)<SO5NA+AP4W"M7OJ=1]HO
M'#QPJ7?MUP"KX0:Y?JJ#><RRKFM95^60ZL+HLZL+:=@S:8\XIMWD#C*8\Y04
M%^QO/A!R3J_)^+(5B\M80G*I.8Y@5%B7RD^5K :^L8=EX4JBPR90/-SE)"U
M%)*V*2I/_%B<P<Z@-RAJVP?AK<3UH[Z\$EZ7U)V"I%B<'9K<5V98C\XW9N1&
MK+[S\JXKF0^LMO7')YTJ>=!7YBEX42EO)N&9C$I=,N6D)&=F&@2 HD@ANOAT
M  !V$6C2\*UR:A%1+$Q0=;9[DYDA(46T=G(W)VL(G W(N^C^Q/T:%( J%24K
MSTM84([*R5)#Y1T+F% G![CYABBR:8*69C,]]OX]'W=[1E7","J I$^>""D;
M6 WOKZ>>MPR8T..^P 6E!T!("/\ 1RG/;'3O@Y./S@ZJR&9E.UGW+WN#=K;'
M^(O8@)E)EK!+,P86MS?Z7O?G"G4R=);"4NLN<I !0#S#'QR!@>F?FZ=]<TA-
MFV&YO[V_>*-4I2'(;XK7^;?+W:(Q_& I0JO#K8]:P/-MS<Z @9"BH1ZS;];8
M='7\%/G18H^!/*-;/?A8K>YX[Q6B?PUO#=26<,9E+6T4T6W(0J81N ^T:=?C
M$PX5'9IA]:PS8=Q/0+=KY*FCQ"G4'V\2Y;FX< =0Y;PP+H=KG!?M6T^Z%/4*
M3>5 5@?@MP;RKCD-!R>I3"DQAT],#H-6=^(*D%#VK<2B6,J:I.%UHL[F?A-$
M9I]9Z9NWK%W_ (;ZO^I=C/!ZYA3WM-+Q;#RQT118WB,B0&+W,A,I]GT$2"B6
MKID)_6,CZ22.OUZPUX#TWN?VL/*,W&F3J"HOL&L?(#;SO NH(Y,+"1CMD]<]
ML ]<]OHZ:D,D?NWWTTZM]8E-,7L3^GRU^FL6B140@**"#UPOFZ%(/JD=SGH!
MTQU/KKKMOMMH2;V V!WY$ZQZD2 &S;:,>?W^D8A4*HV&SS+"#S=,A6?7 Z''
M7']_<ZZ%+*GN/(!G'^NL5&G2ZK[MY :N#OZ!X36LRGG0ORDJ45 CH%*SG/7N
M,=_09^?ITX.=-CK[^45V2&'*X=SR'IIM[=(:W#G.ESS%LM-J)2>F5#.>51Z]
M"2?S'T[:X+S,0 -+N]OF&MZGRBH2BIP2-WTU+W'(_,?LC-RV^T$...SW$* .
M$HZGK\.G?XG/KD=>WA7(6Y+Z7:]WVTZ6^D7'1SV-D)L 18,>;_[-K0W2\;62
MMMQ46>XIU8R$/I2![H/0JZ9SWP!D?M\M0E10H&Q !O:W1M+_ #&UXNJCKIA9
M.66!8$Y=>GR9O7:&<7B)4%Z3'FH2'1S*:5UPH#MRGMW(QU]<=S@6\N4I*Q8A
MU7;JYZWZ_.T7E1STE%T(?06&I&N_KS+^4-RN:8E0>/<H&%'))ZC]7+]>NF:"
MDLYU8D:_S]NL7!1RT30"H,H?\>A+:#<VO?=]B@U?D#*E9Z'/Q]1CL1DGXD=3
M^?)\ZB.[\+D#1R7?<?,@\A:UXKDF7E"4C_D-3<.[CZ>Q",5J2H<Y&%$A0)'7
M&<9PD>I/3YOJUT(9*B3H [$_^YOD;_S%=E(24I)#D9?_ +A]F?4::&)8?!*L
MAZN\3%YWL6?-AV3M_.C*D%/,VQ4*I+BJC*5D92OE;4$D'M^8BZ.%Z;OJOO&(
MR K!LP<-?:Y&Y^L81[>L23*PFFH92DA,V;*EK2XS*2273JX\)42&NVUHVJXZ
M4-VS(<2$^;,B/NN'/+YC[HSTR1^$2>7TZ >G3(<QPFR4J40,UKZ <CS;RT,:
MDSC,F58"')04A#.2 !J+[$ VYPF6[-B2;QVLFT*WV(\:JR/9)KC@"&%O/1VR
M2AYPC(2H]%\W3'3KD:]"9DQ$D!2<K^)08:M;<::WMZ/%T<)8VG">):2NQ*;.
MF2907+2G.H@9BDADW=VTO\Q#/:/P[5*SJ%-O2Y9<5Y^(MKY+@PU!T)>4M(6Y
M(6<A:AD@<HP.^"=8F[?\<_I79SB,X*1WQEH3)2H9@<Y <M:X.KO>[6?,N)]J
M0Q2K7A='**)"Y9[Q:DE*LH26"2;DN1LV46A$=]M_>+O;^?<,>Q>#J#NQ9#+-
M,@T"YH6[-(IEQ3/;(+3TM3=H"/(J+3<%U2VUOK"6_O9=<Z<A5HYP[P_V8XQP
M_1JXJX__ *'BM94E(I5T%2M$M2B"$"8A33%*#@$?"X%XPCC&*8_AM94_E*%=
M32E)F=X%I2I68D$',VA(T<LY%G$.VX8>/KC?M_;^%2KV\*7>BG1HK4==%J-I
M7U0JRBMM%I <F2X\Z'$7#\S 4TD..AQ.3[OK]'NS' L.X=X3PS#<*JUXA0(E
M)73URI<R5WR%I3<H5Y." 0'9[.=4.*,3J,7Q6IJ*I*I<U$Q2>[<>$!2K6N2Y
ML[[/I=SOW1GBCY@#X8/$L.924Y^6;3P 5I25'W^@2%%1^(2>W361(MWT/T_>
M)1*E2V=Q=O)E&N*GSZ(Q?%GNT^MTI3S2*I2&[CHY8J-/4^@.,)GT],QZ.IU
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MEW5&3;5<A1([](5 JCBD4IYM"Y,>(5LK?<*E.%[_ -P)ONY<GY7T/5V!MSL
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M]O[%;@W[0GH\F-=MWV9%A!<NJ5&9$B2JM[+4HK%1EQDO/L@N.<[;IRW\_H(
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M=^;,P=^O*21\#GC\-U4*;M3PM!=JO#\5IAU)I%30X\Y3^8$:O_BFH%578[Q
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M#,E:7HX(<Y5*00<:>_3GZZP+;#D= [M=RS@6;[1&IXB='XKMTJWQN;,2=O\
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MG-O;%LJC[$V)O34;CK>YM%:K='1>2O\ *(=Q6U,:B.T*WZ>C"8ETRYB8U2D
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MC5ZG5&8AZWZ&%HCPMR:I;%,EM0W+YBQ&)+M-=9@2&6RRK,Z,>NGE]O=N<O\
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M+FK #OE15)J)>9Q=!'*+J_#KQKBU=P?PEQ'(J9RE8:^!8AE,PE-7A294D!9
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M;Q'3&=1WG!OS$M9'?)!/^0 &O_(6\C8Y2X=Q:1CV&4V*T"D"EFI$QTE)2I)
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M2P:E3+?98DMI14)4Z-F.R'5$MMJ<YTC*B.O3X9\V!U<G#<8IJBI2H(DK"U)
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M:?OI:.":V#D/<Z@4@))<("5#H">O;UP#V_,==2U900U_A<=''K^MH[!1O8V
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M[MH0\2B[9WS!OVUXE<B!IMU17&G0PH%46=&5Y<I@G)R&W>;E4?PAC'7M]+N
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MZF0J_4D49JNT7=:\AN79EU.K4'6X-*K<*H3HD5Q"WVFW*?R276W5J;3$2?\
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MDT?9_;3>.LU&5?\ ;5*NBGT"8E%$IM3BLOF*'1S*J#,A.'?95\W*VUSE*1Z
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M0B-5>VZ!:5&D*;;>JU1K+#SD8$^\X8B,K7A/9&/>)Z=M5.3PU6S+]WEYYB
M_,V;T!ML;Q:.*=M7#M 2B34"H.7,0A!4H$%F \3N#T=B+/$D>TG@A;96>W'N
M#?2\JY?TJ')"S;-LI]FH]2'0-QYS2$^?R\^?,4AU">3\+5?H^&9,HI75*<A0
M\*2"?4Z@'H-#Y1BO'NW+$JHS)>%4J )H,O-/&1LP8%* 6*MSH+,^T244:)M'
MP]V]!LVWZ)0=I[>88::^3;?CMNW"\PR$H2J;,;^^+2X@@K6HJ4D$]1@XNZ1A
MZ:>63*EIEAA8'QLUG+>6O*SW!LV@PGBGC&9,K2B;7JNO+,5DI$J\1M;)9B
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M:FXA+34E$5F2N$XRHYFT27&?5EQ3W)][_P .?;+P[^*/L<F2<7[I/$='22\
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MS%E).AZW_2&E;@UFB6=O#,:I\?SYLA5"N1-/A)0X[+K$=2FI$1OI[DB:RL*
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MD7*FIE5""J8F7G,O)G6?"[',0DD6(.L6KQ76"NPN9,$D@4Z]%?VU3 G-?7,
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MA!IK8P@TTL(0:0CKY59)!^CKWZ#/I@? ?0-<,C.RB']\XB_($?OTZ#YQQ<Z
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?$V;+?62MZ3)>=><42I:U'KKBKXCZ?:.2?A'K]X__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g142578g10y51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g10y51.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1-44&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M     0 !.$))300F       .             #^    X0DE-! T       0
M  !X.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      -1    !@             !=@  !UL    . $X 90!W %\
M5 !8 #@ ,0!? $8 :0!N &$ ;     $                          0
M           '6P   78                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   78     4F=H=&QO;F<   =;    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   %V
M     %)G:'1L;VYG   '6P    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$%       !
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MAWKY3=VI#WPX'^5#?_,%:4T<&(ZG&!]6"?-9P:&8R[Z4_P#_V0 X0DE-!"$
M     %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M   3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    !
M #A"24T$(@     !+DU- "H    (  <!$@ #     0 !   !&@ %     0
M &(!&P %     0   &H!*  #     0 "   !,0 "    '@   '(!,@ "
M%    )"':0 $     0   *0   #0 "W&P   )Q  +<;    G$$%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,38Z,#,Z,3 @,3DZ-# Z,C,   .@
M 0 #     ?__  "@ @ $     0  !UN@ P $     0   78         !@$#
M  ,    !  8   $:  4    !   !'@$;  4    !   !)@$H  ,    !  (
M  (!  0    !   !+@("  0    !              !(     0   $@    !
M.$))30/]       (          #_X0$P34T *@    @ !P$2  ,    !
M  $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q  (    >
M    <@$R  (    4    D(=I  0    !    I    -    /      0   \
M   !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-CHP,SHQ," Q
M.3HT,#HR,P   Z !  ,    !__\  * "  0    !   '6Z #  0    !   !
M=@         & 0,  P    $ !@   1H !0    $   $> 1L !0    $   $F
M 2@  P    $  @   @$ !     $   $N @( !     $              \
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M@CL!V'8I3V[;[;<-/JZC776^I \,&AL"+<]+6(]FU_RWVPJMJ\=_'<>^_O\
MU?GXX$DG0[CKXXDM@XE8\CW^OM^?\?B/Q=@Q\B8V7 RSU/OGMZ;0ZMCX_E%_
MXIKSV]1:=_ W/;A>%5@JWJF^OCT^NF(RZWQ<(4"K?A!N=[?G[=;;8@WF(T,J
MM9,3:B6]G+KK:A9MIN/*KY[T9+%G*BMMMKD*06UK<*H[2&GVNAV,TN0&E;O$
M\8Z?3HU00A$D+*4**AP.+;Y:W*""=-!YGKC)TVK3*4MU<)8;4\V$+!0A84@'
MB"2% BQ.X.A(!.PQI0PK1?&_TSJ\IS"]M,TI*;*G'+W ,B#,R Z(DUQFRJI,
MT!,Z4TD!Y$</O* =:2W),N.AQ#N(;RK2F91D!#CB2HK#"UJ6A(*K@7N%%()/
MJ\1TWO=5]K3VAY@?IZ8B5LQ74M]PN1%92R^X$IX>\2  A*E)LI12D7-[!((X
M=P60\SW*QI*[#PNUU:TPPY59"BM0L6KK" TFF@J3_-(WW/1M/-T[*6U!2(CC
M$0--$++26R%'*KF4V%:.J3%C]VD<+)4E!0!H/4&J=P;<(&VFM\8*/0LQ5<+F
M,4VI3DNJ*URNY><#JU;J[U?\83S(*N0)V&-97/US9<HVJVFF18YB5[.SG5O&
M&UG ;C'L:N12)LY$F*Q.@OY1-@1:^73JBJ>F+7 =ELJF06%1'EJ4MM_7:S4Z
M-*:6SWW?R6U?=%IM:D\9*4D!XI[LI4+7LK7AMI:^-QROEG-=.E(D*B&'#DMD
M2&WW&TN*0 2V>XXU.)<XE#A*D)(2KUQ;3'/ABFG.2SI:I]\ATMA[UV(2UJ:@
MMN'_ .,8A23)= )V?E%:U;K" A)V.LF0REFS*>$$$%2M5J-C;78 ]$D#K<ZX
MW=V#-#O>3'+\*O40D@,H-R=$ 6)TMQJ]8\K #$_,K541A%<Z?E0K<MC9M93V
M"1OT]'?Y2-AU;=RI( .,=6%*XAM;3V=/'?XZZFX6E. J/K *  TN=K%5]+:7
M(TZ@8B+("95@N4^5!IMQ*D!)VZP@;=*@!V;*E(W\_,@'ON-HB"H60;\0.HUX
M=A< Z<AY7/,XJ*1PK47/5*"FR;Z*T.^^GM%M+<L4$U]NI\C,U1(ZU%MNKBH6
M4@@_)*LGT)*B=ATB44_B-_ 41QT++3(9INUN-Y:CXV2VB^PWX<<NS0]WM3Z]
MVRA%R=@%N+UWVXC;PZ<Y\TDR.Q=TXQB(I12F$B:PCK[ (9M)WI@D 'Y6RA(/
M3V22 K];JUJOQ6E51Y92"5)03IL2V@7ORVY;[\[8V[+DY\4B.UWA"6U.)3;^
MJ'7#PWWL 3IXZ>'HL?8K.J?^S)Y8'EDE3D'511)&QW.N.IOL?'\=AXXW"B)X
M*7$2-DI<'N><QH.85]Y6)J]^);1__P"#77'/_P#\JTU'MZO).7;2N$\XS59A
M16687@0M2/BU8;8SJVFBN!*@'8X>RJ?+<:<!3\1%A.CYFDD9B_W83U6HGQT3
M;W:^_&%YGR ^9_,8XZ@"2  220  -R2>P  [DD^!PS"XV&ZT\I&$:*\GF.Z@
MW5U>2^9-K7RKP'53%$KC-XOIC3Y'I=9YW0X!+;2AR5-U(KXL6OMLZ4J0RQBT
MVX;P23!:R/'<CZ3!C7D"4D*22E22"E0)!!!W!!'<$'N".X/!@QZ#W(_JC<:Q
M\IN@&I.0O.2,AR336@^_9CBE%V?>5#)HK6S=6I2B7;*QK),]W<[=<@[;#8"\
M@DH3_LZ^P:GX:XC( ).IY?\ 5H1X^[Y8N#%=)VW()3MOL=P0=_F\'W[$;;;C
M]H=?Z^OAANY U]N_G[M>7MWPKM*!V)_N_81MV[>.V_@\)S/U[L26%C:Q\];\
M]>O7!Q"MOW_4=OW_ (^>_P#?PN"VFMQ;F-_9SMR'A@TAP?@-CV^GOO[?U[\,
M6GB%K7OOUT&GLPIOO?P'EI?Y:8R%:=R1V]NKW/?<[<-2@V'&>*UB!R&G,$:X
M+#D+7]^"R_F'8G<]SOY/X=]OX_=Q+@%B;CW\C^NWPP46#]>P_/S^S?@PEP-!
M<G>W3Y"V"JM]]B=]N_;V_C\_W<-%_J^F_O'2VGAA+ #EKH2>?NY]=/'D<0]K
M!ECV-4$:'738T.ZR&:FMKB\Y_+^F$*=GOPD!25NR8\5)4G9:"R%*D!:?2"N+
MT&(Y,<(;T""@**Q=(*R0E)Y"X"EF^X0? 8PE;K$:C1B]("E<2'2A+9 5ZB0;
MCB(&JUH;38C58)*0"H0G&OY""S\1UOEOT4(6%$.H<00E#Z'T])2Z@!)+B=ME
M J2$@](Z4U#:#(CJ'& V0HKUXP?Q$W\]CH+BVPM\RO5B7]HNSTW96IY3C?<K
M*.Y 4"CNRDA0*0$@DFY(XB=3AJZQ75[;Z*9M$OZM,NGR:ELHE'8P]U6$5QEI
MI^I3D,'?;T[N;#6:^V@DB,W*@)LX#9]:8OF&98\)"I4>)QJ;[E2';V6V'KJ4
M0VFPLA*>[2;W^]2HBR2D#Z@[/9=4G0Z;-K'"B2Z\VXQ9!2XN"I*$-O/CBX2\
MHEQY00E +"FP4]Z'%'158SY>&UGZ,442XNLDG3'GYM15PWYEO87#A:;]!$9@
M+4MB T(\#UE!,5MF.9KBT)>=6.,R)'HRU,MH<4X7 V$I0KB(&@/#PBXN=3MP
MWVQ]*,0ER^!Y*FQ':0%*=!2&TI]8BYY<92JVESHD@D895)A&H%#DT'4S4-^!
M'DT:G7*_ '&W)LNKERF0&;>SFO@QIEI!CN%R)70X[4:,IPRXUK)=^$+6-D.N
MQU)4^U9SB'$ETV6.)/$E*6QIS"BI15Z@*0E)N5.DLJ>;,=ARS2@4AUL@)44F
MR@HIL2E1XDE-B.2@0;X/66L=FJ=)+;K:$%S=*?AFU;)*4D=RG<D^3OWW/$GI
M$E7K)0 #L-=!RVTQ7;II"$A2%DB]SJ>9\<4OY^-'K71KFFU4J9D)V/2Y=D=G
MJ'B4HI(C3<?S*?*MTHB+._4BHLWK&A="CZB7ZMPJW2MM:^P.)X5$=3<>1QP]
M)N/+3%-^&8=B;.8K6-6OVL66:LJQT8HK*&<79-"FV-X(/Z-XA08IU"T-;4&3
M\8*/X_;[O8^'^*^%W?\ 1^(=,(!86Q?+['?1*YU)YM*;4/X5X8GHK4VN47%@
M6U?"N7MQ5S\<QBG2]^J)K\BQEW3;??>+0R^K;J1U2-BZK].NUSH!L=>8OTPU
M9L+=<=>K:BE8(&Y_C?\ JWXLC0@@;\[Z[7'R]AORMB+"ZT\>E*D'L/ .^P.V
MQ'<=]O'TW[CA^)0$D?"_/3W_ !UPJ-K2X.M/5MW3L?V'P">(E"VG*^]M?+ZM
MB,CA-OE^VQ^&,G#1S/S\?V>WF.H3&A/G0P#5S0O),WRM_4.TN,(U*EVS^/W>
M2RJ^=98U:2U*DOQJB<L0Y%785T=U3<*(\Q/IY#2(\Z''9E,RX[&G5(U>E*DN
ML3 [&F*=*/2K*5&<6">)E04DI* "$((+=D@@<0QTFB?8->:@QI%.;C3J>&0X
MJ"A30G,M<*?\9;X5I<[P@%UQ);<XBI/%P+2!I*G563NM&/!R"PG5MC,]1V+(
MD.@J#RO_ 'I]A;BD)D-@ER2ON2H%2E[$\:&I@I3=Q7>%5EW!602KJ"0;G4&X
MUO?0X[4]-6T$]PE2 VVVW8#\(L4J;18!20!H +7T388V.<J'V7&JVHT6OSS-
MI,?3W$K=+%A4OW3:I-S/KI#>Z)<+'6767@B2WM*C&WEU#3C+S,F.9;3A"]HI
MV7I\UM"EVB,* LM>KBVMTE+8-TDBQ2I1VL0+;\UK>;J?!>=;CI5.F)*@K@(+
M;3FH*>^%[D$J"PD*MZW/;=KI?R0<OVED6,&,<<S.VCJ#IN<P<;G]#P [Q*J,
MU#IHS:5@K;!@//I)!7*=*4J&WP<O4V$$D,]^Z->]?LM0//A2 $)'D"=2"I0Q
MSN?F6L5%:R[(,=M6G<QB6TD::+7Q%Q>W])5M= +"UIDLP(45J#$BQX\6,E+;
M$6,RVQ&CH1^JAIIM"6T)3X"$(Z>Y!'<\9RP  L+"P L+= +;>0QKRU7OJ2;G
M4W.O,GKK]=2;CF^Y/9([[>P^GT [=OIPA4/'3ZM[1?\ ?B/"/-:A/@B0RTX@
M)ZB'$)4>Q!W3N"1\VVP2>Y\#SQ&+D^K[=K;:[Z8/'##ML<QBQZ_C:*I?;6.A
M0DP([JE)V(*5%2"LI4DE)0% =/R[  <2EI'#=:4$\B4I(UTVM<]#;EAP6L;*
M4/(GP_5B!<LY:]"\E:<^\].,86^XD@R8E7&KI*22.Z7X2&'B?E3\W6E?0 D$
M;J'%!RET^0%=Y$CJOHI?=!"B;[A21?;;;V7Q<:JE08*0S-D)X=0.]4I%@0+%
M"B4D>!'6^*GYG]G9I)<J<D8]-M<;6?46E@%FS@MJ)W3TM3=I2ND =E3O._24
M@[##R,IT]U5V5O1]!8((4D$<[+!(ZFRN'R QFF,V5)NP>#,E(-_O$%*__4V4
MC;2Y0?G?KXP*"*O!L+K0OU178GCD$.=/1Z@B4\..%]&ZNGK]/JZ=ST[[;G;?
MC+(1W:4HO?@2$7//A %_AC6G%]XXM=K<:U+MTXB3;V7QYP?V^^B=SI]]H-JS
MJ>(CRL3UJR"RNJ^>EM7PD?),9<;Q;(:4ND;?%I9K*J^4"=EMWH#1/H/(:F<0
M4\!Y*0E0]UORQ&/S/Z_EKC4YH=FF Z=:NZ>YWJCI>SK5@&)9- OLFTIDY,YA
M\+/(-<I4AO'K'(FJ3(W(%7,EHC?>B4TLXSJ]$FOZ61+^(9CPN+ <X_,EHYS,
MY'$SG"=%M3M-L\D2RC)KS/.82!K#5SL<@UL6LQC$\2Q>JT3TDJ< H,4B16X%
M'44H?I*VF9ATU53UD.$T"8,&_LY]";KF YP-&<7@0'I='C&65&HV;RDI/PM=
MB.#V4.[GJF.>&D6TN/ QZ*>ZES[B*@#8J4ER!=0Z#4^0P8[VV"=QOVV.Q\=R
M!XW_ !'N?!XO"W#?F;?EKX]+?JP:6-[WY6N;:;FUO<;_ )85V%J"T[^2""??
M8^-MMO&W;<=QU'\VJV/L^M\);2QUQ#_,SIRUJMH1J9AYA&PL9.+6=GCS3827
MQDU)'<M:+X=2@>E;]C%9AN@;%V+*D1RI*7E*&/FQQ*B2&2+E;*^ :7XP+H__
M & ^M<9"E2?0ZA$D@\(:>05VTNV3P.#8[ME0&AOIX8Y,\EN77*)VL8:;>>LE
MM4#;*_3*I3UJX(C<8!9_6>#JF]@".D]2@$)5T\,DE:9*2@\+B5'3HH*!MK;0
M$?+2V/IVF,LEM:GU#N2RMS:X( -C<':Q&]K!.M[W2^:J%%T]Q*LJ4/U3+M?2
MU]4N-#84W%;775T:%ZR9*Y*@ZJ2IA3REIAH?+SBWEOKZU</NZ^XMUQ1[QQQ0
M(.H"0!PZWL>$'0 :;W!OBBQ%[\-A"5)8:%[@ *4;DJ5P\(*22!Q:V.E\;@>3
M?EKQWESIV^:_F:MZK$[N35)5@F.6SX><PZ+<PUI78R8\=M^38Y[=UCKD.OHJ
M=J9*IZJ1/0\T_;S7X]%TF@4A%*:%3J:FHY2V>Z2XH?=A=_O%J)-G%(]5#:?6
M *K^LJPY]FS,KU>4C*V767I+0>(E.LH(,I;2A]T@;"*TXGO''7.$.+"3<-I!
M5K\YF<)TUUTYH<VYBJD6L;&+Z+C;5=1W,.-!<ES\>IZ^FD6JX<.2_P!$*T<K
M(MFB-.6F47@')[#<@(99URLS&)DR3(BJX8JTMW*QZSCJ&^[)2G\24*3PV"P%
M<7'>P(X=IH<-ZCT6)!J"$KFL*>(+:^]0TTZ\IQ+2BH#C<256/!='JH"2H@DM
MR9E\:+%-9#C,)^&4$]321U.;;=*.W8-I_6V[G?;;8 ;8$+-K)3ZVEE:Z"Y-@
M!8;\][\N6)%V4YWB@4I5>R5&][[DDZ\_: +7&#>FVC6HNMF4-8]A=)*M9TE2
M')LQ8+-520U*"%3[FQ4"Q!AM[[@*ZI#ZMV(;,B2MM@WX%-DS'4-L-%:^:K>H
MD:#C6H^J@7//R'/&+J=6APF2X\L)2E/"!_2=4G7@;1J5*M;7\-Q<['&Q?4G[
M)33;-<0IZVKU"LL6SFOJX4.9EEACJ\ZI'++UU2;>UBX%99-2XTJ2^2VS4_>T
M>UB0F8L=5G7W3G5T]/@T.)%CMH*$N.!(+CMCZZ][WN%< )/ @FP%@H'48Y'/
MKLR=(6]WBVVCQ):9"O4;;(X>&Q%BOFI9'%Q;$ "PY:/LJ<#T$S&1F.=ZL9!K
MQM5RH=;BN18+AF&X9!L);L;JNY%#C:'T6,R+#CF%7PG9#%-'5*EV+U7+M5QI
MT2^8[1!"T)6%"Q2I((UL;D$GE86M;EK;7%A]:2%)4I"P=%)/"18DBQ&H.Q!%
MB"+^5L\GY3>7^_24N:<TM5N@@FA0Y3'P %;07&V]@/Z(1L5$E0)[BHND4UX@
M+AL C6Z$<!W!_H</,C7XVTQ=:K549_!-D&W)Q9='+DYQ7T'ZK7.*Q9A]G#HY
M<1GONNUR*J?<4KTTNO1)L9*5>$*]>*N1TCP5!Q2CX&P/&.>RC3'/XLO-*)!T
M6E2>@ "D=3??6VOAE&LX51NP<##J>BD+25:@7)0M(V%_P\]!MBH>??9BW$)M
MUS$;JGN H)/HOQ/NY\)2-_2+I?6EQ((3^JE 4D!'2A/?C$2,F/I3>-(2K0)(
M=395@;;I/#H1H2-NMCC+L9W959,B(4FWXVE\7X>9"P/;ZVO@+8[#.2G%I^#\
MHG+7AUJ@-V6,:*Z=T<Y"5(4E,JMQJOBO!*FP$* <;.Q2 ".X'&SPV5QXD9AR
MW>,LMM+L;CB0D)-CS%QC3:A(1*G2Y+=PV_(==0#H0E:RH C6QL=1RQQ%?\I@
MT3MZ7G.&O,&"ZYB^:TE#@UU/;25,PLOQBD8FP6YBQV:7<X[-0*]*O\<,=LB"
M/2V-U22$-KY*!%_%*E"WNMOOKBEU^N7Z[XYZ--LPAZ?Y]B&:V.'8IJ'78Q?U
MMQ88+G,%^QQ#+H$.0AR9CV11(DF%,<J[6,'8<ER#,B3HZ7?B84J/*:9>1'A<
M6(UYYD=/<]TSQ+1'0W0U6A.DN.YUD.JEI47.IEMJ]EF3:BY+C]#BTFQEY=9X
MYB+%=C=/18_'@XYC=;CK+\?XVPE7UYDDUR))A&#$;\LNB&0\QFN^F6CF.1Y#
MLG,\HKH=I*8:4ZFFQJ.Z)N3W\G8;(C4M#'GV#A41ZBF$1V^IYYI"E N0.N#;
M'H@P8S42/'B1FPU'C--,,-IW*6VF4(;;0DJ)44H0D)&_T[GB\DBUMSUVTU&W
MUMA"/'G<Z<K6L.?YX7HA'4 022HD=P0-MO;Z[D]Q]>VV^Y15]-;:ZGPL>7/R
MPH-AY6(\ !T_7KA70?;N/&W<=_J1W_N]O<^8QRU.FMO#4FVO.WQP@]_U]<_*
MPTQ&VI][9T+&-3(DN1$@R;O[NL%QTMD%^7'4JM1)+C;@3%4\RZTOJV;4ZXPE
MW<$#C,4HQ5/+;D(%W A*%J'X-5<?""".+5)O;0!1!OOJ^:_M9N&W*I;RD&*'
MW7FDFP?LA);2L"RRD<*[ * *E)X@H;-EK43+5!+,55>A(ZDE1KO3*C\H!WBR
M8Y"@I/S*! 7N00>QXVU67H2SHN0@Z6LI!%AN!=!%AI8^/,XXXWVEU])X?1X+
MA &[#H-^*][I> T %P-+\L.FON<HEL&5-HVK0J5TI++\B.E14 !T-*;E[ 'J
M!3ZA [DD  G#3:%&C)6X)I:0@ A+R$E1ZBX4BY_J@"YL>F-UHG:!4ZDMI@T$
M/NKT)B/+2 !^)9"VW+7 !NI8 &MP-]8?--IEJAAV12<JP'%)%/'U!=EVF1KK
MH<C*&,=D0!'BMJ@M0XPA-75^Z[)L'#*#\)B.AO\ F[TUYY$;FN89U3A\#-+9
M2YWO&#*4VM8: *;6:21]XOBN.-82 DFRCH.\Y5@4V<7'JLXN,X$M\$$O-MA3
MEU%2G9)_S:4\((0 M94!Q( UT\Z@8YEU'<M/7.-O4\B6J=8N.6%/+J[!TOO>
MHJ9-,KH5)>L5..R!LRULE)4 6EI2CG[L=R("J7WBI,HK=<4Z+$J4H+*E:'4J
M41L-K  6&.]TVJ1?1UQ(KP=8BM,,-%+J7&RI*4IX&T)U"$)2 #J -"2J^&/6
M1;"Q< ;BN+6/3Z>AKYU.+&Q2  ?!V'2._4I7OL>,<D.*-P2+&]^1VO8 7ZV
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M=F-U'TT7%#E5E7P420-@K[FO+AI8_E#Z'46D4UL+23LJW0V/N-M=1M?YV>%
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M ;^!-NFGZ\*;1;=3NVM#B-AW0I+B3VWV[$CM_6-P=QP@%];6Z#:POTZ[^&'
M7L=+>.EA??S.NV@]V.9;G"Y=,)T6U\N8.(Y$9%#*A1\WAT2-WI>'V%G(E?\
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MT";;U6(YU71CNM$>TCWC];C=DMA!2Q\?5W#3DUQ)>^Y8"5AE-9<=:3I8CEJ
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MG\?FW/\ <#^'9I*U ).W2UA>WC[>?COA+7U)TO;G?Y'" _-VW]16VY)Z=^Q
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M66T!<M])>:6$^JM4<]4>5"$-DA"$H"S<\( XE6U.FW3W6VQ74M;ANMQ2U)'
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M7*0E[J;;DI0E2>I W6AATLJ5N/32A23TI)4HA224TT!L+7TN-!>_SUM?G;4
M84@CITW&$MV;2 !R(^RVA2MR%2$K )\#=:6U#8*.P5NH^-MR-VJ3<:&Y'B?S
M)Y6_;IA+<[?#KA#R"2F=52V8L@B0XIO8H9<45I#K95TJ(;95\B>KN\DD=1^8
MG90"2#Q'G<D:W&@MZHL!;Y6MA>8OUL?9\N@PW676(C7SEYYPMA*E$%*>K;=0
M/25 =_'SGQV]APETCBTN"+ 7L.IOSW&GCUPJKCU=+>PWY@GF#M[L?#2/O20
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MW/GH>?+?PWUVP2N1\0RPF.IQ"F9;;Z5EK<MI#3J%* 6I(!!6GP%$](/01L>
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MJDW-^ER/KQQ2<J3383PIXUDFX"TV2!:Y7P\7.PL-3L-L-RN=2B;&E=U%3Z7
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M<_/$F_7K?6WS]MOAAQX;,8DY M+*]U,T[Z7 H%*BHOUPW *1N $D$_7;\@U
M/>?ZO"H]0#=.GAS(-N6]\-OH;:D'EKN=-_KIB55_JG^/P_L/$^H.FHWUW\AJ
M,(G<:)Z>.@O?X;XK([=P)M[=LQ9L9U<>QDL.(]=#:VWFWB'F@T[T.%:%CH4
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M+ZR!X_@>?QD%B0+7-@/ "U_KYC$*R0=[<].OY#X>!PV"ZXI'](>IL!VV![^
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MO<[@^=P21X\ C?ZGVX4D"V]R0/K]GSV<+)L5';4[6N/&]K:;C3YX_'W]G.D
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MM4H+],]#DME!'0VA.Q4AQP*\'V3].&&-(_T3OC=MPZWY>KMK?PUZ89WS!/\
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MM(4XZZZYJ5D2&VVVT K6XM9"4(2"I2B$I!) X]'^S\A.0LG*40E*<K4,J42
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M_<F<<4?VR7^<LYI/]8<%_P!TV \?;G8Q_-EE7_AY_P"EZACXC[9_YS<U?\1
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M4H0A*4(0A(2A"$@)2E*4@!*4@ )2     -N/HE*0D!*0$I2 E( L  +  #8
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MOP5;.M&HV9*%E>8X4U"O!U3"N)M++"4\2(P>*E!PN3Y0]%B(;;4%N)<*E(X
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M_D[B09\,-1#\ROB6MOUN-B.9\O!E^0:O!#,:I-TA]WOAP-5-TH#<%9Y2%EQ
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M'+;V7FLON.RFY(S!E^#F!H-MJ08[4UR0VF.YQ$\;C9CJ*EILDA0L!KAG_P"
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M12EMSU)+9Z0KH6:LORJZ_E9V,]'9%"S13ZY)#Y<!=C1&I+:VF.[;6"^HOI*
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M&!P8,#@P8'!@QVUX#_T$PK_5+'/_  >'QY?U;_*M3_YA-_O+F/:J@?Y"HO\
MRFG?W-G'G,<]<Q%?S_<V<]U*UMP>:S628XAO;K6B-JC?/+2CJ*4]:DH(3U*
MW(W('?CT;R(@N]GN4F@0"YE*C(!.P*Z5'2"? 7QYU9[6&NT+-KB@2&\VUE9
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M/QFS'K1=4L--1UH2^N1&6ZLM<;(+8 =P^=0.?7ENP/F'R^FU,Q;4[,)7+O\
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M%A:X3H7US),-1* 2.S&HF74%QI\(17\S9(K$4/JD%],'*L!,*0T^4Q^ RI'
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M&4):[MALALK7<K&RY6[8LFY(<RY3,OTK,[^7Z57<PYFGR*JNEKK+U4J^7Y%
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<ZN^EIN.@8Y1@<&# X,&!P8,#@P8'!@P.#!C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g142578g15c64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g15c64.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1E84&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             $D   #G          $                          0
M            YP   $D                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   $D     4F=H=&QO;F<   #G    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   !)
M     %)G:'1L;VYG    YP    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      /,0    $   "@    ,P   >
M %^@   /%0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ ,P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M8]>KIEIP.GXM53&P&U5M@NTF8K4XQ 4#9G7%PQ/#P#QDQ2RZ7M&^&R.+B/\
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MD;=VWV_SG^C9^B]_^$:O'^M'UPRFVOW65-)VVO\ 9C5_O>E^^[_B_5N_TB]
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M_]D .$))300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0
M;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @
M $, 4P V     0 X0DE-!"(      2Y-30 J    "  ' 1(  P    $  0
M 1H !0    $   !B 1L !0    $   !J 2@  P    $  @   3$  @   !X
M  !R 3(  @   !0   "0AVD !     $   "D    T  .I@   "<0  ZF
M)Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C R.C(W(#$T
M.C S.C$Q   #H $  P    '__P  H ( !     $   #GH , !     $   !)
M          8! P #     0 &   !&@ %     0   1X!&P %     0   28!
M*  #     0 "   " 0 $     0   2X" @ $     0              2
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M  4    !   !)@$H  ,    !  (   (!  0    !   !+@("  0    !
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M  (1 0,1 ?_$ !X   (# 0 # 0$            )!P@*!@,$!0L"_\0 01
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MF'=^=P#D5R!VT[K7C+(6.O5=Z8+A:8!1AEL7>[?$21ZYPV5;]R2!8('9)D6
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M]?F\<CI]'.M<6_=W<-OI-[T)R#W[Q\JBK35S*[<J!L3;FMJO8$P-KB,I2HN
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M<0OQZ5)SEX_AX!&P)"00&S^1*D@@,/3T%Y'ZCN5EY'MR"/J#KRX^,EE/5FB
M02NS,.K $$JWVEG&X8#Z'M96X/OVL#]"-,UW.TXSVH8QEYM;3S7&K1K3K3J%
M-N-N-Q^ODK;<0K&%(6A6,I6A6,*2K&<9QC..L/VTP;K_ #LI#*V]]TLK*00P
M,^7(((]B"/<$>Q&FHW=')#\)<,4L;Q2Q=*-GQRQ2*R21R)B\(KQR(P#(Z,"K
M*P#*P((!&JK=E>.$=DN1<NMI.3P0=5QPS_A/J;$E"-A$FM8SX]6$O/0\>M6,
M*PG.6$Y5A6<)RF_?$W-(L.S*X8B*67/S.OOP9($PZ1-QSQRJV)0.1R.\\$<G
MG'?@<AC:?J98*@S11;/A1^!RL<[[F>50>.0&:M"2 >#V#D'@<.<W,42#I_:Y
MH:LH,#UK>BA583A>4DCU>4>85A&<9PK.'4)SA.<9PKQX\9\]+1MJ-)=QX"*0
M<QR9K%1R#GCE'O0*PY'!'*D^X/MIXMURR0;6W)/">V:' 9B6)@.2LD>.LNA
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M?/W_ "S_ %\9Z9/'U?V?;^OV_K)X_P#'2DY:\O#-S^Y?U)Y]OW^_U'YJ.?J
M3K^=)<O;?Q=M$O.P,>%9*]/L,#V6IR13P(\E@!;RP30Y!E#[L;*A+))9')4,
M:RMDLIE\-[*F7!^7<_3G';\H5ZUN:6C<J.[T<A#&LK0"4()8I86*+-!(J1L\
M?DB8.B,DJ@.KP6V>LF3Z6Y*Y?JUH<KCKD2KDL78F:N+'IRY@FKV528U[2/+)
M'&YAFC=)&22%CXWCMR!WHO?L,8B1T&B-JSA([4L\/L)<M.#"N+2DDP)M50B@
MB71T94ZT"[[&"O;PSDX;+GNMYU+\,_93F,.[3-?$;M75\.*]5Y "4BE89&Q+
M&KGA6E7O*<]WB?CM-\J_&]!+DZL=KI\U3$//$ENS'N/U=V"!F436(J_V+6BF
M:(%G6N98_*%"^9"W(>FVXAUM#K>?4AQ"7$*\9QY0O&%)SXSC&<><9QGQG&,X
M_KC&>E4(*DJ?8J2"/T(/!^FGT!# ,/<, 0?U!'(^ND!?I$6[0:1Q$IVF&"TX
ML.\-E1CKH&'$I4Y2];)199HQ:,>5JPS:R*(PVG*4H7DAUSW,*'PVXP/PYX.2
M]O&WFF7^#X+&3<2<$CUN2YJP1@_0=U47F)Y)^0#MX;D8+\1&;BQ^QX\1RIL9
M_)585C+A7%7'NN0GG5/=G5)X:<+<<!384EN>U67K^C9:T,D]\<AMOJ%SF,IN
MIX;7C93B?X?U38=M!L.$#Y5CPM]H'6Q&'U-YRL=DMI#GI0:G"]%^)C*)%@MN
M88/^+<RL^2:,?7Q8^H]8,WZ*7R7R@^S,C$>\?MG7PS8HOE=S9MHWXK8^IBX9
M2"(V:]8-NQ&I^C.@H5F;CW19%YX$@YV%=)QIP-9W>YGPYNU=V/-\B==0TC.T
MNVN,2UT:AF22Y&F6EIM#)LN2..EPA%?E_88D?JK?EJ.EG3AS/AL.1JR7'Z']
M2,7<PM79N9LPU,GCP]?&-99(X<G08EHJZ.Y"&Y6[GA].>&FKK$T7D<3!/.7X
MH^BF>I[EN=3=K4[>0Q>4,%G.PT(Y9KN&R<$:1/D1%"&E^S[*0Q3R6$Y-2WYF
MF,<+Q,.2IG=XW[6J:-79RHT6Z3\> R"'<9?$R(>7EAE+*#9\"//9%E#U^G#A
M#X:XA)#GJ<<;RM2U*D,E\.VT;N2>Y5R.5QE.:5I9<;7]-)$G>Q8Q5)IHFDKQ
M#GM19!9*+P W &H3"?&9OS&X2/'9+ X/.92O72"'-V)+=628QQA%L9&G7;Q6
MK#D=\S5I:"2.21&G.H-U#IG>?<"WP?=+1]1>AYF<$/V/L5T%8<!!0HOL#X@X
M%64?$=DF(D9N*KD",XZZTAI@B06T&R8>FU;BW+M7I#M.+&4?"MFM4DBPN&$H
MEMV[3][^JM@'R+ ]AVL7;;A58LZ0@R-'":-LS8^_OB-Z@3[BS8L_9EN]#/N+
M<1KO7QU2C 4B&*Q!(,3V8ZL:U*-2-Y6A55L77/XDLKYN=\4!!<(MP0<4.D2,
MAJ96HJ-%1Y] P$=9:R(&.CSG.?2R.RVVGSG.?"<><]*;TIL2V^J&W+5AS)/9
MR=VQ-(?J\LU*[)(Y_>SLS'_#KT$Z\5H:?1#?%2M&L5>KMV&M!$OLL<,%FE%%
M&H_)4154?N&J!=E/_K+?^3?_ .J]:[\3G_H1_P!9?_P&EM^!O_UH?]2?_P!M
MT\F4C1)F,D8@]&7094 R--;2K*%."'#N"DHPM/[R,K9=6G"L?=.<^<??'2L0
M325IX;$1[9:\L<T3$ @21.'0D'V/#*#P?8Z?:Q!'9@FK3#NBL0R02KSQW1RH
MT;CD?3E6(Y_+643(FZNW#R7S+9A$F+AW)B/B#I4$M%6V12)+RS[HAS:6U)R\
MTD0I]()'RX6:#0.4EU##K!+_ /DVQUIV1Z<6C&+"UIK$5>6,W\)E(?F[9(B2
M"%8R1J94\=JK(7C*LRO'Y(F#?'PP]4C>]!ZJ" W:E.Q:AD3%[HV_:(]H[:Q_
M@V $K33+ WFI7ZZI(LU;E+'VN3W,_:O-MRCZXC]?#PL>!._48>GU5<E9YNQ6
M@@-^.%(<>R(.\^H($J09!#"CF?;2<:Z4Z3C#.1^ML7IG@>EZY3,S9AK4TM7P
MV<E?$-"K3H)(DTB!?(ZIY)8X6EDEF;N,42QJGS=_<ZJ=;]U]>6P&U:&UUHP0
MY'U=3#8R6QF,ADLJ:\U:*0R^EK,5KUI[02**LH19II9I'5%,;VN)7&1&K^)H
MFDMCBLG%WF'M3NR(II7AE/X_$>!E(#+R%+PXL& =%ABB6U9;>*'(>8\,J;QA
M3NH^]%W'ORSN+%,R5Z$M.'$S,/F9,8P:*UVD*0)K(DL(A 98W16^8$Z]".BG
M3V?I_P!,<1M3+F*;(31W;N:2,?A+:RTKRRU W<WD])7>*D\P($S0-*J(KA%Q
MD;CT7RT[/W*^,V#6&94*/K5FEU:EVTY$.R%"V54C&7AW8*?]M+4>J0/KQN +
MC47R!9*-+6X;$/X:;A9];?X7/;1ZQ[2EQMMHGELU8?M?$"81W\9<0AA8K=W=
M)XX[$9DIVU5XY$X29>6F@TL.:V_O#HONQ,OCEF:C#8G7%Y5XVFH9"E,"/19(
M1>)!,T3*MBLYA)FC]14(\<4R3YR-[]'+#D!J6<U%#T[7.I1[I$$5ZXV>CHLQ
M=HDHB2&=!EHF (FIDQFN"S Q#HI3S+!\TVPO+8$N&M3CBZ_MOH#M/;V7@S$]
M[(Y<T95LTZM[TT=6.:)UDBFL+#$ILM"RAE5FCA)]Y(G  U8-Q_$'N;/8J;$8
M_%4\-)>B:K9N59[-FXR3(8Y$H\B'TLDG<563\>9 ?PG23B0,$[$';DV3KFU%
M<Q]XU>6I+I-5.@-*U&?%^GSQ@5H:::FM@R<6_P"F2APWX9#T+6A9)@0F6 F)
M&:P+F,7"&G9[U[ZDXS)U4V9@K4-Y4MI8S5R!C) DE4MX<?#*/PIF68B:R\3.
ML<D,</=Y!,B:%T%Z:Y/"2S[OSU>>C9LTVIXG'SJ(YEK6&BEFO68F'EADD$:P
MUX9/$ZQ-.\L;"2$I3WO)\3-S<5^8SG-W5<?),Z]NUZJ^SH2\0HOS$:XW-"N1
MLB<'8TI:6@!4Q9(G-N@CCVDQTKF2,B$.OEQ9;:[CT7W;A-U[,^XN6DB.0I4;
M>+FHS-XSDL+8$L:/6);\0PUYO23I&?)%XTF[0DBD4_K1M//;8WFG4/#12/1G
MMT<@;4*&08O+4EA'%M$'*U;)KI.DSGQ22235Y"I\8EF4?]):V>W1&HTGBO12
M-EHCDLNW!.RYUBE/2N$>,G_J\Q5')ML):_W\QJ=EY=QC.4)DD_;.(9OADQ9O
MM(F[+RXTR$K3.+@:ZL7]#[1]8("X^GD^S0/_ &>I)?B=NBHJ/L^JUX1 -97-
M2K5:;MX,@IG&M*L9;W\7KF8+\OF)^;3:.T#S-Y0\PM36V>Y%ZO)C!X*6;_!F
MZ H8:J5C8X<@X^Z3# UY:V723*OX;958X 4BO'"/- FO"S\>4N5R+K#LK:VS
M<O4K[;RJ3&>$^LPKSM;MXR2(!1-)8 952T>2*]AULQN&=%:!U\>Q=)=Y;FWE
MA;%W<>%:@T4R^BR<<)JT\K!,ID!K5II&G(KJ44V4[ZLX91',9DF1<U/?7_Q)
M=P?Y5U)_IG6>F9Z"?R:XG_+<O_VC/I9_B$_E$F_S/B_]V;6]CI!-/AK\]?M'
M?WVZ'_E78?\ PE(]>A_6'^(]W_+<=_Q*Z0?H-_'U/\SY'_;7TR+5&6.Y?WQ+
M5.W?'XFU'H:3MLQ UXM"2H9RA:/EQZK2Q_B/X?'5$V78\Q$W"<!(0ZS(_7)4
M%Y"6BL-M9KE@W3'H74@H\5<QN".I#8LH2D_KLY$UNXW>O:WFK8R&6G"ZD&+P
MQN"2O+:'BG3J/UXO2WBTV*VDMQZ-255:'LPEF&A$>T%E[9LM9.2[F[F<=D;@
M( B:PMM5Z6M>N;9 P7A4N=&^8]K+J6<$DB$CG(#]U>4MM_-^-D3"G5H9QE['
MNK0WZE85+;]RO0S./MVO[FBFXF;M+=D<J/$TO: 2?%Y/)PH+'M^4$\#3-[BI
MV<AA,C4J>]F6N?"O<%\CQNLHB[B0%\O9XN6(4=_S$+R=+PI7%C:5Y?>=M&,:
M_AVEY1[TFRD^5*7C/[WPX@<QE6&T_?"B#BPT9\I4.@I/K].QY/?N!Q2*M#G+
MV&'=VP,88(Q^7DL/&WN?;A(HY2 "',9XYQ/%]/=PY>1SD.,+61N \Z":S(0?
M?Q5HY5^7]7FEC'/!1)!R1\?<_!Z[5^LR=CHMJ:NJXL1XXRO$1*HB8(&&0IPC
M,2MH^0&DBDM)RX@%S +KV$*;&622MD=SL;:ZHXNW>@IY:@V,$\BQ1W%L>IK*
M[D!!8!AAD@C+'M,J^55)#2!$[W6/W9TBR]/'V+^%R2Y5J\3S2T9:QK6G2-2[
MFJZS31SR\#E8&$+-QQ&SR=D9K9PGT'!\A[Y89BZ8<+HVO6XM^1AFWG&,6":F
M'#<Q<82\TIM]$8TU&'%R?QG&WG<I"#]:6BGE]7;J?NVUL[$TZV+*QY3,-.L-
MDHK>DK5A%YYXT8,AE9IXXX.\%1S++P610<XZ0;,H[^S60MY=6GPV!6LT]0,5
M6_=MF;T]>5T(;T\:5Y9+*QLI?F"(MXY'4/$=U?K=^K/T=VA4]5.)$4"_6/PY
M$I@G15MY:4RJ,2)@3.,MYSCU>UZ\9_>PK"_WNE;7.YI+Z91<MDADHY!*E[UM
MCU:R ]P83^3R \C^EQ^7''MIQ)-NX"7&2823"8E\/+"U:7%MCZAH20,I1HGJ
M&+P,C*Q!4IP>3^NEI*[1NF&=O1EZC;E8!->!S+$V3JDF,8D6R'!R$%MP[%O=
MDFS&*ZMY&&7@RHB1E' ,K&Q-H>5@M.W#XA]S-MV?%3XVG)F9*S58\_'.\#('
M0QFR^.6%HWN!3W)+'9@@68"3TQ4>,K#_ ,C_ &''O2IN.IE,C!@*]Q,A)M&2
M"*Q7DGBE2:*M%E))A/%B^]"):DU:U8DB;Q+>B4>[5Y:6BX"*DYV;D0HB%A8\
MV6EY:2)9"CHN+CAG#)"1/,(6VP($$(RZ242^XAEAAIQUQ:4(5G& 112SRQP0
MQO+--(D444:EY)99&"1QQHH+.[L0JJH)9B  2=-J[I&CR2,J1QJSN[D*B(H+
M,S,> JJH)8D@  D^VOSS>Z%S0=YM\J+1?H5\G&K*:Q^K_4()"5L*54(<LEUZ
MR$#*].6C[C,$'6!Q+S:#!8TF(ARLKS$H5UZ)]*]DC8^U*M"=5^UKS?:&8=3W
M<6YD4+55OS2E"J5_8E&E6:5?:77GCU;WQ]]]USV*KL<-BU;'8@'V66%')L7N
MWN([KTP,B'A6]*E5)%#QL-:[.SAQ0+XK\+::/9XU4=LC<1:MO7H8EGVSXO-B
M "8J5<*]6<O,N0U1#B73H]W#:H^P24\RII+N75+3_K+NU-V;VNO5E\F,PZ_8
M^/96YCE%:1S;LI[ $3VWF[''/DKQP'N(  <'I#M)MH;*Q]6S'X\GDBV7RBGG
MN2S;2,15V!9@&JU(Z\#JI"&9)7 Y=B6K=91K3]'1HU%4KHG2$[*XG9O3>JIB
M;PXIW$S*Z\J,A*X=7C&%N8D"XAXO#B\8QA2_>]2L8QC.<XQU/U]U[HJ5_25=
MR9^M5("FM7S&1AKE1]!X8["Q\#\AV\:J]S9&R\A=3)7]H;7O9")F:._<P&)L
MW8V8 ,R6IJCSHS  ,5<$@ '4EA A1HC $<&* "*WAH8,(=H40=K'G.&V!V$-
MLLMXSG.<(;0E./.?&.H2666:1I9I))97/<\DKM)([?JSL2S']Y).K)%%%!&D
M,,<<,4:A8XHD6.-%'T5$0!54?D% &O0L-<KUNACJY:X&&L]>E&T,R<%88L&:
MAI%EMYLAMHZ+DF"02VT/LM/H00PXE+S3;J<86A*L<M.[<Q]F*[C[=FC<@8M!
M;ISRUK,+%2A:*>%TEC8HS*2C E6*GV)&NOD,=C\M2L8W*T*>3QUM/%:H9"K!
M=I68^X-X[%6RDD$R=RJW9)&R]R@\<@:YVE:MUEK7ZG^KG75$H'UKX7UG\%5&
MOU7ZM].^7]/^I_0H\#Y_P/GG?"^5[OQ?FE^QZ/D/>ONY//9S-^#[9S.6R_IO
M+Z;[3R-R_P"G\WC\W@]7-+XO+XHO+X^WR>*/NY[%XB\%M/:VU_5?=K;6W]N^
MN\'K?L+#8[$^L]-YO3>J]!6K^H]/ZB?P>7O\7GF\?;Y'[N[ZB=6#7P;%5JQ;
MX_,3;*Y VB*4OW%1EBB(^;CU.>E2/7D.2')&ROT+6CU9;\^E2D^?"LXSVZ=^
M]CIA8Q]VW0L <">G9FJS <@\"6!T<#D \=WU .NE?QN.RM=JF4H4LE5;W:M?
MJP7*['@CEH;$<D9]B1[K]"1^>N?I^J=7:]<==H.MJ#1W7TY0^Y3Z=7:TX\E6
M?*DNKA8X)3B59QYSA><XSG\\==O(Y_.Y@*N7S66R@3W09')7+P4CZ%19FE"\
M?NXU'8;:NU]N!UV]MO X%9.>\8;#X_%A^?KWBC7@#<_GSSSKONHG4]KXM@KE
M>MD25 VJ!A;-!')2DZ%L$6#,Q)B4+PXA)4=(L$AD)0M*5IP\RO"5IPK'C.,9
MZYJ]FQ4E2Q5GFK3Q\E)J\KPRIR.#V21LKKR"0>&'(/&N.2**9&CFCCEC;V:.
M1%=&'Z,K J?ZQJ)*EQ=XS4&=3:*)QUT52K,DS$BFQ5+4= KDZF02XIU)Z9>'
MKX<A@Q+JUNX*P1[^'%*7A?J5G.9>WNG<V0@]+?W%G;M;Q^+T]O+Y"S!XN /'
MX9K#Q^/@ =G;V\ #C@:C*>W\#CII;&/PF(HV)I3/-/3QM*M-+,Q)::66&%'D
ME)9B9&8N222>2=3KU!:E]>G(1\?+ EQDJ"')QIX[HAT?(#,F@FBOHRAX8L0E
M#@Y([R,Y0ZR\VMMQ&<I6G.,YQU]QR20R)+%(\4L;!XY(V9)$=3RK(ZD,K ^X
M92"#[@Z^6574JZJRL"&5@&5@?J"#R"#^8/MJO;?#CB&U-9LC7%;C>U8LO?(S
M/MZ.UBB:R1XPGW\RB:O@[+WIQA/N^_Z_&,8]7C&.K"=Y;O,'I3NK<AK <"L<
MYDS !SSQX3:\?'))X[>.3SJ#7:VV$N'(IMS KD&/+7EQ&/6XQ[0O)LBN)B>U
M57W?]D ?0#5BV&&!6&1166AAAFFV!QV&T,L,,,HPVRRRRWA+;333:4H;;0E*
M$(3A*<83C&.JXS,[,S,69B69F)+,Q/)9B>222>23[D^YU.@      < #V  ^
M@ _(#4$WOBIQ>VE93+GLWC=H38MPD6A&)"UWO3VO+=93F(\5H(!DR=L%=D)0
MEH(-AD01MXI:!A66F&<(:;0C$]0W9NG%5DI8O<N?QM.-G:.I0S.1IUD:1B\C
M)!7LQQ*SN2SD("S$LW)/.H+(;5VQE[)N97;F!R=LHL9M9##X^[9,:<]D9GLU
MY92B<GM7N[5Y/ '.I[Z@-3VJ]5'B/Q1U_-L6:A\8^/5)L@K1# M@J.E];UN;
M&8,94.6RQ+0U:"/9:*86M@AMLA*'V5J;=PI"LIS8KF[]V9&!JN0W1N*]69E9
MJ]S-Y*U S(>Y&:*>R\993[J2O*GW'!U 4-J;6Q5CU>+VW@,;:[&C]30P^.IV
M/&_'?'YJ]:.3L?@=R]W:W Y!X&LEW9 O0>GNYGLS6UY<;C9S8=4VWJH/)[F&
M'47JNW:%MRXYUPA2<^^6)2; &@=7\<J24&PWZGE);<;;KCCWS'2_$9.B#)#C
M;.'RC^,%U-"S0EJ>0! >%1[E=^_]E8^\GV]PJ_1?(+B^J^ZL3<=(Y<E]N5(^
M\@/)?HY46/$C,>26KQ779?=F,2G\CK:MTD^G'T=&C4"<G-UA\?-(WG:1#*2C
M(0!D2!"5C.4&6.:+8B81I[&$JSD5DXMHP_&/"L@"E8;S[OHQFV[&VQ)O#=.*
MP*/XX[4S26Y>0#%2K1O8M,O) \C0QM'#^7F>/N^7DBB=3-[5NGFR,[NRRGE.
M.KHE2$ABLV0NS1TJ$;]H+"+U4\33D E8%D8<D :2]VG-WGC[QN6KS49<B]D5
ME<T*Y]O6/8J8HDQK.$X3X;'-A9.9P_Z,X_CB )]*L?=#,_$'M>%]K8S.Q'MG
MPMX59%_FO3R82-O<GN9XK->KV<@_)),?;CYDL^$KJ'9L;ZS^U9T+U,]BFR<$
MQ;YH[^&E/L(@H5([-.[8+D,.UZT"@'N^70YTG.O0[7KEEB@"DG'$CAA!CO%F
M&%O-CBB"CMJ>())(>4AI@=AI"W7GG5I;:;2I:U)2G.<?2(TC*B*SN[!$1 69
MV8@*JJ 2S,2   220 .=?A(4%F(55!+,2   .223[  >Y)]@-8\>\9W<P=WL
M3?%7C%8%/ZE;)^'M39\4^MMK9A ;WJ54:J0WZ5+H Q32'):80K";D0R@8+S5
MFG'[*Y'1GI ^$:ONS=%?MRQ7R8G%S+[XU77VN6U/TOLI(AA(YIJ>]_X20*Z@
M=:.L$.4BL;1VK:$M!^8LSEJ[\QW%!X;'TI5/$E1C[6IU)2ROX$9:NTIE@+LN
M]N0_E3MT'>VT8![]GC3\Z*=AN0'S@+9^PHQ;)T74!4/(RT?7H1[XLM=E^'1W
MF/@5M:'/K1CL?8.MG4F/:N'DP&*L+]XLQ T;&-N7Q>.E!26VY4@QV;"]\5(>
MS*?)9]O%&)*_T.Z;2;DRL6Z,M7<8'#V%DJ+("J93*0.KQHH(YDJ4G DLD?AR
MS+'6)D4647<GTBNG@T=&C2Y*9RSY6[9E=LKU#Q'U=8Z=K'>>WM(-6&U\KY"E
MR\](ZDNDG3SIMRM,<<+.U$,2R@&Y!@),]*?%23D91I.6<ON:1=VEM/$18@9C
M=V6K7<I@L/G&KU-I178:\>8HQ78X!:;<U0S-")#&TAKQ=Y7N[%[NT9_2W-NS
M+-DI,5M?"34J.:S6&CGN[LMT[$[8;)6<;).]6+:EU(!,]8RK&+4W8K!2[$$Z
M\-N[@9FO-.\G;3L'1TE3]X<6*E7KM<]'2.P(<V/LE8N*UIJ5GI>SX2#E IFK
M3"A)4%^2S4V9.$FX@R'FH($A0KA!2Z?)DLSM>IC\Y';P>ZKEBC3SD>/F22M:
MI\>KJW<9//$\5J$/#(L0MF.:":.:&=U[@O/D-Z?9F(W-<MXMHLMMC&#*6\.U
MV(K9K2Q3R59ZM^**4-4M/6LP+,]1)HYJ\RRU5X3O9#UF^KSHZ-&CHT:.C1HZ
M-&CHT:.C1HZ-&CHT:.C1HZ-&CHT:.C1HZ-&CHT:.C1K%5WJ^(^PN*?+ 3F5J
M/ZO"4C:MR O05N@/6T_KG>P#S<M*LODM(5\%VRR(2KO EDJ])\@18X]MO+<1
MC#SM=$=WXW=FTGV3F/#/=Q5.2@U.QP5R6!D4Q1%5)'?Z6-_13HGO'&M:7GF4
ME4QZW;2RFU-UP[_P)F@JW[4%J6W7"\XO.P]H[W 7@0W^Q9U:42)+9:U%-\LD
M4<CI>W3WE-*<J*U7Z!NVPUW4'(L4<:-. G3!X.E;)-;;PU]9H\R<ZW'AR4DM
M.'"*5)%,2;!C^6(!4X&A;P^)]1^C&<VG:L7\)6LYG;CLTL<M=&GNXU"W]HO0
MH#(\<8/"W8T:)D'=/X']FVKIQUAP6\JM>CDIZ^(W*JB.:E.XAKWY%7DSXR61
MNV02 %C39_50D.H6:)5G=V'6(ZV34>[4U92-T46<USL.'Q-U6P-CI.#P00&0
MV\&4R:":$:*XT2&:$8.R0.^RYC]Y&6GDNCN/,N3&!SV4VSE:N:P]GTM^FSF*
M3L21&62-HI8I8I R212Q.R.C#Z'N4JZJPK^Z=KX/>>"O[;W'17(8C)1HEJLS
MR1,3%*D\$L4T+I+#-!/''-#+&ZLDB*?<<@P%HKA7QXXQS$I>*1$2#<^J+*#>
MM-OGUR;T/#+]+\@T&IQ 49&L.H81\P[XN"\C-*969@9Q]MRV;KZG;PWO5@QF
M6M0^B69)11Q]1:Z6+"\K$\O!DGF92Q\<7D\7>P81EPA6A; Z(=.NF5^SE]LX
MJ>/)SUWJMD<C?L7IX*CLLDL-?RL(*Z2%$,LB1"9U15>4IRI@[DGW<>#7&D20
M'F-OQ6S;F&VO#- TX\'?IQXI*%*P(=+QQ:*=7W4+PA)#5@LD<8TE>%-!D*QE
MOKL[9Z0[[W.\;08:;&TG(YR&9#X^NJ<@%TBE7UE@?4J:]:53P06'UU,;GZJ[
M'VJDJWLU7MW8@P^S,4RY"\T@3O6)UA8PU7<=O:;L]9/F4E@#SK*1SW[P?(?F
MHQ)T&'3^I?0Y2U-.ZYK$H^7+6X5#OK85L2UX9!(G6<YPES\/1XD36DKPSDR/
MEC!!Y+ILNG_1K;NR6BR%@_;>?3AER-F()!3<KPPQU0LZPD<D>IE:6R03V/"K
M&/2F]0>M6?WDD^,H*V#V_*'BDJ0R]]S(1%O;[0M*J\1N@'?2K]L/S21S26T[
M6'VNVKVC]J\TYN'V)L069UIQF#+00?;B!\AV'8[0SN</P6MA3&5X>9?6VH0^
MYDL.0<5Y?2"F;E17HMOAZF]7\5LJ"?&XQX<GN=U*)45N^MC"P]I\DZ'V= >Z
M.DK":4]ID\,3"0\_3#HWD]X35\MFXYL;MA>V4.P,5O+KSRL5%2.Z.JX'XMY@
M%*$+5$KLTD&Y76NMJ+IZAU?66M*S&4^BTR)8A:W7(AG+04<"QE2\_=:G'RBR
MGW'C9&1,=(/DY DJ1D"232B'W$4R62O9B_:R>3LRW+]V9I[-F9NZ261OS/T"
MJJ@)'&@5(XU6.-5154/+1HT\93K8_'UXJE*G"D%:M"H2*&*,<*B*/T^I)Y+$
MEF)8DGN.NCKMZ.C1I,7$3<V[Z/CE?!4+B!M'=$ CGKS(*3=JILOCU58ATPC=
M5AR3&-Q6R-KU&S8?C_2A+Y#L,V&\IS'Q'R$)4OK:=X87!WCM.>_O'$X6P=@[
M+4T;>,W':F5%P=;ME,N,Q%RKVR>Y51.74#YU4GC61[4S67I0;@KT]GYO+P+O
M;>Q6]2O;8@KR%MSY-F5(\GGJ-L&,DHQDK(I8$QETX8QQS5UEMZ>XW=PCE=O*
MHQNL;#<N-%+TKK?5 %JB[G*4_6]'NDO;I&1N]C@!FZY(VFUW&X'2 X4"9*@U
MZ%$%C\S,H^\ZL>1V1E,1!N;IWM/!VY,G6I;HN9O(Y62I+2CMY*_3@IQQTJ]A
MC8CJU*=*-&>=(GL3N\GAC55[N#>>-O/MOJ+N3)P+1GO;.&(J8];$=EZU#&C*
M7/+;EB40FW8M9.?NC@DGAAABB"SR,[]LZ\@-<;-X>ZNJ7).O<E=_[ OU.V7H
MZ+VU [%V-(6C6&U8#9NT:-J^[18>M#A<U'7RDN7%R:J9E$C*Z57EAM,+<D&L
MK;<@=O9'%[QRMS;5G;6 Q^/N8O/2XB?'8Z.KE,58Q>*O96C*^21_5Y#D4A!;
M2_+92P'8@1'AA.Y^M=VQ1IYRMFLO;N19C;M3)17KKV:&2K97,8_"VT^SV J4
M'5;[6ZTF,BI-'8AB$GF@,T$LJ\MGM"0.Q(^:Y'<[[IH"NGU.+#I6GZCOM&@7
M7Y >3FES][*+J$G#[#NC)^?H\6*V45^&J^[$',O)/<G<#@Q6T5W!8QTD.V]A
MT]P6([<KW<Q;V^=P*L;Q0"O15+D4^.I-'^-*Q1/4SB9&7Q^G[W[VZ)]OU;43
M[CWC)@J\T*"GCEW -O&26"5GGMK-5L5,A;#=]>*2,SM5C5.UXV,YU0R1Y0VH
MCA'W-8S4_).T;?@N.4A"-Z&Y& V[!U_>J]YIU(N*HDO8,"B-+GY:BV23LU61
M9GLXF21Q_A'E/9#1Z;]%M:HN^.F$F6VU6P\^Y(YCG]MR5#'06S1NWJ/F3'V#
M(M>*_6BK6S6'X*._DB50^J5)NB>;9?4V3$;@;*P[<]6F!S]>U#/9,,V"Q^45
M#>K!4LRXZ[;LTTL<>8Q01I9>:=)99&%F\;;1I^@7/:A/)WDS=-BP>G=DEVS%
MCVF>=KRU6@FBS#F9V,URL)-=U]F!G?;EJBQKL>J_24"BBFJE$X>6[G2;DJYC
M(4L6FV-LTL=/F<<M3TV*C3(5:JWX1X)<B'-C(>>#F*V<BUOR][LGB^4#15PL
MN.@L7FS.:MW%HV/4M9OR/4L3"LX\R4.!4HE)/Q(EQT5100 XDXU3"O:TW/7^
MW#6>:..6W)*8Y"U;B=!<DABYW9\Q)ZLEVH#5X^RF:+9]1/MYI5CCI2N"M5JP
M6&5C2+M,RSA=G(M:90P@A=VL9+"V.I5K97W2VW#MVUNZ?;3)!BX8LK";&4;%
MF_5S"GUU:2&RYM5Z\4JT88@E85#$BJ*#7BRL'36IO0[ASD^X*FRH-PB6>_*^
M.LO#B8\L:=O$#MQUB*=8_23VFKC)M&\DL=^*RYG'4;CK&VM%<-L<X8_DUO\
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2HT:.C1HZ-&CHT:.C1HZ-&O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g142578g21p99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g21p99.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %$ 7\# 1$  A$! Q$!_\0
M'P !  $$ P$! 0            8%!P@*! D+ @$#_\0 6A    8" 0 $! P3
M! @& @,  @,$!08'  $("1$2$Q05%B$V55976':2E9:7T]8*%Q@9&B(Q-SA!
M4G>TM;:WTM35(SEXE"0R-%-A=).S-4)1<7*Q)M&!IKC_Q  < 0$  04! 0
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M8WYNLS^.7$2RN3Q#*G@%^4,SRU_.D0&VMYO:SHPV$:1%FYP>'9>*/)XZZ=2
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M+]KA5J3YZ17=EFMT<#JW,O/+B6X.JQ.@1 O2!)AJE1@22"SG!Y(;D8##1[T
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M[>;.^9T5>KCY60-GECBZ4NL[97"-["7,VD-&NWOR7-<0TMRK42R8U;SFXO\
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MM/MQQR/BMM<]KGM:8W2-:S>P#0Z-?J=P73]RT_"JY,_X@KF_>-),Z7PW]CN
M]I<7^XP+9L;ZG4/Q*K^PC6/N32S5NP_0[?X#DW_Q'S;]WU59Y4\VK[+J_M)3
M_>KZ\^Y7[+.,O;JC_P"E^'EWSYR)64PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81:Q_T2GZ .*OMFMG] KO.[^89Z?S_P"+4/U[:DN%?LXPWM+Q
M%^UPJU)\](KNR^RC3"3"SB3!E'%# :4:4,19A9A8M" 86,.]" , M:$ 8=Z$
M$6M;UO6]9\(!!! ((T(/,$'M!'A!191SGF[RYLN!&UA/>0]J2J"JTJ-"YL+M
M*5QY;\A0=G:)%)5VA =).C3"  PI+(%SD0$TLL[N^]++&'7ZG"?#5"X,A3PF
M.KVVN<^.:.NQIA>_T3X&:='7<[L+H61G0D:Z$A1T.)QD$_68:->.8$EKVQ@;
M">TQM]#&3X2QK2KIP+G785,\7Z[IRDI=8%;6%&+DM&?R63,:Y&GCD@BTXC-=
M-30QJ$0E"GQHL:W:&*701;JT"2H3MMJYM4[7 $)-'W.$:64X@NY/*UJ=ZE/B
MZ%."O,Q[IX;%2Q=DDF#@UO1M?%:$8,<NYXZ1CV[#WV//B(+=^:S;BAG@DJUX
M(XWM)>R2&2PYSP=!M#FS!O>NU(W!PV]M#X]<R)94;]RBL.12BR7BWKUI=YA,
M>LQLD)XI:T6(X6/74V33%XD:QT3/  )T\-6E>&-YRIQ J.0E%)_!N],(O9KA
MBODH>'Z4%>C%C<1E8K<U"2$"M)291O575HH&1NB)<ZTT[7AK"T/)=NT!KNXN
M*RS'PLC@96IVFROKNC'1.@;!/$8FQAI9S,HY. ;H"=== ;$VOR)O*\I&Q2VV
M;2F,XD$63%(XNX.[L=K<93DJ0K0 CJ5'X*B8Q"7!"N.-:TR4Y0M %6>88I"$
MW4OCL)B,3!-6QV/JU(+#BZPR.,?[0YS2TF=S]SYN])8!(YP#"6@!O)9E:C3J
M1OBK5XHF2$F1K6CZ82-/IA.I?RY#<2 .0Y*765S%Y17#$3X'9MXV!,XDM&V&
MNS.\/(C"I"<RF%GM)\I4DEDK94>W*225:,^1J70TA824L+&%24 T.-1X8X?Q
MED7*&)IU;+!((Y8HM#")01(*[22RNU[26N$#8P6DM(VG16H,7CZLHFKTX(I!
MNVN8S3H]_)XC'H8@X$@B,-!!TTT5F9O/IG9+V7))Y)'25/Q3-'X\6ZO"C:E8
M!DBK*ACL=;=&;T'J2M#&VH&U&#J^T3)2P[V(6MBW*5*=6C$8*<$=>$RS3&.)
MNUO2V)7SSR:?[TDLCWN/A<XK+BAB@9T<,;8V;GOVL&C=\CS(]VGC<]SG'V2O
MV!S^:5?*6Z;U[)'2(RUI)=4S;(&51M*Y(B'QG<(^[E$'ZT+8 N#*ZN+:IUU?
M;I5AY?F[77BY3JY"N^I=@CLUI#&Z2&4;F/,,K)HB1X=DL;)&_P#::"ODT,5B
M-T,\;98G%I<QXU:2Q[9&:C_LO:UP]D!?C=/IFT0N35TVR1T10>9.T=?93&"%
M'8:7QXB074$;<'!/U;[Y0S!?';2(?:UHOP\_KT+>P]D^G5DM079((WVZL<\-
M>P1K)#%9,9G8QW@;*8H]_CV!'0Q.ECG=&TS1-D9'(1WS&R[>D#3X-^QNOW@K
MR0+F'RBJ^%M=>5[>EBQ&&L3@<YL3&ROZA*0Q*%;@6ZN!+(HUH2YG;75R+TM>
M6=N5)FEY4#/&ZHEFU*CO8NYPQP_D+4EV[B*-FU,P1S32PM<9FM88V&8>@EDC
MC.V*61KI(@&]&]NUNF--C,?8E=//4@EE>W:][V EXV[1O'8YS6\F/<"Y@TVD
M:#2F5?RJY%TL\2]]JRX9O"G*?J]N$U&T.HM)).Y:5J%Y3H\MBDM0V+75*L6*
MU*%S-1[7H#52D2)0G[\WMW,AP[@\K'6BR&,J6V4V[*O2Q]]7CVAACBD:1(R-
MS6M:^,.V/#6[VG0+[8QU&VV)EFK#*V$;8MS><;= TM8X:.#2  YH.UP !!2$
M<J^2%<2>?3.%758;'*[4[0K'?RY&M6.<V/VJ/7 7R12XC6#='5*L5*E2!W4]
MMS;CU2DU"K3C4';&M\.X.]!3JVL52FKX_E1A,#&QU&[6L+(&L#1'&YK6M?&W
M2-[6M#VN "38ZA.R&*:I ^.O]89T8#8N0!#&MT#6D  M'>N  (.BL,E5*42E
M.M1*#TBQ(>4J2*TIIB=2E4IS FD*$YY0@&DGDF@ 84:6,)A9@0C ((@ZWJ8<
MUKVN:YH<UP+7-< 6N:1H6N!U!!!T(/(CD5F$ @@@$$:$'F"#V@CP@K)NQN;'
M+2W(0.M[*Y!VA,82H"A Y,#S)EAR9^"V;+$WZE!Y>RULJ\#,*)/3^4:IT[I2
M24J#U*"BS0P%'A7AS&V^O4<+CZML%Y9-% T.A,FN\UP=65]P)#N@;'JTEI[T
MZ+ @Q.-K2]/!2KQ2C7:]L8U9N]%T>NHBUU(/1ANH)!Y$JQCA/IFZPJ.5RXR1
MT60:(/$@D$9BYZC8FEE>I64U$R-R0I^K^R5.Y3&T@6#[6^\TA)ZM!WH6Q2[*
M=6.U/>9!&VW9BAAGL!OTR6*N9#!&]WA;&99"T>#>5F"&)LKYVQM$TC6,DD [
MY[(RXL:X^$-WNT\6I5ZF'F9RKB]:@I^/7Y9C17!+2M8$D90R5822W1]RZ].$
M>:7#0MN[1'UP1# K8VMP2-2@LTXHY(,LXT(XJ;A;AVQ?.3GPU"6\Z1DSIWP-
M)DFC^MS2,^M23,Y%LLC'2-(!#M0"L-^*QTECK4E*N^?<'F1T8.Y[?0R.;Z%T
M@\#W-+AH-#R4*J[D)=M*-4S8JILV605EL-N*:IJTL+D).W2)(G*6$I=N",83
M4XEB(EQ7E(7(HLIQ0EK58$BHD*@[0\K(87%962K-D:%>W+2>9*LDS-SX'.+2
M[8X:':XL87L)+'%K2YIT"O6*52VZ)]FO%,^!Q=$Y[07,)T)T/;M):-S3JUV@
MU!T"H"FW++6.%:NJJ:OQ[C3C:SL]7+#%>]GP=LC\@72IE1, ^S_HA#;(G->[
MI0_;;+6*C#.O>MZ#J\W&T&LOQMJPAF3?+)D&AO*W)-"RO*^;_>,D$;(G=FK6
M@*L5H V=HB8&VG/=8 '*9SV-B>7^,NC:UI\8"F4"Y/<@:OE\UG<!MJ91F460
MJ6+K!<$+GL9$W6+W)4\*5,K:51:AG?SMNBU8X$#=&]2)(K5J3TFR!G&;%C7,
M!ALA6JT[F-JV*]%K64F/9SJ-8QL36UY&ELL(Z-C&$1O;N:UH=J %:GQ]*S%%
M#/6BDC@ $(+><(#0T"-PT>SO6AIVN&H !UT7#?.1][R6532;R"UIH\2RQ(0L
MK6:/C@\'JEK]7RXM"4IA:G9O:+)C(BFQ 46SHRTZ%.6E*+3DE UO6ZHL'B(*
M]6I#CJL5:E;;?JPLB#60W6%Y;:;IS-C5[R97%SW%Q+B2OK*-...*%E:)L<$P
MGB8&@!DX)(E'A,FKB=YU<=3J2OY1[D1>,3?*UDL9M*9,3]3S$KB]9.C6\'HU
M<.C;@N>')Q8&D9.PZ"SN*N0/8G%M4:/2+R718E5E')#A$9]GPF)LQ7H+&/JS
M0Y.9EB_')$US;4\;(F1S2 __ '8VPQ;)!H]AC:YI#@"OKZ-21EB.2O$]EIXD
ML-<W42O:UC6O<#_::&,VN&A!:"-"-579ERMY'6$Y11VFMR3B1KH',"9["!N+
ML(9$/EJ<ID)3N\71  6B81)P1QEVG1M:=*WD&H0'E) '&J##;-7AW!TH[,=7
M&5(&7*IIV]D>CK58F8F*P\DOFW&>7<Z1SGD/T+B T"B+'48&R-BJPL$T70S:
M-YRQ]_WLA.I?KTC]2XEQW'4JR;^_/,J?GN3R)Q5/$@D;NY/SZ[KC.]6NCR\+
M#G!S<5AN]:V:J7+5!ZE09O6NV::,75Y\E888J\,5>!C8H((HX88V#1L<43 R
M-C1X&L8T- \  66QC8V,C8T-9&UK&-'(-:T!K6@>(  #V%2,NJI;L/T.W^ Y
M-_\ $?-OW?55GE3S:OLNK^TE/]ZOKS[E?LLXR]NJ/_I?AY=\^<B5E,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6L?]$I^@#BK[9K9_0*[SN_F&
M>G\_^+4/U[:DN%?LXPWM+Q%^UPJU)\](KNR81,(F$3")A$PBROH#C 5;,,G]
MQ6-9S#1M"UBO8V"3V6_,;S*USK,Y.!4='X% 84P]TYS*7+4:%8[+$9:UL;F-
MD3&NSTZ(4PB-G:YF>(#C;5+&4<?-E\QD&2S5Z$,T59D=6N6B:Y<M3:QU:S'/
M;&UQ9(^65PCBC<[72.NY#JTL-6"N^W<L->^.!CV1M;%&6A\T\K^]BB!<&@[7
M.>\[6M//2*6O3T$8'V'H*%N-)R.;YJ0M A3,%?S"'3]F>$"@LDQCD4 =R7(\
MI2M*/*5LRN/ODD;W,@*L(5)*A$>1K)QV3MS0VGYC&.P;ZCF;W37*UFG+$]NH
MF@NQF,%K2"V5LT4#XW;=6D/!5RM:F>R4W*IHNB(U+YHI87M<-=\<S=H(!!#@
M]D;FG3EHX%6M>:YL&.R=)"9!!)DQ3-P,1E((B\QA[;).M-<3>X;RTC"M0D.J
MDQ>=KN48"4@Q*C?[,C0Q^;)"*]2GKNMPW*LU5@>7V8K$4E=@C&KRZ9CS&T,'
M-^KAM',Z!9#)X)(S*R:)\3==9&2,=&-HU=J\$M&@YG4\AVKY4UY/T8XP4K@T
MP2F3;0A0PM3&7H@<N"%0%((48 :B")_T%6,"46VK2O6E PD[_M!:#LV[2<+!
M;;JN%3E:+;$1%;D7?[00_P"D]Z"[Z9MY GL03PGI-)HCT/UW21AZ+EK],Y]Y
MRY]]IRYJXD/I@1LIFL3M]1.Z?=(O64SG*%O65++9*^.;U'68QU8X\ZQ\@;0Y
M1=CD)A0R5T[<BS&2,)0B<W$@Y*$?9PK.4TKU;&,;4R<=B_5J/>W)5H(HXIY1
M'--',1*RQ+ ""RG'I+8=I&PAQ5B6T!'%)6Z&RV2Q%"YPLQ1L:Q[PU[VO.YLC
MV ZMA:0Z0Z-!!4%9*OLN3%:.C==SJ0$[9#9+HYDB3^ZE;CB=8K;CW_1B!O4
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M]TV!%UZ;P>&GFK>PET4'PHXQ3U=Z8(>[G3T!TA$M4=-SE[Z(=*=H9K)_O]X
MS5VO>@-[!HJO/_P)WVG%?#O?>C^J=/OCH!WWTSGWN@Y^#0=BJ+;JUF9]-E#.
M;.FF3''*E!TB;53XA?35"X8C%IYKNE-*<##EA@QC5&C4;&H&,0C1#$+>]VWO
MQ<L(KRFC)7 :T0/Z!\(:P:,:(G:L :  T!NC0-!HOCN/. GLZ-W%/#CH] .C
M=DJ19H.P;#(6Z#0:#3EX%QO ;)T[GR#N9CX^4C5F*7OM._C=08X$G)EYA[EV
MO#31K4Z@\A6(PX0E))YQ1VQ@,&$5738[HA#TE/H6AH;%K#T30PAS (_0@,<U
MI;H.](!&A 7WS_<![0SSU<.[!IHSNG3VC:01HWI-!H0".7(@:+AZ89T%O,:0
MMDE"U'+"7 ULT0X:;S7!.2<F(7&(M:\&&L)3J%!!*D1>SBR3SB@#" T815=9
MH[Q+TU7I TL$F^/>&.(<Y@?KN#2YK7%NNA+02-0%]\__  +NW>>OA[< 6AW=
M.GNVD@D:])KH2 2.S4 ^!5-*5:2%U;'U$*<(WME3I4C,\)3WI.ZM*1"G\$1)
M6QP), K0)T:3>TJ4E*<46G3_ -B4$!?VN4.DQCXY(7NI.BE<YTL3NA='*Y[M
MSW2,.K7N<[OG%P)<[F=2J3Q[P$6N8>*>'"QY)<TY*D6N+CJ2YIDT<2>9)!U/
M,KCNK?8[Z/1CV1,'D>E*U;H;KMV<1Z6.9H#W)7H2L1V]*7 XLLY:?U]ZK-
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M7(^YCOZ>GD:\>N5//<0;YD8Z_#Y)QO\ F'S].HS^5<C[F._IZXD9"[M\UE3
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MGZM^]*3M J92%NXR-L*M&>+C7EXE;?:TQ<(DSO[BZE.S^[P^O34:0+5XV/\
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M >) 6!QU:2TM5BVGC@<EJ^S+)LJ5[K<N W1#J)2M:V/*GH3O-70][5SX*DQ
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M47_IO8\F +7@A28$0@NO@I1O91".[!8MO'$58312=!/I'PD_AXCZ7J;+JLT
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M:91'WDCF"8=Z_;$#7C$??56LK7F@N0AV0GZW/#+K9E9I"R.5SS#$T&0-[UQ
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M/>]SW.>]SGO<2YSWDN<XGM+G$DDGPDG4K/:UK&M8QK6,: &M: UK0.P-:-
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MR?N5?C3ZK>+'>[9^)5F'/9TFB,5D:E.4D42".,;V>D(,&<2E.=6Q*O-3DG&
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MTUAO;*7^#Y53W(Q2281,(F$3")A$PB@55?>OK?VA0_\ 9YNR3S7JSEO;._\
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MCB-'L>TEIZJVM+5/2XZW:JV6=\S=:LSUI'#LCLUII9(I8G>A>=HE:TDQ21O
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M4?I(@0($XPE)D9  D)0=9*8!1 0%A]3T:53&58J5"!E:M"T-8Q@T+B  997
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MVHKT@5I4G"Z^X[H7J96[ 9? G>L*>02!C1+%<69*?BL@#.W92J;U2EX)EY+
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MBW[)\][:W?V[ULG#/V/87VMJ?L6K"/I_?[JWDE_RT0_:QJR8\SK[*JGXM?\
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MO6!Z+X(A]')Q2"'6Q"%2C2$(=:Z][%L3AK6M:_'O>]]6M9YIXR^RS,_CW_\
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MY])7BH( ^6C3<@>7%\C1,'3%NTK@A;NL-7FPYWB19H7MR;6A0H/31QZCZ5X
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M#JK)(YG0O!Z2-KY99FM$C=6.(9O#7'8YKM'#TD"BBR2RR2@!+**  HHL&M!
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K12;")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g142578g21v14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g21v14.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1[^4&AO=&]S:&]P(#,N,  X0DE-! 0
M     #D< 5H  QLE1QP"   "   < E  "4=I;"!(86MI;1P"!0 74&]W97)0
M;VEN="!0<F5S96YT871I;VX .$))300E       0.2EYEG^3EMI5F%K4QQHA
M*CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!3@           "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 \     !  $#P     $  3A"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          3A"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         3@   #$          $                          0
M        Q    3@                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   3@     4F=H=&QO;F<   #$    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   $X
M %)G:'1L;VYG    Q     -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $     SA"24T$#      4E@    $   !E    H    3   +X
M   4>@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M?4-3[,=WHT'TG54_J]5U-%EK?YS^=K_P]A^@X/UAQ,AM?4+Q9B58E5+6M<'
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M?3J_-]OI^S^;5*^K)V/M.-5DEUEE]>'<\"RMMCG6-L-+=S/4VN_2676?J_\
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M!TS'KM]-UKK;JZ&,;/TK3L:YVQMMFUO_  =5KU1Q_K=TRVK'NM#\=F26BLV
M$":*,T^JYA<VO9]J92__ (1EG^#24[J2P/\ GAT\ NLJR*FM>18ZRLM].L,]
M;[5D;O=338QEOH;_ -+=Z?Z-7>G==P>I6BG%]0O%?JV!U;@& 6/QO3M?]!MS
MK:+]M>[_  7J?S:2G!^O'61@WX5-3!;DD.M@F&L#+*;&/='N?OLI]FW_ $:T
MOJCUNKJO2]C:O0NPMN/97.YOM:/2LK?#=S+&?YC_ /MQ0^MW0*.JXK,@-?\
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M[$U.H=3Q^GG%%X>3F9#,6K8)]]@<YN_7VU_HUE-^NO2GU&\57BH5UV%[A6P
MWVVX6)0[U;F?I<C(QK&_Z"K^=R;J*EK=0Z;A]1I;3EL+VL>VVLM<YCV6,.ZN
MVJVES+:WM_D/5.GZK="HQ78M.,65.957I9;N QWV9.*:[?4]6NRB^^VUEU;_
M %?Y:2G/_P"??3@]SS1;]C;C"\Y(=6X"PY%G3?LFUEA:Y_VRKT69%5MF)_A/
M7^S?K"M],^MF!U3*JQ<.B][[*WV6.BLUU"NQ^)9ZUS+GUO=Z]6QGV9V1ZO\
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MS&(B9#4@>EWTDDE8:"DDDDE*22224I))))3_ /_9.$))300A      !5
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(
M     49-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0
M  $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L
M @    H   "PAVD !     $   "\    Z  +YN   "<0  OFX   )Q!!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C R.C(W(#$X.C0X.C(Q
M $=I;"!(86MI;0     #H $  P    '__P  H ( !     $   #$H , !
M  $   $X          8! P #     0 &   !&@ %     0   38!&P %
M 0   3X!*  #     0 "   " 0 $     0   48" @ $     0
M    2     $   !(     3A"24T#_0      "           _^$!2$U- "H
M   (  @!$@ #     0     !&@ %     0   &X!&P %     0   '8!*  #
M     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "@   +"'
M:0 $     0   +P   #H   #P     $   /      4%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I #(P,38Z,#(Z,C<@,3@Z-#@Z,C$ 1VEL($AA:VEM
M      .@ 0 #     ?__  "@ @ $     0   ,2@ P $     0   3@
M    !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,
M   !  (   (!  0    !   !1@("  0    !              /      0
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M 0$!             0($!08' P@)"O_$ $T1  $# P(#!04&! ,%!08'  $
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M<+C7;LVQM,M9063JQV7%4K'V>9AWJ;?V_@7<R>(&"),.!=M&*,FX=!'' A2
M/7Y?/']3G"C.WKGW^[Z'-89V$[,,JO-QZ&:LU8IR/2:S1\!26$5ULUY#87F<
MFW,H9ZE.PU3CF52J3!KC>-(*3N-D'S"85D'<G*)%?@#0Q=%(F,F?K^JZ=Z-F
M%+%)9YS19+?9(B_8<V./+SLMV>6-N!W9'^/$;>Q;R$J611=J1#J7@(S'L962
MOV;1-;\.G9!!8W9QSHDR9QUGUZ<OH0,A6.9%W996VD9Y<0FZE"FDVMY6L47%
M8BSW"I.H=CC&PR";6-5Q_EY-]).XMC'K+))34):U5HDDA^)RK K93\%,<:8\
M0,QY=5+07'0T%SCX@T"7$#<XS Y])SR5E9W"3A(RH"(%(<JA#D."A2))+)B9
M8A^!+PJ0>?'/ZD3B \<\S5<:=)S@=MSCG&,],SRY*@TRZL*1!#R6PR/$3( @
M;YVZGEA4L[E+DEN2W SM.>NG26'-NKEG%3J+9<Z32V9)F6K:>>-GX$'X>1BX
MBN.:P+9F)>1=/Y+W#G*H0A.7=H^,.+J]OWK=+6$%A<R7DZMAI]IV&Q)PT=5]
M,?9WP \)X>SB5:W>R_N#WEJVHRHUQITPR&L&H-+6NU.#M,R^#L%@;)&3(.I1
M*DG.G0KU6A.J+0B2B;!HF3H;V#+IG B8 *)!. "(!U 3!SQKFMW>DMBI4:QH
M@ '2!T/KYGUD[SV*P[ZHXG[M6U5':G/>V2X]"= AH.P&!C"@G9-X4RJV?2U+
MI+0]=:"<B,U/$<IQ[Q4 $_+9X"B*"@*DZJ%$AA 2G*(?+P(Z[7KVSCFXHS!D
M%XVGF9Z[^JVZUX8VHT&I+,S+VN;CXYGE&<'F %'V#W);C<UKV]]0;%5:*XH;
M#XS]&T( LR+W]295VX75<.S*F1.T(X=G$ *""!%#@/0HB$V]R6,#:/BIZG%I
M;EI/XA.1(.^^=X5Y7X#P_NB_[U;BI$:'.?KW&!_%&.F!(QR*FELUS5:L\8FL
M4Q=HR#:7REW)W5%W;.-791\PR&,BWS-RJV,Z4(/9P[>@0R9B%-P< Y$!XR5&
MZK%I/=.$'>(WY;  XZ3U6IW-!]K6 HS4&D@"F#$LYB9+L$3R&(&3/897=#@2
M+LBM,?9 @V<_'O#Q[M$'L>@R-)@*B"\>FJJJ?VEBG!7DOS'3!,QNO)1'7LR^
M8YP95>UC3[1<6@-Q(/(F3#?4^D^C^(<3H4'U&VERXM+8(8)DN:-^Z(YCW3R7
M<;C4ZA?:VW>K$2=^RF+R-EX1R+>98$-R)7,#,MS"O$."G*"@RJHNVASE( -0
M%$PGJ;Q:K:/BV>^H&Y!IZ'@YV!+'1L3).>0!R/"JRGQ:DX<18VD7- <+@N80
M2#)(::<[^R(B,DC"F?LUWR6V#N$/MLW,NDG4X_;'B<6Y47($,C?4H]J<R$18
M^Y@9(6]=FU%58S(K8%WJ3@B;!+N4J?7.R_:=E9E-G$;FE2?H :^M5IL=[,0[
M#!)Y& <1N<?-_P!H'V?T*%2M=\(TU*+G.J5Z%!E2HVDR27U&?Q''2T2YS0=,
M3&AHS=8P<H&8H*>X0I.@_4X<%X$?E$PCYZAP'81^8.#??71:=1M=K:E)S:K'
MB6OID.:X#$@MD':,+A]:E]V>ZD[PBGCQ2,#GG/Y])*W9'""A 4363.0?H<IP
M,7_$!XU5Y<UYM(>):=0ZC/Y+4 Y3#P!@$1#D Y^WTYT4\XY].:^M$31$T1-$
M31$T1-$31$T1-$31%AS..6:C@S$=]RS=G'P]8ID"N_?(%*!W4H[470CH>$:)
MB)?=?3\N]8PC)(QBD5>2")#G(F8QBD6)Z/N*);+72ZM)X[LM6;6;"M=R\>V2
MKFGDK=;9VEY-L6],G8]:SIVYC+LVL$F[=/&U8=U5--\FD-A^,;OVS0,?TY=/
MTY?NH^'GZ>?3\HSS68X#*F)K?,.ZK6,DX^L\RQ9DD',# VJLSK])@'4!='B(
MR4=/4$ ,=/APJV(D/8OMG.4>0*5],,IXPF+(O2H#)-(F;I& 1P]J$/<H)U/L
M4!$Q>[ZOM'ZTDV13Z?KR+-2% /)P #>2+'.*,ZU^[XVE<G3T&_Q#"PUIL%;=
M#E"PT2-332KTJ$46?5E:U;;/ Q4-)<@$*T>RK>901<IM)6)BUS'0*&?K?T4"
M>G]O,=?BL>8KW7XAW'V;<QBE@W;O8# MFB:)<+5-+UJ9HME3LU)K]U+*Q;]I
M-2#)[76\;:$&;QS)? )@NU=$%,42 H9.\=/CY>_SPGNG]/[?%96V[1^WR!Q\
MWJ&VE/&4;CBLF*R85O$\E6'-7@E%2=_PPC>IN'$.R60*W]DK=NH<A2IB!#"0
MO;3D///Q3$SY[YD_'?R\MBN_7VJU:]5V9IUTKD9:JA889Y$6.N34>D_BY"*D
M4U6[EE(1SA)=&0:*%]\%TA25,<BO4B*G80U'XAY#/OV]8RJZ)(N6PZ(82=_$
M)VV@S_XBT9WW5/\ .1F4_2H=ED:LK;<N;#';(T*K36K1W8+MM*239+?@,G!M
MSJB,[A&*4;M81_#0?M2=49K1BL?6WT4Q?.F/E>.(MGO V:=AM'7RG/7D"O2V
M K<;MF._RWU*3';Y:7-!C'@)!Q$B1),B%%?;[9HBT8:F;S69U"1:Y-OEJM;F
MSPBJB+60"3F'#(KENZ5!M)'61B6$8FXBI%FR52 J:?[ E,/!N.&;X'3#C4=,
M-ZGK,^<';?,D+[6M6M%EPL-+7-IVU)K?')&B6AVF(Y :\DD$$",QOR>L>2SK
M.M+.A#*M:55FE@I=!>NR%C[&VF%V*+ATU152%%PE"$>%4CHX40<QZQ&ZJJ+4
MC151+4N*,]K $^+$ 0=L CKRVQ*W#A-9OA:'./X9.K5+3N20#/(F8,XWSB*>
M:J23GXJ41--U"6<@W5;H(@23IB_'4_QK(X^&Q"F R*Z1Q*HF03%#@=:D:!+B
M WF?Y>7J1\EMPJ^'.PVG<^?29'KCX1UQHW:84RGE-W-#_P!!+X_M"I728<D?
M-CO6KV,=]1X\KD13C>!^8/CQ*/)3&#63L:)8T-B(,\L;^?+^V%:7#]69S[QR
MSN/.,'/4+.V)K8YPUL(GLBLQ3B[;F2U6,((B[=14R2LZL,)!CW2(842D"'5-
MW$2@0#E$OWXV$-T4B1&IP(R/:!'+I!D><3@+ N>7W#0X$-ID.!#BWQR1I<!E
MPC2<C,0>JXW/U3J50.WJBS1LYJ];B2Q#)!VB1PW>0T?[3!(B292JJR$U,2R<
M8JJ5-N8S=@=^^6/[;93G#5Z?B<($:HF.A.PWR1^:S]DUER64G^S4$D$%VPF
M# .0,SR/-8:VL9Y##N:&^*F[Q=_CZXR\:G$(LRK?AU-L4D)$EXM11<$$Q4.E
M\*X,DB0>I3EY 1$=>M!L.Z#&=\"1\CT)^,JN[X/:EI T;'_NFP>FT=,&!SPK
M<[K38>^UMU 3@*F,2134C)D ^'E:[9XUQ\2QG8E4WZP6_P 6@4#F;J)J&;K'
MX\"/.=HO  DP!B1U] )(Q^2U2YX+;N)AK,Y'\)LP=_%,SF0,Y$<RK$=@NZ&<
MNK>1V[9I<(JY8QZ5H^B)M4 &-R#27(K-8J?B5EC>\:>@W3!^RG&*B0*H(J1#
MHJJA7P%3[%V4X[3J6EK9.<#6H>&-3Y<TN)]HL U#5L"<0!M ^6OM0[$_<.(W
M-_:V^FQK-#Y8RF&TJ\F8IAX+:=3VB0 &NUET:@76E,R$3 Z1P(43J<\E 1*8
MOGJ<2=0ZG.'!CE_W3>.3<<COQ&H!S1OOMD\\\XVY]<2N*4B:+BQPATD=1 G,
M#&=R.74KDT^ 4 OW @_;[<\_ZZM16!J]QSTE_P #'3]?=S5R6_C.YQ'Q,_F%
MNM>RA-$31$T1-$31$T1-$31$T1-$50_K'M; ?:E4GS!TNC5(C<EMNFLBA[?+
M5>AIYFIZ*K.4.;DB#%&:<0;M=RH8OEH4JAQ*<P"185W&FG'/J&WV0K7XP-0?
M^EG%%B'S)%ZY@"R9LD;A%VJ+9)!0L:XDS1KB,,W2!,RAF9F2A2B50!,3,?'I
MS]WPG^JA)M^P##8@F?0PNF/Z)8:I=+UAF50SQ/0[^85G[&BIM0N\V]8VO\24
MD#RLHXN;&%<,BR@+I,WZ92-VI53DZP-A//Z^O-.HY[QU\^OORL(;9;;1L?;O
M<'U?&\]C3<)9[3N>N+6;IEG@KM3]YN#8Z>OR86"SW2SU3(<- 7#&4")C/HR.
MNV+I!B# JC,KT&A!(,H)@$_$;>Y<K&?C,!M>VOVK/2-N?[3ZWZG.XJ0W-)&5
MG&<<G19&#RU&X\E[NNNZ46_JZ8Y"?TH[\C]ZE% Z/&KK*']HB2D?'?X?#DIW
MVC8<]]MNOU"Z-[24WM\]6:V[/8.Q5;"4QNLH=BAET6-E5;SF(H_!&-&%Z5KS
M=K)HSDQ3Y1XPD?PXL'.,R&(5<T<\:E5*"4J#!CJ.?K\E8!Z32%8G=X>6KMA[
M,E'R9BQKA)I SZNWC'LW4=N;BYNY^JR$(DD]D;E>H=;)+.%CYOW&T9(L7Y8\
MLV$FB].4RZ3Z^OK?*'T\_/ZCR7HU1Z'%-4JH./<(8XK<@;L(*'+P''RE%/K[
M8E*!0 Y#&Z@83<E2,/\ ,MR1B<[>BX"X1;2<KE@A7[=)VPF861B7K1<J*B#I
MO)M%6*C9=)=-5%5%<''MG35(=,P&X5(HGV(;RNQ-I4&\M('J20/FKBQ=HXK;
M/.S*U-YYX8X...> <""=I"\:D%0LE[;XZS9.V[UJ8O6/FV0+W$YNVUI+OWJ;
M)Y!661=)VC%'/Q4A7;&\KSUBFI G"3AIA=NT48P[0"K%7X=Q;NJEYW54]W5:
M\FE6!P73FE5!P&D@:*HC0>\UE[=#6?8[=="PX;<VS2^G4MV.JT0TR&N$BM0,
ME^L G72DM<-!IMIO[QU20RS;"^\[%=>R-4+ :57*HR?5_)%=>M&-AK$THV%X
MI"SJ"*;E$3"J!HV=K2R:)V_==B (2!$'+?5N(4' D.:X.:=MCG8P0>OF,G"V
M7A5X'ACZ;@YI&\[$8)WW'KC&5"3,^2LF[6D!2RC3U;?6W29D$KRQ14@5G?<Y
M_:0=OP16@U?:1ZBFFXCE7*)3@158_&L/3M02,$YB<<\G$;1'3F(6VBYBF270
M "3,@"=Y/+;YCIG!4E?&NXBP4L:7&A'1#F*;UR4C@DTI5RHZ?.F#>-4=O&R3
M=-=$\\$:HJW%$J() ='H!3=0N>Y#*H:-L3/.8@X&#/T><FJ#2U3 ,]2  2=X
MW@=8YX4[-^%;C*'M)K5;,Y"*_1.4HP-D6O5-1233-,.G2+1 @D3X6>*G^B9Q
M)P'4 $3".3+!H,\AR&PZ#&!G<_T6'%7^+R(GGT^@H>VBL[O]R4G&2[>D,(VN
MHL4F[268*J$>S;7V"I*/DFZB+A%JM+-1,Z.NR31709K./AUDP^<N,J4M3Q&_
MBG'(#>8\O@<K,4JSV-#FPV(#3JC> .8@$3SC5@+,U0V^T#;.\KF3L\3XV:PH
M2BB^.\:4M,JIRV-LVC%5I6636-)R$VYB5#LR+&64%,"NTTSD*4" %3*89)<>
M1TM&^TYD$P9SB3R]E>5:YO'$-IEND$&HZH:G^7)G0>\;%0@;GPLC+3(4R*CN
MFQW:[3'4>RMK+C"ZRSP\7"0>1:\Z@W$A((@<RL'7G#\S%-14@(JI>XZ9R3L4
MTC]C]Q[ZJ;4.3M$8$^F\@#>9/3KE8^HZY$3X@>9>0.;B1DZO9/..8V63<D-+
M1 /:]DO&AA1R)C60"9JPH'4!&7?KBC\36GYVIDE'<<\-%(&?("<"!V2$"%]S
MD<EP6^JVO$-;7G2TM('B(W.T'/Z")W6,XSPNWXQPQ]G7IAQ>Q[7>S)!!W>X.
M.VVT'8[3Z -O6;:WN(Q#3<JU=4",[%$,W3^/$Y3NH*:,@@,Q7G_ B9*0@GYE
MHUZBH4BR3ENH14A3%$NOH;A?%*5[1IO&"\-D:7 !T"1DGF=^D+XC[5\"J\$X
MG<6CX_@U'!CM;7:J9=%-Y+6M&IS=)<! !)B%GMJ(&,4P"(B!1*;G\_KJ\-$"
MX-;/LEL<M^0CUYQ'FL%3?JI-',$#GR']<K?Z]E*:(FB)HB:(FB)HB:(FB)HB
M:(L6W^A5?*M%M5!O,6VG*Q=(%>'L$<Y1*<[I%RGT1(*)TU4$7397J[9K <XQ
M\BW:N$A[HE.4GU]?6%U$DA2-NF.:C"3UE=1%/KR=<H]??S3B7G) YC<LJ]%2
M#UBQ>N5%%C$-'%^0[9LU:(&552*IU*19<]XB9BH,3)E116,FH@D"A4B$*FH5
M)$2"F7JF @4%OABN%"* F0R7MF.H0AQO]1]<E\J)-T5'3HS-L85&A2.%&R)C
M*O@)[AC-5"BD4J@(%/RB4ZG!SJJ ($,!@ BX2Z7"LX\KLE8K=()PT P!JM(3
M*Z0N63!20EV$.07!@Y5$57DDB*BAD0(@@"RZQR$2.($GH?(_J%V2/<H/&S>2
M8.BR#5V@@Z:+('Y278.&Z*K91)0HB19$Y#"X2$IN (X#CZ\B2/GS^LPM^5BW
M$$S@90QR)BF5;W!]P43@ F2[!Y]HP@4XI_L]BE-]2AHB^A0 %0X$P_( !V,(
M@  ''!?R#QSQ^8B/WT5#I#I G'3S7%R#1%P4ON@!5$3E426YZG1/Y)RB;CDI
MUB',V-P)>4ECE$1 P@/G<2;=X&X&H>7BB/><>4YD;31>&W#*CHD.S(P)D3!Y
MR?CRY+SW7/'ZN*MSF>L=K-.L7=5(?,5,,HU+\.\:RR+J!F&S0X<D%S'RM7<N
MGJ1 \)R#54P\KCKB/:2TJ4JUS<0Z:;35IF'1)+CD1&F1I )\U]D=BN)T..=F
M:3KG2;BTI]P&LJ!NG2QK6AS/:<2V'' $.&>2Z-#46JP=@L5JA:K"0\[;'B3R
MRS3!NW924[+)(.&P2LVLDD5>1?J)NW7O.W!CJJ&<+&$WSFUI)N*M: ^#Y:>I
M$QT/NRMXLN'TZ=$U*8A^D:LDZB!B?#&!($[;<\=H*;N0&'LIDCG8F<OUSE!1
MHD*( @9DJT^CE5R5/W0Y#]@X%$.->[:;FCP#T#LR< $XZ=,<]]_)EW6[\4W.
M;HD@>&' 3&#YQ'([[PJE]UNW.,Q1-2^X/%*J%?CH9Q%O+_3D!(P;E:6V69Q*
M$M$*-0]L)Y.;F(]R2+421.<P*.2K#\*8PJE-_BK$?Q(S Q ,#'[9C.V5?W-P
MZG4[FG_E>'V@)+MW>(<\DB3'GD+=R$+E[=\I0VUQ50AL;8]:M13>)(JDE)><
M=&(HT6E2(@HDNH@Q1:E%L#A<Z)CG<J>W\:7MC:U[>-<UK2S1@?Y9D[[X_.3,
MKQ&C<8,S[QOTYC($3,>0F_ ;;*;"RU3L<XX#\7JYC.V3>+2,S*+P6:K<H+E3
M+U6;"BJL@BV,(%1*H3CPF ![6G>U:[#7,L)+H C.E\9QSW7M2OJ['M%/3,D
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M\\=3$^<#!^?!RAP <?X!Y]V@/;#OY?S^&QY>?DO%[8(($B1[B#.W/:?DJ_\
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M>TP676)'U>'*NNJP8)F5.X<IQCL7BA6QBK>/$*U.FXT@,"'D@072/,D@?AW
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M@F^.D*O0';=V- 0M@NF1[GDN96>L8FMUYBK#%4CT'[X+*Y12?+1T X1]M1;
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MISF(""AR@0!#D/'.4M9K-U3/B$]8.1OMT.2?FO&_HM:UQ($EA(\(\M\R#O\
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M3&,DF.AZQM^VZOPWH 3R/OQF(]/6)Q*ST& MS;9E_65M_N5/GXNR?])2]&L
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M;)%2.]K&%YUFW4;,+31ZQ;HUDJ/ZY&,L\0PG(\BBG4I3&29.R$,8$R@<P"(
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MBP<F)(-_TTARD%0Z<=-%<..E@61(H84'$8]D$R$,"1CIFX*&KAM1E0ZF:AJ
M#B0UP!.#B2[G@>?OT5O$ZEM4=0K<,H$ D.JU'A^K3C#=+M)ZG5D^F8IYFRM2
M/_2SV87=%Z[C&QU,G4.Q-IF#>1;IB,IC>Y3[1)PDJE_:0"3AF:8"GW+[G53G
M@O8-A:XW/#[FD[_+ITV/J9F *U)K?#'BEY;N1&8G 6NTK>RJ]I^%5Q<B@^K6
MN:;:3*9T_P"BN*CI= _#3($-R8G3DJ=!\I4$J1"#8&"JJ F57X8.!-T.')?
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M12EVA-0.Q#PD@4P?F MS@(:M[IQ9;5WMC4VFYPG:0)$K(<) /$[$'8W5*?\
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M;<I2N*&$X"5!U 4>2@': *<=$S$<#P)1\EZ^V(=A 2\:JXO73C13<TSB((9
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M4%!,)1  3$!\<FI4G\0KN?3+6ZVC_,)!U&HUT^ .W@YZYV)7U,RV_P +XO\
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MA3KBG7K=W4J,G34=$.#W@D3+3S5MIBE[E^4OV^P?GK>7$ZAGI^:Y; Z!?28
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M. %=R=/F<=1+A$H_1PLDE)N#&,0>4RE.!B^>0L>QETWNJ+"-[:BS5."\-:"
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MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+26'A,1_[R?\
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M7'#*)V89MF<OY<F[N:P04ID:0L0UA:9DJZUKM9LB+N;75@SMBEG7<2B+)".
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M2I6>ZI5J/JU'&7/J.<][B=RYSB7$GJ2NGLILI,;3IL;38P!K6,:&M:!L&M:
M !T 6[U0JU1;_2.__BG,[?\ VZVV?_N<P[HI&X]1^:AH2O,]S?K.[6-OFXFM
MIVW!N*_3%Q]E[&>,9Y:1_0BQWN2L]ABI*^S-?^*3CK2]8-:[$Q*3631>0Z"#
M<Q5H]0SE03%.PQSP?GB/AGYK%FX\JFR7U?;_ %79@(8ZKV4]@FZ7)^7L64EB
MW;TF+O5*PS;+GCVQM:PFBM&5Y^^N45!/T5(AK&%446".2)\ Y4:*/KZ_HIR6
MB1,;>>0(CY*6_HZ;*-I&YGTS<.Y+S;C.LYGRCF28L^2,MW^SO';O(B>14+3*
MQ7X>A>XAY&W"O-(R*C8I5O ,)IHT0,Y%R+<17((%!)!QC$#S'7W^2Z-E_(^
MMP62_4)H&V;TVXS<]9,1-LD8]W"Y]RQE4E;BJUD*OL)N*G8NA/,EU_()&LQ5
M95@^581U)?UI0S>+.HT19HI^VF3/A^0GTZ;3^<JDR_.E,J?T;.OV7)T-#V:W
MXPWE'QI2INP1L3/V2G4Q,!DE:E%VERQ&4&,(_?. 7%-P0K\J;?WBF30;D2*7
M>UZM)Y=#^2NH]?S&F.,8^FAC"*QM0*3CV+?;A]L3Y]&T>JP538/'ILFT3L\=
M,X%@P;N'1NY^SA9,ZH]C<G^8>:7;?'_I*AN_P_Z@NB[;(.!W?>M+FF@;I8]C
MDFG;8MK& QV\XLN()OZ,S0L!+4^LMN&E.@-#V*6^,:1S%S)R+-Z4&J+1FY*H
MFD@5.>?Y?+Z]Z3 QSW_^K]%U&T5EEMY]1SU?L 8&KI:O@2W^FAE3+EXQ_"'D
MR4FE9&G\6_BJ]B@8<7BL56U+"_DUTBQ$<W90K)O+':1$<R;$;((RGX3/E&WP
M_7Y[E8FHFS7;:S_HT%DS\OC"'E<SN, 6_-;#)LJXDGETKE^K=DG8:#?U6PG>
M_B=<CHYJS!1."B'#6$6>+KO73!=R8JI"DF70>L>Z?K\]\KRH_P#K7=[?_P!?
M>4/_ ,;V'_\ GZB!Y_$_NO2!T'P"_KV:E>":(FB)HB:(FB)HB:(FB+14$"CV
M_P"[Q_(1$/\ 714O]G//^ZAKOS=-6VV2Y)/ETVS1U8L5MG2ZRI$$$FJN6Z-\
M6==90Q2)( U!;W3G$"%3$PG'J ZQO$ZNBW>W<N  '4D[==@?HK9>R=$U.*6[
MQM2UO?.P;H<V3C:79GDO,1FC?UM]H.7=_P#$L[-*6N=OV/JWC.B/J9!O9V'3
M/'THC!QVFBE0BSMF<DY714&/>.UDUTU^R ?+WYSQ!M)EU4=<7=G;E[ T-K7%
M-CW2UL33!<]@QN\-&=UW/AG9WM!QOAEH>!=F>TG&K>UNGU7W7"N"\0N[5M2E
M6J/-,7;*'W>HX=X":=-[W $2!+9]*.QO=5MJW%8EKL7@/*4)=E*)6H"*G(!-
MG+5ZQPB;9BVC!*ZK=CCXB8*T;+"1L,@W9JQGO"DFD\-[J/?HG 7,=9TQ3JTJ
MH#0-5*HRJSPM\0#J;G P01Z]5POM?87_  _B]U0XAP^]X;<"L\NM;^UKV5TP
M%Q(-2WN:=*K3U3(#VA3N ."$#\B@'^>L@[VQ[OS6ML]D>_\ ,JGWU J?NHSQ
M-LL>8UQ987>-:^Z!TO(EFJPQ2LTPF4Z9%_AG5@;K P:B=0S<':*9U3"BL9-(
MR?77>/LRONQO9NVJ<4XMQFU9Q:Y86-I=Q>5#9T#!+=3+9S>]? #]#B&@.:'.
M!7%_M)LNV':"M3X7PKA%P_A5!S7OJBXLZ8NZPD Z'W37=TPF1K:)(:Z!!48-
MKFQ?,<#F*MOLWX!=RE!,I\/(?'SM,>,8Y959 4I1\P2G7AW[1H0JPK-4VZJJ
M@&X(F81UN';#[1N W/ KNGV>[3,H\3 U4N[MK^G4JM#7:J-.HZV8*=1Y+=+R
MX <R%J/8_P"S_C=MQNVJ\?[..J\.RU_>U["I3IN+FZ:KZ8N'ZV,$ES0TN(V!
M7H;C8V/AV+6,BF3:.CF*"39FR9HD0;-FZ)"II(H(I@4B::9"E(0A0 "E   /
M&OE^M6JW%1]:O4?5JU'%]2I4<7O>YQESG.)))))))W*^E:=.G18VE28VG38T
M-8Q@#6M:! :T#  & !L%OM>:K31$T11MW9;4\1[T\(67;YG%G.O\<VR2J,K+
MMJW-KUZ6.[I-Q@+U!"A*MTE54$TY^MQBCDA2"#EJ59L80*L)@(L+;BO37VR;
MF7>%)^Z,+S5,@[>8IK"XDRWBRYOL?9:J,:Q19),VT=?X=#\=0(U48INT 0<(
M@D]6=.B "C@XZ)Y+G-L?I\;=-JLSDJWTJ/M]YR1E])=IDG+.9[6[R?E.X1;I
M8'+N%G+U/(#-R,,Z=$3=.8YVX6;K.445CE$Z91 IDF/+91C)Z)&S!H:QQ<')
MY_JV-K=;W%\LN#*MFNQ06"9FV.U2J.IN0Q8Q;IUET^<%33;K.%FQUE&J2:!E
M!(0O!)/RCW+L^1_1UV@9%R/E'(Q5\T8]_KO>DD<S8_Q/EB;Q]BK*[[XLD@X=
M9!H$(W3A;6L_D4RR$@I+IN3.WO+E415'MHFHX\MEW"E>D_LQHNSFV[$XVBS$
MGM[N$Y.61["6*>--3L7/3S5FS6EJ]/.F?O0SY@W9(DB'#5#W8[LM[!N%3!HD
MG'D(7"6+TE-LEWV]M-L^1K;N(R=CF.N5#NT8YR+FZS6^WQ;_ !J_C9"G14=9
MY=-=ZTK<0>)CVJ,&D4K0K%N1H0")%* 1 ^O2/R23]1UG\UWC<3Z9NVS<E=<5
MY1L3C*>.<MX;JK2D4?+N$<C2V*\H,ZDP5^)8UYY=J\B2;>1+)X=R^:LC.2-T
M7KY^Y(F"CI41GS23$3@KE,,^F[M@P9CS.] J4%:)5WN9B[G&9TR9<[.YM.8<
MD_I]'R<=9Y*TY'?M_P >EYA\G+/7/XD_5<+E?* [$3JEY$DD\UV2.V%;>XO9
M,MZ?[:,LX[=5\>R^,5(M:RN5;2:JS<D]EGR/Z3BC\3\89X_<&3>>QW33$B8%
M$"^2B<SSW55'_N7+TG/_ *#9B_\ S>E?_P"MT56MW7Y#]EZ)M%2FB)HB:(FB
M)HB:(FB)HBVRYN.? C\G/C]PB.I DQLJ'^S/3*H:_I!.79VF;*JWC^!$S(,_
MYFJF,):61.H1_%1,3%SV4W:L>LF<H(+R 8[+"K+&(H9-G).!;BBZ]APCJ?:V
M^=PO@W$.(,;-2VHZJ)<)#:E6HRW8Z-G:'5>\ ,@EHD$2%V3_ &?^R=+[0/M5
M[&]C;BH:-GQSBC:5\0XM-2PL:%;B=[;AX+2PW5M95;</:0YIJRTAP$^0%A'L
MXQJFS8-TFS=(/E32*!>QA .RBAOVE5E!#LJLH)E53B)U#F,(B/RA<7%>[K/N
M+FJ^M6J.+GU*CBYQ),\]@)PT0 ,  +^E3L]V<X)V4X19\#[/<-M>%<+L:3*5
M"UM*+*+/ QK.\J: #5K/#&]Y6J%U2H1+G%9OVPY;M^WC<]@K+^/))Q$3*65:
M#3+*T;**$8VRH9$M,709R'GF:9R)R:+5K9!FXPBX&.A-148NF;]3[9NB?9GQ
MN]L^T%KPQM0U+/B K4WT7DN;2=3HU*XJTQ/A=%(L(]DM>XENH!P^'_\ ;Y^R
M'LMVB^R#C/VC"RM[#M-V+K<-NQQ&UHLIW'$[/B7%K+@]6QO7- %9@J<2IWC:
MKP;AK[5E)E5M*I58_P#HSH/B.&J#E-,X$6(F8A3_ "GZJ$*H43%\\#U.')?J
M @(:^E-)<\1RC\ROPIJ#N0!.OT\R?5<FF/)0'^.JE*^]$31$T1-$31%B_+N;
M,0X!IKG(>;LETK%%$9O8V.=VZ_V*,J]>;OYB0;144S6E99PV9IN)&2>M&#-(
MRH'<.W**"8&44*42+(<9)1\S'1\Q$O&TC%2K)I)1D@S6(X9OX]\@FZ9O&JZ8
MF37;.FRJ:Z"R9C$42.4Y1$I@'1%O=$31%%/=_O+PGL>QDPRWGA]8H^G25PJM
M&:K5FON+'(&G[C.1]>A4SL6RJ)R-5)*3:E<.1/U;HB=4P"!! 2 3M]<E)F$E
MV=@AHB>CC*&CYN,82[$RJ8I*F9R35)XU,JD(B*:@H+$$Z8B(D-R41\:(N3T1
M-$31$T1-$7R8>H<@43<<> XYX$0 1\B > \CY^@>.1\:(M+X@@>YR!@Z"(?3
MR?J0IQ$@ (B( !@#SP//V^G)%\E=)G#L'/'R^>2#Y,43"!N##[?0"CV%3J'C
MY>1\:)U'3'OZ+Z]\!#DA#G^;J(%Z!P' #V 3'*4Y1 P" D$WUX^H" $7U[Q/
M//8 \<"(< ;D.> ^_/\ > /W<^=$7P#D@B;D#%*4!'N/4Q>2^3E^0QA*8H<"
M(& !\AQSYX(OCXQ+QX,/ G*H !R9(2#U-V3Y]PQ0.($[)%.7L(>>OD"+[*Y(
M/81 Q *8 #D ,)NWT'H03'*'Y]REX^^B(+E,HG[<E(0#"93Y1* D$ ,7@IC'
MY#GSR4 #@0$>> $B 8JWS<" &((?-X'@>1*/W#R @8/KX'@?/(:IF' >7S^@
MH(D8YJNWU.]G#7>9M/M^.(YTWC<AUATVR+BF67!11NRN]7377(T7!-)54J-A
M@%)NKJKIE[-239G71;V?94Q_%["CQ*QNK2NT&E7HOIO\(= (\+FM, N8X![<
M@RT96S]A^TW$>Q/:G@7:?A3]%_P3BEIQ"V\;F![K>LU[J+WM\0I7%,/H58!F
MG4<(<#"\'4["Y HLHRK&1<:9 K-J>*OVS&/;4ZPV9I/*13Y>,>N:[)56/FV,
MFV^.;+)D1(N202X*5TR04,4@_,_$NP?&[2Z?2M*=&_H$DTZU*YH4O"7$!KZ=
MS4H5 \ "=+7,SAYS'[N?9Y_MP?8WVE[/4;WM;Q:[[%\:H4V4^(6/$>$\3O:-
M6NVE3=5N+&YX):\5HNM'N>0S[RZVN YCPZW:T,<ZR+TI]C-WWG9ZJV2IJ*<5
MC;_@6_,[+:G-@#\-L-RO=(D1>5RHQE;5[344:%MK&.G9=:RL84Q$X%9HW2<+
M+% .B?9YV(JV%VWC/$JE+[Q2:YMM;47BJ:+JC"Q]2K49+->ASF!M)[VEKG'5
ML#\7_P"V7_M9V'VD=G__ &>]@K;B5/LS7O65^+\<OJ)LV<<IV57O+6WLK1U0
MUS8FY91O.]OJ5K696MZ#?NTESF>[ HIB7R'(";R " \#P'/^'[_/YZ[(014'
MI^Y^IYK\S)[P$[@8S^6.?SW6[('!0X_?_GJI2OK1$T1-$31$T15:^LAF/'&
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MJ;R2YK'B'.;L"!@Z29$Q&".2["02F*4Q! 2F #%$!Y 0'R @/W =2I$QG?\
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MSAWV2"5VP/)4F-?%48E+^L.!YUC("5=$"I\@"? F(.N76- 6U_<6$?ZAYXD
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M< 4P@//D .( </J'R"8>?''.LRPASFP1DC',;'(W&ZUE[P&ND$$ ^%PAQC.
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MO&M<]K2Z>]=2>"\YEN9PO1+78EE PL=#1Q"IL(MJBQ9$*4"E(U;)E10*!0
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MS&V((!\\>9B=X WE;-2ICO3(,B8W&WG$?O\ !36K;49=6%N12"R3G2)Q[L1
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MG< >^?B3@>41[QU5#A$[B<#5MM[@1N<_GA<E7(!TM2(^8>%*E)Y9LR:*?NE
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?J:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g142578g29c20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g29c20.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1DX4&AO=&]S:&]P(#,N,  X0DE-! 0
M     #T< 5H  QLE1QP"   "   < E  "')R,3DU-C<V' (% !Q-:6-R;W-O
M9G0@5V]R9" M(%))1$524RYD;V-X #A"24T$)0      $!!2"Z>4!W/CWSB?
M"4&5MZ@X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q ==            IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ /      0 ! \     !  $X0DE-!"8
M  X             /X   #A"24T$#0      !    '@X0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M              *3   $_0         !                          $
M            !/T   *3                      $
M        $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   *3     %)G:'1L;VYG   $_0    9S;&EC97-6;$QS
M     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M      =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/
M<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54
M>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
MDP    !29VAT;&]N9P  !/T    #=7)L5$585     $       !N=6QL5$58
M5     $       !-<V=E5$585     $       9A;'1486=415A4     0
M    #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M    "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U
M;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F
M875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
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M$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_
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MY_N53+_.3_O2_-LX_DC_ '0^:_6O_P 4>=_6K_\ /-*O?4+_ )9O_P#"Q_\
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M&[M_K-_*%["O'N[?ZS?RA>O[&^?WE6.=_0_PO^Y8N5_2^BYX*\=K_FV_ +V
ML: 3KQXE>/U_S;?@$N1_3_P?^Z1S7Z'U_P"Y>_\ J%_R+9_X8L_(Q=%9_-N^
M!_(N<^H;0>BV3_W)L_(Q=$\ 5NCP/Y%7S_SL_-GQ?S<?(/\ _]/U.O\ FV_
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MRDDI^IO?_+_Z"7O_ )?_ $%\LI)*?J;W_P O_H)>_P#E_P#07RRDDI^IO?\
MR_\ H)>_^7_T%\LI)*?J;W_R_P#H*+]^QWT^#SM7RVDDI__9 #A"24T$(0
M    50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <
M !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $
M.$))300B      %&34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    )    L(=I  0    !    O    .@ -4#0   G$  U0-
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP,CHR." Q
M,3HR-SHS,0!R<C$Y-38W-@       Z !  ,    !__\  * "  0    !   $
M_: #  0    !   "DP         & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M             $@    !    2     $X0DE- _T       @          /_A
M 4A-30 J    "  ( 1(  P    $      1H !0    $   !N 1L !0    $
M  !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @
M  D   "PAVD !     $   "\    Z    \     !   #P     %!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C R.C(X(#$Q.C(W.C,Q ')R
M,3DU-C<V       #H $  P    '__P  H ( !     $   3]H , !     $
M  *3          8! P #     0 &   !&@ %     0   38!&P %     0
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M            "@$&!PD%" L$ @/_Q !O$    P4#! @-#0H("@@'   !! 4
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MY?\ (!=WY1VU]=@L_P#$ CI7&/+%;@[W)9/URM_=1Z$'9][6+_\ !VL\N_\
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M#_\ X*GE:1/YOM-G]]-#/O52\G;SKIG\L='X@I#_ /(CR=IOT*O_ $@%T/\
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M=.D??9,\?*^=8B^HN<)G ?$H;+&@AYH1!+QX4<'!> 1=!_:GGLW. !%VM*@
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MB/E[\J,6&#X$S;!IF0XP&70&AC' EI:@ [B$\601I0?]&@:*]_$- A?7OW"
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MN/0H]U0$/#?0 X;K] B'@$:Z6L200<6@&<G5'48RSDH78\&@Y.+<)R#Q0<
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MH8,XV3*#LH0QC!I,," 1)MBDP; $-)0REJB'739Y\S3%]7V%JQ^R![MT9/\
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M= 'A#.>I7#.&^\6LU['P/9=*/";H)A_R[PV>?8H+Y8A\)T>U5-Y]%.P,H]U
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M6@8-Z'7$?M'<PE]J;MSB#8ZAWR$L"J97M"]+R#RO"VRR[;K@7GJSC@L8T#0
M7XZ+KM=]:W!2E!QO!MJY:)EE$DQG@S1C,!Q,K7N<282US:4&@Y=Y0FJ"(B&@
M=( .-*#?CX,?"#) B.(.3PU<992*R  <1FTG>4N,N!7H6V='5L+/I$!Q$@/N
M!)DKYKPJ\-T7@Z1D:"+O08T$=51XV\Z+Q[XV]PWPVU0_]>L5T+ _:-C8..U+
M,Q=G_H:'!7ET<N[Q0.6(7,VX:YD>I]6WJ8.CEW>*!RQ"YFQ8B\H9NG1R[O%
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M#YEU/+P2(1 *..P0(LC...PW77''77'''0<<<< '77'70 '7770  ===
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M-+G [+RQ,I>/+,P[LK3E"98J/,1>4)K/SM-+QDBA(R4).$A0+2#3YD5NV29
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M-9N73$*! ,+DTR>B3$LQX)6&$$M!C*BP3.GHL(M!==A%X<0P\Y!A.A#A.NN
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M#Z+;Z,.CI+(J]6P:];085_' ZJ[UL$0#FBIU;![F@Y8'T6S%MG2_H15&VP:
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$=T7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g142578g49x55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g49x55.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X6&!:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM
M<#I#<F5A=&5$871E/C(P,38M,#8M,#94,3,Z-#,Z,S K,#4Z,S \+WAM<#I#
M<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL
M;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I-;V1I9GE$871E/C(P,38M,#8M,#94,3,Z-#,Z,S$K,#4Z
M,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T
M93XR,#$V+3 V+3 V5#$S.C0S.C,Q*S U.C,P/"]X;7 Z365T861A=&%$871E
M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH
M96EG:'0^,3$V/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G061!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E"958O2R]L<51Y,7!,=G!.
M:S=V)B-X03M:5S=->E<X4DI*:55K:VQC:U-B44%M9BM&4$LS+U9N<V8K:V%(
M+VUN0GA&841V.$%#;FQB+W%Z,E O4TY$+WI4:GA&841V.$%#;FQB)B-X03LO
M<7HR4"]33D0O>E1J>$9A1'8X04-N;&(O<7HR4"]33D0O>E1J>$9A1'8X04-N
M;&(O<7HR4"]33D0O>E1J>$9A1'8X04-N;&(O<7HR)B-X03M0+U-.1"]Z5&IX
M1F%$=CA!0VYL8B]Q>C)0+U-.1"]Z5&IX1F%$=CA!0VYL8B]Q>C)0+U-.1"]Z
M5&IX1F%$=CA!0VYL8B]Q>C)0+U-.)B-X03M$+WI4:GA&841V.$%#;FQB+W%Z
M,E O4TY$+WI4:GA&841V.$%#;FQB+W%Z,E O4TY$+WI4:GA&841V.$%#;FQB
M+W%Z,E O4TY$+WI4)B-X03MJ>$9A1'8X04-N;&(O<7HR4"]33D0O>E1J>$9A
M1'8X04-N;&(O<7HR4"]33D0O>E1J>$9A1'8X04-N;&(O<7HR4"]33D0O>E1J
M>$9A)B-X03M$=CA!0VYL8B]Q>C)0+U-.1"]Z5&IX1F%$=CA!0VYL8B]Q>C)0
M+U-.1"]Z5&IX1F%$=CA!0VYL8B]Q>C)0+U-.1"]Z5&IX1F%$=CA!)B-X03M#
M;FQB+W%Z,E O4TY$+WI4:GA&841V.$%#;FQB+W%Z,E O4TY$+WI4:GA&841V
M.$%#;FQB+W%Z,E O4TY$+WI4:GA&841V.$%#;FQB)B-X03LO<7HR4"]33D0O
M>E1J>$9A1'8X04-N;&(O<7HR4"]33D0O>E1J>$9A1'8X04-N;&(O<7HR4"]3
M3D0O>E1J>$9A1'8X04-N;&(O<7HR)B-X03M0+U-.1"]Z5&IX1F%$=CA!0VYL
M8B]Q>C)0+U-.1"]Z5&IX1F%$=CA!0VYL8B]Q>C)0+U-.1"]Z5&IX1F%$=CA!
M0VYL8B]Q>C)0+U-.)B-X03M$+WI4:GA&841V.$%#;FQB+W%Z,E O4TY$+WI4
M:GA&841V.$%#;FQB+W%Z,E O4TY$+WI4:GA&84-796%02R]L<5!Y,7%Z<'!.
M:VIP)B-X03M:6$1+>3(X44E):5EG9VAC24IT4T5Z.'%F.&]T;R\X07I!,C,O
M2FQC175A:FMM;4),>3,O04IY1'0Q=69,=FQY,V5Y+U-3>F59.4]J)B-X03MB
M5'53>"]707AK0F<U=5969E5R>'%4459X5DDO2SEN-2]W1$QE="M79DQ*=E P
M2EDV-69A,V9,<% W<2LK<E=-070U3&5Z17HX=G,X)B-X03MP3C!A;GAD-EEQ
M:2]Y4B]-=GI8-7,Q<3AI,6E14&)3,E%V;V]74S-I83-K*W-V15EO:$5Z4U!$
M=T,O1DU!,TE.,GA62F9+9FU(>GHO)B-X03M!279I,%-0>DE$1G%(;6I8<E<V
M53(X8W)O;&Q%,'%G97$P:DEJ1F9G5F%"9CAO67%H.4,O3V)Z:&1295DW:E5.
M4E-Y=&]R2V4V=#5P)B-X03M,83-K*W%44C9K=&Y&1F)W>'E#5UE322]'<S1(
M-WHO2G=Q9UEV4#-N>2MV=$1V3&I84'$Q>%I.-6UT:#9K54Y::G X551P-GE1
M=CA!)B-X03M6;FQ)8TMP549627%/5F-65$AY>BM:2#5I=')E:%$S,G1I.71R
M=34X=DQC>$YA,C!F3DYB,"ME-&Q8;$=I:V5M.75#<$9$56UU,C)")B-X03M5
M=3 S.#90>D5V.$%Y,7)T.$PP5SEX.5AS<G$P9&]B4W1R2DYQ>5=K:U5586U2
M<$EF4F5N2UI1,TQL-TA&57=H.#-E95I03T]J:38Q)B-X03LK2C(P,U5033EI
M<'5K:G1O8FQD3D52:D9X-F)24D1M1T-H=5!W8G1V:%8W=F]T,U!E-DY96&QX
M-DEU3&TS:6UM1G1)2EE/8VE";3E+)B-X03M19F)3<"M&=30S=TMJ359F3S-M
M5'EN<E!M2#@R+T]I84AP9DQ6-$QV4DAT+TUN,6A)4#!C<3)S5'E(,"M195@Q
M55%R4E90=FEQ=G!F)B-X03LU<BMF<GDR,58Q,65Z1GAC861C6#%S:WE147!9
M5%%A=TQ"3&9M,GA-<U!X2C8Y9FEP*WIH5DU0>38X,38O<FXU;F%18FIZ03EX
M0TY&)B-X03MV:W9B4V4S4T)P2C=E.3E->&Q)<%1"-GE65FI,1T-#<7-!04<K
M1E91,79Z3#4P,#<X>"]-9'!P+VU!44QC82]O1VYP8DY#:S-P=U@P)B-X03M+
M8VEI4W-W5E%P-'1X035..%963T)697DO3F)Z6D0K63)P-EAF,WE,;S%H2G%6
M=$\P,$YU<TU596Y7275&=7AW65A5:G,V:WE)1C1")B-X03M33TIR,$MS6&(X
M=V90=7-X2F)495E$06QN<FYL.6].4FQT-V5*=E0Q25-S5$Q(87EQ;F]Q67<S
M<'4S27(X3&M(1E8W+T%*<&9M:$9O)B-X03MK,G!$>D%(6F1+=3E75TIR3S%O
M1W,Y82]2-&AQ<4PX3'AT.%(V-V)53E1G5DY.4R].-WHT=FUF>E!B45A0<%=L
M:U!-1G9B471$84-/)B-X03M!-E9A4U,R,#A437I817-H:VER27)O56]W<&EQ
M1FXX-&5F<GDY,'4P=F9-9U57*W9A14)D=&)X4D-M<&%5,3)Y4TQ#649E2DAQ
M3TQD)B-X03MA:F9B0W(S8GEN<70Y<75G5S$O9D,Q1C%+6E$T<TIH8S(O=U-U
M:3A*4G,S=W%/6&<Q4C)W2VTK2W5X5C)+=7A6,DMU>%8R2W5X5DLO)B-X03M.
M9CA!>6DR<V8X=TYZ+WE:8D1(;6<X;F564#A!;$9T2"]W0UE',B\U37)J3&UO
M-4EV53E5,'I3<DM3+S%/-VAS3$=(:C8Q,6-Y2D1%)B-X03MN2F=I.'!(2W%+
M<W=!<65U0DQ$9DU0;E X<TY:=%E)5#5Y,$]#5S)U23=Q,VY.,7!T=S!C<U9E
M1&]T=UI65C%*<4A!-41S8U93;6)8)B-X03MV2F,Q-6(S<S,U;V%82F579V1B
M4S5D.45A5TE39T-14G59*U-C=V\U54\Y3CA657)$5E!)5VYZ6$TY:"M:5VM7
M8S$T,W%88W-",$]*)B-X03MP6"]M:UI)=UA/+U4T<71T-5!Y*T]Q<F8R,S5G
M-D]D5V%2<$5U-#$P3#9W6EA1>',T:T584&MY17%45W!',DI+;S,O1&9L:'9R
M;R]X)B-X03M864@Y2V(V:5!Q=6I(-GE/=%IV,T@W,W@K2W51:FQJ3%E%1DY&
M1#-0;"]Y4EHR56-D>C5T,'$S<V\S965*2DQB43!I5C5">&5243!!)B-X03M5
M37DW1G4K5U5525-.+WEZ:6MI:VHO34A1,&MG3411=7$V0T-H=$5A3S)+:U)B
M96EJ<W-D4'-G:T-L8T-U.50X<W94=30O.$%L64]H)B-X03LK;F9U<W0X;DA1
M94TX:V)",&5596PX8DMW1$%T,$]+=%1T*U=.=VI*4"M91VA3;S P='EY=75G
M34104"]!2#!P0FDK,THK,C-5.3A+)B-X03MS>C!$>G8X06PQ1F)A9F]T:C5P
M,&4V;5)9<E,P9V=U-TI79&A33T]/3T=";%56,E954F991$%Q9F%X<C)H-DIB
M3&0V>G%.<G!L<3=I)B-X03M*2C=Y84\S:F%19W-%1%-&45=)56UN=&ER0DQR
M6%!Y=&LQ93DQ5S O34-X,#(U,45X1S<K<#,K;$HV:&AJ16%C,EI(:V9I;S(U
M36%D)B-X03MT<U93,44O2CE$96Q04#A!67%D4W%D4DEV3D9(,6EV6#$V469V
M4#A!6E9X5E4P-GDO2UI*<E X05(S;G$P5V94;&1D4"MR,U=J0C=D)B-X03M*
M05))265%1EEW,TDX=4Y+-#)K06Q%6$]I9FQV8S-W,4,U.#51>C,V=$<V,VMK
M*VM034=H4$M*:$DQ=5=R1S(V;74S8D<R6&AY-VER)B-X03MP-60X:50S.#)P
M2C5U170O8U(K:&-8:7IA53 P:UI&4%1E45<O2FQP*WE45$<Q.$M88U5+;FM,
M.'-B93%M<S Q*S-I=$QJ,"]R1G50)B-X03LP3W-C;F]K;5!M;C%B:3-!<V5.
M96Q45$<Q.$]88U9/-#AS9FQ41&%S;'@U<G19-U@P;G0R5U-84FQJ.4=36#$S
M:4E.=G@T3DXK.$LY)B-X03M#,WAD8V)165-(34M5<U U4%,S5C%D>2MF<D=3
M-G9O;6=V8FAR=E)7:VUH66-7:FQC=V-N47%A1E<R>%ER6'1F>6%D2DDS.#DR
M1%)Z)B-X03M'1G!53C-O:$1T8DE)-$-W34<U:5%"57(Y:V)$1E=7951V35@U
M83)&<&$K6'1$.'IA6&50>F-7=')$9#)*;&1P2&%29VM6=#9A:VQM)B-X03M*
M*T909D97631Q-T9867$W1EA9<3=&6%EQ-T95<C@Q+SAO=')(+TU$8R\X04IL
M<TUE841Y9#55+S528E(O=T1M0G1V*U1+-'DU<4]4)B-X03M"=CA!;DI8+T%-
M:W U:B\V378X07%09W=*9D,K1E58<&UL-FAQ;#=&63)%1%A&,4UA2D=V-GE4
M44M",THR1U)L35)&;FMR,G)Y9CA!)B-X03MK;C5F=$E43C5M9CE*6'!*-#)T
M<S!N;TMU,4-30D1)5T)R,$Y08G9M<GIA.&YA2$PT5WEP;FAF4TY-=&UT-T\R
M9W,Q1E-);T933D%3)B-X03MD+V=J5E9"*VXW.#$P<%-K9E5B.3EH;4=,-FAQ
M17(S845'<V112S!#3#0O85 S-7,Y2$@X8S)F0S-C3$)W-7)X67-A:'0U1#DY
M1C<Y)B-X03LO=T)853=11W4W-3!S0VLR<F%(<%=P9TYD,F-C;UE#<S-&66YO
M1"MY.4$Y4$1P.'-4.&9V8D1'*V)Z,WI*-4)U3$MK*VUC<FE#;GAW)B-X03MK
M:#519'E33T%O5D%P-S5!4S=Y,'EW;F]X16=G:TAQ36TP<VTO2R\O04UM6C53
M+S=B5VYF.5)594MV<'(O;DU,+W=!;&YP;B]!1S)O)B-X03M0*V]7-G=+*U V
M67%Y9GDQ-5)A.7!C,S1A3S%R.$594$9N3F4O9W5236Y)>%EB,U!*;CEN65=L
M<$=)-V%&66]602M&4E1P-"M0,#58)B-X03MB;5)I0GE8+T%&65-41#-.5RM7
M17-W>7%Y5T\P<W@X2$)J4VYF96Y8>#<T,U1906]#5U=34C1N2DIQ4U-D*W5#
M,6Y&45,R:F$Y3E)2)B-X03MD=F)(<7<V2DXU<B]!0WHP>E5,5U<V,"M.8E15
M4V53<TMR1DED=&U55D%R-'%"=FMX2GAC=4%6='IE439J<'0W<'0S2F%8<U)H
M=4EZ)B-X03LX4TAW-T5(;U%E>$=48TEI;5AF:V%+9FTW-5@O04]9=V8X46)&
M1#<R;&QJ:6IA4U)G<V%!<S=%,$%!,TI*3TI+9U=X5B]W07=,0DQY)B-X03LP
M=$A2:%!C<#9H5&IU<6QQ0W4K>'I%,"MR1U=61'5C<DYP:D-.;G9P;&%-2%)7
M2%)G1#DK6F)I=#1Q-T96:SAN<%%V2C-64U(Y1TMS)B-X03MD9S@W-F4P.6I&
M341'8C1/<UIP,&QI67)*1V0Y:4M::5ET6$=5=4AR=CEH,V-N2G!:4FIX9$(K
M;FMY54=O<FU7-'E6*V$O.$%L1G19)B-X03LO=T-91S4O-4UT:&IZ4654=DMN
M+T%#:3)J+SA!341B9CAM5GAL>E5C;41F.#5++RM353AX+W=$4FPO,4AW645V
M:#9X<W)I*W9)<E,S)B-X03M8;$Q-=U92=E%E2DY+-T%B;C)W<3EP.&TV1$AO
M1G(V9'4Y6C-)835N2S!,34MG9&5G5W5W>4]42'A"5U4O<&5D:#9B5DA4-%A*
M4%0T)B-X03M2.$E&4'=Z535T2EA0-U%M2E-Z54Y24E502F=V261G1DHS1F5M
M,S-D36YP=7HX=54Q:D8K-VPY<DA.<6]9>&-Z4U-V965T37)+<E!W)B-X03MB
M;%5R-FA09CER<&Y164]W6E$S>5-I2$-(8F508U%J2UAU4F8V5CE-:C%)6EDQ
M0BM';%5.854V9VEU,EIW-TQ*1E)M0W=08DEJ.55*)B-X03M!93<K>&8X07!#
M2S5P=79,=UE&,E P:U90=CA!,'I886I16DUE.&=+-S-:8518-'-U,$IB.3-)
M+V%P365(>%)M;%(K>7=157)7;G=N)B-X03MX,S8U:'E*-C,Y-VUL9W9N6'EU
M:G!0<3ET=$MV>%A-4V=K3E%G1G=2-&14.2]8<5EL<'DT*V]3=CAR+R]!0UIN
M;$PO='1A9"\Q1E(U)B-X03M.>#,P,R]Z;48O-4Q45% K,C%"+S%#,U="6'DO
M-5<P2F)U5#8U8V8W>GA(-$4O;F-5+T%:0U5Q8G-73SEY>BLS<45#8C%'+S,U
M5S5W)B-X03M41T=(:VQE-T0T:&MG1C1K=S K>7!,0T@S17!*-#!Q84PP<FAP
M;4-M.3AW5F=.-DAD44%4461V,5E#1U%+:71W-D5M2T]R3V1U-$)')B-X03M!
M<#5O-U(Y3FUK85-E459K0G%X25!4,GE.;TI:175L4V5I5$YS4T]207(O2'1K
M9S!Y3'IJ.'E02U9P<3A!5TYE1V]12WAT<'$P53%O)B-X03M3:F5)3E!O-B]/
M=T9X<VM,1$$O>5%2:R].-WEW<D%Q>3-O1$M246=H1T9$:VY&9F$S;E<T<'!-
M9&E#03)Q5'@R4DQ#;S135DUV,WA+)B-X03MW>D0Q*U1H>#!/8VE)+U!:>71(
M1S4S+TY&+TPY<GIR>61B+W W>FIE86EY.%EK6E5J6'=#,$=59&QW.4)N+T]0
M,D1:>4\P<%9+35 U)B-X03MO*S O9U!:04%!04]G>EIU=&1I<G-685I1>6Q4
M,$EP:7)Y>E@W23)&='(X55$O96%D8U)A<%IG2'(V>FHQ9V$O>DU$;6<Q24=,
M35IF)B-X03MZ5$=9*U!P:S=N5&YX25)I9C1G66XT8GAE:#9"<4@Q+U196BLU
M559P.',S-W!L;FUV+VQ&=%DO-6=B;B]!2DUT:&IZ4654=DMN+TM,)B-X03MA
M4#A!.'=.="]W06U6>&QZ56-M1&8X-4LO=T1K;%!-9B]2;"\Q2'=9179L-SAT
M+TQK:7=(5G!60F%C8V)C2%EH05-'4"MY22LT92M4)B-X03MI1TIL5#!A>G-1
M1C9$8EI246XV2T=M4TU74$5%3G%6.#A:5WET,#E3-VM.1FI&0T%4<TYG0G8X
M034W1&)-+U-A1T]18V,Y;T1Z-75")B-X03MR3F-915%H=FM+>%!,<E(P;'9:
M5FQM8F-G2&U".4DR4"MD4%DV;G1!9V-'26-%0C5F:6MA6',V3CAE6#%Z*WA%
M:4%24C!4.3)N8VMH)B-X03M/;F)X3D1V,3(Y>G9M<S1R,W-K+S%R*SDS35DP
M2TA*83AL=D5G5E%+-T)U24Q%*S%'3E)89G<O:&=*04YN-W$K,$YK64I29'=1
M4U!Y)B-X03M596UA8DUD:EAR5V=(-GHW,7I0,#-A531B9E9(=74O=C-D9G%U
M>4UE5&5U1UAE1D)*;FIB,#546"M6,4%A<#9E4"MF-#5F<4Y&:GI1)B-X03LX
M6$-09DAK-#)M,7540DU98R]W;"M0>#-Q>'1W4#-S;C--4T%+.4M505AB9G1M
M;7(X8S-D,E-X3'DO<%-72#5Y*U9V4E%*8EA'<S9D)B-X03M,0W$O6E=T,TAY
M6'<R4%ED<5I)3TY-55@P1B]Z;#-$2E K6$]L4E)+5VMF5S1!<6IX3G)D66]!
M=#1B85=K9'!A45<P64)73D%T44M6)B-X03M05FHY2C-Z2$IS=69%54M41T=-
M=CA11E<Y=D1#>G1/9$U!5UI#+S)2,D]30EE35%<Q9' W;VMB<716039$,G)K
M;5544TEA>75P2FDT)B-X03LR4V=7:'(R3F-7,'ES2FI&841I:4)0:3=N05=&
M<W!S8DM#1TPT:T1T,%5D44-E<#A-9T%P2VYQ8S5534]8=W%.>G0T66)935 Q
M1D1/)B-X03LO2F0R1F9O>'1I5TEE5TY%1FHK9"]L4SAJ44Q(95A:36Y'=3AQ
M:&EZ2'0X45EF:FQK6$5Y1&0Y32MF5SE-85)C3G1"0F9X=$MX,D%$)B-X03M2
M>5)G+W=$0D]-,2]A9R]D9SE"3TI,;&1N;C%K9%1%<T(X:F59;TY!9W8S14EU
M,D1S635F559)5T%!979Q;FQ18U=R5VQ+06YO37$P)B-X03M7<$5-26E2-F@K
M=#)';S=/;FQY;68P>$YF<35E.&9C<E0O;3-D86AR-E<Y:'%C549S=UAH87A+
M:DTW3E-G*W--<S!B9%0X2SA7<G1L)B-X03MK.5A).'1M+T@R4&I%9E9U9G,O
M46UT,7%V;75E0U8T.5%93'8V57-A14MT2$YE5$M653!!-#%)03<O2T)Z-4-/
M85EA6%1!9T=0,C@Y)B-X03MV=U5V=B]/,VUJ5$DS83EU;6=G<5)(35%I0W)5
M-$IZ;5)W94E",W!V55I(.#-K2$YV:#)8<#AN,#@O9F8V97%V-6(O3TAM<5=L
M.5!")B-X03MF,TA*5CEC13(W>6-Q;FEK4E%L-5 R449&0V9#;T=:14Y996]C
M3%5D:3E91W9)+W(U25AZ4C5N<V)P9&)V;6EL=%=U<E-'>71O<&=")B-X03LV
M<G$W4VM+>6QK-4M(3E)7=6$O5WE/5UIO8D=-66HS.%9P,"MM3T5!4S9%>5!U
M<6UD+VPX:VEA0D=(-FM,,2\Q8S9"-35-=DYF+TM,)B-X03MA>"]Z03-0+T%#
M6F)$2&UG.&YE5E K55<P9CA!-6=B8B]K>75-=6%J:W=F+T%*>515="M3=FU)
M2TMK+U5G05 K62M$06PT+V]7;GA7)B-X03ML;&(R:U%01T=.67=E24I)554U
M2%E$,R]!338U94$T,'!B<'!E5'@R3VYY,TUG4$M-55)',G$U-DM!3VQ$+VXR
M3C)M=RM*35)$5&YZ)B-X03LK2$%Y-VM&-5AS;6E",4,U2$LT=5)Y1&Q1,T97
M3S,R='9I-B],-E)M8C)J;D)0:'@K:4QJ.6TV9F)X2F)Z:VID56QI-4]:2F9H
M;V9T)B-X03M';%(X>%9T+UEF,7I3;5AD.3EF93=V2$5L26YV6D]01TE"0C)%
M5E%E;FE4=G9T:U1V>BLW.51K.$%(-'!"6&141U,X:%ER46A(,E@O)B-X03M!
M249/43(O>C,R>4<T-69F*W1U0B](3D-26&,Q95!#:7(Q2T%(:C-053 R*V53
M2$QF-W8Q3$ED,S9L67AP3T-(9FDU1E%82G(T,39F)B-X03MF=#DR6E=I,5IX
M5#1H=4]U-W)U,$Y'33)->%!0;S%"4$LX2FI**TM0-%-!1G(Y-38U;#EP86%-
M2CAC9G!N=GEC3'-R57EN07=L.6-.)B-X03MI<S!V5&QM.#<K56)X:7EZ5W5U
M86-A3G966DQY2E-$5'98:FUT061J:T)E-B]W1$]2,$5C=FLO4UAK3D5H,6%/
M42\X05-*8W%0*TI:)B-X03M#6C)2:$9Y94%40E-X2VII;T<R575A:7)2<4Q7
M;7<V;F]-25138U<V1#9S2E8W;6EN0WAP3DQ"9E-(23 K3&1S:T-P6D)P-U<W
M>'4U)B-X03M7<F1D:E0W.$YP,U)U:W=O.7=G;T<S*TE(8T1):W%75#-C155.
M<TM!06XW4S=D341',DU857%33S9T46(Y4$56.&-J855V;7168T]5)B-X03M5
M2W9E;5-$5U5M,$]Z1"]M1C5:8U9"='12:FLS2%=Q=$A4+V@X<VDP-4]4,D@X
M,&14,'<V8S)K6$UV<#@P1GAD4T)E4FIH46QG,WIR)B-X03M'>F0O:%)Q8C!Z
M2#%C:'<X4&4U,UI706UF2%<P9G@K>C1H-$U.63%N6'!:5D5Z,BMN4TUE3G!(
M>%5C0T%P5FU254Q+858T;C1D>G1M)B-X03MT37$U4%@T3DU#3&PP5&4P.'!1
M<7A-9$EV4EAM.&I':%5J<%0S*U=2-%I8-4XP<'=!<75B2F)(5W1E=#=/4WAH
M;%-E2U%#:S!S5$UW)B-X03M).2M153E.-FIF=FMH6D9$<31/6%(T>DE33S%)
M3S@P*S9V0W%A:$LP,79Z37$R<U)!:5)M04A*67=4,D%!1F%$-SA)9S)W-%)U
M3V16)B-X03MU;#DQ-59T2&I-;'5Y;%8S;T)X:U%J<#E/1&=03GE";D(Y36=P
M,DUU<7E8<T]M,W-J6&1G-U5)8BLX56]L1E5%9F):*T-Q3U930T9O)B-X03M6
M<&="3BM984Y4<&]#0DE(<$EO+T@W='HY<#)E>F9L=G),6&5N>3)5<65N8U=:
M0W-P24I+;%%663!!*S!R06MD=6UB;D)K-#0R.%!R)B-X03M.4#1747A(2E!F
M3F8O2TQA>"]Z03-0.$%Y6F),;S@S15!*,VQ4+VQ&=$@O-6=B8B]!2DUR:DQM
M;S5-5R]033 O3$A61C=35#9F1S,K)B-X03MR2G%&=6IF9S))579)=%!9.%%/
M230W53-&4$5D2UI92V-5<&8U;%8U8G%W,#AN-%I8-4]"6%IA,$(K-'0P>F-D
M;BMI33AH-D0X9F]D)B-X03M:<G=:4VAJ-WHK4#!P:F4V=D=#26]52$=%1E9,
M1VQ/,4]P.% V-V):<$IZ<S<O<60O:7AB2D)D4V=L-4-X.5%G=%)19FU4.%<O
M=T1N)B-X03LQ>7,X6&Y8>F,V16%14S-C:F=K9T%B:6A*3SE00DYV.#ES<4UH
M-W9M1S1X-VY&4W1(2DQ#;S0X4EAT4VA,07(K3U-&:G8K=W-5=G5:)B-X03M3
M6FE!0E1A;%148G%0<S=F9"MV25=,-F9C,U)&:$AA6F%X:'I)051*-%50:E1Q
M43-F8BLS8DUI1416+W1C5$Y0;W1U5T%V1UE#<7ER)B-X03MV53E33R]8,C<U
M=5%F13!:=FY!+VHW,VY14$0Q=W)L:T@T*S<W55HU86=J9GIB-65R<U)Q*VY%
M8U(P-#-S5$0Y5V%D,VLT:T1D-TXO)B-X03MZ:VM72&MA>$DO-G5C5F8K:V5F
M2SAN2FIG-79N,C-N3'!X4%1V;$QL<&Y9;U-'56)T2G1I;3!Z4BM585%O,595
M8CEU*RM&2E1/,T-S)B-X03MG2%%!8FIW2&IH=&%4;E(Q-'-A9VE+;$)867-0
M2&%M0S)2,EI:<#!D0T-I<49"<C1F-3%X=&A6<5!M0SEK:6I:0G0T;G<K;D-O
M:6PY)B-X03MJ67522DEX<65.85E!1TUI9V)K0TXR-&MH96]!3S(O='1I5DM8
M-D9/:F5E=DPV:G%B,DPO04EL:'AN9'@X=DIN9C5O2DID-FYE-F9B)B-X03M2
M4U,S='AP<E%1<4-%46UF,4DQ2$TW03@V03$R;V4R675R*W-E-3(S6E(O9%-U
M<45R.#EN;$AL4V1485)U9T)65T97*VY-06,S<WE!)B-X03M90VUC23EN8GIA
M87 Y4U-E+W=$5F]19TU34$4R>7E.5W9*=V%R=#0U:V=$6C%-<%1*:TLY35)Z
M*U-D<G!K:&8Q1W!):F)Q<4]G<'0P)B-X03MO4W!Y6&AK;7DT:'II<4<S>E4W
M;457>$5K<VEW2W136%EG.%%/<$I8;"MR0U)42T5U3%E#,&AM=F)A-G1F<C%R
M2T=39%=D1S1U:$MQ)B-X03MA8G$T5F@P-VI+-75:9S,R24]Y57A01DQF=W93
M3&LW.&A(3"]!2&(K;4,W2V$Y:7%(2U)Z8W)/2VAW,F5N=C5V4U!Y=V]D8S%:
M559L)B-X03MI=#!J=%)Y24I*=&Q316YA;E5X-V4R8F)44G%$=W9A3U54>6LO
M:F-K+W!:<#5R+S528E=0*UE'-2]W0U1,6FMX-75!951V2VXO2TQA)B-X03M0
M+WI!,C,O2FQC6F,Q2$II4"]/444U="]Y:3$K8T-R46DQ:U@U<F51:V9I34-8
M:D9J<59%54ED:4(X44=X2&%M*U=75VYG470S3#9V)B-X03MM3WI:>E5E;'95
M,3-O+VAM,G=F-'!0,R]!4$5U<'IB875(=2\T<&1C*W!(2WER='98-%)X4%@R
M4#AF-C5P5'IE:F=D9VPP>7%24U%K)B-X03MS9'EN2V\R.6=0-#58264W-VY*
M:$I185)W94UD2V0O:$$W9&EF.#9F9&="+TA0-S(S;71C<'E,>45M=3%72F1J
M*W)R+T%*,#8U0W$O)B-X03M&9F-G8S!).&Y/9C1+055(,E)X<E@W=C@K=WE1
M3B]I,F1B27DQ83165T))8G!15D1+9'0Y;&]0>'EY<4@W1VLX3C=Q53-Q8S!Q
M2TY5)B-X03LY1C0P*U=B:G,O.$%U370X<2]16%$Y<'DO=T%*=VU09BMK27)1
M6G92.#$K5VM:=4IL,793,%%6-FXV-T5X04@K<7!Z53 W8DQ,6C=6)B-X03LO
M=T$U3'I#4'E2<&EN+V1U<E))4"MK5S5B+VI8250U3F5)*W T0D5R3'A39T))
M0D9/.6-P8W-),C-K;#)5535.,7 R07A:0DY6:6I5)B-X03MO;UDP2BM.:64U
M3TQ)1S)1-D)9<F,S43E19S(T231K:C1I4CEK:C9C1G-R<FMN5C1T8G19;W9G
M8U8U0W9H-#!W;U1#1RMA2S%O,5(O)B-X03M+4#A!5C8Y359!56ES;#E)<E-F
M1D5U.5!';$U72DY,>F1,8E%&56)B96M:-E5R=#$Y<V)147AB6&13<#EI5&,Q
M2C0Y=G9Y5$%P1C5.)B-X03LQ3C50>DXX<U)->&(Q8C56*S578B]J6$I11&HU
M4RMH=GI#,$]A.'-F<G1Q:&$V='AT=S)C<C%)5G%R4G%G374T2$E#=3)$4&DT
M-#=C)B-X03LR-U%A<G=C9THK;G$X4&XP95=Y;D9Z;S!A>#(W17!E,C=/<U-C
M,4-V>6E%>%5I;V-6:G)8;U9(6F123THV-U-E,3!U;VI7>#0T2&Q7)B-X03LU
M2'DO2#944%-V36-51C9W8W%:86Q*-&TV,4%O=UI$.%-U=$]V55E94TE.;'-Y
M-%DU23%%:GDO2&-Y;5!6<E9W,T(Q26]'54=H27%.)B-X03LO<')L+T=(6%,P
M.&AZ4WI59%912G=!0F-K:SAG1T%!<'91-U9/5GEM-5=(0C$V35-7-$8S66$U
M9&%J<4]S5VUQ0FY84TQ3>'-)<FDP)B-X03MN0W-W6#%*>7-V.$%+4%5$>5%C
M9'=+,'I-:&EX.$%-=79E-E!5-GI6>'IN2&HO:$]W04(Y,V9Z5&%W82MT3$MZ
M:5-N-F5U;UEV<DU%)B-X03M:.5)9<$I)5EEK57%Q<6I-5U%G='E012]'=$]/
M4&IW.%5T=G!T>4Y8,FAW=W5F.$%E,7DW:C$V;C0O3&)R,EAY0C5B1VDV549:
M3T5S)B-X03MG2$QX-EIT44ME5DI*3FQ.4$YF+T%#:3)S9CA!341C+SAM5W=X
M-7-4>60U52]W0U57,&8O04IG8F(O:WEU375A:FMW>B]N278O=T%K)B-X03MX
M-6LO-'@R,R]56$1G4RM:9DHK=2]73D=T:TA%>5<V:4=64G52=S)862]Z2T)K
M9WII06YT>&15=4Q7-5AQ:&\R,4MB+T%/,VTT-U Y)B-X03ME3$IJ-C%F-"MX
M,"]A569$>30X;E,V4#0K84MK=4AL57-#0TMG155,93-H5#A-,#!O,WID-T=O
M;T]D448U9#9B,&]L9G4R-UI#<35.)B-X03LP6F)O651->E9B8S=J9C1U*U8Q
M9E W;3=:>G=C;39M=&5G05%E1R]1+V8X07)W9V0S,W)X57%25W)S-55%8U%F
M=$%L*W=.930K+THX)B-X03M&."]U65-Y04)(4U=0;W@W3E930G-25#,W:V8U
M*S(K5S!">2LY>&AL2T%:*U9Y9U5!3$=/;%0K<S5T.%DX4%-32B]J4#0O4S98
M3$QX)B-X03M.9$5D241F.&9*2S=0545M+TYV>51A2E0O4CE7,#EP4%IP3'5,
M-%0X;%5(-F,P>G1:;#=J+W=!-6-Z=D(K6%=K>DEA3VUT=T5F4F$S)B-X03M7
M06AI1%)E27<S558U1$1*1G5S<4LT2C=!-S!.4$1-66AZ26Q(,D5G665Q934T
M9T1!,D)-;VEZ:T%';&5T9D1&:T=5841E4C(P6G5()B-X03MO5FDO=7@S2G!3
M=4E357AH;5EX1SAL6#DU23%%53E13W5&:&4Y3E-3=5933G%!=60V92]152](
M03-G<&Q)23=E05(X>79%1G5T4E@O)B-X03M!1$]&<4I384\T85IP9'%D4T(K
M>G1I1TUY>%!Z2F92>'IY3'-!;S8Q>6)75'-X;CAT9%5&.2MD4&QD52]U-&)Y
M9TDW:W$Q8W-I2$5K)B-X03MB9F)J2W)+5EE60C))>51&:'9M1#AV-')Q5C=R
M5'!48C-%:65M-$E$<7=Q1TA*2$1+845B5D<R5C5-55HX,C="<4HT:F-3=V4Y
M,$AZ)B-X03M,<&MJ>4YA3$MI25DT:$,P<7%.9T]24U0Q5DY+5D%(2&9-4U=I
M+VUL,C!E,E-25U-.-S<X=C)-9'9R4TM/2G)Q,VED255:;78Q-"MM)B-X03MS
M8D%--4IJ0F9H>C1.,T,P2U5&4U-C4V5/44Y(;4AF84A74DE&9E1+-C8Q*U Q
M*U-/;%EA9&5I0S-T1%!Q-TMJ>7-G05I"46AU56IR)B-X03M--CAI05)&5&I3
M:F0X=7@T2E0U8D]T,65V:$-U26-23B]J<#@K9DY&-DHU93AZ6&QX3&(R<"MP
M<U%V<GEN;$I+16%V2#1M1D$S9FUQ)B-X03MH<3E+8C5T1&@O8W=I5%E(13@O
M3%=M5V9*3TDT5$QH+T9F;V5H955V>35S3D=55%1-6C=O;FMZ<U-35S=K:S=K
M-$%!3F<P>6M:16LX)B-X03MY>DQ#>%-V>E@O>6DR<V8X=TYZ+T%-;5=W>#5O
M4$HS;%0O;$9T2"\U9V)B+T%*37)J3&UO-4U,+T%/8VI$5#AM4$UN*W!B9CE2
M:T]")B-X03M,-' X<S8P9$PQ14\W15<P;S149U9/,UIQ9C5*+T-U4T)6-FA#
M.%9Z84)O5U=33GAY4C%.46-Z3DAM.%!)2F1/<FDV,T0T=4EX-CE0)B-X03ME
M<C)L>$MY.%-D,3)A=% Y=F9,=3!D4'=4-&@Y36UR<S=6*TIJ-%0Y8V1I=4Q2
M0E-4478S3E18.&,Q,&=885%M:#5:6"]:0D9E<'!4)B-X03LY5U5L>4)*8D4V
M<3-):V1.;#-.4'=P:E)3:6]B9VQX,3-/-6]!2T1P:V\W3$TW26EE5DDP36I-
M1TLY4E4Q<699*THS+T%--EIK-F9$)B-X03M,3$U21'(Y4FUJ:&=:>5DY<D]T
M4F%465-88W)$-GI,+T%(15<Q5THV8F1E4&HW6FYD<#59,DU59G!H.3=R=7DX
M57%/5U@Q5"LW.&9O)B-X03M9<"M81GI.9&9M<#56=4HR3'I3-C-P-T]X-VLS
M8V1C,4QS,S!T+WIM1"\U3%144"LR,4(O,4,S5TMV;5!Y>')P9U@V:$MA2350
M<$]4)B-X03LP2B]:*U)Y=6-E<F1I;#!:=G!Z<V%)5'-0=WEL>D%M.6HK.75G
M0V%P*S!E9W O8F=,2DY*-44Y94]/0G@V568R-DA9;G<K-T-T-TIR)B-X03M(
M<4UK:3AG47%X06A396AR,S9G9FIH0EE21S8Y3&U,,6986GEZ5DA'=$LW9DQB
M1G1T<2\Q9$IQ8E5(,F5W<75,6&1*9&4V,49:>#A5)B-X03M*-5509G94,W=G
M3F-I.',X-&5:955K:T5B,6QA=%-$,'EY26-E8S$S-4=-5"MB;FQE=F4X0B\T
M4G-S85@S>&ER<U9A6E9955E!:G=/)B-X03LK2W9-4'I8,%-#4%-T66YT-%,P
M,35A=WA"54)0,EIW1%%$=3-Q0W9J5#)Z1#%-9#=D=#):;$DY4%-Y9FY%;VHX
M=$Y):&MV.$%63E)M)B-X03MH2$]E-&MK2$EF>G57-R]036I&1V]H,3)E4DUZ
M-6)F2FPK;&=$>DIR44%O3T9P<U Y4CAY.&XY,T@T=4I$-C5F0D]C;V)N67%L
M9FUV)B-X03LO;$9T62\U9V)N+VMY,D=03D(U3SAQ9CAO=&\O+TU$8F8X;59X
M;'I58VU$+T%03U-B1F9Y5CAX:V1A5UDK*RMG1T),-%=W<7E(>7HU)B-X03MU
M=61*6F)A665T649Q;%0Y<$%4.%)4.610,5E22VM%4%%O3'4R=FM&,W X<7EQ
M979!*W=.0T]O3D]X,WIC851646Q$=W-N,#E02C%')B-X03MR,&LT>CA81CE8
M560O=T-0>'5V.5AN-#AU-FY+3E0R9E!(=4XT=51P3S!O6DYJ-EID>7ED:%%%
M,#(R<E$Q>E<P-U=-,7%&5'5+:RLK)B-X03M#;5A'<4LT5D-394HW57%$;51G
M,&LX<#)',S)/3G%.9FIW:35(-&15<#%Z>DIB86)'4%=B,7 K<V1R5VI(<'4Q
M065)<#!R.4=B3V54)B-X03M(<$E'14XX:#5N=2](8S9E35HV>5EN36-/26-H
M,R]J*W@U-7%U<EAM<5AJ6%8P=TQN6E9'>7%O-DMO.$TP:$QU53<O2R]W1#AM
M6C53)B-X03LO=T,R,7 S+T%&1E(T<2MM=BMC=W8O2EHV6B\R,F]0*V]7-G=+
M*U%&66HU:G9I<DQV3&YM=TPO;S)O4V-0-4QN9F9F;SE0,3562TAC)B-X03LU
M5U!.,$Q0<E,X9VIG<D-Y>4)H<S1.45(T9VI+<6-G;'5#-61M2G)4:U-A659*
M5&$Q=E57,V1705EN<%AO34%99W%%=7!+:UE59D-F)B-X03M%13E4=FA36DE+
M.3%Y0TM-33!G2C9!:SE":$%A>DYG+VU4>G V:&%+,5E-+U%Y0W4S>7EW4F%*
M6D='5%-Y4T]:2D=,3S(U2GEX<%IT)B-X03LK4F8O04I.>GEV.$$X>&<O-&<R
M2W9V;D974&$O-3!T3D0Q5T-Y=F)'-DYT3&%Z6'-M<'@K9V)E1T<R2VEC>4M:
M5FYQ;G%)84I%,651)B-X03MP5VI55E%-;C5T*U%)-4]-;6]Y2W9P3$U:>F%8
M;F]I3C0T<%9*;3E(,&@X3GI&='ER5C%8-U)P:7$Y=D\O:S-5<F$X:VHY4SA3
M=W5,)B-X03M7,'99,G1P;VI(3F,S0W=X;S,Q:$EH>5-19W5T95,Y>#!Q1$<R
M55I%8VQM;65F=DE+<F-J5#5P3TYV1#EB=694<W)Y:7A-;G%O>'!$)B-X03M4
M.35(.&-9-G5U-C%'1VU*2T)S=GI7+TPU<G$V=E5L;FA36D9C,W(R."]#84M+
M1T-:6&I4:5@T:4\Y5G$X0E%";6%G1F-K6D5G1&]')B-X03M):4%B5"M$>G@U
M8W5B2S=V8E,T831H<V(Y3DMU*TUB;U5U;FUJ9S0P:T-C;$1Z3#A3,4)(46Y)
M<VM8-64X>6%.-6@P+SE)85)/,#ER)B-X03MY0VQN:6QG645O<VDQ:FU73GAY
M4U)71E8S0D)',DMT96$O.$%L1G19+W=#64<U+S5-=&AJ>E%E5'9+;B]!0VDR
M:B\X04U$8F8X;59X)B-X03ML>E5C:VHO3C-Y9'%F;DPX=DY7.'0V6DQ$1&98
M+W="6#E'4S5:,6E(;S--57IC:6EY3CEM33!O=EA!;#@S9CA!46YV-6UF.$%6
M>C!8)B-X03LO:V9D9CEK=4MU+S9%.2]->B]Q-39,+WE0=78K>5A&5E<R+S5X
M2"].5S%K.5,R,6I325I/;DI,:3=5,#A.<F)$87-J=&8K8V5V>F%5)B-X03M"
M8G4W,$LT049/83-&,T<U4&E4.59:9G=Z33 O84=41G-$63=I-%=O,$=,3'52
M=C-H35E0*V-F4%!X5W,Q-7!A3B]+<SEX25!V3G-N)B-X03LV<WEZ,FAH;CEE
M4&1X0C)F;6@Y1U$Q-75F+VY(<GHR1E!P,VUL;'5W33%W=C1I,V)(.#=P;R]4
M:BMF-$MF>65P:U!6:W(S9F=*3G%0)B-X03LO3T]0-79844M7*W!A2F%O,U5R
M8UAB4V8X1V)552MG6E1M-U5Y5$9$,&IY8F-06F5+0G,K<5AM:T1F.$%/2"\U
M;7-3>F%P;WA9-VMM)B-X03ME-W%4+W="275A,3)46"]1;G8U;68Y6%!29CA!
M:V9D9CEK=4MP>#5.+W=#8U9F>D,P5'IF;V5S,V5O85$Y<G!M;U=T-4]K53%Y
M6D=J)B-X03MT-3%K64E'=#%"66AD<6M9<3EH+U!N.'1T8R]-2'EH6C9.;S Y
M<F(S5G9Q160T-S-J>4I'63!G;6I)0FIJ;%!+<V\W67$X1R\V13DO)B-X03M-
M>B]Q-39,+T%-:C=R+W-L>%9D+S!*+RM:;B]6>C!8+T%*2#-8+UI,:7%+<U K
M8U4O=T$R8D=14&(V=F\V9T=P:DTY,E50>E@V=&=))B-X03M"6E)M4GE:0D(O
M>FHU*V%Y>&A:8G)21V8K9$QM-U5F8V)6=C$U030R=UII:3 O240X>#!483DP
M;TXS2'(S3E K;V)"-&%4;5,V."\U)B-X03MX>B].5UII578Y1T$W13-&,R\R
M4S1E0FEC<5,S;B]/2U@U<UA:<DQQ,FI52%)24&0P+S9H<VU)9TY::U-H9CA!
M;U0O.'DO.$%Q-6%,)B-X03LO=T%J-W(O<VQW;V$O=T-H4'9Z32]W0W)N;W8O
M04-0=78K>5A&5U,O;'0O>FI(-3DX<V5E=$<Q*R]V.$%3<&)05')G5%12=U18
M1%-L)B-X03ME2DAW:#=D1G)V,UE9<2MM.%93-U9V3#)J-G5'1V\R+W(X<F$T
M<VHX8G K-'5W9VU4-$=8-UAP<G8Q1DYI359E6B]M0D8U1#AO>'A7)B-X03M.
M,359;3%$4S)S:$I02DAD3T-S359X65=N04-354TW0DDT5S-)<G=!<CA42$-Q
M65=U<V52661",3E.1C!M92MJ<SE9=%9V-UIR9VU3)B-X03LU=E=V;S1&;5=A
M4V%1.&A.1GEP2WE&=4Y7;W)C:7%X:3$X>&9L0S$W8V%8*VA.44)V-$QD26\T
M<GE::&-24&%X>3)S8VE.9$HV8G%S)B-X03MH:F@U9D%N13A807%!<6].-6HO
M2V%#>717,41Y-60R.7!.65)S>B]86D@T>4<R<U%B5TEV8U)L:4Q6;U))>#0X
M*U!%8WEX1TMV55!+)B-X03LK:V563E$P;2]E=S!Y4S%S<G962G)I-%-:>E=A
M-W,W<6AN6&I,2598,7)E<6HT96TV,'=+;FUI-D)P3VE7>E=U;5<O,65":6A:
M07IV)B-X03MV1D1(8G!U-5DW4E%O=C!E3TMQ6&UV.$$U4F)74"M91S4O-4UT
M:&IZ4654=DMN+TM,85 O04UW3G0O>5I81UA.4GE45$%L,DMU>%8R)B-X03M+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMO2%5T0S!45D=2=%,P*S)V;6I6:VI.>D1()B-X03M-5E9Y<DUQ.'<Q
M07AJ56ME=SA-5E=0-6$X=5!"9#(W-E9:=&(V9W=E+VA.=D55;F-(:T=M6&I3
M46<W,6%U2W%$*U1F2T1Y;5HY1# Y)B-X03MP;6HY0G!$87=&:D9W.5 P>5-L
M95!P+T1X-E4R>%9P=DIF:S5L6D<P3%1I:E)X=TUP=$E#1$9$5#!O>4](,E4T
M3'A8;TM#;4MP<D)B)B-X03M7.79(-E9V16M-9DIN-%)Q1EAL27AD,F]+8G-Z
M1FHT;D965$95<C@Q+W=$2TQA>"]Z03-0+TIL<TUE841Y63EP,S9-+U(Y<CE2
M+U1N)B-X03LQ3#!9+W%V2#%U4'!C4G=P6&5N1VU3,SAV<U)S:68S4"]A*R\U
M2S0W*U@R3',W.7HO=T)R-R]K<FIV-699=7IV,U X03)V=BM3=4\O)B-X03ML
M.6DW3R]C+SER-R]!2DLT-RM8,DQS-SEZ+S)V=BM3=4\O;#EI-T\O8R\X06$K
M+S5+-#<K6#),<S<Y>B]!3G(W+VMR:G8U9EEU>G8S)B-X03M0+V$K+W=#4W5/
M+VPY:3=/+V,O.7(W+VMR:G8U9EEU>G8S4"]!1W9V*U-U3R]L.6DW3R]C+W=$
M82LO-4LT-RM8,DQS-SEZ+S)V=CA!)B-X03MK<FIV-699=7IV,U O82LO-4LT
M-RM8,DQS-SEZ+W="<C<O:W)J=C5F675Z=C-0.$$R=G8K4W5/+VPY:3=/+V,O
M.7(W+T%*2S0W*U@R)B-X03M,<S<Y>B\R=G8K4W5/+VPY:3=/+V,O.$%A*R\U
M2S0W*U@R3',W.7HO04YR-R]K<FIV-699=7IV,U O82LO=T-3=4\O;#EI-T\O
M8R\Y)B-X03MR-R]K<FIV-699=7IV,U O04=V=BM3=4\O;#EI-T\O8R]W1&$K
M+S5+-#<K6#),<S<Y>B\R=G8X06MR:G8U9EEU>G8S4"]A*R\U2S0W)B-X03LK
M6#),<S<Y>B]W0G(W+VMR:G8U9EEU>G8S4#A!,G9V*U-U3R]L.6DW3R]C+SER
M-R]!2DLT-RM8,DQS-SEZ+S)V=BM3=4\O;#EI-T\O)B-X03MC+SA!82LO-4LT
M-RM8,DQS:'12+U)N-E!U=G(S-F,K<&5J2CEA-65T>#E,:65D86(P-#%X,SAV
M<UA:+R\R43T]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4
M:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @
M/'!D9CI0<F]D=6-E<CY!8W)O8F%T($1I<W1I;&QE<B Q,"XQ+CD@*%=I;F1O
M=W,I/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B
M/@H@(" @(" @(" \9&,Z9F]R;6%T/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\
M+V1C.F9O<FUA=#X*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/G)R,C$Q-#8Y/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC
M<F5A=&]R/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U
M;'0B/DUI8W)O<V]F="!7;W)D("T@1&]C7S$S,C<P-C0U,U]V7S%?57)O1V5N
M("T@1BTQ("T@4DE$15)3(%\V+C4N,C Q-E\N9&]C>#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z
M<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE
M;G-I;VYS(R(*(" @(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL
M;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @
M(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @
M(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!4
M4&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM<%109SI(
M87-6:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E
M<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^-C$R+C P
M,# P,#PO<W1$:6TZ=SX*(" @(" @(" @(" @/'-T1&EM.F@^-SDR+C P,# P
M,#PO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S
M=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @
M(" @(" @/'AM<%109SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^5')A9&5';W1H
M:6,\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$9A;6EL>3Y4<F%D92!';W1H:6,\+W-T1FYT.F9O;G1&86UI;'D^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y-961I=6T\+W-T1FYT
M.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^
M5'EP92 Q/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.G9E<G-I;VY3=')I;F<^,# Q+C P,3PO<W1&;G0Z=F5R<VEO;E-T<FEN
M9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO
M<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=$9I;&5.86UE/E1'7U]?7U]?+E!&0CL@5$=?7U]?7U\N4$9-/"]S=$9N=#IF
M;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/E1R861E1V]T:&EC+4)O
M;&0\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$9A;6EL>3Y4<F%D92!';W1H:6,\+W-T1FYT.F9O;G1&86UI;'D^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF
M;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y
M<&4@,3PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IV97)S:6]N4W1R:6YG/C P,2XP,#$\+W-T1FYT.G9E<G-I;VY3=')I;F<^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T
M1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M:6QE3F%M93Y41T)?7U]?7RY01D([(%1'0E]?7U]?+E!&33PO<W1&;G0Z9F]N
M=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @
M(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*
M(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @
M(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3
M=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R
M;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z
M9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM
M<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM
M+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM
M;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX
M;7 N9&ED.C0P-3DU1#)$03$R0D4V,3%!-#%"04,V138Y0C U,40Q/"]X;7!-
M33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N
M:6ED.C0P-3DU1#)$03$R0D4V,3%!-#%"04,V138Y0C U,40Q/"]X;7!-33I)
M;G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$
M/GAM<"YD:60Z1#)%,4,P-C!!-3)"138Q,4(P04(X-C!!-C@Q0S8T,C \+WAM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I
M=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @
M(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C-&
M-3DU1#)$03$R0D4V,3%!-#%"04,V138Y0C U,40Q/"]S=%)E9CII;G-T86YC
M94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C-&
M-3DU1#)$03$R0D4V,3%!-#%"04,V138Y0C U,40Q/"]S=%)E9CID;V-U;65N
M=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM
M<"YD:60Z1#)%,4,P-C!!-3)"138Q,4(P04(X-C!!-C@Q0S8T,C \+W-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I
M=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @
M(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES
M=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z1#)%,4,P
M-C!!-3)"138Q,4(P04(X-C!!-C@Q0S8T,C \+W-T179T.FEN<W1A;F-E240^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,38M,#8M,#94,3(Z
M,S,Z,3<K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN
M9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C0P-3DU1#)$03$R0D4V,3%!-#%"
M04,V138Y0C U,40Q/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#$V+3 V+3 V5#$S.C0S.C,Q*S U.C,P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS
M;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E
M9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O
M<GD^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO
M>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E
M;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0'_P  1" $. ET# 1$  A$! Q$!_\0 'P   00" P$!
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M_"_^@ETT_FQH/ZC2F=77X#Z4?6@_"_\ H)=-/YL:#^HTIG5U^ ^E'UH/PO\
MZ"733^;&@_J-*9U=?@/I1]:#\+_Z"733^;&@_J-*9U=?@/I1]:#\+_Z"733^
M;&@_J-*9U=?@/I1]:#\+_P"@ETT_FQH/ZC2F=77X#Z4?6@_"_P#H)=-/YL:#
M^HTIG5U^ ^E'UH/PO_H)=-/YL:#^HTIG5U^ ^E'UH/PO_H)=-/YL:#^HTIG5
MU^ ^E'UH/PO_ *"733^;&@_J-*9U=?@/I1]:#\+_ .@ETT_FQH/ZC2F=77X#
MZ4?6@_"_^@ETT_FQH/ZC2F=77X#Z4?6@_"_^@ETT_FQH/ZC2F=77X#Z4?6@_
M"_\ H)=-/YL:#^HTIG5U^ ^E'UH/PO\ Z"733^;&@_J-*9U=?@/I1]:#\+_Z
M"733^;&@_J-*9U=?@/I1]:#\+_Z"733^;&@_J-*9U=?@/I1]:#\+_P"@ETT_
MFQH/ZC2F=77X#Z4?6@_"_P#H)=-/YL:#^HTIG5U^ ^E'UH/PO_H)=-/YL:#^
MHTIG5U^ ^E'UH/PO_H)=-/YL:#^HTIG5U^ ^E'UH/PO_ *"733^;&@_J-*9U
M=?@/I1]:#\+_ .@ETT_FQH/ZC2F=77X#Z4?6@_"_^@ETT_FQH/ZC2F=77X#Z
M4?6@_"_^@ETT_FQH/ZC2F=77X#Z4?6@_"_\ H)=-/YL:#^HTIG5U^ ^E'UH/
MPO\ Z"733^;&@_J-*9U=?@/I1]:#\+_Z"733^;&@_J-*9U=?@/I1]:#\+_Z"
M733^;&@_J-*9U=?@/I1]:#\+_P"@ETT_FQH/ZC2F=77X#Z4?6@_"_P#H)=-/
MYL:#^HTIG5U^ ^E'UH/PO_H)=-/YL:#^HTIG5U^ ^E'UH/PO_H)=-/YL:#^H
MTIG5U^ ^E'UH/PO_ *"733^;&@_J-*9U=?@/I1]:#\+_ .@ETT_FQH/ZC2F=
M77X#Z4?6@_"_^@ETT_FQH/ZC2F=77X#Z4?6@_"_^@ETT_FQH/ZC2F=77X#Z4
M?6@_"_\ H)=-/YL:#^HTIG5U^ ^E'UH/PO\ Z"733^;&@_J-*9U=?@/I1]:#
M\+_Z"733^;&@_J-*9U=?@/I1]:#\+_Z"733^;&@_J-*9U=?@/I1]:#\+_P"@
METT_FQH/ZC2F=77X#Z4?6@_"_P#H)=-/YL:#^HTIG5U^ ^E'UH/PO_H)=-/Y
ML:#^HTIG5U^ ^E'UH/PO_H)=-/YL:#^HTIG5U^ ^E'UH/PO_ *"733^;&@_J
M-*9U=?@/I1]:#\+_ .@ETT_FQH/ZC2F=77X#Z4?6@_"_^@ETT_FQH/ZC2F=7
M7X#Z4?6@_"_^@ETT_FQH/ZC2F=77X#Z4?6@_"_\ H)=-/YL:#^HTIG5U^ ^E
M'UH/PO\ Z"733^;&@_J-*9U=?@/I1]:#\+_Z"733^;&@_J-*9U=?@/I1]:#\
M+_Z"733^;&@_J-*9U=?@/I1]:#\+_P"@ETT_FQH/ZC2F=77X#Z4?6@_"_P#H
M)=-/YL:#^HTIG5U^ ^E'UH/PO_H)=-/YL:#^HTIG5U^ ^E'UH/PO_H)=-/YL
M:#^HTIG5U^ ^E'UH/PO_ *"733^;&@_J-*9U=?@/I1]:#\+_ .@ETT_FQH/Z
MC2F=77X#Z4?6@_"_^@ETT_FQH/ZC2F=77X#Z4?6@_"_^@ETT_FQH/ZC2F=77
MX#Z4?6@_"_\ H)=-/YL:#^HTIG5U^ ^E'UH/PO\ Z"733^;&@_J-*9U=?@/I
M1]:#\+_Z"733^;&@_J-*9U=?@/I1]:#\+_Z"733^;&@_J-*9U=?@/I1]:#\+
M_P"@ETT_FQH/ZC2F=77X#Z4?6@_"_P#H)=-/YL:#^HTIG5U^ ^E'UH/PO_H)
M=-/YL:#^HTIG5U^ ^E'UH/PO_H)=-/YL:#^HTIG5U^ ^E:=7U4STH=-G2E>_
M1E!Z;=D]N]DH=ZVKO=+NV-MU;L.VF;ADT.K[9,T=^JA !M);E-:JE1;B$[E6
M1F2$'".%I69DYLTZQ$:#QK<:\(C\%[T$?R6-G?T/INE85^NK^I7S-6+Z5;1I
M2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*
M4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2
MC2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4
M:4HTI1I2C2E&E*-*4:4HTI1I2M%'ZL:^^#T%?Q-Z@_Z[VDTJ0Q^?_3^M;2_A
M$?@O>@C^2QL[^A]-TK"OUU?U*^9JQ?2K:-*4:4HTI1I2J _$P\>6T_#CZH;7
MZ6YG2YN)OI==V;9VKN+2:A9%XTVE.RENNXKOMV);T.WW;9K=2G5%IZTG7T.,
MX7M"36FFXZ&T1&K(AO,"J0 #&O@ 9K#=$7U1=TO=6&_EN]+VY6T6\'2CO9>U
M1BT2QJ/NO'ILJV;DN.H ATBTUKL?Y*K%#N>X.3;5NQ*[:D"EUN8['I<.LE6)
M]+IT]0MD#,"% ;E)F/O[TK85TK'1I2C2E&E*A=L=X@O2GU&]0F^72UM%N).N
M7>WIQFUVG[O6I(LB^*#&MJ7;=U?N+K#<>XZ];U-MNO)&N+^XA.@56I-R _NN
M.3D3[=I5Q20 2-#L=*FCI5M&E*-*4:4IE>HGJ$VHZ5-F+ZZ@=\;C?M+:K;>#
M3JC>%Q1J'7+D?ID2JUREVY!=;HEM4ZK5R>KM7K-/C*W3Z?)<;%Y7W1!AIUP%
M5 )( W-??3SU ;5=4^S5B[_[(W$_=FU>Y-.FU6S[ADT2N6X_4X-/K%1H,MUR
MB7)3Z56X"MU2DSHZ-U"GQG#%E'@ F76G#4(()!W%//I5*-*4:4HTI1I2F4ZB
MNH7:?I2V7OGJ!WRN-^TMJ=N(5-J%WW%&H==N1^F1:O7:5;4!QNB6U3JM7)ZO
M5BM4Z*H0*=)-H7UD.B$=IYT%5 )( W-<O3WO_M7U2[-6)O\ ;)7"_=>UFY--
MEU:S[ADT2MVX_4X$&KU&AR7G*+<E/I5;@*W4Z5.81JH4^,Z8M(\ $RXVX:A!
M!(.XIYM*I1I2C2E&E*-*5K/>)SXX?4ET7]>%L=$?3]TD6WU&7/>>W]CW1:L4
M;@NQJ\[@N"[I-RLE;U)M^@4V:DPF&J!YL?R5)]U''>0(C:95E0A*DE2E0 8^
M7UKXZ/\ ZH+NV\NK2R.B;K^Z+KZZ)]Y=T9U&H^W-4KDZOE1JS<%TR'85G4NM
M6O>%J6Q7Z-3;OJK!V_;-U4BH792:E<C\>ERFJ6PW,J,95%-P,R5!0&\;CV:U
MLR:5CHTI1I2JX/$*\4+I]\-5G9-[?FU]W+E#?JZ:Y:-G)M5;UHU\H%3M\;>.
M:]<:75?=DI#A.)<L#V9VG+5GS5J5YD9GRVO/5<E)5,<A/LJQ_2K:K@ZT?%"Z
M?>A3>?I?V+W?M?=RNW?U:72MH[;3]O+>M&L6]2*FEUV;9_G7I,N&^[4J--A?
M*=\4A[S:+2KA?]A8J#OLWGLQXTI5P25!1&R1)^/TJQ_2K:-*4:4HTI1I2JX.
MC_Q0NGWK8Z@NJ3IMVHM?=RB7WTCW35+1W+J5_6]:-)M6KU.DWM<UAR7K*GT"
M^[GJM3A'6+4J,AEVM42W7RISL-XX[<EQZ)'5<4%(!.RMOG5C^E6T:4HTI1I2
MC2E&E*K@Z//%"Z?>MK?[JDZ<MI[7W<HE\](]TU&T=RJE?UO6C2;6J]3IEZ71
M8DAZRI] ONZ*I4X15BTJD^T[6J+;KY4YZ$\<<)#KT2.JXH*0%'8[>Z:L?TJV
MC2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4
M:4K11^K&OO@]!7\3>H/^N]I-*D,?G_T_K6TOX1'X+WH(_DL;._H?3=*PK]=7
M]2OF:L7TJVC2E&E*-*4:4K0^\<S?2RNF3ZH0Z*.H+<9FN2+$V?VJZ>K\NQBV
M8,:IU]VB4'=G>27."D4^7.ID69.5H5\AA^H0VW#[$^VG?2I#8*FE ;DGY"FU
MZD>I*G>.[XN/0I6>AC9?=2F6WL%5=NG]S-V[QMBF42J4:V;=W6C[A5JZ;D?M
MRKW)3J!;-FTR),"S?EJX8]4N&ZZS,HM+IK,V?3@GJ =FA68B5;)Y[1]Z:?"I
MF]7V^/B6[L>/IO-T&])/5[7ME+;N[:FVH]$CW15*Q5-O=M*<]TWV9?-Y75;-
MI1&9C WK,="K-T&<$3S:?7*^Y6F)5,G1V*M!5:D)#>8B3F]_AY5D/%5ZO.M7
MI2D>&EX6\7K/B;'WSN)M?8C_ %5]==9N:H#4GV9MV2=O';O?W#N^73+DH%(I
MSULW1>5S50JS0KBKKYT2EN7/1:<W52J3[]]$)!SJ*9CU4CQY?(>_3:DMX?77
M/U!=,'BV[6] \WQ'Z?XIO2_U"VN\[3]WW+KA[@5.R[Q?M>\JY368ES)>^Y54
MI%=I%;LU:/<%JN[@U>BRK4N:G7&E+I]7]BCQE54D%!5E*""!&NNW7S_2MT.N
M,U611*Q'H4MF!6WZ74&:-.D +D>%578CP4^6^V;$D'&8\LF7G0*-($@ A)AU
M%5LE8*\_?P>MK?$7E>-5U;4NWNI';&G;C[;;T5"H]?5RR;6HKM+Z@K&HG4/3
MF=WJ#MS$/:>4Q;50O&JM5&719-'I.V#L%F2TW&J5!$48:5(64]FGN[^KKM]:
M?#;*]?%RZ^/$5\5?I Z=^OBYME+*VTWLWH=A5J[;EN^3+L:R[.W[NVU;1V_V
MF?M]J34K%8J/GTZ/5JY0CIU4@4&V8U.A3BBRYE+J:A"$I0HIF0-.L@:GRY4^
M/B@=<G49NGXI]%\,ZC>(#!\-?8+:7;BTZENMU%)=#%FU*X;VK6U%)W0*5(O6
M3=6W]7>]NC7%;MI6W;$>^;7AOU!RM5VJN5J4E.IT55J4@(SY<Y)@#73<3I^M
M._X&G7YU#U'KVZFO#>W=ZL:7UZ[7[>V17-PMD^J.)6(5TS:]'MFM6/"?98O"
M-5[AE7!1KBHU]A(J$:L77=\BU+IMF71J979<&3)=THXD!*5!.4G0CW_3PID^
MJ_9WQH;CHO5?U@]8/B0N>&C;.WL&Z+EZ8.GZR-Y[?I5H;C!1:=7*]1-M':KM
MWNK:L JW(C4^C6Y'J-P1-Q[LNJY:XX\U0!@18M/E* M]U(1FF)/.? ?'I\Z9
MC=;JRZV?$!^IIKZW;N3=:W K>SN^#FW'4W6ZW0:.->WWV=MNH67*M>!%&+:=
M1B4N\HUY;@;:SJI6*2]9TFJP+(J,J967Y-7J-.K"KH2EV(WVUV)^SI6;Z8KE
M\0?IH^IO^H3J F]35/@;>OV!L=,Z):;MC&B6MN3L+3@ZJZC;&\D>X+GI=C6S
M5*E(OB1788P')UVWP<>E!4(C+]%:D.1)2ARJ= R\U9M9G32HO]174YXJ^Q_A
MV^'?XEM4\1C<VM5'<&_FK+H.R%'@SJ3:#U#H+5\56)6]XJP5?<+>VX;GD6)4
M$NJ)>E"DTR-#K46ET!R)$I+:OJ!*"I2,NTF9UY;:>.F_C,U-;<_?#Q(NCOQ;
M_#+9W5ZZ;TWMH_795]JYFZ&R],IE0L_I[L>C[L[CQK J5BV%MO(K]:I#M.M&
MDUV [;5\2J?2[XGU.CC5JW*=DSI;9JM 26U=T=W8\S]]*6/BJ==O4%O#XL_U
MMJV>ON!X973GM79-OUG<C?X;EAV/4:U=EP[7TK=9DG[P.[+ J1K(@W1;=G6Y
M:D.^[8IQS4K5<J+E:D)3Z='42D!&?*5DF /UTGI3I^!CU^=0U5Z\^ISPW]WN
MK"E]>6V&W5DUW</9/JCBU>%=,ROQ;8KUCTZ0TS>$:K7#*N"C7'1[\:E38]7N
MJ[Y%J7/;4VC4RO3(,I]U%'$@)2H#*3H4^_D?*J\NA?<?Q3NOK:?Q/4A>)9NY
MM%9'3"[6KW9FQ1J]S;J7!6:?2MVJM:5A6Q?G[H:%4]KMO?(L>65S3+2F#7JC
M+.CLDS*I\1UE%57D3E.69&HY>)\^FL;Z;5BJAU&=<_6C]3/[R7Y=>_0W%_L)
M]4$NP-\ZYN*VQ<=^;N[!T^/M17;9M1;DJ-MUZJ2KJI&ZFYEIU8KB>J]OUF5;
M-J%3YER30-ZF52A_4?/3XU6$I> C2-/ ]:L8\(K?#JQZ!?!9W ZSM_KKM+J!
MZ;;1VRLRZ>E#8.UCI-C7;8-$C;M;@VKN?1[NO-G:UF3(D7+<-Q6_6Z3*J=4W
M'*+%H\J)'.B#))I^M6K 4YE&AF%'KMKOYZ:?2_#PU>N2%XBW239/533]MI6T
MT6\Z]?%#"R9EU-7H_3RLNZJG:YR2K[%OVPW)2HE35FBTE'86*+R,*X^H><:L
M:TY5%,S$:[;@&IZ:5;1I2C2E&E*T(?&IW[#I=^J'^F[J"<L:XMRPVIVPV3NL
MK#M)4&Y+H2+*W+8^2Z.I1IB),<]I\P56,][K9>XOP5G0,S2A('>W.VF4ZTHJ
MD_U9^._XK/1MU!6WT<;I=,O3ATMU?;BHW1N'N3 JT=E^@V#N8>Z==5+MJ%NV
MU3*E=-Q20C6K:5F6PW<$RC2'RN6JR6Z1)JCU*4[K:%#,%%4C37E'6G/ZD;-W
M@\8/QV^H;H-OSJ9W=V1Z;NF3;.77+8M';"IN169C]LTK:R)6)KU,.8Q0)5RW
M%>.Y,NJO716J76)T.VJ5!MB(TTTTQ*CJ"$-A64*)/.--]M^GQ]E.OX(V\_5/
ML?U1^*;X:J[LW7U'4_I;MC<^O].<W<F?.J$R)=^W%WOV)2Z3!&J52HOT2@WW
M)KUK3*M:[-7=H5)JM,E2J,D1RJU>34%4< *4K @JW VJFOH<L6L]=T_<JY[Q
M\5+>KIJ\8JF[YHSMQ:^^FX%R[=[?W'1F:A0F:C0HM9;I[M<BWK&JKEV4J+MY
M0)$,J5\C4JUXVV4NARGZE!5>HY8A"5(C< 3T)D?./;4VOJG?8[J*H=1\.6]M
MX>I9^^:W<-GPMGZY:EL6M4K9L&D[U64[1IU^[_6I2G+ME0Z=4MQRN^A0Y=$B
M46DOP(UE4Q$K3\5Z'3J*JUHI[PR\B9G\NG=_O6Y;T8;&;I]-O3=M]LSO5U$7
M;U6;E6BY=YW#OQ?-/J5+NB]QN&][CN>CMU*#5[NOJH,);%#K--M&%Y]TU-'8
M%!BO-)"9<;I\56%1!)($#ITK3M^J4=B-UJCXF_0+5H74;=U+I_4'=5LV=M!1
M6*?4RC=,MR4.]-HK2JE]6887>P%2J=Q7!7J3>LMBE1K+D-U&W(;+E3EON-5*
M&K,T1D<TF!)\1!T^!]]*GQF[:ZL>GK??P3NFV@=96YUR[RNSELBJ=0]2DW)3
MWKTOJI;Z;:0K=O\ OFR7[QN-NY HDBL1/:*'7Z_7FJA3X3M/>DK&F.,BHW!#
MIC2)CH.]H#^M.]XJ=.ZD/!8\*<=F-K>KC=3=;<KJEZPJW.N_J-N!:G;F[-,M
M*X]LAJET6_2[A6[KHK46M5:LV%3E*[H-:@U%JBU>M4V.Q&ENI57%41#B]4@
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MJ8GB*VQ<L[ZIW\,JX85O5R90*?LSM8U/KD6DSY%'A.M[A]3YN-2ZDU'.%&<
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M/8FI4]9#0F8MO>S^8 F2"2(2Y4[@V*_</K7=LFVO&KVUM^):6W.Q/@S6!:L
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M1_WQOI<_H'2O^T'I24?RJ_ZA_P!E'[WSQD4[)XC?2XB?R#I7_:#TI*/Y5?\
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MZX3"?%=.T1MF^!^E45PMQ @PK#'@8!@K9V)(_P#5Z@UCG?$8Z*F (W=_;9
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M?5._W0@_\<C?^N#51O[#\C2O;RVC^]3MC_D]LO\ 1NFZI2G"TI7X1(*97/\
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M;M*0%G1@\M-D&!N08!/@#UJ0K- J]NU.;1:W DTRK4^0<673Y;1M2F7VR45
MFU3*YQD2%5 DPHDJ*BK>3&X4/,1SCGI7++0I"BE:2E23"DJ$$$3,@Z\HK#Z
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M\MQC .P"W[?,K\RFP-!O(3OM$F>6T#2J9#C*V^Z#S1LOQW"8?:<%0-LVR42
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MHR[_ /3I8F]]*(90NQKOCQC"V[K@TRJ1GH;[CS<N.!HE+IC,RFSY$V-+;:?
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M$(4N3 )1E.XKW3T+8,E-]BG%%\GLV,#MG&L/?*4@*OGT93+BA$&V?6@@:Y7
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MO%F"8R\X046[.*6B;K4@:6;SB+N221JR.>DUD":!G*A3ZE2S;('F7)=$FNI
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M:ANBRXZI/&>5-L1!5]%(<"*IA!^Z1/74-3A6O,K6- >0WC3[CG6Q*&VD'(D
M&3IRVU]GOWDU*RU:%4&X\+V9D84<''%4<@ZXV31ES4)1 A-*9Y120>PKY:9]
M4D3F20!R$"9\M=/U]^E:EUY"2I*E%6^TG7>.?,$2)VUUFG#1UR?5X5,BD!QH
MR'-F(TOFBKN/+:!QP5Y..D3F4Y+A!#YE35NJ8!V/F?/7>?;'OJ&4A*5%25 J
M$IT D3I$=#.G/7V.G3;?FR&!@QP5I%(6G'$$5$5RG(>6<<ERN>ZD*HOQ74Q
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M@T*>\4$$>L>M=7Z5,55PGZ+&K!A2&\2Q0LX<$$9LUNZ,M[OFRI5;E24PDYE
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MU.@UZU\>$93FS%4G,21KWM8&W4"8'NJ76E7T:4HTI6BC]6-??!Z"OXF]0?\
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MQ;:/X?>!"T(W0K3?*#E[V\P(-4;R([\20_$E,N1Y,9YV/(8=%0=9?9,FW6G
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MNWD#I/NW I..TZ<D<Y)3"*:T*QLDWS-H"3+IM(*^]A13X\43WO3&<>7UMID
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M JY(0I$APEPGJ@BA*2_ 4)?1%US7&2<_"?$2(G-A-[[NP7/(\B?*NV]&H_\
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MP*.-4A5BWB($$"HU;5JH16PPI(0Q3?=B<N646.J$@KD$WB%2D&-Q'EI'WI7
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M9=/:%KL2M(/9](&L>'L_6N)Q#*;IU2 0E:B=?YI[T>'SWKU6?!W_  5_A_\
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MBJ^\(^ZJ91<^E3OH(,[;CV>WZ5)MGD9_5!,'?U>?*)ZR1K'.EI2+5E'$8BN
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M4XVV0:.0KH*<A#=ZTW>O6UY;*<?4IFW_ !*@'6;1:EA2&D);+.C:@F%))0D
MI(.E>=XNSAJ6."VN/N%,?L;3AIO$5XMB6%!EY_%;FX:MDL/W=^BY3=+;+K1>
M4M]U"V@M4!.M1?N;92U;/N?]VUES;=E5FCSZQ4-T-NK;GU23 H4:/**34;JL
MMJK1(C+I-E%276+/ITJ3. Y$MVCTTF8[C3>PX&Q3!<#QY&+7J;<7CMNO#[HM
M$NH2EQ;4.%*4MG-E;!"]0$RD)(((X_TV^CSB/B[A/\)A&'8HQ@?;V&)X)B6*
MFR8NGW6[2Y8:PN\:MG;B;%35XZXQB+Z6VW'D6J;FX!56PAT-O4*;;-)J-.E1
MW8,^'$FQ93;H.!+C2&FW&9+9@I K;S*@0$*XQ\_Q^D+5;3K+;K+B76EH2MM:
M=1D4 0"8G,9$SKJ)K\Z;FVNK)^XM+IEQAZU>7;+8<04NME@]BKMT[(<[5MT%
M"2H)$#-)*4V[@J* J*HHJ**BIZ*BIZIJ16,??.OK2E&E*T4?JQK[X/05_$WJ
M#_KO:32I#'Y_]/ZUM+^$1^"]Z"/Y+&SOZ'TW2L*_75_4KYFK%]*MHTI1I2O+
M?\>"T%OWZH)ZBK16,4R/6KTZ6H\^."JANTL.F'86151 O*?036G,R>"FT;:'
MQ\W#?(DD,I*RA $E2@(&^I^E8W5AMM:SLE)/N%6/42F10@LLE":8CQR]G;8:
M8Y>3%;!UAYEL0I9FVTCCDN&QPX"TT%,7*+';QTH3;N ?B6@A2AE.N@2-$P.F
M4 QSKC7W6BI23FUYD[YN\>9T\]YC2G5@0X0,.D^X_)<=\X'&4@U%I7C?5U'^
M#T.+$X'.:=J BB$VD<9T?B0N1V4&]#>&-)4@7'9A1!@#977V3MKKMS%8T*>2
M3^'<4E)&L'\T['2!(WGE[#2YB1B8RC\=TW7"<>>R^]%:=%7)2R'1*?<D,!&?
M)=F$K8BB $AQ&PP(()ZUO$@&TOFEJ,9P$A.5,'O<AT!W,GSB_/<*@.J*PG77
M:0(G[Y>-*:G/QXP.2I$K+,1LW7)M5J=#.(<<1,G3>Y5Z:.76BDE(\X4\MNJ5
M)"3B8(6)IO'$NI;1;_C%O.(;0TVDE3SCJLB$-I3!*E*4E*0"9) '**+O&+=I
MQRX#:666U.NK<*<B&VTE:U**B0$H2"I1S   DZ54[NY?S^Y=]U.N-"XE,%P:
M9;T3@@FW2HI*W&<-IL!S.J3I.U.>O%3.?-?1"44!$_0O@7AEKA#ABQPY8:1>
M=D+S%WDY0AS$'6TJN27- IJW"4VS2S$L,(40"55\'\<<3.\7\2WV*)2I-J7/
MPN%VP21V-@RI2;=(0)(=?*E7#R94>W?<2DE(2!8ML)MHWMG:,-J;"D_NEK3+
M%3KLB-3+C=?C3G4)V#27R9M-X/+I0^R->0U/E1W)Y3)#1K'J"*GQOZ4N.\.X
MXXA<<*W7,%PE3UIA*)6AMQO.D7%^$@B5WBVTN D)4+9NW;4G,A4_8'HIX+P_
MACAMMERZ2WQ!B@9N\57D/\)PI*F,/"A$HLD**%0HI5=+N'$$H6E(?Q*BVX$<
M')3C)@/E1V#AU]GR(ZQ8;369#SU$!'#BQJ,[E]Q6TDQ0/(G*D\_-'K:PN$I7
MA^,0)A;>N=)CNZG4C:-]I/AZVNTQ%21V+H1ETD""H::R>:HTWWC6)**N=Z/W
M@0W>;J.M.HX=>@0XT6,@,MLDRY5+^812<,J?+;$B7'R9'YX-I[&L=M<8M4K<
MM+Y;JR4]FVMP+2Z#$PDZ0->O76I++EZDH9<LW'BDA*W08S3SW]D1R,"F0G.1
MY1&^_4H$=MSR^7M$VADK*(D5EI&!"IU)P189-IIEQA#56J5"4W$*$[QU;V(<
M4L+*58:E\994L$)&HU[FQTD0!^E=,TFQ2E+;]GV3P 42N5#*=1.P.D$]!XFF
MYJCJ1T5(C,2*/!SSB]F9<>PXZ7VS,.TYI#ADGX@(KV8RK'-11('$-8>(\/;<
M4;S 4J>1(5H0$';8$1KU.O*NG9P["'V6W&;L- P2$@H21 @@'DDR>7C2,E5
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MOE+0HD\HCEORWU)^7C4A:EA,SXSI/+IYC>-_*DW>E4=K<T8K$0Q: E%EILF
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MI[E]U[JJF$7&-A9ZZD[#YP?GS^>U:#%T@MSS"IT]N_7].IKTV-I.VU&V2_\
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M-=!)F=-)\CRTKKEVL(257SJTD )RDJY:0!I'('^U-7=]W/LNG'CJY4@4&@2
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MLC6J?7:317!CLC,"*VBM)_>91BJY51(44'W$[H.5%33"*J:M2E6:9YSS\8\
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MC-F!!&V@GEO]++2Y=^D'B:Z>X?;P%NSML.P^VPU+_;,-J"G+UZX"0.Q1=O\
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MC*4!OBJ<6FZC60<45CKY>V5=)0%%RU*PG504 O-.XS:>S0:Z5RKKC(62Z<H
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MU!XBEDY=QI'A5-:HU+GJH-A&BWA=C1JB4MXFJ-7W%#3#]S=X2F[;0I)1D0-
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M./1QF"1N^^_GS!;XN<LI').*\<]VVT3U7NO;69MHE4GD-!XF"/'7_:M9<W
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M%)E+C2HKDF T?^&41,R.)*N,KE$1,KV[ZWJ\(-GE"U=J^E4!L$)@0<TA4D[
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M8PK,:CSADN/$L<R6=3?9VJF==EBZ.$\FGW\\"< I -ZC)1QM:H=-K<M7#:8
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M<3!\F^9.F(DB(LBIJW[YHH C:UF(*!*;<='& 1D9C:956AXXE8K=@_Q;-(\
M ) ZQ/\ FV,U'R-)C.D[^([NT:=1.LR-_"E ->1(SB&L$QCM/.>8CC3C3[;0
MJ19&57GR!9#1NHO!"41J1H(^8&1"_MGU-,FP[/,XA.:#JM:@G41M)]V\5F+6
M'H:=6%"W[-M;JU)DE82DJ*-#&L23M/4ZU4Q;[15*YZ(R:L\Y]>IK1K)3,?E*
MJ#($KZ<',LY<574X'D.7N%Z+^G&,N)L,!Q5UL]FFSPB^<01ID3;V3JDD?TA
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MV&W(U<RSB2$ANW0I\)F08D:SOJ?.8Y\]^E4X#!1.$9B93#:!1 GJC.*1#5A
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MZ^TZZ>YM9]4<\X4@N<)=2<-H%;1.3 =U>-$+L*(TAI[N"PJ*G==0.T)4&TJ
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MP<*O@MBZLY"7'6)2IC.2$%QDIT02$@K!5"U][037O?HO_:=]'W&X3P[^'O\
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M=YV,B=XK'U)UAJ!YL>&;3[C8*".NJ3K*MK%=!7!;M)$=>C)"BR)8B?%YVG7
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M>_H]]V':=W-N!(.OT"FU,U5>*>UOL 4QE.4/MY$X' _O#:9CNH HBH.LK<I
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MPHKK/)6TX(V2"Y=#?OB#$5DD4!7G28I)E9$@W-]<XNV^YGN\,2%9A'<A)_F
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MHU4ERV6D5.1L2)TKS<*G$D$"(5]<)Z95.VM!BS.5P.C983/@4I2GX[]-J[3
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ME4XS5FN*.7PS(<LW D!F[6M:M^^02F)$#E(W'LTJ$N^Q1@!2.S?U*2F/5!$
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MIM->D56/<Y.OO,H;Q^RWK<D$5-5'X!%$17*^Z(IZ^G;^E/\ ]O>(/_>8?_\
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MQ9:JX?G)YB$:KAM3% +N&2)R4X*HWA%+W$P@.JJ=U5)QMD+'<6@%,&"=P=H
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MIY^6F9@>9\MOOGM[)470(A:UQ"*(B)0*NB(B(G9*=(QZ:DV?_C+3_P")8_\
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M?0]/'<ZY!=Y%E(3.3GO,^[W3]:2M>I"P^$IE"-@E1ITD:(!!SNC2JJ--AEP
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MQ_'M\,*O_P"?IJRE2HZ?]WCMZ8S;%>F&E&F.BU#>>(R2'(-1$$+N2"RXJX+
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M% MMILP(#PU]T.%5$9;3_P#Q]/\ /WUT/(>9/OC]9K@>9\@/GX_/ZTM+J_\
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M>G;5S9W^FORK'*#$IU C].O/^W2D?3G4<E< 4E#'W19XF2K^/YOQ8RB(NLA
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MN5+_ #_-VULPE*0 D  =!]]/"M:I149.]?O%%7*HF?GPF=5JVL4?W9?\(O\
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MU<#PJ3*5$G4J3Y[*G]/A5M>E6T:4HTI6BC]6-??!Z"OXF]0?]=[2:5(8_/\
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M/I@EI1.&X>2-03;VSJ[M4'DN_+:AHMH@D5$&N=&77W<U1>JUQ=)_5W7*F_\
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M8T"=.>A/GMJ?=YU"4^ZO0J,=!MI^D?+SI+ET*]<!KDNCCJI4OB2]/>[:JO\
M"JVCK+&GK)UWU^_#E[:PU]!T+=;X**_O-^JA<?\ W>]V_P"R.J9?\R9\_OY4
MK[+H9ZWU-#_>;=5/;';][WNWWQ__ "CV_P!>F7_,GWTKY<Z%^M\S0TZ-^JD5
M%$1/^][W;^"JN?\ Q1^==7 """4^^E<:]"?6^JJJ]''52JKW5?WO>[?]D=6Y
M?\R??2OS]XEUO_0WZJ?Z/>[?]D=,O^9/OI1^\2ZW_H;]5/\ 1[W;_LCIE_S)
M]]*[<#H4ZW1G0R+HYZJ!$9<<B(NGO=M!%$>!54E_<CV1$[JOP32(Y@Z'8^S]
M:5[)VUD>1#VQVXB2V'HLJ+8=H1Y,:0T;$B/(8M^G-/,/LNB+C+S+@DVZTX(F
MV8D!BA(J:MI2\TI1I2C2E&E*-*4U5P;X[1VO;%]WE6K_ +=CVUMA<;-G[A52
M-,6J-V?=4A;>1JWJ\Q2@FRX%84;KMMXZ>['22U'K=/E.MA'D [I2G5TI1I2D
M;2]P+-K5[W=MO2Z]%F7O8=&M"X;NMYMN4,NAT:_7+E:M"?)=<8"(XU7'+.N4
M8HQI#[K:TE_VEMA#85Y2AK<&S7]P9^U35>BGN#2[-I&X,^V$;E>VQK-KM;K=
MN4BO&ZK"0EBS:W;E;I[;822E"]3W2=8!HFG'%*66E*1K.X-FR-P:CM4S7HKF
MX-(LVB[@U&V$;E)-BV;<5;K]N46O&ZK"0EBSZW:]?I[382CE"[37B=8;:-EQ
MU2@MP;-'<%O:HJ]%3<%ZS7MP6[8\N5[:=FQZW'MQ^O([Y'L7LK=;E1Z>K:RD
ME>:Z)(PK67$4I9:4HTI1I2C2E&E*-*4:4K11^K&OO@]!7\3>H/\ KO:32I#'
MY_\ 3^M;2_A$?@O>@C^2QL[^A]-TK"OUU?U*^9JQ?2K:-*4:4HTI1I2C2E&E
M*-*4:4HTI1I2C2E&E*-*4:4HPGS:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*
M4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2
MC2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI6N3?.TT6V.E[Q>:A2K]W5D3Y_6+'M
M=AVY-P:[>4&E*<?I/K#-PT^A78]6:!^Z>+*JI,-U>93);C])@4NBS&Y-*@LQ
M$5<K\LZZ ]/9I3K]1FY>]729+ZY;!VOW;W8O*%;W3[X?VX=!K^Z>X+%VW-MW
M<74GU5[^;![Z;C4"\;X@5*B693*1MM9%(ON-3)M+<VOL&LVO+KU/M2F4%ZK4
MN0H!,>9GI  ,0(\=M3RJ8O17!WYM'=3?"P]SY=;IFWP67L[>.W&W^YG4E3NI
M'>.UK@K-1W1HNXE:G7,^)WE%VPO!FW;)D67&N>=48L6[:3N3%MN1&I -TBEJ
M&($;ZR8 '*-N>\^RF'OO;>EWQUR=>=;J/4'NKL8YM]TF])UU0:IMSN,W8=-H
M,N$_U7S&MR;Q@LQE&\J79OR<9I;EZN5?;.7%E5)NY;4J[SD1^$H-AI.ITZ[:
M=1[*:>A=1M5]LKW4_O+4+SVPNRZ?!7Z4MR;XE[84*@3+_M#<#<.]]X)TJ+8-
MO7O!J5JK=4*\[A"GVU3[RAO6W&JGL;=RJS2FISS:JD:P->\H#Q C7W=*;69O
MKU.;&53JUVQJ%T7GM?#A;4]"%P0&=P.I!OJLW0V"B]1O5;=&Q&\.\-RW;=%J
M_(]@7)0-JS7<,MO8M?W/VFMEZR*;=E J+5(K==I"OO[^_=0 &.>_A,"8Y>4[
M_"ECO<5P=(F^/6S6]J]X=RZU7*!T =-4N+=V[-[%N]7]EX-V=2V]UKW-?K5<
MO=FK5N52K)H$ZM;K-4Z_*A<5!@R:5-%B+&M$?D-A5!K$]5>'(::?2?A75ZDB
MNGHVWBZF;YV9W6W1W!O6S?"ROB^;=E[O;@%NW5+!J*;TTB-)W"8JMX1ZG6!H
MT1EB?>\BBUZ=4+$BG:TMJ@T*C43Y6I[S[B@$Y1XQY[?'RW\ZZ6Z5Q=8.RNS/
M4X=!W%N[;>#6NG_;*[-JW-S>J.A=36Z=(W07>FVK5K&ZUJO1FX-R1=L;NMZ[
MJ9#N>BL3 L"'6*73H=E4ZU@N&IQYJFF\:2.0 \1]/C5ZVU%@2=L+!H-DSK\O
MS<^H4D9SM2OW<RLL5V\[EJ=5J4RKU&H567#@TNF165FSGVJ51*)2Z70+>I#<
M&A4&F4^D4Z'$95;\*<32E&E*-*4:4HTI6BC]6-??!Z"OXF]0?]=[2:5(8_/_
M *?UK:7\(C\%[T$?R6-G?T/INE85^NK^I7S-6+Z5;1I2C2E&E*-*4:4HTI1I
M2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*
M4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2
MC2E&E*-*4:4HTI1I2C2E&E*-*4R+_35T^2KDW%N^5LKMC)N;=UNCM[I5F19E
M!?F;AI;Y4@J*Y>).PC&X7Z85OT%8DFIA)D-?(E(1'<4V$C*D\N5+NI;<;?5B
MIW76JO8]HU:K7W9U,V\O:HU.W:1/F7?8-&D73+I-DW._+B/.5ZTZ;)OB\WX5
MO5195*C.W9<9M1!*M5!9"E)+:#I]V+Z?J=6*3L=M!MQM)3KAEQ9]>B[>6=0K
M3;K4JGQO8::[55HT*(=0^2H&*?26Y1.MTJGB,"GA&A@+**3.]8#<OI2Z8]YK
MEBWENWT^;,[EW;";@QX]S7SMO:5T5Y(=-=61!IKM5K%)ES9%)C2.,END2'G:
M9[2VU(*(3S+3@*K)ZGK2_N/:?:Z\7;F>NW;FQ[H<O2QO]C&\"N&U:'6?W5;<
M>T565^X*XDJ,&0E9L[VFNUJ1^YNHI(I'G5>I.>Q\YLA7%4I!6-TJ],VV=(N"
M@;?=/VS=G46[K;D6?=],M_;BTJ=$N^U9CL]Z9;UV-1Z4*7-1YCM4J12X%=]O
MCRO;Y:/@X,AU"563U-?NVO2KTS;.1KDA[4[ ;.[>1[RHR6[> 6AMU:E"6[;?
M%)0-T*Z'(%+9<N"CL,S946-3*N<R%&A/%!88;A\6$4D]37QM?TI=,FR;]6E;
M0=/NS>V<NOTB3;]<EV/MQ:=MRZS;\HHA/6_5)5*I4:1/H*) @,LT:4X[3(T:
M#"B1HK4:)':;522=S-=*R^D#I4VYH=VVS873CLC9]NWY\CC>=#MW;*SZ52KG
MCV[-6HVY K4&'2&HT^EVY/(YEO4E]LJ;0I+CKU)B0W'7")22=S-2,TI1I2C2
ME&E*-*4:4K11^K&OO@]!7\3>H/\ KO:32I#'Y_\ 3^M;2_A$?@O>@C^2QL[^
MA]-TK"OUU?U*^9JQ?2K:-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4H
MTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&
ME*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HT
MI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*5HH_5C7WP>@K^)
MO4'_ %WM)I4AC\_^G]:6?1!]5!](_2_T@=-O3M=W3]U&W!<^RVSEB[<5ZN6X
MSMFM!JM4M6AQ:7,G4A:G?D"H+3Y#S!.1EFPHLCRR'S6&RR**HIE142"F"2>?
M,^52F^R^NB7Z,W5/^0VE_:/I5.P7U3[S]*/LOKHE^C-U3_D-I?VCZ4[!?5/O
M/TH^R^NB7Z,W5/\ D-I?VCZ4[!?5/O/TH^R^NB7Z,W5/^0VE_:/I3L%]4^\_
M2C[+ZZ)?HS=4_P"0VE_:/I3L%]4^\_2C[+ZZ)?HS=4_Y#:7]H^E.P7U3[S]*
M/LOKHE^C-U3_ )#:7]H^E.P7U3[S]*/LOKHE^C-U3_D-I?VCZ4[!?5/O/TH^
MR^NB7Z,W5/\ D-I?VCZ4[!?5/O/TH^R^NB7Z,W5/^0VE_:/I3L%]4^\_2C[+
MZZ)?HS=4_P"0VE_:/I3L%]4^\_2C[+ZZ)?HS=4_Y#:7]H^E.P7U3[S]*/LOK
MHE^C-U3_ )#:7]H^E.P7U3[S]*/LOKHE^C-U3_D-I?VCZ4[!?5/O/TH^R^NB
M7Z,W5/\ D-I?VCZ4[!?5/O/TH^R^NB7Z,W5/^0VE_:/I3L%]4^\_2C[+ZZ)?
MHS=4_P"0VE_:/I3L%]4^\_2C[+ZZ)?HS=4_Y#:7]H^E.P7U3[S]*/LOKHE^C
M-U3_ )#:7]H^E.P7U3[S]*/LOKHE^C-U3_D-I?VCZ4[!?5/O/TH^R^NB7Z,W
M5/\ D-I?VCZ4[!?5/O/TH^R^NB7Z,W5/^0VE_:/I3L%]4^\_2C[+ZZ)?HS=4
M_P"0VE_:/I3L%]4^\_2C[+ZZ)?HS=4_Y#:7]H^E.P7U3[S]*/LOKHE^C-U3_
M )#:7]H^E.P7U3[S]*/LOKHE^C-U3_D-I?VCZ4[!?5/O/TH^R^NB7Z,W5/\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g142578g51j14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g51j14.jpg
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M,%(7&"EQC&,8%Y,29D+*XUSJ7(I_@E5_P]#>KFPLKC7.N\O)B3,FXZ,4*@
M!%-FE9Z.U5TQ8-)UXE 6*/NK27KO<<,I'NW,1&-9*/E.[5(L\\@];G.=OA)M
M,(QJK<YNZ&"R_!KIU3$NN?M1"BXTRK^"E:Y'5_4N$J%(N^+1B17U@K<\Z;U]
M_"0&(K3"1>R]=2@9-@:/C8^9?Q=,8SB["X-[1+3)I:419.&[J 2[I9.:R19Y
M-N!=\IY,I2:X)=>3%AE;CPX<RYEZBU3^M$.?4"MUJ[8F,:?*1-B<7.QMZ/%/
MV\1.4V:>MF%J.A6&=97K\!9(=.7M:L% P]J/2I5LC"N#S#/NF5)+7@DGLQ9^
MJ<\.3$PX<.*W\>J6:2R]BK,>E6I#2\IS*3E^ZQ8$I"0?+5]W!2</BO1)91[!
MM(9L]?1C-I8'\*XAW#"YN8J2GV\/=LS4-E^@U0C625%3S;YZL"8)%=]GGQPD
MGOWYV7!;$=(2'"[>_P!P)MS\%L;&]PO=#EMO;>WG8V-O?V#[6SO8VJ%3SN/E
M^;EA_+QWO, ./E^;EA_+QWO, ./E^;EA_+QWO, ./E^;EA_+QWO, ./E^;EA
M_+QWO, ./E^;EA_+QWO, ./E^;EA_+QWO, ./E^;EA_+QWO, ./E^;EA_+QW
MO, ./E^;EA_+QWO, ./E^;EA_+QWO, ./E^;EA_+QWO, ./E^;EA_+QWO, .
M/E^;EA_+QWO, ./E^;EA_+QWO, ./E^;EA_+QWO, ./E^;EA_+QWO, ./E^;
MEA_+QWO, ./E^;EA_+QWO, ./E^;EA_+QWO, ./E^;EA_+QWO, ./E^;EA_+
MQWO, ./E^;EA_+QWO, ./E^;EA_+QWO, ./E^;EA_+QWO, ./E^;EA_+QWO,
M >9-75M7X>6GI:#L+:*A(Q_+R3G#1DKW/'QK55Z\7X)&1.JKP39%13@TB'4/
ML[)"F-G&,WJO5VM:K#"JL**4FU9;,JNQHJJ44I-6U.BS9T5I4E2C11:=)$G2
M5$3&JHA9K#=G56#>LME6BQJ[%HW:TD1:2T6;*A2:4U2C115I*E&BJR1%5<2)
M,I?\IUN1N=]F_P!#V/L8]%]44=_)3#^9N[_<F@^M2"?E1M_+GA_MA\IUN1N=
M]F_T/8^QAZHH[^2F'\S=W^Y'K4@GY4;?RYX?[8?*=;D;G?9O]#V/L8>J*._D
MIA_,W=_N1ZU()^5&W\N>'^V'RG6Y&YWV;_0]C[&'JBCOY*8?S-W?[D>M2"?E
M1M_+GA_MCWZI_:)[F&ZV>O4^MV2RO[#:9J-K\(QS39QMAY+2[Q%@P;9<.FZ+
M9#"[I=)/A5U4T4]K:4.4F,FQ^6O7+XS=M2K;PK;M8LZK4JNVK58:(\*BT6@Q
M8,Z35K22A0K%*G35*%%52C1HK27$B*I^FI7280>%<JM1JKQ:M*S7*PRJU7H+
M4*]02FV;TZ+-G16G3J]&A12E3I(GI4E2BDYJJ)A+B<?+\W+#^7CO>8\^-[''
MR_-RP_EX[WF ''R_-RP_EX[WF ''R_-RP_EX[WF ''R_-RP_EX[WF ''R_-R
MP_EX[WF ''R_-RP_EX[WF ''R_-RP_EX[WF ''R_-RP_EX[WF ''R_-RP_EX
M[WF ''R_-RP_EX[WF /082"CW*N#QLBPX/!<XR_3;$PKM;6_A+N=TYSG)-G?
M-M8)O;1=[.?GW@/1 %%K7X4V3[_F/6+D7TQ)F3<6%QKG7>7&I_@E5_P]#>KF
MPLKC7.N\O)B3,FXZ,4*@  !R<M1ZQ.6*!M<I&G<S]8X;B)_B0DV_%_=._ASL
M-6SU%DKW07/!N.Z&RW#)8*BKM)%*3 'CH:3:;H.; Z+3X=4UH8SD9-(.T3OH
M]S&VAT5_:(Y"+>*+QL<QM$@4DE96<8U9M[!))IR,PF]>ID7+6:^?/5U6%))8
M>A%:>4R%B'L%'P:)8V3DVTQ+$=.7TBZF)-GF.PV>34E(NG<E,*HH1$6Q)QF[
M=$XKCV<3DN8QNDT+2962'W86EU2NRDW-0<#'1<K8ES.9EZT1PFL^6.[>2*IC
M?/DB)7$G(R4JZ3;E12=2TC(2C@BL@^=N5@.G
M                    !&VLOT0:K=&UY]EY099P<NN72SNXQB8M^<BOC1;P
MX1L8T!/H@V     3UN6/&7T Z9--_:Z)&LQIS0B?0+UX)L;%"'.J&]..OC6)
MK^$%2:P                   !1:U^%-D^_YCUBY%],29DW%A<:YUWEQJ?X
M)5?\/0WJYL+*XUSKO+R8DS)N.C%"H
M                       !&VLOT0:K=&UY]EY099P<NN72SNXQB8M^<BOC
M1;PX1L8T!/H@V     3UN6/&7T Z9--_:Z)&LQIS0B?0+UX)L;%"'.J&]..O
MC6)K^$%2:P                   !1:U^%-D^_YCUBY%],29DW%A<:YUWEQ
MJ?X)5?\ #T-ZN;"RN-<Z[R\F),R;CHQ0J
M                            1MK+]$&JW1M>?9>4&6<'+KETL[N,8F+?
MG(KXT6\.$;&- 3Z(-@    $];ECQE] .F33?VNB1K,:<T(GT"]>";&Q0ASJA
MO3CKXUB:_A!4FL                    46M?A39/O^8]8N1?3$F9-Q87&N
M==Y<:G^"57_#T-ZN;"RN-<Z[R\F),R;CHQ0J
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M;BPN-<Z[RXU/\$JO^'H;U<V%E<:YUWEY,29DW'1BA4
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MF_M=$C68TYH1/H%Z\$V-BA#G5#>G'7QK$U_""I-8
MHM:_"FR??\QZQ<B^F),R;BPN-<Z[RXU/\$JO^'H;U<V%E<:YUWEY,29DW'1B
MA4                  (MUR^A36#HMU ]DY<9F'.<+BTRZ^.8&(B#D%]Z(>
M7!MC&R)[D'@    "PFY,\9S0+I:HOM"Q&KQMS/B;0;RX1J;+!O.R'-,N_B69
MKT$%R:9E)W87C/ZX=($U_60<MKKW2;&NG:U^0ZRW&^BV!>SU2^S2*VCS@]+
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M2J-<D9B*B7+IP=V4D2E,23ANU1;K/56SQRO&L:+GF$6?5+SYP'7@5
M      "+=<OH4U@Z+=0/9.7&9ASG"XM,NOCF!B(@Y!?>B'EP;8QLB>Y!X
M  L)N3/&<T"Z6J+[0L1J\;<SXFT&\N$:FRP;SLAS3+OXEF:]!!<FF92=V%XS
M^N'2!-?UD'+:Z]TFQKIVM?D.LMQOHM@7L]4OLTBMH\X/2P    #7!N;_ !=]
M!>A?2WV'@AU?N=]'\"]CH9]R5$Y"72ND6/NVL5>_:^30-Q-*
M "-M9?H@U6Z-KS[+R@RS@Y=<NEG=QC$Q;\Y%?&BWAPC8QH"?1!L     GK<L
M>,OH!TR:;^UT2-9C3FA$^@7KP38V*$.=4-Z<=?&L37\(*DUBEM_W?6YVTTN=
MBH=IE[.A8:O(J1<LBSJSYXV3=ID(<Q4721^#6)LJ%S@Y?FSOYQ_ >-OZ[O<^
MAM\/!Q/2MO.@\'96*56K5!B[&[9E1:T:-&DJ4&M%?1IT94DPH>V0_P#V?[H\
M3.5W/]U5-UM'<]:M1K54IMGK5V+6DQI+2HHM-E33TJ%*=%?BKA./^4SW*_\
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ME91$,I(JPT#$EE7KPL3 0ZDO*GBX>/PW8L>,')4$2$,4A*3GY\ZP=R
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MBY%],29DW%A<:YUWEQJ?X)5?\/0WJYL+*XUSKO+R8DS)N.C%"H
M        1;KE]"FL'1;J![)RXS,.<X7%IEU\<P,1$'(+[T0\N#;&-D3W(/
M   %A-R9XSF@72U1?:%B-7C;F?$V@WEPC4V6#>=D.:9=_$LS7H(+DTS*3NPO
M&?UPZ0)K^L@Y;77NDV-=.UK\AUEN-]%L"]GJE]FD5M'G!Z6     :X-S?XN^
M@O0OI;[#P0ZOW.^C^!>QT,^Y*B<A+I72+'W;6*O?M?)H&XFE
M !&VLOT0:K=&UY]EY099P<NN72SNXQB8M^<BOC1;PX1L8T!/H@V     3UN6
M/&7T Z9--_:Z)&LQIS0B?0+UX)L;%"'.J&]..OC6)K^$%2:QE3W9WC2ZV_C9
MY_M6@Y=78^D^--,M?N6)U@N+=%4#Z#8_>MBL8\T/4     #6UN9_%ST%Z&],
M_8V&'5RYOT>P+V/AKW/4SD/=-Z2(_P"VD4>^ZZ3<-T-'        "BUK\*;)
M]_S'K%R+Z8DS)N+"XUSKO+C4_P $JO\ AZ&]7-A97&N==Y>3$F9-QT8H5
M               "+=<OH4U@Z+=0/9.7&9ASG"XM,NOCF!B(@Y!?>B'EP;8Q
MLB>Y!X     L)N3/&<T"Z6J+[0L1J\;<SXFT&\N$:FRP;SLAS3+OXEF:]!!<
MFF92=V%XS^N'2!-?UD'+:Z]TFQKIVM?D.LMQOHM@7L]4OLTBMH\X/2P    #
M7!N;_%WT%Z%]+?8>"'5^YWT?P+V.AGW)43D)=*Z18^[:Q5[]KY- W$TH
M         (VUE^B#5;HVO/LO*#+.#EURZ6=W&,3%OSD5\:+>'"-C&@)]$&P
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MH(+DTS*3NPO&?UPZ0)K^L@Y;77NDV-=.UK\AUEN-]%L"]GJE]FD5M'G!Z6
M   :X-S?XN^@O0OI;[#P0ZOW.^C^!>QT,^Y*B<A+I72+'W;6*O?M?)H&XFE
M            !&VLOT0:K=&UY]EY099P<NN72SNXQB8M^<BOC1;PX1L8T!/H
M@V     3UN6/&7T Z9--_:Z)&LQIS0B?0+UX)L;%"'.J&]..OC6)K^$%2:QE
M3W9WC2ZV_C9Y_M6@Y=78^D^--,M?N6)U@N+=%4#Z#8_>MBL8\T/4     #6U
MN9_%ST%Z&],_8V&'5RYOT>P+V/AKW/4SD/=-Z2(_[:11[[KI-PW0T<
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M)'7+GK0_.27_  "1WKU<GR*\_K:K_41^]2CX^6'=]56.X?)(ZY<]:'YR2_X
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MV\>T;LT#NG:IEW3DR39--,SARN<ZSA;)<J+*G,HH8QS9SD#[P
M   //E96+@HU],S<DPAXB,;*O9*4E';=A',&:!,J+NGKUTHDV:MT28R=59=0
MB:9<9,8V,8WP!XT5>*=.0#ZTP]H@I*N1F)#,G-LI1HO&QN8E,RTH60=)JY28
MJ1R1<JODG1DE&J>-M<I"YQD)=76#Z=0U(T^U [OY#76K6_BL_!27)N<CIG#!
M7NARTRF[S'N%\-U,.F;ML8BNR8J[5PB;&%$5"E25,:2$TM.U
M                   'UGCQI'-'4A(.FS%@Q;+O'KUXNDV:,VC9(RSETZ<K
M&(BW;-T2'5775.1))(AE%#%(7.< <]7;S3;='/I>KVF L$9%KG;23Z(E6;]M
M'N$VB$@9%ZJV64*U4S'NFD@0J_!Y4CW;5\GMM7*"JB4L8/-J>J.F]\>/HZE7
MRI6Q_&$RI(LZ[/QDNY8$+E IC/$&+E=1M@N73;&>&*3..Z$=_P#^83?K)4QH
MHFEIW@H                   HM:_"FR??\QZQ<B^F),R;BPN-<Z[RXU/\
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MSR19YV@CAXU(_>2$BB@R9%22:,V4:L2/220X4I%'2[MTXHJS7)U2P'T2P*
M            *+6OPILGW_,>L7(OIB3,FXL+C7.N\N-3_!*K_AZ&]7-A97&N
M==Y>3$F9-QT8H5
M                                         HM:_"FR??\ ,>L7(OIB
M3,FXL+C7.N\N-3_!*K_AZ&]7-A97&N==Y>3$F9-QT8H5
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MC7.N\N-3_!*K_AZ&]7-A97&N==Y>3$F9-QT8H5
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M4ZD2W-9[<76+%PX\\L"_CX8#PGD!NGSPL;"03VSMI-_I"[MAYV3G&[G,?JO
MT:Z5%K37IWDHF9-.?LD_IM<VB6WF#7=4RV+2[E/,EDKI\7;+KQ319[TMPC#A
M]LM:VSE@EYF=[!TG4.P:!:W4Q>8LSR=N,/>(6BGN;&P5YS$\>:=QT,U8(N[3
MJ)JA<E8M.UFEGAYB?L!'23MZ_3@V.*RS@';Q-)HN95\R1/-LRLL"I;GLRS/Y
M8G,U97,-+1>DNHE*K+5]3XG41U".>2FHDW5HJN:G&84^'0I<NVLBD)0[S+U%
M\I(UN?(SE&DU.-X/,G!H37=M,77FZTZL/M2>.RTICE@5+<.>Q;=> \6JTS65
M=:L2EPD-0>-D)/32*E6R=YEFT<6LNM/%F%Z4D8V!G4*^]F4YEP7$I.-VR[IO
M8F_&]:>-C%1>&JJIU9>K*OX2*IU+D\Y-AQ-%TYU1A]/:VU99U:B6U-T-W/57
M4J?+&Q-'"LW'7JV-]T*A#IO9TKAS9N0;5",ID@G(I1[%!Y7E:6[99:0KR,K-
M)]6-<,LB2VX^NW&LZ(BX,>*CKZ\>+SUDSZ55VZHWJ,GYMA9DZZA5]48JO.+<
M_<2=E90<GJ)69&IQUA>R+^0F%W[B)8/7C'$LY<S#2%)'LIY1*:;O$"T54EJV
M(L_P]I5._P X?.XM /DJ                          !1:U^%-D^_YCUB
MY%],29DW%A<:YUWEQJ?X)5?\/0WJYL+*XUSKO+R8DS)N.C%"H
M                           ?S.,9QG&<8SC.-[.,_/C.,_MQG'\<9 'U
M63!C'(8;1[-HP;8.=3#=DW1:H8.H;:4/A) A$\'.;.3'-L[YC?.;.<@#[8
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@."X793X3@^$V.$X-/;WMK8+O[.+B8$1+"VN%56T__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g142578g56i55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g56i55.jpg
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M 0$! 0$! 0$! 0$! 0$! ?_  !$( $, 6 ,!$0 "$0$#$0'_Q  =  $  @,
M P$             !PH("0L#! 8%_\0 1!    8! P,! @02"P       @,$
M!08' 0 ($0D2$PH4(14B,9$6%Q@:-#E14U176'B2E[71T]8D06%C=).4E;/7
MXO_$ !X! 0 !! ,! 0             # @8("0$$!P4*_\0 3A$  0,"! $$
M!Q,)"0       0 " P01!082(4$'$S%1"!4B<8&1T0D4%A<R,U)3559A<I*4
ML;+3U/ 85'.3EJ'!TM4E0D-$8Z*CI.'_V@ , P$  A$#$0 _ +_&B)HB:(FB
M)HB:(O"ISPG/S]PDW/S %JB3UN3XCOJE21;RQC_49]8*FO\ 1ZY?@:'YE'\;
M6DOM=![*7Y3/Y%O!]#5'[?4^.+[)/H]<OP-#\RC^-IVN@]E+\IG\B>AJC]OJ
M?'%]DK2^V.V'VU(DN4/B!I0#8/@5N2X:BUA832C&W Q#4>V+%F<F8R7C&/'D
ML/&<\AS[N-M')=FROS5@\[ZZGI(#APH:6'SHV9H>QU*#JDYZ::[^X&[2T;GN
M5J.Y5LG8?E#&:>'#ZFMJ&X@:^HE-8^!Q8]E46@1\Q!  TAQN'!QOQ62^O3UY
M6FB)HB:(FB)HB:(O57?82S_"J/\ B'J*?UB;]%)]0J6#U^']+']<*BKYC?OI
MGZ8OWZU!V'4/$%^@G0SV+?DCR)YC?OIGZ8OWZ6'4/$$T,]BWY(\BV+5$O7%M
M"[!:U67C(T.<X I.#S_1L_+VCQSK&+.E?715L BK*J,$5&T=1,P;36&S7@;#
MH6,><Z>!U;#JAA=;SP!JC8;#GNC=JW%=/U2I4MUI>T*#S^Q;$>SS&F&]O<1(
MN[M[Q"[>>,<\<<\8Y^36P+S/6IJ:G#^54U%1/.65N3PPS2R2Z;P9DOIUN=IO
M87M:]A?H6$_9(111U.4>;CCCU08U?0QK;VDPRU](%[7-K]%RMBFMCBQE31$T
M1-$31$T1>DY9X;E^?N(E6?F(,SJ.47BD'7&\?[2IJ<7J(!US1#QO:N:=],O^
MZ<O]9_ZU@;Z$W^VTOZH^1;Z_0[6?GK/^59!0&T40(PB"<WKS3/*LY'DXH><X
M]K.X^,,7=[L>[^S5@8]DZI?B<[F55,QNF$:=$@_P67V LK]P/*%7-AL$GGV#
M=TWJFR$[32#<^!9\UWN;C[2WJB3(R\G9&)+G @*40<8[",ASS@0OZ_EUC9F3
MD=Q7%*J.6/&,/B#.>!#X:DDZY-0MI'!>1YFY)<2JZJ)[,6H66YZX=#4?WI+\
M!P6QK:/U$(/5R2=DN%>RMTR\J8Z85E&X-!6"<(2GD(\&><>,BR9E4'(>WY.S
M//RXUG)V#?)_792H^4F*IKZ6K-;594>PP,F8&""+,+2'<X!?5S@M;J-UB_RT
M]C3C^:ILO/I\RX12BBBQ-KQ-35K]?/OH2"W0-M/-&]^FXLK%.LY%K-31$T1-
M$7XTC>B(W'GV1*235"9A9G1Z4$$=GG.(:T1ZXTDGR""7Y3"R! +[Q!!WBQW"
MP'G.HY9!%%)*02(HWR$#I(8TN(%]KD#9=JAI7UU;1T4;FL?655/2L>^^ACZB
M5D+7.T@G2TO!=8$V!L+JOY]<8;;?Q$7A_GP+^9M>:>FEA/N=B/\ UOMEFO\
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MF#\8"BL%E *(DDDGI.ZEC1<)HBXS&[BZK<OK<)9T[NFR)G:4P!+)#'B)#.)
MY2)R11]D?W4AF8&XYQ//^#6-I*&8!M9T 4S<BP:=E,F+R<9D1=YH :+"VP/[
MET'?2V7C<M\=/"R'V[+4L"VWV'[L)Q (P^V/+7N9O;+"6BF*"=VF+(7>0+7!
MQ+8VQQ?WE4WM^5(DZ,3BH G 64+  EUI@ _86N 3W[GR*R5HHDT1-$31$T1-
)$31$T1-$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g142578g58g66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g58g66.jpg
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M=9&3M-(7(R4R<X&2H;&RL[75,T)RI<'64I;P)':"H[;A)C=#8H/C\43"_]H
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MA)DQ)@^.MM]G&[+[0VL9$YSZI:RU3<\ZOZ&F+@UKSV3'(R2,.))<UC7.ZYQ
MU/"VU!+>QU]S'WL3>FQUJ6-G)QV'1-CFKVF1ZGDQ;I3UK1BU(B=,Z,%P8'&_
M+,25PF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+6/^B4_4!Q5]
M\UL_F%>9O?T#/3^?^+4/W[:DME?7QAOD7:+^+A5J3YTBM[)A$PB81,(F$7T"
M4:(!AH2S!%E=C1I@0"V O9F]Z+T8/6NR#M[UO0.UO7:WK>M=?5O/-1J!J-3K
MH.R=.?3MZ=E->QV2OGGJ+]UK>]ZUK6][WO6M:UKKWO>_2UK6M>GO>]_8UA%^
MB"( A &$01A%L(@BUL(@B#OJ$$0=]6]"UO6];UO77K?I;PB" ,.@[$$0=##V
MP;$'>M#!VA![0=[U_2#V@B#VM=>NT$6NOKUO&O/[W ^]V>/YB#^=%_.$3")A
M$PB81,(F$3")A$PB81,(F$3"+=A^AV_N')O_ ,Q\V_9]56<J>C5Z[J_R)3^M
M7US[E?79ME\M4?\ TOL\L\^:B5%,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$6L?]$I^H#BK[YK9_,*[S>_H&>G\_\ %J'[]M26ROKXPWR+M%_%
MPJU)\Z16]DPB81,(F$6R/0%8V"ZU)T:+97=:\0W2K['C;T/D"7<\5XOJ)5,D
MXK]F;4ZF)P3U-]/21+M0XC3>T#K8"Y6%P)0I$8@K2=%@T;F<A2BR6W;[M[:6
M/(49HNDQQ5C:!M>L>DU61@)INZ40,Z)._(+Q8W<<]SNL.JP6]8@;:SSI[&3;
M8@>SH+H63(".+_L4+V@\B>@V-Y4[SA.6C0DGAQ5DHF"/1;CUTPL<B,:D$-B+
M'?''-LB,3EB!R:Y/&XHDO:VB8VRO[<\!"[(7=N9 H4K@F<==^E*2C *=B.T,
M6\JY:>QFO0RGLSPVK,V(S;[-BL]DE>>R[#XXSRPOB^]NB?-ON86=86D;O#12
MP>^2[LS)*]DLKZ5YTLD9:Z-\IJ53(]A9UI:YY<6EO6Z'AP5'(QQ INSJPM-_
MI^^)]+K!J"H)!<\@2OU K8=44D9(6G0+)O'(;9"FP'*0'2%A0JE2I#N25W'2
M)!MN/((*0;& [)2QM-DZ&0Q\.3Q%.M2R>3AQ<+H<PVUDX);1>VI/:HMILA$$
MSVM:_D+LYAWPXE_,KF3)VJ]BNRU3AB@LVF56%EP2VHWREPA?+7$+6!CR!O<G
M._DPX$EVA"J9Q^XH5'!95PWDUT\AE5=VY>3]7MM5C7:&K5LKBB&%#L;P7"E=
MF3Y+*D"Z+*+(<(^X%L(6&&2\EE2=YN4D,1)%1VT5AF=HLE<K[3P8O"MNXW$P
MW<=?NOR#:UE]L4N4M-H4W5GLL-HLF89N6M5C*[>9!O.: ^A<R-F:/*1U*(GJ
MU&35K$[K BE=-R&],*\+HR)! U[=\OEBWSJV/>(&O.NOC=!9M?O2"<@;PM-W
MJ2F8#S/M.MD2R*0(JR)O.+)F-CV(](8Q&8XKED(:24[+'&)RD<A=G:2) )T)
M:9*@2+E2L6TOQBL[;JX?8S#8G'QY+*7-EL??<VS<-&I4HU:-&)]B>=M>U*72
MSS1P0QQP.U>7.>YC6]=Y5ORPT\+2J5VV;4^+KSD23<A%#!%! PR22"*9Q+GO
M:QC6QG4ZEQ: -:K\D>,!-WV-P"IJN+):GN#M/1_)9HYW%J+R$I"BJV%V#?,Q
M?I>=!^YBDPGHAE3;1%PPD1JT^6'D1\MR$29X6U'X//G$TML<I>HR0VY=LC5C
MQG+PE[\A:HX>M#6%O7H?DG2NWS:.C!6!F,>\.25I0R!J09JU/ YLSLT8FU>4
MCWG698:D3(A-KR>[OG7E3H!$"_=X;JM*L/A5&T4"@EL55/[(>8!(;PCE!2U/
M<%*CJ*=1*5RI H=8[(4,>2SN<,\HA[XV-CZ<F5IY,VN+>X-@6ET0D&+$ZO>1
M4=JIWW+F.R-.A%<AQ,^8K.QF5&2J6:U=[8YH'S.IU):]J&22(.:8)&/8\RQO
M(:6J4@RLCIIJUB&NV:.H^[&:MOHF&2.,AKV%YAA?'*QSF @QN:6NWFDZ$*#<
MP^.-0\8)J_U-%K[6W#:<%G<EBD_;T-:*(K#V1&VJ5 &H3=*%<K=E#O)222B$
M\P9 ,I#<P/IZQH;)!(26DQS67FS.<R>?JPY&QAV8S'VZ=>Q3>^^VQ9E>]H,H
M?7;7C;' 22ZM*92^:%K9)(83*(V5<7>LY")EF2F*M>:%DD)=.))7EP&]O1B-
MH9&3J8G[Q<]@#G,9O!HKZTR!NX;\-..EM0&#US(KXY7/UPR!38UE5]$;.W6U
M;U++B*[:HI!HU/6B11%O=)2_$OKU()$<R*'?P>%$U%G ($#9$-)#)M1M1G,;
M=MWH</L[#C(6T:-VS0Z/O9*L;TEBW/3D@LOCKPF&*& 2B+?+I""X'6R<QV4R
MMZM--/'3QL=5@@@GEK]$6+41G=)+)"YDI;'&6-8P/#=[5Q';MP*E-9\F+*6R
MZ\7)DHH2>+-20YKXW4 E=G6T920O-),7-M<MDK@=?L,B<42GOJ1.1+Q%6,_P
M<4H01Y6[+%G=IPU[^!HMK8EDN7WK$CA)G<RZ.+'URP$,DO25[EV:!CV[L$9B
ML2C?+7SLC:S20,=BA (JC7W-9'$.O72UM>,@=:Z=T<T[V-(TC:62.ZXASPT-
M5?2>CL1O')JGZ.8;FVEA%\\?Y+R%@5E32O%T6=6:/,4+LV0B8K$@8)$ZGQYT
M12"L'>//JEJ?Y G2-QQ4C;"7;K SF0[MMG18')Y:;%[UO#YF#"W*%6ZRQ'+-
M-:H0\M2N<A&V:-\-^*>%LD,+G/!@D,7&46)SA90M6W5=9J=V.C-7BG$C7/?+
M S?@FY-H>TLG:]@=&PEP+';OXRIC8G$VNATHTW5QONIZN]L3W0Q4#,F%_JTZ
ML'I'.):PNC]#7N)D'S"5>'H7*@,;PWH5#OXM2%"L3)-.;$GVN,*;[^EM'=&5
MDQ6<Q46)D=BYLQ5FAR#;\3ZE::.&U%8(K5S#:KF6.1S8A/"]CG\G,[<!?<09
M*<6WU+]5E1QJ/NQ/98Z(:88WM9*R4B*/<ECWV$AO*,()W7G34_2^N+=(4LLF
ME5(N1[O-.3=<.K/&I-7*"FW%)73]-E+TTL4G@T"M J8N3DY/D*5KUVUJZ40"
M),;YX$<T[6X 7^#DCEYA]H<ME6U<B_!QU<!>CEG@O/R;'7H:C8I)J]RYCS68
MR.&VUC-QE>Y9EBY6-TC"S?<Q3R%RV(;!H-BH6&ODCG=::9XX0QSXIIJYB:UK
M)@!H(YY7,WVES=W>(K5*>C7;613:57M-ISIWY%4U7<IG\N8%5&N;31;VL@,=
M%*)[7\%NHR9J7%YE4=:TCL%"X.M=,<9D[HU*&UL="=&I%BF*K[=OE;C\A+CZ
M<6$R=VO3K3-R\<N7A;<FY"I=N8H56LBKSR.CWF1W9;%>.0/DC/7,;:QYXO%>
MPZO"VC:GCAB>+;77&"9_)PS35.2#61/>6@AL[Y(VN#BT\0*+SOBC4-6\=JHN
M*=<AEI$[O6IEEA5G4C!5Q[NKTZ-4QE$9<4,RDQDQ1HH_%E(&) 6P25,@<W)U
M>%KVD.C"!!&1.3O*4]HLGD,WD<93PC#3Q&2;2OY*;("-O)R5J\['U:XJN=-8
M:97F:!SV1QQ-B<+#WV-R*ZAR-FQ=LU8:0Y&G9$%BR^P&C==%'(#%&(B7R O.
M_&2UK6!CA(YTFZRP_,P4PF$3")A$PBW8?H=O[AR;_P#,?-OV?55G*GHU>NZO
M\B4_K5]<^Y7UV;9?+5'_ -+[/+//FHE13")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A%K'_1*?J XJ^^:V?S"N\WOZ!GI_/_ !:A^_;4ELKZ^,-\
MB[1?Q<*M2?.D5O9,(F$3")A%DS.O?A=9=*<5(9=1'*%NF''"#R2'+D-6LM7!
MC<M)>+.D\^),1RR23$M[8C1)GPAO,7:B2P:$\LTXA&LT64(W ^E&U-'*[16L
M4< ^MG+4%EC\A+D.7K&+'UZ9#JT%4PS .B<\,Z):'M(!<S4Z0/0F5@MY":H<
M>8KTL4H=8=8Y2(LKQ0'6*./<?Q87 <J-X: EO%<&V.=C-<S1T@"Z1PMSC\KY
M?3F@9+#VYF,1.4>B;13C\^''-TF>%2ML<UCDICRIH(+<V]E/T[O);DM5D-!1
MQ0=_6.V0EQ<FQC(+4<U?9FIF8++Y0]DUF7)PQ-#X(FMDC9&V82N,;Y1R41C8
MTR$$KVMB'5'89L<K7QXR&Y'*YVK7R.M,9UT;0'-#0]KCNN=UK2T NT*NCG/2
M34>^EWP[LKSRR)0W5QEFM'Q7C@>KA[7QOH%SD5;IXH@W#FENG"@J41Y&](0;
M0*2X3 G1E:G1V<U"63O)VTYD!4V%RT)Q$<L6SA?BL]5RUC.-;:DSF8C@NNL/
M%J5]1IKS.B?UX-JY'*^..-IKQ .$=#@;;.@VN;C2ZID(K<EX"5UZZUDYD/*N
M=#K'(6'KARTS7N:UH,;>*H"P<J>*$K;N)\_O")7LHN;B=#H;7"*-UYN#DUM:
MT6K.7NDHKA:^2E[>291"7%I*=C&N3(VN+R/4D1H$I;<[1HY4-:WS$VSVT==^
MT=/$V<0,7M%9M7G3W>BS>QUB_6CKWF15XHC7M,D,8DKNDL0<@Y[B^.<-#7WK
M\=D8SDH:<E,5LE++.9)^5,]:2Q$V.<,B8PQS->6[T9=)'R9<2YLFFA^3GRXX
M\6X7S K>ZV>XF*I[UY8OG+*J9373/#'N?PB5+7.=(O LLB<AEK#'W5 ^PB9!
M;EPFR8@$Q/C>!4GV^)3-;)]9LWF\:=F;V*EQ<N1Q&SD6SF1KWI;45.W7;'3<
M9:]F"M--&^*W5WV<I5^^Q/W7<DX<0QMZL<9/4?5?8IXUF-LQSNE9!+&&PG?B
MECC>]KFRQ:MWHB'L.AW"IGKI"JCB-V<=Y55T"MAEJ>L.)$CXBS=G72QG06BJ
MB\E?+0[[F4+F[)H*)%,$K=,8_+V]8)K9$Z*7MZ]D1D)6@E"^&6O47DK.*S5?
M(7,=+DK^TD&TE25E:1^/;8KQ8_<JVJDNKGUG/K35GMY25SZSV3/<Z0OA%+I)
M9EJ7H[$U9]FQDH\G"YL;S6$D;*^D4T+^+HBZ.2)S=Y^L;FO.KB6"@5J7]6BU
M;6ZB+7WS4NQ/&;1C,W=VKD&H8F^-MK.P'F*-$L4?0VK907:7Z[J),1(%+A&T
M9*0Q>F W""X=V33./P]]C;PL8?97%.GQ]BI%)A1,^=\DP#=9IGXZAR=8Z;SH
M6LG<7!CB_5FAO:].P!.)*>*J%]>2)CJ6^Y[GO&FKY#6@W(N&I8&R$G0[W6Z&
MWSE':;%>')"]KCC"%V;(Y:-L3N>,3>_%(R'M$TRB1N#P@3.Q+>M<D)+B2F5E
M@6%(W!:F ?H8251Y>@FBF=G\?-B<%B,78?')/C\=4J3/A+C$Z2"%D;W1E[(W
MEA<T[I<QCB-"6M/ 7N/KOJ4:=60M<^O6AA>YFI871QM82TN#3NDC4:@'3G 5
MQ-><@^/,]XY0KC7RO8K;1(J8E<RDM(VO2*:(/LFC[38RE&YS>OY5#)N\QEI>
MXVX2%$"2MSHADK>[-KF<<2 HU&-04KA;N%S5/.6\[L[+C7ORE:M!EL=EG68:
M\TM%KHZEVO9J16)(IV0N->2-\#XWQ@'4.#2VQGI78;TU_&OK.=;CBCMUK9E9
M&]\ +89HY8FR.9((R8W-,;FN:!S'0B?TIR<XL4BXWK$ZS!R=J>-VA6T&B,7Y
M"1L^!OW(N+/\9ERB2RU8B:$3_7K-&HM9C<>CC+VP1BPBW%O;8^VC/?G_ ,(.
M)0;'*X#:++1XFQ?. R,]"_;LV,+.+D.#L0SUFP5F/D=#=EGL4'M?/%-8I&-\
MD[](80QFM&W0R-MM.6?I?9DKSS2R4G\LRC(R2(1Q@O=',]\E=P,C'O@W7%[N
ML9HTJH;ST@]2*N2?'>WBF^]Y-'*8XD6;QW?G2Q7&.2BT)A*)5'[^86:7K77<
M@)1+$:P5HQQQ>0K%Q2YE+(>&E"&0@:FYR?+.+8O)-P.;QA?B*\^4VDHYN&.B
MR>#'U:]>;#32UF1\@7M<P8^=D6ZPLE)BD?R/*/9%;LPED4;M;6G&^UDZ]YC8
M&R1UXHXGTWOB#=PD.'(2-;H-U^K7'D]YS66=5OR1:JZXP2NI&]N>=V,MY,TO
M>\8>MI6\Z*I$56QF>MIZ-T,&YDNGA(]WDK0>C3)VP]&>B(7[4."0XM.4IR:]
M@I+VT%;)/?%T"S Y3$6(MYXLN?D)ZCPZ,",Q\F(X90YSI YKRS=8X$ELK/0=
M/D([3G-Y 8^U3D9J>4)L20N!;UI;N[K'@DN!!W=&D$D55Y'7?Q"L^9V#R0KI
MEY"Q[D/9$N;K)!"GTJO U#7MC+I0URF;O*26HW5SE\]9'!66^ C[&KB4)/0G
MNQ*MP=%)38% MC\'B=I:%6E@[LN%GPE&M)1Z*A-WIG=HLKR5ZD3JSHXZM.5C
M3"9I6V;8>(RUD;2_?;;T:F3KQ049W49*4$3J_*L,_14T#8S'"TQ%C8H7@;F^
M\2S AI :"[>%4^0W-:K+U.LNRDEU\[H--;,8WE6NH)IE#0KHEGG#ZSF$.*-#
M,C[/+>#:M4O)QRHR)BJ<EP\#'J&$IQ(!W%>7'X397(X@4*#L5LA;J4)8FLS,
ME>5N7EJ0R@L<^J*!B&0;$ T6>F)9RH;,6..K#;4<59I\A7-7#RPUWM#;KHWB
MXZ%C]6ET0K[HLA@ Y462W? ?NGF5GG(*\8Q;5=\4H@P-C\@<*(HL^KY4H>"&
M\I&Z/AEF3Z9A6Q\:)Q7'J&G37*6]/LUQ(;%FEY*PK2+:<LA4HR;"XFQC;NT5
MF:2%[,OEQD*XB+R^.$4*=7<F#XV!LG*5WG1CI&[A:=_>):V4I5)*T^1E>YCF
MW+@L1AI<2UG0\,6C]6@!V]&XZ-+ANZ'74D"US,@4@F$3")A$PBW8?H=O[AR;
M_P#,?-OV?55G*GHU>NZO\B4_K5]<^Y7UV;9?+5'_ -+[/+//FHE13")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%K'_1*?J XJ^^:V?S"O,WOZ!G
MI_/_ !:A^_;4ELKZ^,-\B[1?Q<*M2?.D5O9,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81;L/T.W]PY-_\ F/F_[/JJSE3T:O7=7^1*
M?UJ^N?<KZ[-LOEJC_P"E]GEGGS42HIA$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PBQ5=+IPBDO-7C<E:ZY"2?:U7OATPA;6I4$I2I*E4HMHY#%BE
M2D1:9(O<R26]:VGJ3"DYBUJ);SCDI2\:Q-L#T.-JX=E<Z9KN\,?>A%:T]H+C
M"0[>AG+0"YS8W%P>&@NW7EP!+=UU..U:Q62QF<I0FU-C)91/3:YK'W<?;BY&
M[6B<\M8VP (K57E'LC?8K1Q2/9'(Y[=%N:4K;==/ZZ+3JMYI$Y"VGFIUK0_1
MQU:UY!I0]@'H:9:E).UKKUUAWL&NL.PBUZ6]9UM4S&*O0LL5,A4GA> YLD<\
M;FD$:CB'$+:T'HC;%31-DEV@H4'D#?JY60XRY"[3BR6K=$,K7-.K20US"02Q
M[FZ.,3\4)5['7GXN5>3RYZ,J>V8/I6>-5ON@[#>ZW9_PI4\JGBA*O8Z\_%RK
MR>.C*GMF#Z5GC3[H.PWNMV?\*5/*IXH2KV.O/Q<J\GCHRI[9@^E9XT^Z#L-[
MK=G_  I4\JGBA*O8Z\_%RKR>.C*GMF#Z5GC3[H.PWNMV?\*5/*IXH2KV.O/Q
M<J\GCHRI[9@^E9XT^Z#L-[K=G_"E3RJ>*$J]CKS\7*O)XZ,J>V8/I6>-/N@[
M#>ZW9_PI4\JGBA*O8Z\_%RKR>.C*GMF#Z5GC3[H.PWNMV?\ "E3RJ>*$J]CK
MS\7*O)XZ,J>V8/I6>-/N@[#>ZW9_PI4\JGBA*O8Z\_%RKR>.C*GMF#Z5GC3[
MH.PWNMV?\*5/*IXH2KV.O/Q<J\GCHRI[9@^E9XT^Z#L-[K=G_"E3RJ>*$J]C
MKS\7*O)XZ,J>V8/I6>-/N@[#>ZW9_P *5/*K\\4)3OKZH\\>EZ6__3U/I;ZM
M;ZM_Y/TO2WK?^[>MXZ,J>V8/I6>-/N@[#>ZW9_PI4\JOWQ0E7L=>?BY5Y/'1
ME3VS!]*SQI]T'8;W6[/^%*GE4\4)5['7GXN5>3QT94]LP?2L\:?=!V&]UNS_
M (4J>53Q0E7L=>?BY5Y/'1E3VS!]*SQI]T'8;W6[/^%*GE4\4)5['7GXN5>3
MQT94]LP?2L\:?=!V&]UNS_A2IY5/%"5>QUY^+E7D\=&5/;,'TK/&GW0=AO=;
ML_X4J>53Q0E7L=>?BY5Y/'1E3VS!]*SQI]T'8;W6[/\ A2IY5/%"5>QUY^+E
M7D\=&5/;,'TK/&GW0=AO=;L_X4J>53Q0E7L=>?BY5Y/'1E3VS!]*SQI]T'8;
MW6[/^%*GE4\4)5['7GXN5>3QT94]LP?2L\:?=!V&]UNS_A2IY5/%"5>QUY^+
ME7D\=&5/;,'TK/&GW0=AO=;L_P"%*GE4\4)5['7GXN5>3QT94]LP?2L\:?=!
MV&]UNS_A2IY55)J[CE>=T2EOAM8U;-)A(')24F*1L["O4A([H((=J5ZG16DS
M<A(T+NBI>N.3HDA.A'JE!) !F!L,AG\-BJ[[-[(U8(F-+B7S,U=I_=8T'>>X
MG@UK07..@:"2 K:WZ(^R$$+GU,O7S-C=/(T,*X9&W.\#K6 5]Z* $\#/;E@K
MQCKI)6-&JW[NC@XDJ>%_%:&5 ]*TJZ:JUSC-K"4(#-'-X9A(BD)*E A.UK6E
M!#,TMC.R"5AWLI>H;CUY&BR%)11?'>VVT8VHV@M9.-KF5@UE:FUXT?T-#O;K
MG#L&1[Y)=WG:'AIU().J(76IY;V0OM8R]EKTV1M11.WXZ[I6QQ0562:#E&U*
M<%:J9=!RSH72AK0_=%]V8FKA,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*!Q+U26C[]&O]G$#R2O>E,/\
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M(LJ@YFZNW=.8:GKN).OO<1IK[W;5>>,<(I&X.;' ^GS94T<J^/''/H8898]
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M#MB[HRLVN3TKP@Y,-N5;>^!T_.\2:H9IPX/+M>MT-O-M?DYI*DAQM%IJ6'6
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M^WY%.6B]EC_3;XT[8/P@_"U_CCI%F^XV5\'V_(IRT7LL?Z;?&G;!^$'X6O\
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MXP<?>/ 7#Z2U20VOE+L4%.Z.C*V]M]<4H!A-+1K9 O,6/:I"6< )Q:$YP&D
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MEI]O8WOQGV4Z8M]IY'O.1/'P'L0GGR94>6QTM/M[&]^,^RG3%OM/(]YR)X^
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M:>1[SD7>1Z2(9(4X&)$[BC-:G';4XHG5":WK4JWO! YA+,(-Z^L)B!S0J2S
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M-]S@QIY&/K2=>NTW>.FFGO$@]A0VS%&?.9BM1DM6&Q.WI)B)GZ\G&TO>!UW
MD @>_H.RM>EXN.TGM<>X*Y[*2#3S!#[@V/*]I0D]H6]]A.@;3TJ0D >OLZT
MK0MAUKM"%OT\PLRR$Z[[OS$@?,- NA(,'B*\;8V8ZHX  ;TL$<TCM.RZ25KW
MN/PGX %U?TS+(]L&;_*M^_C\\Y23V1_Z3O&JW2K%]S:'>=?R:?3,LCVP9O\
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MZO(3[[HW^F46?<?]I'_C;^\%99+U.O\ Q*U_ D7HL]/?_8^OW^^H?S$6:#V
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M+PQ\I(^5^Y',UK=Z21SI'NT'%SW%SCJ2225]Y ESZSCIJZG7<= &C5S23H
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M^#BL@V@!&(Q((T+<AB@?>.A''\_#X5YN6;Z4:F$3")A$PB815]XP &.[H=H
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M^A;ZB9#Y5=]4K+!\SZOGY'J_7;RU&LV6K=,(IO6?VR*^]^\4_3R#/IGX[?\
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M7@\I&U\LLS6B1NK'$,WPUQW'-=HX>D@44626624 )910 %%%@UH("RRPZ"
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FI-A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g142578g61v53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g61v53.jpg
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M-U.1E-+3&2(Q0;$)&",R5Y*T,V&6T21")6)Q_\0 '0$!  $% 0$!
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M?4^;,!T0P^'"*VKBH@EB8(.1]3YLP'1##X<(K:N*B"6)@A#*SXPVLMA;-\<
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MZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU
M12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_
M!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!>
MX]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<
M<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[
M#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&
M+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU
M 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12
M_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!>
M X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]
M<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V
M[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z
M&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+ZU 12_!> X]<<V[#Z&+Z
MU 12_!>!SV$@H]RIA2,DH_@\%SC+\C4F%=]DVW"?8SMSG.2[-IM_@F-AB[,Y
M^G8*QC_A4WG9 ""%N[J[/Y0S7M)R+Z5)H3<6%K72N\F93^Y*K^3T-[.;"RM:
MZ5WEY*DT)N,C%"H   8=)Z=Z?S5EC;G,46G2UPABMR1%KDZQ"/[+%%:*J.&I
M8V==,591B5LNLJLWPU=)8155443P4YS&RBMH@=<7232DD3.P)-,M/205H?IR
MMFA2TNMEB;%)I+E=)2,['8C<,Y=^DZ*5RF\D$7#@BY2K%4PIC!A6*UQ6(AQ.
M\Y%T[L+,;R3K7%QJZ6H&C^(HOL'-3(4Q"5C+3L7L?->*0YR%A>#XMP0QBX;;
MW.<"D5MO]=H.XC8R-A8]G$P\>QB8J.;I-(^,C6B#"/8M42X(BV9LVJ:39LW2
M)C!$D44R)IEQ@I2XQC8 .<
M                                      ((6[NKL_E#->TG(OI4FA-Q
M86M=*[R9E/[DJOY/0WLYL+*UKI7>7DJ30FXR,4*@
M
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M\-9-C
M  @A;NZNS^4,U[2<B^E2:$W%A:UTKO)F4_N2J_D]#>SFPLK6NE=Y>2I-";C(
MQ0J                  &M=9_J>U7\VMZ]UY09:8.?9EUM-W?')BY\YEGC5
M<X=T?%-$3Z(-@    $BMR+WT&@GG4IOMEL-4IUT.I+J:7>X:-FH9TLHYKB0=
MX8+=P@T32                         .%)2+*'CI"7DG!&D=%LG4C(.E,
M'RFV9,4%'+IP?"93GR1%!)10V"$,?."YP4IL[,9N.73Q^]=.'+*MO7SQATZ8
M2"*V\>-(PPRBJJ)%II41(JB9\ZEMZ]=N'3Q\]:1ATY=MO7C:Q@P[=LJVVTL$
M58,LHJK!%7-F0BK_ '[]R/\ ZWUC\%8NI1NGU;4X_#LL_J27_P"@U#ZPZ&>?
MY)_)*?[ _OW[D?\ UOK'X*Q=2A]6U./P[+/ZDE_^@?6'0SS_ "3^24_V!_?O
MW(_^M]8_!6+J4/JVIQ^'99_4DO\ ] ^L.AGG^2?R2G^P/[]^Y'_UOK'X*Q=2
MA]6U./P[+/ZDE_\ H'UAT,\_R3^24_V#NJWNS-S#;[!"U:MZOUV6L%BE&4-"
MQB#2=(O(2DBX3:LF:)EXE)$JCAPJFD3*JJ:>#&QOCEQMR/SRN@%,)#)91+97
M,4J<262N7DHE#YIN3*RZ<NF5;>/&D9?M-*C+**JP15S9D52_):<T3ELI<222
MSW)GTIE3YVX<.F6)0C3Q\]:1AVPRK3E&45III$2*HF?.J(2=&GFV
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M[W;O<&SC&W9MSC RTP<^S+K:;N^.3%SY'Z%GC.G-<X=B_P (^O*=XGT0<
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M)?H ,]J8+Q&VU_9U[TTE^@ SVI@O$;;7]G7O327Z #/:F"\1MM?V=>]-)?H
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MW]/O>>-&L4UZ(4GU%.G<WIL=#^E='-=S9WQT6^1!8FJ
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MB%;G%8?Q+'JX;B:5!;5V<!Q"MSBL/XECU< @MJ[. XA6YQ6'\2QZN 06U=G
M<0K<XK#^)8]7 (+:NS@.(5N<5A_$L>K@$%M79P'$*W.*P_B6/5P""VKLX#B%
M;G%8?Q+'JX!!;5V<!Q"MSBL/XECU< @MJ[. XA6YQ6'\2QZN 06U=G P'5:#
M6)I=J2?,_/GP6@W$V\.Y99(?>UZ1SO3XQ'ESDIMFPV,&QG9G.S.,_2,G,G/,
MT:SD'>G1C9Y3_I$ZYUYMEUG\*]N*<PGZ0:     -];EE/*VZ4T&2PJJCE35N
M@DPLCDI5DLFLT=CA$C'*<F%";=\3)B&Q@V,9R7./H&L4UZ(4GU%.G<WIL=#^
ME='-=S9WMT6W>(5N<5A_$L>KA!8FI!;5V<!Q"MSBL/XECU< @MJ[. XA6YQ6
M'\2QZN 06U=G <0K<XK#^)8]7 (+:NS@.(5N<5A_$L>K@$%M79P'$*W.*P_B
M6/5P""VKLX#B%;G%8?Q+'JX!!;5V<!Q"MSBL/XECU< @MJ[. XA6YQ6'\2QZ
MN 06U=G <0K<XK#^)8]7 (+:NS@.(5N<5A_$L>K@$%M79P.P81YV65<GDI%_
MPF"XQA^JW4PEO=]]*7 MF^<9-OMAM]DVW>EV8QLSM"%ZKA^B(=B!4@A;NZNS
M^4,U[2<B^E2:$W%A:UTKO)F4_N2J_D]#>SFPLK6NE=Y>2I-";C(Q0J19W0&K
M5IT]<+Q-2D(]_*S]34CV$&V@)5W9*I8IUS)PE/O)9?L.3IJL8[L1VL8C4[IF
MMYL"T4]+5IB=F4#5*4^D1.WY3MS5X5=MI15@OZ=O#&%T:C*=SE+VJ=HK^3M=
MO8VY9>S/B1>4)DD[*UV/;1L.U=5FT/LZ;:2/4;*PL",XYD(B7H<-,0*;]K!R
M.%EX_*@HL.SYVKV7A*JXV?,$W&_10J             &M=9_J>U7\VMZ]UY0
M9:8.?9EUM-W?')BY\YEGC5<X=T?%-$3Z(-@    $BMR+WT&@GG4IOMEL-4IU
MT.I+J:7>X:-FH9TLHYKB0=X8+=P@T32*IF[%[Z'6_P O97^B(Y;Y7^LVFNO)
M3^5@ZQY&>JR@VH))O;(U#S<]-     +<&YO[W?07S+Z6^X\$.K^3OJ_H+Z'4
M9^"2$Y"92NL6GWIK2KX[+S= W$TH             -?ZL_57J7YO[E[N20R<
MR\\S3K.0=Z=&-GGF>==6R[NKTICB?I!D     W_N4N^:T!\[^GWO/&C6*:]$
M*3ZBG3N;TV.A_2NCFNYL[XZ+?(@L35                    ((6[NKL_E#
M->TG(OI4FA-Q86M=*[R9E/[DJOY/0WLYL+*UKI7>7DJ30FXR,4*D7-;;CH+4
MKE79'4^MRTI,P4;'61Y9(NKV*<B*576-AV5V>O[F#34:(P;:UE<N:]QPVDR1
MLFTEIQHU8HL).30^D15J_P U1A^MQ189H_X[$\/#-N/3NT,+I&2=FCZ3:J8C
M(S!RE-<ZRG4IVT)-8V-0;652$76S86C-9N5.*:)VZ/@[$F2),FM#-H\D<NYH
MNF/S\U%46/CF-@"@             #6NL_U/:K^;6]>Z\H,M,'/LRZVF[OCD
MQ<^<RSQJN<.Z/BFB)]$&P    "16Y%[Z#03SJ4WVRV&J4ZZ'4EU-+O<-&S4,
MZ64<UQ(.\,%NX0:)I%4S=B]]#K?Y>RO]$1RWRO\ 6;377DI_*P=8\C/590;4
M$DWMD:AYN>F@    %N#<W][OH+YE]+?<>"'5_)WU?T%]#J,_!)"<A,I76+3[
MTUI5\=EYN@;B:4             &O]6?JKU+\W]R]W)(9.9>>9IUG(.].C&S
MSS/.NK9=W5Z4QQ/T@R     ;_P!REWS6@/G?T^]YXT:Q37HA2?44Z=S>FQT/
MZ5T<UW-G?'1;Y$%B:H                   !!"W=U=G\H9KVDY%]*DT)N+
M"UKI7>3,I_<E5_)Z&]G-A96M=*[R\E2:$W&1BA4AGJ_3M)K_ *Y$J&J#J6K2
M,OH^Q49OX[6'4K3 VH*+*X3?959*RIUUJL)8F]%*ZQ+2B$DTE9)#-YB56YV3
M--QAU])%$S6V(L*KNW]"F:/SGX^NTV%N=)""78:IP]6EYNRUBIZL2-=A+7-:
MD7G5+E$BG2J+*R"K"SWVSVZ0PC SDM*T^1CHJ7S"-[!6YI=%FQD74FU2HO9H
MJA"&$-(3YK_7YW)(H4*@            !K76?ZGM5_-K>O=>4&6F#GV9=;3=
MWQR8N?.99XU7.'='Q31$^B#8    !(K<B]]!H)YU*;[9;#5*==#J2ZFEWN&C
M9J&=+*.:XD'>&"W<(-$TBJ9NQ>^AUO\ +V5_HB.6^5_K-IKKR4_E8.L>1GJL
MH-J"2;VR-0\W/30    "W!N;^]WT%\R^EON/!#J_D[ZOZ"^AU&?@DA.0F4KK
M%I]Z:TJ^.R\W0-Q-*             #7^K/U5ZE^;^Y>[DD,G,O/,TZSD'>G
M1C9YYGG75LN[J]*8XGZ09     -_[E+OFM ?._I][SQHUBFO1"D^HIT[F]-C
MH?TKHYKN;.^.BWR(+$U0                   ""%N[J[/Y0S7M)R+Z5)H3
M<6%K72N\F93^Y*K^3T-[.;"RM:Z5WEY*DT)N,C%"IC-JI5.O4<6'N]2K-QB"
M+D=$B[5 Q=ACBN4RF*1P5C+M7C8JY"G.4BN$L*%*8V,&Q@V=J,*@=K$Q$3 Q
MK.&@HN.A8B.1*VCXJ)9-HZ-8MR;<D09L6:2+5JB7.<Y*D@D0A=N=A<;0!V(
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M2NL6GWIK2KX[+S=&W'AQ]^!N)I0VX\./OP &W'AQ]^  VX\./OP &W'AQ]^
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M!HFD53-V+WT.M_E[*_T1'+?*_P!9M-=>2G\K!UCR,]5E!M023>V1J'FYZ:
M   6X-S?WN^@OF7TM]QX(=7\G?5_07T.HS\$D)R$RE=8M/O36E7QV7FZ!N)I
M0             :_U9^JO4OS?W+W<DADYEYYFG6<@[TZ,;//,\ZZMEW=7I3'
M$_2#(    !O_ '*7?-: ^=_3[WGC1K%->B%)]13IW-Z;'0_I71S7<V=\=%OD
M06)JE57=H=]-K;Y:.?\ ALAR[RR=9]--<-^X<'5[(GU4T'U*[]^_(PCS,]2
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MR569.EF+Q)-TT460.HT>MG#-R0JF3(.D%FZN"*I'(4#L
M         <=X\:1[1T_?NF[%BQ;KO'KUXNDV:,VC9(RSETZ<K&(BW;MT2'57
M75.1))(AE%#%*7.< 8I5M1]/+RJ\0I-\IEQ7CTTEGZ-6M$'856*2YCD05>)Q
M+YV=LFL=-0B1UL$*H8ARDSG)<XP@J5I &9@     #KXN6BIQD22A9./EXY19
MVW3?Q;UM(,E%V#M>/?(D=-%%4#K,G[5RR=IE/D[=VW7;+%(LDH0H'8
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M#&2SV8.)S-ESP.TLOE@WXRQGL;)F^W#WAL9['-E';_TLY)O<CY/H[P
M      !!"W=U=G\H9KVDY%]*DT)N+"UKI7>3,I_<E5_)Z&]G-A96M=*[R\E2
M:$W&1BA4
M                                  ""%N[J[/Y0S7M)R+Z5)H3<6%K7
M2N\F93^Y*K^3T-[.;"RM:Z5WEY*DT)N,C%"H
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MQE%/S56*D$1<T54I!?RUYZE2*QT?X3M^AP^3Z
M    @A;NZNS^4,U[2<B^E2:$W%A:UTKO)F4_N2J_D]#>SFPLK6NE=Y>2I-";
MC(Q0J                                        ?DA")E*1,I2$+C!
M2D(7!2EQC^&"E+C&,8Q_+&,; !^@
M            00MW=79_*&:]I.1?2I-";BPM:Z5WFUXC6KBB*C(GDUV1Q9'L
MX_LCCG@N'[#;IM^&X+BI7@^$X/?\'PBF\V[W?FV;[/QY$<\:\]5OK/ORX9H5
M9J[/4=AV^_%3U[\F#D[]GB.4NV^ [??BIZ]^3!R=^SQ'*7;? =OOQ4]>_)@Y
M._9XCE+MO@.WWXJ>O?DP<G?L\1REVWP';[\5/7OR8.3OV>(Y2[;X#M]^*GKW
MY,')W[/$<I=M\!V^_%3U[\F#D[]GB.4NV^ [??BIZ]^3!R=^SQ'*7;? =OOQ
M4]>_)@Y._9XCE+MO@.WWXJ>O?DP<G?L\1REVWP';[\5/7OR8.3OV>(Y2[;X#
MM]^*GKWY,')W[/$<I=M\!V^_%3U[\F#D[]GB.4NV^ [??BIZ]^3!R=^SQ'*7
M;? =OOQ4]>_)@Y._9XCE+MO@.WWXJ>O?DP<G?L\1REVWP';[\5/7OR8.3OV>
M(Y2[;X#M]^*GKWY,')W[/$<I=M\!V^_%3U[\F#D[]GB.4NV^ [??BIZ]^3!R
M=^SQ'*7;? =OOQ4]>_)@Y._9XCE+MO@.WWXJ>O?DP<G?L\1REVWP';[\5/7O
MR8.3OV>(Y2[;X#M]^*GKWY,')W[/$<I=M\!V^_%3U[\F#D[]GB.4NV^ [??B
MIZ]^3!R=^SQ'*7;? =OOQ4]>_)@Y._9XCE+MO@.WWXJ>O?DP<G?L\1REVWP'
M;[\5/7OR8.3OV>(Y2[;X#M]^*GKWY,')W[/$<I=M\!V^_%3U[\F#D[]GB.4N
MV^ [??BIZ]^3!R=^SQ'*7;? =OOQ4]>_)@Y._9XCE+MO@.WWXJ>O?DP<G?L\
M1REVWP';[\5/7OR8.3OV>(Y2[;X#M]^*GKWY,')W[/$<I=M\!V^_%3U[\F#D
M[]GB.4NV^ [??BIZ]^3!R=^SQ'*7;? =OOQ4]>_)@Y._9XCE+MO@.WWXJ>O?
MDP<G?L\1REVWP';[\5/7OR8.3OV>(Y2[;X#M]^*GKWY,')W[/$<I=M\!V^_%
M3U[\F#D[]GB.4NV^ [??BIZ]^3!R=^SQ'*7;? =OOQ4]>_)@Y._9XCE+MO@.
MWWXJ>O?DP<G?L\1REVWP';[\5/7OR8.3OV>(Y2[;X#M]^*GKWY,')W[/$<I=
MM\!V^_%3U[\F#D[]GB.4NV^ [??BIZ]^3!R=^SQ'*7;? =OOQ4]>_)@Y._9X
MCE+MO@.WWXJ>O?DP<G?L\1REVWP';[\5/7OR8.3OV>(Y2[;X&CY5SQM*24KO
M.Q^,Y!Y(<!ON%X#LQPHYX'A=ZGPG!\)O.$X-/?[W?;PNW>X>7#-"K-79ZAY$
)<\:\]5OK/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g142578g74a36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g74a36.jpg
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MTM0A.79XMC-SLK6W&"(F,2,D.&%W>;DR-#4V0D5&4KC_Q  = 0$  04! 0$
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MIJIK02='8ZDD;YH))(+CKWA+ZSN#(]KS&PX,L9?"YP\B1W):B:S4CT.72XK
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MSPP[)(!X8;D-P-V>6228=ES72G8(PT-8W_#8&,W!C>)M  RWB;]KCDEN.>,
M<T>1^U-AX2+8G(71+[DJ4#ZSY:ZTU<6W)/\ DP3U_HY@N*Y P#2^T=,ZHXIQ
M6SN%[ABK HYDD#/2W9T#C4D5D*APU'-G'W\9&.LXDSW9=+&92&3,;Q'3%L?*
M1D;XF0M\F1N=S2Y[6G.2'N+0I<3&$-BEX(+X7N#&0M?)SB=(R229QW,<1M<&
MM<X8P'1C)68;^83J1-^F&VMEOGD1'BO%-NYD?'V-PC=$X@L'UY)HKP'TKN!
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MS8&W;L$XI;PXKSV/D#FR.#29)#CR(3G!=C=Z-WTMO+=A2@X2RT6/9&6.C:7
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MU"8LJ&BO'X<\TDZU^D7SE@*]V,.0;XX 7N@>TV?H[Y^(Z5K"=GDX!(C=EY!
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MW1FZ9+-XOBX)V5XYHH&WS9BW.GD>][7:77)XZ-N_H-?2:$U.M3BCKRMI0C4
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M*"I.8$O*XO)QF4$%Z_TR5U^0AHQH>< Y!&I=(LH\)4D@^S1XUM@2F;XW(;R
M<WZDK;(D\1=5T"+6H[VD6"S4FTKE.8:E-J?2"'5(K\TE5EBK<HU?"YQ4EXD;
MLQ:?'7J^"S/W0XBC<QKLFD/I:I7#]-==J6XCI\.FZ'-ILM*)EAU>S5NVC5A-
MJ,,>S$MZ2Q9\)B;MF_Q9&OS':5HR4G','6S77>MH]%]91N0R"%VC4' "#P@\
M"V= PV)'&6HL\I2NW(#395H\CZYC.+(HNL<!8,=9HSZC7Z*;<.G= ]7?JNKV
M[NL6ZM74/"]2M3UIZUG1M3L&(T72"DUT4U>"2.RV 77.CS-9E+Y-\[6!4EO]
M-M+9IFEUJFE5)[-'P73ZT-F&Q!JVFP<476QFVYLD5B9DE9TYIAK\0UXMD99$
M_)R9E9*(T(-<B(BUQ7TG#35LX]!XI'G]WCHK+6=V2+T"'8/< ^..&.;<"FM8
M2@[RS=(,L'*F:N6]Z'Z?#3GZ33,GO/+>D.H5\6M1NVHN&R&C)Q'1V;$L9GR2
M'67-,[F88Z0L  TW2N]-;AZ.Q/AI,#M!HSYK:?3K2%[Y;;-@DK01R"$ #96#
MN UWEMC#R7'4C+&^-[XY6OCEC>^.6.5KVOC>U^Y>U[7_ &VO:_[+VO\ MM>O
MN <\QS!Y@CTKXQ?RB+Y+_P!@M_=*?X+UK]6\U:G^K[OY:13M,\Y:?^G5/S$:
MARO Z]Q)1$HB41*(M&S$8,NI[OS8<+:9/-@ZLVQ%)( 8HW[U63A%M%ZP;S&"
M9Y?^SDG*P>&:3"V=KX-Y(QCY"_<\"JTCRG$=8+<?ALR/VK*#R:TG#7-(/IP=
M[L']AZ_9D+#6<C$R_1?QK!.+N@LCYEQHV*<989)9JL"?(R.O&N2B6?\ OHJ]
M2MC95'.ULT5+9)YVMEC>U4'4?\_^X5Q!#\'K$+A__4Y;&[>R1<;4XVLQ66&4
MM;["DA7/%*^/A3> (ZYES.7KN;6[N28E<F\BC3.ZEK(JEE!*>-[N<4>]N/6W
M[_A@Y_V5C.39.PM _P#JW#&/;U_LRM3C<ME3A"9[Z::SEA 0(WTQV (V(W*0
M7  EJK6:>>KC2> Q67(S:S-_$,9\4M="+KXKNCN+O%-9C?PNU/;CTYSRZAR[
M<]62.7IZBL@ Y,+FC+"TMP_.]WE#T;<YV^GT8[%TW253633614P515PP5253
MRMFFHFIC;/!3#/&]\<L,\;VRQRQO>V6-[7M>]KU<HZ_=$2B)1$HB41317Z$+
MP>E$6WFJ]F2YCI/<F2"P')6$"->819P[AD,?NQ6)2;-QY"^#M\ <NG6;IDJH
MW44?*N5.KR_W<L;VM>WPNM:11DZ0Z '-LANHV-4-UC-0U"-D_!TY\L661VF,
M8&2-#P(VL&1S&,A?::/JMV/0==VNKDT(--\$<^E1D?#Q=0CBDP^2NY[B^-SF
MN+W..#]R_42UI%G,@XO$\IF>2V3O:8QLTHBTCP'(+#VZ^[Y1 E3>6#S!5D56
M=K1])\*!_!>(Y!=F23)648.6+2J7]7NQU>F4(T^J[2.C>GVJX<^U9%B^X=':
M6I-K@QD20MC;:='/8XQE<U\)AVRLD>E+2JCK/1*7PZP-4Z0WJLY:RM7,%%KN
MD%S33/A^Z.9SW5FR15S"(FN9*)<QNC8K3J308K94>Q=.LI<*(E5Y6T%R1ZI#
MH_"$7\?%*D&@\=A(#+8[L0@]53Q1,CHBBW(QI!=%UX$9[O45GUSI-/I%K8P4
M)H864GS5(Q?M:BZ.U,V)\DIJUWUM*BC:[=7EO.?%;<US.)7^DL.B]'8=5K!S
M_#899C<9#:D-&M0$E:$RLBA%F=MC4Y7D;9XJ89+5:YK]D_4H]V>S9M8-QU7;
M-&S=<CJ \[(+(())*OG:>_-VL,'3Q1/''-TXP8LF;+!9>^:F+1HV;VRLB@EA
MAM='D>_4NE;7O>YL6NU8XFN<7"-AZ,='92R,$D,89)))"UN 7R/?C<YQ.MU:
M-C-/Z,.8QC72Z)9?*YK0UTCQTCU^,/D( +W"...,.=DAC&,SM: ,R)Z=B8W5
MP/8#52<2EJH+C1:22*(VBIB+!'A8JW:&8=(6:!#.10(L';+*-V)Z2MEV9\TF
MU;,0N PHS+5KX=>O3:S9TMXTVD\36X*E2]X;!=LQPPO?7OU9'1"IJ4$[VA\E
M:H\25JY>^2P9H7P*;+HE.+2:^HL-^VTQ59K5FEX'/4KOFF:R:E98V4VM.FA:
M7-CL6F.CLV QD< BF9.I G6K==R+>FR \9C4Z0C\7','KL6 ^(\?"#WBV0]!
M9T3EIE09%8%%TFSI%3!Z69OLGYC+)A;)KX8FY1U>FZSJM7HWI-BY;TUUJY+)
M&R:SXQM6)8VB5S60T:XENZG<<]C@8X'QB*N!(0_AN:[9:AI.F6>D&J0U:NH-
MJU(HY'Q5_%]:")Y,;7/FN3F*GIU0->TMDF8_B3DQY9O:X8Y,]#Z^UP*V*6E4
MQD3^\7G8V%Q89'60-PM(;R&%83$4_?E<2+T.R9BVJR:9=X+<FD7ZW@Z(7!5J
M]R*L)>G])=4U:?2H*5"I$+FFS:A<FM266MJ^"ZBZA-%%"8HK$DDSV$P1S,KN
MB;N=8(?&(98U[H]INEQ:G-<NV9?!-0AHU(JS*[G6?"J(O0R23"22"-D3"!,^
M%\[9';6P!S)#-'F<KU-JF6;;E06.(G1MPFOM=EAD#'DX+&S$Q,%HS#<G2,6<
MEL&(;PMH-)+R N-3:DCI\GB]N,:=6LY=LM?2US6Z6ATK%MU:86=4U6"74Y8=
M2MP4((+E\,-UD!DGV22Q-JP3%\-:K"8Q,_+6,DG7-'T>YK-N"JVQ%P-,TR>'
M3XY=/JSW9YZE$N;4=,(X#(R.5UF>)K)+%F7B<%@!<]FG<P!VC,JD,>LVD#3$
M,7?#L&TK"VCDE03;.,TTTS@*SPA823QPQQ\+8XOG6*"O?88KJ6M;*_WM"SX9
M2JVM]60V((I2^E8\*J.+V DUK/#B,\))/#D,;"YN"6@\E\3=K^"7+-;99CX$
MTD89<@\%MM#7$ 6*^^3@S8QOC$CPUV0'$<UC=2U%7:/HSODMV!_'^/\ 3HBN
M ?*[YYTS]6'\U.NZ_)3YIU+]8C\M"NDM<F74THBP<)K:#QR<3K9(2/-1\WV6
MUB3*=2!)9YFZD36",R8^)(ND5G*C-'$*S,DT&]V39MDKB[4NZR7SQ3RPM#&A
MSG@8<_;N/;MR&^[)5Q>XM:PG+6;MH[-V"[WX"C!]Q0X\D=49:/=:P#7U;C+B
MD]&Q5N].,\(U-"\N)3QS*(679E6YZ"FF\O,%#H=_#B@->/NWSC$#D-;Y]35G
M!B+.'L&S=N Y\G%Q=N:<Y:=Q)!:1CT85XFE#^)O._:&DG!RT-#0UP((<-H (
M<#G'/*M#7AGQH::T/ZDMJYD[ATIE3&>2-8M(9@;FQJ>BLQV8>?$=I&9"^V>Y
MG@.P<2D FN<PO* 386.:B"K)LR;))4$$086;,M+MQR7%Q<,8<7DE^X8&';L@
M  $ !5X\Q>'[_*:W8,!H:&>E@8 &;3DY;MVG)R#DJ[1GBAQ_B$:&1,+KQO\
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M7K**96QZ7I\5^?5(JD4>H6HVQV+3 6R3-8V)C>)@[7N:R&*,/+2\1QL9NVM
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MS@K-M1<F=I;#AW ]E+)HP*$]_P#"/?>UMLLL!$88O))+HC'=&8BSN#0>-:K
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M5LA_&?CEKT 8BL$T)IJ&QB0'X[*CL=C&LH6#!F)+#R@\W$#Q,2."MV#TM$C
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>B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g142578g80t12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g80t12.jpg
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M>+C2(S(V.7%VDK.TM24T-4%3=86'X212<X.$Y2<S0O_$ !T! 0 " @,! 0
M           $!0,& 0('" G_Q !F$0 " @$" P(%#0D*"0D' @<" P$$!0 1
M!A(3%"$5,564TP<6%R)!4U22DY71TM0C-%%68761M=4R-3929'%T@9:T)#-"
MH:.QLK/P0U=S=H.%ML'A""4W16*$P_&"AN-$8V5RQ?_:  P# 0 "$0,1 #\
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M(*^KIIV8^_\ CS^WCP?0^!5?D%?5TT[,??\ QY_;QX/H? JOR"OJZ:=F/O\
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M05]733LQ]_\ 'G]O'@^A\"J_(*^KIIV8^_\ CS^WCP?0^!5?D%?5TT[,??\
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MI0H^0=VC \#54\@6[S :W*WL4N:]8+"(.GV,>TFV;*BE!E;CN6LSY(DQ@IV
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M@*=A'D+O9[?VP\N\U_JAM-?KU?#IHNM2Q>JTG8NN*Y=#(VV2K*'I&T'KQ*M
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M_P#=-\T/-?OE9_['^[JUA/\ =3_5_JC6QQ?^K1__ ,#7^[3S<:'WC4_HR?\
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M-H)>')3EN2I/A"YJ>ZUX5>? LK;81V-M(QCVCA/,7\_P_C\MDVP^];[5UVP
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MF_G',?K:[J6>5FK'3C33C33C33C33C33C33C33C35?>J#ZCI#_7K3/ZY]?\
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M3FJ>)[+AA=>H)% TK&!FZB^KK&AN0*;R$\=,"XDMIM_^O?W;>/\ _7Q?EU)
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MR\U1ZD[7M;#G@.X)Q2,J1)J>L460$M+[[.(AA6R=<UW,E:&7&T24^2; 5C^
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M;GH[9<C:>EME5@F29(BH!^E68J8D3QYRMV4-;/ 5.,8B>2:W)$GO)=>I[_\
MG_G[IUJUPZ2 ]['*BV7<FZ9I,U3KGKC8EB;(:YC%]H:WO))H@7HUF98UJ@'7
MQ$)I$@57B.LPU!M  <3,.#; R6*2RKC3?_\ 3OVB?P^/_7K<A73900Q0,5A3
MK,EX%<]S7B#'5-%8B8*[R637;8CC385M7DL=Y5D(K<=IQI^"AMA)"45[B\N-
M<;_1^C_]-0C3NBEBOVN;%F[&N6=/AX/3-!K&NX<VI.LVQ?36'"8J9'94Z3KM
M%C:F1[-6:^7>C4:VU\/8V1R8)\8L1)G!I;7:9_)W]_?_ #S/Y?RZYE,Z$:90
M!$D/6=N[?BL*I0C7(W,F#HTA'&4H0=GV#(>4'FZ4>K]QDG990BFVV/8@FXVR
MU+F.$S9Z6?:B%XS7&_B_3[OC_3^3W-M9<#T0ZZ 2=/)9NNPIP'1S#.:)6)T7
M5:8 TDBOG*[*(P3@_5\"[UF&3AGY2Y]+HUKJFN%-L1 T2F0ZOXZ FM-_'^7^
M?Z?]>LI6.C77]1=J4(-<]E-TNLOZ>,D]<OD*>]4[S=-$56IU#6M]MTCUE)MW
MKC#CM?:ZE2HM8M-9JI0I0:Q,F5MQ+)-DHTWW_P _X?=__6=8PMT.:L)T2DT%
MJRW^!!U[K/3.K:V32_2"\Q(715O#W6EDC JS44[4+ 6?,!(>#K)FLS:_-8[S
MD("-(,PI\1IO_KW]W\OY?RZ\&>AW6^03=:*WC:%A"3Z=U)4>[1#$^CI<V&&Z
MH[_/V?L!RQ2Q%"$RPQ 1="+Q2ER]?/4K 5MN-!F-%8;"&>--^_?^;_-&VIXU
M'JAC4P<J*1<;-=WRY1!.05LXK70.0SX(;!&-0H@K5U#UU5F(^$0LRWG_ %OK
M)RYTR4Y+(/1TPHT-KC^K;_C\NH'IO157*)7YU?!;EW,ME6K]7:6 22C>FBN*
MGJS4,VQR:G3!PB;IUVMGX#\.TE0UBFWT)<#)P8J/F0200BL3T-<[[^Y'NS[O
M?,_U_P"K;7AK[H9UEJTS5BU&MM\!L@4519H.S"U4X-ND^FF")D-/)+=U@LK3
M4)R0;#.@M0$]:U5%6$@JI! 0J\)C#L-)G?Q_\?\ 'Y=]9K<?327W)M5P_-V+
M9J9KHOHRRZ?N(6DR:W'.W&!:K-"GEPA)^RT6T."04T"S,@^7:>:J]S'29:UB
M2D-SP<Z.US$[1M[N^^ME(=,%14/ALU>W7J@G VV[+N:L6VK.4U\S5[/;Z^<J
M5@&C!]JIEFJ4VKS:Q9#(=(:PUDWF*B1&)Q93)P4(*06N-_R1XMO=]S^O50P?
M0OL+7?4."V1K0G2VZK7B^I80<_;R-3L=QBZ_J5> @]BCB JQ=.-IN3UWO.)&
MS)$>R4+J&U9781"^*.*IJ)^;NSL5KG>-O%^'Q?E_KV_S3/Y?%M-UFZ"M8V*J
MZ^IS5[VD $:^T")Z:X[HE[6TPJ<UJ'AC8;#<\M9]:V*: -D$BHRK$2U\Y2FK
M2EN-#L<,F-% X0MIS?DCQ[^[X_TZE2-TOZ^BJBJ;)V[.8DKJ7F-=\B)SVN]5
M5ZF[!V*E?=!)[6Q1N<]'I^,=U0T8EM@PH_)PJ8MKC?\ \O\ -&VL]K72(W7%
MJ)V5@[.-)3K35FH*G"G16&5URAZLB''(;4F4RYE!:Q6*P6@V5L!J-#"0Y,&/
M5Q#05I5>62*-<?D_X]SZ-3AQIJD_J@6JH&X>G G4B):6&CJOVK'/'(3#,A[&
M2=^!59>/!OJ2CL:8L3TM/O\ \IV,TWGL0M6<;=P1DCQ>?79!0M+L61CE,I&/
MN=)UB.^-Y[Y1 S^0IGQQK5N,<>&2PC*YL)4=LQ\\PQ!3]TN*K^*=H[H?)?SC
M$>*=74:1AIIMK&>W#;:$8SG^?.$)PG&<_P"GLYJ4SO,S^&9G],ZVB(VB(_!$
M1^C7LYQKG3C33C33C33C33C33C33C33C33C342WCZKW2+_6&*?V;NH7EWB?O
M3B+\R#^N\+JGRGWU@?SP7ZGRVNPKE)JXTXTUU?\ JN/]%*!^&+7'^_*\].]2
M+^&M/^BV_P#8'7F_JK_P-N_TBK_O)UT*U79TBMAAX2;4ZE;HH&P2[56%6B.:
M?S7SA".*CD'F6!1L3",#YWD((_*"62(9$.2!;64PT1YQJ,4^JKN'&W8;87>O
M43LU0I7(IE7'M591/)0D3J[V5VK[38$+%0Z[X%T_=)-=<T_+U/+E50NNRC2O
M!7LG;J3<%Y36L-%(M*!382MZF=GKD5>V#TR28V"!8\7;"*WO9 \@&4A@:MZX
MQ+]"Q.LCK!I1&QBM:D1!.J 3,9!QL.V-C.UZN,37 HT02G1J\)2N>A])"00B
MNX:J/"REEJYV1XY/IU(*O"JC\NIZ;ME!S7EY-.+5LEQ8<]*SM.F%2/2%4I/$
M=I)5W!6I]J26-ZEN1?+;2<2U#:59X18A J":M46374AK JIW9S0PF:T.V<3A
M 5UJ0&!DA+E$(4%3<K!9E_R=-OL?9#)'P\$K$5Y4@6:'$5&5W<0'1['B<R!)
MRZX^J6W#I9:BX%BPE\9)63B0Z!#U5XP\22N5B3CHMIL9!QOU8:746T-H&(B\
MNT*W9"17:F<<W&['UA+I,R0946\RW!]V7;6$C.W3E0\AK+>2G*XW5:<$ A+R
M> \.!L 6R1$>*D?!.S@56#5&(U)3Y4[ZXC@T'$?D(:<9>7-<D.-/LL*;C-8?
M6]2Z=A75M<MFI8IG/.KFA=F[8O,()Z.T'#;)B$S!#"X&"$BB3G-&>MPRNWI5
M^:M:1;".5FTLKTT4@$_NN\A*JX$41(E)R4P0C,"//%[WL@2(&R( U>#8 R:*
MAJVI9.O&I#>N"L,K5&WXD@\[7$IB.#X4:9F."940C16_&%9?6^^]B=PU4L'8
MZ]FXRM8G)25&2KC7"<LAB+LB85AM[G#6&OFLE"C.>2(&!$<B>(K5<$="M479
M1X.@;L#8EY1BG ZG! 5B:OM96L&<M<98(1S3S21%I%ZO$J]3X<Z2,B"L0H:H
MC<>*5MAG"\.2I$M;CDRX6.S$\=U4CP###4YJ*U&99_P"Y:I<R58XW'!C5,6+
MF/ZC(.3-%*OML A$0NA4II[X'F(I7)D9%[: @%A7Y'('D6+8201TPD($'7'[
M[F1S,LO6K;O\KE$89 "(C[63DS/FR=EG96RC^TEQ!*3]B/6JPS(:6)GD=J;;
MU%%$FHK&9V9J(K&2TCQ)#I!YUO"&?#O2>ZYX3&&(K!B*V&AC^S5:U*JMDDOK
MDNCT>E)ETX7)ET!ZDBH1G<N41[MLA9:P>6L9B5I[39LW+3%P)]"&7>MU8 99
M+( >L73B6%,;#S$7?O[HVQD+@BAA^DT^U00P& !'(+(LD.5&9'&+ 99E-D@%
MC#$4/27K)/BD8R9.!<V(W!6N DC AD6.IXF88YU;(WZ3+%EMELHFH8&345:Y
M!*;52PJ1 :BS4<AUEG+(ALJ8Q1<AE(Z:56<?2N+17775#NU 8PI]E\'#:UE#
M8DRM,!H0?2,(7,KAJP:.IVBQDK?9#MI,98R4L):>8G^+-> C)E$)+DEU$9GO
M+RU';4YE#+:EN*0TE*5.+5C*\SJ=15&I6I(YNC50JNKG+F.04$ ,F6T;E,1N
M4Q$1,S.T1'=J%<M-O6K%Q_++K3F/9RQRCSM.3*!'>=AB9V&-YF(B-YF>_6!Y
M)U'TXTTXTTXTTXTTXTTXTTXTU17<GU2+'_Z1_P A%\U3(_?C_P"</]V&MPQ7
MW@C_ +7_ 'S-6XJ)46BIUA"R4!"T5X*E253(Z5)4D;&PI*DY<QE*DYQG&<9Q
MC.,X[,\NTW:0)4)6ZHD*EB0E85!"4!$2)1)Q,3$QM,3WQ/=.J"Q2NF]Y#4M$
M).:0D-=LB4293$Q,!,3$QWQ,=TQK8?+ G[:#OSV-\[S+V^C\-J><I^OK#V"]
M\"M^;.^IIY8$_;0=^>QOG>.WT?AM3SE/U].P7O@5OS9WU-/+ G[:#OSV-\[Q
MV^C\-J><I^OIV"]\"M^;.^IIY8$_;0=^>QOG>.WT?AM3SE/U].P7O@5OS9WU
M-/+ G[:#OSV-\[QV^C\-J><I^OIV"]\"M^;.^IIY8$_;0=^>QOG>.WT?AM3S
ME/U].P7O@5OS9WU-/+ G[:#OSV-\[QV^C\-J><I^OIV"]\"M^;.^IIY8$_;0
M=^>QOG>.WT?AM3SE/U].P7O@5OS9WU-;C2MFLT@@1E1':P:'G LRNV*OGGU/
MACX.:]$ENCI_DTD+*L):(#QQ.),%%!I*$1'PY<2:RXSC.8&0C&9%2@/)+KMK
M6%VZMJM;JC8K65B:X:KK0Y);J:U)K<EJF*:P#64%J=0\)X]C3#'->JP@ZMJM
M9J6219KL(&2IG2E+AV:I30-+E-6U0&#!D=9LONE1*P4DW#;IM?A:[2/;I]7"
MNR_6^)9@GY5G6VK)8X6/$7"!V=-G$9I4[.(R/&/%D3&8<:#'BQT5<2JKD:[,
MI%IF5ZLW[EBW3[4\FU@IQ,=!:*RH566M:5IK+4')SRLF&PCD/LY5MG'V%XLJ
MJ\7THHU*]2WV9$+LG;F)ZQNL-)MAAL:QUAC3YN2#%8+ /6"W(D,5N$Z6S3;(
M,OR7TVNL'7YOD(GA9IBPQEMN!3H8^-D#2\9F3 F"CD&:VWAZ$](?@3)T63S9
MKXJPF@L,K%1V,Y9I7*UNEVE.U<JIQ,6%V*S1:@R!JW5F+F>5@@+5K,.*S\I7
M=>8>*FVG)047:EBK<[.W>P-H)&:[$65&IP"2V)L R(YED1+8P#SOMA9+A>?*
ME0=?S*P1J8ZC/:[?R033&ZH'FQRH@9%S&L<>UQI XU&0;9/-6E-D>)O3GIAF
M4T3),RXW@S#PA0!ES7<5>;DARHW*,Y";MA9(>X^=)4C%M<YKE6*E-04BL00$
MI402?".8E[#/$BRHVDK'%BRIW8H120P7(2'(T;@$IX0\;(V^U2XF$;SAK8/1
M;AL:-<B<>?)=K(>(.&00@4$">Q&# PPY*\11P]$T@0(.H\*[(F2IA,B1*$2$
MN80(SY<R4\^NRH3C:"24&278-KF6+%FS;K'8LV&S$FULKZ2AG:!6"TJ4E2@6
MI2@6 C%;>')7FBP\<U *2NO7KUZE@$5T*B>12X9U6E&\D9L<UKFL,V-89F13
MJGE@3]M!WY[&^=Y-[?1^&U/.4_7U#[!>^!6_-G?4U./0]U_BNGRU;*J6ZK?<
MB.K(;A9C6]< AXQR"&*3KF7.&I+"6G(;S;<YPA)D9=<E2$+=?7A"4)[.SPKU
M0^##S]GMN%K4^W.N-9<M&[IS81"Q4C8_;@<"(! \L1[6(G>=>Y< \7#@ZHT\
MN^WV)5-05*P)@^@Z62QVXSR&,S)%,\TS[:9C:-?2R*)1C L:7A^$\4*P(9*+
MX5'@W?%IT=N4QX1':KN.>"=3WT=N>ZKMQVY[.WGSDU9*8Q1[<RS-9;3O',!2
M,[3[L;Q.TZ^@%F+5@P=^5@"8[QM/*8P4;Q[D[3XM=94CU7OI!C/O1W7]F^$C
MO.,N=VC=J>^TM2%]F?*^.W'>3GLSV>_CW^>@CZE_%)1!0%#8HB8_PR/%,;Q_
MR>M%GU1^&XF8DKV\3,3_ ()^#N]\U=O0>^Z#U(:_:V5K=1E=:>+D@B,G1ODF
M?XZ)4RF7C,3QB3V-=KZ/!N>%_E^__)QV<U'-86[@;LX_(0J+$*6Z82SJAR-W
MY?;;#W^UG>-N[6TXC+T\W3B]1ZLHEAJB6ATSYE[<WM>8N[O[IW[]5^WIZHCT
M[=/&Q2>KMB.W=%H$PA4^6D)5O*@_Q<S!9(P_!S/*,?OK\7?1X5/@L>#7VI[5
M=G;R[P_ N=SE!>1H#4*LTV ,ML],^91RL]QD)V]M'=.\[QM_-JGRW&F%PUUE
M"Z5J+"A69=*OU V:$&.Q<\;^U*-^[NGNUL_3EUQZ-ZI;.=J6K';<LO70/KC(
MXL-=\C1L#O*$09VL/^/2O"O^,S6/\%W$_P"#[Z^]_)[,Q\]P?F.'*Z;.2&L*
MGNZ"^B_JE+.0F=\0([#RA/?OX]HVUGPG%>)S[VUL?-B6)3USZR>F/)SBONGF
M+>>8X[OP;S[FMSZD.JC5?2N$K=@VHNQ('VHK*#BLUT-Y9?S,AQ,37O&&O&HO
M@6O 9_DN=Y?>7_)[N/Y^1,#PYDN(W6$8V$2RLL6LZ[>E'(9<D<L\I;SOXX[M
M2LWQ!C^'U(=D)= 6&$M?15U9YA'FGFCF':-O%/?JN5"]5-Z6-CWBGZ^K;VP\
MV&\68'4P>)]-\4A9+6 E&%#\2Y7E1SQ>-F5*:\,]X-?@F^\ON*[.S-]=]3GB
M2A3M7K 4H13KNLND+4$720LFGRCTXYBY1G:-XWG:-XU25./^'[MJM305SK6G
MJKJYJW*/4<P5AS%U)Y1YBC>=IVCOU>?9-_K^JJ%;=CVK,U-;I8.=8361T7QV
M=@>.:R](S$B>$:\8?[F,]QKPB.]GWN]CFGT*+\E=K4*W)-BVX$)@RY EASL/
M,6T\L;^[MW:VR]<3CZ=B[8YNA543F\@\Q\@1N7*.\;SMXHWC777[L#T??^/L
M[S%__N.;S[%W%7\2AYY'H]:7[)/#7\:]YI__ #-70Z9KU!V=IP'L05*(S UU
MLNS;,!>+8<01Q7C&T;G-K[$IEUU]45<0,[!B)A8=6W";91$:SX)E&,:IQ!3/
M'Y5U%H@#:B,?7="]I#KJQ]4'R,Q$<W,V#*3VB3F9*>^9ULV"MA?QBKJR,E6K
M%]Z99O!]!F0M$F"B9GEY52 P.^P1$#'=$:JG<O55^E.BV^U4@Z_L;!NG60Y5
M3.(=,\9B8*UXG*$$<19'E5OP\?$N&]X![N(\*UW5]Q/>[,;)5]3?B6Y5K6TA
M2Z-I";*N:W ETWK%H<P\D\I<I1O&\[3W:H+/J@\/5+-BJXKG5K/;7;RUN8>H
MEA+/E+J1N/,,[3M&\=^K/].74[K#JEJYVW:M78%B*\>S7".;"'\C2<$L#X9/
ML88\:E>%8\5G,?X7OI_PG?1W?Y/;G7<]P]D>'+":V2A,->GKKA+>J/3YR7WS
MRCM/,$]WX._5[A,]0SZ'6,?+I6EW1/K+Z1<_()]T<Q;QRE'?OX^[4==1?7=H
MCI=N8FB;1<N"#QJL1+;"Q7JWY8AY$3"I@,SEV3X_%\')\<!SN^QX-7=:\"YW
M\^$[$S\%P;FN(JC;F-&L256"K'UG](NJ"U-G8>0MQY'!M._CWC;NU#S7%N(P
M-I=2_-F'-KC9'HHZ@],V-5&Y<X[%S)/>-O%M._?K%:$]4'Z>^I#8#.M-;NW5
M=FD"29IO!VL>2H'B0E#2Y>52_*$GL=[KR/!M^"_EY[<=['9S)FN",Y@:)9#(
M#5&N+%JF56(8?.V9@8@>2.[NG>=^[6/$<98;-W(HT9M2\EL;'51TPY5Q$EN7
M.7?WQM&W?J<.H+J$U[TST-G8VS%FT5QX^/K:,@!?E>=Y2)QI\J+C,7QB-V,>
M"&R?".^$SW%>#QW<]_MQ483!WN(+DT,?"IL0D[$PYG2#IK(!+VVQ>VW8.T;=
M\;_@U:YC,TL%4B[>EL(EP(CHKZA<[!,A]KS#W; 6\[]W=JF@OU7'I&+DAPF(
M_LOQLG.B#XOA:1W&_&)LAN,SX1?E?/<1X1U/?7V9[J>W/9GL[.;4SU,>*%+-
MIA0@%@1E,7(G80&2+NZ??W1.M97ZHO#C#!8E=YF&(#O5VCF*8&-YZG=&\Z[)
M+"<@U@ <LI/+V!M>#DSA#,=OPTC$$3"?GR\L,]Y/A7O%X[G@F^\GOK[J>]CM
M[>:$A)V'IKKVZCVK2'-.P\[3@!WG:=HYBC>=IVCW-;NYHH2UY[\B5L:?+&Y<
MJQDRVCNWG:)VC?OG76;[L#T??^/L[S%__N.>@>Q=Q5_$H>>1Z/6B^R3PU_&O
M>:?_ ,S5_P#3VV*GO'6]8VI1E$E56W1YTD0HO"\G$<MCBT\-(\9A>%?\ KQT
M;)PC'A5]]KP;G;CO]F-*RF-LX>_8QMR%Q9JD MA1]0-V*!H\I[1O[1@[]WCW
MCW-;AC<C7RM%&0J<\U[,'*^H/(>P,-1<P[SM[8"V[_%M.NHWU2[KKI4&GW?I
M_P!>G+B$W%5;Y37"<IL&TR&PR!G0;/G$8NZ^^E[+,MH/,8QXFG*Y,9*<Y[J5
M85Z=P!P;<.U3S=Y-5N*LTK73B73+9EX'7[U1 R.XRT"]M^Y*?PZ\YXYXLJC6
MM8>FVRK)5[E:63"HA6R3&QW,F9WV*%''M>^1_!KNWC*4N.PM>>U2F6E*SG^?
M*E(3G.<_Z<YYY&7<11'B@I_UZ]2'?E'?Q\L;_P ^VO=SKKMIQIIQIIQIIQII
MQIIQIIQIIQIIQIJ);Q]5[I%_K#%/[-W4+R[Q/WIQ%^9!_7>%U3Y3[ZP/YX+]
M3Y;785RDU<:<::ZN?5>)#$7I-B2)+S,:.UN#7"G7WW$,LMI\.5QWG'7%)0A/
M;G&.U2L8]_GIOJ1S \:4Y*8B(JVYF9G:(]H/CF>Z-><>JJ,EP=<$8DBFQ5B(
MB)F9^Z3XHCOG7S8>NBL_"(%^EQ_TCGU]UT>_*^4#Z=?)G9['O#ODC^KIZZ*S
M\(@7Z7'_ $CCKH]^5\H'TZ=GL>\.^2/ZNGKHK/PB!?I<?](XZZ/?E?*!].G9
M['O#ODC^KIZZ*S\(@7Z7'_2..NCWY7R@?3IV>Q[P[Y(_JZ>NBL_"(%^EQ_TC
MCKH]^5\H'TZ=GL>\.^2/ZNGKHK/PB!?I<?\ 2..NCWY7R@?3IV>Q[P[Y(_JZ
M>NBL_"(%^EQ_TCCKH]^5\H'TZ=GL>\.^2/ZNGKHK/PB!?I<?](XZZ/?E?*!]
M.G9['O#ODC^KIZZ*S\(@7Z7'_2..NCWY7R@?3IV>Q[P[Y(_JZ>NBL_"(%^EQ
M_P!(XZZ/?E?*!].G9['O#ODC^KIZZ*S\(@7Z7'_2..NCWY7R@?3IV>Q[P[Y(
M_JZ>NBL_"(%^EQ_TCCKH]^5\H'TZ=GL>\.^2/ZNGKHK/PB!?I<?](XZZ/?E?
M*!].G9['O#ODC^KIZZ*S\(@7Z7'_ $CCKH]^5\H'TZ=GL>\.^2/ZNGKHK/PB
M!?I<?](XZZ/?E?*!].G9['O#ODC^KIZZ*S\(@7Z7'_2..NCWY7R@?3IV>Q[P
M[Y(_JZ>NBL_"(%^EQ_TCCKH]^5\H'TZ=GL>\.^2/ZNJ5[;E1INP;!)AR6)<9
MWR5X.1&>;?8<[@0:VON.M*6VON.(4A7=5GNK2I.>Q6,XQK%\H*VXAF"B9#:8
MF)B?N8>*8[M;9C!(*2!,2$HZFXE$C,;N9,;Q.TQO$[_S:^S;I*_HK=-/X M/
M_J^KW/C?B?\ A)G_ ,]93^^OU]:\._P?P?YHQW]S3JP?*/5SIQIIQIIQIIQI
MIQIIQIIQIIQIIQIIQIIQIIQIIQIJO73&E.=8%<Y2G.<[MZGNW.<8[?Z2VV^7
MW$4S&27M,Q_[HX>_\/XS5+@HCL#.Z/WUSWN?_P"=R.K"\H=76O'N(_\ M3_L
MX_9SG>?PS^F=<;1^"/T1K]QC&/>QC&,?>][G&^_CUSMMXM,I3GW\IQG/W\8S
MSG>?PS^G7&T?@C]&F$IQ_-C&/]&,8XWF?',ZYVB/%&VF<8S_ #XQG_3CMYQO
MMXM-M_'K\[J?_M3^+'.=Y_#/Z=<;1^"/T:\NSM][/OXYQKG7CW$?_:G_ &<?
MLYSO/X9_3.N-H_!'Z(U%&EO\C2OX5=[_ *\-B<LLO]]K_-V'_5%'5?B_O9OY
MQR_ZVNZE?NI_^U/XL<K=Y_#/Z=6&T?@C]&OW&,8_FQC'^C'9SC>9\<[ZYVB/
M%&VF4IS_ #XQG_3C&><[S'BF=<;1/CB-,)3CW\)QC/WL8QQO/X9_3IM$>*(T
MSC&?Y\8S_IQV\XWV\6N=?G<3_P#:G\6/V<YWG\,_IG7&T?@C]$:\N<:YUX]Q
M'_VI_P!G'[.<[S^&?TSKC:/P1^B->6,8Q[V,=F/K8][G&N=5[ZH4I]AXCGNI
M[?7UIGW^S'QSZ_Y>\.S/A5<;SMV/*_JF[JES\1X,/NC[[QGZSIZL)RBU=:<:
M:<::<::<::<::<::<::<::<::<::B6\?5>Z1?ZPQ3^S=U"\N\3]Z<1?F0?UW
MA=4^4^^L#^>"_4^6UV%<I-7&G&FJO=4$2+/9T%#G1H\R)(ZEM7(?BRV6Y$=Y
M'@;%GN.L/)6TXGMQC/=6G..W&,]GO<O,&1!.6("(2C"WI@AF1*)W3WQ,;3']
M6J;,C!1C!*((9S%*)B8B8G_&^.)[IU._K%I'P.JOF\(^A\J^UVOA-CY9GUM6
M?9Z_O"?D@^KIZQ:1\#JKYO"/H?':[7PFQ\LSZVG9Z_O"?D@^KIZQ:1\#JKYO
M"/H?':[7PFQ\LSZVG9Z_O"?D@^KIZQ:1\#JKYO"/H?':[7PFQ\LSZVG9Z_O"
M?D@^KIZQ:1\#JKYO"/H?':[7PFQ\LSZVG9Z_O"?D@^KIZQ:1\#JKYO"/H?':
M[7PFQ\LSZVG9Z_O"?D@^KIZQ:1\#JKYO"/H?':[7PFQ\LSZVG9Z_O"?D@^KI
MZQ:1\#JKYO"/H?':[7PFQ\LSZVG9Z_O"?D@^KIZQ:1\#JKYO"/H?':[7PFQ\
MLSZVG9Z_O"?D@^KIZQ:1\#JKYO"/H?':[7PFQ\LSZVG9Z_O"?D@^KIZQ:1\#
MJKYO"/H?':[7PFQ\LSZVG9Z_O"?D@^KIZQ:1\#JKYO"/H?':[7PFQ\LSZVG9
MZ_O"?D@^KIZQ:1\#JKYO"/H?':[7PFQ\LSZVG9Z_O"?D@^KIZQ:1\#JKYO"/
MH?':[7PFQ\LSZVG9Z_O"?D@^KIZQ:1\#JKYO"/H?':[7PFQ\LSZVG9Z_O"?D
M@^KIZQ:1\#JKYO"/H?':[7PFQ\LSZVG9Z_O"?D@^KIZQ:1\#JKYO"/H?':[7
MPFQ\LSZVG9Z_O"?D@^KKXF_5<X$$9ZH7U!0AL.*/A,>Q1X&)"CLQ(K/A-(:U
M><\%'80VTWX1UQ;J^XC'><6M:NU2LYS].>IX9LX/Q!F1&4^$-R,I(IVREV(W
MF9F9VB(B._Q1$:^<^.Q$.*\J("(C'8=A&(&(WQM.9VB-HC>9F9_+.^OH@Z5M
MI:R'=,/3F/(;&HD&?!T5J6)-A3+?7XTN'+C4( S(BRHSY!#T>0P\A;3S+J$.
M-.(4A:4J3G&/!.),;D6<0YTUT+I@>8R9 857D!B5QTB0E"Y@A*)B8F)F)COC
M7MW#^0H!@<*!W:@&&)QXD!64B0D-142)#)Q,%$]TQ,1,3W3J>O9>U-\:&N_/
M6M>D^4O@K*>3;_F=CT>K?PECOA]+SI'I-/9>U-\:&N_/6M>D^/!64\FW_,['
MH]/"6.^'TO.D>DT]E[4WQH:[\]:UZ3X\%93R;?\ ,['H]/"6.^'TO.D>DT]E
M[4WQH:[\]:UZ3X\%93R;?\SL>CT\)8[X?2\Z1Z33V7M3?&AKOSUK7I/CP5E/
M)M_S.QZ/3PECOA]+SI'I-/9>U-\:&N_/6M>D^/!64\FW_,['H]/"6.^'TO.D
M>DT]E[4WQH:[\]:UZ3X\%93R;?\ ,['H]/"6.^'TO.D>DT]E[4WQH:[\]:UZ
M3X\%93R;?\SL>CT\)8[X?2\Z1Z33V7M3?&AKOSUK7I/CP5E/)M_S.QZ/3PEC
MOA]+SI'I-/9>U-\:&N_/6M>D^/!64\FW_,['H]/"6.^'TO.D>DT]E[4WQH:[
M\]:UZ3X\%93R;?\ ,['H]/"6.^'TO.D>DT]E[4WQH:[\]:UZ3X\%93R;?\SL
M>CT\)8[X?2\Z1Z33V7M3?&AKOSUK7I/CP5E/)M_S.QZ/3PECOA]+SI'I-/9>
MU-\:&N_/6M>D^/!64\FW_,['H]/"6.^'TO.D>DU O3;M+64'6I-B=L:B0WU;
MFZDY2695OK\=U4:?U&[5G09.&WB"%Y8F0I$>9$>QCP<B*^S(94MIU"U7?$&-
MR+,@LET+ICX)P \P57D/,&!QH&.\+F.8#$@*/&)#(SM,3&JC!Y"@%%@G=J#/
MA3.%L5E(SRGF\@8SM)Q.Q"4$,^*1F)C>)B=3U[+VIOC0UWYZUKTGRD\%93R;
M?\SL>CU;^$L=\/I>=(])I[+VIOC0UWYZUKTGQX*RGDV_YG8]'IX2QWP^EYTC
MTFGLO:F^-#7?GK6O2?'@K*>3;_F=CT>GA+'?#Z7G2/2:>R]J;XT-=^>M:])\
M>"LIY-O^9V/1Z>$L=\/I>=(])I[+VIOC0UWYZUKTGQX*RGDV_P"9V/1Z>$L=
M\/I>=(])I[+VIOC0UWYZUKTGQX*RGDV_YG8]'IX2QWP^EYTCTFGLO:F^-#7?
MGK6O2?'@K*>3;_F=CT>GA+'?#Z7G2/2:>R]J;XT-=^>M:])\>"LIY-O^9V/1
MZ>$L=\/I>=(])I[+VIOC0UWYZUKTGQX*RGDV_P"9V/1Z>$L=\/I>=(])J+-.
M[6U=%J)1J3LF@QW%;/W?(2V_<:ZRM4>7NF_RXC^$.$4JRS)BO,R8[N,=QZ.Z
MT\VI3;B59L<KC,D5I<CC[Q1X/Q([C4?,<P8JD)1O"_&)1(E'C@HF)[XG5?C,
MACQK,@KU,9\(98MILIB=BRMPAGO/Q$,P0SXIB8F.Z=2G[+VIOC0UWYZUKTGR
MN\%93R;?\SL>CU8>$L=\/I>=(])I[+VIOC0UWYZUKTGQX*RGDV_YG8]'IX2Q
MWP^EYTCTFGLO:F^-#7?GK6O2?'@K*>3;_F=CT>GA+'?#Z7G2/2:>R]J;XT-=
M^>M:])\>"LIY-O\ F=CT>GA+'?#Z7G2/2:W]EYF2RU(CNM2(\AIMYA]EQ#K+
MS+J,+:=:=1E2'&G$*2MMQ"E(6A6%)SG&<9Y!F)&9$HD2&9@AF)B8F)VF)B>^
M)B>Z8GOB=3(F"B"&8F)B)B8G>)B>^)B8[IB8[XF/'KV\XUSIQIIQIIQIJOO5
M!]1TA_KUIG]<^O\ EYPY^^J_Z'E?U3>U39_][#_I>,_6E/5@N4>KG3C33C33
MC33C33C33C33C33C33C33C342WCZKW2+_6&*?V;NH7EWB?O3B+\R#^N\+JGR
MGWU@?SP7ZGRVNPKE)JXTXTU53JM,AZZ.T4;L!8:###>I/5\@B7,3HHP9 CI:
ML*<OS9\UUB+%9PI24Y=?=;1C*L8RKMSCE]@%,<>54E9M:>%O""U@1L.=T]P@
M,213^2(F=4F<8M(8UC6 I89>E)L80@ Q]TC<C*8$8W]V9C4D^V(Z?_CST[\I
MM*]-\A^!LQY*R7F-KT6I?A;%>4\?Y[6])I[8CI_^//3ORFTKTWQX&S'DK)>8
MVO1:>%L5Y3Q_GM;TFGMB.G_X\]._*;2O3?'@;,>2LEYC:]%IX6Q7E/'^>UO2
M:>V(Z?\ X\]._*;2O3?'@;,>2LEYC:]%IX6Q7E/'^>UO2:>V(Z?_ (\]._*;
M2O3?'@;,>2LEYC:]%IX6Q7E/'^>UO2:>V(Z?_CST[\IM*]-\>!LQY*R7F-KT
M6GA;%>4\?Y[6])I[8CI_^//3ORFTKTWQX&S'DK)>8VO1:>%L5Y3Q_GM;TFGM
MB.G_ .//3ORFTKTWQX&S'DK)>8VO1:>%L5Y3Q_GM;TFGMB.G_P"//3ORFTKT
MWQX&S'DK)>8VO1:>%L5Y3Q_GM;TFGMB.G_X\]._*;2O3?'@;,>2LEYC:]%IX
M6Q7E/'^>UO2:>V(Z?_CST[\IM*]-\>!LQY*R7F-KT6GA;%>4\?Y[6])I[8CI
M_P#CST[\IM*]-\>!LQY*R7F-KT6GA;%>4\?Y[6])I[8CI_\ CST[\IM*]-\>
M!LQY*R7F-KT6GA;%>4\?Y[6])I[8CI_^//3ORFTKTWQX&S'DK)>8VO1:>%L5
MY3Q_GM;TFGMB.G_X\]._*;2O3?'@;,>2LEYC:]%IX6Q7E/'^>UO2:>V(Z?\
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M%NY:I@O)OJ*ZH55*:=X+$]G2I$=0@>#)(:[!@!M6"DH7C&]3S8S5P'EWVFK
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MB9,0A"C,3H[R4J[<,KBR^CN",]7I<(OI!AKU_!8B[ALEC<D;YQUZK?226P#
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MBU;L@DC77RBJ0#6H0J@FM132.BEB%!7-1SSP0 +.4=/)[@I)@6JFS:39TT1
M"CCXL>-=!B+4T;H,FX+&FG#+E+<%.QB,&\V*#-$>0$XC+E0YC,]Y0W#$V>G
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M2KT^;FY1_=]#G@=O:07)N7+S3.S.Q]<GHFU"UG8/*D76@ZVADPX\A "DI5U
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M>'\[Y:RWSC<]-IX#POD?%_-]3T.GM;>G;XA-+?);1O07'A_.^6LM\XW/3:>
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M'RBU<Z<::<::<::<::<::<::<::<::B;2W^1I;\*N]_UX[$Y9Y?[[7^;L/\
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M5.'$0K2N9%;FEN 1$ A+'LG>8VWA:CF(\93&T;SK/U/2T>X"C1N$-H H0!)
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MG7,YSE.$YR5.-O5$NV!K(XVXMEA"PYEG%.62M:TJ-SVM:V^"UJ2E;&L,RB!
M"GW-M=DU!>R%K4GFF"+<H6 B( 3#,C/E$1 !(R(IB($9G6REM%OB(A(DY6ZC
M.$#:Z-MGED7D%/&$*\5LJ:A$)#)#*>]+3BR^&#RXN&T3H$V'.8G1H[D-]*)C
M^*/5+K@UI<;<4L0JHJ]%A/%F5:EM1UOL .20W]SB+G-7,-H8IBV"P!E9;9V8
MTEB9RI!+!(6.H$J,#2;HKB83'[K[M,K(=H,"$H(8D2VQ\K3F82I:955KK.(-
M/ WN4M48/EMJMV7 + 66IQ*,IP[,=LH5C$7.</,OS$H?2WX-W*,1\7>J2N3Y
M^-.+!Z="MDSGUTY?8:ESLT5SF>W;<S"MUQY/W0DS8HC8ICH5"1YN9"HY:ZK1
M3L&T)=TNF4S$>,I<J-O'$E$3MM.V8=T')9MF:<L!2,D6JW#MTN>W,K+]>A5N
M96HMLP6D6%E;@I<5D+,8=7F+)DK?E+0/@(F37H[#V<N)O5+&]./GCCB;K#47
M>-L<89(JBZC*@7NN5H<C*) :[!*>0SDCF%+AC"$2R3C"A\U^E6YX2+R*#3*1
M221L=271,KD8643[4IF2]H,$4Q$ZU:=70JA/C0"H"KNXGC8A@7/%LAR8LJ)G
MX<\4(0)T1MQIUEQ;3S#K2_!2H<N/)A3H\:9&?8;B7>-/5$H-!3^-^*RZJ5V$
MM3Q5EG)>AN_(U3%WI$AF8(2B=C6P#4P08!#&%U,4$(FI,\X"P""%F!K/]R0D
M,3$QW3$Q.Q"4$)0)#,1K7K:KGP?"?HJ!\QR'[(/'OX[\7_VES/VW6'HJ]Z7\
M0?HT];5<^#X3]%0/F./9!X]_'?B_^TN9^VZ=%7O2_B#]&GK:KGP?"?HJ!\QQ
M[(/'OX[\7_VES/VW3HJ]Z7\0?HU3O:D:-#OAV-$CL18[?DOP;$9IMAEOOAAS
MB^XTTE*$]Y:E+5W4X[RU*5GMSG.>?JO_ .S;D+^5]17@R_E+US)7G^N+KW;]
MEURV[I<69U*NK9L&QS.FE:U+YSGD6L%CL(C$4ER(&PR!B!B.3:(B(B/:#/BC
M4]V(Q:J[H0I8:/''3+> U<Z;KL(M&DS!T\J)K7E") E1H<R!)=1.<CXB8PS,
MCJ2MY"^_V)SC/YG<?5Z-OU;.-:F2-RZ%KU3.)*UME<P6Y2'\375,:!L6T(E0
MGS^V6<3 S&W?K9<.JN]^.3:(QK.;64\UD(F"V$($8D0&,2$%S=X%$[;;:KT
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M:F1KJ9>>Q"[',0\L,"/;L(%@),, +,SAZ]8N9 *E5=9-.XNLQ;[R)BN3YF%
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MN'90*NH0MI=*H19%@\H@!E!E!F;"EAF32,YQ&SMHA;<)<6-3ALZ>":H"'LQ
M8ZNP(<+7M%B#2<""/#L1!;8PS:7FIC4*!#B1H^*F.D88;Q(:0C!F<U7OHF4]
MUFU6PE>UTZR:B@7BL:"G*6JN()A-BZ0LA:UK >PJ/ECGB(QW;J[ 3(?XUJJ*
MV\J@2 C4J@!@(+@5P#'[% @(P/0 MHYHC6U0]B4>N[)&V@+:9#[D?4(.DBK
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M-?M&M='2I3D5V+/JMMV/8;@^5'M,RGGD/MM*3B2N2W&=PP9;A]B\,J4C:?5
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MBJ.IT)F97R;=+;>=^GO[NM,RQRS(VCF]X2DC&>W=.5=H]H'M^G,S([?N-O\
MZ=_=U+/*+5=J?[Q3=4TI1^C3Y5T9V+7:^)F.V11 5+IQ2W2(8DB7I[54CUMH
MT,APVY\\7!M3UOGHF$!+<J2!@PB_=$[1DL?A,=-G&L/(CEJE5#"MRU!T'7B6
MASZ T0J182M<-8E5TK[88U$&=92W[(M;->C6ZM8BLQ<2H"EW.LJYV)@#97A$
M)A@",$2Q?-@^8U\TJ$6;+W<5HZGN62V!&H]MO!<-5]0FJ]KRO6JM5:YVG-^H
M@VU6D@%FEJQ86S::K/FQH,>IA*Y.L9&*;AS6W%1@A>0]9)X;H3<O5A"]DK%>
ME@;%3%5;U.ED+OA3&)O76UV/I6XLQ2:P%A1K5&6VA86R)D*SR*2&,K]5ZXBQ
M98M&/:FHEZ467]KJK>\ED:'=3H&8A"%)-QBT3CVJF3,(L54,]M1JGM8L2 B[
M:@.B,='M@K9F+X]AGR40']^6R-L+G_9BD9RZRT14EQ326^UI.N#2KEFAH#%N
M*TWHKP%E45KW)U>7H-5N8IMS_B9CVP"Z=]N7NU60E<W81'6A77Z?*T84_EYM
MNF8^V@'?Y$^.(/OVV[M>P>"II:)AB#,(J)PZG8BAF4[WVA\<D-"XL8YZ*VY#
M3W(KDM+M"DQ9<Q2I!-< V.DOI(MC(_95;'O7RK8[K!1MNL'.\*!R:W:U$$2O
MN7+(+&&#&3).E5A1E#82/(*KF.PD<F*'&PI[@@P7U@F(Y8VB2WJE!%.Y\K F
M>> CT!*A EZ^LMPGNS/'6[-5J75(45V.PQ(,&FBI<J2)K>CR%O#A(<+B!XE'
M7"D.D[&+G8F9BC)D&;TKT%LQ5R^V6=2+E+'T5@0")V+ O>YKI(#DE(KU^GTP
ME9RZVEG4Y$L6SA=<2JNL%)<T.170(S$1+&0;&&>\3N +7R\L2,R;@+FY0(2E
M()TWF\7J)5;$7 2H;-FL%(LTJJV87)S5K@* V(M""FYTYE Z"D@JNSW&2>,R
M0S\4:9:23:F"Y[<.ZK\)68R2Z5M]4UC<M8ZX=&XD^Q7T5K;UU[#6#"5]6:K9
M%VYUR!5B(<+$MA<U>(9%D4-8HAAS:SB0X"Z%@%-,5L(H@!Y^D4P?>N1!D<\$
MLX'0']0EXI03"DVBBL##E:5:Q-G<L"L B0INQSZ@ZV.;Q!R>)DV;,+(B5B!H
M.614F%)+M1G*^TLMBK+ O!Z%G=QHILTYO(NS:GLSD1;;0F%1TIM.=%Q+4=!5
M8W3TS? 35&7ZBS08)K$GUH!J>NM\MGI&N'%7F CEZIG#@,)6"B.>0F0,JCJ:
MY-AT?<ZD-,D+/(K8%T2:L@)@62/169YZ;4<0%6'(!S"5C)Z8:"D%R,TLC'FF
ML/X0!B$W4K;3WM<-Y"BFPVX=.J2+%RL*760%MEE"%3:[+.TI;TX<N0&7 RQS
M;5EN*)B.S<;80##<252MCE0!M&#:5?EZW2\8%RP83$28DSFCI"??MBKAJBST
MD8^3*OA)/DLU%K%H@"BC<XE3+1.A3R$*N6>-AMM,0I(BB#/8F&[/BLRPI<;)
ME,$QLN&U@OX.YCDDYY5CZ-@*=Q27PQV/N,6UJZEP-HY'$"'_ .+EH"==Z3,7
M*-8X[%%U8),Y47(P4O%;(,Z[R$C%+HV]J<PMG[F3B"6P"*# ACW *S5RVK-@
M6-YD\W;:B4J?B<EHJ/Q79 JPS)4!^+)"J!K)*(,NQLOM$&K$S&PVK#"QCBL9
M?YVJTZ3\+E+9#:B]1=1Z9P]79"1:8:C Z\UI=+1D>86C:$-O:RF9]MKE24,I
M6FS#8L(-$B4,#HRMI2$B2NES\\3&\'#H';ND)\>MEM6EGAM=!V.O&!9/QC6M
M=V"<KKIF(Y:8< DI$8J4C#&8C*/(\"8\SCQ-<E\ZP/RX:>A.!&72;<N[P\2:
ME>W5>EW-B*F4LU"L!-U:G3 .>"16,=G4PACIR9615,V"6582=&9^.D$K<I@'
MO33:8J6#+Q$Y@3. @8^YB4Q[69EL!NR1E<2<:/LJJC:G9&HX-Z;(KINOUBW5
MUPDMATBT(M0& ;:'$7XT>)&E$0<B9) D)L:'#C3IPR1,C1(T=]IE%=EZ2J-L
M1K$PJEFK3OU)=(DT47:R[ I:8 L#;6,SJM8"U@QB38  !0,1KB 0Z(7)2EBD
MO3)S$GTWJ%D <C Q)JDB490(P1@1",#,1K0.5>HNITZ>.GFY=2EV76J\Y(!T
MX$]'5L+8&&$.L5Z*\E+Z 8-+Z%QB-V*QE85 A+2[%"PW4G33:X_DX<9^@?4D
M]2=><!/%_%R#'AA32\%8J2--CBJT@Y$XYAD6U\!5:,AD+P2++;1+&X\X=%NU
MC[K!8*UGK<I5S)J)F)N7-NY43M/13O&QV6#^Y'O%0SU&=W*!]]_3)4PE"U -
MI%:C+AUZH77<%9!QG7W93S H'N&^#8#;\I]2WY3^(T9OP\I]:WY+W?>>6MQ:
ME9^M\ZXGY&7' 03:6)9(K 5K&3Q5(N5:QB 6L=]@6$0(#$",1$1&O9L#633Q
MH5*X\J:UO)H4,S,S"U9.XL-RGO(N48W*>\IWF>^=3[RGU<:<::<::<::<::<
M::<::<::<::K[U0?4=(?Z]:9_7/K_EYPY^^J_P"AY7]4WM4V?_>P_P"EXS]:
M4]6"Y1ZN=.--.--.--.--.--.--.--.--.--.--1+>/JO=(O]88I_9NZA>7>
M)^].(OS(/Z[PNJ?*??6!_/!?J?+:["N4FKC3C375UZKO_1-A_AAUO_Q!7E)Q
M;_ ;CS_JED?][5UI7'W[P_\ W]/_ &RU\^T*BQG*:U;2UI%@EE'[%&K(B7#+
M27S;M6ACI9)+DJ!#D1AGCKA..,!*D>$1.*M2F9RQ,)I!!WX/7C0G'Q>?=36E
MQ6PIH-;S*R5):C;$FI9BGJ2X4UN?>&O$Q;*%Q#2\G&M'9XL,>M7/+H2LA81,
ME @1[R E <W/ *WWYV04%TQB#F1)'3_(C3C$1R\5_#51F7$/>I>!YY3=;L%(
M#OF2HQEIL>MXVQ.;ADH(0C"0AB61%SL3$#A^81*;:GPN0,>$Y*KM19D*^2/I
M6IBG:QM<K#DC$*DK LA;E5W+B!-J&=2%)Z;F2YQ4P3!FRF.SE87:+E;LEM9<
ML,(V"9;!<I@HQB((P+F@ Y3+8 ?3^(Q9A$0A=A1L,LO4H!Q4&#81BQT+8NOK
M%L&E$<N2!BGW\Y"U^2_8(<*/)=&2? P83AC+RWF9=;A:OVQ .R*+->;%%5GI
M*MIE*\MBK>5QSIDT\Q?X/5,K2U <I/E6LK'-)#E7BE]98G96Q?40#>46AR#;
MJNM5CWD-R^Y*F6B(S(%L RS?>-3@:7>(-Q%B#0<P,LT2H2JX>>:+CGF6K'L2
M7KMWQD4IM66),,X,(-S&'U2FU#4L3H+KCDEM"("^'R;T^A80]-U=$ZEHA>HA
MBUE3Q1<Z9B>4UV5-%@E)Q*8%JRF3&(P#CI*!E;%L!PUY2V88$QUK95)Y@V[B
M%BS@HF2]IRF,SS1MY1=&.3R@N*+MC!H80@620LF%J]IGO-2ZF5AB3<=([(YA
MQD>RHA$)-GC<@$)2)R\Y.?@$T,B9/(<-RUZEHO#84Q=LB;7I76$+*+EHL#"N
MD,BH9:#HLV3K(A'-+"4Z!0:,;S& @^& 8.*36AY3!(9"V1R<D3 QS"SJME00
MO>2D61"RV QHP=78\06^;B$[M!.]0=?LPS*238%I6G*Y,(JFB23#$>0^KPD)
MR5$P\E+4]V8.9E,1H\<@ER4_AI50%I*RMV179XJJW$_=8K1/#]1C997<( 13
MNLC7S1 M(TB8@ MB<K,8*A@):)V1;EDN#V_2CP<F3YEG Q,]XR0[]Q2004#$
M'OA8^@9DE<AA-SKS,H"A2;PB1#.X9J,M6NK=LMB,X[''2736$!J/8AI)T1&?
MS".0O%8[1"%(A$)4<.%VG)C&0J"=6)C(P2[/+19.)OY@0DA296-J^-MI:2 +
MIVE\@"U1K<>.,61;QVA,$J)[3S"W:N79+%V!F1 I9]RK. Y6,\K0Y1@QD3G5
MV==#8FRZ/4"1_$NN6^129;1Z!#DQY&05N\0>0O(^0AQZ*1CMRW(CS.?&F6I;
M2G&G9<;N..0AQ20S&.H-M=2I>/''%E2S NS7^D43TCB2!PBR0(?;B)C,B3 V
MF<$5 &Y60;MTOFN4-$"B>D_EF)Y"C<3B"Y9CVT04;Q)#M,[T1TU5Y-;>DUVV
M-9-1K!O!$-@A!*I\O@=3U.OW!_.,MQ51!,AD6H^VTX^XM9(EF%'4Q#B*5-9L
MV\/TCJ$=2\,V M<1PL6J?':JN#HU<@?B"000HFT(R4S+G=()%83+!E%CTDF2
M4^.J+<ERP8L^ZJHH38GQ#RK* ENTS^[/E'81]M',F]+=F%2XL0Y9!%>PU'M#
MEBEG1EB@0PKU3II*[%/$5^2WG[3!2/#DAB"%>CS$.'(GBC3+L2>%(%<C."[B
M& %FXBIRA=FVRRFTI=<J./=D7=*>B1W5])#DPVJ!Q-D.01);:S7]RPCEE M>
MM.T/EQ-!P"N:]<[)\D].9>/(LU\Z1+[J/+$2)K,\4%Z=3-@$5(T.L4-F%;+9
M5:NQ), K(&BM(N4DM&%&(;DT<F0<&P7 TAHY($1),6-*=9C"99M2):HN"OPG
M8M(H6%6EBN]?HTA.Q6N5P&,@;P1863$P5E*IKF-HJX&"S( 0RS[>5XU8AKEU
MV T8&Q80B)8MRQB+$L@&#)!NT!E90R5B4"4P($SVTCPP^CR%@3&15"@:TL6@
M?7\5<BXDN&=27+[.!:X6.=A2&L89F-%BC"G%2LRH*P1%B>TX@GWX,/I7X;;:
MY!HNKW1NJJ]B=/7KS#WYFMB)42S'VK!>X9GGYUS6:+1F'?<@Z+QANVZ!K=#@
M5T2GG7/49=53Y9$H[BAAQ,\TR/2.#B8.) =A]K">S/5$184*[X3RM#@^M6UJ
MMDG*#$H-*7BC-#7;4X''JBH+3RX\<26P"GCY21[I!4X5 E>LRU+97%J)WKP]
M:^Q79O'M8.NR8QL*FZ5=4AUVO4ILC68HX3+98A6;P*WGY8;ONOG$>A8Z\[,E
M9?X- 2^5AMU"8 'LH@* DI(!K!G&<9SC..S.,YQG&<9QG&<>]G&<9]_'^C/O
M\TS5+K\XTTXTTXTU2?;GU0[!_P"D_P#(QO/UZ_\ 9>_^!? W_P#$W_C#B#5#
M=^^6?_L_W8:MG3/\CZK_ *N!/^6QN?F-ZK7_ ,4_5*_Z^\7_ *_R&KBO_B$_
M]&'^J-;+SS[6;3C33C33C33C33C33C33C33C33C34XV+;%;LL0B8(:[CO[*-
M5@?5RMKFG6Y];5XD/@!W;6.I3X##T"\$18Y#<LRY:9HN.0F$#(D -)K@OC]D
MMYRI<!UAN*$\Q8IJI.O,LPVI]S4I!7DXXJO,K)-2J(.P5UB :QMA%5+I4:K-
MUY+A-A5(FXQ (8\FP:9Y0!<O"M*8D+1@$03)>2X(C8"@.1D/5.VA5;,;,3[O
MKYPO *@=>B8Z@5H37K2#F:^J(RHQYH>QRZ[88"(1Z- =D&Q!"LD&G5K@^+28
M\H7'FKX9FJ5RS8;DL5-A3ZN*0/9KD5+M9F*H)H Q%ME2VN%V0416:[:;1*97
M(&!H!D\'=0]C"LU.H!IJ+CIOZ3U%4KKKP2W$IH<K1"9:LT'$[CRS$A!3I^Q[
MY-V)=2-R?B^2WI3 *!#C(FR9\F- K($76P^9A63V2RA?(P-"=*F7\-R"I54L
MDXTRY)RVBORV39E<@V^0=$C"JI80PVF"J=5%.OU'GL;G]&NLGV"@2<^3=,#)
M[1'N6BMV3L3'),PH!CFDB@$*6E?,R?;&SD6,L9.TL9S',1);1HV'7$X<PEQ>
M,/)[CV,+5C#J/"(=[KG9G^6GPK;;G=5VX\(A"^SO)3G%;$S&^TS'-&Q;3/MH
MW@MI_#'-$3M/NQ$^.(U%W\?Y>Z?R^[W_ -<1/]6I%K5O'0Z8=IIAB5E,JU5&
MX@"$;#;B1Y8$HD**1)S:UH7@87 G9,EY^,F1+05KX-AMCQ65.>:MJE]2\?9Q
M[Q/8[U#(56A$3"GUNLARV1,Q/1?6LF9$$&<.JUQ@>0V$,Q-@!KLKLB=I?7L*
M.-IY&*YUF)1X^1BFD4R.Y=1*HB.4BF)PN6_JL,V'?"6N:M(<!67:UIO96>5L
M3\W%FD*@[ KM8EAHSE:#2ZN(8';!L)50HD@V4?DSX[$LDTB"VTG8\AQ123E<
MD[$TBFM;SEW)O:^V3.V'*\I5I,KA-2NRE7%.4M.E#HLO,VB+'#"Q&+*QE$A;
MM'41,J=>=:,C;)=:>6VI!+B5+)"X"VTY6?5.9(8(X@8C6FT[>Z:R,"BGJ^63
MY%UO-U[&/52W9J5NCHF;//[(>("K#FOFUAV9Z3[]7-P(L3,@H%2\V@K!1,D,
M9KZ'$W8TUTE5?'9\0S%!9HWNPWAAF9M9<FIM=ELR@6]J*G84L.=U>"B'KAA#
MJ/7RG1!82IGW.F506HL=GL#S7FW),'=)O3@NK*& (\QKWB&#S3&L[/ZD4D'-
MES%U4TS(V/FS9F@T7\A*U^Z[8Z_Y"C$;#2RH4EBP'JHM3A>I'HY@$1'%&1TF
M8Z27!RJ3*;Q=#9S#)I6!/+S<EE:,HT\44VZO9@;;QSZS>UV:,S+Z-D+%5RGB
MDV$Z5>VR%F(.;A2AD%<ZW,N+1S4F7*Z4$ZNQ9]9J-Y97:+%&!P$G+.6>;7=O
M;[+[>@NI,YNJB92PLVDT@ULL]9*?&,)AD8\K-+I,J)#@52%-D%9DK+$R;9)(
MUKP0L#-$"LS(<V)GN)WYY4Q8G(RYUH;MB+.8LW* 6(6T#\'8XUK516PW,.0-
MELTCRIK,0CJ+9BR&49D!GJ=IYS=#VPRXUU>&<IP79JQ"(H$I84[$3B"-@42U
M\PEIU8NU:":^O=.(U@X3*W)P8MDY"MD 4/%9 J7+#8<!/T\O((]PB_)>)]T^
M/\>A*8AQ?)C[*R#]?3R-.MBLG0;2LN?D)3(V5WEH4CLTR=>)JE0>;=G$9.F+
M2NHN16'1(9:<=-E*ZMJN:6&RQR;-%X@"^E/,O=4UV2?MYF3^ZAS#L(\DQ)SM
M$K<8IVOM,1*;(AW%&M(FJ<V5=F\:$)K:&VXQ&>U5\@67T6(B/S*$^.+LC@J*
M-F.=P(LHALJF:?$")JP(8\@R$8=>$[9-SG1%.(@&M&EV82BVU7.CJ3;E )9.
MU>71#XS%D%RK8:Y#8[&-'K=;=?1C:#*$]*"AQCS+YNM*X I^Y2>S-:'L>U0;
M=9$2P\:5# !P-:J==CS_  6)_D6J H *+-((CN/1V29E<)XX4CQGWXL8D3EL
M17G8S;2\UF7O+OVX.N!KJUZM.C4!O+U>ST:RJP,; 20"ZQ*RLN$"( :XQ I"
M!G4:X\7NYEB0J6I*%06W-TT*!0D<#,Q#&<LM9$3(P9E SRQ&MPZ?NG^Z=2-X
M54ZLMT-60SD9W8-^5'2_#JH]_&'6QHU+R<QB5S+1\*R'%*[[$%E7EHPC$!J/
M&(^T>I+ZE <0PKBSBQ+5\*(<<8_'\QHL\5W*Y<IH28R+:^$K-CDR>27(FTX+
M'8\^US8L8^=@\):SUOH(W565(S=N;;B@)[^FO?N.RP?\6'? 1/59')$07T;:
MQUC2M/4H+K^@!F@M;!LJ0PRE2GI<V6\K+LXN7G.=L@F9*25+F$R4I:Y$N2XM
MQ:L)[J$_5;WD\QF14H%K6BO7KJ!%6I50$*KU*E=<"JO5K*$5(0H16M8P(QKW
M2A0JXRJJG35"D)C88CO(BGO)C"GO-C"W(S+O(I_FC6$TM_D:6_"KO?\ 7CL3
MDW+_ 'VO\W8?]44=8L7][-_..8_6UW4L\K-6.G&FG&FG&FG&FG&FG&FG&FG&
MFJ^]4'U'2'^O6F?USZ_Y><.?OJO^AY7]4WM4V?\ WL/^EXS]:4]6"Y1ZN=.-
M-.--.--.--.--.--.--.--.--.--1+>/JO=(O]88I_9NZA>7>)^].(OS(/Z[
MPNJ?*??6!_/!?J?+:["N4FKC3C375UZKO_1-A_AAUO\ \05Y2<6_P&X\_P"J
M61_WM76E<??O#_\ ?T_]LM?/0.OU@&5I^IM>1Y0AQTP]%\I@ I6<(>L$"(,.
M.A2)"#(FBW"<&!#9>7$>;4PY&;F0LQ9V,RL_!2<I:34.D/9S1,O(.M5KO;7*
MTL$V9K.:LV(ERUK$I HD9"&+Y&[G/D@6F@F41TR7,LD>=2S)<M$0;*S,9(),
M0&)Y9[I&"'E+VVM@+[FOQI,A,P@-;R09L*3#L$ #'O'IMK'-"K":.O0H#+A8
MX3@LH;=*S%.2FGG)<V.IF<1)29DI_$&4L04,<J.K%OKRNK645EEY,(MV+)+4
M,OLN4,1+V21B4L8$BQSC9F9D;3.:",8Y^KU)%2AEI/" :QLB$2QAC$;F4R43
M)%$P1G)<<?M^^BYJ2$,K%3*3*I<SM?"A9K"G]?5(K1JKEV'-@2(<AJ#6C1&!
M(C2&'8Q++_C!)J5(;0XGJK/91+.JMX0?4QS/;5Z[!YL51?C:6ZV*-9"JG9<H
M@,2!W-SN$SB"C@<A: N<3'FYJQ>V6LHF:B#K(W$AD9@4L,)&8F#WW."F-]>:
M]P7CQN+)BS!@UN P BC!PL"&@"AD:M61ZX"F( Z/"1&80BS2IAF7GN*<(S9L
MQP@N3XPYC/,Y[(]0& Q*H4-4$J36KJ0D*ELKZ04D%P QVPSL,[MVL8R627/.
M[M]GF&8( @(5  "EB "ETV @0@=HCK$3"]TR(I+?>=>H/MFYA84@8Q($31<J
M,5BRA9FN@C0Z2T8.A+-*S(A%!\IA]2#U=#$H_A4+2TN%XMW509,R+(ZHSF0K
M@:A)#%,!ZV)L5*UA1Q8LU[A\RW*,"F+52NX-XF!E?)MTS8!<+OV5C(1*R A,
M2!B5, H8U;YW$P*)V:I9QOXI';]S)#/*(;FOA1V?*G3AKT\D?V#8Y)' (.S-
M\H;1#R0EX;9=9AMI8@&84IW.![2$Q1\G#4D:W$=:0K&1O$&3=+38Q),=:RML
MVQ6KBSJYJN=;)0)"N(%5A9E/2&(!1[&F%D,;=CR-HY,B()(VVW$?27!<]Y<K
MLQ$P/<+!*?:Q&P3M(<LQ&OQ_<U^?A)A9(CFDK@2!Q&3&  XT\ZT]3#&O6W[!
M/8@(E&IT*H6 T(@3Y[KTJ+DG/(H=R6F2ISW!<090EPOJJ&)426F%6L#;(EC[
M&*@K315!V&KH6K%=36R1AUFM@NNPVDG(VI'EYPCVD@90I<&V)K,J1+2@=V$-
M=K%@93)#SF>_4(CG47;<?>*U\TN:GRE5XH*&$D)C14^)L5O#7D=.6L,^!D*B
M^!;SE<EMU3^4_P#U&7>W/; *]9)]6Q+(ZU,*P5S@ ]H-3EBO[7EY2D.4>\X+
MFV]MOO.H\O;)J9)>W2*Q7/*/M83MT^[;:>7:/W43O[N^M@E;2M\F2N0W('04
MJ7?G$11X<;$A,9V;7&ZK<\,1T1^XVDJ%:2PA..W$![*I4#Q:2K+G)9YJ^1R<
M$E6\Y28!5=*UCX9J11R'*$!M$.K# 1$?XHMS5R',EK*5U\E,Q(#]]3R@L!&.
MV)A%C:(CNYUQ$1_%GVP[3WZY$[;ES(94\^Z"20D#"HHF9CU>NQ3AR.:KTJJD
M'#AA@8V0)RWPDV2PY+DR%/NS'G3#ZWC3SQ!SLW.Y!NY$5:&DER'6 I5 LV0L
M53I-FS8%,-<9UV&),,Y(F%-@Y*Q,MGL60LGWS*H.08LV"A(M:+4D@Y:R @S*
M5$424SO)3+)F6S)SM=4Z@;>!+4V228#%1=5-:^)R8[5>KD(N<CZS9;'U."1L
M& [Q"2R*"MI$1FI2Y$1<5*%38LM_ONKG4>*;]9^/-PUW(I6<4\P&I46^R.'&
M%45.M= FF*:\0@!9)A(1$L!A;E.>OEK"65B.%L6AE4R&%)%C8IQ ($V].3*%
MJCIC!3(R,1S04[S.J.;?O>'VGH!*$#Q%@#!P^/7@H<'$%LB;7&O$-T;&&PH[
M4*;BUQ&3+LYG"9;KR<1UO9@MLQ6X,Y[)\PDIRZW(I*E#4KHK @47@R2R2"5A
M"V=N ;!-'[H11 273@0'!X0M1,2!BK8  14M:A"%OBT,A #$"77&&2<>VF?:
MS/+$#'(C[BM$0NP;B"=?Q9L13$B)B/K6BLQXA*-/448+Q6&P*4L$FR"O#8=;
M[K.6$,BU,9#QXX]KN.?NA8&R",6# D3#DQ&,$ :#9<+P$:L0+8;/-S1[7E@4
M\O9P!0\QD'BR&BNJ)#M(\M.J,"8ESPR(A4;'!]^_BVV7MTH@(C"3)?F2)$N4
MZM^3*>=DR'G,]KCS[[BG7G5Y_P"];CBE+5G_ +\YSGE,9DPR8921F1&93XR(
MIDB*?RS,S,ZA3,E,D4[R4S,S/CF9G>9G^>=>GG77&G&FG&FJ3[<^J'8/_2?^
M1C>?KU_[+W_P+X&__B;_ ,8<0:H;OWRS_P#9_NPU]3W31T<],=HZ<]!V4_IR
MJ%#MATOJ\X:)R<$O&")8M20D\C.?\&00CPTN8^\^[W$(1WW%=U*<=F,:5Q+:
M,>(L\,)HS YG)QN>-Q[#G:ZZ-R,ZI&93_E&9$13O)3,S,Z^@,'PQ@+&%Q#W8
MNLQSL91:UA0?,;&55&9SL<1N13,SM'CG4V^T<Z3/B.IWXBOI+E)VL_>,?\UX
MS[)JT]:7#GDBK^AGU]/:.=)GQ'4[\17TEQVL_>,?\UXS[)IZTN'/)%7]#/KZ
M>T<Z3/B.IWXBOI+CM9^\8_YKQGV33UI<.>2*OZ&?7T]HYTF?$=3OQ%?27':S
M]XQ_S7C/LFGK2X<\D5?T,^OI[1SI,^(ZG?B*^DN.UG[QC_FO&?9-/6EPYY(J
M_H9]?3VCG29\1U._$5])<=K/WC'_ #7C/LFGK2X<\D5?T,^OI[1SI,^(ZG?B
M*^DN.UG[QC_FO&?9-/6EPYY(J_H9]?3VCG29\1U._$5])<=K/WC'_->,^R:>
MM+ASR15_0SZ^GM'.DSXCJ=^(KZ2X[6?O&/\ FO&?9-/6EPYY(J_H9]?3VCG2
M9\1U._$5])<=K/WC'_->,^R:>M+ASR15_0SZ^GM'.DSXCJ=^(KZ2X[6?O&/^
M:\9]DT]:7#GDBK^AGU]/:.=)GQ'4[\17TEQVL_>,?\UXS[)IZTN'/)%7]#/K
MZ>T<Z3/B.IWXBOI+CM9^\8_YKQGV33UI<.>2*OZ&?7T]HYTF?$=3OQ%?27':
MS]XQ_P UXS[)IZTN'/)%7]#/KZA30'1YTS6;7Q F?T_5RA!K;/4"$;E2LE%.
MH%5C?>RJT @XRD@G'@!0$2-%Q4]G:F+#92K*E8RK-QG&!7O@M%3&J7.,PCI$
M<5C8CJV,+C[#S^]/&QS6,+_ZCG;;57A^&<"^F;'8RNPXR.95!%S[PNOE[R$A
MW'XEI6"Q_P#I&-]YU-?M'.DSXCJ=^(KZ2Y3]K/WC'_->,^R:M/6EPYY(J_H9
M]?3VCG29\1U._$5])<=K/WC'_->,^R:>M+ASR15_0SZ^GM'.DSXCJ=^(KZ2X
M[6?O&/\ FO&?9-/6EPYY(J_H9]?3VCG29\1U._$5])<=K/WC'_->,^R:>M+A
MSR15_0SZ^GM'.DSXCJ=^(KZ2X[6?O&/^:\9]DT]:7#GDBK^AGU]/:.=)GQ'4
M[\17TEQVL_>,?\UXS[)IZTN'/)%7]#/KZ>T<Z3/B.IWXBOI+CM9^\8_YKQGV
M33UI<.>2*OZ&?7U/-!UU1M6UR/4=>5</4*W&D2YC0D+%3&CJF3GLOS)CZNU3
MTJ7)<SC+TJ2Z\^M*&V\N>#:;0C&^PZR8FX^>06"5Q$" +4H>5:E+"!6I81W"
MM8B$;S,1O,S-Q3I5,>@:U*NJL@9(H6H>4>8IW(I]TB*?&13,S$1&^T1K=.8=
M2M1-I;_(TM^%7>_Z\=B<L\O]]K_-V'_5%'5=B_O9OYQS'ZVNZEGE9JQTXTTX
MTTXTTXTTXTTXTTXTTXTU7WJ@^HZ0_P!>M,_KGU_R\X<_?5?]#ROZIO:IL_\
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M=\&\/?B=P%_8'@W]AZA^LCAKX"[YRRGVS3W*SH<^*JT?+COK^)G'@WA[\3N
MO[ \&_L/3UD<-? 7?.64^V:>Y6=#GQ56CY<=]?Q,X\&\/?B=P%_8'@W]AZ>L
MCAKX"[YRRGVS3W*SH<^*JT?+COK^)G'@WA[\3N O[ \&_L/3UD<-? 7?.64^
MV:>Y6=#GQ56CY<=]?Q,X\&\/?B=P%_8'@W]AZ>LCAKX"[YRRGVS3W*SH<^*J
MT?+COK^)G'@WA[\3N O[ \&_L/3UD<-? 7?.64^V:>Y6=#GQ56CY<=]?Q,X\
M&\/?B=P%_8'@W]AZ>LCAKX"[YRRGVS3W*SH<^*JT?+COK^)G'@WA[\3N O[
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MRD*2I.<XSC/+++5K$VUS"'3'@[#QO"CGQ8FC$_Y/N3W3^75=B["(K-W>F/\
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M3I[&G#OPC/\ ]H,I]HT]T3ZV_NE-J>=!#YWCU@<&_B[C?D(^G3V-.'?A&?\
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MT>)L?<:I)3-5CJU)ZQ>03)'=MWJ0I@ER:^ZS2E2VPR56#>D4$9&$%A1DZ[B
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M+>W8IV&+!*EA,U'UK \_3Y>J?4K M36P;%(-H$36,EL7<48ZS7=6=VM2PA@
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MKA(2*$C*X* F%A$A!_NH&8C<8+W=MM_=U[$TFF)!2JNFI5E-9G9=5-KR00O
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M'&5>I\VU*<95G.Q-?8QC&,YSG/CD_P![&,>_GGIWJ13$<:5)F=H['=[Y[O\
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M [[A,Q'MAF-IG?NUW&<T;4K3C359NI7_ !^GW^LSJ[_<6/EWA?%E_P R7O\
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M,4(LT5F-22<A(U^'/@CYTI:Q:,=?AD+)5Y#)K!-YV*K4FLJN@FORS,E73#E
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MVG79&6-I=\L%QM=7L!J=$G.!M;56B/6*PT^:U)D H!.^4ZX#C6O5/S9M=@V
ME%%V!UX%5CL4JU7AQ,^LQE>\L66JB*U>PE0$$-O6+D)3;&1%QKIV:K%7=@!Y
MI F)@76$DN<,9$UR:W#$M2*5F Q,<[VMY 9&T'(I:N0=L,,)8D0;&P)'4)G.
MF$N'(+B1[M5C41:][+A$A+N9\21$T=HZJ;WG*<>@ORXK) T MT*ON#6I<K(&
MSP2<"?)>;B^&7;IX@4U<&52PHO\ W1!+9'(0EELO8PX;0<"4@IU8G0R1'K5S
M68#$EMJ2%\2'>5,"?\$W$HVF)M6F5!VYMID1-<GS3$<ZY$ACOVUM=CZ1V:_9
M+#4$[7 ECT"Z["UC6DCJV=P+L^R-6!(UBN]<<GS%17P<,=$,5<'%.RH$J(0M
MY[Q!IE%8%$;BS&1Q++D)LSC7*2=6ED+$F]4G7HY!Q(J/@ @H<1DJPXDB0D%5
M//O-A@59Z!D9,%L[.8@2D/9S&',M%@I!1\L;\\S(,(@B8D5AO_C"%4^9#I)&
MPHT]AK;@R988*KN+\C-4XXU&?L])U<QMV6-;+/RVVTB':VZL,X;=BHD,W##,
M&,%(5IQVVQ^%\2F<@4XTP045&]6;2I(:]K(%C89*A"9E@O&&PJ"F"K;F30?$
M5BX'(%/+/9B@"Z)<TM#>%N?->"D8B9YH/8X")VE6\R8LB%3C2?2I@-%N14CL
M:#@+J":9!;OE0ZU/D3J5:0\^L O(U:'O3X;5Z9)VJU0ZL-*(GUZ/Y2&&YQ)H
M;7F1)LUD7Q'+2JK"@?5R8*=B1)X"%JNT+#>K8. *:<KKURL,7R/+D8H%RQTL
M4KD<AS2H13//9@3J1+(B&K(6'SLF!F4\JURPAY3]J00,D?.(>[8W3-%&VV>Q
M3;%$S6%YW3@0N:T0<DO-:)Z?J3O(_+<R\RR\ENU0K7@>%9>:;>@2FU8((0TG
M'.M#/DRL!6D%VB/!75Y)"!B<QF[>(2,;3,;URK<[9B9@QGVDS.N4WIE<=4)A
MD=FYH';:)MW&U CQ]_3)>YSXIC]S^#6<-])\2>]L$L!L#]="5 +Y7'Q3(_#S
M!EFKZDJVT;\P/.DB@;!H]$#F)T\96:G!M).,VPV[;TTT#,%'B&)/$A!%%3DB
M]UIG3,EGRRJ;&2L8^G)I6IO2235 #'V3KA,EM7[4X6*#H.0F.B)A!DPN69&=
MN7J665TS(P)\H201!,82XF9V5U3@P'W[ Z7JD*M^TQU4MLAG7NM=J;:KA&VG
MA,J1;85=UH#@E)47 ""1;$G)[\N;%!AGF7PJ2IB:U,*R*X#\8?&]:7$5EE;'
M'9K05V_CL:]=9+!&L;[SB4)=8P)J0$1)K8F&]-02*Q<[E%G"<@PE5Y8K=[Z]
M9@K HA4F\B&)YRCF =ADSW@^48V&#+]UJ1'I4<&@Y9)W8HA^>0'[#/T49' %
M\MVBJZ\T=0.HF2=)D'W(Z:PHYK+8(QP0+7&+3T6>.^#*('Q,^66Y*^(^HX%Q
M09  =%-QDO5O7LWLM<P@I6$1,V(5?I,ZK.9037*&KYR^Y3D'(<QP/1*(&4@X
MI,?N;'6W4H 8C?J<MA)<Q;@/3F#&2GVFNZSU$;_(/47]?RQ_V+ME\\B]5K]]
M[O\ U*5_XJHZ\K]4K]^^%_Z7_P#\_.Z^MSGSUJDTXTU6;J5_Q^GW^LSJ[_<6
M/EWA?%E_S)>_UIU3YC_Y7^>*7_Y=69Y2:N-.--.--.--.--.--.--.--.--.
M--.--.--.--.--.--.--.--?#WZL!_G%>H?_ -I?U&:SY]1>IU_ W#_]X?K6
M]KYOX^_A9EO_ +']6T]?2CTE?T5NFG\ 6G_U?5[GSSQ/_"3/_GK*?WU^O=^'
M?X/X/\T8[^YIU8/E'JYTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTUT
M@]0]4M-HU)K--9K1^Q9A;VZV,S, @Y$OF)B1U)6[$?,G ^-(RQA_++V&<N]S
MPO@G>YWO!J[/I7U,LA0H9?B'MUZG2ZN$X'Z7:[*:_4Y,"//T^L8<_)SCS<N_
M+S#OMO&_SKZI="_>Q>!BE2MW)5F>,Y9%6LZQT^?-ER<_1 ^3FY2Y>;;FY2VW
MVG5: H?J#KP:2 $4S8,47(61=0TK7Y&5)'/&(+0LR^"(S ,@E79!D8PP.,2
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MV=4VWO+GV2K)I1R3GLK.,=\C5D(#/XQC"<14X4VE#_\ A>=XN<)0,!&2PO+
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M9GA@DM6T8N<LDHQ9$3X.SD[3(3,1.TQ.WCVF-?5ESP/51IQIJLW4K_C]/O\
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MK\5TER4)4I74[U))2G&5*4HCI/"4IQCMRI6<Z1QC&,8QVYSGWL8]_/'ABOY
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M1VL5AO25CW ^X$*5FO5O(N/ML6/LQ\$Y70=X/U; ^.FTRJI%>:XC\GC[MO\
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MB-/\G\/B_J[RCZ/TZEOHEZBKEO>>F-8K0FSM@>D+HTL]R7'KT$4P)ZA[V_U
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7.--.--.--.--.--.--.--.--.--?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g142578g87e13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g87e13.jpg
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M 0$! 0$! 0'_P  1" $G 6X# 1$  A$! Q$!_\0 '@ !  $% 0$! 0
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M_P"'DE&..SNCKRA?:&TDSVDULG&CGU-H>YK,M4$F$S,,(^X-XB/@IV%@)A"
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M,@FBCJ5GY"4E76&,'"P\)'I+O5$H^'BHV+9$08LFR"4MM[QV^1>@@
M
M
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M/FK9%ZXY)+N770;)'7<K)-T$\=)19=0B229>?&.<ZBF2D+CGSC'.;.,<^<8
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MS?[%/P@!U1K[LW^Q3\( =4:^[-_L4_" '5&ONS?[%/P@#T
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M3TW0ZA72X^9;QAM3H:GUZIG0J,N&E0
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MZZ=^:;/YP,NQ>4EH:4@LYO4=F(SZZ=^:;/YP$7E):""SF]1V8C/KIWYIL_G
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MNEQ\RWC#:G0U/KU3.A49<-*@
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MLGINAU"NEQ\RWC#:G0U/KU3.A49<-*@
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MZJXZ&$S+(X+GI9*;I]+/_CT>;Z>?%)<^GBY9/3=#J%=+CYEO&&U.AJ?7JF=
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M3_'@!U"Q?$+;@:?X\ .H6+XA;<#3_'@!U"Q?$+;@:?X\ .H6+XA;<#3_ !X
MU=Y4BIUYW5L)"JQM:NDHC>UX#8TQMN:TZQ@8V.1JZE@JJ<U!P-D6LDC;RN(R
M1;5%]&&C5FE.D;.=PD_JL>57I8\,(1]ET\\R'P[3<'ON,@<F*R5"P:C@4ZFE
M',<1;VT,YJ,8W9381\SB=SLK:;LQ[>\PC+6AE>YYI+W*(M<NR8/K3'S*4XLS
M;*NU6Z44M\N$."N]2NUWA;KM38,02                !!IZ8[\Z<G[]0V;
M_$40:,YA?!<J/26/\-IF?^>_PO)OT=K?%9Q"D-"%#@      2Q^B%_3IL?\
M9,Z_G"J"DN?3Q<LGINAU"NEQ\RWC#:G0U/KU3.A49<-*@
M                          :C<J4Z^%M>,#N=0-&5L=3%!8O]I9IBCR!N
M%MDZ>A VFHQEPB)9.SR4%"L[<9.HQY"YG9YY6"RR*L&UD5V<KUXW1W878X\"
M'ZO7VPCP<HF2M!5-E5Z-T,-*D>8//6Z)D;#5XBDQB]CC*U=K1#55S934"*AZ
MTK:&U>19I69M%Q[)A&6<\ZS:Q\=@JC-(WY_7'BLPMT]WGAP,WB"0
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M*QBF+6.9E7=+'<.5BMF:2*&%7"ZBBZZF"8.LL<ZBF3'-DV0*D
M(-/3'?G3D_?J&S?XBB#1G,+X+E1Z2Q_AM,S_ ,]_A>3?H[6^*SB%(:$*'
M    EC]$+^G38_[)G7\X504ESZ>+ED]-T.H5TN/F6\8;4Z&I]>J9T*C+AI4
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MEO&&U.AJ?7JF="HRX:5
M T#Y4Z[2XS];1A(J^%MFMI%?JJLIR8=U;0HSDSZ9I-FS+0$W3X-!HVL<>M3V
M4;'V:'D9,B$/,VV!,W(K+&>,.J/L>:3XKCY_<0UN=UV*^? V=T1&FC=80F%G
M4J]>RTK=+3*N)FE3VN79IRY7BQVV>31I%HY[#6XE"9FGR$#'2ZKIZ2"2CE%7
M\AZS#YQ#W]GP)_R95?$>J,GB<:X;-)$[5P1@Z>-%'[-L],D<K5P[8HO(Y9ZV
M17R11=HE(,5'*13(IO&ICX7) -'VVVMOEEW%!;6^MV'%AWS"Z>JNWDZ81DS:
MK,]8VS8VS6J%?1G%XF=>U1S29&G1DHF[Q'L[+)KP\TUE9.HR[=]U=OON46I)
M7PXQCH1VW>?S^;ABGN+>;\HC=,*JWE;)$M9BK4^ZVC74_)UZNMT&^P)JM[#V
M31W&$57L_G%3L;YK$:M5K<.596.E;3;+''*.?8T4H\A$%P\^_<H)X7\=W!8D
M1ORBU&&'KNP3OB^"-M=,7<E^HK&;6L438YGUZN+">%9/H^.AY*32;V-I ,V\
MHRCI->.C8"<A,0DT_8MEK57UHFV)I]6G$#&AJ#P[=O<2MQD]RX3:H*.%2K&3
M2+TC%;MG#M?..?&/^VV:)+.%3?3_ .*21S<W/GFYL9SB"2B=J(WW:P?*EH\G
M$P>4UJ1%9R>@[41ONU@^5+1Y.$'E-:B*SD]!VHC?=K!\J6CR<(/*:U$5G)Z#
MM1&^[6#Y4M'DX0>4UJ(K.3T':B-]VL'RI:/)P@\IK416<GH.U$;[M8/E2T>3
MA!Y36HBLY/0A&]+_ ";:2D]!9;IR"?J6.RL'Z]%2D9G/3<4;F]5B29M,K<W1
MST\H^L]7SE]9T>F3I:,YA5#8\J/26/QC^S:>!0'/>X[7DWZ.UN#7[5G8D,0T
M&4.      !*MZ)200CMX;%5<)O5"GU2Z3QAC'2$DI@V;=53<YT8YLZ5(3F+G
M_N'(5/!NB7I=(Q<9I+GS\7+)Z;H<8?Z"NXEQ\RWC#:G0U/A'_6U/ Z .U$;[
MM8/E2T>3C+L'E-:FE(K.3T':B-]VL'RI:/)P@\IK416<GH.U$;[M8/E2T>3A
M!Y36HBLY/0=J(WW:P?*EH\G"#RFM1%9R>@[41ONU@^5+1Y.$'E-:B*SD]!VH
MC?=K!\J6CR<(/*:U$5G)Z#M1&^[6#Y4M'DX0>4UJ(K.3T':B-]VL'RI:/)P@
M\IK416<GH.U$;[M8/E2T>3A!Y36HBLY/0=J(WW:P?*EH\G"#RFM1%9R>@[41
MONU@^5+1Y.$'E-:B*SD]!VHC?=K!\J6CR<(/*:U$5G)Z'Q<7"':-UW3E*>1;
MMD57"ZQZI:,$211(9150^?8_T%(0IC&S_IC&1U0V=.G2HT*"[JG3I*C1HIJ-
M*E2:5%*_>VTCFGM*%"C2ITWW-"A1=*E2:<*-&BFZ3=VY)-FM7_7KR1?_ '97
MN&6?R(?[/O<<M_\ CM>G5_[Q_D>^!R-\OU*6W_LC_KUY(O\ [LKW#+/Y$'>X
MY;_\=KTZO_>'? Y&^7ZE+;_V1_UZ\D7_ -V5[AEG\B#O<<M_^.UZ=7_O#O@<
MC?+]2EM_[(_Z]>2+_P"[*]PRS^1!WN.6_P#QVO3J_P#>'? Y&^7ZE+;_ -D?
M]>O)%_\ =E>X99_(@[W'+?\ X[7IU?\ O#O@<C?+]2EM_P"R/^O7DB_^[*]P
MRS^1!WN.6_\ QVO3J_\ >'? Y&^7ZE+;_P!DV0C[O RK!E)QV)MY'R31L_8N
MT*K:#(NF;Q$CAJY1-['_ ,22Z"A%4S?ZD-C(_P =M=CM=AM=KL-M1^CVNQVE
M/9;6A2=&-#:;.DZ%.@X-J-&DFG![T?ZW9;;9[;9;/;;*EW>RVNSH;79TTJ4*
M>SVE%4J%)12<*5%IK)GK[41ONU@^5+1Y./YP>4UJ=Q6<GH.U$;[M8/E2T>3A
M!Y36HBLY/0=J(WW:P?*EH\G"#RFM1%9R>@[41ONU@^5+1Y.$'E-:B*SD]!VH
MC?=K!\J6CR<(/*:U$5G)Z#M1&^[6#Y4M'DX0>4UJ(K.3T-2N5_B#9N]73EQ7
MU#)4IDM<HZ4I.Z=RNM0U>>F91I KP,W'G0KME0L]@K247,(-(]_'*M8^-L$L
M_3)A\5FZ:31XPC&[<H]N ?#5KMV? OKDG.[BOJN.0L'8.2KJ#B76I%GH6VI?
M;<7*0C^TV5VE!)3,Q4:ZZ3C:$S/&TR%<+2EA>R+*)SF068NFADW$/?\ XAP^
M87:]OCF;&RT:A,Q4G#N57K=M*Q[V-<+QK]W%R**#YLHU55CY./6;OXYZFFJ8
M[5^R70=M%RIN&RR:R9#E@DP5$\F36D+3F-&8N;X6!@WU=DZGA78=N6?T>2JQ
M'J40]I<@>5RYKBI6\B\9R"; Y&\RP<+1\P@^8K+-U)B^R5_GQ]8@KLMQ=T5I
M77L0PJ\4WBG3F,J*EO>QK&4E9*73=3][.]/:;9-K2;ET\F[9*YF+'A:?DG+A
M_C%JLG14P:56-A'VP]G#M@B(0AE\^/GU96M>:VJVL(=U"51"03;/GK9^^<2T
MO)3DB\<L(&$JL:9S(RKETZ5+'5FMP$$T*93_  L(EKZS*KC*[A8W'MVXD]NW
M;VE^B           0:>F._.G)^_4-F_Q%$&C.87P7*CTEC_#:9G_ )[_  O)
MOT=K?%9Q"D-"%#@      2Q^B%_3IL?]DSK^<*H*2Y]/%RR>FZ'4*Z7'S+>,
M-J=#4^O5,Z%1EPTJ                  %NV_\ RG:/]NS?_&N1ZJC]MJ?X
MJK_FT#RU[[%7/PM8_*IG%2/T&,(@       !V;ZE_15K/]GU,_ER-& [<^^K
M8Z4M#K>V-S6-]SV5T;4>J[(R"/EGT@        U Y26+3'W[35DKCG84$A&Q
MNSXN6MNK]4O-LV>/1F4:4NT@7T0:%L,/%U>><0_79&25BG,]F<KU9:Q&48A:
MT.$NEN?JWN&/;LB'PA[O-FM<#8/63Y](T: >R4K:IM\NB[RO*7:H=@K0[R21
M>)D-+5+$1!8AU$TR$1;I>R6?66:;=]T5.M>O5Y?:%^I)?@
M   "#3TQWYTY/WZALW^(H@T9S"^"Y4>DL?X;3,_\]_A>3?H[6^*SB%(:$*'
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MB%_3IL?]DSK^<*H*2Y]/%RR>FZ'4*Z7'S+>,-J=#4^O5,Z%1EPTJ
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MZ(7].FQ_V3.OYPJ@I+GT\7+)Z;H=0KI<?,MXPVIT-3Z]4SH5&7#2H
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MOYPJ@I+GT\7+)Z;H=0KI<?,MXPVIT-3Z]4SH5&7#2H
M6[;_ /*=H_V[-_\ &N1ZJC]MJ?XJK_FT#RU[[%7/PM8_*IG%2/T&,(@
M  !V;ZE_15K/]GU,_ER-& [<^^K8Z4M#K>V-S6-]SV5T;4>J[(R"/EGT@
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MI?T5:S_9]3/Y<C1@.W/OJV.E+0ZWMC<UC?<]E=&U'JNR,@CY9](
M    -?.4I6JO:*#%-+;-NJ_'1MYJ=B:R*5&>[#8^U*\\4E6#6<KK2.D4E(5X
M=L9N[7D2-V/K5&[7+HCIVU26E1C=[X;[KL\"'"%^XU44IE[N$%JBYL(E:J[5
M?H3$5$Q,'KXE5BX>EZKM.S25;:+&%L!73W6[ZR5:]LY@] ?]<<3MKLU-JLVD
MSK\-9W24QW\5=QOX1\^Z[@M^!"6Z[%;H77WKBO5_ZVCY+\Y)R^L4&3^IXJC2
MMO&,-#D+'V2-Q,,W52J]FDI!9"W%[0.9:,L]AL%2LLQ)JK.K!::S.3SCJSB2
M68-(I;]\>T/<HK)HE=L\?;[=YL(Y*Y,@H5HJ@BYR7_M*N4%'*!#<^/I402<-
M%%"\W/CHE<)9Y\XSTN;'-F"2B]7M?>]>^79+^J!-V#FM"+\5)ZCJ]K[WKWR[
M)?U0%V#FM!?BI/4=7M?>]>^79+^J NP<UH+\5)ZCJ]K[WKWR[)?U0%V#FM!?
MBI/4=7M?>]>^79+^J NP<UH+\5)ZCJ]K[WKWR[)?U0%V#FM!?BI/4A%]+^G*
MIR>@O:;N/=9RQV5ZGJ$<Y88)C#BC>L];AQ*27K<FYR=#H91Z'1-TL*=+'0T9
MS"P^BY40CX2Q_AM/)% <]\?I>3<?]NUN$/VK.S9#$-!E#@      2K>B3)(G
MWAL7$:Y9-5L:I=9.=\Q7?IF3[757G*1-O(1QB'Z71ST\JG+T<&+ZOG-@Q:2Y
M\_%RR8^6Z'4*[DRX^9;QAM2'D:GUVIYHZ >KVOO>O?+LE_5 R[=@YK0TI?BI
M/4=7M?>]>^79+^J NP<UH+\5)ZCJ]K[WKWR[)?U0%V#FM!?BI/4=7M?>]>^7
M9+^J NP<UH+\5)ZCJ]K[WKWR[)?U0%V#FM!?BI/4=7M?>]>^79+^J NP<UH+
M\5)ZCJ]K[WKWR[)?U0%V#FM!?BI/4=7M?>]>^79+^J NP<UH+\5)ZCJ]K[WK
MWR[)?U0%V#FM!?BI/4=7M?>]>^79+^J NP<UH+\5)ZCJ]K[WKWR[)?U0%V#F
MM!?BI/4=7M?>]>^79+^J NP<UH+\5)ZEO6UO:>REGZ4M7\E[/372P6O2)39+
M[-<\^,&S9S8QG./R9R4V,9^G.,_D'JJ,/KM3N?VJK\5_NT,CRUZ/U*N7K[+6
M.'_ZJ>9QDC]!3"0        =C&J$+1G5NM<IRL 5/- IV4RGK\B<Y2=G8[HE
M.<ME3*<V"\V#&*F3!L\^<$+C/1Q@2W(?]:M>Y_>EH<?_ .O:Y&Y;&C_T>RKU
M]VU'@_W799E_]7M?>]>^79+^J!\N[!S6A]*_%2>HZO:^]Z]\NR7]4!=@YK07
MXJ3U'5[7WO7OEV2_J@+L'-:"_%2>HZO:^]Z]\NR7]4!=@YK07XJ3U'5[7WO7
MOEV2_J@+L'-:"_%2>HZO:^]Z]\NR7]4!=@YK07XJ3U+A$$@
M      $&GICOSIR?OU#9O\11!HSF%\%RH])8_P -IF?^>_PO)OT=K?%9Q"D-
M"%#@      2Q^B%_3IL?]DSK^<*H*2Y]/%RR>FZ'4*Z7'S+>,-J=#4^O5,Z%
M1EPTJ                  %NV__ "G:/]NS?_&N1ZJC]MJ?XJK_ )M \M>^
MQ5S\+6/RJ9Q4C]!C"(        =F^I?T5:S_ &?4S^7(T8#MS[ZMCI2T.M[8
MW-8WW/971M1ZKLC((^6?2                              (-/3'?G3D
M_?J&S?XBB#1G,+X+E1Z2Q_AM,S_SW^%Y-^CM;XK.(4AH0H<      "6/T0OZ
M=-C_ +)G7\X504ESZ>+ED]-T.H5TN/F6\8;4Z&I]>J9T*C+AI4
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M2Y_5I)E*C'>"X@
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M/7N54U'*QN+"4% RJ()
M
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MA6B_PW*&6CU)TMRVO*PY=962U1&I[=$/))C3PA'&_AO?%1]4,.,"8P#D
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M_IR /[@I2YSDI2XR;/2-G&,8R8V<8QG.>;\N>;&,<^?IYL8Q_I@ ?H
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7G+"NZ;FE\1[,0S.X           __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g142578g97l59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g97l59.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1ED4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "T< 5H  QLE1QP"   "  (< @4 &7!W8U]M87-T97)?;&]G;U]S:&]R
M=&9O<FT .$))300E       08?^!W]??J,G42:,CZ+6WF3A"24T$.@
MY0   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 \     !  $#P     $  3A"24T$)@      #@             _@
M.$))300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M          $ .$))300*       !   X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      -3    !@
M            Q@   08    / %  =P!# %\ 9@!L %\ - !C '  ( !C &\
M< !Y     0                         !              $&    Q@
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    Q@
M  !29VAT;&]N9P   08    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3004       $     CA"24T$#      .L@
M  $   "@    >0   >   .+@   .E@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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MK=98=K& N<?  22DIDDN';_C=^K1S!4:LEN*3'VPL;LC_2FH/^T^E_UGU?\
M@EVS'LL8VRMP>QX#FN:9!!U:YK@DIDDN7ZO_ (Q_JMTJUU!O=FWL,/KQ&BR#
M^ZZYSJ\;=_(]99-?^./H3GP_!S&L!@N J<1\6^NDI[Y)9?0_K+T;K]+K>F9
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MZR,^L/UMZHT.9C8V394#JPY(I>ZBM@=.ZGIU/I_]<^S_ /"I*>1=POH[J']
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M=,Z#T7I.X]-PJ<1UFCW5,#7.'[KG_3<U7TE*22224I))))3_ /_5V_\ &_\
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M)2DDDDE*22224I))))2DDDDE*22224__V3A"24T$(0      50    $!
M#P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E
M "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %^
M34T *@    @ # $   ,    ! D\   $!  ,    ! <    $"  ,    $
MG@$&  ,    !  4   $2  ,    !  $   $5  ,    !  0   $:  4    !
M    I@$;  4    !    K@$H  ,    !  (   $Q  (    >    M@$R  (
M   4    U(=I  0    !    Z    2  "  (  @ "  MQL   "<0 "W&P
M)Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C S.C$P(#$V
M.C0P.C,V   $D   !P    0P,C(QH $  P    '__P  H ( !     $   $&
MH , !     $   #&          8! P #     0 &   !&@ %     0   6X!
M&P %     0   78!*  #     0 "   " 0 $     0   7X" @ $     0
M            2     $   !(     3A"24T#_0      "           _^$!
M@$U- "H    (  P!   #     0)/   ! 0 #     0'    ! @ #    !
M )X!!@ #     0 %   !$@ #     0     !%0 #     0 $   !&@ %
M 0   *8!&P %     0   *X!*  #     0 "   !,0 "    '@   +8!,@ "
M    %    -2':0 $     0   .@   $@  @ "  (  @   /      0   \
M   !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-CHP,SHQ," Q
M-CHT,#HS-@  !)    <    $,#(R,: !  ,    !__\  * "  0    !   !
M!J #  0    !    Q@         & 0,  P    $ !@   1H !0    $   %N
M 1L !0    $   %V 2@  P    $  @   @$ !     $   %^ @( !     $
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M6723E9BSP=36U__$ !X! 0  !P$! 0             " P0%!P@)!@$*_\0
M31$  0," P0& P@+$0       0 " P01!08A!Q(Q00@3(E%A<106,Q4R0G2!
MD:&S"1@D-#525'.4LM8E4U565Y*5EZ*QP=+3U-7A\/_:  P# 0 "$0,1 #\
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MN@D7N5674(DDF7Y=QU%!*0A>1 .3" >=$7#=RW=HD<-%T73=0!%-=NJ19%0
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10(0 Y$1^8Z(K[1$:(C1%_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
